<SEC-DOCUMENT>0001628280-21-010083.txt : 20210513
<SEC-HEADER>0001628280-21-010083.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513071142
ACCESSION NUMBER:		0001628280-21-010083
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cerecor Inc.
		CENTRAL INDEX KEY:			0001534120
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450705648
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37590
		FILM NUMBER:		21917163

	BUSINESS ADDRESS:	
		STREET 1:		540 GAITHER ROAD
		STREET 2:		SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-522-8707

	MAIL ADDRESS:	
		STREET 1:		540 GAITHER ROAD
		STREET 2:		SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cerc-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4f7a87f1-b6d6-4918-8a41-8e0f9da38f3e,g:12909dcc-0657-4b99-8650-be04def8faa3,d:c7bb257d793b4c13bdc2f5247f8e819f--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:cerc="http://www.cerecor.com/20210331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cerc-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl80LTEtMS0xLTA_a4ca7b07-bde3-4b76-88a7-7022c432aff9">0001534120</ix:nonNumeric><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl81LTEtMS0xLTA_12a446d1-04f9-4fc6-aca4-4f4cd540e017">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl8xMy0xLTEtMS0w_f8a72044-f0da-4ddd-950c-58c1b5d2dc53">2021</ix:nonNumeric><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl8xNC0xLTEtMS0w_e5baed66-5d20-44f9-b241-4404cef05d59">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl8xNS0xLTEtMS0w_b45e9211-3c52-4f79-b3f4-dac9e4fef92f">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i1b37c73849e9467f95d35e15bd0b8503_D20181201-20181231" decimals="INF" name="cerc:StockholdersEquityNotePreferredStockConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80Ni9mcmFnOmY2NzI5YWViODg0NzQyYWU4ZDBiNzg0ZjllNWMzOWJmL3RleHRyZWdpb246ZjY3MjlhZWI4ODQ3NDJhZThkMGI3ODRmOWU1YzM5YmZfMjQ_fda18e8e-6984-4b34-bae8-440d91748156">.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9ec411596a6843a496aa5fc4c66a5283_D20181227-20181227" decimals="INF" name="cerc:StockholdersEquityNotePreferredStockConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82MS9mcmFnOjBlYjI2MWJkYThiMTRmODI4M2UxMzM4OWE2OTI4OGYzL3RleHRyZWdpb246MGViMjYxYmRhOGIxNGY4MjgzZTEzMzg5YTY5Mjg4ZjNfNDE_34b33294-5753-4c0c-92bf-4392c5a9ebc4">.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i014f146895fb4927a75a9cdec07aaa18_D20210101-20210331" decimals="INF" name="cerc:StockholdersEquityNotePreferredStockConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82MS9mcmFnOjBlYjI2MWJkYThiMTRmODI4M2UxMzM4OWE2OTI4OGYzL3RleHRyZWdpb246MGViMjYxYmRhOGIxNGY4MjgzZTEzMzg5YTY5Mjg4ZjNfNDE_d22b0db5-540e-46d7-ac08-bcb4a363c166">.20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6063b66d7fe140e18f3cd8924bb75c11_D20181226-20181226" decimals="INF" name="cerc:StockholdersEquityNotePreferredStockConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82MS9mcmFnOjBlYjI2MWJkYThiMTRmODI4M2UxMzM4OWE2OTI4OGYzL3RleHRyZWdpb246MGViMjYxYmRhOGIxNGY4MjgzZTEzMzg5YTY5Mjg4ZjNfNDE_ea330e8f-1b31-4682-a9b2-545bfb371583">.20</ix:nonFraction><ix:nonNumeric contextRef="i9a4bbd01132947da84d8a776d5a0b90e_D20210101-20210331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4MQ_63efab90-69fc-42af-b1b9-73b3e29c5cf7">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i63645a96f5bd4cfea3a83a7db78ff588_D20210101-20210331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg2Nw_e865b985-b902-43d4-a27a-a09d25dc86dc">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38">us-gaap:AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8">us-gaap:AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl84ODEvZnJhZzozY2YwOWQ0MGUzNWM0ZjhjYjhmN2FhMTY3ODRhZDhiMS90YWJsZTpmZWY3NGUwYjg2NTc0YTAyOWJhNWUxNWJkNmYyYWUxZi90YWJsZXJhbmdlOmZlZjc0ZTBiODY1NzRhMDI5YmE1ZTE1YmQ2ZjJhZTFmXzAtMS0xLTEtNDE4OQ_3a6d4a46-c7e1-4097-b14c-015836148d34">cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl84ODEvZnJhZzozY2YwOWQ0MGUzNWM0ZjhjYjhmN2FhMTY3ODRhZDhiMS90YWJsZTpmZWY3NGUwYjg2NTc0YTAyOWJhNWUxNWJkNmYyYWUxZi90YWJsZXJhbmdlOmZlZjc0ZTBiODY1NzRhMDI5YmE1ZTE1YmQ2ZjJhZTFmXzAtMS0xLTEtNDE4OQ_c51d4dfc-b33c-4c8e-9134-b97e55bae4b6">cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cerc-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i457f29798d7f4a138d9ba9c629c704fb_I20210511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idedefda4bb914378b63f3c9b8b6ee172_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i66f50cdd8bac484bb18c5e75cf2515ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6051bdc503c644b88a48cbfbf8982a59_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97014661c9674a1aa49d94115f232a8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i888ee0d094224a8c9d478400fe2c9087_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2cf49ee253f4aa884cbc90462dfac03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f1b44d7eb742ad8b64d152e535816f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690cbeed41364aeabc936a485830713d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0527fb21cb6e422a81b0d2b896ce2a12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b59ac211a5411c8a1466475097bdbd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1824d4fdd18644d08279a67df7329d8f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief11578c5a3d4120889bfb43d5e8c59e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7f7fe58b1947a1af4d75615be3a866_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3698e2a15da04d2582ead896c9da1bdb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8858464917a44129a19e5fd629e46e2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5248b004c3024ef7844b36f897f76171_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbd4365662c24c30b28e21ce069efe37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc41f7eca88947c9a35e4be0dc501644_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aed8d010f6b4643ab5cf935d95e3ddb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b1d9aca4484c4d8668324b0b5763d2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293bef8c2ab840b6bfc576a532a95a7e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icca7fddb46cc489688e478d5cee8ffe0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7acefac7b962485a8c15861ff10d0200_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60933515d1434308883ae1bb020e0a13_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>cerc:product</xbrli:measure></xbrli:unit><xbrli:context id="i628f57f6215a46b79ad5e7d53f734b1a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:NeurologicalClinicalAndPreclinicalStageCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8d13d67faf489fa328978709bcf27a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:ClinicalStageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e92ff68bdc846f39796a8688fdb85c6_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9f33420b794d6b82ec040bbdcda9ac_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb32bfec45e942d4a910555a806195f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a0d41b8169040d484988356bf9f4cdb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66052a9dae424dca80a7f82db41f4f83_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625aa7d5128448528ad08b7663090142_D20210501-20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2b8460cb924cb9b2aea21da6564fbf_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id606c2359deb445f9a0a8ae38b02ddb5_D20190101-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e29f50e08944917829774bcbe7aff76_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec26640aabfa4148bdbe5fd031d0b667_D20191101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763dfef39718433ead8376b849f71b21_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d85ed913ebe404ab54475135f67de89_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5751c8b6986481696dc10ecdf31864b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc1c0e3c3fc4ff5b491ac78fb641632_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b8c7fd991847e8837bd5a30646756a_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if834bd2acf0f4a6cbbc998c9d3a0ec9d_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c24c03ec1214b87aa2626d83a326856_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icf18c62a06294fc58da61652b71d9234_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cerc:MajorCustomerNumberOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i927b204af3c04c0bbd2188ed6a3eb0cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cerc:MajorCustomerNumberTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c7116f8756475caf3bf460b774b112_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cerc:MajorCustomerNumberThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67565b970d24f429f156729cd22f735_D20210401-20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cerc:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:MillipredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="class_of_stock"><xbrli:measure>cerc:class_of_stock</xbrli:measure></xbrli:unit><xbrli:context id="i014f146895fb4927a75a9cdec07aaa18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2105f80d294440588767dee094560b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629fbb798db048ea9b95506876d74823_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df572689a424ea28bc48c6a42dbc0bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:WarrantCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id922871740784b9b88673ef935b11162_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:WarrantCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9167fb87d13406f85d22cdf0ee9c556_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb2884fecf704a3ab359a11213837e2f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a62490f94c4f49b56fb7acc1da3613_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:UnderwritersUnitPurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8caa450d984e75b7af9b3d66541996_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:UnderwritersUnitPurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50329ad27a3d4d858d5e36be03888359_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:NantahalaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b37c73849e9467f95d35e15bd0b8503_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc103a37d52c4b8d9aab7c7d78bd8dab_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950a8c7a799e4212b6120485b875cc33_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cerc:AssembledWorkforceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8340a3cbf64f1ab5d3614c69eea675_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00fa8b9a9a0a48da86b188ca05a629de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a66b18e75cf45d289497fdebf1a0e33_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf61356e0974feb98765a9f2a41e09d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9358ce44d144a59aa2cf6bce55c55b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590b811c4dca4dbca6d871776b523532_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="change"><xbrli:measure>cerc:change</xbrli:measure></xbrli:unit><xbrli:context id="i2d38bb42b8534eff87ac8d23d0d697ea_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:ArmisticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87e47a24f4a454290d837ab00a53c08_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:NantahalaCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11a884079f7b4e2db9df7f885c73462d_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:NantahalaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4b3944edc64b9eab3475e9c9ce4eb4_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:NantahalaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ffa7aeea1749d0b4cdf2eac8066e73_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83186431d6e54ca9af494baa43072af0_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04419c05a564471cafd04ce10e0ea363_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:ArmisticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4830d434af540fab7f362a2f6851391_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:OfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d25c29ccea491bb940f8ab428a1a67_D20200317-20200317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:ArmisticePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5666247a03f94008beee4c2791508959_D20200206-20200206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-06</xbrli:startDate><xbrli:endDate>2020-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1d24a349414177befd56fcc3bbf5f0_D20200206-20200206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:ArmisticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-06</xbrli:startDate><xbrli:endDate>2020-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc18b2fcdebb49ae970fee17a9b37770_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cerc:CommonStockWarrantsExpirationDateOfMay2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb3043f210a045168b002098fa42b497_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cerc:CommonStockWarrantsExpirationDateOfJune2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7278c7eb9d8c4d468fdc7b1b16998399_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cerc:CommonStockWarrantsNoExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d433fb05b0421e829cbc118f401dfb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb1f30979714ea79f95d4802ff984ef_I20181226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie34e5b7882f4464fb323bd265625bb05_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87335e7fb2f644479af541532f926a9d_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cd83eb2a4284855bc679909757c91ed_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9884fb9a86405fb7c325756d06accd_I20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a57959625a746b382f212a041c26d2b_I20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78630f60e5b4ecca96e7de37d2b0ede_I20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a48ca344334551b7645592e589572f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3edf5294c94a15b1515cb8bac0fbf5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7987a16d51476399f00aba786832f0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec411596a6843a496aa5fc4c66a5283_D20181227-20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-27</xbrli:startDate><xbrli:endDate>2018-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6063b66d7fe140e18f3cd8924bb75c11_D20181226-20181226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-26</xbrli:startDate><xbrli:endDate>2018-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf49c9a4875b435fb1444f3db3551e0d_D20160518-20160518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-18</xbrli:startDate><xbrli:endDate>2016-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95616c1bb6fd48dba5535428036866f9_I20160518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6364a4c535f944fc8d6272cec44a6605_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib80218def2434edb83018969f2462fd9_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:A2016SecondAmendedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a4f6b0df275417caf8e9588d5879953_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:ThirdAmended2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e9f70e9f7b4f01be2ea582e6fc1273_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f47b2beb7b41178e355e797e2f3729_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4bbd01132947da84d8a776d5a0b90e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c13bb871c0f4896b5ef4d28dafbd2d6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63645a96f5bd4cfea3a83a7db78ff588_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee83b81d1c04985a8e197982cd1072c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id696367226144fa4b944f70aa62c42fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9100bedc06f0427a92077cbcaacfb3bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060be613e08b4af9bfd9b2dc947d28f0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44363498ae0d4459991baef00bff6710_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754b22e1563e4e3aa874036b82bf942c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ba6fbf1c5441209f70f012cc625abf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e623503adb43afb6fb5459058e0547_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1461faa4f454dce8429a63ea92a7a06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9171628f1093474caf84d9d7559dbe75_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8030e840d448409f8fe845f94ea3abbb_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12e73acc1c964f5888c9864531a2b698_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af98390081b4750881153e96552c18c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da3c9dfb0d14dec942761d660b32921_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f071b1803cb487eab728baa86ce1d1b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2f493114e24792b6ab7231ebc4f3a2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e5c0a81c6c46b5bee3450a25f025e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7429f77f36e348619c1595052db52037_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6388e36dd5e54d04841bac2d0313519d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a18d4e138304f578791e2ee584457c9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25979dec2f3d4ac2862b695cf3514d3f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e8cecccd934890847824b3ae4a7ef0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b6d96bcc1749caadd5b13f2bf8889b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6185a21763b4022bb98a98a1f7511a0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088e1fb0e42744319b8607076b983489_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43534f2ad884d3c93e916333b4e6fe3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4809744336f94a308a12efafbd45bd1e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e67ffefb48e414f85fa6311d88d3fde_D20160405-20160405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-05</xbrli:startDate><xbrli:endDate>2016-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bfcb4e632484858beac101b5287566c_I20160405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830174ed95fc44a1bd5ebc384320dfc9_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1a839c0c2f4008a983a171019b82d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc7327a9c14482fb8f5db8aaf0f48d9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>cerc:contract</xbrli:measure></xbrli:unit><xbrli:context id="i09cca0b1b8484ffda61d0f7e6de54442_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>cerc:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i5c920d35386546eb9e87448a6e1d8613_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>cerc:unit</xbrli:measure></xbrli:unit><xbrli:context id="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:TRISPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cerc:KarbinalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d61bbf3f01410cbe5cb14793b039dc_D20200101-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cerc:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:MillipredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a82b49fc85849e9b165488476f66b9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC611Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cerc:ArmisticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC611Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0da54fc099444480f1290196a28e52_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC611Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa172516dbef43d4a1c0924d5edda6d8_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d40f7899394f23b9dadb48b6bcfb61_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe9f3116d8e45d4a2a1a175df1addb6_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC002KKCLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09f167c7bc048a9bc324012285069cf_I20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC002KKCLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia883540f2ef34a27a1304fff4fc68648_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC002KKCLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC006AstellasLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7017084953a4b4da0c861f92df38447_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC007AstraZenecaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic249f77612fd40feb83d3691de9d3623_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC007AstraZenecaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a16536d275e465da455b4c203c89422_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>cerc:milestone</xbrli:measure></xbrli:unit><xbrli:context id="ic77ef76142994d109c2c47014a1f6c8d_I20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14700ec8a6124480982805c40bb35d5b_I20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196aed014b0d4c248e5addc0ece06d67_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="therapy"><xbrli:measure>cerc:therapy</xbrli:measure></xbrli:unit><xbrli:context id="i5971bb063e474274b182039d0516e79b_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC801CERC802AndCERC803Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3a6dd6de704eda88270dee17a54df9_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC913Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d92807dcac45b09cb550ee806b75f2_D20200203-20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7386371b6dd84a49af329b3ccfa42f9a_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b8acd95e6a4be8b07437719d50a52d_D20180901-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f98b2dbe45438893e30257af07b4bc_D20180901-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab022d6245a44ee3a9b76763b77c8a31_D20180901-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7287b6670b3448ea1ab4049c76715ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:22.777%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzUz_b4fb192b-aebb-4f56-8d63-aa0eb20e060d">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NWYxNjJjODNlMjFiNDRlZGExYTIxOGFiYmE2NTRmMzMvdGFibGVyYW5nZTo1ZjE2MmM4M2UyMWI0NGVkYTFhMjE4YWJiYTY1NGYzM18wLTAtMS0xLTA_f1d9c3a4-2bbf-4eff-8a18-fa668b506fdc">&#9745;</ix:nonNumeric><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">for the quarterly period ended <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NWYxNjJjODNlMjFiNDRlZGExYTIxOGFiYmE2NTRmMzMvdGFibGVyYW5nZTo1ZjE2MmM4M2UyMWI0NGVkYTFhMjE4YWJiYTY1NGYzM18xLTAtMS0xLTAvdGV4dHJlZ2lvbjpiZDg2OTQ4ZjdjZDc0MmZmYmY4MjYxYTU4NGNhNGUwM18zNQ_013d636a-4e16-492a-908b-7c21eb6b1d00">March&#160;31, 2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NWYxNjJjODNlMjFiNDRlZGExYTIxOGFiYmE2NTRmMzMvdGFibGVyYW5nZTo1ZjE2MmM4M2UyMWI0NGVkYTFhMjE4YWJiYTY1NGYzM18zLTAtMS0xLTA_47869884-ec2b-49e8-b4a5-d7b8787c1fad">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER: <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU0_bef06f51-3882-4848-afdf-424d1bf0357d">001-37590</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU2_153cfdf9-8932-4828-a1f9-a3aed160256a">CERECOR INC.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8wLTAtMS0xLTAvdGV4dHJlZ2lvbjpjMGQ0NzE0OWNmZDE0MWQxYTRiOWI1M2U2OTE0MDBlYl81_2c266157-a113-484d-a6fc-7c6c1b05658c">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8wLTEtMS0xLTAvdGV4dHJlZ2lvbjo0ODg5MjdiZjU3NmY0MWViYWZjNjRlZjNmMWRjNGJlM181_34102b2d-bb34-4869-8027-c756904ae3f2">45-0705648</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV81_3d3a1a45-314e-495d-aeea-3f049d6cd366">540 Gaither Road, Suite 400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV84_81411c67-43b2-46db-88a0-2c918ad1f268">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV8xMg_cdb35bec-a4a9-47bd-b117-705087a62e47">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV8xNQ_b1f5571b-3337-4a86-9877-ecc6ebbce5cc">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTEtMS0xLTAvdGV4dHJlZ2lvbjo4NjUzOTc3YTc0OWE0NTQ5OTdmMzE3ODVjNjExZmYzYV82_4971dbd2-cbcb-4c26-a959-b6b3a15fefb4">410</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTEtMS0xLTAvdGV4dHJlZ2lvbjo4NjUzOTc3YTc0OWE0NTQ5OTdmMzE3ODVjNjExZmYzYV8xMA_f3386e0b-febe-4a79-a0f6-3fc9e2e6e99e">522-8707</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">including area code)</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:33.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6N2FjYjg0ZDE5YzQwNGVkYmE0ZjE1MzVmNDE1ZDIwMTQvdGFibGVyYW5nZTo3YWNiODRkMTljNDA0ZWRiYTRmMTUzNWY0MTVkMjAxNF8xLTAtMS0xLTA_5a878026-9207-46a5-a790-5a6e3ac22774">Common Stock, $0.001 par value</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6N2FjYjg0ZDE5YzQwNGVkYmE0ZjE1MzVmNDE1ZDIwMTQvdGFibGVyYW5nZTo3YWNiODRkMTljNDA0ZWRiYTRmMTUzNWY0MTVkMjAxNF8xLTEtMS0xLTA_76aa721c-cb69-4c7b-a726-abffa81298e4">CERC</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU3_59fcc410-3485-4ff7-a6ef-c5a71f569efb">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU4_0572975d-cb80-4b0f-9115-e80197a7e9d2">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b&#8209;2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:26.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer &#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NzhiODQ4NDRhNjQ5NDJkMTkwMzI5YjgxZjc5ODQ3OTUvdGFibGVyYW5nZTo3OGI4NDg0NGE2NDk0MmQxOTAzMjliODFmNzk4NDc5NV8xLTAtMS0xLTM1L3RleHRyZWdpb246M2RmNzUwMGVjNmQwNDBjY2IyYThjZjJiZGZmNTk2MzdfNDk0NzgwMjMyNTA0NA_c97475ac-53f6-41de-a210-d0ff689236e3">Non-accelerated filer</ix:nonNumeric> &#9745;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NzhiODQ4NDRhNjQ5NDJkMTkwMzI5YjgxZjc5ODQ3OTUvdGFibGVyYW5nZTo3OGI4NDg0NGE2NDk0MmQxOTAzMjliODFmNzk4NDc5NV8xLTItMS0xLTAvdGV4dHJlZ2lvbjo1M2FmZDFlNDFkOTc0MGYxYmNhOWM3MmYwYmY5MzY0Yl8zMA_82192efa-9819-46d4-8a19-6fa7605d8592">&#9745;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NzhiODQ4NDRhNjQ5NDJkMTkwMzI5YjgxZjc5ODQ3OTUvdGFibGVyYW5nZTo3OGI4NDg0NGE2NDk0MmQxOTAzMjliODFmNzk4NDc5NV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjplNWJlMmE0NjA0ODY0NDUxOGE5YjgyMjg4OWJmMjdmOF8yOA_855be068-cef5-4d93-b738-d1943bc84b0b">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b&#8209;2 of the Exchange Act).&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;No&#160;<ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF80OTQ3ODAyMzI2ODM0_b384f063-8207-4350-92d9-992c4ad1ef8b">&#9745;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 11, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i457f29798d7f4a138d9ba9c629c704fb_I20210511" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzEz_fc1c065f-9b94-41dd-80da-c94068739be9">95,471,843</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERECOR INC.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the Quarter Ended March&#160;31, 2021 </span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.869%"><tr><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_10">PART I.&#160;</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_10">FINANCIAL INFORMATION&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_13">Item 1.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16"> (Unaudited) and December 31, 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">02</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_19">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">Condensed Consolidated Statements of Changes in Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25"> Equity (Unaudited) for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">20</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">Condensed Consolidated Statements of Cash Flows (Unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">20</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_22">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_28">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_79">Item 2.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_79">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_82">Item 3.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_82">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_85">Item 4.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_85">32</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_88">PART II.&#160;</a></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_88">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_91">Item 1.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_91">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_94">Item 1A.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_94">33</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_97">Item 6.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_97">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_97">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_100">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_100">35</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements.</span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERECOR&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNC0yLTEtMS0w_8a950d83-195a-4acb-9ede-e3d38995a51c">38,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNC00LTEtMS0w_b6575cd3-faa2-45e9-b3c0-135aac86c792">18,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNS0yLTEtMS0w_771d6283-7057-4e96-9464-a19b71ffbf38">3,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNS00LTEtMS0w_8078b57d-191b-493c-911b-8ee5a9281f39">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNi0yLTEtMS0w_8d54d2a9-81f1-4634-8fdb-57034a237812">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNi00LTEtMS0w_d5a35113-ffe8-4a4f-b63a-53b81ee50ec8">2,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNy0yLTEtMS0w_7de96452-f8df-4495-abbe-47c07a9be069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNy00LTEtMS0w_5450113a-d8b3-4485-8434-52bb32637065">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOC0yLTEtMS0w_443c7d88-d8be-4ae8-8708-44acc28559d2">2,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOC00LTEtMS0w_dcdf5263-327b-44c9-a40a-606ac65c50b4">2,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOS0yLTEtMS0w_2d8c2550-b93f-4246-887e-a715f57732f4">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOS00LTEtMS0w_524aad90-5024-4966-87ea-27b556701a03">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTItMi0xLTEtMA_93e5dabf-dfd7-4b4d-989c-f5d26294af42">46,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTItNC0xLTEtMA_2cab460e-c3fa-4d42-b5de-77a4ebbb3a0f">26,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTMtMi0xLTEtMA_e0604595-215a-4657-9893-d92a5032e0bb">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTMtNC0xLTEtMA_77d5e91c-0b7b-486a-b473-725ae4c228c5">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTQtMi0xLTEtMA_7b60a041-6f97-426e-9339-4faae8d61a24">1,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTQtNC0xLTEtMA_8381b89f-5e32-446a-a0a5-89fd03f8089d">1,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTUtMi0xLTEtMA_1e749be3-9a7a-4e2f-9488-546950420967">14,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTUtNC0xLTEtMA_373257f9-357e-4c92-a192-68568f1f0bc3">14,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTYtMi0xLTEtMA_c509aa71-f1c3-4b13-91c7-fbd7c7a932d3">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTYtNC0xLTEtMA_998dd4ef-3410-4d00-ae69-455f6aa0ad58">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTctMi0xLTEtMA_3944ae0c-22cc-4c5c-94f0-e2fd2556e801">63,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTctNC0xLTEtMA_d7c10c92-0165-4ab3-910d-8404f414fa90">43,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjAtMi0xLTEtMA_683cb0e2-58b4-4ba3-ae75-10a4a3a12d75">11,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjAtNC0xLTEtMA_64b5e9f7-50c4-4b23-9894-7c295362a3e6">2,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjEtMi0xLTEtMA_f2f71bf2-0354-430b-9f46-9f2f0f129539">14,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjEtNC0xLTEtMA_3139cf80-9302-4132-8f11-9387fbf66ee4">11,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjMtMi0xLTEtMA_c635481e-29b0-4757-8d1e-0399c64f2281">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjMtNC0xLTEtMA_64997439-124a-4e6f-8b70-bc95e8894030">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjQtMi0xLTEtMA_79ba5a42-703f-4a5e-af88-766e3137c2cf">26,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjQtNC0xLTEtMA_054ef17d-7eef-498b-93b5-64ac36df0ec4">15,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjUtMi0xLTEtMA_871638a3-5c6f-4371-9a1c-b363fd0920ec">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjUtNC0xLTEtMA_3308f81b-3252-4652-806b-d339d984c9ec">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjYtMi0xLTEtMA_8860fe69-96c9-4b26-aae6-282e6d8916fb">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjYtNC0xLTEtMA_d34dfe09-02d2-4685-8eac-e68669f9fe6b">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjctMi0xLTEtMA_8fa66867-ae03-4bfb-95f7-5e50f804f1d9">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjctNC0xLTEtMA_cb6fbe10-4258-46a8-8b3d-6b1c6910e37b">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjktMi0xLTEtMA_b76b9b45-5542-4fe0-bf52-38e24eec925d">30,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjktNC0xLTEtMA_745fd749-0efd-4463-8ca7-e64bc5edf592">19,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzE3_791960c8-ee74-4910-9db7-2278cd1aaa3c"><ix:nonFraction unitRef="usdPerShare" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzE3_d0d290ad-b632-41c2-8213-7dc38b70a605">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzMx_50dbcd2d-fe58-42cd-b58a-e758223a1433"><ix:nonFraction unitRef="shares" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzMx_a356e564-a28a-4cb8-a791-0a47f8aad027">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzk3_4bcb252e-fa17-4fe8-955d-e74e83291f91"><ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzk3_68157309-a849-4346-ac58-a5c95f04cbf6">89,104,816</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzEwNA_b2a5849f-f23c-4e0f-82c0-4f5b143dcc3b"><ix:nonFraction unitRef="shares" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzEwNA_c81f2aad-d940-4c2f-99ae-df7808bc5ef6">75,004,127</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMi0xLTEtMA_bf8c42eb-9836-41b0-a602-3b90c45c7a8c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtNC0xLTEtMA_ee119997-89bb-4e3e-98df-39ad60d0c8e6">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#8212;$<ix:nonFraction unitRef="usdPerShare" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzIx_d1a111ff-694a-41ce-a574-44e39a1d3d1b"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzIx_e9e34be5-76c5-4e4f-82d2-ae2af23a9edd">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzM1_360b8c10-fb5f-4e5f-bb17-6122658ac1fd"><ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzM1_7be50919-1449-4624-9632-b5bc5b60d5a0">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_0e3b1688-9051-4bba-860a-a765932dc5e3"><ix:nonFraction unitRef="shares" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_26e93e0d-121e-4dec-bcb7-52005605dbfa"><ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_ab7b44cd-98a3-4aa7-8652-4d38fcf36089"><ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_c3e79afe-af79-4b5c-adfa-6a4736dbd8d6">1,257,143</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2021 and December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMi0xLTEtMA_54fa29be-8d7f-41cd-a0b5-e523ab446d2c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItNC0xLTEtMA_69bdce94-3610-4263-8942-5cc2686998ff">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzMtMi0xLTEtMA_09a0956c-9ce0-46f1-b200-6f2781726d57">241,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzMtNC0xLTEtMA_9e7316dc-c936-4ae6-a62a-e93e50196770">202,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzQtMi0xLTEtMA_66b8bb8f-a7c2-4f8e-b2e6-aeab3707567e">208,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzQtNC0xLTEtMA_4d6cf7f3-01a0-4138-ae85-074b3990f382">177,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzUtMi0xLTEtMA_02cb0604-85f7-4222-8be0-9605b7608401">33,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzUtNC0xLTEtMA_6429ea63-1e1b-41a0-a0cf-9c59c8d55322">24,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzYtMi0xLTEtMA_69757674-a641-46b6-9aa3-e1186c0ae238">63,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzYtNC0xLTEtMA_9381ad5f-2971-49f6-88c7-64de53c64c27">43,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERECOR&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f50cdd8bac484bb18c5e75cf2515ca_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNC0yLTEtMS0w_2c8be31f-9e9c-4fea-9dd3-e1698c35e610">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6051bdc503c644b88a48cbfbf8982a59_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNC00LTEtMS0w_f0813d51-55ea-4ce8-b7f3-f4cb427fa425">2,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNi0yLTEtMS0w_590d111a-edcd-4ab7-8547-bb2dddd4b9b9">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNi00LTEtMS0w_612bb52a-8204-4f0c-9b5a-d90345d40f5b">2,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfOS0yLTEtMS0w_c6149be6-0654-46c0-ab4d-d2cd186d7b4f">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfOS00LTEtMS0w_4db293ab-cc22-4b43-a1a4-c19161de776e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTAtMi0xLTEtMA_a03a6deb-5b86-4453-a16a-0ec0866e7598">25,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTAtNC0xLTEtMA_2436ffb2-5201-4b98-a562-7a194f0647c2">4,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTEtMi0xLTEtMA_d9dd12ef-37f9-4376-ba97-409dfcd7ee06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTEtNC0xLTEtMA_a9617214-39b4-4c4f-9c23-3147520bf9df">25,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTItMi0xLTEtMA_4abbfc8b-a4da-4c6f-90fa-2f3edb2960ad">4,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTItNC0xLTEtMA_ea7d6327-6b08-457f-9715-ebae6eead8fd">2,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTMtMi0xLTEtMA_3e4709b4-5268-4e51-9647-1bc794c42bf8">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTMtNC0xLTEtMA_39be4bd8-8779-40f2-a37d-93f44dbba27d">677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTQtMi0xLTEtMA_d4cb5607-5866-49fb-a48b-4f7acccbba72">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTQtNC0xLTEtMA_0d7da33f-131d-4cf5-bdbd-edc5bf3d0f11">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTYtMi0xLTEtMA_583b0af3-8b08-441e-b1d5-037281e370ed">31,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTYtNC0xLTEtMA_c3602322-c02e-48e2-ab15-86b0210d0266">34,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTctMi0xLTEtMA_e57ca779-d4e0-440e-b5eb-ca07a227967f">30,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTctNC0xLTEtMA_6ccb930c-626b-4056-bb7d-39bab04af0b8">31,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of Investment in Aytu</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktMi0xLTEtMA_7f6d7424-8ea2-47ca-bb0b-18f4dc299c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktNC0xLTEtMA_cb0495f1-6e68-4408-b975-05ef9fb251b1">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktMi0xLTEtMjQyNw_fb5527fb-cf1f-4e92-8794-d42fe1da8ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktNC0xLTEtMjQyNw_961e1283-ae5f-4100-8ac2-d591e0bb95df">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtMi0xLTEtMjQyOQ_49d9e084-e519-4ee6-9ce7-bf1cee183705">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtNC0xLTEtMjQyOQ_f90e75f8-d415-42ed-9355-1f70dc6f2ece">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtMi0xLTEtMA_22c82cb7-2cdc-4b0e-9e84-1bc6101a63b6">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtNC0xLTEtMA_21fcd62a-e010-43ce-80bb-655d1c8d48d0">7,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjItMi0xLTEtMA_b8e65fa1-32d4-4c17-a72b-8955917574a7">30,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjItNC0xLTEtMA_ea59cea2-b6a8-4418-abef-3033b856c9c9">24,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjMtMi0xLTEtMA_72b90d4c-52d3-41ff-b4d1-a113c024b29e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjMtNC0xLTEtMA_68099313-b32b-45d2-8f4a-92113e0b34f8">2,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjQtMi0xLTEtMA_dd0e93a4-6c75-4665-931d-fc24d255d9db">30,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjQtNC0xLTEtMA_70d2d27f-b8b5-4547-9a8b-a84d38290d4d">22,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjUtMi0xLTEtMA_f044c3b6-058a-4b3b-9741-698a4199709b">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjUtNC0xLTEtMA_3eff5c4d-4e0f-4632-8917-760206387629">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjYtMi0xLTEtMA_96692009-5b79-421d-ab0e-178210f47a53">30,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjYtNC0xLTEtMA_1762d37c-33f4-425a-bf4c-fad6d726fd03">21,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share of common stock, basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktMi0xLTEtMA_2011e9a7-a1b4-4ec9-a376-7d71eb007b8f"><ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktMi0xLTEtMA_70792f2e-a14e-4f05-b1eb-e27b1807480a">0.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktNC0xLTEtMA_b6e10e14-88f3-4466-9df8-37c34821dc33"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktNC0xLTEtMA_dc010ad0-0e53-47b3-993d-9162c8118f37">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtMi0xLTEtMA_79936e63-aab8-4e8c-a642-8588543acc53"><ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtMi0xLTEtMA_7a78a974-54b1-4f2f-ba60-968d0be438c0">0.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtNC0xLTEtMA_10e77e86-f50b-41d2-92cc-63a9327357b9"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtNC0xLTEtMA_42cfb0c1-97da-4558-b849-08b79f3ff884">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtMi0xLTEtMA_59a599f0-ce4b-4ec0-8bed-0d2e4842d00c"><ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtMi0xLTEtMA_5ddee8b4-4a22-45d1-954c-4b1ed0ffd49f">0.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtNC0xLTEtMA_a937b330-94a4-4566-b874-bb8ac6e5963a"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtNC0xLTEtMA_f7dcb4d1-40bc-4324-8ba1-1b106c7a93a0">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share of preferred stock, basic and diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtMi0xLTEtMA_0bc9d3d8-7dc2-4da9-8f22-94057e57e560"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtMi0xLTEtMA_269cedb8-247b-497b-b72a-a5f11ca3740b"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtMi0xLTEtMA_d4ee7f77-e951-4d31-9d91-96f549d58e4d">1.61</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtNC0xLTEtMA_53049003-d4da-4099-b8e0-acb1b98fad9d"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtNC0xLTEtMA_6491b092-cfd9-441c-9567-ddc97afc09b5"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtNC0xLTEtMA_b70cc2fa-183d-4310-a30a-6a5b5aba53be">1.78</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtMi0xLTEtMA_6e121168-330f-460d-a4eb-d1a06c39d982"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtMi0xLTEtMA_95f19155-c0f7-4a98-bc60-4eb65bb24ec3"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtMi0xLTEtMA_c5597371-6a5c-4270-ace3-122912449367">0.01</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtNC0xLTEtMA_ab867d2e-aca4-4f6f-8854-2133be067c12"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtNC0xLTEtMA_eec64f17-803d-41c7-b21f-a8c1dffa814b"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtNC0xLTEtMA_fde5db28-6897-4e9f-8045-564bf481263e">0.08</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of preferred stock, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtMi0xLTEtMA_0823dec6-1c6f-4490-969f-6eaa9aa31b71"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtMi0xLTEtMA_318314b3-599a-4ab2-b18f-6c401d10622b">1.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtNC0xLTEtMA_7c5b2d2e-738a-446d-ad46-9572426e2084"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtNC0xLTEtMA_a4fe51ab-222e-49d5-ac92-3cf5c5b6994d">1.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERECOR&#160;INC. and SUBSIDIARIES</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">equity </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97014661c9674a1aa49d94115f232a8e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0xLTEtMS01MTYw_a299804e-20fd-4440-8012-c15efebbcb2d">75,004,127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97014661c9674a1aa49d94115f232a8e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0zLTEtMS01MTYw_72d719f4-0c82-4830-a472-56425a72d917">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i888ee0d094224a8c9d478400fe2c9087_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy01LTEtMS01MTYw_ef43976b-489d-4fc4-acaf-1969215b2cc3">1,257,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888ee0d094224a8c9d478400fe2c9087_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy03LTEtMS01MTYw_2f86666d-07d5-45f6-b074-2db69e2872e5">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2cf49ee253f4aa884cbc90462dfac03_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy05LTEtMS01MTYw_30085b6c-d75b-41d2-aea3-8156d521e950">202,276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f1b44d7eb742ad8b64d152e535816f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0xMS0xLTEtNTE2MA_20c8b522-29ee-4857-bef1-2b7f9c323514">177,790</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0xMy0xLTEtNTE2MA_780bd65d-c986-4125-96f6-37067199601a">24,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC0xLTEtMS01MTY4_43812fbb-5168-4abc-8b2e-de74335ce022">13,971,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC0zLTEtMS01MTcz_ca229cf6-82b3-43d8-8962-db880a134eda">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC05LTEtMS01MTc1_96e33f3d-f99d-4167-add6-4280329ed3e2">37,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC0xMy0xLTEtNTE3Nw_0a49c246-2716-4a0b-8880-0d1680320d8f">37,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="cerc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNS0xLTEtMS01MTU4_b1764741-8d44-4a4e-bf83-3ac2bcb4c3f7">128,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331" decimals="-3" name="cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNS05LTEtMS01MTU4_967714c4-f145-483b-b878-af19e630d631">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNS0xMy0xLTEtNTE1OA_1bdf02f4-1252-4271-8974-c3e2ed5ad0d9">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNi05LTEtMS01MTU4_3c3d4b5f-d54d-4057-91a8-aff62ebd2141">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNi0xMy0xLTEtNTE1OA_ee72faae-dd8d-44af-a953-14fe4481ebb1">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i690cbeed41364aeabc936a485830713d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNy0xMS0xLTEtNTE1OA_8cba46a3-c0ee-4e39-b53f-9628b36ad8a5">30,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNy0xMy0xLTEtNTE1OA_e61f3ee5-e0ed-4e78-b98a-3cc9ca235e34">30,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0527fb21cb6e422a81b0d2b896ce2a12_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0xLTEtMS01MTU4_1426d368-b90d-40be-a47a-2e1877579b6d">89,104,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0527fb21cb6e422a81b0d2b896ce2a12_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0zLTEtMS01MTU4_ff5e2612-c3b1-4429-82a3-8f8848961e08">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84b59ac211a5411c8a1466475097bdbd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC01LTEtMS01MTU4_8f0b1e90-1d01-4956-be14-bb194f93913b">1,257,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b59ac211a5411c8a1466475097bdbd_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC03LTEtMS01MTU4_6f65f118-a136-496c-b417-779cdf5815b6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1824d4fdd18644d08279a67df7329d8f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC05LTEtMS01MTU4_4efc1fd0-6e84-4d4c-b563-88484b2d3952">241,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief11578c5a3d4120889bfb43d5e8c59e_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0xMS0xLTEtNTE1OA_62d4b94d-b0d0-4832-a505-b67486255243">208,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0xMy0xLTEtNTE1OA_7898c5b7-b057-4aab-ac21-f5b6e095908e">33,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">equity </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f7f7fe58b1947a1af4d75615be3a866_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0xLTEtMS0w_ce938281-4e63-4f87-82a7-fcf88dcb899d">44,384,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7f7fe58b1947a1af4d75615be3a866_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0zLTEtMS0w_270b8122-c8c2-4ebb-8033-a8f6764b938f">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3698e2a15da04d2582ead896c9da1bdb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy01LTEtMS0w_fde048ad-18dd-4ede-9603-c57fbb81d7f8">2,857,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3698e2a15da04d2582ead896c9da1bdb_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy03LTEtMS0w_101a0a3e-9cfe-4769-a897-d61db0520b6c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8858464917a44129a19e5fd629e46e2a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy05LTEtMS0w_f749db90-818d-4154-94c8-c416441f5285">135,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5248b004c3024ef7844b36f897f76171_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0xMS0xLTEtMA_8a90961f-3028-4e2b-a747-0246fba74470">114,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbd4365662c24c30b28e21ce069efe37_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0xMy0xLTEtMA_ebc43e72-a80e-4c26-bbb1-92c7b11ac619">20,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0xLTEtMS0yNDg1_8573d531-4b29-45cc-9b4d-37ec11d8aa1b">8,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0zLTEtMS0yNDg1_4156bf63-5bb8-4313-8eb4-b04ef36b3317">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icc41f7eca88947c9a35e4be0dc501644_D20200101-20200331" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC01LTEtMS0yNDg5_3571d8dd-8277-4067-853d-0b1e214c8f5b">1,600,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc41f7eca88947c9a35e4be0dc501644_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC03LTEtMS0yNDg5_f075b8ad-0e34-48fc-a2f0-30b8fd52c45c">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC05LTEtMS0yNDg1_6e7bc185-d26a-4059-821c-b085da3baf5b">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0xMy0xLTEtMjQ4NQ_70d62690-6ccc-46c7-90d4-51e9a735575f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares related to Aevi Merger </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xLTEtMS0yNDg1_6878c079-38bd-46ca-88a6-9973f7b11e81">3,893,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0zLTEtMS0yNDg1_308acea9-1b87-4298-ab94-9ad852169c7c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS05LTEtMS0yNDg1_8d93ab15-5b53-4904-a409-4159d075cd04">15,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xMy0xLTEtMjQ4NQ_e6ab747d-926a-42bc-9cd6-bda457258856">15,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares pursuant to registered direct offering, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="cerc:IssuanceOfSharesSharePursuantToRegisteredDirectOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xLTEtMS0yNDg1_20b1a02e-c369-43ca-93c2-59b633ed827a">1,306,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="-3" name="cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0zLTEtMS0yNDg1_614714ec-af1b-4cd1-9dfd-fce19ea4fa17">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi05LTEtMS0yNDg1_8ef032e6-0a9f-4026-8266-510eacd05c22">5,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xMy0xLTEtMjQ4NQ_e69939e5-9dc2-41fd-a99a-d62f8ea8faa2">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares pursuant to common stock private placement, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="cerc:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy0xLTEtMS0yNDg1_b5ba4035-02a4-4331-a452-8fe1ea7f0336">1,951,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="-3" name="cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy0zLTEtMS0yNDg1_c0c52a67-176f-4b4f-a98c-8827eb0aaaae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy05LTEtMS0yNDg1_43e49205-a618-4119-9360-da72d81cedf7">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy0xMy0xLTEtMjQ4NQ_b7ffc2d8-3940-43e3-bc10-13f3eb55abde">3,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options and warrants </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="cerc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfOC0xLTEtMS0yNDg1_76c8c999-eda7-4939-a2a4-f11b5717380b">25,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331" decimals="-3" name="cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC05LTEtMS0w_8745f6ac-6451-41f7-9215-d30c86e501ca">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0xMy0xLTEtMA_72fa2019-ae19-4018-968c-4d4cd3d0d38f">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfOS05LTEtMS0yNDg3_4c9b0398-c0fb-4064-a743-a1b9630bc1e7">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfOS0xMy0xLTEtMjQ4Nw_60f3c792-63dc-4a99-8df9-a20d9f2055c8">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3aed8d010f6b4643ab5cf935d95e3ddb_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xMS0xLTEtMA_28edd4f3-c032-4df2-986a-7e4db354ae83">21,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xMy0xLTEtMA_f0634f12-e08b-4d7e-8445-2b762f6eab72">21,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5b1d9aca4484c4d8668324b0b5763d2_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xLTEtMS0w_dff3ffef-ceeb-43aa-b6a7-1198a0a1decb">59,560,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b1d9aca4484c4d8668324b0b5763d2_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0zLTEtMS0w_4e5f2160-b428-42e1-851c-a582cbf2981c">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i293bef8c2ab840b6bfc576a532a95a7e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi01LTEtMS0w_e767626e-0c8f-42a3-8648-e3f723b5f33b">1,257,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293bef8c2ab840b6bfc576a532a95a7e_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi03LTEtMS0w_c5d3a0e2-fc3b-441c-a5ec-190c55ddeec2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca7fddb46cc489688e478d5cee8ffe0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi05LTEtMS0w_dcb55d8f-78c3-48fb-8517-2819fbfcd539">160,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7acefac7b962485a8c15861ff10d0200_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xMS0xLTEtMA_8b40d2e3-91f2-4be1-aba0-fe5cd1d43ea4">135,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xMy0xLTEtMA_9b014c0c-431d-473f-ba50-6b411a6c1d45">25,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERECOR&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMy0yLTEtMS0w_96692009-5b79-421d-ab0e-178210f47a53">30,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMy00LTEtMS0w_1762d37c-33f4-425a-bf4c-fad6d726fd03">21,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNS0yLTEtMS0w_c5caf297-3e18-4666-8c97-f685364c4708">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNS00LTEtMS0w_2eb9a827-c0b7-4842-b02e-969ad61c6a94">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNy0yLTEtMS0w_665d1e99-5939-420d-a925-be8e63adb65d">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNy00LTEtMS0w_f61f8f35-3f7e-4773-bbc1-71ae6d3abc68">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development, including transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOC0yLTEtMS0w_0b59399e-f234-4073-9efa-9527be721ae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOC00LTEtMS0w_76ca9a67-892b-4c0a-8a28-ea5813597d45">25,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOS0yLTEtMS0w_119660d3-56af-49a5-8017-9c74e0b1b447">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOS00LTEtMS0w_cf884b2d-7099-4f5e-a571-81c72ace7ad9">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of Investment in Aytu</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTEtMi0xLTEtMA_df357639-cfa9-43eb-bf68-db81f34ec1a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTEtNC0xLTEtMA_b6912478-3db8-4634-8ffb-acf30e45badb">7,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTItMi0xLTEtMjc4_e213f011-5036-4fe1-93c5-fd4cd50fa93d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTItNC0xLTEtMjc4_b53498c0-f744-48a7-b3f9-94892c482559">1,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability and unit purchase option liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTMtMi0xLTEtMA_04a2e791-c0f6-426e-a08a-6f82e089b3ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" name="cerc:FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTMtNC0xLTEtMA_d9f4d9fc-a200-4e36-94c8-92e68e941ee2">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTYtMi0xLTEtMA_0f063c1f-848a-49ff-8505-03491c781858">953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTYtNC0xLTEtMA_dd20b427-644a-410e-9ccf-c66dea17a107">696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTctMi0xLTEtMA_8ceb14cf-65d1-4164-bd66-93516fc1ee0c">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTctNC0xLTEtMA_a9c3a6af-367a-4c99-a2c8-1268580e43f8">1,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTgtMi0xLTEtMA_0b208bb9-df3b-4749-b10d-49e46c9a711c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTgtNC0xLTEtMA_fa96c7c6-9e61-4185-be26-a79ff749b5dd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTktMi0xLTEtMA_f77b5af6-f371-497f-9521-e2b2202f056b">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTktNC0xLTEtMA_6a0b8ad3-69e9-43a4-b5b3-d7ac9150e777">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjAtMi0xLTEtMA_056c188e-375e-4609-84d9-d6da761bc29e">9,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjAtNC0xLTEtMA_b76952f3-26ed-4068-91d7-71a0e99d5cea">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjEtMi0xLTEtMA_1c0811b5-0eb4-4b6a-8893-7d92b412efb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjEtNC0xLTEtMA_cd4fc6c9-296c-4f56-8a4a-f8c845a0c302">551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjItMi0xLTEtMA_8a974e1e-7ffd-4b6d-9e52-408c52548665">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjItNC0xLTEtMA_48ac87f3-c088-4f65-9659-1ce432191bc2">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" name="cerc:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjQtMi0xLTEtMA_2a1d2d8d-e85e-4ee3-b880-367135c11ada">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="cerc:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjQtNC0xLTEtMA_aae93992-5bb8-4a85-96d3-139f17bc8bd1">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjUtMi0xLTEtMA_c4593d4c-d06c-44c9-9739-4a9a65a2a17f">18,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjUtNC0xLTEtMA_3030c5d1-864d-4610-905e-3e7f36f79a16">5,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in merger with Aevi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:PaymentsForAssetAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjgtMi0xLTEtMA_447dde79-cd2a-4d37-b548-a7eed57e5dac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:PaymentsForAssetAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjgtNC0xLTEtMA_23f123b6-2811-4b37-87cb-9e0ba3526ec2">1,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjktMi0xLTEtMA_f0e228c2-c5b2-42ba-b874-02ffa65beb33">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjktNC0xLTEtMA_85bf9d9a-dc27-4b61-a2a3-ca2862c759b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzAtMi0xLTEtMA_b4f8ad6a-31fe-469a-8374-dbba74a9f9dd">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzAtNC0xLTEtMA_39eaf5a2-61fb-449d-8eda-86dd80eb4fca">1,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and pre-funded warrants in underwritten public offering, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="cerc:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzItMi0xLTEtMA_1f405b95-7a30-4b4c-99c7-185dd4099439">37,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="cerc:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzItNC0xLTEtMA_fa9272b5-5f34-44ac-b18c-6347f495d8eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from registered direct offering, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:ProceedsFromRegisteredDirectOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzMtMi0xLTEtMA_ab5e2ab4-47b2-46fe-8c17-cfe2de987535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:ProceedsFromRegisteredDirectOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzMtNC0xLTEtMA_a6db07ba-3342-4e69-958f-a0af44bec625">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of shares pursuant to common stock private placement, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzQtMi0xLTEtMA_01e07918-2670-4b8c-a3a5-e526c935befb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzQtNC0xLTEtMA_66970af9-dc09-45ec-aae3-a62209aeb5dc">3,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="cerc:ProceedsFromOptionOrWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzUtMi0xLTEtMA_e454466c-8aca-4c23-be40-67906c74cbde">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="cerc:ProceedsFromOptionOrWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzUtNC0xLTEtMA_9af9b646-c77d-4613-b466-df6f3c7fbb88">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDAtMi0xLTEtMA_fb3cdc63-88b9-4475-8d35-bcc1a7617a37">37,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDAtNC0xLTEtMA_02209069-5976-4f23-9e19-9dcbba62136f">9,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDEtMi0xLTEtMA_1089ec6e-54c7-4e28-903c-a7f46c46eba3">19,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDEtNC0xLTEtMA_69847ca8-7c38-4f12-9a3e-a516ca133c00">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDItMi0xLTEtMA_c9bb3b97-3468-4da7-b55c-cbaf624b0d11">19,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbd4365662c24c30b28e21ce069efe37_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDItNC0xLTEtMA_dd86c64e-15fd-49d4-b8ec-c3cd35f160fa">3,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDMtMi0xLTEtMA_804034aa-8cc1-4b88-a727-8523b531db89">38,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDMtNC0xLTEtMA_48e38221-e838-46fb-a44b-38b5638d94ab">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDYtMi0xLTEtMA_156ede2c-a639-4e1b-baec-ce7a0a24cdfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDYtNC0xLTEtMA_a5c49a79-f004-4ea5-ab98-01125396df6e">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in Aevi Merger</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDgtMi0xLTEtMA_cd76de10-8442-49af-81b7-f079a7e3bb61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDgtNC0xLTEtMA_74fb3fed-ae58-46c0-baa8-2f7bc59fd6f3">15,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfMy0yLTEtMS0w_8a950d83-195a-4acb-9ede-e3d38995a51c">38,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfMy00LTEtMS0w_d2b6b665-681f-4e0f-9398-39de1a5b9805">5,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNC0yLTEtMS0w_2d8c2550-b93f-4246-887e-a715f57732f4">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNC00LTEtMS0w_39c96523-da41-4dad-888e-d48f2b45e0e0">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNS0yLTEtMS0w_c509aa71-f1c3-4b13-91c7-fbd7c7a932d3">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNS00LTEtMS0w_410fa61c-7962-42a7-b071-0947236dc69f">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNi0yLTEtMS0w_33eda749-a58a-4f17-9117-c82c5c77960e">38,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNi00LTEtMS0w_62ddaa6e-7286-42e8-8286-fee312b74956">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERECOR&#160;INC. and SUBSIDIARIES</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_31"></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNzA5OA_448e783c-c36f-4292-b4b2-2f1fa67462af" continuedAt="i875592c74eb2418cae5e3d119f799b8e" escape="true">Business </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i875592c74eb2418cae5e3d119f799b8e" continuedAt="i2bb322d2e5ec4664a3f73eac41d2087d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cerecor Inc. (the &#8220;Company&#8221; or &#8220;Cerecor&#8221;) is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases. The Company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company&#8217;s rare disease pipeline includes CERC-801, CERC-802 and CERC-803 (&#8220;CERC-800 compounds&#8221;), which are in development for therapies for congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor in development for the treatment of complex lymphatic malformations. The Company is also developing <ix:nonFraction unitRef="product" contextRef="i628f57f6215a46b79ad5e7d53f734b1a_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:NumberOfProductsDeveloped" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDk0NzgwMjM0Njk5Mw_fa49fc62-8b5c-402d-abd0-3f611f688948">two</ix:nonFraction> monoclonal antibodies, CERC-002 and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for the treatment of severe pediatric-onset Crohn&#8217;s disease and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still&#8217;s disease (adult onset Still&#8217;s disease and systemic juvenile idiopathic arthritis) and multiple myeloma. CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all <ix:nonFraction unitRef="product" contextRef="iec8d13d67faf489fa328978709bcf27a_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:NumberOfProductsDeveloped" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDk0NzgwMjM0Njk5Ng_3cc27e2b-0612-4867-98ec-ae4f1ef1acba">four</ix:nonFraction> eligible for a priority review voucher (&#8220;PRV&#8221;) upon approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company continues to explore strategic alternatives for its non-core assets, including its commercialized product, Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, and for its neurology pipeline assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cerecor was incorporated and commenced operation in 2011 and completed its initial public offering in October 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i7e92ff68bdc846f39796a8688fdb85c6_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNTQ5NzU1ODE2MDc2Nw_73cdf724-1ce1-473b-9d10-695a37805515">13,971,889</ix:nonFraction> shares of its common stock and <ix:nonFraction unitRef="shares" contextRef="i2d9f33420b794d6b82ec040bbdcda9ac_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNTQ5NzU1ODE2MDc5MA_92fa76f7-4cf7-4650-abd5-9cb8459bb84e">1,676,923</ix:nonFraction> pre-funded warrants for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNTQ5NzU1ODE2MDgwMQ_957ae941-b933-45f1-a082-60b684ede504">37.7</ix:nonFraction>&#160;million (see Note 9 for additional information). As of March 31, 2021, Cerecor had $<ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDk0NzgwMjM0OTEwMQ_3d4ce3ae-7a08-4f87-acf6-96af47caa56f">38.3</ix:nonFraction>&#160;million in cash and cash equivalents. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company&#8217;s resources between investing in the Company&#8217;s existing pipeline assets and acquisitions or in-licensing of new assets. For the three months ended March 31, 2021, Cerecor generated a net loss of $<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfMzg5OA_505e853a-deca-4ffe-b4e4-43d9e7cdfaab">30.7</ix:nonFraction>&#160;million and negative cash flows from operations of $<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfMzk0NA_bce31e4b-9532-40bf-b1c2-e27cc33b12d7">18.3</ix:nonFraction>&#160;million. As of March 31, 2021, Cerecor had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDAxMw_fa08797f-a851-4e38-9915-0dd0f214eeac">208.5</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its core research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy at least one year after the date the condensed consolidated financial statements included herein were issued. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate these conditions and to meet the Company&#8217;s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive financings, (ii) federal and/or private grants, (iii) other out-licensing or strategic alliances/collaborations of its current pipeline assets, and (iv) out-licensing or sale of its non-core assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report were issued. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bb322d2e5ec4664a3f73eac41d2087d">Over the long term, the Company&#8217;s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any PRVs it receives.</ix:continuation> </span></div><div><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_34"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNC9mcmFnOjRiZWQ3M2IwZjJiZDRjODU5ZmM4MGY3YzY3NThiYzExL3RleHRyZWdpb246NGJlZDczYjBmMmJkNGM4NTlmYzgwZjdjNjc1OGJjMTFfNjgyNg_5c1b194f-6cb2-4a31-8149-b61e70c17197" continuedAt="ibdc31440ba2b40b8bcb06bdaf5b9fa51" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibdc31440ba2b40b8bcb06bdaf5b9fa51" continuedAt="icf44c409275b43348a4df3cf6319fef6">&#160;</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="icf44c409275b43348a4df3cf6319fef6"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNC9mcmFnOjRiZWQ3M2IwZjJiZDRjODU5ZmM4MGY3YzY3NThiYzExL3RleHRyZWdpb246NGJlZDczYjBmMmJkNGM4NTlmYzgwZjdjNjc1OGJjMTFfNjgwNA_2f55fef4-f840-4475-863b-cc07db54d01d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2020 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2020 audited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, there were no significant changes to the Company&#8217;s summary of significant accounting policies contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 8, 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfOTM1NQ_e121e825-a586-43c2-b20c-35f169b60b42" continuedAt="i82c51e793a29498fbb8552392c6251d8" escape="true">Aytu Divestiture</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i82c51e793a29498fbb8552392c6251d8" continuedAt="icf4b6c165cbb40fdbde0419b5bc5c1da"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Sale of Pediatric Portfolio and Related Commercial Infrastructure to Aytu BioScience</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company closed on an asset purchase agreement to sell the Company&#8217;s rights, title and interest in assets relating to certain commercialized products (the &#8220;Pediatric Portfolio&#8221;) and the corresponding commercial infrastructure to Aytu BioScience, Inc. (&#8220;Aytu&#8221;). Aytu paid consideration of $<ix:nonFraction unitRef="usd" contextRef="icb32bfec45e942d4a910555a806195f9_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2NTE4Mg_a480395e-cf9d-488d-aadf-1e9d89dbcedf">4.5</ix:nonFraction>&#160;million in cash and approximately <ix:nonFraction unitRef="shares" contextRef="i5a0d41b8169040d484988356bf9f4cdb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2NTE4NA_8ba051a5-d1e3-4554-98f1-92bdc30395fa">9.8</ix:nonFraction>&#160;million shares of Aytu convertible preferred stock, and assumed certain of the Company&#8217;s liabilities, including the Company&#8217;s payment obligations to Deerfield CSF, LLC (&#8220;Deerfield&#8221;) and certain other liabilities primarily related to contingent consideration and sales returns. Steve Boyd, Chief Investment Officer of Armistice Capital, LLC, a significant stockholder of the Company, serves on each company&#8217;s board of directors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cerecor retains all rights to Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to a transition services agreement entered into between Aytu and Cerecor upon the divestiture close date, Aytu managed Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial operations for <ix:nonNumeric contextRef="i66052a9dae424dca80a7f82db41f4f83_D20190101-20191231" format="ixt-sec:durmonth" name="cerc:MonthlyOperationPaymentsTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfMTg0OQ_5ce5e6f3-6c1f-4e1f-bfe9-952cc60c3af2">18</ix:nonNumeric> months (post November 1, 2019). In May 2021, the Company entered into an amended transition services agreement in which Aytu will continue to manage Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s commercial operations for an additional <ix:nonNumeric contextRef="i625aa7d5128448528ad08b7663090142_D20210501-20210506" format="ixt-sec:durwordsen" name="cerc:MonthlyOperationPaymentsAdditionalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2NTIwNQ_ef92713f-8c1e-44ca-a236-fbfb670ede98">two months</ix:nonNumeric>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the sale of the Pediatric Portfolio to Aytu, the Pediatric Portfolio met all conditions to be classified as discontinued operations.  Therefore, the accompanying condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and as of December 31, 2020 reflect the operations, net of taxes, and related assets and liabilities of the Pediatric Portfolio as  discontinued operations. Refer to the &#8220;Discontinued Operations&#8221; section below for more information, including Cerecor&#8217;s continuing involvement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Guarantee </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the closing date of the Aytu Divestiture on November 1, 2019, Aytu assumed the Company&#8217;s debt obligation to Deerfield and the contingent consideration liability related to future royalties on Avadel Pharmaceuticals PLC&#8217;s (&#8220;Avadel&#8221;) pediatric products. In conjunction with the closing of this transaction, the Company entered into a guarantee in favor of Deerfield, which guarantees the payment of the assumed liabilities to Deerfield, which included the debt obligation and includes the contingent consideration related to future royalties on Avadel&#8217;s pediatric products (collectively referred to as the &#8220;Guarantee&#8221;).   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aytu publicly reported that it had paid the $<ix:nonFraction unitRef="usd" contextRef="i1a2b8460cb924cb9b2aea21da6564fbf_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfMzU3MQ_237cc7ee-2a0a-417f-a13c-992a9c56a31c">15.0</ix:nonFraction>&#160;million balloon payment to Deerfield before it came due in June 2020 and the fixed monthly payments to Deerfield ended in January 2021, thus satisfying the debt obligation. Of the contingent consideration, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="icf4b6c165cbb40fdbde0419b5bc5c1da" continuedAt="iff412859eca44539bc7e6007ae42f29a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="id606c2359deb445f9a0a8ae38b02ddb5_D20190101-20191031" decimals="-5" format="ixt:numdotdecimal" name="cerc:DebtInstrumentContingentConsiderationPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ1MA_525e4732-312a-4c58-8609-55caff2ccbf5">3.2</ix:nonFraction>&#160;million was paid to Deerfield prior to the Aytu Divestiture and therefore, as of November 1, 2019, Aytu was responsible for the remaining $<ix:nonFraction unitRef="usd" contextRef="i0e29f50e08944917829774bcbe7aff76_I20191101" decimals="-5" format="ixt:numdotdecimal" name="cerc:DebtInstrumentRemainingContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ2NA_76e9d99b-d554-41ab-b2e6-8ca876ff9142">9.3</ix:nonFraction>&#160;million. Aytu is required to pay an amount equal to at least $<ix:nonFraction unitRef="usd" contextRef="iec26640aabfa4148bdbe5fd031d0b667_D20191101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ3OA_b3d917b8-0125-44dd-a744-5aa0b4c70950">0.1</ix:nonFraction>&#160;million per month. Cerecor&#8217;s Guarantee will end upon the earlier of (i) February 5, 2026, or (ii) upon $<ix:nonFraction unitRef="usd" contextRef="i763dfef39718433ead8376b849f71b21_I20191101" decimals="-5" format="ixt:numdotdecimal" name="cerc:DebtInstrumentFutureAggregateDeferredPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ5Mg_41ca1177-afa2-434a-b6fb-27de9803c8f8">12.5</ix:nonFraction>&#160;million in aggregate deferred payments has been paid to Deerfield. Cerecor is required to make a payment under the Guarantee upon demand by Deerfield if all or any part of the fixed payments and/or deferred payments are not paid by Aytu when due or upon breach of a covenant. The remaining minimum commitments payable as most recently publicly reported by Aytu was $<ix:nonFraction unitRef="usd" contextRef="i7d85ed913ebe404ab54475135f67de89_I20200630" decimals="-5" format="ixt:numdotdecimal" name="cerc:DebtInstrumentRemainingContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDUwNw_86b3b5b6-6064-4db8-89d6-b5e735d0561b">7.3</ix:nonFraction>&#160;million as of June 30, 2020, which represents Cerecor&#8217;s estimated maximum potential future payments under the Guarantee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Guarantee, which relates to the Company&#8217;s obligation to make future payments if Aytu defaults, was determined at the time of the Aytu Divestiture as the difference between (i) the estimated fair value of the assumed payments using Cerecor&#8217;s estimated cost of debt and (ii) the estimated fair value of the assumed payments using Aytu&#8217;s estimated cost of debt. Subsequent to the close of the Aytu Divestiture, at each reporting period, the value of the Guarantee is determined based on the expected credit loss of the Guarantee with changes recorded in (loss) income from discontinued operations, net of tax within the consolidated statements of operations and comprehensive loss. We considered key drivers of cost of debt both at Aytu and Cerecor, including but not limited to, recent financings, cash position, operating cash flows and trends and Aytu&#8217;s ability to meet its financial commitments. Based on these facts, the Company concluded that the expected credit loss of the Guarantee was de minimis as of March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfOTM1Ng_8be03e11-5872-46bd-8847-78f7e468dfce" continuedAt="i84e6d5963a814e0f984ba8d0e943f20c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the liabilities of the discontinued operations as of March 31, 2021 and December 31, 2020 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5751c8b6986481696dc10ecdf31864b_I20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTAtMi0xLTEtMA_55c8572b-34b7-454d-9bd1-d72cc386cae0">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc1c0e3c3fc4ff5b491ac78fb641632_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTAtNC0xLTEtMA_c7228248-5465-47dd-90f0-c919052c1b86">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5751c8b6986481696dc10ecdf31864b_I20210331" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTEtMi0xLTEtMA_36456d8c-25a1-492d-9e18-dadb2bdc80de">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc1c0e3c3fc4ff5b491ac78fb641632_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTEtNC0xLTEtMA_5edf3816-6505-4541-b524-ac3323e77bc4">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 related to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed&#160;$<ix:nonFraction unitRef="usd" contextRef="i99b8c7fd991847e8837bd5a30646756a_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzIzNA_931a5a8f-0907-4a3b-892e-801ebbe2a91f">2.0</ix:nonFraction> million&#160;and are less than&#160;$<ix:nonFraction unitRef="usd" contextRef="if834bd2acf0f4a6cbbc998c9d3a0ec9d_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzI1NQ_7e17db09-cec9-46be-b0b0-1927a78f7fde">2.8</ix:nonFraction> million&#160;(in other words, Aytu will only assume $<ix:nonFraction unitRef="usd" contextRef="i0c24c03ec1214b87aa2626d83a326856_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzI5Nw_3a55d0fa-876e-46f7-bc1e-d12340851495">0.8</ix:nonFraction> million of such returns). Therefore, Cerecor is liable for future sales returns of the Pediatric Portfolio sold prior to November 1, 2019 in excess of the $<ix:nonFraction unitRef="usd" contextRef="i0c24c03ec1214b87aa2626d83a326856_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzQ0OA_24a95818-89f7-44d0-8de4-81842da2458d">0.8</ix:nonFraction> million assumed by Aytu. As of March 31, 2021, the Company estimated future returns on sales of the Pediatric Portfolio made prior to the transaction close date to be $<ix:nonFraction unitRef="usd" contextRef="if5751c8b6986481696dc10ecdf31864b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDUyMQ_6ae96b2a-1831-481b-9090-c7540b6ee79f">0.2</ix:nonFraction>&#160;million, which was recognized within accrued expenses and other current liabilities from discontinued operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s estimate of sales returns related to the Pediatric Portfolio is included within discontinued operations on the statement of operations and comprehensive loss and is shown within product revenue, net in the table summarizing the results of discontinued operations below.  In future periods, as additional information becomes available, the Company expects to recognize expense (or a benefit) related to actual sales returns of the Pediatric Portfolio in excess (or less than) the returns reserve recorded, which will be recognized within discontinued operations. The Company expects this involvement to continue until sales returns are no longer accepted on sales of the Pediatric Portfolio made prior to November 1, 2019, which in line with the products&#8217; return policies, returns on these products may be accepted through the second quarter of 2022.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84e6d5963a814e0f984ba8d0e943f20c" continuedAt="i5afdd7ede38d40829f2f22a6f1f4e732">The following table summarizes the results of discontinued operations for the three months ended March 31, 2021 and 2020 (in thousands): </ix:continuation></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="iff412859eca44539bc7e6007ae42f29a"><ix:continuation id="i5afdd7ede38d40829f2f22a6f1f4e732"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMy0yLTEtMS0w_29bc8c45-6f89-4633-aa04-27c5d090961c">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMy00LTEtMS0w_c67a82ec-a75c-4837-942d-74bb7b4d6447">717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNS0yLTEtMS04ODEz_91480f6a-f019-4bc9-ad5e-3fc9d4683668">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNS00LTEtMS04ODEz_95b7f7cc-9a63-4689-aff8-9d6222d8d2a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNi0yLTEtMS04ODEx_a4a02a49-8bb8-4875-80a5-dc9156318bce">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNi00LTEtMS04ODEx_defe751b-4002-423b-b9ae-9e020eac85cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTQtMi0xLTEtMA_a482e17d-2d8a-4143-aadc-1a5cc02ea861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTQtNC0xLTEtMA_22b40548-c824-4ed0-b65c-7b1e7966170a">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTYtMi0xLTEtMA_e13ecea6-60d8-45e1-812b-29463945a50b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTYtNC0xLTEtMA_7b11c4d4-513e-4ac3-bf77-714c3c7f4fa8">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTctMi0xLTEtMA_17d1a532-5ce3-4074-8a53-73012572222f">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTctNC0xLTEtMA_c1ee367b-332d-4d71-b76b-d31ecd43f8a8">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no non-cash operating items from discontinued operations for the three months ended March 31, 2021 and no non-cash investing items from the discontinued operations for the three months ended March 31, 2021 and 2020. The significant non-cash operating item from the discontinued operations for the three months ended March 31, 2020 is contained below (in thousands). </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmE5MjYyMTRhZTBiMTRhMmJiMmJmZGI4MzYzMDUxN2I1L3RhYmxlcmFuZ2U6YTkyNjIxNGFlMGIxNGEyYmIyYmZkYjgzNjMwNTE3YjVfNy0yLTEtMS0w_2041c2c4-a820-4ace-b34b-63900863173e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmE5MjYyMTRhZTBiMTRhMmJiMmJmZGI4MzYzMDUxN2I1L3RhYmxlcmFuZ2U6YTkyNjIxNGFlMGIxNGEyYmIyYmZkYjgzNjMwNTE3YjVfNy00LTEtMS0w_7aecad03-b88f-471e-b73a-13c7306bf8b8">1,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfMjMyNA_60bf368f-073d-483b-afd6-b978965c323c" continuedAt="i58ed9d1ed33144f1b94344f1a717e6ee" escape="true">Revenue</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i58ed9d1ed33144f1b94344f1a717e6ee"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates substantially all of its revenue from sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, which is considered a prescription drug. The Company sells its prescription drug in the United States primarily through wholesale distributors and specialty contracted pharmacies. Wholesale distributors account for substantially all of the Company&#8217;s net product revenues and trade receivables. The Company also earns revenue from sales of its prescription drug directly to retail pharmacies. For the three months ended March 31, 2021, the Company&#8217;s three largest customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="icf18c62a06294fc58da61652b71d9234_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0Nzg1Mw_d94d776b-9555-4cbd-9a25-6c2f9dc297e1">67</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i927b204af3c04c0bbd2188ed6a3eb0cf_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0Nzg1OA_779821f4-f186-4d98-bf13-78e12ecefd41">18</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i15c7116f8756475caf3bf460b774b112_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0Nzg2Mw_6c9b315b-dc71-40b0-acff-09ba819acfe6">15</ix:nonFraction>% of the Company&#8217;s total net product revenues from sale of prescription drugs from continuing operations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license and supply agreement for the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;), which expires on September 30, 2023. As part of a prior amendment to extend the contract to its current term, Cerecor agreed to pay Teva <ix:nonFraction unitRef="number" contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401" decimals="2" format="ixt-sec:numwordsen" name="cerc:LicenseAgreementPercentOfNetProfitForInstallmentPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDMxMw_09761cb4-adbd-49b0-9cac-7e20b609d5f0">fifty</ix:nonFraction> percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $<ix:nonFraction unitRef="usd" contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementInstallmentPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDI3Mg_5ab2dd0b-c712-4e83-959e-d328c3b4963c">0.5</ix:nonFraction>&#160;million quarterly minimum payment, which was set to begin on April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#8217;s board of directors and also serves as the Chairman of Teva&#8217;s board of directors.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of prescription drugs was $<ix:nonFraction unitRef="usd" contextRef="i66f50cdd8bac484bb18c5e75cf2515ca_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDI4Ng_e6423489-3f49-4462-9277-1b336e65bb3b">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6051bdc503c644b88a48cbfbf8982a59_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDMwMA_989dc130-f7f3-4a05-bf76-76394db0019a">2.8</ix:nonFraction>&#160;million for the three months ended March 31, 2021 and 2020, respectively. During the first quarter of 2021, the Company&#8217;s inventory on hand became short-dated (which the Company considers inventory within <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:durwordsen" name="cerc:InventoryPeriodBeforeExpiration" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNDk0NzgwMjMzNDU4OQ_09c2184c-7d36-4c08-b513-cfc88b8a433f">six months</ix:nonNumeric> of expiration) due to manufacturing delays. The Company recorded a full allowance of $<ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0ODQ2MA_f1c3d9d8-fb35-49db-a123-0607efca78b7">2.9</ix:nonFraction>&#160;million for returns on the sale of short-dated inventory given the high likelihood of return. The Company received the delayed inventory lot in April 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzA0NQ_3e2dd843-4de0-486c-b98c-7d5da66cffa5" continuedAt="i9cf41a256bda4c548002f2389fd36c3f" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9cf41a256bda4c548002f2389fd36c3f" continuedAt="i6546897f019a4295a6a9352e4f030173"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes earnings per share (&#8220;EPS&#8221;) using the two-class method. The two-class method of computing EPS is an earnings allocation formula that determines EPS for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="class_of_stock" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:ClassOfStockNumberOfClassesOfStockOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNDk0NzgwMjMzMzY1Nw_98ffdf0d-a6ea-4f69-a77e-7473fc4d6611">two</ix:nonFraction> classes of stock outstanding, common stock and preferred stock. The preferred stock outstanding as of March 31, 2021 has the same rights and preferences as the Company&#8217;s common stock, other than being non-voting, and is convertible into shares of common stock on a 1-for-5 ratio.  Under the two-class method, the convertible preferred stock is considered a separate class of stock for EPS purposes and therefore basic and diluted EPS is provided below for both common stock and preferred stock. In April 2021, Armistice Capital Master Fund Ltd. (an affiliate of Armistice Capital, LLC and collectively &#8220;Armistice&#8221;), which is a significant </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i6546897f019a4295a6a9352e4f030173" continuedAt="i8562522bddf1489aaf9099277e8a70e8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, converted the remaining <ix:nonFraction unitRef="shares" contextRef="i014f146895fb4927a75a9cdec07aaa18_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNTQ5NzU1ODE0Njc0NA_d76b7444-2ae3-4c55-9d76-a3a5689851c4">1,257,143</ix:nonFraction> shares of convertible preferred stock into <ix:nonFraction unitRef="shares" contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNTQ5NzU1ODE0Njc1NQ_6f26535c-ecc3-44ad-bf37-67dae6238d89">6,285,715</ix:nonFraction> shares of Cerecor&#8217;s common stock. Refer to Note 9 for more information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS for common stock and EPS for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. In applying the two-class method, undistributed earnings are allocated to common stock and preferred stock based on the weighted average shares outstanding during the period, which assumes the convertible preferred stock has been converted to common stock. The weighted average number of common shares outstanding as of March 31, 2021 includes the weighted average effect of the pre-funded warrants issued in connection with the January 2021 underwritten public offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock (refer to Note 9 for more information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net (loss) income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the &#8220;treasury stock method&#8221; when dilutive; and (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the &#8220;treasury stock method&#8221; when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company&#8217;s losses.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzA0Mg_641f69b2-f14d-484a-932e-8d8f41e0a910" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net (loss) income per share of common stock and preferred stock for the three months ended March 31, 2021 and 2020 (in thousands, except share and per share amounts):&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"><tr><td style="width:1.0%"></td><td style="width:45.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS0yLTEtMS0w_6e3b38d5-1c98-436f-bbd3-19f2cf9698bf">28,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS00LTEtMS0w_5115eb30-8418-4a39-bbf2-e1752b8e84fd">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS02LTEtMS0w_a6c59989-60fa-47fd-8d58-624e7394e0a3">2,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS04LTEtMS0w_481cee85-2265-4de0-9aa5-d626d39f9e9a">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy0yLTEtMS0w_1704d63a-0de1-4301-b7c8-9d5a305ced05"><ix:nonFraction unitRef="shares" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy0yLTEtMS0w_5f6651f0-5953-4728-9059-7ea1b4f264d0">88,576,559</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy00LTEtMS0w_2d1d0d48-dbc4-48c3-94dc-21397dfb74de"><ix:nonFraction unitRef="shares" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy00LTEtMS0w_91867ca1-2e4a-436e-9f06-8a3166a48031">88,576,559</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy02LTEtMS0w_4314b865-0f8d-4dff-ae49-aa0e5275325f"><ix:nonFraction unitRef="shares" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy02LTEtMS0w_bdb1ec35-e733-4309-813f-6583442bb215">1,257,143</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy04LTEtMS0w_2e17e817-938b-4745-9925-a44bd5e962e3"><ix:nonFraction unitRef="shares" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy04LTEtMS0w_c9664b7e-5ea2-405e-949d-5b7bbc3a6d2b">1,257,143</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC0yLTEtMS0w_2011e9a7-a1b4-4ec9-a376-7d71eb007b8f"><ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC0yLTEtMS0w_70792f2e-a14e-4f05-b1eb-e27b1807480a">0.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC00LTEtMS0w_79936e63-aab8-4e8c-a642-8588543acc53"><ix:nonFraction unitRef="usdPerShare" contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC00LTEtMS0w_7a78a974-54b1-4f2f-ba60-968d0be438c0">0.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC02LTEtMS0w_0bc9d3d8-7dc2-4da9-8f22-94057e57e560"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC02LTEtMS0w_269cedb8-247b-497b-b72a-a5f11ca3740b"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC02LTEtMS0w_d4ee7f77-e951-4d31-9d91-96f549d58e4d">1.61</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC04LTEtMS0w_6e121168-330f-460d-a4eb-d1a06c39d982"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC04LTEtMS0w_95f19155-c0f7-4a98-bc60-4eb65bb24ec3"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331" decimals="2" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC04LTEtMS0w_c5597371-6a5c-4270-ace3-122912449367">0.01</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"><tr><td style="width:1.0%"></td><td style="width:45.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS0yLTEtMS0w_096a2327-7b0b-4950-8f18-b0eebb4def5b">19,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="-3" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS00LTEtMS0w_faaa0990-671d-4f69-bfd8-311a3c2dc0d2">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS02LTEtMS0w_9a28ce45-d0a0-4ff6-a97a-e8bd0994b454">2,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="-3" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS04LTEtMS0w_b15c50e2-5eb0-4d47-b811-bbf45405496d">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy0yLTEtMS0w_4d5d8ecb-5307-46cc-bfb7-bdf73ba8cf14"><ix:nonFraction unitRef="shares" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy0yLTEtMS0w_5c7d1bf0-5055-4770-b9e9-93c0cec87402">53,934,760</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy00LTEtMS0w_19bc7312-8adc-437a-b772-4b043d841d89"><ix:nonFraction unitRef="shares" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy00LTEtMS0w_659efc54-192a-4a9c-a70d-33110ba7b07b">53,934,760</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy02LTEtMS0w_19813e7b-7684-4fba-bf6c-4f50dd863671"><ix:nonFraction unitRef="shares" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy02LTEtMS0w_743556cd-3746-4ad1-8ce0-2d87bb3e1ef5">1,657,143</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy04LTEtMS0w_3c4890fd-307e-4eed-b32d-b7a62ae233c5"><ix:nonFraction unitRef="shares" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy04LTEtMS0w_5da18fc4-3cbb-4265-8a1e-fc3eba7585b6">1,657,143</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC0yLTEtMS0w_b6e10e14-88f3-4466-9df8-37c34821dc33"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC0yLTEtMS0w_dc010ad0-0e53-47b3-993d-9162c8118f37">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC00LTEtMS0w_10e77e86-f50b-41d2-92cc-63a9327357b9"><ix:nonFraction unitRef="usdPerShare" contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC00LTEtMS0w_42cfb0c1-97da-4558-b849-08b79f3ff884">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC02LTEtMS0w_53049003-d4da-4099-b8e0-acb1b98fad9d"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC02LTEtMS0w_6491b092-cfd9-441c-9567-ddc97afc09b5"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC02LTEtMS0w_b70cc2fa-183d-4310-a30a-6a5b5aba53be">1.78</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC04LTEtMS0w_ab867d2e-aca4-4f6f-8854-2133be067c12"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC04LTEtMS0w_eec64f17-803d-41c7-b21f-a8c1dffa814b"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC04LTEtMS0w_fde5db28-6897-4e9f-8045-564bf481263e">0.08</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzAzOQ_04d2b70f-04a0-4a80-9ff7-b98f172c5f5f" continuedAt="ic20e4812e04046568b6d3dface225196" escape="true"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzA1MA_941d80a5-c751-49c7-8381-b5285e270c57" continuedAt="i78285bccea524c80b2be6c4582257b5e" escape="true">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March&#160;31, 2021 and 2020, as they could have been anti-dilutive:&#160;</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><ix:continuation id="i8562522bddf1489aaf9099277e8a70e8" continuedAt="ie4ae74e07931423b8ee3a96136ef3e32"><ix:continuation id="ic20e4812e04046568b6d3dface225196" continuedAt="iafb98bf7d40e473faac9f576a50cd258"><ix:continuation id="i78285bccea524c80b2be6c4582257b5e" continuedAt="i1fda5e88723c4b42a3314e8eee16aa20"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2105f80d294440588767dee094560b3_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfMy0yLTEtMS0w_a39b7a32-2351-4ea5-b130-997ea308bc78">12,944,891</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i629fbb798db048ea9b95506876d74823_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfMy00LTEtMS0w_ce4095fe-01cb-46af-85bc-534cb0477b72">7,712,680</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants on common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3df572689a424ea28bc48c6a42dbc0bc_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNC0yLTEtMS0w_a57eaaa1-f85a-43e9-ade7-acc9cbdf8f23">4,002,380</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id922871740784b9b88673ef935b11162_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNC00LTEtMS0w_3f7c0213-95ec-4383-b035-e26101de94ee">4,024,708</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9167fb87d13406f85d22cdf0ee9c556_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNS0yLTEtMS0w_7f37fff6-a473-48fe-b940-99cb4347878e">155,833</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb2884fecf704a3ab359a11213837e2f_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNS00LTEtMS0w_65b25185-3980-49bd-9bc3-61d4917471b0">267,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underwriters&#8217; unit purchase option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53a62490f94c4f49b56fb7acc1da3613_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNi0yLTEtMS0yNTcz_623a3d27-aff3-48f7-850a-c75aeea37165">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e8caa450d984e75b7af9b3d66541996_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNi00LTEtMS0yNTcz_f1041bac-a286-49d8-b6ef-1ab6902e3a7f">40,000</ix:nonFraction></span></td></tr></table></ix:continuation></ix:continuation></ix:continuation></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ie4ae74e07931423b8ee3a96136ef3e32" continuedAt="i59ae973232dd4050a459a2e702988992"><ix:continuation id="iafb98bf7d40e473faac9f576a50cd258" continuedAt="i23fea07fddee44fcaff6d087f94bebb8"><ix:continuation id="i1fda5e88723c4b42a3314e8eee16aa20" continuedAt="i5c5f9a21d706478294ed1f53864090eb">1 </ix:continuation></ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i59ae973232dd4050a459a2e702988992"><ix:continuation id="i23fea07fddee44fcaff6d087f94bebb8"><ix:continuation id="i5c5f9a21d706478294ed1f53864090eb">The above table excludes <ix:nonFraction unitRef="shares" contextRef="i50329ad27a3d4d858d5e36be03888359_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNDk0NzgwMjMzMzI1OQ_de258652-7fa5-4c48-b693-f782970abea9">1,676,923</ix:nonFraction> pre-funded warrants. See the &#8220;Q1 2021 Financing&#8221; in Note 9 for more information.</ix:continuation></ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="cerc:AssetAcquisitionDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNDU2Ng_08c0837f-9796-4b23-a77d-4a42be12017d" continuedAt="i59ec55fa173241ba89c0797d439efb6d" escape="true">Asset Acquisition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i59ec55fa173241ba89c0797d439efb6d" continuedAt="ia0f0498340424670a2078aa30e95b1d8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company consummated its merger with Aevi Genomic Medicine Inc. (&#8220;Aevi&#8221;), in which Cerecor acquired the rights to CERC-002, CERC-006 and CERC-007 (the &#8220;Merger&#8221; or the &#8220;Aevi Merger&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger consideration included (i) stock valued at approximately $<ix:nonFraction unitRef="usd" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfMjA5NQ_b0b85f74-ce18-4c5e-a3c6-122289111d1d">15.5</ix:nonFraction> million, resulting in the issuance of approximately <ix:nonFraction unitRef="shares" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM0NA_8a0a97e4-9a08-4813-b97c-f5583bad1f6d">3.9</ix:nonFraction>&#160;million shares of Cerecor common stock to Aevi stockholders, (ii) forgiveness of $<ix:nonFraction unitRef="usd" contextRef="idc103a37d52c4b8d9aab7c7d78bd8dab_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM1Nw_d4067cc5-e0f1-4d0d-ac9d-38a801cebac6">4.1</ix:nonFraction>&#160;million the Company had loaned Aevi prior to the Merger closing, (iii) contingent value rights for up to an additional $<ix:nonFraction unitRef="usd" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM3MQ_b211ff25-3f15-4674-9ee0-14ab9687f213">6.5</ix:nonFraction>&#160;million in subsequent payments based on certain development milestones (discussed further in Note 13), and (iv) transaction costs of $<ix:nonFraction unitRef="usd" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM4NQ_388ae954-a10c-4d78-9c7e-2b2d7c6872cc">1.5</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0f0498340424670a2078aa30e95b1d8">The Company recorded this transaction as an asset purchase as opposed to a business combination because management concluded that substantially all the value received was related to one group of similar identifiable assets, which was the in-process research and development (&#8220;IPR&amp;D&#8221;) for two early phase therapies. The Company considered these pipeline assets similar due to similarities in the risks of development, stage of development, regulatory pathway, patient populations and economics of commercialization. The fair value of $<ix:nonFraction unitRef="usd" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTI4Ng_eb10289c-fedb-43f7-95c0-e29aac2c6953">25.5</ix:nonFraction>&#160;million (consisting primarily of $<ix:nonFraction unitRef="usd" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTMwMQ_5ce519f2-65b8-44f8-a90d-40308d261e10">24.0</ix:nonFraction>&#160;million IPR&amp;D, $<ix:nonFraction unitRef="usd" contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionCashandEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTMxNg_92746faa-211f-4bef-ab79-815b4807398d">0.3</ix:nonFraction>&#160;million of cash and $<ix:nonFraction unitRef="usd" contextRef="i950a8c7a799e4212b6120485b875cc33_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTMzMA_306d6366-c905-4575-81d2-7f2f4bafe91a">0.9</ix:nonFraction>&#160;million of assembled workforce) was immediately recognized as acquired in-process research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss because the IPR&amp;D asset has no alternate use due to the stage of development. The assembled workforce asset was recorded to intangible assets and will be amortized over an estimated useful life of <ix:nonNumeric contextRef="i950a8c7a799e4212b6120485b875cc33_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfMzM1Mw_019f8bfc-19ec-422b-a7d8-3ece044dd7dd">two years</ix:nonNumeric>.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNjgyMA_386faede-29ad-47d0-b55a-309d9449d05b" continuedAt="i5cb8eb2e6cd04302b50d24b4fb2ac06d" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i5cb8eb2e6cd04302b50d24b4fb2ac06d" continuedAt="ic892f53858724a7b8cd0bbae47bf2834"><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC No. 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three&#8209;level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model&#8209;derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&#160;</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></div><div style="text-align:justify;text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNjgyNA_437388c5-f475-47f0-840c-f0399cdf2e53" continuedAt="i87dc23e2911841a9b96c55a9784b4732" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></ix:nonNumeric></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic892f53858724a7b8cd0bbae47bf2834" continuedAt="i6923249c02664ee9bda19d11d191c46e"><ix:continuation id="i87dc23e2911841a9b96c55a9784b4732"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8340a3cbf64f1ab5d3614c69eea675_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjE2NGFmZjBiN2UzYjRiYmViM2FiMWE4MDczNWUzZmI2L3RhYmxlcmFuZ2U6MTY0YWZmMGI3ZTNiNGJiZWIzYWIxYTgwNzM1ZTNmYjZfNy0yLTEtMS0w_ebb113ec-d0d6-48a1-942d-61fe77a4f941">37,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fa8b9a9a0a48da86b188ca05a629de_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjE2NGFmZjBiN2UzYjRiYmViM2FiMWE4MDczNWUzZmI2L3RhYmxlcmFuZ2U6MTY0YWZmMGI3ZTNiNGJiZWIzYWIxYTgwNzM1ZTNmYjZfNy00LTEtMS0w_7226da4b-93ee-4c92-9139-b919dd248b84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a66b18e75cf45d289497fdebf1a0e33_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjE2NGFmZjBiN2UzYjRiYmViM2FiMWE4MDczNWUzZmI2L3RhYmxlcmFuZ2U6MTY0YWZmMGI3ZTNiNGJiZWIzYWIxYTgwNzM1ZTNmYjZfNy02LTEtMS0w_b6d2c569-1613-4bab-9c7e-4249c1970d29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:55.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf61356e0974feb98765a9f2a41e09d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjkxYzQ1YWQxYTdjODRhZmU4YmZjYzg5ZDQ5ODA3YjBhL3RhYmxlcmFuZ2U6OTFjNDVhZDFhN2M4NGFmZThiZmNjODlkNDk4MDdiMGFfNy0yLTEtMS0w_f1d1076d-3cf6-47cc-b121-ef23dd9d455a">17,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9358ce44d144a59aa2cf6bce55c55b6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjkxYzQ1YWQxYTdjODRhZmU4YmZjYzg5ZDQ5ODA3YjBhL3RhYmxlcmFuZ2U6OTFjNDVhZDFhN2M4NGFmZThiZmNjODlkNDk4MDdiMGFfNy00LTEtMS0w_c1a183f3-a0e5-4629-8616-6826292084b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b811c4dca4dbca6d871776b523532_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjkxYzQ1YWQxYTdjODRhZmU4YmZjYzg5ZDQ5ODA3YjBhL3RhYmxlcmFuZ2U6OTFjNDVhZDFhN2M4NGFmZThiZmNjODlkNDk4MDdiMGFfNy02LTEtMS0w_8297e605-736f-4272-ae5e-743aa663cf46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investments in money market funds are reflected in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December&#160;31, 2020, the Company&#8217;s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities. The carrying amounts reported in the accompanying condensed consolidated financial statements approximate their respective fair values because of the short-term nature of these accounts.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6923249c02664ee9bda19d11d191c46e"><ix:nonFraction unitRef="change" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:FairValueMeasurementsChangesInValuationTechniquesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDA5Ng_38692bd8-944a-4523-bc4a-a1d5bb37388f"><ix:nonFraction unitRef="change" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:FairValueMeasurementsChangesInValuationTechniquesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDA5Ng_ee34b814-1017-4cf3-a1bd-4b6ed778179e">No</ix:nonFraction></ix:nonFraction> changes in valuation techniques or inputs occurred during the three months ended March 31, 2021 and 2020. <ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_0f51ddc3-7ef7-4fbf-a940-a60961826c9f"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_25aa4641-c04b-48c8-9d89-4957e2f4b7e7"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_9885874c-2ff5-4935-8ba2-3e649313ff30"><ix:nonFraction unitRef="usd" contextRef="i60933515d1434308883ae1bb020e0a13_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_f74f0ace-86cb-436e-9db9-fb934f934fcd">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the three months ended March 31, 2021 and 2020.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfODY3_140c4000-f79e-4785-b240-e51ec2be1ca0" continuedAt="ie280715e4382418ba734c3d5c39b256c" escape="true">Accrued Expenses and Other Current Liabilities  </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie280715e4382418ba734c3d5c39b256c"><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfODcw_03fe7ea4-59a9-4602-8fce-e8912b2ccf2e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="cerc:AccruedResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMi0yLTEtMS0w_998af465-752b-4f66-b908-b24227bb89ba">7,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="cerc:AccruedResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMi00LTEtMS0w_78034d3f-a61b-4216-8106-44d4b4e726d4">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMy0yLTEtMS0w_460df067-067c-4975-b368-c4620984d811">1,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMy00LTEtMS0w_3c655a31-aa00-4fb4-85e7-f14d49f4d7ca">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="cerc:AccruedGeneralAndAdministrativeExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNC0yLTEtMS0w_476366d9-dc32-42d3-83ed-35859610205b">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="cerc:AccruedGeneralAndAdministrativeExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNC00LTEtMS0w_2e4bcc0c-a552-40d8-ad75-4a95689e62eb">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNS0yLTEtMS0w_a7d7057a-bbd0-49a9-81b3-ebba44725b1d">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNS00LTEtMS0w_9a185921-2e19-40d0-8ad8-fe0fa5970b88">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="cerc:AccruedSalesReturnsAndAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNi0yLTEtMS0w_1b5bfddf-79d1-45ab-a9ed-a11613304b54">3,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="cerc:AccruedSalesReturnsAndAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNi00LTEtMS0w_c89c480c-114a-47ca-b481-19ccef87cabd">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="cerc:AccruedMedicaidRebates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNy0yLTEtMS0w_cd37333c-0a95-4121-9504-b650d3a83ca4">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="cerc:AccruedMedicaidRebates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNy00LTEtMS0w_d45736f7-804f-468d-9275-448d78e35068">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOC0yLTEtMS0w_f7538dac-cf4c-4c84-bfc8-432168bd73e2">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOC00LTEtMS0w_db39670c-9641-46ce-add4-8036f083506a">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOS0yLTEtMS0w_91583f05-a259-4b32-a5e5-bdcc783cc164">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOS00LTEtMS0w_cf321830-4438-4853-98db-6626e5a06057">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMTAtMi0xLTEtMA_086b72d9-5cef-4193-a734-d2262a9c80f6">14,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMTAtNC0xLTEtMA_5cd3bdf8-9dd1-4e78-ade5-5a02bd1dad4a">11,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfNDk0NzgwMjMzMDY2NQ_1ce2d687-0cd2-47db-a3c0-9852ea6f4fde">2.5</ix:nonFraction>&#160;million increase in the research and development accrual as of March 31, 2021 was driven by an increase in manufacturing activities for CERC-002 to support the program&#8217;s clinical development. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company&#8217;s inventory on hand became short-dated (which the Company considers inventory within <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:durwordsen" name="cerc:InventoryPeriodBeforeExpiration" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfNDk0NzgwMjMzMDQwNg_09c2184c-7d36-4c08-b513-cfc88b8a433f">six months</ix:nonNumeric> of expiration) due to manufacturing delays. The Company records a full allowance for the returns on the sale of short-dated inventory given the high likelihood of return, which was the main driver of the increase in sales returns and allowances as of March 31, 2021.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 14</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="cerc:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNjg0Mw_30354ebf-0d48-467f-92e1-ce76a7347029" continuedAt="i02947c7a942a4a4d91460ac6d92226ff" escape="true">Capital Structure </ix:nonNumeric></span></div><ix:continuation id="i02947c7a942a4a4d91460ac6d92226ff" continuedAt="i559685f5a9ce48ca8406b210f6b3f8b0"><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s amended and restated certificate of incorporation, the Company is authorized to issue <ix:nonFraction unitRef="class_of_stock" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:NumberOfClassOfStockAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTQy_8454d057-9980-46e6-bffb-0563507771a2">two</ix:nonFraction> classes of stock, common stock and preferred stock. At March 31, 2021, the total number of shares of capital stock the Company was authorized to issue was <ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="cerc:CapitalStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMzA1_92c97e96-6bdc-4a3e-bb66-c79a9a172a71">205,000,000</ix:nonFraction> of which <ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMzE3_118252f4-32f1-44da-96e2-9a3b8295a4c9">200,000,000</ix:nonFraction> was common stock and <ix:nonFraction unitRef="shares" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMzQx_90f6f1e3-e6d3-40cc-9973-c31030aaed08">5,000,000</ix:nonFraction> was</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock. All shares of common and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock have a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDI3_84e12528-86d5-46de-a139-c61755b577ce"><ix:nonFraction unitRef="usdPerShare" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDI3_f886796e-aade-44bf-a74b-cc99cc8628af">0.001</ix:nonFraction></ix:nonFraction> per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Q1 2021 Financing </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODU5MA_05249c2f-9d5e-4970-adcb-43db9ba3301d">13,971,889</ix:nonFraction> shares of its common stock and <ix:nonFraction unitRef="shares" contextRef="i2d9f33420b794d6b82ec040bbdcda9ac_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYwMg_d4d129a6-815a-4046-8f63-32b2f84f2cb9">1,676,923</ix:nonFraction> pre-funded warrants for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYxMw_fe29fd4d-0d8c-40bd-b7b6-ae750361919c">37.7</ix:nonFraction>&#160;million. Armistice, which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, participated in the offering by purchasing <ix:nonFraction unitRef="shares" contextRef="i2d38bb42b8534eff87ac8d23d0d697ea_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYyOA_e54c3c46-6340-438e-937e-5a8d8fa94687">2,500,000</ix:nonFraction> shares of common stock, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC (collectively, &#8220;Nantahala&#8221;), which beneficially owned greater than <ix:nonFraction unitRef="number" contextRef="ie87e47a24f4a454290d837ab00a53c08_D20210101-20210131" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODY1MA_2ab5fbe9-7849-423a-bb86-4a79aa8085e6">5</ix:nonFraction>% of the Company&#8217;s outstanding common stock at the time of the offering and, therefore, were considered a related party pursuant to the Company&#8217;s written related person transaction policy, purchased <ix:nonFraction unitRef="shares" contextRef="i11a884079f7b4e2db9df7f885c73462d_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYzOQ_02b1b615-0f3c-49ae-8610-def6303ed70a">1,400,000</ix:nonFraction> shares of common stock, on the same terms as all other investors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nantahala also purchased the pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i50329ad27a3d4d858d5e36be03888359_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc3MQ_4bd97359-0c93-40cf-8be6-cea9ba3f7f53">1,676,923</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3d4b3944edc64b9eab3475e9c9ce4eb4_I20210131" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc5MA_3554178d-9e57-4370-806f-0d39528b8036">2.599</ix:nonFraction>, which represents the per share public offering price for the common stock less the $<ix:nonFraction unitRef="usdPerShare" contextRef="i30ffa7aeea1749d0b4cdf2eac8066e73_I20210131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc4Mg_5fce869a-63dc-4e28-b185-0573231e23fb">0.001</ix:nonFraction> per share exercise price for each pre-funded warrant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants are exercisable at any time after their original issuance at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. A holder will not be entitled to exercise any portion of any pre-funded warrant if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed <ix:nonFraction unitRef="number" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="INF" name="cerc:ClassOfWarrantOrRightPercentOwnershipThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc5OA_c3ceb0a4-9ab0-41ae-845b-fabc198d617d">9.99</ix:nonFraction>% following such exercise. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of certain fundamental transactions, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind of amounts of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the pre-funded warrants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and pre-funded warrants, of which $<ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1MzgwNQ_4304c5cd-67c1-493e-981c-b9c87efb6512">4.4</ix:nonFraction>&#160;million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Financings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i83186431d6e54ca9af494baa43072af0_D20200611-20200611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTI5MA_a4ed1926-ee8b-48d0-a475-1dda982f40b5">15,180,000</ix:nonFraction> shares of its common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i83186431d6e54ca9af494baa43072af0_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTUwOA_c420faaf-8377-4c3e-b1dc-00f53d3d4888">35.4</ix:nonFraction>&#160;million. Armistice participated in the offering by purchasing <ix:nonFraction unitRef="shares" contextRef="i04419c05a564471cafd04ce10e0ea363_D20200611-20200611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTU2Ng_edc9bb5b-03e3-4e53-b26c-908846d07856">2,000,000</ix:nonFraction> shares of common stock, on the same terms as all other investors. Additionally, certain of the Company&#8217;s officers participated in the offering by purchasing an aggregate of <ix:nonFraction unitRef="shares" contextRef="id4830d434af540fab7f362a2f6851391_D20200611-20200611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTc0Mw_7f1136c3-4e4e-4676-9b2d-3b4bb36a7bbe">110,000</ix:nonFraction> shares of common stock, on the same terms as all other investors.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2020, the Company entered into a securities purchase agreement with Armistice pursuant to which the Company sold <ix:nonFraction unitRef="shares" contextRef="i79d25c29ccea491bb940f8ab428a1a67_D20200317-20200317" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTk2Mw_0cb84194-e801-4fc3-92d6-cb5cf48f669d">1,951,219</ix:nonFraction> shares of the Company&#8217;s common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i79d25c29ccea491bb940f8ab428a1a67_D20200317-20200317" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjAzNw_472f007a-7070-4957-b035-855c12bd43c7">3.9</ix:nonFraction> million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2020, the Company closed a registered direct offering with certain institutional investors for the sale by the Company of <ix:nonFraction unitRef="shares" contextRef="i5666247a03f94008beee4c2791508959_D20200206-20200206" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjIwNQ_e007da4b-fa32-4d7b-bfd7-cdeb59f19026">1,306,282</ix:nonFraction> shares of the Company&#8217;s common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5666247a03f94008beee4c2791508959_D20200206-20200206" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjI3OQ_68bb03ee-d6b5-4e99-b63c-de898d6f52a0">5.1</ix:nonFraction> million.  Armistice participated in the offering by purchasing <ix:nonFraction unitRef="shares" contextRef="i3b1d24a349414177befd56fcc3bbf5f0_D20200206-20200206" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjMzNw_ce5fc6e6-9072-4de3-9229-3796d0c47622">1,256,282</ix:nonFraction> shares of common stock from the Company, on the same terms as all other investors. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i559685f5a9ce48ca8406b210f6b3f8b0" continuedAt="i5e7e2716b11b4bae876cbd380a03c708"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, under the terms of the Aevi Merger noted above in Note 6, the Company issued approximately <ix:nonFraction unitRef="shares" contextRef="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjUzNg_3f1e12a1-8458-4e5e-86b9-a47d53a7ec29">3.9</ix:nonFraction> million shares of common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNjg0Ng_81d4e3d6-8736-4262-bb75-5ebc3d8f5c30" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the following common stock warrants were outstanding:&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">underlying&#160;warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc18b2fcdebb49ae970fee17a9b37770_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0wLTEtMS0w_edc873e4-262f-4dbb-903f-7163148b319e">2,380</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc18b2fcdebb49ae970fee17a9b37770_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0yLTEtMS0w_73fc2706-3905-4004-a584-462ff4198925">8.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb3043f210a045168b002098fa42b497_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0wLTEtMS05MTkz_86292866-eb1c-4083-9eb9-b42529cd91a4">4,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb3043f210a045168b002098fa42b497_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0yLTEtMS05MTk1_03631345-2071-41ec-96d4-f421d475e0ae">12.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7278c7eb9d8c4d468fdc7b1b16998399_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0wLTEtMS0yOTA3_20caa62b-df13-44bd-80ca-1ac9ac675890">1,676,923</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7278c7eb9d8c4d468fdc7b1b16998399_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0yLTEtMS0yOTE5_388f3033-09f9-444a-bd32-be406eac8019">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7d433fb05b0421e829cbc118f401dfb_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfNS0wLTEtMS0w_2b46576a-5a05-425c-b42b-06f5d6ee423a">5,679,303</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2018, the Company filed a Certificate of Designation of Preferences of Series B Non-Voting Convertible Preferred Stock (&#8220;Series B Convertible Preferred Stock&#8221; or &#8220;convertible preferred stock&#8221;) of Cerecor Inc. (the &#8220;Certificate of Designation of the Series B Preferred Stock&#8221;) classifying and designating the rights, preferences and privileges of the Series B Convertible Preferred Stock. The Certificate of Designation of the Series B Convertible Preferred Stock authorized <ix:nonFraction unitRef="shares" contextRef="iffb1f30979714ea79f95d4802ff984ef_I20181226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjc0ODc3OTA4NTYyOA_03ca97e6-7cd5-4392-b2e6-e5f3fddef22f">2,857,143</ix:nonFraction> shares of convertible preferred stock. The Series B Convertible Preferred Stock converts to shares of common stock on a 1-for-5 ratio and has the same rights, preferences, and privileges as common stock other than it holds no voting rights. During the first quarter of 2020, Armistice converted <ix:nonFraction unitRef="shares" contextRef="ie34e5b7882f4464fb323bd265625bb05_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc1Ng_a9fa6f0f-00f6-4a5c-9e4a-1b7f82daa993">1,600,000</ix:nonFraction> shares of Series B Convertible Preferred Stock into <ix:nonFraction unitRef="shares" contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc2Nw_7a8f0685-baa3-47a4-86f1-399249c2cf17">8,000,000</ix:nonFraction> shares of Cerecor&#8217;s common stock. In April 2021, Armistice converted the remaining <ix:nonFraction unitRef="shares" contextRef="i87335e7fb2f644479af541532f926a9d_D20210401-20210430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc3OA_7dd04445-a742-4744-a04b-bd352ea7cc6e">1,257,143</ix:nonFraction> shares of Series B Convertible Preferred Stock into <ix:nonFraction unitRef="shares" contextRef="i6cd83eb2a4284855bc679909757c91ed_D20210401-20210430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc4OQ_4f1e2a10-0b83-458b-8002-8ebce6817d0d">6,285,715</ix:nonFraction> shares of Cerecor&#8217;s common stock.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2018 Armistice Private Placement</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5e7e2716b11b4bae876cbd380a03c708">On December 27, 2018, the Company entered into a series of transactions as part of a private placement with Armistice. The transactions were considered one transaction for accounting purposes. As part of the transaction, the Company exchanged common stock warrants issued on April 27, 2017 to Armistice for the  purchase of up to <ix:nonFraction unitRef="shares" contextRef="i6d9884fb9a86405fb7c325756d06accd_I20181227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDkxNw_f50178a6-8f6c-40a4-9226-db7685f5a4b5">14,285,714</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6d9884fb9a86405fb7c325756d06accd_I20181227" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk4MQ_f98d93cd-09cd-4822-bff6-9801077f5373">0.40</ix:nonFraction> per share (the &#8220;original warrants&#8221;) for like-kind warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i1a57959625a746b382f212a041c26d2b_I20181227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTA2MQ_4da9c2a5-e963-4e9c-8038-6584519bb0e8">2,857,143</ix:nonFraction> shares of the Company&#8217;s Series B Convertible Preferred Stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1a57959625a746b382f212a041c26d2b_I20181227" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTE2OA_ba0eb358-c778-4134-95c0-8d3390993659">2.00</ix:nonFraction> per share (the &#8220;exchanged warrants&#8221;). Armistice immediately exercised the exchanged warrants and acquired an aggregate of <ix:nonFraction unitRef="shares" contextRef="id78630f60e5b4ecca96e7de37d2b0ede_I20181227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTI5NA_c596d5c4-5412-4785-b135-ccafad47ee30">2,857,143</ix:nonFraction> shares of the convertible preferred stock, which it has since converted into <ix:nonFraction unitRef="shares" contextRef="ie6a48ca344334551b7645592e589572f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1ODY4OA_1e78ac3d-acb4-41b4-8304-1b62f9ed3c33">14,285,715</ix:nonFraction> shares of Cerecor common stock. Net proceeds of the transaction were approximately $<ix:nonFraction unitRef="usd" contextRef="i1d3edf5294c94a15b1515cb8bac0fbf5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTM5Mg_caaa824e-edfa-464f-bea4-00943c9a93aa">5.7</ix:nonFraction> million for the year ended December 31, 2018. In order to provide Armistice an incentive to exercise the exchanged warrants, the Company also entered into a securities purchase agreement with Armistice in December 2018 pursuant to which the Company issued warrants for <ix:nonFraction unitRef="shares" contextRef="i0f7987a16d51476399f00aba786832f0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTY1Nw_cd42b029-320c-4928-b1bc-dc604ea25feb">4,000,000</ix:nonFraction> shares of common stock of the Company with a term of <ix:nonNumeric contextRef="i0f7987a16d51476399f00aba786832f0_I20181231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTcxMw_0787b8e4-d8df-41d7-9eac-5d5207103f57">5.5</ix:nonNumeric> years and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f7987a16d51476399f00aba786832f0_I20181231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTc0MQ_796e991b-4710-4b08-9519-ddd047b385a6">12.50</ix:nonFraction> per share (the &#8220;incentive warrants&#8221;).</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MTM_2d5f4a24-56e4-40e2-88c8-9d249e1b2bbf" continuedAt="i08009846fea84f6a88bbe59f7599a7b7" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i08009846fea84f6a88bbe59f7599a7b7" continuedAt="ie911b493ff8a493385d5a72a279acb47"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2016, the Company&#8217;s board of directors adopted the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) as the successor to the 2015 Omnibus Plan (the &#8220;2015 Plan&#8221;). The 2016 Plan was approved by the Company&#8217;s stockholders and became effective on May 18, 2016 (the &#8220;2016 Plan Effective Date&#8221;). Upon the 2016 Plan Effective Date, the 2016 Plan reserved and authorized up to <ix:nonFraction unitRef="shares" contextRef="icf49c9a4875b435fb1444f3db3551e0d_D20160518-20160518" decimals="INF" format="ixt:numdotdecimal" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDQy_e43ecbcf-8ee9-43f2-9caa-b39649a6e567">600,000</ix:nonFraction> additional shares of common stock for issuance, as well as <ix:nonFraction unitRef="shares" contextRef="i95616c1bb6fd48dba5535428036866f9_I20160518" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTA0_879fc212-b269-40da-bafd-003da758c5db">464,476</ix:nonFraction> unallocated shares remaining available for grant of new awards under the 2015 Plan. An Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016 Amended Plan&#8221;) was approved by the Company&#8217;s stockholders in May 2018, which increased the share reserve by an additional <ix:nonFraction unitRef="shares" contextRef="i6364a4c535f944fc8d6272cec44a6605_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNzc1_b41e95ba-e7dd-4711-aa12-2fc4339746c2">1.4</ix:nonFraction> million shares. A Second Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016 Second Amended Plan&#8221;) was approved by the Company&#8217;s stockholders in August 2019, which increased the share reserve by an additional <ix:nonFraction unitRef="shares" contextRef="ib80218def2434edb83018969f2462fd9_D20190801-20190831" decimals="INF" format="ixt:numdotdecimal" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTg3_201a31cf-4a80-41e2-87c1-31aa63c5b73f">850,000</ix:nonFraction> shares. A Third Amended and Restated Equity Incentive Plan (the &#8220;2016 Third Amended Plan&#8221;) was approved by the Company&#8217;s stockholders in June 2020 which increased the share reserve by an additional <ix:nonFraction unitRef="shares" contextRef="i4a4f6b0df275417caf8e9588d5879953_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTE4OQ_29a798f4-6214-4110-86e5-61cb625f3451">2,014,400</ix:nonFraction> shares. During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year by an amount equal to <ix:nonFraction unitRef="number" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="INF" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTM3NA_4d86936d-945b-4525-ba99-8cc33c9fe4fe">4</ix:nonFraction>% of the total number of outstanding shares of common </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 16</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie911b493ff8a493385d5a72a279acb47" continuedAt="i4e0264b116454dfa93b469c88ef2c18f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock of the Company on the last trading day in December of the prior calendar year. As of March&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i29e9f70e9f7b4f01be2ea582e6fc1273_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTUzNw_828941e6-e581-492e-a39c-552e5c5f88a6">2,728,771</ix:nonFraction> shares available for future issuance under the 2016 Third Amended Plan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants expire after <ix:nonNumeric contextRef="i31f47b2beb7b41178e355e797e2f3729_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY0MA_1be079c4-a197-4121-b99f-1027519be1c6">ten years</ix:nonNumeric>. Employee options typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4MQ_63efab90-69fc-42af-b1b9-73b3e29c5cf7">three</span> or <ix:nonNumeric contextRef="i0c13bb871c0f4896b5ef4d28dafbd2d6_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4Nw_f7123f55-19d0-45ae-ba2f-b7c2382357dd">four years</ix:nonNumeric>. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. Options granted to directors typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg2Nw_e865b985-b902-43d4-a27a-a09d25dc86dc">one</span> or <ix:nonNumeric contextRef="i0ee83b81d1c04985a8e197982cd1072c_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg3Mw_27fef0c8-76b1-4060-96fd-d9be84745c4c">three years</ix:nonNumeric>. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company&#8217;s stock-based awards is amortized ratably over the individuals&#8217; service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options, restricted stock units and employee stock purchase plan shares. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MDQ_a8283835-7fe7-460b-a152-15f19a0f1b0a" continuedAt="i8a0087a149234412bb5b0fe1728c219f" escape="true">The amount of stock-based compensation expense recognized for the three months ended March&#160;31, 2021 and 2020 was as follows (in thousands):&#160;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt"><ix:continuation id="i8a0087a149234412bb5b0fe1728c219f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id696367226144fa4b944f70aa62c42fe_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMi0yLTEtMS0w_e506bc12-073b-41f0-a16a-000baf187eb6">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9100bedc06f0427a92077cbcaacfb3bc_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMi00LTEtMS0w_aad9e85b-a349-4d6f-8f3a-0ef57e18e0fc">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060be613e08b4af9bfd9b2dc947d28f0_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMy0yLTEtMS0w_2ea4cc85-4522-4f84-a92f-b0572a9e8a66">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44363498ae0d4459991baef00bff6710_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMy00LTEtMS0w_a86e9ee6-06f0-488d-9b94-8db7b510517e">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754b22e1563e4e3aa874036b82bf942c_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNC0yLTEtMS0w_ca918ad2-7554-4f4e-abb7-b9ad0af6dc01">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ba6fbf1c5441209f70f012cc625abf_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNC00LTEtMS0w_c0a4b042-3117-4b70-a473-b8ed7ed0c18a">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNy0yLTEtMS0w_4cad3993-0d3c-4666-93af-90c6ea53381f">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNy00LTEtMS0w_a34e2484-70e8-440b-9341-047798e981c5">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with service-based vesting conditions</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted awards that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MTA_2821d224-4dc3-4b1f-91fd-83c3de8fd032" continuedAt="ia635c77c6c384495bde32cb2a81cf549" escape="true">A summary of option activity for the three months ended March 31, 2021 is as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ia635c77c6c384495bde32cb2a81cf549" continuedAt="i8dd030e42d3f49d0ab11e63a88dc2115"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:39.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91e623503adb43afb6fb5459058e0547_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi0yLTEtMS0w_2134024c-d93f-49b2-ad7b-0e8ee39350d8">8,830,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91e623503adb43afb6fb5459058e0547_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi00LTEtMS0w_34414dfd-a26c-4e51-b42b-762568b2951f">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91e623503adb43afb6fb5459058e0547_I20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi02LTEtMS0w_2d2af87f-01f4-493a-9a49-8ac46512b16c">2.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1461faa4f454dce8429a63ea92a7a06_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi04LTEtMS0w_b2f8e254-5f4b-4a36-b5c7-5961f884d2c7">7.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMy0yLTEtMS0w_7f76776b-5774-4410-b3ed-af32a0740fc4">3,467,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMy00LTEtMS0w_bfbcaf72-2af8-4994-8a98-da1c89718b91">3.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMy02LTEtMS0w_5753f65f-ed05-4951-b3ad-b575be64c372">2.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNC0yLTEtMS0w_f6a6f07c-1aba-4a7f-b5d3-69fe612295e4">128,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNC00LTEtMS0w_60be77ef-4c22-45b8-a64e-2f5c37dd9768">1.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="2" name="cerc:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNC02LTEtMS0w_04124337-bce1-473f-9053-77beea09e571">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNS0yLTEtMS0w_9047555a-ed1b-4c81-906c-bc7e5cb0af81">224,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNS00LTEtMS0w_95533b2a-b46d-4aa4-8c01-92b847d90674">3.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNS02LTEtMS0w_8106944d-1190-4c6e-a59c-8c69bec85dc5">2.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy0yLTEtMS0w_fcab7797-bfcd-4c1a-a19d-2a1e34fc6ab4">11,944,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy00LTEtMS0w_28c7b0b5-1bf8-4ace-851a-ef0f156c1204">3.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy02LTEtMS0w_44ccd370-b44e-45d7-adee-ff7f5e090c99">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy04LTEtMS0w_6df1a7b1-3988-4cf3-aa4f-ae3ad840c264">8.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS0yLTEtMS0w_13b9bf17-a6bd-4428-91dd-209dfdd46049">3,914,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS00LTEtMS0w_9e9639bc-1f3e-4ae2-a67f-17aeea87eb6a">4.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="2" name="cerc:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS02LTEtMS0w_7794f089-5b04-4d11-b395-13e3f0d13d3b">2.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS04LTEtMS0w_42ad3df5-678d-4693-9109-85b934a4f941">6.0</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company granted its newly appointed Chief Financial Officer options with service-based vesting conditions to purchase <ix:nonFraction unitRef="shares" contextRef="i8030e840d448409f8fe845f94ea3abbb_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1MTE0NA_40aaba9a-45bc-406a-a638-dc099cb28809">0.5</ix:nonFraction>&#160;million shares of common stock as an inducement option grant, pursuant to NASDAQ Listing Rule 5635(c)(4). In January 2021, the Company granted <ix:nonFraction unitRef="usd" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1MjkxMQ_fa2db1d1-dab6-429b-9691-2164e298038b">2.7</ix:nonFraction>&#160;million options with service-based vesting conditions to its employees as part of its annual stock option award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, our Chief Executive Officer entered into an amended employment agreement in which his salary in cash was reduced to $<ix:nonFraction unitRef="usd" contextRef="i12e73acc1c964f5888c9864531a2b698_D20200301-20200331" decimals="0" format="ixt:numdotdecimal" name="cerc:AnnualBaseSalary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMzIxOA_ff210a92-861b-4af9-8dc9-eb96eaf37ed3">35,568</ix:nonFraction> (the &#8220;Reduction&#8221;), which represents the minimum exempt annual salary. In consideration for the Reduction, on a quarterly basis, the Company grants stock options, which vest immediately, for the purchase of a number of shares of the Company&#8217;s common stock with a total value (based on the Black-Scholes valuation methodology) based on a pro rata total annual value of the foregone salary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. As of March&#160;31, 2021, the aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDA2NA_c3bedbda-6fbc-44e0-861b-30f1701c7e6b">1.6</ix:nonFraction> million.  The aggregate intrinsic value of options currently exercisable as of March&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDE2MQ_f9345a1a-9ba9-4141-b789-47ee22704357">0.7</ix:nonFraction> million. There were&#160;<ix:nonFraction unitRef="shares" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDE3Ng_5ab112a2-bdfe-4414-8688-7689fd657f3f">1,137,239</ix:nonFraction>&#160;options that vested during the three months ended March 31, 2021 with a weighted average exercise price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDI2MA_9910be71-c412-4feb-9482-d06052e320d3">3.96</ix:nonFraction> per share. The total grant date fair value of shares which vested during the three months ended March 31, 2021&#160;was&#160;$<ix:nonFraction unitRef="usd" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDM1NA_1c764cc5-cd28-4914-ae98-04174a7a9ebe">2.8</ix:nonFraction> million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDQxOA_42dc0b84-df34-490d-ac8f-1b0a5afd0e97">1.3</ix:nonFraction> million related to stock options with service-based vesting conditions for the three months ended March 31, 2021. At March 31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDU5NQ_895b001b-14ff-4f98-a619-1e4dce81ef26">16.1</ix:nonFraction> million of total unrecognized </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i4e0264b116454dfa93b469c88ef2c18f" continuedAt="ie78e836bfae841e8af263804a492f0bc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjU5NzA2OTc3ODkzNA_fd1e5274-8d65-4866-bf00-3eda16d98ac3">3.1</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation assumptions</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1NTM1OA_31169520-8c33-4af6-9c58-8449563295d3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the three months ended March 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service-based options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMS0yLTEtMS04OTA5_59b9afc5-7495-4b91-97d0-dfbdf5c782c5">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3af98390081b4750881153e96552c18c_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMi0yLTEtMS05NzA2L3RleHRyZWdpb246OGJiMGM1NGJmYzIwNDM1ZGFkMDU0YWMzZDU4NGJjYTZfNDk0NzgwMjMyNTAxNA_f2b7f0ee-6138-4cd8-acaf-faf687e2a97d">73.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1da3c9dfb0d14dec942761d660b32921_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMi0yLTEtMS05NzA2L3RleHRyZWdpb246OGJiMGM1NGJmYzIwNDM1ZGFkMDU0YWMzZDU4NGJjYTZfNDk0NzgwMjMyNTAzMA_3bf0472e-82b0-4193-9234-eb0637481db5">75.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of option (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6f071b1803cb487eab728baa86ce1d1b_I20210331" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMy0yLTEtMS05NzMyL3RleHRyZWdpb246MDkwOGM3MmU0ZTlmNDZiZGEzMzU2MmZhYTIwOWMwZDhfNDk0NzgwMjMyNTAwOQ_5e221f03-c15f-4efa-a221-7cf88db91b4d">5.0</ix:nonNumeric> - <ix:nonNumeric contextRef="i1e2f493114e24792b6ab7231ebc4f3a2_I20210331" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMy0yLTEtMS05NzMyL3RleHRyZWdpb246MDkwOGM3MmU0ZTlmNDZiZGEzMzU2MmZhYTIwOWMwZDhfNDk0NzgwMjMyNTAxNg_b93bc29a-e23d-495f-b3ef-c08f29d161b7">6.25</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3af98390081b4750881153e96552c18c_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfNC0yLTEtMS05NzQwL3RleHRyZWdpb246N2Y1OTRiODAwZTdiNDlhOWFiY2YzNjE0MGI0YWU4NjFfNDk0NzgwMjMyNTAxNA_7f11e326-2d68-468a-b1b2-de5e07a13b50">0.36</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1da3c9dfb0d14dec942761d660b32921_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfNC0yLTEtMS05NzQwL3RleHRyZWdpb246N2Y1OTRiODAwZTdiNDlhOWFiY2YzNjE0MGI0YWU4NjFfNDk0NzgwMjMyNTAyMg_68b3747e-3f61-4651-ac5d-656ae155a0c7">1.12</ix:nonFraction>%</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with market-based vesting conditions</span></div><div><span><br/></span></div><ix:continuation id="i8dd030e42d3f49d0ab11e63a88dc2115" continuedAt="i1d99e14d846b4170be9e9585ff933ac2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s market-based option activity for the three months ended March 31, 2021 (in thousands except, for share amounts): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:39.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate intrinsic value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi0yLTEtMS0w_7423361a-d974-41aa-857c-e031655357e6">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi00LTEtMS0w_77e751e5-0195-44f0-87c5-68724797c0dd">3.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42e5c0a81c6c46b5bee3450a25f025e4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi02LTEtMS0w_b272a53a-5801-4c5c-ae83-d87cd9317c0d">9.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi04LTEtMS0zMDIx_570801e7-9630-427d-b803-67a91a3bdeca">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMy0yLTEtMS0w_9a19cf01-3c8d-49a5-9170-a5db6c0b6eb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMy00LTEtMS0w_7a62ab8e-4a5d-4d77-b516-02bc84c2d0be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNS0yLTEtMS0w_df193d93-0871-4a75-8449-7cfbc6d7a308">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNS00LTEtMS0w_e9fd5daf-6d7c-4bff-919b-8c5adeaa315a">3.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNS02LTEtMS0w_d7d21735-d4d5-4ea0-a0ed-10280f9e1a8c">9.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7429f77f36e348619c1595052db52037_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNC04LTEtMS05NjAy_138b138e-c75a-4af9-94a2-212a877f9913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNy0yLTEtMS0w_2b989a47-b440-4896-97be-d948c1b8970b">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNy04LTEtMS0w_c3b386a7-1556-40c6-885a-cc2fb24fe1ba">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d99e14d846b4170be9e9585ff933ac2">(1) The aggregate intrinsic value in the above table represents the total pre-tax amount that a participant would receive if the option had been exercised on the last day of the respective fiscal period. Options with a market value less than its exercise value are not included in the intrinsic value amount.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, the Company granted its recently appointed Chairman of the Board an option to purchase <ix:nonFraction unitRef="shares" contextRef="i6388e36dd5e54d04841bac2d0313519d_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTgyMw_c9395b13-77f6-49e9-9e60-9af2ef3e823b">1,000,000</ix:nonFraction> shares of Company common stock with market-based vesting conditions. <ix:nonFraction unitRef="shares" contextRef="i3a18d4e138304f578791e2ee584457c9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTg5NQ_d27f65df-e6d0-4bf4-bc66-99cead933ba2">500,000</ix:nonFraction> of the shares vested immediately on the date of grant with an exercise price of the closing stock price on the date of grant of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a18d4e138304f578791e2ee584457c9_D20200401-20200630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjAyNg_53d019e5-bad9-41b8-92fa-1ee09dcc5dfd">2.51</ix:nonFraction>. <ix:nonFraction unitRef="shares" contextRef="i25979dec2f3d4ac2862b695cf3514d3f_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjAzMQ_bc968361-6132-4ba7-b9e8-7e56fb59cc8f">250,000</ix:nonFraction> of the shares vest upon the Company&#8217;s common stock reaching a <ix:nonFraction unitRef="number" contextRef="i25979dec2f3d4ac2862b695cf3514d3f_D20200401-20200630" decimals="INF" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjA5Ng_d0d845db-7cb7-441e-8ce8-90961cd68e99">50</ix:nonFraction>% premium to the stock price on June 18, 2020 and has an exercise price of the stock at that time and <ix:nonFraction unitRef="shares" contextRef="if7e8cecccd934890847824b3ae4a7ef0_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjIwNQ_63a57890-c7d9-45d5-91e2-ae1f8a35501d">250,000</ix:nonFraction> of the shares vest upon the Company&#8217;s common stock reaching a <ix:nonFraction unitRef="number" contextRef="if7e8cecccd934890847824b3ae4a7ef0_D20200401-20200630" decimals="INF" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjI3MA_86762340-d038-4d7a-bc2c-9649b5f79c55">75</ix:nonFraction>% premium to the stock price on June 18, 2020 and has an exercise price of the stock at that time. Each vesting tranche represents a unique requisite service period and therefore the compensation cost for each vesting tranche is recognized on a straight-line basis over its respective vesting period. The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA5OTUxMTY0MjYyMQ_72edbaf2-ab5d-462e-872e-7f88e9266c10">0.1</ix:nonFraction> million related to stock options with market-based vesting conditions for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the second tranche of <ix:nonFraction unitRef="shares" contextRef="i36b6d96bcc1749caadd5b13f2bf8889b_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1MjkzNA_c4833fde-0772-45ec-a59a-67ab2a0ad61a">250,000</ix:nonFraction> shares and the third tranche of <ix:nonFraction unitRef="shares" contextRef="ie6185a21763b4022bb98a98a1f7511a0_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1Mjk0Mw_810b3ddf-f537-4a8c-87b5-d2387d17e7fa">250,000</ix:nonFraction> shares both vested upon the Company&#8217;s stock price reaching a <ix:nonFraction unitRef="number" contextRef="i36b6d96bcc1749caadd5b13f2bf8889b_D20210101-20210331" decimals="2" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1Mjk1Mg_10db5196-17c6-434c-b290-7ed47b67c7ac">50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie6185a21763b4022bb98a98a1f7511a0_D20210101-20210331" decimals="2" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1Mjk1Nw_cc9ff62c-5ab3-4b38-ace0-feb640dd70b8">75</ix:nonFraction>% premium to the stock price on June 18, 2020, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of the restricted stock units using the stock price on the date of the grant. The restricted shares typically vest annually over a <ix:nonNumeric contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA1OTY_d9943618-a36c-4918-b419-da77e6743e0f">four-year</ix:nonNumeric> period beginning on the first anniversary of the award. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MTI_8b0d54f2-9f31-4ae4-8b55-a02bc23c6319" continuedAt="ib30a673f8d1a4e78b982b4902dd57b95" escape="true">The following table summarizes the Company&#8217;s restricted stock unit (&#8220;RSU&#8221;) activity for the three months ended March 31, 2021: </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie78e836bfae841e8af263804a492f0bc"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="ib30a673f8d1a4e78b982b4902dd57b95"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie43534f2ad884d3c93e916333b4e6fe3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMi0yLTEtMS0w_a49f8013-0d98-4776-9735-0a99e13ea1bf">155,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie43534f2ad884d3c93e916333b4e6fe3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMi00LTEtMS0w_9fea017b-cf53-4190-b39a-c4a3ed5aceb5">4.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMy0yLTEtMS0w_0a175bbd-a7c0-49d5-bb91-786bdd241813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMy00LTEtMS0w_6a2067a5-7223-4021-aaf3-39d948af74c5"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4809744336f94a308a12efafbd45bd1e_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfNC0yLTEtMS0w_921149a3-80c1-4646-910d-a04f295989d7">155,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4809744336f94a308a12efafbd45bd1e_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfNC00LTEtMS0w_ab1e7afe-f1f8-42d6-b234-f532c09c2308">4.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized expense of less than $<ix:nonFraction unitRef="usd" contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNzkyNg_af901bd8-e058-46af-b834-10c99cc0980a">6</ix:nonFraction> thousand related to RSUs for the three months ended March 31, 2021.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2016, the Company&#8217;s board of directors approved the 2016 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by the Company&#8217;s stockholders and became effective on May 18, 2016 (the &#8220;ESPP Effective Date&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company&#8217;s board of directors. Under the ESPP, eligible employees may purchase stock at <ix:nonFraction unitRef="number" contextRef="i4e67ffefb48e414f85fa6311d88d3fde_D20160405-20160405" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfODU1OQ_5c11792b-5226-40b8-82dd-26b11b2a05e0">85</ix:nonFraction>% of the lower of the fair market value of a share of the Company&#8217;s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="i0bfcb4e632484858beac101b5287566c_I20160405" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfODc1NQ_013018a9-9b47-42a4-b38b-e77be219b1c4">15</ix:nonFraction>% of their earnings during the offering period. The Company&#8217;s board of directors may establish a maximum number of shares of the Company&#8217;s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction unitRef="usd" contextRef="i4e67ffefb48e414f85fa6311d88d3fde_D20160405-20160405" decimals="-3" format="ixt:numdotdecimal" name="cerc:ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTEwMw_8c4126ef-5838-4972-b8c0-e50d8fbc81cf">25,000</ix:nonFraction> of the fair market value of the Company&#8217;s common stock for each calendar year in which such right is outstanding.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the ESPP Effective Date, the Company reserved and authorized up to <ix:nonFraction unitRef="shares" contextRef="i0bfcb4e632484858beac101b5287566c_I20160405" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTI5Mw_a6a93db9-b481-43c1-b667-f2b380441062">500,000</ix:nonFraction> shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP shall automatically increases by a number equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i0bfcb4e632484858beac101b5287566c_I20160405" decimals="INF" name="cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTUxOA_df98f98e-72ea-4f16-bbbb-b3c3766b7cbd">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, and (ii) <ix:nonFraction unitRef="shares" contextRef="i0bfcb4e632484858beac101b5287566c_I20160405" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTY1MA_81810605-fdea-4439-b8f2-91f8f33dd4c3">500,000</ix:nonFraction> shares of the Company&#8217;s common stock, or (iii) a number of shares of the Company&#8217;s common stock as determined by the Company&#8217;s board of directors or compensation committee. The number of shares were increased by <ix:nonFraction unitRef="shares" contextRef="i830174ed95fc44a1bd5ebc384320dfc9_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTg2Ng_d68909d5-ffc2-4110-8304-31a7b9d3b782">500,000</ix:nonFraction> on January 1, 2021. As of March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i4e1a839c0c2f4008a983a171019b82d6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTkwMA_d0303835-f0a7-4b90-bb14-43aa6037e1f6">1,925,308</ix:nonFraction> shares remained available for issuance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 718-50,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Employee Share Purchase Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="icbc7327a9c14482fb8f5db8aaf0f48d9_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA1MTM_3f78cd55-d8c9-4adc-98af-cbe32b41fd9d">34</ix:nonFraction> thousand for the three months ended March 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82Ny9mcmFnOmIwZWQ5ZjZiZWQ1NTQ0NWU4M2M1ZmM2ZDEyMTk5ODlmL3RleHRyZWdpb246YjBlZDlmNmJlZDU1NDQ1ZTgzYzVmYzZkMTIxOTk4OWZfMTA1NQ_54b1566d-7e2b-46e3-8edb-904783f8fc23" continuedAt="i2ae98144d8ff4f9db0ffa19b70cba33a" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i2ae98144d8ff4f9db0ffa19b70cba33a">The Company recognized minimal income tax expense for the three months ended March 31, 2021 and an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82Ny9mcmFnOmIwZWQ5ZjZiZWQ1NTQ0NWU4M2M1ZmM2ZDEyMTk5ODlmL3RleHRyZWdpb246YjBlZDlmNmJlZDU1NDQ1ZTgzYzVmYzZkMTIxOTk4OWZfNTQ5NzU1ODE0MzEyNw_77a033d9-050c-4826-a05c-12f0b2c47165">2.2</ix:nonFraction>&#160;million for the three months ended March 31, 2020. The tax benefit recognized for the three months ended March 31, 2020 was a result of a tax law change signed into law as part of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), which allowed the Company to carry back certain losses for taxes paid in fiscal year 2017. Due to the full valuation allowance against the Company&#8217;s deferred tax assets and the current year losses, minimal tax expense was recognized for the three months ended March 31, 2021.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE5NA_5088731d-782c-47d7-a4c3-b1f9796a8f84" continuedAt="ib174c557e1c54a9baed8268e0e6e54b6" escape="true">Leases </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib174c557e1c54a9baed8268e0e6e54b6" continuedAt="i5ebb87c7735b4362a22ed858805d43c6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently occupies <ix:nonFraction unitRef="contract" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:LesseeOperatingLeaseNumberOfContracts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNDk_96db3681-62d5-41fa-bb78-a2297e59028e">two</ix:nonFraction> leased properties, both of which serve as administrative office space. The Company determined that both leases are operating leases based on the lease classification test performed at lease commencement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent for the Company&#8217;s office located in Rockville, Maryland is $<ix:nonFraction unitRef="usd" contextRef="i09cca0b1b8484ffda61d0f7e6de54442_I20210331" decimals="0" format="ixt:numdotdecimal" name="cerc:LesseeOperatingLeaseLiabilityAnnualBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMzM4_495b6bc9-bdba-47e5-833f-e7080cb272e2">161,671</ix:nonFraction>, subject to annual <ix:nonFraction unitRef="number" contextRef="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331" decimals="INF" name="cerc:OperatingLeasesRentExpenseAnnualIncreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMzYw_2f1681a3-51ba-4f70-9812-5cd5438d15bb">2.5</ix:nonFraction>% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of <ix:nonNumeric contextRef="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331" format="ixt-sec:durmonth" name="cerc:LesseeOperatingLeaseRentAbatementPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNDY5_b83d8e91-6918-4926-a197-a49491159ad3">12</ix:nonNumeric> months following the Company&#8217;s date of occupancy. The lease has an initial term of <ix:nonNumeric contextRef="i09cca0b1b8484ffda61d0f7e6de54442_I20210331" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNTQ5_09e0a73b-22e7-49b1-b548-a443241248d8">10</ix:nonNumeric> years from the date the Company makes its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease <ix:nonFraction unitRef="renewal_option" contextRef="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNzAw_5acaaf72-9643-42a0-b38d-845378c06c35">two</ix:nonFraction>&#160;times, each for a period of <ix:nonNumeric contextRef="i09cca0b1b8484ffda61d0f7e6de54442_I20210331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNzMx_35da7232-781d-4a60-9804-a367d4fd5515">five years</ix:nonNumeric>, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. As of the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i5ebb87c7735b4362a22ed858805d43c6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease commencement date, it was not reasonably certain that the Company will exercise the renewal periods or early terminate the lease and therefore the end date of the lease for accounting purposes is January 31, 2030. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a sublease for additional administrative office space in Chesterbrook, Pennsylvania in May 2020 (the &#8220;Chesterbrook Lease&#8221;). The annual base rent under the Chesterbrook Lease is $<ix:nonFraction unitRef="usd" contextRef="i5c920d35386546eb9e87448a6e1d8613_I20210331" decimals="0" format="ixt:numdotdecimal" name="cerc:LesseeOperatingLeaseLiabilityAnnualBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMTMwNQ_0ddcea26-f219-4c08-a4d2-a185a5cd6b98">280,185</ix:nonFraction>. The lease expires in November 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining term of the operating leases at March 31, 2021 was <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" format="ixt-sec:duryear" name="cerc:LesseeOperatingLeaseRemainingLeaseTeam" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMTQzMw_0b26cfa4-714b-4f54-8b9e-e57fca447d10">7.7</ix:nonNumeric> years. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="cerc:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE5MA_512656cd-abe5-4699-b487-b8c667bfd169" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leased property is as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfMi0yLTEtMS0w_bc4db5c8-4f00-4542-b742-99daaf9813e9">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfMi00LTEtMS0w_4dd91736-91d0-458a-af96-1223e2a480bf">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0yLTEtMS0w_95666a30-b990-4b20-89a6-ad89201e3b5b">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC00LTEtMS0w_038991fd-484c-434a-abdd-c5dd15eecab6">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0yLTEtMS0w_2dfe9606-f320-45c9-8efc-70986b792bbb">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS00LTEtMS0w_ab0f13d3-4d4e-4e1a-b873-c6f920e6b9d5">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNi0yLTEtMS0w_63b51834-389b-4734-b83f-b1072381270f">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNi00LTEtMS0w_7544f934-fba7-42ed-94e4-8a480b79f8d3">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease right-of-use (&#8220;ROU&#8221;) assets are included in property and equipment and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our condensed consolidated balance sheets. The Company utilized a weighted average discount rate of <ix:nonFraction unitRef="number" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMTg0OQ_1462c418-3539-4507-8443-6e0440b039c9">7.4</ix:nonFraction>% to determine the present value of the lease payments.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE5Mg_fcc329ad-0722-4322-a6d2-8cb5b0bcf13b" continuedAt="i8c0e6ba394254748aab8f57f7692335d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three  months ended March 31, 2021 and 2020 were as follows (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjllMzUxOGUwODRkMjRlZThiMTQ4MTQ3YzY2ZDRkZWViL3RhYmxlcmFuZ2U6OWUzNTE4ZTA4NGQyNGVlOGIxNDgxNDdjNjZkNGRlZWJfMi0yLTEtMS0w_b7a454d3-9f2d-467f-bf93-54ebee3889b3">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjllMzUxOGUwODRkMjRlZThiMTQ4MTQ3YzY2ZDRkZWViL3RhYmxlcmFuZ2U6OWUzNTE4ZTA4NGQyNGVlOGIxNDgxNDdjNjZkNGRlZWJfMi00LTEtMS0w_910fa71d-5881-4bcc-85ce-8ccbb4989739">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c0e6ba394254748aab8f57f7692335d">*Includes short-term leases, which are immaterial.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE4Nw_841cc030-429e-4611-a8e8-daa06cd9f560" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a maturity analysis of the operating lease liabilities as of March 31, 2021 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"></td><td style="width:70.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2021 through December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMi0yLTEtMS0w_17044292-3211-4cd6-91ae-8c0108c86385">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMy0yLTEtMS0w_36be97b7-0877-462e-ac8f-deb610985a02">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNC0yLTEtMS0w_21b82e0a-2522-43d4-b20c-17a480a232e9">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNS0yLTEtMS0w_966bc1da-4689-4337-aeaf-11d7d7311f42">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNi0yLTEtMS0w_24405fc9-468b-47e2-9d1c-35cec6d0f383">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNy0yLTEtMS0w_6d879e98-0d21-4d39-8e2f-8a4c03134868">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfOC0yLTEtMS0w_2200361c-f11d-4d86-8cc9-f28dc5819a89">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfOS0yLTEtMS0w_0f0ac636-2d96-4453-b16e-4338b1e60a56">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less implied interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMTAtMi0xLTEtMA_e53afad5-9f94-463e-84d1-864be2a92244">474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMTEtMi0xLTEtMA_7834044a-f76c-4760-948b-ad6d155c7945">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTkyMA_4ec079df-2ae4-49d2-8d56-e64e9bbe3b49" continuedAt="ic2f219b8d608442f87f711d418eb2eba" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="ic2f219b8d608442f87f711d418eb2eba" continuedAt="i3ceb18a474ac44f09651583fdbf82054"><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation - General</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Karbinal Royalty Make-Whole Provision </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3ceb18a474ac44f09651583fdbf82054" continuedAt="iab493ea9a987474589dfa0fa6afb28ba"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, in connection with the acquisition of Avadel&#8217;s pediatric products, the Company entered into a supply and distribution agreement (the &#8220;Karbinal Agreement&#8221;) with TRIS Pharma Inc. (&#8220;TRIS&#8221;). As part of the Karbinal Agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of&#160;<ix:nonFraction unitRef="unit" contextRef="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTg3Nw_94fc9c39-ac07-4e61-8c5c-f941bc7f63fb">70,000</ix:nonFraction>&#160;units through 2033. The Company was required to pay TRIS a royalty make whole payment (&#8220;Make-Whole Payments&#8221;) of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231" decimals="INF" name="cerc:LicenseAgreementMakeWholePaymentPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTk5Mw_c9e81c9d-f814-47a0-bf88-5cb7ca173470">30</ix:nonFraction>&#160;for each unit under the&#160;<ix:nonFraction unitRef="unit" contextRef="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMjAyMA_797474cb-a0d6-4fe4-b6c0-389a38dd6a6f">70,000</ix:nonFraction>&#160;units annual minimum sales commitment through 2033.&#160; </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the Aytu Divestiture, which closed on November 1, 2019, the Company assigned all payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the &#8220;TRIS Obligations&#8221;) to Aytu.&#160; However, under the original license agreement, the Company could ultimately be liable for the TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Millipred License and Supply Agreement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License and Supply Agreement for Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Watson Laboratories, Inc., which is now part of Teva. Pursuant to the License and Supply Agreement, the Company is required to make license payments of $<ix:nonFraction unitRef="usd" contextRef="ic7d61bbf3f01410cbe5cb14793b039dc_D20200101-20210430" decimals="-3" format="ixt:numdotdecimal" name="cerc:LicenseAgreementSemiAnnualLicensePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjU5NzA2OTc3OTcxOQ_673e6288-e0e7-42f2-a852-29305dee3c6a">75,000</ix:nonFraction> in February and August of each year through April 2021 and purchases inventory on an ad-hoc basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a prior amendment to extend the contract to its current term, Cerecor agreed to pay Teva <ix:nonFraction unitRef="number" contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401" decimals="2" format="ixt-sec:numwordsen" name="cerc:LicenseAgreementPercentOfNetProfitForInstallmentPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTA5OTUxMTY2MDg3Nw_09761cb4-adbd-49b0-9cac-7e20b609d5f0">fifty</ix:nonFraction> percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $<ix:nonFraction unitRef="usd" contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementInstallmentPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTA5OTUxMTY2MDk3OA_5ab2dd0b-c712-4e83-959e-d328c3b4963c">0.5</ix:nonFraction>&#160;million quarterly minimum payment, which was set to begin on April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#8217;s board of directors and also serves as the Chairman of Teva&#8217;s board of directors.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Proceeds for Out-Licensed Compounds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-611 License Assignment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into an assignment of license agreement (the &#8220;Assignment Agreement&#8221;) with ES Therapeutics, LLC (&#8220;ES Therapeutics&#8221;), a wholly-owned subsidiary of Armistice, which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board. Pursuant to the Assignment Agreement, the Company assigned and transferred its rights, title, interest, and obligations with respect to CERC-611 to ES Therapeutics. The Company initially licensed the compound from Eli Lilly Company (&#8220;Lilly&#8221;) in September 2016. Under the Assignment Agreement, Armistice paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4a82b49fc85849e9b165488476f66b9c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzI3MQ_45dd81e5-ce20-43c8-94af-949336976532">0.1</ix:nonFraction> million.  The Company recognized the payment as license and other revenue in 2019. The Assignment Agreement also provides for: (a) a $<ix:nonFraction unitRef="usd" contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestonePaymentNumberOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzQzNw_ff882fa8-ee63-4fb5-83fb-c561516f4ad0">7.5</ix:nonFraction> million milestone payment to the Company upon cumulative net sales of licensed products reaching $<ix:nonFraction unitRef="usd" contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzUyOQ_fb3ddd45-96a2-422e-b2ff-6e92285f0d39">750.0</ix:nonFraction> million; and (b) a $<ix:nonFraction unitRef="usd" contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestonePaymentNumberTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzU0Mw_d650a8f8-48d4-438b-8914-324d9bf42cf8">12.5</ix:nonFraction> million milestone payment to the Company upon cumulative net sales of licensed products reaching $<ix:nonFraction unitRef="usd" contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831" decimals="-8" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzYzNQ_9093c134-b966-444c-acd9-718cf6e02c67">1.3</ix:nonFraction> billion. The Assignment Agreement also releases the Company of obligations related to CERC-611, including the $<ix:nonFraction unitRef="usd" contextRef="i3b0da54fc099444480f1290196a28e52_I20190831" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseObligationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzczNg_1d02602f-9e94-448c-8f49-22c947e4a1e1">1.3</ix:nonFraction> million contingent payment to Lilly upon the first subject dosage of CERC-611 in a multiple ascending dose study and from additional potential future payments due to Lilly upon achievement of certain development and commercialization milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-501 Sale to Janssen</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company sold its worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) in exchange for initial gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="iaa172516dbef43d4a1c0924d5edda6d8_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDMzMQ_639d8a1d-5895-4a97-b076-3c561203299b">25.0</ix:nonFraction> million. There is a potential future $<ix:nonFraction unitRef="usd" contextRef="i66d40f7899394f23b9dadb48b6bcfb61_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="cerc:PotentialFutureRegulatoryMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDM2NA_826d7365-856d-4b24-bf91-b5b4976688ec">20.0</ix:nonFraction> million regulatory milestone payment to the Company upon acceptance of an NDA for any indication. The terms of the agreement provide that Janssen will assume ongoing clinical trials and be responsible for any new development and commercialization of CERC-501. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Payments for In-Licensed Compounds </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to license and development agreements with various third parties, which contain future milestone payments and other future payment obligations (discussed further below). The Company recognizes a liability (and related expense) for each milestone if and when such milestone is probable and can be reasonably estimated. As typical in the biotechnology industry, each milestone has its own unique risks that the Company evaluates when determining the probability of achieving each milestone and the probability of success evolves over time as the programs progress and additional information is obtained. The Company considers numerous factors when evaluating whether a given milestone is probable including (but not limited to) the regulatory pathway, development plan, ability to dedicate sufficient funding to reach a given milestone and the probability of success. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iab493ea9a987474589dfa0fa6afb28ba" continuedAt="i4fbeeb8f95ee4e218be30e7eff7fb203"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-002 KKC License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) for exclusive worldwide rights to develop, manufacture and commercialize CERC-002, KKC&#8217;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the &#8220;KKC License Agreement&#8221;). The KKC License Agreement replaces the Amended and Restated Clinical Development and Option Agreement between the Company and KKC dated May 28, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the KKC License Agreement, the Company paid KKC an upfront license fee equal to $<ix:nonFraction unitRef="usd" contextRef="i1fe9f3116d8e45d4a2a1a175df1addb6_D20210325-20210325" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3Mjg5Nw_0f093e3a-764c-4363-a1d2-c7d224eddc75">10.0</ix:nonFraction>&#160;million. The Company will also pay KKC milestone payments based on achievement of certain success-based regulatory milestones that equal, for each of three separate indications of CERC-002, mid-teen millions of dollars or less depending on the territory to which the regulatory milestone achievement relates. In addition, the Company will pay KKC (a) royalties during a country-by-country royalty term agreement equal to mid-teens percentage of the net sales of CERC-002 by the Company, (b) sales milestone payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i1fe9f3116d8e45d4a2a1a175df1addb6_D20210325-20210325" decimals="-6" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestonePaymentNumberOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTQ5NzU1ODE2OTczNA_998c2649-dba9-4858-94fb-3bbb326459ad">75</ix:nonFraction>&#160;million tied to achievement of annual net sales targets, and (c) a double digit percentage (less than <ix:nonFraction unitRef="number" contextRef="if09f167c7bc048a9bc324012285069cf_I20210325" decimals="INF" name="cerc:LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDk0NzgwMjM1NzQ4NA_42441b10-478a-4fc1-8583-7d8182cdfa3e">30</ix:nonFraction>%) of the payments that the Company receives from sublicensing of its rights under the KKC License Agreement, subject to certain exclusions. Subject to the option described below that allows, upon exercise, KKC to develop, manufacture and commercialize CERC-002 in Japan, the Company will be responsible for the development and commercialization of CERC-002 in all indications worldwide. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted KKC an option to exclude Japan from the scope of the worldwide rights granted to the Company such that, upon exercise of the option, KKC can develop, manufacture and commercialize CERC-002 in Japan. Upon exercise of the Option, KKC will be required to (a) reimburse the Company for a pre-agreed percentage of certain of its costs incurred to develop CERC-002 as a condition to KKC accessing the Company&#8217;s data that would be required to be included in an application for marketing authorization, (b) pay the Company for its services (such as transfer of data and regulatory support), (c) pay for all further development of CERC-002 in Japan and (d) pay any royalty due to the Company&#8217;s licensors on sales of CERC-002 in Japan. KKC will also have the right to purchase CERC-002 from the Company for use in Japan. No other amounts would be payable by KKC to the Company such as license fees, royalties and milestone payments. The option will expire if KKC does not exercise it within a set number of days after the FDA accepts for filing a Biologics License Application for a pre-defined indication of CERC-002. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ia883540f2ef34a27a1304fff4fc68648_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="cerc:LicenseAgreementUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTQ5NzU1ODE2NjI5Mg_e596512d-d849-4e6e-8cf9-955d664ef501">10.0</ix:nonFraction>&#160;million within research and development expenses for the three months ended March 31, 2021 and made the payment in April 2021. The Company has not recognized any liabilities related to the milestones outlined in the KKC License Agreement as of March 31, 2021. The Company will continue to monitor the milestones at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-006 Astellas License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly owned subsidiary of Astellas Pharma, Inc. (&#8220;Astellas&#8221;), for the worldwide development and commercialization of the novel, second generation mTORC1/2 inhibitor (which we refer to as CERC-006). Under the terms of the license agreement, the Company paid Astellas an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3MjkyMw_efdc6f5f-5742-4d91-b22f-799fd4b818f9">0.5</ix:nonFraction>&#160;million and Astellas will be eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestonePaymentNumberOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3MjkzNw_8e8a1a69-8a4a-418f-8eeb-a362182e8887">5.5</ix:nonFraction>&#160;million based upon the achievement of specified development and regulatory milestones. Upon commercialization, Astellas will be entitled to a tiered, single-digit royalty on worldwide annual net sales. Cerecor is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, the Company accrued a $<ix:nonFraction unitRef="usd" contextRef="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementMilestonePaymentRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTA5OTUxMTY1MzkwOA_af2f6997-8ab7-4be1-b21c-29ece9412c9a">0.5</ix:nonFraction>&#160;million milestone payment due to Astellas upon confirmation from the FDA that an initial signal finding study may proceed in the United States given the Company concluded it was probable the Company will begin such study in 2021.  The Company will continue to monitor the remaining milestones at each reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-007 AstraZeneca License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive global license to develop and commercialize a Phase 2-ready fully human, anti-IL-18 monoclonal antibody (which we refer to as CERC-007) from Medimmune Limited, a subsidiary of AstraZeneca plc (&#8220;AstraZeneca&#8221;). Up to $<ix:nonFraction unitRef="usd" contextRef="ic7017084953a4b4da0c861f92df38447_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="cerc:LicenseAgreementPotentialMilestonePaymentNumberOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3Mjk2NQ_87416eac-6f2d-4bb4-ae85-d32e78129133">162</ix:nonFraction>&#160;million may be due to AstraZeneca upon achievement of certain development and sales-related milestones, in addition to a tiered low double-digit royalty on global annual product sales. Cerecor is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, Cerecor recognized a $<ix:nonFraction unitRef="usd" contextRef="ic249f77612fd40feb83d3691de9d3623_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cerc:LicenseAgreementMilestonePaymentRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTQ5NzU1ODE3MTM1OA_18a74a7f-2fd5-4245-9dd7-e2a83d7ecb5e">1.5</ix:nonFraction>&#160;million milestone payment to AstraZeneca within research and development expenses, which was due upon initiation of the first proof-of-concept study which uses CERC-007. The Company made such payment in the first quarter of 2021. The Company will continue to monitor the remaining milestones at each reporting period. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4fbeeb8f95ee4e218be30e7eff7fb203" continuedAt="i129dea12b99e4b1183806f2a3cb194bd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party and Acquisition Related Contingent Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-006 Royalty Agreement with Certain Related Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to Cerecor entering into the Aevi Merger, in July 2019, Aevi entered into a royalty agreement with Mike Cola, Cerecor&#8217;s current Chief Executive Officer, Joseph J. Grano, Jr., Kathleen Jane Grano, Joseph C. Grano, The Grano Children&#8217;s Trust, Joseph C. Grano, trustee and LeoGroup Private Investment Access, LLC on behalf of Garry A. Neil, Cerecor&#8217;s current Chief Scientific Officer (collectively, the &#8220;Investors&#8221;) in exchange for a one-time aggregate payment of $<ix:nonFraction unitRef="usd" contextRef="i2a16536d275e465da455b4c203c89422_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="cerc:RoyaltyAgreementPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTU0OA_630601d0-19fc-438a-a955-0d80a0526b8a">2.0</ix:nonFraction> million (the &#8220;Royalty Agreement&#8221;). Collectively, the Investors will be entitled to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of Astellas&#8217; second generation mTORC1/2 inhibitor, CERC-006. At any time beginning <ix:nonNumeric contextRef="i2a16536d275e465da455b4c203c89422_D20190701-20190731" format="ixt-sec:durwordsen" name="cerc:RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTgwOA_4ab143fb-faa0-4e19-825d-8fa864edb003">three years</ix:nonNumeric> after the date of the first public launch of CERC-006, Cerecor may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of <ix:nonFraction unitRef="number" contextRef="i2a16536d275e465da455b4c203c89422_D20190701-20190731" decimals="INF" name="cerc:RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA1NA_fe461645-ae35-47da-98fb-0f87f0f08d1c">75</ix:nonFraction>% of the net present value of the royalty payments.&#160;A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cerecor assumed this Royalty Agreement upon closing of the Aevi Merger and it is recorded as a royalty obligation within the Company&#8217;s accompanying condensed consolidated balance sheet as of March 31, 2020.  Because there is a significant related party relationship between the Company and the Investors, the Company treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which would result in a corresponding increase in the liability balance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger Possible Future Milestone Payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the consideration for the Aevi Merger includes <ix:nonFraction unitRef="milestone" contextRef="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203" decimals="INF" format="ixt-sec:numwordsen" name="cerc:AssetAcquisitionContingentValueRightNumberOfMilestones" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDk0NzgwMjM1NzU0MQ_4ee375fd-0907-40a0-8185-67950c4d4dc1">two</ix:nonFraction> future contingent development milestones worth up to an additional $<ix:nonFraction unitRef="usd" contextRef="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNzMzMg_28c07a6c-535a-4460-80ef-25c7921a19c9">6.5</ix:nonFraction> million. The first milestone is the enrollment of a patient in a Phase 2 study related to CERC-002 for use in pediatric onset Crohn&#8217;s disease, CERC-006 (any indication) or CERC-007 (any indication) prior to February 3, 2022. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ic77ef76142994d109c2c47014a1f6c8d_I20200203" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNzYwMg_8d69cf6f-0f35-4f6f-9f50-968237fb8acd">2.0</ix:nonFraction> million. The second milestone is the receipt of a NDA approval for either CERC-006 or CERC-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i14700ec8a6124480982805c40bb35d5b_I20200203" decimals="-5" format="ixt:numdotdecimal" name="cerc:AssetAcquisitionContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNzgyMQ_22d698f2-560f-404f-bead-f3f3eba7a256">4.5</ix:nonFraction> million. All milestones are payable in either shares of the Company&#8217;s common stock or cash, at the election of the Company.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated.  As of the consummation of the Merger on February 3, 2020 and as of March 31, 2021, <ix:nonFraction unitRef="usd" contextRef="i196aed014b0d4c248e5addc0ece06d67_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTQ4NDM0MDcwMDc0ODU_a243afed-a676-4301-9822-9cb79b2f6ba3">no</ix:nonFraction> contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ichorion Asset Acquisition Possible Future Milestone Payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company acquired Ichorion Therapeutics, Inc. including acquiring <ix:nonFraction unitRef="therapy" contextRef="i5971bb063e474274b182039d0516e79b_D20180901-20180930" decimals="INF" format="ixt-sec:numwordsen" name="cerc:NumberOfPreclinicalTherapies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfODUyMg_24577fad-41c9-400f-9fdc-3b1170cad4ed">three</ix:nonFraction> compounds for inherited metabolic disorders known as CDGs (CERC-801, CERC-802 and CERC-803) and <ix:nonFraction unitRef="therapy" contextRef="i6b3a6dd6de704eda88270dee17a54df9_D20180901-20180930" decimals="INF" format="ixt-sec:numwordsen" name="cerc:NumberOfPreclinicalTherapies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfODYyMQ_91694c10-8ac9-4cbb-8122-425c36f48910">one</ix:nonFraction> other preclinical compound. Consideration for the transaction included shares of Cerecor common stock and <ix:nonFraction unitRef="milestone" contextRef="i88d92807dcac45b09cb550ee806b75f2_D20200203-20200203" decimals="INF" format="ixt-sec:numwordsen" name="cerc:AssetAcquisitionContingentValueRightNumberOfMilestones" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDk0NzgwMjM1OTgwMA_339c45c2-fc89-4988-adf0-d6def3249a36">three</ix:nonFraction> future contingent development milestones for the acquired compounds worth up to an additional&#160;$<ix:nonFraction unitRef="usd" contextRef="i7386371b6dd84a49af329b3ccfa42f9a_I20180930" decimals="-5" name="cerc:AssetAcquisitionContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfODgzMQ_d35d4a9b-dfe5-46e9-aebc-68d525ae62ed">15.0</ix:nonFraction> million. The first milestone is the first product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="if8b8acd95e6a4be8b07437719d50a52d_D20180901-20211231" decimals="-5" format="ixt:numdotdecimal" name="cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTA0MQ_dd0f9866-4ab8-4c60-9bca-42149ec8bbb8">6.0</ix:nonFraction>&#160;million. The second milestone is the second product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i12f98b2dbe45438893e30257af07b4bc_D20180901-20231231" decimals="-5" format="ixt:numdotdecimal" name="cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTI0NQ_b3224efa-c3bb-49d8-9153-06663075a475">5.0</ix:nonFraction>&#160;million. The third milestone is a protide molecule being approved by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="iab022d6245a44ee3a9b76763b77c8a31_D20180901-20231231" decimals="-5" format="ixt:numdotdecimal" name="cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTQzNA_b2de801b-1ca4-47c2-aa07-127047aba6dd">4.0</ix:nonFraction>&#160;million. All milestones are payable in either shares of the Company&#8217;s common stock or cash, at the election of the Company. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i129dea12b99e4b1183806f2a3cb194bd">The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated. As of March 31, 2021, <ix:nonFraction unitRef="usd" contextRef="ib7287b6670b3448ea1ab4049c76715ed_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTc0Mw_02a32b36-2b98-447c-8586-b490fce94d92">no</ix:nonFraction> contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;aims,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;pro forma,&#8221; &#8220;anticipates,&#8221; &#8220;potential&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of product candidates or products, technology enhancements, possible changes in legislation, and other statements that are not historical. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II &#8211; Item 1A, &#8220;Risk Factors,&#8221; as well as in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March&#160;8, 2021, and in our other filings with the SEC. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.</span></div><div style="text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December&#160;31, 2020 appearing in our Annual Report on Form 10-K filed with the SEC on March&#160;8, 2021. &#160;&#160;&#160;&#160;</span></div><div style="text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cerecor Inc. (the &#8220;Company&#8221; or &#8220;Cerecor&#8221; or &#8220;we&#8221;) is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases. The Company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company&#8217;s rare disease pipeline includes CERC-801, CERC-802 and CERC-803 (&#8220;CERC-800 compounds&#8221;), which are in development for therapies for congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor in development for the treatment of complex lymphatic malformations. The Company is also developing two monoclonal antibodies, CERC-002 and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for the treatment of severe pediatric-onset Crohn&#8217;s disease and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still&#8217;s disease (adult onset Still&#8217;s disease and systemic juvenile idiopathic arthritis) and multiple myeloma. CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Designation, which makes all four eligible for a priority review voucher (&#8220;PRV&#8221;) upon approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company continues to explore strategic alternatives for its commercialized product, Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, and for its non-core neurology pipeline assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Management&#8217;s primary evaluation of the success of the Company is the ability to progress its pipeline assets forward towards commercialization or opportunistically out-licensing rights to indications or geographies. This success depends not only on the operational execution of the programs, but also the ability to secure sufficient funding to support the programs. We believe the ability to achieve the anticipated milestones (as presented in the Research and Development Updates milestone chart below), represents our most immediate evaluation points.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have made significant progress in 2021 toward our key goal of advancing the pipeline as highlighted by the successful CERC-002 COVID-19 ARDS Phase 2 proof-of-concept data release and subsequent receipt of fast-track designation (&#8220;FTD&#8221;), completion of the first cohort of the CERC-007 Multiple Myeloma Phase 1b trial, obtaining FTD for CERC-803 and enrollment of the first patient in the CERC-007 AOSD Phase 1b open-label proof-of-concept trial. We also believe that the expanded license agreement with Kyowa Kirin Co. (&#8220;KKC&#8221;) will allow us to explore CERC-002 in other indications and to enhance the pipeline asset&#8217;s potential for business development opportunities. Finally, the financing executed in January for net proceeds of $37.7&#160;million provided cash runway for the development of our pipeline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expect COVID-19 to continue to present both challenges and opportunities to our business. However, there were no recent developments impacting the Company related to COVID-19. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Recent Developments</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Research and Development Updates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 25, 2021, the Company entered into an expanded license agreement with KKC for exclusive worldwide rights to develop, manufacture and commercialize CERC-002, KKC&#8217;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications. KKC has an option to retain the rights in Japan. The Company paid a $10.0 million upfront license fee to KKC in April 2021. KKC is also eligible to receive additional payments based on achievement of regulatory and commercial milestones, as well as royalties, and a share of sublicensing income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In May 2021, the Company announced that it dosed its first patient in a Phase 1b open-label dose-escalation clinical trial of CERC-007 in patients with adult onset Still&#8217;s disease (&#8220;AOSD&#8221;). The Phase 1b clinical trial is a global multi-center, open label trial of CERC-007 that will enroll approximately 12 subjects with active AOSD. The primary objective of the study is to determine the safety and tolerability of CERC-007 in AOSD patients. Key secondary endpoints include assessing pharmacokinetic profile of CERC-007 and determining the effect of CERC-007 on systemic clinical manifestations and systemic markets of inflammation in subjects with AOSD. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In May 2021, the Company announced the FDA had granted FTD to CERC-002 for treatment of hospitalized patients with COVID-19. FTD is granted to drugs being developed for the treatment of serious or life-threatening diseases or conditions where there is an unmet medical need. The purpose of the provision is to help facilitate development and expedite the review of drugs to treat serious or life-threatening conditions so that an approved product can reach the market expeditiously. Sponsors of drugs that receive FTD have the opportunity for more frequent interactions with the FDA review team throughout the development program. Under FTD, a Biologic License Application (&#8220;BLA&#8221;) for CERC-002 is eligible for both rolling submission and priority review.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following chart summarizes key information about our clinical-stage pipeline and anticipated research &amp; development milestones: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><img src="cerc-20210331_g1.jpg" alt="cerc-20210331_g1.jpg" style="height:491px;margin-bottom:5pt;vertical-align:text-bottom;width:675px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for increasing stockholder value includes: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 25</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advancing our pipeline of compounds through development and to regulatory approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquiring or licensing rights to targeted, complementary differentiated preclinical and clinical stage compounds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing the go-to-market strategy to quickly and effectively market, launch, and distribute each of our compounds that receive regulatory approval; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Opportunistically out-licensing rights to indications or geographies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2021 and 2020 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, net&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue was $0.5 million for the three months ended March 31, 2021, as compared to $2.8 million for the three months ended March 31, 2020. During the first quarter of 2021, the Company&#8217;s inventory on hand became short-dated (which the Company considers to be within six months of expiration), due to manufacturing delays. The Company recorded a full allowance of $2.9&#160;million for returns on the sale of short-dated inventory given the high likelihood of return. This led to a minimal amount of net sales being recognized in the first quarter of 2021, which drove the decrease as compared to the three months ended March 31, 2020. The Company received the delayed inventory lot in April 2021. Therefore, we expect net revenues of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to return to levels consistent with prior periods over 2021, however we continue to explore strategic alternatives for our non-core assets, which includes Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, our ability to increase revenue in the future will depend on developing and commercializing our current clinical pipeline of product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Product Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales was $0.1 million for the three months ended March 31, 2021, which was consistent with the cost of product sales for the three months ended March 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license and supply agreement for the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;), which expires on September 30, 2023. As part of a prior amendment to extend the contract to its current term, Cerecor agreed pay Teva fifty percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $0.5 million quarterly minimum payment, which was set to begin April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#8217;s board of directors and also serves as the Chairman of Teva&#8217;s board of directors. Beginning in the third quarter of 2021, we expect cost of product sales to increase as compared to historic periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMC expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and milestone expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $20.4 million for the three months ended March 31, 2021 compared to the same period in 2020. The Company&#8217;s merger with Aevi Genomic Medicine Inc. (&#8220;Aevi&#8221;) (the &#8220;Aevi Merger&#8221; or the &#8220;Merger&#8221;), which closed in February 2020, was a transformative event as it significantly broadened our pipeline by adding the rights to three new </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets, as well as bringing in critical leadership to guide the Company and development of the expanded pipeline. Given the timing of the Merger, the first half of 2020 was spent integrating and initiating the additional programs. Therefore, a main driver of the increase was due to a full quarter of expanded development activities for the three months ended March 31, 2021 (compared to preliminary activities for the prior year period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the increase was driven by a $10.0 million upfront license fee, which was recorded in March of 2021 and paid in April 2021, related to the expanded indication license agreement for CERC-002 entered into with KKC in March 2021. Furthermore, clinical expenses increased $4.9 million primarily due to costs incurred to advance the pipeline, most notably the CERC-800 compounds and CERC-007. Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;) expenses increased&#160;$3.5 million due to additional spending on manufacturing to support development of the progressing pipeline. Preclinical expenses increased $1.0 million due to an increase in non-clinical toxicity studies and biomarker studies to support clinical development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expense to continue to outpace historic periods, as the Company advances its maturing pipeline in anticipation of multiple clinical data readouts over the next twelve months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company consummated its merger with Aevi, resulting in the Company acquiring $25.5 million of in-process research and development (&#8220;IPR&amp;D&#8221;). The fair value of the IPR&amp;D was immediately recognized as acquired in-process research and development expense given such asset has no other alternate use due to the stage of development. There was no acquired in-process research and development for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the three months ended March 31, 2021 and 2020 (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal, consulting and other professional expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $4.9 million for the three months ended March 31, 2021, which represents a $2.2 million increase from the prior year period. The increase was largely driven by a $1.8 million increase in legal, consulting and other professional expenses. The largest drivers was higher legal costs in the current quarter, including costs to execute the KKC expanded indication license agreement and to advance other business development activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense increased $0.3 million as a result of increased headcount in the first quarter of 2021 (inclusive of a full quarter of expense for the executive leadership team, as opposed to a partial period in the prior year due to timing of the Aevi Merger) and as a result of service-based options granted to employees in January 2021 as part of its annual stock option award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect general and administrative expenses to continue to increase compared to historic periods as a result of the increased infrastructure to support the Company&#8217;s expanded research and development efforts.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Expenses </span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sales and marketing expenses for the three months ended March 31, 2021 and 2020 (in thousands):&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, benefits and related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising and marketing expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses consist of expenses related to initiatives to support the go-to-market strategy of our pipeline assets. For the three months ended March 31, 2020, we incurred costs related to market research projects for multiple programs and indications that did not repeat in the current year, thus driving the $0.2 million decrease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our amortization expense for the three months ended March 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense relates to the amortization of the assembled workforces acquired as part of previous acquisitions and mergers and was consistent for the three months ended March 31, 2021 and 2020. In 2020, as a result of the asset acquisition accounting treatment of the Aevi Merger, the Company recorded an assembled workforce intangible asset of $0.9 million, which was assigned a two-year useful life. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other income, net for the three months ended March 31, 2021 and 2020 (in thousands): </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of Investment in Aytu (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net decreased $7.1 million for the three months ended March 31, 2021, as compared to the prior year. For the three months ended March 31, 2020, other income, net was mainly comprised of a $7.1 million gain on change in the fair value of the Company&#8217;s investment in Aytu. As consideration of the Company&#8217;s divestiture of certain commercialized products to Aytu BioScience, Inc. (&#8220;Aytu&#8221;) in 2019 (the &#8220;Aytu Divestiture&#8221;), the Company received 9,805,845 shares of Aytu Series G Preferred Stock (the &#8220;Investment in Aytu&#8221;), which was remeasured at fair value each reporting period. As of March 31, 2020, the Investment in Aytu was $14.7 million, representing a change in fair value of $7.1 million from the prior reporting period (driven by a significant increase in Aytu&#8217;s stock price from December 31, 2019 to March 31, 2020). The Company subsequently converted such shares into common stock and sold that common stock for net proceeds of approximately $12.8 million in April 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense (Benefit)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense (benefit) for the three months ended March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognized minimal income tax expense for the three months ended March 31, 2021 compared to an income tax benefit of $2.2 million for the three months ended March 31, 2020.  The tax benefit recognized for the three months ended March 31, 2020 was a result of a tax law change signed into law as part of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), which allowed the Company to carry back certain losses for taxes paid in fiscal year 2017. Due to the full valuation allowance against the Company&#8217;s deferred tax assets and current year losses, minimal tax expense was recognized for the three months ended March 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed an underwritten public offering of 13,971,889 shares of its common stock and 1,676,923 pre-funded warrants for net proceeds of approximately $37.7&#160;million. As of March 31, 2021, Cerecor had $38.3 million in cash and cash equivalents. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company&#8217;s resources between investing in the Company&#8217;s existing pipeline assets and acquisitions or in-licensing of new assets. For the three months ended March 31, 2021, Cerecor generated a net loss of $30.7&#160;million and negative cash flows from operations of $18.3&#160;million. As of March 31, 2021, Cerecor had an accumulated deficit of $208.5&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its core research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy at least one year after the date the financial statements included herein were issued. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate these conditions and to meet the Company&#8217;s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive, (ii) federal and/or private grants, (iii) other out-licensing or strategic alliances/collaborations of its current pipeline assets, and (iv) out-licensing or sale of its non-core assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financings and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the long term, the Company&#8217;s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any PRVs it receives.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uses of Liquidity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cash to primarily fund the ongoing development of our research and development pipeline assets and costs associated with its organizational infrastructure. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the three  months ended March 31, 2021 and 2020 (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $18.3 million for the three months ended March 31, 2021 and consisted primarily of a net loss of $30.7 million, which was primarily driven by research and development activities as the Company continued to fund its pipeline of development assets. The three months ended March 31, 2020 included a one-time non-cash acquired IPR&amp;D expense of $25.5 million recorded in connection with the Aevi Merger, while the three months ended March 31, 2021 did not include a similar offset to cash used in operating activities. Additionally, the three months ended March 31, 2021 included a full quarter of development of the expanded pipeline from the Aevi Merger compared to a partial quarter in the prior year (in which the focus was integration as opposed to pipeline development). Changes in net liabilities increased by $10.4 million, mainly driven by a $9.3 million increase in accounts payable and $1.7 million increase in accrued expenses, partially offset by increased accounts receivable of $1.0 million. Accounts payable as of March 31, 2021 included the $10.0 million upfront license fee related to the expanded KKC license agreement for CERC-002, which was entered into March 2021. The Company subsequently paid the $10.0 million fee in April 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $5.7 million for the three months ended March 31, 2020 and consisted primarily of a net loss of $21.1 million, which was driven by research and development activities, and non-cash adjustments to reconcile net loss to net cash used in operating activities including a $7.1 million gain related to the change in fair value of the Investment in Aytu and a $1.8 million gain related to the change in the value of the Guarantee associated with the Aytu Divestiture. This decrease was offset by the following non-cash adjustments: non-cash acquired IPR&amp;D expense of $25.5 million and non-cash stock-based compensation of $1.1 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash used in investing activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was minimal for the three months ended March 31, 2021 and consisted primarily of the purchase of property and equipment. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $1.3 million for the three months ended March&#160;31, 2020 and consisted primarily of transaction costs incurred as part of the Aevi Merger, partially offset by the cash acquired as part of the Merger. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $37.8 million for the three months ended March 31, 2021 and consisted primarily of net proceeds of $37.7&#160;million from an underwritten public offering of 13,971,889 shares of common stock and 1,676,923 pre-funded warrants. Armistice Capital Master Fund Ltd. (an affiliate of Armistice Capital, LLC and collectively &#8220;Armistice&#8221;), which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, participated in the offering by purchasing 2,500,000 shares of common stock, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC (collectively, &#8220;Nantahala&#8221;), which beneficially owned greater than 5% of the Company&#8217;s outstanding common stock at the time of the offering and, therefore, were considered a related party pursuant to the Company&#8217;s written related person transaction policy, purchased 1,400,000 shares of common stock, on the same terms as all other investors. Nantahala also purchased the pre-funded warrants to purchase up to an aggregate of 1,676,923 shares of common stock at a purchase price of $2.599, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $9.1 million for the three months ended March&#160;31, 2020 and consisted primarily of net proceeds of $5.1 million from a registered direct offering with certain institutional investors, which included Armistice, that closed in February 2020 for the sale of 1,306,282 shares of common stock of Company and net proceeds of $3.9 million from a private placement of equity securities with Armistice during March 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Estimates, and Assumptions </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our unaudited condensed consolidated financial statements included in this Quarterly Report, which have been prepared in accordance with GAAP.&#160;In preparing the financial statements in conformity with GAAP, the Company makes estimates and assumptions that have an impact on assets, liabilities, revenue and expenses reported. These estimates can also affect supplemental information disclosed by us, including information about contingencies, risk, and financial condition. In our unaudited condensed consolidated financial statements, estimates are used for, but not limited to, revenue recognition, cost of product sales, stock-based compensation, fair value measurements, cash flows used in management&#8217;s going concern assessment, income taxes, goodwill, and other intangible assets and clinical trial accruals. The Company believes, given current facts and circumstances, that our estimates and assumptions are reasonable, adhere to GAAP and are consistently applied. Inherent in the nature of an estimate or assumption is the fact that actual results may differ from estimates, and estimates may vary as new facts and circumstances arise. Our most critical accounting estimates and assumptions are included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC on March&#160;8, 2021. There have been no material changes to our critical accounting policies during the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined by applicable SEC rules and regulations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 31</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide the information required by this Item.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule&#160;13a-15(b)&#160;and Rule&#160;15d-15(b)&#160;of the Securities Exchange Act of 1934, as amended, or the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form&#160;10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 32</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.  </span></div><div><span><br/></span></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_94"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021, which could materially affect our business, financial condition, or future results. Our risk factors as of the date of this Quarterly Report on Form 10-Q have not changed materially from those described in the Form 10-K referenced above. The risks described in the Form 10-K referenced above are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results of operations and the trading price of our common stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_97"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="kkclicenseagreement_redact.htm">License Agreement, dated March 25, 2021, by and between Cerecor Inc. and Kyowa Hakko Kirin Co., Ltd</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12021cercex-311.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12021cercex-312.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12021cercex-321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020; (ii) Condensed Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2021 and 2020; (iii) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2021 and 2020; (iv) Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited) for the Three Months Ended March 31, 2021 and 2020; and (v) Notes to Unaudited Financial Statements.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in XBRL (included in Exhibit 101).</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*  Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+  Filed herewith.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;  This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ic7bb257d793b4c13bdc2f5247f8e819f_100"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic7bb257d793b4c13bdc2f5247f8e819f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:5.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cerecor Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 13, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Schond L. Greenway</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schond L. Greenway</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(on behalf of the registrant and as the registrant&#8217;s principal financial officer)</span></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>kkclicenseagreement_redact.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i74883bf4c3b6450ca7f018b6b98cc87e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTION COPY</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTAIN INFORMATION IDENTIFIED WITH THE MARK &#8220;(***)&#8221;, &#8220;(***%***)&#8221; AND &#8220;(***$***)&#8221; HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">by and between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">KYOWA KIRIN CO., LTD.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AEVI GENOMIC MEDICINE, LLC</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RT</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 1. DEFINITIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_74" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2. GOVERNANCE </a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_74" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AFTER ELECTION OF THE JAPAN OPTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_74" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 3. DEVELOPMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_85" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_96" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4. COMMERCIALIZATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_96" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_108" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5. DILIGENCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_108" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_119" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 6. LICENSES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_119" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_131" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 7. FINANCIAL PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_131" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8. INTELLECTUAL PROPERTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_142" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_153" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9. CONFIDENTIALITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_153" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_165" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10. TERM AND TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_165" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_176" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 11. REPRESENTATIONS, WARRANTIES, AND COVENANTS&#59; DISCLAIMERS&#59; INDEMNIFICATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_176" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_63" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE</a><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_188" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 12. MISCELLANEOUS PROVISIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i74883bf4c3b6450ca7f018b6b98cc87e_188" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">55</a></font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedules</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 1.14 &#8211; Amino Acid Sequence of Anti-Light mAb</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 1.53 &#8211; KKC In-Licenses</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 1.57 &#8211; KKC Patent Rights</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_225"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LICENSE AGREEMENT</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This License Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), dated as of March 25, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is made by and between Kyowa Kirin Co., Ltd., a company organized and existing under the laws of the Japan and having its principal office at 1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan and formerly known as Kyowa Hakko Kirin Co., Ltd. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Aevi Genomic Medicine, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  KKC and AEVI may each be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTRODUCTION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Parties have entered into the Amended and Restated Clinical Development and Option Agreement, effective as of May 28, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development and Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Clinical Development and Option Agreement, KKC granted AEVI the right to conduct the Initial Development (as defined in the Clinical Development and Option Agreement) with respect to the Anti-LIGHT mAb (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and granted AEVI certain options to enter into various license agreements&#59; and </font></div><div style="margin-bottom:12pt;padding-left:24pt;text-indent:-12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Parties have decided to supersede the Clinical Development and Option Agreement and such options with this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_63"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 1.<br>DEFINITIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When used in this Agreement, each of the following terms will have the meanings set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means with respect to a Party, as applicable, (a) United States generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (b) Japanese generally accepted accounting standards, or (c) International Financial Reporting Standards, in each case consistently applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Acquirer Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Patent Rights and Know-How owned or controlled by a Third Party acquirer of AEVI or KKC, as the case may be, immediately prior to a Change of Control transaction, and Inventions thereto following the effective date of such Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a day on which banking institutions in New York, New York are open for business other than Saturday or Sunday.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the License Agreement between The Children&#8217;s Hospital of Philadelphia and Medgenics Medical Israel Ltd. (***).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any and all Inventions made or generated hereunder solely by employees or contractors of AEVI (or its Affiliates), as determined by the United States patent laws for inventorship, in each case while performing activities under this Agreement or the Clinical Development and Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Know-How that is (a) Controlled by AEVI or any of its Affiliates on the Effective Date or during the Term (other than KKC Know-How pursuant to the licenses granted hereunder) and (b) reasonably necessary or useful in connection with Development, Manufacture, use or Commercialization of Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Lonza License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Licence Agreement between AEVI and Lonza (***).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI&#8217;s Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Net Sales of AEVI and its Affiliates for all the Indications of Licensed Products excluding, for the avoidance of doubt, the Net Sales of  Sublicensees of AEVI or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (a) any Patent Rights included within AEVI Inventions that are reasonably necessary or useful in connection with the Development, Manufacture, use or Commercialization of Licensed Products and (b) any Patents Rights included in Third Party Technology (i) in respect of which AEVI obtains Control after the Effective Date and (ii) are reasonably necessary or useful in connection with the Development, Manufacture, use or Commercialization of Licensed Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI&#8217;s Sublicensee Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a milestone payment received by AEVI or any of its Affiliates under a Sublicense for achievement of a Milestone Event by the applicable Sublicensee of AEVI or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means AEVI Know-How, AEVI Patent Rights and AEVI Inventions other than Acquirer Intellectual Property. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.12&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to any person or entity, any other person or entity which controls, is controlled by, or is under common control with such person or entity.  A person or entity will be regarded as in control of another entity if it owns or controls more than fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the laws, rules and regulations, including without limitation any rules, regulations, guidelines or other requirements of the Regulatory Authorities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">applicable to the Development, Manufacturing or Commercialization of Licensed Products or other activities conducted by the Parties under this Agreement, that may be in effect from time to time in the applicable territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Anti-LIGHT mAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the fully human monoclonal antibody targeting LIGHT (TNFSF14) consisting of the amino acid sequence set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Title 11, United States Code, as amended, or analogous provisions of Applicable Law outside the United States. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BARDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Biosimilar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a reference brand biologic product and a particular jurisdiction, a biologic product&#58; (a) that is highly similar to such reference brand biologic product notwithstanding minor differences in clinically inactive components&#59; (b) has no clinically meaningful differences from such reference brand biologic product in terms of safety, purity and potency&#59; and (c) for which a Biosimilar Application is approved by the relevant Regulatory Authority of such jurisdiction.  Notwithstanding anything to the contrary in this Agreement, a &#8220;Biosimilar&#8221; does not include any biologic product sold under a BLA or approved Biosimilar Application of any Party or any of its Related Parties or manufactured or produced by or on behalf of a Party or any of its Related Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Biosimilar Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a Regulatory Approval Application for a product claimed to be biosimilar or interchangeable to any Licensed Product, or otherwise relying on the approval of such Licensed Product, in each case in accordance with Applicable Law in the jurisdiction in which the product is sought to be marketed and sold. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a Biologics License Application filed with FDA or the equivalent thereof filed with any other Regulatory Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Bristol-Myers Squibb Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to KKC, a KKC Business Day, and, with respect to AEVI, an AEVI Business Day. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger or consolidation, (b) except in the case of a bona fide equity financing in which a Party issues new shares of its capital stock, a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party&#8217;s business to which the subject matter of this Agreement relates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.23&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CHOP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means The Children&#8217;s Hospital of Philadelphia.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means importing, exporting, marketing, promoting, distributing, offering for sale and selling a Licensed Product in the Field and will include activities required to fulfill ongoing post-approval regulatory obligations, including adverse event reporting and sales force training.  When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; will mean to engage in Commercialization. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a Party, the carrying out of obligations in a diligent and sustained manner using such effort and employing such resources as would normally be exerted or employed by a similarly situated biopharmaceutical company for a product of similar commercial or strategic importance, and at a similar stage of its product life, based on conditions then prevailing, taking into consideration safety and efficacy, development costs, the anticipated prescription label, the nature of the Licensed Product, the clinical setting in which it is expected to be used and all other relevant factors.  Commercially Reasonable Efforts will be determined on a country-by-country basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.26&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to each Party, proprietary data or information of such Party or its Affiliates or Sublicensees, including, without limitation, (a) with respect to KKC, all KKC Technology, and, with respect to AEVI, all AEVI Technology, (b) any information designated as Confidential Information of such Party hereunder, in all cases that is identified as confidential either in writing or orally, provided that any orally disclosed information is described in reasonable detail in a written notice sent by the Disclosing Party to the Receiving Party within (***) of the oral disclosure requesting that such information be treated as Confidential Information hereunder, (c) all information that is manifestly confidential, whether or not marked as such and (d) all of the foregoing disclosed under the Clinical Development and Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Contract Quarters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the successive three (3) month periods in each Contract Year ending on March 31, June 30, September 30 or December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Contract Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the twelve (12) month period beginning on January 1 and ending on December 31 of each calendar year, provided, however, that the first Contract Year will be the period of time beginning on the Effective Date and ending on December 31, 2021.  Each Contract Year, except the first Contract Year, will be divided into four (4) Contract Quarters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means with respect to any (a) material, item of information, method, data or other Know-How, or (b) intellectual property right, the possession (whether by ownership or license, other than pursuant to this Agreement) by the referenced Party or its Affiliates of the ability to grant to the other Party access and&#47;or a license as provided herein under such item or right without violating the terms of any agreement or other arrangement with any Third Party existing before or after the Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Crohn&#8217;s Disease Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the clinical study of the Licensed Product defined in the protocol No. MDGN-002-CD-101 and listed on clinicaltrials.gov at NCT03169894.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.31&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Data Exclusivity Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a particular jurisdiction, the time period of legal protection and confidential treatment provided for clinical test data required to be submitted to a Regulatory Authority for such jurisdiction in order to demonstrate safety and efficacy of a new drug or biologic, and all similar protections on such clinical test data intended to prevent generic drug manufacturers or biosimilar manufacturers from relying on this data in their own Biosimilar applications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.32&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a Licensed Product in the Field, non-clinical and clinical drug development activities performed on or after the Effective Date, including without limitation the conduct of clinical trials, test method development, toxicology, pharmacology, pharmacokinetics formulation, data management, statistical analysis and report writing and clinical studies, and regulatory affairs and all activities associated with obtaining and maintaining Regulatory Approvals.  When used as a verb, &#8220;Develop&#8221; means to engage in Development.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.33&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means all costs and expenses, including FTE Costs and Out-of-Pocket Costs, incurred by or on behalf of a Party or any of its Affiliates in accordance with this Agreement and attributable to, or reasonably allocable to, the Development of the Licensed Products in the Field in the Territory, including costs and expenses for Regulatory Approvals and pricing and&#47;or reimbursement approvals, and costs incurred after Regulatory Approval, including Phase 4 Clinical Trial costs, costs of non-clinical studies, costs of CMC activities, costs of clinical studies for Indications in the Field and insurance costs incurred in connection with Development activities (but excluding costs that are allocable to Commercialization Costs and the costs of general company management, financial, legal or business development personnel).  In this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Phase 4 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a post-registration clinical trial or post-marketing surveillance study performed in accordance with Applicable Laws and required as a condition to, or for the maintenance of, any Regulatory Approval or pricing and&#47;or reimbursement approval for a Licensed Product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a written comprehensive plan for (a)&#160;the Development of any Licensed Product in the Field in the Territory, including, but not limited to, activities designed to generate the preclinical, process development&#47;manufacturing scale-up, clinical and regulatory information required for filing Regulatory Approval Applications in the Territory and (b)&#160;the preparation and submission of related Regulatory Approval Applications in the Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.35&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the European Medicines Agency and any successor agency having substantially the same functions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.36&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8220;European Union&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means all countries over which EMA has jurisdiction from time to time and all countries that exit the jurisdiction of the EMA from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.37&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Chief Executive Officer of AEVI (or an executive of AEVI designated by such Chief Executive Officer) and the Chief Executive Officer of KKC (or an executive of KKC designated by such Chief Executive Officer).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.38&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (a) with respect to investment by a Third Party in exchange for equity securities of AEVI, (i) for so long as AEVI&#8217;s common stock is publicly traded on a securities exchange, the volume weighted average closing price of a share of AEVI&#8217;s common stock on the principal exchange on which such stock is then trading for the ten (10) trading days ending on the date that is twenty (20) trading days on such exchange prior to the first public announcement of such equity investment, and (ii) if AEVI&#8217;s common stock is no longer publicly traded on a securities exchange, the fair market value of a share of common stock of AEVI as of the date of closing such investment as determined in good faith by the board of directors of AEVI, taking into account such factors and for such time period as the board of directors of AEVI reasonably deems is appropriate, and agreed to by KKC, such agreement not to be unreasonably withheld, delayed, or conditioned, and (b) with respect to any </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">non-cash consideration (other than equity securities), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the fair market value of such consideration as determined in good faith by the board of directors of AEVI and agreed to by KKC, such agreement not to be unreasonably withheld, delayed, or conditioned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.39&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the US Federal Food, Drug, and Cosmetic Act, as amended from time to time (21 U.S.C. Section 301 et seq.), together with any rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.40&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the United States Food and Drug Administration, or a successor agency in the United States with responsibilities comparable to those of the United States Food and Drug Administration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.41&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means treatment, prevention, and diagnosis of any and all diseases and conditions in humans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.42&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a given Licensed Product in a country, the first commercial sale in an arms-length transaction of such Licensed Product to a Third Party by or on behalf of a Party, its Affiliate or its Sublicensee in such country following receipt of the applicable Regulatory Approval of such Licensed Product in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.43&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a full time equivalent person year (consisting of a total of two thousand (2,000) hours per Contract Year, subject to a proportionate reduction in the first Contract Year) of scientific, technical, marketing, sales, distribution and certain general and administrative activities related to the Development of Licensed Products and&#47;or the Commercialization of the Licensed Products in the Field in accordance with this Agreement.  For the avoidance of doubt, no individual will count as more than one (1) FTE, and any individual who works less than two thousand (2,000) hours in a given Contract Year performing activities under this Agreement will be counted as a fraction of one (1) FTE, the numerator of which is the number of hours such individual performs activities under this Agreement and the denominator of which is two thousand (2,000) hours.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.44&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FTE Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means all costs for FTEs calculated by multiplying (a) the actual number of FTEs utilized by KKC or AEVI in performing activities in accordance with any Development Plan and&#47;or Commercialization Plan by (b) the applicable FTE Rate, provided that, to the extent either Party is unable to fully track the number of FTEs utilized, the Parties will agree on a mechanism for estimating such number.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.45&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to an FTE, the applicable amount set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as such amount may be adjusted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.46&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Governmental Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, institutes, bureaus, commissions, councils, or other government entities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.47&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an Investigational New Drug Application, as defined in the FD&#38;C Act, or similar application or submission that is required to be filed with any Regulatory Authority before beginning clinical testing of a Licensed Product in human subjects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a separate and distinct disease, disorder, illness or health condition for which separate clinical trial(s) and a separate BLA approval for the Licensed Products are required.  By way of example, (a) all indications for treatment of suspected or confirmed COVID-19 are considered the same Indication whereas (b) an indication for treatment of suspected or confirmed COVID-19 is a different and separate Indication from an Indication for treatment of pediatric onset inflammatory bowel disease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.49&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any and all ideas, information, Know-How, data research results, writings, inventions, discoveries, modifications, enhancements, derivatives, new uses, developments, techniques, materials, compounds, products, designs, processes or other technology or intellectual property, whether or not patentable or copyrightable, and all Patent Rights and other intellectual property rights in any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.50&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Japan Option Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Development Costs incurred by AEVI and its Affiliates and reasonably allocable to Development of the data and information that would be required to be included in a Regulatory Approval Application including pre-clinical data, safety data, chemistry, manufacturing and control information and data from proof-of-concept clinical trials and Phase 3 Clinical Trials but excluding the following Development Costs&#58; (a) Development Costs for Phase 3 Clinical Trials the data from which KKC and its Related Parties do not and will not include in any IND or Regulatory Approval Application&#59; (b) Development Costs incurred by AEVI and&#47;or its Affiliates prior to the Effective Date, including, without limitation, costs for purchasing raw materials, for manufacturing clinical supplies of Licensed Product or for any labeling or packaging materials, whether or not such raw materials, clinical supplies or labeling or packaging materials are used by AEVI or its Related Parties for Development activities&#59; and (c) on a dollar-for-dollar basis, Development Costs incurred by AEVI and&#47;or its Affiliates after the Effective Date and funded or reimbursed by any Governmental Entity (such as BARDA), charitable organization or any Sublicensee of AEVI or any of its Affiliates.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.51&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any and all Inventions made or generated hereunder jointly by at least one employee or contractor of each Party (or its respective Affiliates), as determined by United States patent laws for inventorship, in each case while performing activities under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.52&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a day on which banking institutions in Tokyo, Japan are open for business other than a Saturday or Sunday.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.53&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Third Party agreements listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.54&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any and all Inventions made or generated hereunder solely by employees or contractors of KKC (or its Affiliates), as determined by the United States patent laws for inventorship, in each case while performing activities under this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.55&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Know-How that is (a) Controlled by KKC on the Effective Date (including all such Know-How to which KKC had rights under the Clinical Development and Option Agreement) or during the Term (other than AEVI Know How pursuant to the licenses granted hereunder) and (b) is reasonably necessary or useful in connection with the Development, Manufacture, use or Commercialization of Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.56&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Licensor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means LJI, BMS, and Sanofi, respectively defined in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and its respective successor and assigns, which has licensed rights to KKC pursuant to the KKC In-Licenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.57&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (a) the United States and foreign patents and patent applications listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and any Patent Rights arising from those patents and patent applications prior to the completion of the Term, (b) the United States and foreign patents and patent applications licensed to KKC under the KKC In-Licenses but not listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and any Patent Rights arising from those patents and patent applications prior to the completion of the Term, (c) any Patent Rights included within KKC Inventions prior to the completion of the Term that are reasonably necessary or useful in connection with the Development, Manufacture, use or Commercialization of Licensed Products in the Field in the Territory and (d) any Patents Rights included in Third Party Technology prior to the completion of the Term (i) in respect of which KKC obtains Control after the Effective Date and (ii) are reasonably necessary or useful in connection with the Development, Manufacture, use or Commercialization of Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.58&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means KKC Patent Rights, KKC Know-How and KKC Inventions other than Acquirer Intellectual Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.59&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any non-public, proprietary invention, discovery, process, method, composition, formula, procedure, protocol, technique, result of experimentation or testing, information, data, material, technology or other know-how, whether or not patentable or copyrightable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.60&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any product containing as an active ingredient the Anti-LIGHT mAb.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.61&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">LIGHT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means TNFSF14 (Unigene cluster number&#58; Hs. 129708).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.62&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">LJI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means La Jolla Institute for Immunology (formerly, La Jolla Institute for Allergy and Immunology) and its respective successor and assigns, which has licensed rights to KKC pursuant to the LJI Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.63&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">LJI Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means License Agreement between La Jolla Institute for Immunology and Kyowa Kirin Co., Ltd. (***) (including the LIGHT Addendum between La Jolla Institute for Immunology and Kyowa Kirin Co., Ltd. attached thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.64&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Lonza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Lonza Sales AG and its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.65&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, as applicable, all activities associated with the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and storage of Licensed Products and including without limitation process and formulation development, process validation, stability testing, process development, manufacturing scale-up, pre-clinical, clinical and commercial manufacture and analytical development, product characterization, quality assurance and quality control, whether such activities are conducted by a Party, its Affiliates or a Third Party contractor of such Party.  When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; will mean to engage in Manufacturing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.66&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;With respect to Licensed Product manufactured by AEVI, its fully-burdened costs (including the costs associated with product testing and release activities) of producing (including startup and validation but excluding what will be covered under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and packaging Licensed Product for sale in a given country, determined in accordance with the applicable Accounting Standard, based on the sum of the following components&#58; (i) direct costs, including manufacturing labor and materials directly incurred in producing and packaging such Licensed Product&#59; (ii) manufacturing and accounting personnel costs incurred by AEVI and attributable and reasonably allocable to the manufacture of Licensed Product, including quality labor and manufacturing and quality supervisory services, depreciation, and other operating and administrative costs which of the manufacturing, quality and accounting departments and associated occupancy costs which are allocable to such company departments based on space occupied or headcount, or other activity based method of allocation&#59; (iii) any other reasonable and customary Out-of-Pocket Costs incurred by AEVI for the testing, transport, customs clearance, duty, insurance and&#47;or storage of such Licensed Products, including payments made by AEVI to Third Parties for filing, finishing, packaging, labeling, testing, storage and shipment of such Licensed Product and AEVI&#8217;s handling cost with respect thereto, as applicable&#59; and (iv) AEVI&#8217;s reasonably allocated share of cost of Licensed Product process improvements developed by AEVI or a Third Party on behalf of AEVI.  For Licensed Products manufactured by AEVI, Manufacturing Cost will not include any general corporate overhead, any excess </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">capacity cost or charges or cost for process development (except to the extent expressly provided above).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;With respect to Licensed Product manufactured for AEVI by one or more Third Parties and supplied to KKC hereunder amounts actually paid (net of any discounts, credits or refunds) by such Party to such Third Parties for the manufacture and supply of such Licensed Product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.67&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a Licensed Product, activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, such Licensed Product, including, with respect to such Licensed Product&#58; (a) conducting service based medical activities including providing input and assistance with consultancy meetings, recommending investigators for clinical trials and providing input in the design of such trials and other research related activities, and delivering non-promotional communications and conduct non-promotional activities including presenting new clinical trial data and other scientific information&#59; (b) grants to support continuing medical education, symposia, or Third Party research specifically related to such Licensed Product&#59; (c) development, publication and dissemination of publications relating to such Licensed Product and relevant disease states&#59; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call or email&#59; (e) conducting advisory board meetings or other consultant programs&#59; (f) support of investigator-initiated clinical trials&#59; (g) managing relationships with cooperative groups, physician&#47;hospital networks and advocacy groups&#59; and (h) establishing and implementing risk, evaluation and mitigation strategies.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.68&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the gross invoiced sales by AEVI or any of its Related Parties to Third Parties for Licensed Products sold, less deductions, consistent with the applicable Accounting Standards used in the applicable reporting period for the selling party&#8217;s consolidated financial reporting purposes, which will be limited to&#58; (a) price adjustments, chargeback payments, credits, or&#160;rebates&#160;(or the equivalent thereof), allowances allowed and taken, quantity or other trade discounts and other amounts paid on sale of Licensed Products, including those granted to and actually used by group purchasing organizations or other buying groups, managed healthcare organizations, pharmacy benefit management companies, health maintenance organizations and any other providers of health insurance coverage, health care organizations or other healthcare institutions (including hospitals), Third Party health care administrators or patient assistance or other similar program, or to federal, state&#47;provincial, local and other governments, including their agencies, or to wholesalers, distributors and other trade customers&#59; (b) sales, use, tariffs, value-add, and&#47;or excise taxes, or other governmental charges and tariffs incurred in connection with exportation or importation directly imposed and with reference to particular sales&#59; (c) reasonable and customary freight, postage, shipping, insurance and other transportation expenses and delayed ship order credits reflected in the applicable invoice and paid by the customer&#59; and (d) amounts allowed, repaid or credited due to defects, returns, rejections, recalls, rebates and replacements and allowances of goods or because of retroactive price reductions&#59; (e) normal and customary rebates, trade, cash or quantity discounts&#59; billing errors&#59; coupons for price reductions&#59; (f) required distribution commissions&#47;fees payable to Third Party wholesalers for distribution of the Licensed Products&#59; (g) allowance and write-offs for bad </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">debt made in accordance with generally accepted accounting principles, consistently applied to all of the selling party&#8217;s products&#59; (h) discounts pursuant to indigent patient programs and patient discount programs including coupon discounts&#59; and (i) any item, substantially similar in character or substance to any of the foregoing permitted by the applicable Accounting Standards and customary in the pharmaceutical industry.&#160; Net Sales also includes the Fair Market Value of any non-cash consideration received in connection with the sale of the Licensed Products to Third Parties.&#160; In the case of any sale of Licensed Product for value other than in an arm&#8217;s length transaction exclusively for cash, Net Sales will be determined by referencing Net Sales at which substantially similar quantities of such Licensed Product are sold in an arm&#8217;s length transaction for cash.  For purposes of calculating Net Sales, transfers of Licensed Product between or among AEVI and any of its Related Parties, whether or not value is exchanged therefor, will not be booked as sales. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.69&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NMPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the National Medical Products Administration of China and any successor agency having substantially the same functions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.70&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Pocket Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to specified activities hereunder, direct expenses paid or payable by a Party or its Related Parties to Third Parties (other than employees of such Party or its Related Parties) that are specifically identifiable and incurred to conduct such activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.71&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means all patents (including all reissues, extensions, substitutions, confirmations, re-registrations, re-examinations, revivals or revalidations, supplementary protection certificates and patents of addition) and patent applications (including all provisional applications, continuations, continuations-in-part and divisions).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.72&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PHS Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the Public Health Services Act (Title 42, U.S.C., Chapter 6A). As used herein the PHS Act will refer, more specifically, to 42 USC &#167; 262, which governs the regulation of biological products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.73&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Product Labels and Inserts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (a) all labels and other written, printed or graphic matter affixed to any container, packaging or wrapper utilized with Licensed Product, or (b) any written material physically accompanying Licensed Product, including product package inserts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.74&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Product Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the trademark(s), service mark(s), accompanying logos, trade dress and&#47;or indicia of origin used in connection with the Commercialization of each Licensed Product in the Territory.  For purposes of clarity, the term Product Trademark(s) will not include, without limitation, the corporate names and logos of either Party, and will include any internet domain names incorporating such Product Trademarks.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.75&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the approval of the applicable Regulatory Authority necessary for the commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export and sale of a Licensed Product in a regulatory jurisdiction, including, where required, separate pricing and&#47;or reimbursement approvals.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.77&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Approval Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an application submitted to the appropriate Regulatory Authority seeking Regulatory Approval of a Licensed Product in a regulatory jurisdiction, including without limitation a BLA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.78&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any applicable supranational, national, regional, state or local regulatory agency, department, bureau, commission, council or other government entity involved in granting of Regulatory Approval for a Licensed Product in a regulatory jurisdiction, including without limitation the FDA, the EMA and the NMPA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.79&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any regulatory submissions, notifications, registrations, approvals and&#47;or other filings and correspondence made to or with a Regulatory Authority, and any other records required to be maintained for possible audit by a Regulatory Authority, that may be necessary or reasonably desirable to Develop, Manufacture, or Commercialize Licensed Products in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.80&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, with respect to a Party, such Party&#8217;s Affiliates and permitted licensees and Sublicensees, which term does not include wholesale distributors of such Party or its Affiliates, which distributors purchase a Licensed Product from such Party or its Affiliates in an arm&#8217;s-length transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.81&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, on a country-by-country basis, the period of time commencing on the date of the First Commercial Sale of the first Licensed Product in such country and extending until the later of (a) (***) from the date of the First Commercial Sale of such Product in such country&#59; (b) the expiration in such country of the last Valid Claim of the last to expire KKC Patent Rights&#59; and (c) expiration of the Data Exclusivity Period in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.82&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means Sanofi, successor in interest to Sanofi-Aventis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.83&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (a) a grant by AEVI or any of its Affiliates to a Third Party of the right to Develop or Commercialize a Licensed Product in any jurisdiction, (b) a covenant not sue granted by AEVI or any of its Affiliates to a Third Party in respect of such Third Party&#8217;s Commercialization of Licensed Product, (c) the grant of an option to receive or negotiate for either or both of the rights in clauses (a) or (b) by AEVI or any of its Affiliates, or (d) a grant by KKC or any of its Affiliates to a Third Party of the right to Develop or Commercialize a Licensed Product in Japan after KKC&#8217;s exercise of the Japan Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.84&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any Third Party granted a Sublicense by a Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.85&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sublicense Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means income received by AEVI or its Affiliates in consideration for the grant of a Sublicense such as license issue fees, milestone payments, royalties on the Commercialization of Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and the like but specifically excludes (a) amounts received by AEVI or any of its Affiliates as payment for manufacture or supply of any Licensed Product by AEVI or any of its Affiliates up to (***%***)&#59; provided that, for clarity, amounts so received in excess of (***%***) for such manufacture or supply shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">included as Sublicense Income, (b) AEVI&#8217;s Sublicensee Milestone Payments, (c) payments received for funding research and development services pursuant to a written research and development or funding agreement between AEVI and&#47;or any of its Affiliates, on the one hand, and any Governmental Entity (such as BARDA), charitable organization or Sublicensee of AEVI or any of its Affiliates up to the fair market value of such services, (d) proceeds received for the sale or issuance of any debt or equity security of AEVI or any of its Affiliates up to the Fair Market Value of such securities, and the sum of any cash consideration and the Fair Market Value of any non-cash consideration received by AEVI and its Affiliates in excess of the Fair Market Value of such securities will be included in the calculation of Sublicense Income&#93; and (e) reimbursements of documented out-of-pocket patent expenses incurred by AEVI or any of its Affiliates on a pass-through basis for reimbursement of patent prosecution or patent maintenance expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.86&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, (a) prior to the effectiveness of the Japan Option or following the expiration of the Japan Option Period without KKC making the Japan Option, worldwide, and (b) following the effectiveness of the Japan Option, worldwide except for Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.87&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any person or entity other than a Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.88&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Party Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any Patent Rights, Know-How, inventions, or other intellectual property owned, in whole or in part, by or licensed to a Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.89&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any claim in an issued and unexpired patent within the KKC Patent Rights which has not been disclaimed, abandoned, revoked, or held unenforceable, unpatentable or invalid by a governmental agency or competent court.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.90&#160;&#160;&#160;&#160;Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The following terms have the meanings set forth in the corresponding Sections of this Agreement&#58;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.435%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Term</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Section</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8220;AEVI Study Report&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BARDA Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BPCIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development and Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Introduction</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controlling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cooperating Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Defending Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.2(a)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Defensive Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.2</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.435%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Enforcement Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Global Clinical Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Infringement Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.7</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Japan Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Japan Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Joint Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Managed Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prosecuting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Publications&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Reference Product Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Section 351(k) Applicant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.1</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_74"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 2.<br>GOVERNANCE AFTER ELECTION OF THE JAPAN OPTION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Joint Steering Committee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Establishment of JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within (***) after the KKC exercises the Japan Option, the Parties will establish a committee to facilitate the Development and Commercialization of Licensed Products in Japan by KKC and in the rest of the world by AEVI (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Composition of the Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC will be comprised of two (2) representatives designated by each of the Parties.  Each representative will be an individual with significant experience or expertise in biopharmaceutical drug development.  Each Party will appoint its respective initial representatives to the JSC within (***) after the Effective Date, and may from time to time substitute its representatives, in its sole discretion, effective upon notice to the other Party of such change.  Additional representatives or consultants may from time to time be invited to attend JSC meetings, subject to such representatives&#8217; and consultants&#8217; written agreement to comply with the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will bear its own expenses relating to attendance at such meetings by its representatives and consultants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will designate one (1) of its representatives to be a co-chairperson (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Co-Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Co-Chairperson or its designee will conduct the following activities of the Joint Steering Committee cooperatively&#58; (i)&#160;scheduling meetings at least once per Contract Year, but more frequently if the JSC determines it necessary&#59; (ii)&#160;setting agendas for meetings with solicited input from representatives of each Party&#59; (iii)&#160;preparing and confirming minutes of the meetings, which will provide a description in reasonable detail of the discussions held at the meeting, and delivering minutes to each Party&#8217;s senior management for review and final approval&#59; and (iv) conducting effective meetings, including ensuring that objectives for each meeting are set and achieved.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC will meet in accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than once per Contract Year.  The JSC may meet by means of teleconference, videoconference or other similar communications equipment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Role</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC is a consultative body and may discuss any matter that a Party&#8217;s Co-Chairperson includes in the agenda for the meeting including&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;sharing information and discussing all Development Plans and amendments and updates thereto including Development of Indications beyond those being pursued by AEVI&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;sharing information, discussing, and coordinating global regulatory strategy, global clinical development strategy, and global clinical supply strategy&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;sharing information and discussing Commercialization of the Licensed Products, including strategic objectives and plans (including pricing and reimbursements), the Commercialization Plans and budgets and material amendments or updates thereto submitted to KKC by AEVI and Commercialization issues&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;discussing disputes between the Parties and discussing potential resolutions thereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC is a consultative body only and has no decision making power.  For the avoidance of doubt, AEVI has sole decision-making power to with respect to Development, Manufacturing and Commercialization of the Licensed Product in the Field in the Territory. </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_85"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 3.<br>DEVELOPMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will be responsible for all Development of the Licensed Product in the Field in the Territory.  AEVI will bear all costs and expenses incurred in connection with the Development of Licensed Product in the Field in the Territory including any and all regulatory activities.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;AEVI Development Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will provide KKC with a copy of its initial Development Plan for Development of the Licensed Product for treatment of patients in the United States with acute respiratory distress syndrome associated with COVID-19 within (***) after AEVI is permitted by the FDA to proceed with its next clinical trial investigating such treatment based on the protocol submitted by AEVI to the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than (***) and annually thereafter, AEVI will provide an updated Development Plan for the following Contract Year to KKC for informational purposes.  Each Development Plan will contain the specific Development objectives to be achieved by AEVI during the next Contract Year and the projected timeline for performing such Development activities.  AEVI will use its Commercially Reasonable Efforts to perform the activities set forth in each Development Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Global Clinical Study or Study in Japan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Until the expiration of the Japan Option or if KKC exercises the Japan Option, then thereafter, if AEVI plans to conduct a Global Clinical Study in various countries in the Territory (including Japan) or a clinical study of the Licensed Product in Japan, at KKC&#8217;s request AEVI will in good faith discuss with KKC including sites in Japan for such Global Clinical Study in order for KKC to consider exercising the Japan Option and join such Global Clinical Study or other clinical study in Japan.  In order for AEVI to include such sites in the Global Clinical Trial or if KKC exercises the Japan Option, such discussions must result in a mutually satisfactory amendment to this Agreement that addresses all relevant matters related to Japan including operational matters (such as allocation of responsibilities between the Parties), regulatory matters (such as preparation of any required IND, management of communications with Regulatory Authorities and which Party will be the holder of the IND&#47;sponsor of the trial), risk matters (including KKC indemnifying AEVI for Losses resulting from Third Party Claims arising from the trial at such sites including product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">liability and from AEVI&#8217;s performance of its allocated responsibilities) and KKC bearing all costs associated with (i) the services of AEVI and its Affiliates (such as transfer of AEVI Know-How and regulatory support to obtain Regulatory Approval in Japan) and (ii) further Development of the Licensed Product in Japan.  In this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Global Clinical Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Development of Licensed Products, a study with a unique protocol, the results of which are designed to be submitted to Regulatory Authorities of the United States and European Union and other countries as mandatory for obtaining Regulatory Approval of such Licensed Products in the respective countries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;KKC Development Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within (***) after KKC exercises the Japan Option, KKC will provide AEVI with a copy of its initial Development Plan for Development of the Licensed Product in Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than (***) prior to the beginning of the Contract Year that begins after the Contract Year in which KKC provided its initial Development Plan under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> KKC will provide an updated Development Plan to AEVI for informational purposes, except that if KKC&#8217;s proposed Development Plan in Japan is likely to, in the reasonable judgment of AEVI, present a substantial and identifiable risk to the Development or Commercialization of the Licensed Product outside of Japan, then the Parties must agree to changes to KKC&#8217;s proposed Development Plan that eliminate or reduce the risk to a level acceptable to AEVI before KKC may proceed with such Development Plan.  Each Development Plan will contain the specific Development objectives to be achieved by AEVI during the next Contract Year and the projected timeline for performing such Development activities.  AEVI will use its Commercially Reasonable Efforts to perform the activities set forth in each Development Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Development Event Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. KKC will inform AEVI of the occurrence of each of the following events in writing within (***) after such occurrence&#58; (a) commencement of the first Phase 3 Clinical Trial for any Licensed Product in Japan&#59; and (b) receipt of the first Regulatory Approval for any Licensed Product in Japan. In this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a registration or pivotal clinical trial performed in accordance with applicable laws and conducted in subjects with a particular disease or condition which is designed to establish the efficacy and safety of a Licensed Product given its intended use and to define warnings, precautions and adverse events that are associated with such Licensed Product in the dosage range intended to be prescribed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Development Responsibilities for Licensed Products in the Field in the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting the generality of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, AEVI will be responsible for Development activities for Licensed Product for the Field for Territory as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will develop a regulatory strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the Licensed Product for such Indications in the Field in the Territory as AEVI determines in its discretion.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to and in accordance with such regulatory strategy, AEVI will use Commercially Reasonable Efforts to prepare Regulatory Approval Applications or other submissions to Regulatory Authorities that are suitable in content and format for use in such countries in the Territory that AEVI determines to so file a Regulatory Approval Application (e.g., use of ICH eCTD format).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Communications with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to KKC&#8217;s exercise of the Japan Option, AEVI will be responsible for all communications with Regulatory Authorities concerning the Licensed Product in the Field in the Territory&#59; provided that (a) AEVI will keep KKC informed of any planned or actual material communications with any Regulatory Authority regarding Development of the Licensed Product in Japan and (b) AEVI will disclose to KKC any and all material correspondence between AEVI and any Regulatory Authority in Japan and minutes concerning the Development of the Licensed Product in the Field in Japan received from any Regulatory Authority in Japan within (***) after receipt or transmission thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will be responsible for preparing and filing Regulatory Approval Applications for the Licensed Products in the Field for the Territory as AEVI determines in its discretion.  Such Regulatory Approval Applications and any resulting Regulatory Approvals of the Licensed Products in the Field in the Territory will be made and issued in the name of AEVI or its Related Parties.  If KKC makes the Japan Option, KKC will cooperate with AEVI to provide all reasonable assistance and take all actions reasonably requested by AEVI that are necessary or desirable to enable AEVI to comply with any Applicable Law, including, but not limited to, reporting adverse drug experiences (and serious adverse drug experiences) to the applicable Regulatory Authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will develop a clinical development strategy for Licensed Product in the Field in the Territory as AEVI determines in its discretion.  AEVI will conduct clinical Development for Licensed Product in the Field in the Territory as necessary for preparing and submitting Regulatory Approval Applications in Field in the Territory as AEVI determines in its discretion.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will be solely responsible for all chemistry, manufacturing and control activities for the Licensed Product to support Regulatory Approval in the Field in the Territory, which, for clarity includes all CMC activities up to and including manufacturing process development, commercial scale-up and validation.  AEVI will bear all costs and expenses incurred in connection with the Manufacture of clinical supplies of Licensed Product for Development in the Field in the Territory (including failed batches and any batches, or parts thereof, that are Manufactured after the Effective Date, in anticipation of clinical studies but which are not actually used), and disposal of clinical samples.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Preclinical Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If deemed necessary by AEVI, AEVI will develop a preclinical strategy for the Field in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Drug Safety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibility Before Exercise of the Japan Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to exercise of the Japan Option and if the Japan Option expires, then thereafter, AEVI will hold and manage a safety database and will lead safety monitoring and reporting for the Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to KKC exercising the Japan Option, the Parties shall jointly develop and enter into a global safety data exchange and pharmacovigilance agreement to facilitate this exchange of information no later than (***) prior to the date of initiation of the first clinical study sponsored by KKC. In such case, AEVI will be responsible for holding and maintaining the global database for the Licensed Product and KKC will be responsible for pharmacovigilance activities in Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will maintain scientific records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which will fully and properly reflect all work done and results achieved in the performance of Development under this Agreement by such Party. Until expiration of the Japan Option Period or after KKC&#8217;s exercise of the Japan Option, KKC will have the right, no more than once per Calendar Year and on at least (***) prior notice, to inspect during normal business hours and upon reasonable notice and copy (or request the AEVI to copy) all records of AEVI maintained in connection with the work done and results achieved in the performance of Development under this Agreement.  All such records and the information disclosed to KKC in accordance with this Agreement will be maintained in confidence by KKC in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;Know-How Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In order to facilitate Development of Licensed Products, from time to time during the Term, KKC will disclose or transfer to AEVI any applicable KKC Know-How existing as of the Effective Date or developed after the Effective Date that is reasonably necessary or useful for the Development or Manufacture of the Licensed Products.  Except as otherwise provided under this Agreement or explicitly authorized in writing by a Party, all KKC Know-How delivered by KKC to AEVI or any of its Affiliates will remain the sole property of KKC.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_96"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 4.<br>COMMERCIALIZATION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will be solely responsible for all Commercialization activities relating to the Licensed Products in the Field in the Territory, and as between AEVI and KKC, AEVI will record all revenues on sales of Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Manufacturing and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">For the Account of AEVI and its Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will develop a manufacturing and supply strategy for the Licensed Product in the Field in the Territory as AEVI determines in its discretion.  Pursuant to this strategy, AEVI will be solely responsible for operational management of Manufacturing and supplying any Licensed Product for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization in the Field in the Territory.  For the avoidance of doubt, in the event AEVI&#8217;s Related Parties manufacture and supply the Licensed Products, it is necessary to obtain Sanofi&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Supply by AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following KKC&#8217;s exercise of the Japan Option, AEVI will Manufacture and supply all of KKC&#8217;s requirements of Licensed Product for Commercialization and&#47;or Development in Japan.  AEVI will supply KKC with unlabeled Licensed Product (vial or any other formulation) for clinical trials conducted in Japan and unlabeled Licensed Product (vial or any other formulation) for Commercialization in Japan, in each case (***).  AEVI will ship all Licensed Product FCA (INCOTERMS 2020) AEVI&#8217;s point of distribution.  The Parties will use Commercially Reasonable Efforts to complete within (***) after the date on which KKC exercises the Japan Option a supply agreement governing the terms of such supply by AEVI to KKC containing reasonable and customary terms contained herein and those additional terms typically associated with supply of pharmaceutical products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and a quality agreement related to the Supply Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will be solely responsible for Medical Affairs Activities with the Licensed Products in the Field in the Territory.  Follow KKC&#8217;s exercise of the Japan Option, KKC will be solely responsible for Medical Affairs Activities with the Licensed Products in Japan.  The applicable Party that is responsible for Medical Affairs Activities will have the exclusive right to respond to all questions or requests for information about the Licensed Products made by any medical professionals or any other Person in its respective territory that are beyond the scope of the Product Labels and Inserts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Cross Territory Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">KKC Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC will not Commercialize or authorize the Commercialization of any Licensed Product in the Field in the Territory.  KKC will not, itself or through any of its Affiliates or any Third Party, directly solicit, advertise, sell, distribute, ship, consign, or otherwise transfer any Licensed Products in the Field in the Territory&#59; provided that following exercise of the Japan Option, KKC may ship, consign, or otherwise transfer any Licensed Product inside Territory for purposes of Manufacturing the Licensed Products for Development and Commercialization of the Licensed Products in Japan.  Without limiting the generality of the foregoing, KKC will not, and will not permit any of its Related Parties to, sell any Licensed Product to a purchaser if it knows that such purchaser does, or intends to, promote the use of such Licensed Product in the Field in the Territory.  KKC will use Commercially Reasonable Efforts to ensure that its Related Parties comply with all of the foregoing obligations, including via the enforcement of KKC&#8217;s contracts with any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AEVI Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following exercise of the Japan Option, AEVI will not Commercialize or authorize the Commercialization of any Licensed Product in Japan.  Following exercise of the Japan Option, AEVI will not, itself or through any of its Affiliates or any Third Party, directly solicit, advertise, sell, distribute, ship, consign, or otherwise transfer any Licensed Product in Japan.    Without limiting the generality of the foregoing, following exercise of the Japan Option, AEVI will not, and will not permit any of its Related Parties to, sell any Licensed Product to a purchaser if it knows that such purchaser does, or intends to, promote </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the use of such Licensed Product in Japan.  Following exercise of the Japan Option, AEVI will use Commercially Reasonable Efforts to ensure that its Related Parties comply with all of the foregoing obligations, including via the enforcement of AEVI&#8217;s contracts with any of the foregoing.</font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_108"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 5.<br>DILIGENCE</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Diligence in Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will use Commercially Reasonable Efforts to Develop the Licensed Product in the Field in the Territory and to obtain Regulatory Approvals for the Licensed Product in the Field in France, Germany, Italy, Spain, the United Kingdom, the United States and China.  AEVI shall use Commercially Reasonable Efforts to complete the Crohn&#8217;s Disease Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Diligence in Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will use Commercially Reasonable Efforts to Commercialize each Licensed Product in each country for which it receives Regulatory Approval, including identifying and committing sufficient resources for pre-launch, launch and subsequent Commercialization activities in each such country.  Both Parties acknowledge and agree that there may be cases that AEVI may use Commercially Reasonable Efforts and choose not to Commercialize the Licensed Product in a given country due to reimbursement pricing or for some other material reasons, and in such cases AEVI will not be liable for a breach of the diligence obligation set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect of such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will provide the following reports and notice to KKC&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.1&#160;&#160;&#160;&#160;the Development Plan updates required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.2&#160;&#160;&#160;&#160;no later than April 15 of each Contract Year beginning in 2022, AEVI shall provide to KKC a written report summarizing (a) the status of its Development (including the status of any Regulatory Approval process) activities in the Field in the Territory as of March 31 of such Contract Year as compared to the most recently provided Development Plan and (b) its Commercialization activities with respect to the Licensed Products in the Field in the Territory on a Licensed Product-by-Licensed Product and country-by-country basis for the twelve month period ending March 31.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.3&#160;&#160;&#160;&#160;no later than September 30 of the Contract Year that follows the Contract Year in which the First Commercial Sale in any country occurs and annually thereafter, AEVI shall provide to KKC a sales forecast for the next Contract Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.4&#160;&#160;&#160;&#160;until expiration of the Japan Option Period, no later than (***) after AEVI receives top-line data for any proof-of-concept study of a Licensed Product, receives a substantially final clinical study report for any proof-of-concept study of a Licensed Product or substantially finalizes a protocol synopsis for a Phase 3 Clinical Trial of a Licensed Product (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Study Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), AEVI will provide each AEVI Study Report to KKC&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3.5&#160;&#160;&#160;&#160;AEVI will provided KKC notice or (a) commencement of the first Phase 3 Clinical Trial for any Licensed Product in the Territory&#59; and (b) receipt of the first Regulatory Approval for any Licensed Product in the Territory, in each case within (***) after the occurrence thereof.  </font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_119"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 6.<br>LICENSES </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;License Grants to AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, KKC grants to AEVI, under the KKC Technology, an exclusive, non-transferable (except in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) license, with the right to grant Sublicenses solely as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.1&#160;&#160;&#160;&#160;Develop Licensed Products in the Field in the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.2&#160;&#160;&#160;&#160;Manufacture or have Manufactured (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Licensed Products&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.3&#160;&#160;&#160;&#160;use, offer for sale, sell, have sold and otherwise Commercialize Licensed Products in the Field in the Territory&#59; in each of clause (i), (ii), and (iii)&#160;in accordance with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;License Grants to KKC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, following the exercise of the Japan Option, AEVI grants KKC, under the AEVI Technology, a non-exclusive, royalty-free (except as to the AEVI In-License as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.6.4(b))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> license, with the right to sublicense solely as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 6.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.1&#160;&#160;&#160;&#160; Develop, have Developed, Manufacture, have Manufactured, use, offer for sale, sell, have sold and otherwise Commercialize and have Commercialized Licensed Products in Japan&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.2&#160;&#160;&#160;&#160;Develop, have Developed, Manufacture, have Manufactured, use, offer for sale, sell, have sold and otherwise Commercialize and have Commercialized any diagnostic product that is reasonably necessary or useful in connection with the Manufacture, use, offer for sale, and&#47;or sale of the Licensed Product in Japan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160;Rights of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon KKC exercising the Japan Option, each Party hereby grants to the other Party the right to reference any and all Regulatory Approval Applications and Regulatory Approvals filed or obtained by the other Party in respect of a Licensed Product solely for use in connection with exercising such Party&#8217;s rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AEVI&#8217;s Right to Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the penultimate sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, AEVI may sublicense the rights granted to it under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to its Related Parties or Third Parties at any time.  AEVI will remain responsible for the performance of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicensees under this Agreement, including for all payments due hereunder.  AEVI will provide KKC with notice of each permitted Sublicense.  In addition, AEVI will provide a copy of any such Sublicense to KKC after execution of such Sublicense. All such notices of Sublicenses provided by AEVI under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be deemed to be Confidential Information of AEVI subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> whether or not so marked.  AEVI acknowledges and agrees that sublicensing of Manufacturing rights to, or subcontracting Manufacturing activities with respect to, the Licensed Product, and the right for using any Patent Rights, Know-How, inventions, or other intellectual property owned or controlled by Sanofi and licensed to KKC may be subject to Sanofi&#8217;s written consent.  If Sanofi&#8217;s written consent to sublicensing is so required, both Parties shall cooperate with each other to obtain such consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of Sublicenses by AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Sublicense granted by AEVI pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be subject and subordinate to the terms and conditions of this Agreement and will contain terms and conditions consistent with those in this Agreement.  Agreements with any Sublicensee of KKC that include the right to Commercialize any Licensed Product(s) will contain a requirement that such Sublicensee comply with the confidentiality and non-use provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to both Parties&#8217; Confidential Information. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">KKC&#8217;s Right to Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC may sublicense the rights granted to it under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to its Related Parties or Third Parties at any time, other than rights under the AEVI In-License which sublicensing by KKC requires the consent of CHOP.  KKC will remain responsible for the performance of its Sublicensees under this Agreement, including for all payments due hereunder.  KKC will provide AEVI with notice of each permitted Sublicense.  In addition, KKC will provide a copy of any such Sublicense to AEVI after execution of such Sublicense. All such notices of Sublicenses provided by KKC under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be deemed to be Confidential Information of KKC subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> whether or not so marked.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of Sublicenses by KKC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Sublicense granted by KKC pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be subject and subordinate to the terms and conditions of this Agreement and will contain terms and conditions consistent with those in this Agreement.  Agreements with any Sublicensee that include the right to Commercialize any Licensed Product(s) will contain a requirement that such Sublicensee comply with the confidentiality and non-use provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to both Parties&#8217; Confidential Information. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Termination on Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If this Agreement terminates for any reason, each Party agrees to use Commercially Reasonable Efforts to enter into direct licenses with the other Party&#8217;s Sublicensees&#59; provided that the Sublicensee is not in breach of its Sublicense agreement and such Sublicensee agrees to comply with all of the terms of this Agreement to the extent applicable from the rights originally sublicensed to it by sublicensing Party.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will be entitled to utilize the services of Third Parties, including Third Party contract research organizations and service providers to perform their respective Development activities&#59; provided that each Party will remain at all times fully liable for its responsibilities under this Agreement.  Any agreement with a Third Party to perform </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Party&#8217;s responsibilities under this Agreement will include confidentiality and non-use provisions which are no less stringent than those set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and intellectual property provisions that will such Party to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.5&#160;&#160;&#160;&#160;Japan Option</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Option Grant. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to the terms and conditions of this Agreement, AEVI hereby grants to KKC an exclusive option to remove Japan from the Territory and to obtain an exclusive license to Develop and Commercialize Licensed Products in Japan in accordance with the terms and conditions as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Japan Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Option Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  KKC may exercise the Option by giving AEVI written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at any time beginning on the Effective Date and ending at 5&#58;00PM United States Eastern Time on the date that is (***) that FDA accepted a BLA for (***) Indication of a Licensed Product filed by AEVI or any of its Related Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Japan Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  If KKC exercise the Japan Option prior to the expiration of the Japan Option Period in accordance with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the Territory will no longer include Japan.  As conditions to AEVI transferring any AEVI Technology to KKC for its use Japan, the Parties must enter into an agreement in form and substance acceptable to both Parties that obligates KKC to (i) pay AEVI an amount equal to (***%***) of the Japan Option Development Costs for the Licensed Products through the end of the Contract Quarter in which KKC exercises the Japan Option, (ii) pay for AEVI for its services (such as transfer of AEVI Know-How and regulatory support to obtain Regulatory Approval in Japan) and (iii) pay for all further Development Costs for the Licensed Product in Japan.  For the avoidance of doubt, if KKC fails to exercise the Japan Option prior to the expiration of the Japan Option Period in accordance with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, KKC will have no rights to Develop, Manufacture or have Manufactured, or Commercialize Licensed Products in the Field in Japan, and Japan will remain part of the Territory during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.6&#160;&#160;&#160;&#160;In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">KKC In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All licenses and other rights granted to AEVI by KKC under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are subject to the rights and obligations of KKC under the KKC In-Licenses.  For the avoidance of doubt, if KKC Controls only a non-exclusive license under a KKC In-License, KKC&#8217;s grant of exclusive license rights pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means that KKC and its Affiliates will not exercise and will not sublicense such rights with respect to Licensed Products in the Field in the Territory.  AEVI and its Related Parties, and the applicable rights and licenses granted to AEVI hereunder, shall be subject to the rights retained, and obligations imposed, by the US government pursuant to the Bayh-Dole Act, Chapter 18 of Title 35 of the United Stated Code, Sections 200-212 with respect to the KKC Patent Rights solely owned by LJI.  AEVI agrees to be bound by the pertinent sections of Sections 1, 2.2, 2.3, 2.4, 2.5, 3.1, 5.3, 7.3, 7.4, 7.6, 7.9, 8.4, 8.5, 8.6, 10.4, 10.5, 10.6, 11.1, 12.6, 12.7 and 12.10 of, the LJI Agreement to the same extent that KKC is bound thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AEVI In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All licenses and other rights granted to KKC by AEVI under this Article 6 are subject to the rights and obligations under the AEVI In-License.  KKC </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and its Related Parties, and the applicable rights and licenses granted to KKC hereunder, shall be subject to the rights retained, and obligations imposed, by the US government pursuant to the Bayh-Dole Act, Chapter 18 of Title 35 of the United Stated Code, Sections 200-212 with respect to the AEVI Patent Rights licensed from CHOP.  KKC agrees to be bound by the pertinent sections of Sections 2, 3.6, 8.1, 9.2 and 12.3 of the AEVI In-License to the same extent that AEVI is bound thereby.  In addition, the sublicense to KKC of the AEVI Technology licensed to AEVI under the AEVI In-License automatically terminates if and to the extent of termination of the AEVI In-License, subject to the right of KKC to request a direct license from CHOP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.7&#160;&#160;&#160;&#160;No Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly provided in this Agreement, under no circumstances will a Party, as a result of this Agreement, obtain any ownership interest or other right in any intellectual property rights of the other Party, including items Controlled or developed by the other Party, or provided by the other Party to such Party at any time pursuant to this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.8&#160;&#160;&#160;&#160;Obligation under the BARDA Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI shall be responsible for all requirements and obligations under the contract between AEVI and BARDA (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BARDA Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  KKC has no obligation for any research, Development, Manufacturing and&#47;or Commercialization of Licensed Product under the BARDA Contract.  </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_131"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 7.<br>FINANCIAL PROVISIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Initial License Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within (***) after the Effective Date, AEVI will pay to KKC an initial license fee of Ten Million dollars ($10,000,000).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, AEVI and its Related Parties will be solely responsible for payment of the Development Costs they incur in respect of Development of Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3&#160;&#160;&#160;&#160;Milestone Events and Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For up to three (3) different and separate Indications, AEVI will pay to KKC the amounts set forth below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) no later than thirty (30) days after the earliest date on which AEVI or any of its Related Parties receives written notification that the corresponding milestone event (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has been achieved with respect to a Licensed Product for a given Indication with the Milestone Payment equal to the amount in the column labeled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Payment if Achieved By AEVI or its Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if AEVI or its Affiliate is the person that filed or received approval of the relevant Regulatory Approval Application or in the column labeled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Payment if Achieved by AEVI&#8217;s Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if its Sublicensee is the person that filed or received approval of the relevant Regulatory Approval Application&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Milestone Event</font></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payment if Achieved By AEVI or its Affiliates</font></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="background-color:#b6b6b6;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payment if Achieved by AEVI&#8217;s Sublicensee</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***) for a Licensed Product by AEVI or its Related Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The greater of (***$***) or (***%***) of the AEVI&#8217;s Sublicensee Milestone Payment received for achievement of this Milestone Event</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***) for a Licensed Product by AEVI or its Related Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The greater of (***$***) or (***%***) of the AEVI&#8217;s Sublicensee Milestone Payment received for achievement of this Milestone Event</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)  for a Licensed Product by AEVI or its Related Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The greater of (***$***) or (***%***) of the AEVI&#8217;s Sublicensee Milestone Payment received for achievement of this Milestone Event</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***) for a Licensed Product filed with FDA by AEVI or its Related Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The greater of (***$***) or (***%***) of the AEVI&#8217;s Sublicensee Milestone Payment received for achievement of this Milestone Event</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***) for a Licensed Product filed with EMA by AEVI or its Related Party</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The greater of (***$***) or (***%***) of the AEVI&#8217;s Sublicensee Milestone Payment received for achievement of this Milestone Event</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***) for a Licensed Product filed with NMPA by AEVI or its Related Party</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The greater of (***$***) or (***%***) of the AEVI&#8217;s Sublicensee Milestone Payment received for achievement of this Milestone Event</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Repetition of Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the avoidance of doubt&#58; (a) a Milestone Payment in respect of Licensed Product in a given Indication is paid only once upon the first achievement of such Milestone Event for such Licensed Product in such Indication, (b) each Milestone Payment can be earned a maximum of three times, one per different and separate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indication, (c) the maximum amount payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect of a Licensed Product in an Indication is $(***$***) and (d) the maximum amount payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is $(***$***) (i.e. all Milestone Events achieved for the Licensed Product in three different and separate Indications). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Sales Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will pay to KKC the amounts set forth below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) no later than (***) after the end of the Calendar Year in which the following sales milestones (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) have first been achieved with respect to a Licensed Product&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Milestone</font></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Aggregate AEVI&#8217;s Net Sales in a Calendar Year exceeds (***$***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Aggregate AEVI&#8217;s Net Sales in a Calendar Year exceeds (***$***)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Sales Milestone Payment Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If both Sales Milestones are first achieved in the same Contract Year, then AEVI shall pay KKC the Sales Milestone Payment equal to (***$***) (for aggregate AEVI&#8217;s Net Sales in a Calendar Year exceeding (***$***)), and KKC will remain eligible to earn the (***$***) Sales Milestone Payment based on AEVI&#8217;s Net Sales in subsequent Contract Years.  For the avoidance of doubt&#58; (a) a Sales Milestone Payment is paid only once upon the first achievement of the associated Sales Milestone, (b) each Sales Milestone Payment can be earned only once, (c) the maximum amount payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is (***$***) and (d) only AEVI&#8217;s Net Sales, and not the Net Sales of its Sublicensees, are relevant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.5&#160;&#160;&#160;&#160;AEVI Royalties&#59; Sublicense Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AEVI Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On a country-by-country basis, AEVI will pay to KKC royalties equal to (***%***) of the Net Sales of AEVI and its Affiliates from such country during the Royalty Term. If there is no Valid Claim and a Data Exclusivity Period does not exist or has expired in such country, the royalties in such country will be reduced for the remainder of the Royalty Term to (***%**) of AEVI&#8217;s Net Sales.  For the avoidance of doubt, no royalty is payable to KKC under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect of the Net Sales of  Sublicensees of AEVI or any of its Affiliates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sublicense Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will pay to KKC an amount equal to (***%***) of Sublicense Income during the Term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reports and Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within (***) after the end of each Contract Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">during the Term, AEVI will deliver to KKC a report setting forth for the previous Contract Quarter the following information on a Licensed Product-by-Licensed Product and country-by-country basis&#58; (a) the gross sales and Net Sales (with AEVI&#8217;s Net Sales and the Net Sales of Sublicensees of AEVI and any of its Affiliates reported separately) of each Licensed Product, (b) the number of units sold by AEVI and its Affiliates, (c) the Sublicense Income </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">received by AEVI and its Affiliates, (d) the basis for any adjustments to the royalty payable for the sale of each Licensed Product, (e) the royalty due under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and (f) the applicable exchange rate as determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The total royalty due for the sale of Licensed Products during such Contract Quarter will be remitted at the time such report is made but no later than (***) after the end of each Contract Quarter during the Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.6&#160;&#160;&#160;&#160;Payment Provisions Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes and Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Applicable Laws require withholding of income taxes or other taxes imposed upon payments set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the paying Party will make such withholding payments as required and subtract such withholding payments from the payments set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The paying Party will submit appropriate proof of payment of the withholding taxes to the payee Party within a reasonable period of time.  At the request of the payee Party, the paying Party will, at the payee Party&#8217;s cost, give the payee Party such reasonable assistance, which will include the provision of appropriate certificates of such deductions made together with other supporting documentation as may be required by the relevant tax authority, to enable the payee Party to claim exemption from such withholding or other tax imposed or obtain a repayment thereof or reduction thereof and will upon request provide such additional documentation from time to time as is reasonably required to confirm the payment of tax. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment and Currency Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All amounts payable and calculations hereunder will be in United States dollars and will be paid by bank wire transfer in immediately available funds to such bank account as may be designated in writing by the payee Party from time to time.  Whenever for the purposes of calculating the Profit or royalties payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, conversion from any foreign currency will be required, all amounts will first be calculated in the currency in which the activity was paid or sale was recorded and then converted into United States dollars by applying the rate of exchange quoted in the New York edition of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> on the last Business Day of the paying Party of the applicable Contract Quarter.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Overdue Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any payment due under this Agreement (other than payments that are the subject of a good faith dispute between the Parties) is overdue by more than thirty (30) days, the paying Party will pay interest to the payee Party at a rate per annum equal to the lesser of the prime rate of interest, as reported by New York edition of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> on the last Business Day of the paying Party of the applicable Contract Quarter, or the highest rate permitted by applicable law, calculated on the number of days such payments are paid after the date such payments are due.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Matters Relating to Third Party Technology as of the Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All amounts payable in respect of Licensed Product and&#47;or this Agreement under the KKC In-Licenses will be paid directly by KKC or its Related Parties to the KKC Licensor, provided that AEVI will reimburse KKC, within (***) after receipt of invoice therefor, in the amount of (***%***) of&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the payments stipulated in <br>(***) in respect of sales of Licensed Product by AEVI and its Affiliates and Sublicensees&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;payments stipulated in (***) in respect of sales of Licensed Product by AEVI and its Affiliates and Sublicensees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All amounts payable in respect of Licensed Product and&#47;or this Agreement under the AEVI In-License will be paid directly by AEVI or its Affiliates or Sublicensees to CHOP, provided that KKC will reimburse AEVI, within (***) after receipt of invoice therefor, in the amount of (***) in respect of sales of Licensed Product in Japan by KKC and its Affiliates and Sublicensees after KKC exercises the Japan Option (with the royalty rate to be based on annual worldwide sales of the Licensed Product as required by the AEVI In-License).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;AEVI is solely responsible for payments due to Lonza under the AEVI Lonza License Agreement.  The allocation of costs for Third Party Technology acquired or licensed after the Effective Date is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Record-Keeping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will keep, and will cause its Related Parties to keep, books and accounts of record in connection this Agreement in sufficient detail to permit accurate determination of all figures necessary for any and all financial calculations required by this Agreement, including Development Costs, Net Sales and Sublicense Income.  AEVI will maintain, and will cause its Related Parties to maintain, such records for a period of at least five (5) years after the end of the Contract Year in which they were generated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon thirty (30) days&#8217; prior written notice from KKC, AEVI will permit an independent certified public accounting firm of nationally recognized standing selected by KKC and reasonably acceptable to AEVI, to examine, at KKC&#8217;s sole expense, the relevant books and records of AEVI and its Affiliates as may be reasonably necessary to verify the amounts reporting or payable by AEVI to KKC.  An examination by KKC under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will occur not more than once in any Contract Year and will be limited to the pertinent books and records for any Contract Year ended not more than five (5) years before the date of the request.  The accounting firm will be provided access to such books and records at AEVI&#8217;s facility(ies) where such books and records are normally kept and such examination will be conducted during AEVI&#8217;s normal business hours.  AEVI may require the accounting firm to sign a standard non-disclosure agreement before providing the accounting firm access to AEVI&#8217;s facilities or records.  Upon completion of the audit, the accounting firm will provide both AEVI and KKC a written report disclosing any discrepancies in the reports submitted by AEVI or, as applicable, the amounts payable under this Agreement, and in each case, the specific details concerning any discrepancies.  No other information will be provided to KKC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Underpayments&#47;Overpayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If such accounting firm concludes that additional amounts were due to KKC, AEVI will make such payments as is necessary for KKC to have been paid the correct amount due under this Agreement for the audited periods.  If such underpayment exceeds five percent (5%) of the amounts that were to be paid, AEVI also will reimburse KKC for all Out-of-Pocket Costs incurred in conducting the audit.  If such accounting firm correctly concludes that AEVI overpaid amounts due to KKC, KKC will refund such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">overpayments to AEVI within sixty (60) days of the date KKC receives such accountant&#8217;s report so correctly concluding. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All financial information of a Party that is subject to review under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be deemed to be Confidential Information of AEVI subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and KKC will not disclose such Confidential Information to any Third Party or use such Confidential Information for any purpose other than verifying payments to be made by AEVI to KKC hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.7&#160;&#160;&#160;&#160;Adjustment of FTE Rates.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective upon each anniversary of the Effective Date, the FTE Rates will increase by the percentage increase, if any, in the Consumer Price Index published by the United States Bureau of Labor Statistics during the most recent preceding one (1) year period for which final data is available, and such increase will be effective for the then-current and all subsequent FTE Costs hereunder unless and until further modified under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_142"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 8.<br>INTELLECTUAL PROPERTY </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.1&#160;&#160;&#160;&#160;Ownership of and Rights to Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AEVI Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As between the Parties, AEVI is and will remain the sole owner of the AEVI Technology.  KKC acknowledges that certain of the AEVI Patent Rights have been licensed to AEVI from the AEVI Licensor pursuant to the AEVI In-License.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">KKC Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As between the Parties, KKC is and will remain the sole owner of the KKC Technology.  AEVI acknowledges that certain of the KKC Patent Rights have been licensed to KKC from the KKC Licensors pursuant to the KKC In-Licenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will jointly own all Joint Inventions, and each will have an undivided interest in the Joint Inventions subject to the licenses granted under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inventorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of determining whether an invention is solely invented by AEVI or solely invented by KKC, or a Joint Invention, questions of inventorship will be resolved in accordance with United States patent laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.2&#160;&#160;&#160;&#160;Filing, Prosecution and Maintenance of Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">KKC Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not apply to the KKC Patent Rights over which KKC has no right to control the filing, prosecution or maintenance thereof, and, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the KKC Patent Rights over which KKC has the right to control the filing, prosecution and maintenance thereof, including those described in clauses (a) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (c) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, but excluding those described in clause (b) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, are referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Managed Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As between KKC and AEVI, KKC, through counsel of its choosing, will control (but not be obligated to control) the prosecution (including any interferences, reissue proceedings and re-examinations) and maintenance of the KKC Patent Rights in the Territory. AEVI will provide all reasonable assistance required to prosecute the KKC Patent Rights in the Territory. AEVI will have the right to review and comment upon any substantive communications received from the applicable patent offices with respect to the KKC Managed Patent Rights, including, but not limited to, official actions, examination reports, documents relating to patentability and&#47;or amendment or cancellation of the claims, and documents related to patent term adjustment and patent term extension. KKC will consider all comments received from AEVI with respect to the KKC Managed Patent Rights and will comply with all reasonable requests. In addition, AEVI will have the right to review and comment upon any substantive communications that KKC plans to make to an applicable patent office in the Territory with respect to the KKC Managed Patent Rights, including, but not limited to, draft responses to official actions, draft responses to examination reports, drafts relating to amendment or cancellation of the claims, and drafts relating to patent term adjustment and&#47;or extension. KKC will provide AEVI with a copy of each such communication or filing reasonably in advance of submitting such communication or filing to the relevant patent authority. KKC will consider all comments received from AEVI and will comply with all reasonable requests. In addition to the above, KKC will keep AEVI reasonably informed with respect to all such prosecution and maintenance activities to which KKC has access, including written communications with patent office officials, and consult with AEVI regarding such matters, including the planned abandonment of claims thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If KKC determines in its sole discretion to abandon or not maintain any KKC Managed Patent Rights, in one or more country(ies) or in the entire Territory, then KKC will provide AEVI with at least sixty (60) days prior written notice of such determination to abandon or cease maintenance (or such other longer period of time reasonably necessary to allow AEVI to assume such responsibilities). If KKC provides such a notification, then AEVI will have the right (but not the obligation), to control the prosecution and maintenance of any such KKC Managed Patent Rights in its sole discretion and at AEVI&#8217;s sole cost and expense by providing KKC with notice thereof within such sixty (60) day period.  In the event that AEVI so elects to control the prosecution and maintenance of any KKC Managed Patent Rights, then in the concerned country(ies) or in the entire Territory, as applicable, KKC will provide all reasonable assistance required to prosecute such KKC Managed Patent Rights in the concerned country(ies) or in the entire Territory, at AEVI&#8217;s sole cost and expense, including allowing AEVI to exercise all rights of KKC under the KKC In-License with LJI relevant to prosecution and maintenance of the KKC Managed Patent Rights.  KKC will have the right to review and comment upon any substantive communications and filings made by AEVI with respect to the prosecution of such KKC Managed Patent Rights before they are sent to any patent offices in the entire Territory. AEVI will provide KKC with a copy of each such communication or filing reasonably in advance of submitting such communication or filing to the relevant patent authority. With respect to all such prosecution and maintenance AEVI will keep KKC reasonably informed with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respect to such activities (including by providing KKC with access to all filings and correspondence with and from any patent offices or officials upon request by KKC), and consult with KKC regarding such matters, including the abandonment of claims thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), the following terms and conditions will apply with respect to the KKC Patent Rights&#58; (i)&#160;with respect to those KKC Patent Rights solely owned by LJI, LJI and KKC will have the joint right to control the filing, prosecution and maintenance of such KKC Patent Rights, including the extension of the patent term(s) of such KKC Patent Rights, and if both LJI and KKC determine in their sole discretion to abandon or not maintain such KKC Patent Rights, then AEVI will have the right, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the other applicable terms and conditions of this Agreement, to control the prosecution and maintenance of any such KKC Patent(s) and KKC will request LJI to provide all reasonable assistance required to prosecute and maintain such KKC Patent Rights&#59; and (ii)&#160;with respect to those KKC Patent Rights jointly owned by LJI, on the one hand, and KKC and&#47;or its Affiliates, on the other hand, in the event that both KKC and AEVI determine in their sole discretion to abandon or not maintain any such KKC Patent(s), then (A) LJI will have the right to control the filing, prosecution and maintenance (including, without limitation, the extension of the patent term(s)) of such KKC Patents, and (B) all rights and licenses granted to KKC under the LJI Agreement (and therefore the sublicense to AEVI under this Agreement) in and to such KKC Patent(s) will immediately terminate.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, to the extent that KKC does not have the right to control or participate in the prosecution or maintenance of Patent Rights under a KKC In-License, no right to prosecute or maintain such Patent Rights are granted to AEVI by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;All information, if any, exchanged between the Parties or between KKC&#8217;s outside patent counsel and AEVI regarding preparation, filing, prosecution or maintenance of the KKC Patent Rights will be deemed Confidential Information of KKC.  In addition, the Parties acknowledge and agree that, with regard to such preparation, filing, prosecution and maintenance of the KKC Patent Rights, the interests of the Parties as licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature.  The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the KKC Patent Rights including without limitation, privilege under the common interest doctrine and similar or related doctrines.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. With respect to any potentially patentable Joint Invention, the Parties will meet and agree upon which Party will lead (in a joint effort with the other Party) the preparation, filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of patent applications covering such Joint Invention (any such patent application and any patents issuing therefrom a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Joint Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in any jurisdiction. Joint Patents are included within both the KKC Technology and AEVI Technology and within the licenses granted to each Party hereunder. The Party that leads prosecution of a patent application in the Joint Patents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prosecuting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will provide the other Party reasonable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">opportunity to review and comment on such prosecution efforts regarding the applicable Joint Patents in the particular jurisdictions, and such other Party will provide the Prosecuting Party reasonable assistance in such efforts, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. The Prosecuting Party will provide the other Party with a copy of all material communications from any patent authority in the applicable jurisdictions regarding the Joint Patent being prosecuted by such Party, and will provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses. In particular, each Party agrees to provide the other Party with all information necessary or desirable to enable the other Party to comply with the duty of candor&#47;duty of disclosure requirements of any patent authority.  Either Party may determine that it is no longer interested in supporting the continued prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which case&#58; (i)&#160;the disclaiming Party will no longer be obligated to pay any costs for filing, prosecution or maintenance thereof&#59; (ii)&#160;the disclaiming Party will, if requested in writing by the other Party, assign its ownership interest in such Joint Patent in such country or jurisdiction to the other Party for no additional consideration and (iii)&#160;if such assignment is effected, any such Joint Patent would thereafter be deemed a patent of AEVI in the case of assignment to AEVI, or a patent of KKC in the case of assignment to KKC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">New Inventions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> AEVI will retain ownership of, and be entitled to file patents (in its sole discretion) in its name, on all AEVI Inventions, and KKC will retain ownership of, and be entitled to file patents (in its sole discretion) in its name, on all KKC Inventions.  Each Party will disclose any such inventions or improvements to the other Party within ninety (90) days of filing a patent application claiming the Invention. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby agrees&#58; (a) to make its employees, agents and consultants reasonably available to the other Party (or to the other Party&#8217;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake patent prosecution as contemplated by this Agreement&#59; (b) to cooperate, if necessary and appropriate, with the other Party in gaining patent term extensions wherever applicable to Patent Rights that are subject to this Agreement&#59; and (c) to endeavor in good faith to coordinate its efforts with the other Party to minimize or avoid interference with the prosecution and maintenance of the other Party&#8217;s patent applications that are subject to this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC will bear all of the costs and expenses of filing, prosecuting and maintaining the KKC Patent Rights, and AEVI will bear all of the costs and expenses of filing, prosecuting and maintaining the AEVI Patent Rights.  The costs and expenses of filing, prosecuting and maintaining the Joint Patents shall be borne solely by AEVI for costs and expenses incurred inside the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.3&#160;&#160;&#160;&#160;Enforcement of Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will promptly report in writing to the other Party during the Term any (a) known or suspected infringement by a Third Party of any KKC Patent Rights, AEVI Patent Rights or Patent Rights covering Joint Inventions or (b) unauthorized use or misappropriation by a Third Party of any Confidential Information, including KKC Know-How </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or AEVI Know-How, of which it becomes aware, and will provide the other Party with all available evidence supporting such infringement or unauthorized use or misappropriation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights to Enforce in the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will have the right, but not the obligation, to take any reasonable measures it deems appropriate to&#58; (a) stop infringing activities described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect of the KKC Technology in the Territory including initiating or prosecuting an infringement or other appropriate suit or action against the alleged infringer, but not granting adequate rights and licenses necessary for continuing such activities by the alleged infringer or (b) defend the KKC Technology in the Territory against any declaratory judgment, opposition, patentability or invalidity actions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Defensive Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  AEVI may request that KKC grant such adequate rights and licenses&#59; provided that KKC will have no obligation to grant any such rights or licenses&#59; and provided further that upon making such request, KKC will have the right to participate in all negotiations with the alleged infringer concerning such adequate rights and licenses.  Before AEVI takes any action to stop the infringing activity against an alleged infringer of the KKC Technology in the Territory, AEVI will consult in good faith with KKC concerning the alleged infringement, including selection of counsel, litigation strategy, litigation risks, the damage being caused to KKC and&#47;or AEVI and any other matter relevant to enforcement of the KKC Technology against the alleged infringer in the Territory.  In the event that AEVI elects not to take action pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, AEVI shall so notify KKC in writing of its intention (***).  Thereafter, the Parties shall consult with one another in an effort to determine whether a reasonably prudent licensee would institute litigation to enforce the KKC Technology in question in light of all relevant business and economic factors (including, but not limited to, the projected cost of such litigation, the likelihood of success on the merits, the probable amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims against the Parties or likely patent challenges, the impact of any possible adverse outcome on the Parties and the effect any publicity might have on the Parties&#8217; respective reputations and goodwill).  If, after such process, it is unanimously determined that a suit should be filed and AEVI does not file suit or commence settlement negotiations forthwith against the infringer, then KKC shall have the right, at its own expense, to enforce the KKC Technology in question on behalf of itself and AEVI and KKC shall have the right, but not the obligation, to take any such reasonable measures to stop such infringing activities by such alleged infringer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">KKC Rights to Enforce in Japan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Solely in the event that KKC elects the Japan Option, KKC will have the right, but not the obligation, to take any reasonable measures it deems appropriate to&#58; (a) stop infringing activities described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect of the KKC Technology in Japan including initiating or prosecuting an infringement or other appropriate suit or action against the alleged infringer, but not granting adequate rights and licenses necessary for continuing such activities by the alleged infringer in Japan or (b) defend the KKC Technology in Japan against any declaratory judgment, opposition, patentability or invalidity actions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Procedures&#59; Expenses and Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Party having the right to initiate any infringement suit or defend a Defensive Action under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controlling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will have the sole and exclusive right to select counsel for and control any such suit or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Defensive Action.  The expenses of the suit or the Defensive Action, including attorneys&#8217; fees and court costs and the reasonable Out-of-Pocket Costs the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cooperating Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in rendering assistance requested by the Controlling Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Enforcement Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (***).  If required under Applicable Law in order for the Controlling Party to initiate and&#47;or maintain such suit or to defend the Defensive Action, or if either Party is unable to initiate or prosecute such suit or defend the Defensive Action solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each case, the other Party will join as a party to the suit or Defensive Action and will execute and cause its Affiliates to execute all documents necessary for the Controlling Party to initiate litigation to prosecute and maintain such action or defend the Defensive Action.  In addition, at the Controlling Party&#8217;s request, the Cooperating Party will provide reasonable assistance to the Controlling Party in connection with an infringement suit (***).  The Cooperating Party will have the right to participate and be represented in any such suit by its own counsel at its own expense.  If the Parties obtain from a Third Party, in connection with such suit, any damages, license fees, royalties or other compensation (including any amount received in settlement of such litigation) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in the Territory, such amounts will be (***).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">LJI Enforcement Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge and agree that in the event that (***), LJI will have the right but not the obligation under the LJI Agreement to bring, defend, or maintain any appropriate suit or action involving such infringement or Defensive Action at its own cost and expense against alleged infringers and to defend such KKC Patent Rights from Defensive Actions. Subject to the foregoing, if LJI finds it necessary or reasonably desirable to join AEVI and&#47;or KKC into such suit or action, AEVI and&#47;or KKC will execute all papers and perform such other acts as may be reasonably required, and AEVI and&#47;or KKC, at their respective options, may be represented by respective counsel(s) of their own choice, provided that (a)&#160;(***), and (b)&#160;if any amount is recovered on any such action or suit, whether by judgment or settlement (any such settlement requiring the consent of KKC), the balance of any such recovery will be paid to or retained (***) (including, for clarity, the LJI (***) set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) in respect of the applicable KKC Patent Right(s) and Licensed Product(s), after reimbursement for the reasonable attorneys&#8217; fees incurred with respect to such suit or action by LJI, KKC and AEVI. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.4&#160;&#160;&#160;&#160;Claimed Infringement of Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that a Third Party at any time provides written notice of a claim to, or brings an action, suit or proceeding against, any Party, or any of such Party&#8217;s respective Related Parties, claiming infringement of such Third Party&#8217;s Patent Rights or unauthorized use or misappropriation of such Third Party&#8217;s Know-How, based upon an assertion or claim arising out of the Development, Manufacture or Commercialization of a Licensed Product (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Infringement Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Party will promptly notify the other Party of the Infringement Claim or the commencement of such action, suit or proceeding, enclosing a copy of the Infringement Claim and all papers served.  Each Party agrees to make available to the other Party its advice and counsel regarding the technical merits of any such claim at no cost to the other Party and to offer reasonable assistance to the other Party at no cost to the other Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Right to Defend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will have the right, but not the obligation, to defend any Infringement Claim brought against either Party or any of its Related Parties arising out of the Development, Manufacture or Commercialization of a Licensed Product in the Field in the Territory.  Solely in the event that KKC elects the Japan Option, KKC will have the right, but not the obligation, to defend any Infringement Claim brought against either Party or any of its Related Parties arising out of the Development, Manufacture or Commercialization of a Licensed Product in the Field in Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Party having the right to defend an Infringement Claim in which either Party is named as defendant will be referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Defending Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; The Defending Party shall bear the expense of defending the Infringement Claim.  The Defending Party will have the sole and exclusive right to select counsel for any Infringement Claim&#59; provided that it will consult with the other Party with respect to selection of counsel for such defense.  The Defending Party will keep the other Party informed, and will from time to time consult with the other Party regarding the status of any such claims and will provide the other Party with copies of all documents filed in, and all written communications relating to, any suit brought in connection with such claims. The other Party will also have the right to participate and be represented in any such claim or related suit, at its own expense.  AEVI and KKC will have the right to take action to invalidate Third Party&#8217;s patents which would be infringed by the activity under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 11.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, THE FOREGOING STATES THE ENTIRE RESPONSIBILITY OF KKC AND AEVI, AND THE SOLE AND EXCLUSIVE REMEDY OF KKC OR AEVI, AS THE CASE MAY BE, IN THE CASE OF ANY CLAIMED INFRINGEMENT OF ANY THIRD PARTY PATENT RIGHTS OR UNAUTHORIZED USE OR MISAPPROPRIATION OF ANY THIRD PARTY&#8217;S KNOW-HOW.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.5&#160;&#160;&#160;&#160;Third Party Technology Acquired or Licensed After the Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Party reasonably determines that any Third Party Technology not already the subject of this Agreement is reasonably necessary for the Development, Manufacture, or Commercialization of a Licensed Product in the Field in such Party&#8217;s territory, then such Party will notify the other Party.  Unless such Third Party Technology is specific only to Japan, AEVI will control the negotiations to obtain a license to such Third Party Technology with a right to sublicense to KKC but otherwise on terms and conditions determined at AEVI&#8217;s sole discretion.  If such Third Party Technology is specific only to Japan, KKC will control the negotiations to obtain a license to such Third Party Technology on terms and conditions determined at KKC&#8217;s sole discretion.  If AEVI elects not to obtain rights to such Third Party Technology for Japan, or is unsuccessful in obtaining a license to such Third Party Technology for Japan, then KKC will have the right (but not the obligation) to negotiate and obtain rights from such Third Party Technology at its sole discretion and expense and on such terms and conditions determined at KKC&#8217;s sole discretion.  AEVI shall (***) and allocable to the activities of AEVI and its Related Parties in the Territory.  KKC (***) and allocable to the activities of KKC and its Related Parties in Japan following KKC&#8217;s exercise of the Japan Option.  Notwithstanding the foregoing, with respect to any lump sum payment (such as license fees and milestone payments) under any such agreement that is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">made with respect to a license covering countries or jurisdictions both AEVI&#8217;s territory and Japan, the Parties will negotiate and decide in good faith the allocation of the payment based on the scope and territory of the acquired rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.6&#160;&#160;&#160;&#160;Other Infringement Resolutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Third Party Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of a dispute or potential dispute that has not ripened into a demand, claim or suit of the type described  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the same principles governing control of the resolution of the dispute, consent to settlements of the dispute, and implementation of the settlement of the dispute (including sharing in and allocating the payment or receipt of damages, license fees, royalties and other compensation) will apply.  Notwithstanding anything herein to the contrary, within (***) after Regulatory Approval is achieved with respect to a BLA for a Licensed Product in the Territory (or such shorter time as the Parties agree in the case of a Licensed Product in the Territory that does not earn reference product exclusivity under the PHS Act), the Parties will consult as to potential strategies with respect to unexpired Patent Rights Controlled by either Party that potentially could be asserted if an unlicensed person engaged in the making, using, offering to sell, selling, or importing into the United States of a product described in a Biosimilar Application filed by a Third Party applicant (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Section 351(k) Applicant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cooperation and Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If AEVI or any of its Related Parties receives notice of a Biosimilar Application filed by a Section 351(k) Applicant that references such Licensed Product and related manufacturing information in accordance with section 351(l)(2)(A) of the PHS Act or receives a notice of commercial marketing in accordance with section 351(l)(8)(A) of the PHS Act, then AEVI will provide notice to KKC, and the Parties will discuss and cooperate with each other in determining AEVI&#8217;s course of action with regard to (a)&#160;engaging in the information exchange provisions of the Biologics Price Competition and Innovation Act of 2009, Section 351(k) of the Public Health Service Act, as may be amended, supplemented, or replaced (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">BPCIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including providing a list of patents that relate to the relevant Licensed Product, (b)&#160;engaging in the patent resolution provisions of the BPCIA, and (c)&#160;determining which patents will be the subject of immediate patent infringement action under Section 351(l)(6) of the BPCIA.  In the event that the Parties do not agree with respect to the exercise of any such rights, AEVI will make the final determination with respect thereto, including without limitation with respect to (a), (b)&#160;and (c) above.  If any patent litigation commences with respect to a Biosimilar Application filed by a Section 351(k) Applicant that references such Licensed Product, then the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will thereafter apply as if such Section 351(k) Applicant were an infringer or suspected infringer. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.7&#160;&#160;&#160;&#160;Product Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Product Trademarks in the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will own the Product Trademarks for each Licensed Product in the Field in the Territory and will be solely responsible for filing and maintaining the Product Trademarks in the Field in the Territory (including payment of costs associated therewith).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7.2&#160;&#160;&#160;&#160;Each Party agrees to (a) conduct its business in a manner that will not damage the reputation or integrity of the Trademarks of the other Party, (b) conduct its business in a manner that will not damage in any way the goodwill associated with the Trademarks of the other Party, (c) use the Trademarks of the other Party in a manner that will not cause a negative impact upon the good name of such other Party, and (d) conduct its business in compliance with all applicable trademark Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.8&#160;&#160;&#160;&#160;Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC will use reasonable efforts to obtain all available supplementary protection certificates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and other extensions of Patent Rights.  KKC will execute such authorizations and other documents and take such other actions as may be reasonably requested by AEVI to obtain such extensions.  The Parties will cooperate with each other in gaining patent term restorations, extensions and&#47;or SPCs wherever applicable to Patent Rights. KKC will have the right to seek patent term restoration or extension of any KKC Patent Rights or any SPC related thereto&#59; provided that if in any country KKC has an option to extend the patent term for only one of several patents, KKC will consult with AEVI before making the election.  If more than one patent is eligible for extension or patent term restoration, KKC will select in good faith a strategy that will maximize patent protection and commercial value for each Licensed Product.  All filings for such extensions and certificates will be made by the Party to whom responsibility for prosecution and maintenance of the Patent Rights are assigned, provided that in the event that the Party to whom such responsibility is assigned elects not to file for an extension or SPC, such Party will (a) inform the other Party of its intention not to file and (b) grant the other Party the right to file for such extension or SPC in the patentee&#8217;s name, and (c) provide all necessary assistance in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.9&#160;&#160;&#160;&#160;Patent Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI (and its Related Parties) will mark Licensed Products marketed and sold by AEVI (and&#47;or its Related Parties, as applicable) with appropriate numbers of the KKC Patent Rights printed on the appropriate portion of the packaging.  Without limiting the foregoing, AEVI shall mark each Licensed Product sold or offered for sale by or on behalf of AEVI with the patent number or numbers of any issued patents encompassed within the KKC Patent Rights solely owned by LJI, if applicable, and AEVI shall ensure that the content, form, location and language of such markings is in accordance with the applicable laws and practices of each jurisdiction in which the Licensed Products are made, used or sold.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_153"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 9.<br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All Confidential Information disclosed by or on behalf of a Party (together with its Affiliates, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other Party (together with its Affiliates, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) during the Term will be used by the Receiving Party solely in connection with the activities contemplated by this Agreement, will be maintained in confidence by the Receiving Party and will not otherwise be disclosed by the Receiving Party to any other person, firm, agency, government or private entity (other than a Party&#8217;s Affiliates or as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), without the prior written consent of the Disclosing Party, except to the extent that the Confidential Information (as determined by competent documentation)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;was known or used by the Receiving Party without restriction as to its use or disclosure prior to its date of disclosure to the receiving Party&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;either before or after the date of the disclosure to the Receiving Party is lawfully disclosed to the Receiving Party without restriction as to its use or disclosure by sources other than the Disclosing Party rightfully in possession of the Confidential Information&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;either before or after the date of the disclosure to the Receiving Party becomes published or generally known to the public (including information known to the public through the sale of products in the ordinary course of business) through no fault or omission on the part of the Receiving Party or its Sublicensees&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;is independently developed by or for the Receiving Party without reference to or reliance upon the Confidential Information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All obligations of confidentiality imposed under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will expire five (5) years following termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Required Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not preclude the Receiving Party from disclosing Confidential Information to the extent such Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Laws, to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and takes reasonable and lawful actions to avoid and&#47;or minimize the degree of such disclosure, except that AEVI shall not be required to provided prior written notice of confidential disclosures to Regulatory Authorities.  If a public disclosure is required by any Applicable Laws, including, without limitation, in a filing with the Securities and Exchange Commission or submission to an exchange on which any securities of a Party is listed, the disclosing Party will provide copies of the disclosure (but shall be permitted to redact or omit portions of any filing, submission or disclosure not relevant to this Agreement) reasonably in advance of such filing or other disclosure, for the non-disclosing Party&#8217;s prior review and comment and to allow the other Party a reasonable time to object to any such disclosure or to request confidential treatment thereof. The disclosing Party will negotiate in good faith with the applicable Regulatory Authority concerning the confidential treatment request.  If the disclosure is substantially similar to prior disclosures made by the Party and for which the obligations of this provision have been satisfied, the disclosing Party need not share such disclosure ahead of it being made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. KKC and AEVI each agree that they will provide Confidential Information received from the other Party only to their respective directors, officers, employees, consultants, suppliers, Sublicensees, collaborators and advisors, and to those of such Party&#8217;s Related Parties, who have a need to know for such Party&#8217;s Development, Manufacture, and Commercialization of Licensed Products in accordance with this Agreement, including in connection with Regulatory Filings and obtaining Regulatory Approvals, provided that such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Parties are bound by confidentiality obligations at least as strict as this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition, each Party may not disclose the terms of this Agreement (to the extent such terms are confidential) to any Third Party except to actual or prospective lenders, investors, acquirers, licensees&#47;Sublicensees or strategic partners (including the KKC Licensors and AEVI Licensor) or to a Party&#8217;s accountants, attorneys and other professional advisors&#59; provided that such disclosures will be subject to continued confidentiality obligations at least as strict as this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;Publications by the Parties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following the KKC&#8217;s exercise of the Japan Option and subject to Section 9.3&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.1&#160;&#160;&#160;&#160;except as required by Applicable Law, during the Term, each Party agrees that, unless explicitly authorized  in this Agreement, it will not without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed, file patent application, issue any press release, make any public announcement, or issue any scientific or other presentations or publications, with respect to the results of any Development work relating to this Agreement without the opportunity for prior review by the other Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.2&#160;&#160;&#160;&#160;with respect to any such proposed publications or presentations by one of the Parties, each Party will provide to the other Party for information and review any (a) abstracts, posters and slide presentations that the Party proposes prior to any scientific meetings and the other Party will provide feedback to the publishing Party within ten (10) of its Business Days of its receipt of such abstracts, posters and slide presentations, and (b) primary and final manuscripts and review articles that the Party proposes prior to journal submission and the other Party will provide feedback within fifteen (15) of its Business Days of its receipt of such manuscript or article&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.3&#160;&#160;&#160;&#160;each Party agrees, upon request from the other Party, not to submit any abstract or manuscript for publication or to make any scientific presentation until the other Party is given up to forty-five (45) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which it reasonably believes is patentable.  Once such abstracts, manuscripts or presentations have been reviewed by the other Party and have been approved for publication, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication.  Expedited reviews for abstracts or poster presentations may be arranged if mutually agreeable to the Parties.  The other Party also will have the right to require that its Confidential Information that may be disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3&#160;&#160;&#160;&#160;Publications by Third Parties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following the KKC&#8217;s exercise of the Japan Option and notwithstanding Section 9.2, the Parties understand and agree that any restrictions on scientific or other presentations or publications will not be construed to prohibit the clinical investigators of any clinical trials conducted under this Agreement, from making scholarly publications, manuscripts, abstracts, oral presentations or other disclosures with respect to the results of any Development work, including without limitation clinical data resulting from such clinical trials (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that AEVI will ensure that (a) any such clinical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">investigator must agree to submit to KKC for its review and comment, a copy of any proposed Publication, abstract or other disclosure resulting from such activities, simultaneous with submission of the same to AEVI and at least forty-five (45) days prior to any such presentation or publication, (b) such publication will not contain any references to, or otherwise disclose any of, the Confidential Information (other than clinical data) without KKC&#8217;s prior written consent, and (c) at KKC&#8217;s request, such clinical investigator will, for a reasonable period of up to ninety (90) days from initial delivery to KKC, delay revealing any subject matter included in the clinical data in any publication or disclosure in order to permit the filing of patent applications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4&#160;&#160;&#160;&#160;Public Announcements and Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font><font style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except for public disclosures </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;resulting from the issuance of one or more press releases to be mutually-agreed upon by the Parties, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> otherwise permitted under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">required by Applicable Law or by the rules and regulations of any securities exchange on which a Party&#8217;s securities are traded</font><font style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, neither Party will disclose any publicity, news release or public announcements, written or oral, whether to the public or press, stockholders or otherwise, relating to the execution of this Agreement, any of the terms of this Agreement, or any amendment hereto without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_165"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 10.<br>TERM AND TERMINATION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement will commence on the Effective Date and will remain in full force and effect for as long as any Licensed Product(s) is Commercialized by either Party and&#47;or its Related Parties, unless terminated earlier pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;Termination by KKC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent permitted under Applicable Laws, KKC will have the right to terminate this Agreement in its entirety, at KKC&#8217;s sole discretion, upon delivery of written notice to AEVI upon the filing by AEVI in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of AEVI or its assets, upon the proposal by AEVI of a written agreement of composition or extension of its debts, or if AEVI is served by a Third Party (and not by KKC) with an involuntary petition against it in any insolvency proceeding, upon the ninety-first (91st) day after such service if such involuntary petition has not previously been stayed or dismissed, or upon the making by AEVI of an assignment for the benefit of its creditors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC will have the right to terminate this Agreement in its entirety, at KKC&#8217;s sole discretion, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, upon delivery of written notice to AEVI in the event of any material breach (other than a material breach of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or a material breach that is specific to a given country in the Territory) by AEVI of this Agreement, provided that such breach has not been cured within (***) after written notice of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such breach and KKC&#8217;s intention to terminate is given by KKC to AEVI&#59; provided, however, that if such breach relates to the failure to make a payment when due, such breach must be cured within (***) after written notice thereof is given by KKC (except that in the case of a bona fide dispute over whether or to what extent a payment by AEVI to KKC is due, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not be triggered provided that AEVI will pay the amount in dispute into escrow until such dispute is resolved).  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any such termination of this Agreement will become effective at the end of the applicable cure period, unless AEVI has cured any such breach or default prior to the expiration of such cure period, or, if such breach is not susceptible to cure within the cure period, then, KKC&#8217;s right of termination will be suspended only if and for so long as AEVI has provided to KKC a written plan that is reasonably calculated to effect a cure within (***) thereafter and such plan is acceptable to KKC (such acceptance not to be unreasonably withheld, conditioned, or delayed), and AEVI commits to and carries out such plan as provided to KKC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Diligence or Country-Specific Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the case of a material breach by AEVI of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or a material breach by AEVI that is specific to a given country in the Territory, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, KKC will have the right to terminate this Agreement only as to the particular country to which such breach relates and not as to this Agreement in its entirety, upon delivery of written notice to AEVI provided that such breach has not been cured within sixty (60) days after written notice of such breach and KKC&#8217;s intention to terminate is given by KKC to AEVI&#59; provided, however, that if such breach relates to the failure to make a payment when due, such breach must be cured within thirty (30) days after written notice thereof is given by KKC (except that in the case of a bona fide dispute over whether or to what extent a payment by AEVI to KKC is due, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not be triggered provided that AEVI will pay the amount in dispute into escrow until such dispute is resolved).  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any such termination of this Agreement will become effective at the end of the applicable cure period, unless AEVI has cured any such breach or default prior to the expiration of such cure period, or, if such breach is not susceptible to cure within the cure period, then, KKC&#8217;s right of termination will be suspended only if and for so long as AEVI has provided to KKC a written plan that is reasonably calculated to effect a cure within six (6) months thereafter and such plan is acceptable to KKC (such acceptance not to be unreasonably withheld, conditioned, or delayed), and AEVI commits to and carries out such plan as provided to KKC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If AEVI or any of its Affiliates directly claim, or cause a Third Party to claim, or knowingly supports (other than as may be necessary or reasonably required to assert a cross-claim or a counter-claim, or in response to a subpoena or court or administrative law request or order), including by providing information, documents, and&#47;or funding, a claim (a) to the validity, scope, enforceability or patentability of any of the KKC Patent Rights in any formal legal or administrative action or proceeding, or (b) that no Earned Royalties, Sublicense Royalties, Net Receipts, milestone payments, Patent Costs or other payments (as such capitalized terms are defined under the LJI Agreement) are due or required to be paid to LJI under the LJI Agreement because the applicable KKC Patents licensed by LJI to KKC under the LJI Agreement covering or claiming a Licensed Product are invalid or unenforceable except where such KKC Patent Rights have been found to be unpatentable, invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">appeal is taken or can be taken, or have been admitted or determined to be invalid or unenforceable through reissue, re-examination, disclaimer or similar formal proceeding, or where a pending application within the KKC Patent Rights has been abandoned or finally rejected (in each case, other than pursuant to a claim by KKC, AEVI or their respective Affiliates or by a Third Party caused by any of the foregoing entities) in any Challenge, then (x) if and to the extent permitted by Applicable Law, (***) during and after the pendency of such Challenges from the date KKC, AEVI, or any of their respective Affiliates first institute or make such challenges. In such event, notwithstanding anything to the contrary in this Agreement, (i) AEVI will not be obligated to (***) in case such Challenges are initiated or conducted solely by or on behalf of KKC or any of its Affiliates (in which case, KKC will be responsible for (***)), and (ii) KKC will not be obligated to (***) in case such Challenges are initiated or conducted solely by or on behalf of AEVI or any of its Affiliates (in which case, AEVI will (***)).  (***) under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (x) may be exercised at any time after AEVI (or any of its Affiliates) may have Challenged or knowingly supports (other than in response to a subpoena or court order) a Challenge to the validity, enforceability or patentability of any of the KKC Patent Rights.  If a Sublicensee of AEVI or any of its Affiliates Challenges the validity, scope or enforceability of or otherwise opposes any of the KKC Patent Rights under which such Sublicensee is sublicensed, then AEVI or its Affiliate will, upon written notice from KKC, promptly terminate such sublicense.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will refer to a legal action or filing with a patent authority or tribunal or a court that could, if successful, result in a holding of invalidity, unenforceability, or unpatentability of a patent or application within the KKC Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If AEVI reasonably and in good faith disagrees as to whether KKC has a basis for terminating this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, AEVI may contest the allegation in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is understood and acknowledged that, during the pendency of such a dispute, all of the terms and conditions of this Agreement will remain in effect, and the Parties will continue to perform all of their respective obligations under this Agreement.  No termination by KKC pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be effective unless and until KKC&#8217;s right to terminate this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has been finally determined by arbitration in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any payments that are owed one Party to the other Party pursuant to this Agreement affected by such dispute may be paid into escrow pending resolution of the dispute, and then paid or refunded to the appropriate party as determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Abandonment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If AEVI, in its discretion, decides to abandon all of its Development and&#47;or Commercialization efforts with respect to the Licensed Product, AEVI will promptly notify KKC in writing of its intent to do so.  KKC will have the right to terminate this Agreement immediately upon receipt of such notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.3&#160;&#160;&#160;&#160;Termination by AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent permitted under Applicable Law, AEVI will have the right to terminate this Agreement in its entirety, at AEVI&#8217;s sole discretion, upon delivery of written notice to KKC upon the filing by KKC in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of KKC or its assets, upon the proposal by KKC of a written agreement of composition or extension of its debts, or if KKC is served by a Third Party (and not by AEVI) with an involuntary petition against it in any insolvency proceeding, upon the ninety-first (91st) day after such service if such involuntary petition has not previously been stayed or dismissed, or upon the making by KKC of an assignment for the benefit of its creditors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will have the right to terminate this Agreement in its entirety, at AEVI&#8217;s sole discretion, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, upon delivery of written notice to KKC in the event of a material breach by KKC of this Agreement, provided that such breach has not been cured within (***) after written notice of such breach and AEVI&#8217;s intention to terminate is given by AEVI to KKC&#59; provided, however, that if such breach relates to the failure to make a payment when due, such breach must be cured within (***) after written notice thereof is given by AEVI (except that in the case of a bona fide dispute over whether or to what extent a payment by KKC to AEVI is due, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not be triggered provided that KKC will pay the amount in dispute into escrow until such dispute is resolved).  Such termination will be effective upon expiration of the applicable time period set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any such termination of this Agreement will become effective at the end of the applicable cure period, unless KKC has cured any such breach or default prior to the expiration of such cure period, or, if such breach is not susceptible to cure within the cure period, then, AEVI&#8217;s right of termination will be suspended only if and for so long as KKC has provided to AEVI a written plan that is reasonably calculated to effect a cure within (***) thereafter and such plan is acceptable to AEVI (such acceptance not to be unreasonably withheld, conditioned, or delayed), and KKC commits to and carries out such plan as provided to AEVI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (***), such termination to be effective at the end of such notice period, AEVI may terminate this Agreement as to such Licensed Product and&#47;or such jurisdiction for any reason or no reason, including if AEVI, in its reasonable discretion, decides to cease all of its Development and&#47;or Commercialization efforts with respect to such Licensed Product in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If KKC reasonably and in good faith disagrees as to whether AEVI has a basis for terminating this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, KKC may contest the allegation in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is understood and acknowledged that, during the pendency of such a dispute, all of the terms and conditions of this Agreement will remain in effect, and the Parties will continue to perform all of their respective obligations under this Agreement.  No termination by AEVI pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be effective unless and until KKC&#8217;s right to terminate this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has been finally determined by arbitration in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any payments that are owed one Party to the other Party pursuant to this Agreement affected by such dispute may be paid into escrow pending resolution of the dispute, and then paid or refunded to the appropriate party as determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No obligation to KKC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   In any termination pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, KKC has no obligation for further Development, Manufacture and&#47;or Commercialization of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licensed Product.  AEVI shall be responsible for all negotiations with BARDA for the abandonment, and KKC will not take over from AEVI any Development, Manufacture and &#47;or Commercialization for Licensed Product requested by BARDA.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.4&#160;&#160;&#160;&#160;Consequences of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon termination of this Agreement in its entirety or with respect to a country in the Territory (in which event the following will apply only with respect to such country)&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All rights and licenses granted to AEVI in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will terminate, all rights of AEVI under the KKC Technology will revert to KKC, and AEVI and its Affiliates will cease all use of the KKC Technology. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will assign, and hereby does assign effective as of the effective date of such termination, to KKC all Regulatory Filings (including all INDs and NDAs) and Regulatory Approvals and all other documents necessary to further Develop, Manufacture, and Commercialize the Licensed Products, as they exist as of the date of such termination, (and all of AEVI&#8217;s right, title and interest therein and thereto).  AEVI will provide to KKC one (1) copy of the foregoing documents and Regulatory Filings, all documents and filings contained in or referenced in any such Regulatory Filings, together with the raw and summarized data for any preclinical and clinical studies of the Licensed Product.  For clarity, KKC will have the right to use the foregoing material information, materials and data developed by AEVI solely in connection with KKC&#8217;s development, manufacture and commercialization of Licensed Products.  KKC will have the right to seek specific performance of AEVI&#8217;s obligations referenced in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and&#47;or in the event of failure to obtain assignment, AEVI hereby consents and grants to KKC the right to access and reference (without any further action required on the part of AEVI, whose authorization to file this consent with any Regulatory Authority is hereby granted) any and all such regulatory filings for any regulatory or other use or purpose. Without limiting the foregoing in this paragraph, to the extent applicable, AEVI&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will continue with respect to all countries in the Territory for which there is a failure to obtain assignment of all regulatory filings and Regulatory Approvals.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Know-How Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will provide to KKC all data and information generated during the Term necessary for the development and&#47;or commercialization of the relevant Licensed Products and assign (or, if applicable, cause its Affiliate to assign) to KKC all of AEVI&#8217;s (and such Affiliate&#8217;s) entire right, title and interest in and to all such data and information.  AEVI will provide to KKC the tangible embodiments of all other Know-How Controlled by AEVI and its Affiliates in existence as of the effective date of such termination relating to the Development, Manufacturing, and Commercialization of the Licensed Products, including without limitation  the  cell line(s), master cell bank, working cell bank, cell line(s) for analysis of the Licensed Product, AEVI&#8217;s manufacturing processes, techniques and trade secrets necessary for and used in the manufacture of such Licensed Products as of the effective date of such termination and all Know-How specifically relating to any composition, formulation, method of use or manufacture of such Licensed Products.  AEVI will grant, and hereby does grant effective as of the effective date of such termination, to KKC a non-exclusive, irrevocable, royalty-free, transferable, sublicensable, worldwide right and license under such Know-How for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">developing, making, using, importing, selling and offering for sale Licensed Products.  AEVI will reasonably cooperate with KKC to assist KKC with understanding and using the Know How provided to KKC under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If AEVI has decided to abandon all of its Development and&#47;or Commercialization efforts with respect to the Licensed Product,  and this Agreement is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, AEVI will provide to KKC all technology resulting from such abandoned Development and&#47;or Commercialization efforts. KKC will have a royalty-free, irrevocable, world-wide, unlimited license to such abandoned Development and&#47;or Commercialization efforts including the right to sublicense and to contract with Third Parties for further Development and&#47;or Commercialization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the extent that AEVI owns any trademark(s) (including without limitation any Product Trademarks) and&#47;or domain names that pertain specifically to an Licensed Product that KKC believes would be necessary for the Commercialization of a Licensed Product (as then currently marketed, but not including any marks that include, in whole or part, any corporate name or logo of AEVI), AEVI will assign (or, if applicable, cause its Affiliate to assign), and hereby does assign effective as of the effective date of such termination, to KKC all of AEVI&#8217;s (and such Affiliate&#8217;s) right, title and interest in and to any registered or unregistered trademark, trademark application, trade name or internet domain name in each country. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. AEVI will grant, and hereby grants effective as of the effective date of such termination, to KKC a non-exclusive, irrevocable, royalty-free, transferable, sublicensable, worldwide (excluding the countries of the Territory to which AEVI retains its rights) right and license under any Patent Rights owned solely by AEVI or its Affiliates as of the effective date of termination to the extent that such Patent Rights cover or claim the composition of matter, use, or manufacture of Licensed Products and for the sole purpose of developing, manufacturing, and commercializing Licensed Products.  AEVI will grant to KKC, under any Patent Rights that AEVI&#8217;s Controls but does not own at the time of termination, to the full extent permitted under the agreement(s) of AEVI covering such Patent Rights, a non-exclusive, irrevocable, royalty-free (as to AEVI), transferable, sublicensable, worldwide (excluding the countries of the Territory to which AEVI retains its rights) right and license, to the extent that such Patent Rights cover or claim the composition of matter, use, or manufacture of Licensed Products and for the sole purpose of developing, manufacturing, and commercializing Licensed Products&#59; provided that  KKC enters into a written agreement with AEVI with respect to each such Patent Right that (a) ensures compliance with the applicable contract between AEVI and its licensor including KKC agreeing to all provisions thereof that must be imposed on Sublicensees, (b) requires KKC to pay all amounts payable to its licensor by AEVI related to KKC&#8217;s exercise or enjoyment of such rights including milestones, royalties and patent expenses and (c) indemnifies AEVI for any breach of such agreement between KKC and AEVI.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Continued Supply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If AEVI has any inventory of any Licensed Products suitable for use in clinical trials, AEVI will offer to sell such Licensed Products to KKC at (***) (but KKC will be under no obligation to purchase the foregoing inventory of Licensed Products unless it agrees to do so in writing at such time)&#59; provided, however, that, in the event of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">termination pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (***).  If AEVI has the capability in place as of the effective date of such termination to commercially Manufacture and supply to KKC all or part of KKC&#8217;s requirements of the applicable Licensed Products, if KKC so elects in its sole discretion, AEVI will use Commercially Reasonable Efforts to supply to KKC (***) as much of KKC&#8217;s requirements of such Licensed Products (and to develop a reasonable inventory level) during such period, (***) for such Licensed Products, under terms and conditions as may be mutually agreed between the Parties.  If KKC, despite its best efforts, is unable to Manufacture, or to secure a supply of, such Licensed Products in an amount sufficient to meet its requirements (***), AEVI will continue to supply such Licensed Products to KKC to the extent necessary to meet KKC&#8217;s requirements, so long as KKC continues to use its best efforts to develop the capabilities necessary to Manufacture such Licensed Products and&#47;or to secure a supply of such Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer of Manufacturing Technology.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> In the event, at the time of such termination, (a) AEVI manufactures the Licensed Products at its own facility, AEVI will complete  manufacturing technology transfer to KKC without limitation  the  cell line(s), master cell bank, working cell bank and cell line(s) for analysis of the Licensed Product, and (b) if AEVI engages a Third Party to manufacture and supply the Licensed Products, AEVI will, at KKC&#8217;s election, either (i)&#160;have such Third Party conduct manufacturing technology transfer to KKC or (ii)&#160;will use reasonable efforts to assist in the transfer of such supply arrangements to KKC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party will be relieved of any obligation that accrued prior to the effective date of such termination.  All amounts due or payable to KKC that were accrued prior to the effective date of termination will remain due and payable.  Except as otherwise expressly provided herein, no additional amounts will be payable based on events occurring after the effective date of termination&#59; provided that the foregoing will not be deemed to limit either Party&#8217;s indemnification obligations under this Agreement for acts or omissions incurring prior to the effective date of such termination that are the subject of such indemnification even if the indemnification amount cannot be accrued or determined as of the effective date of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retention of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. KKC will have the right to retain all amounts previously paid to KKC by AEVI. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will not owe any compensation to the other Party for the research, development, manufacture, or commercialization of any Licensed Products in the event of any termination of the Agreement by itself, without prejudice to any rights that either Party may have to bring a claim for damages arising out of this Agreement and the termination thereof or any other amounts payable with respect to activities conducted prior to the effective date of such termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any costs and expenses incurred by AEVI in connection with the assignments and transfers made by AEVI under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be borne by AEVI. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.5&#160;&#160;&#160;&#160;Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon the termination of this Agreement, each Party will promptly return to the other Party, delete or destroy (with written notification of such destruction) all relevant records and materials in such Party&#8217;s possession or control containing Confidential Information of the other Party&#59; provided that such Party may keep one copy of such materials for archival purposes only.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.6&#160;&#160;&#160;&#160;Effect of Termination&#59; Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The termination of this Agreement will not relieve the Parties of any obligation accruing prior to such termination.  The provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Representations and Warranties&#59; Indemnification) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Miscellaneous Provisions) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 6.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Effect of Termination on Sublicenses), 6.8 (Obligation under the BARDA Contract), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Joint Inventions) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (No obligation to KKC) will survive any termination of this Agreement.  Except as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or as otherwise set forth in this Agreement, upon termination of this Agreement all other rights and obligations cease.  Any termination of this Agreement will be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement before termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.7&#160;&#160;&#160;&#160;Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All rights and licenses granted under or pursuant to this Agreement by either Party, including without limitation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, licenses of right to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States (hereinafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Parties agree that each Party, as a licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside the United States that provide similar protection for IP.  In the event of termination of a Party pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the terminated Party hereby grants to the other Party and its Affiliates a right to obtain possession of and to benefit from a complete duplicate of (or complete access to, as appropriate) any such IP and all embodiments of intellectual property, which, if not already in such other Party&#8217;s possession, will be promptly delivered to it upon such other Party&#8217;s written request therefor.  The term &#8220;embodiments of intellectual property&#8221; includes all tangible, electronic or other embodiments of rights and licenses hereunder, including all Licensed Products, all Regulatory Approval Applications and Regulatory Approvals and rights of reference therein, and all Information related to Licensed Products KKC Technology and AEVI Technology, as applicable.  The terminated Party will not interfere with the exercise by the other Party or its Affiliates of rights and licenses to IP and embodiments of intellectual property licensed hereunder in accordance with this Agreement and agrees to assist such other Party and Affiliates of such other Party to obtain the IP and embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for such other Party or Affiliates of such other Party to exercise such rights and licenses in accordance with this Agreement.  The Parties acknowledge and agree that Milestone Payments and Sales Milestone Payments made under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, respectively, do not constitute royalties within the meaning of U.S. Bankruptcy Code &#167;365(n) or relate to licenses of intellectual property hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.8&#160;&#160;&#160;&#160;No Limitation of Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as herein expressly provided, notwithstanding anything to the contrary in this Agreement, except as otherwise set forth in this Agreement, termination of this Agreement will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination nor prejudice either Party&#8217;s right to obtain performance of any obligation.  Each Party will be free, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to seek (without restriction as to the number of times it may seek) damages, costs and remedies that may be available under Applicable Law or in equity and will be entitled to offset the amount of any damages and costs obtained in a final determination under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of monetary damages or costs (as permitted by this Agreement) against the other Party against any amounts otherwise due to such other Party under this Agreement.  It is understood and agreed that either Party will be entitled to seek specific performance as a remedy to enforce the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in addition to any other remedy to which such Party may be entitled by Applicable Law.  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be deemed to limit any remedy to which either Party may be entitled by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_176"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 11.<br>REPRESENTATIONS, WARRANTIES, AND COVENANTS&#59; DISCLAIMERS&#59; INDEMNIFICATION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party represents, warrants and covenants to the other Party that as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Existence and Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is a company duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Execution&#59; Binding Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and approved by all necessary corporate action on its part&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;This Agreement has been duly executed and delivered by it and constitutes a legal, valid, and binding obligation enforceable against it in accordance with this Agreement&#8217;s terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws relating to or affecting creditors&#8217; rights generally and by general equity principles, including judicial principles affecting the availability of injunction and specific performance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party and by which it may be bound. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">All Consents and Approvals Obtained</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except with respect to any consent required from Sanofi, (i) all necessary consents, approvals and authorizations of, and (ii) all notices to, and filings by such Party with, all governmental authorities and other persons or entities required to be obtained or provided by such Party in connection with the execution, delivery and performance of this Agreement have been obtained and provided, except for those government approvals, if any, not required at the time of execution of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It will at all times comply with Applicable Laws in all material respects.  Neither such Party, nor any of its employees, officers, subcontractors, or consultants who have rendered services relating to the Licensed Products&#58; (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred by the FDA (or subject to a similar sanction of a Regulatory Authority) or (ii) has ever been under indictment for a crime for which a person or entity could be so debarred. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.2&#160;&#160;&#160;&#160;KKC Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC represents and warrants to AEVI that as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;KKC Controls the KKC Patent Rights existing as of the Effective Date and is entitled to grant the rights and licenses specified herein.  The KKC Technology existing as of the Effective Date constitute all of the Patent Rights, Know-How and Inventions Controlled by KKC as of the Effective Date that are necessary or useful to Develop, Manufacture and Commercialize the Licensed Product.  KKC has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the KKC Technology in a manner that conflicts with any rights granted to AEVI hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the knowledge of KKC, there is no actual or threatened infringement of the KKC Patent Rights in the Field by any Third Party that would adversely affect AEVI&#8217;s rights under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To the knowledge of KKC, the KKC Patent Rights existing as of the Effective Date are subsisting and are not invalid or unenforceable, in whole or in part&#59; there are no claims, judgments or settlements against or amounts with respect thereto owed by KKC or any of its Affiliates relating to the KKC Patent Rights&#59; and no claim or litigation has been brought or threatened by any Third Party alleging, and KKC is not aware of any reasonable basis for a claim alleging that (i)&#160;the KKC Patent Rights are invalid or unenforceable, (ii)&#160;the KKC Patent Rights or the licensing or exploiting of the KKC Patent Rights violates, infringes or otherwise conflicts or interferes with any intellectual property or proprietary right of any Third Party, or (iii) any Third Party other than a KKC Licensor has any right, title, or interest in, to, and under any KKC Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;To the knowledge of KKC, KKC is not in default, and to KKC&#8217;s knowledge, none of the KKC Licensors is in default, with respect to a material obligation under, and neither such party has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under, any KKC In-Licenses, and KKC has not waived or allowed to lapse any of its rights under any KKC In-Licenses, and no such rights have lapsed or otherwise expired or been terminated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;There are no claims, judgments or settlements against or owed by KKC or its Affiliates or pending or threatened claims or litigation relating to the KKC Technology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;As a result of AEVI entering into the AEVI Lonza License Agreement, (i) no rights are sublicensed by KKC to AEVI under the Multi Product Licence Agreement between Lonza and Kyowa Kirin Co., Ltd. (***) and (ii) AEVI has no responsibility for any payment due, whether now or in the future, under such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.3&#160;&#160;&#160;&#160;KKC Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC covenants that during the Term&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;KKC will use Commercially Reasonable Efforts to fulfill its obligations under the KKC In-Licenses to the extent such obligations have not been delegated to AEVI and to the extent that failure to do so would materially adversely affect AEVI or its rights hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;KKC will not assign, transfer, convey or otherwise encumber its right, title and interest in the KKC Technology in a manner that conflicts with any rights granted to AEVI hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;KKC will not enter into any subsequent agreement with any KKC Licensor that modifies or amends any KKC In-Licenses in any way that would materially adversely affect AEVI&#8217;s rights or economic interest under this Agreement without AEVI&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;KKC will not terminate any KKC In-Licenses in whole or in part, directly or indirectly, without AEVI&#8217;s prior written consent if such termination would materially affect AEVI&#8217;s license granted hereunder&#59; for clarity KKC may (i)&#160;terminate any KKC In-Licenses by acquiring all of the intellectual property licensed thereunder, or (ii)&#160;terminate its obligation to make royalty and milestone payments by making a lump payment, and KKC will promptly notify AEVI after the occurrence of each such event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;KKC will furnish AEVI with copies of all notices received by KKC relating to any alleged breach or default by KKC under any KKC In-Licenses within (***) after KKC&#8217;s receipt thereof and, if KKC cannot or chooses not to cure or otherwise resolve any such alleged breach or default, KKC will so notify AEVI within (***) thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;KKC will not grant any right or license to any Third Party relating to any of the intellectual property rights it Controls which would conflict or interfere with any of the rights or licenses granted to AEVI hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.4&#160;&#160;&#160;&#160;AEVI Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI covenants that during the Term&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;AEVI will not engage in any activities that use the KKC Technology in a manner that is outside the scope of the rights granted to it hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All of AEVI&#8217;s activities related to its use of the KKC Technology, and the research, Development and Commercialization of the Licensed Products, pursuant to this Agreement will comply with all Applicable Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;AEVI will not assign, transfer, convey or otherwise encumber its right, title and interest in the AEVI Technology in a manner that conflicts with any rights granted to KKC hereunder&#59; provided that this covenant will terminate upon the expiration of the Japan Option Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;AEVI will use Commercially Reasonable Efforts to fulfill its obligations under the AEVI In-License to the extent such obligations have not been delegated to KKC and to the extent that failure to do so would materially adversely affect KKC or its rights hereunder&#59; provided that this covenant will terminate upon the expiration of the Japan Option Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;AEVI will not enter into any subsequent agreement with CHOP that modifies or amends the AEVI In-License in any way that would materially adversely affect KKC&#8217;s rights or economic interest under this Agreement without KKC&#8217;s prior written consent&#59; provided that this covenant will terminate upon the expiration of the Japan Option Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;AEVI will not terminate the AEVI In-License in whole or in part, directly or indirectly, without KKC&#8217;s prior written consent if such termination would materially affect KKC&#8217;s license granted hereunder&#59; for clarity AEVI may (i)&#160;terminate the AEVI In-License by acquiring all of the intellectual property licensed thereunder, or (ii)&#160;terminate its obligation to make royalty and milestone payments by making a lump-sum payment, and AEVI will promptly notify KKC after the occurrence of each such event&#59; provided that this covenant will terminate upon the expiration of the Japan Option Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;AEVI will furnish KKC with copies of all notices received by AEVI relating to any alleged breach or default by AEVI under the AEVI In-License within (***) after AEVI&#8217;s receipt thereof and, if AEVI cannot or chooses not to cure or otherwise resolve any such alleged breach or default, AEVI will so notify KKC within (***) thereafter&#59; provided that this covenant will terminate upon the expiration of the Japan Option Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.5&#160;&#160;&#160;&#160;Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party hereby covenants to the other Party that during the Term&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All employees and officers of such Party or its Affiliates working under this Agreement will be under the obligation to assign all right, title and interest in and to their Inventions, whether or not patentable, if any, to such Party as the sole owner thereof, and under the obligation to maintain as confidential the Confidential Information of such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Such Party will perform its activities pursuant to this Agreement in compliance with good clinical practices and good manufacturing practices, in each case as applicable under the Applicable Laws and regulations of the country and the state and local government wherein such activities are conducted, and also with the standards in the pharmaceutical industry for the development and commercialization of pharmaceutical products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Such Party will not employ (or, to its knowledge, use any contractor or consultant that employs) any individual or entity debarred by the FDA (or subject to a similar sanction of a Regulatory Authority), or, to its knowledge, any individual who or entity which is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the subject of an FDA debarment investigation or proceeding (or similar proceeding of a Regulatory Authority), in the conduct of its activities under this Agreement, and each contractor or consultant used by such Party in connection with the conduct of clinical trials under this Agreement will be subject to a covenant that is the same or substantially the same as the foregoing covenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Such Party will not practice or exploit the intellectual property licensed to such Party under this Agreement except to the extent expressly permitted under the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Such Party will not grant any right or license to any Third Party relating to any of the intellectual property rights it Controls which would conflict or interfere with any of the rights or licenses granted to the other Party hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.6&#160;&#160;&#160;&#160;Consequences of Partial Termination of an In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that a portion, but not all of KKC&#8217;s rights under the KKC In-Licenses terminate, then AEVI will owe no further obligations to KKC under this Agreement with respect to such terminated rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.7&#160;&#160;&#160;&#160;Warranty Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge and agree that nothing in this Agreement (including, without limitation, any exhibits or attachments hereto) will be construed as representing an estimate or projection of either (a) the extent to which Licensed Products will be successfully Developed or Commercialized or (b) the anticipated sales or the actual value of any Licensed Product.  NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY LICENSED PRODUCT OR, IF COMMERCIALIZED, THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL OF SUCH LICENSED PRODUCT(S).  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.  EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY LICENSED PRODUCT UNDER THIS AGREEMENT WILL BE SUCCESSFUL.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.8&#160;&#160;&#160;&#160;No Consequential Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.  NOTHING IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY OR TO LIMIT A PARTY&#8217;S LIABILITY FOR BREACHES OF ITS OBLIGATION REGARDING CONFIDENTIALITY UNDER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.9&#160;&#160;&#160;&#160;Indemnification and Insurance.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by AEVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  AEVI will indemnify, hold harmless, and defend KKC, its Affiliates, and their respective directors, officers, employees and agents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">KKC Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all damages, losses, liabilities, costs (including without limitation reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) or judgments of any kind (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) arising out of any Third Party claim (including any claim to each Party from BARDA or Sanofi), suit or proceeding, whether for money or equitable relief (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), arising out of or resulting from, directly or indirectly, (a) any material breach of, or inaccuracy in, any representation or warranty made by AEVI in this Agreement, or any breach or violation of any covenant or agreement of AEVI or a Related Party in or pursuant to this Agreement, (b) the negligence or willful misconduct by or of AEVI or any of its Related Parties, and their respective directors, officers, employees and agents, (c) the practice by AEVI or its Affiliate or Sublicensee (including a sublicensed contract manufacturer) of any license or sublicense granted to it under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or under the Clinical Development and Option Agreement, and&#47;or (d) the Development, Manufacturing and Commercialization of Licensed Products (including product liability) by AEVI or any of its Related Parties (including any of the foregoing accomplished under the Clinical Development and Option Agreement).  This indemnification excludes Losses arising out of Third Party Infringement Claims resulting from AEVI&#8217;s exercise in accordance with the terms of this Agreement of any intellectual property rights granted by KKC hereunder.  Furthermore, AEVI will have no obligation to indemnify the KKC Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any matter for which KKC must indemnify AEVI under this Agreement.  In addition, AEVI will indemnify, hold harmless, and defend LJI and its directors, officers, employees, and agents from and against any and all Losses (including costs of investigation and court costs) arising at any time from or in any manner connected with, directly or indirectly, any activity of AEVI involving the KKC Patent Rights solely owned by LJI or any information furnished under the LJI Agreement, including the use, handling, storage, distribution, containment, sale and&#47;or disposition of any product (whether or not a Licensed Product), or provision of any service, related to or derived directly or indirectly from or using any KKC Patent Rights solely owned by LJI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by KKC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  KKC will indemnify, hold harmless, and defend AEVI, its Affiliates and their respective directors, officers, employees and agents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">AEVI Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Losses arising out of Third Party Claims arising out of or resulting from, directly or indirectly, (a) any material breach of, or inaccuracy in, any representation or warranty made by KKC in this Agreement, or any breach or violation of any covenant or agreement of KKC in or pursuant to this Agreement, (b) the negligence or willful misconduct by or of KKC or any of its Related Parties, and their respective directors, officers, employees and agents, and&#47;or (c) the Development, Manufacturing and Commercialization of Licensed Products (including product liability) by KKC or any of its Related Parties.  Furthermore, KKC will have no obligation to indemnify the AEVI Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any matter for which AEVI must indemnify KKC.  In addition, KKC shall be bound by Section 12.2 of the AEVI In-License in the capacity of &#8220;Licensee&#8221; in respect of KKC and its Related Parties&#8217; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">activities under this Agreement and use of the AEVI Technology licensed under the AEVI In-License, and KKC agrees that the Indemnitees (as defined in Section 12.2 of the AEVI In-License) are intended third party beneficiaries of this sentence.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any such claim against any AEVI Indemnitee or KKC Indemnitee (individually, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the indemnified Party will promptly notify the other Party in writing of the claim and the indemnifying Party will manage and control, at its sole expense, the defense of the claim and its settlement.  The Indemnitee will cooperate with the indemnifying Party and may, at its option and expense, be represented in any such action or proceeding.  The indemnifying Party will not be liable for any settlements, litigation costs or expenses incurred by any Indemnitee without the indemnifying Party&#8217;s written authorization.  Notwithstanding the foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> may apply, the indemnifying Party will promptly notify the Indemnitees, which will then have the right to be represented in any such action or proceeding by separate counsel at their expense&#59; provided that the indemnifying Party will be responsible for payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party.  If the indemnifying Party does not assume the defense of such claim as described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, above, the Indemnitee may defend such claim but will have no obligation to do so.  The defending Party will not settle or compromise such claim without the prior written consent of the other Party, and will not settle or compromise such claim in any manner which would have an adverse effect on such other Party&#8217;s interests, without the prior written consent of such other Party, which consent, in each case, will not be unreasonably withheld, conditioned, or delayed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will use its Commercially Reasonable Efforts to maintain insurance, including product liability insurance, with respect to its activities hereunder.  Such insurance will be in such amounts and subject to such deductibles as the Parties may agree based upon standards prevailing in the industry at the time in order to fulfill the obligation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">11.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including, but not limited to, the indemnification against any Losses involving any actual or alleged death or bodily injury arising out of or resulting from the Development, Manufacture or Commercialization of any Licensed Product. </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="i74883bf4c3b6450ca7f018b6b98cc87e_188"></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 12.<br>MISCELLANEOUS PROVISIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.1&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement will be construed and the respective rights of the Parties determined according to the substantive laws of the State of New York, New York, U.S.A., notwithstanding the provisions governing conflict of laws of any jurisdiction to the contrary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.2&#160;&#160;&#160;&#160;Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.1&#160;&#160;&#160;&#160;With respect to any disputes between the Parties concerning this Agreement, the dispute will be submitted to escalating levels of AEVI and KKC senior management for review.  If the dispute cannot be resolved despite such escalation, then the matter will be referred to the Executive Officers to be resolved by negotiation in good faith as soon as is practicable but in no event later than thirty (30) days after referral.  Such resolution, if any, by the Executive Officers will be final and binding on the Parties.  If the Executive Officers are unable to resolve such dispute within such thirty (30) day period, each Party may submit such dispute for arbitration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If any dispute will arise between KKC and AEVI in connection with or relating to this Agreement, then such dispute will be resolved exclusively by and through an arbitration proceeding to be conducted under the auspices of, and pursuant to, the Commercial Rules of the International Chamber of Commerce (together with any successor organization thereto, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in New York, New York, U.S.A.  Such arbitration proceeding will be conducted in the English language applying the law provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and in such an expedited manner as is then permitted by the ICC&#8217;s commercial arbitration rules.  The Parties also agree to take reasonable discovery, with reasonableness to be determined by the arbitrators.  Each of the foregoing agreements to arbitrate all disputes and the results, determinations, findings, judgments and awards rendered through such arbitration will be final, non-appealable and legally binding on KKC and AEVI and may be entered and enforced by any court or tribunal of competent jurisdiction.  Notwithstanding anything to the contrary in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Party may seek injunctive relief in any court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any arbitration proceeding will be initiated by written notice from either KKC or AEVI to the other Party.  The arbitration will be conducted before a panel of three (3) arbitrators.  Each of KKC and AEVI will have the right to select one (1) arbitrator.  The third arbitrator will be selected by the mutual agreement of the arbitrators appointed by the Parties.  The Party initiating the arbitration proceeding will appoint its arbitrator within ten (10) days following service of the demand for arbitration to the other Party, who will in turn appoint its arbitrator within thirty (30) days of receiving service of the demand.  The two appointed arbitrators will agree upon an arbitrator within thirty (30) days of the date of the appointment by the parties of the second arbitrator.  If either Party or their appointees fail to appoint an arbitrator within the specified time period, the ICC will exercise its powers pursuant to Article 8 of the ICC Rules of Arbitration to appoint such arbitrator.  The ICC&#8217;s appointment will be binding on the Parties.  Each arbitrator will be an attorney in good standing in the Bar of New York and experienced in commercial disputes involving pharmaceutical companies.  Time is of the essence of this arbitration procedure, and KKC and AEVI will instruct the arbitrators to render their decision within ninety (90) days of the arbitration&#8217;s completion.  The cost of the arbitration (including, without limitation, reasonable attorneys&#8217; fees, expenses and disbursements) will be borne as the arbitrators will decide&#59; otherwise such costs (including, without limitation, the prevailing Party&#8217;s reasonable attorneys&#8217; and accountants&#8217; fees, expenses and disbursements) will be borne by the Party against which the judgment of the arbitrator is to be enforced.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.3&#160;&#160;&#160;&#160;Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned.  Notwithstanding the foregoing, (a) KKC may monetize the value of its payments under this Agreement by assigning to a Third Party the right to receive payments and the right to receive payment reports from AEVI&#59; provided that KKC gives thirty (30) days prior written notice to AEVI, and (b) either Party may, without the other Party&#8217;s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate (but subject to the consent of CHOP in respect of the AEVI Technology licensed under the AEVI In-License in the case of assignment by KKC) or pursuant to a Change of Control (but subject to the consent of Sanofi, to the extent required under Applicable Law, in respect of the KKC Technology licensed under the KKC In-License with Sanofi in the case of assignment by AEVI).  The assigning Party will remain responsible for the performance by its assignee of this Agreement or any obligations hereunder so assigned to such assignee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.4&#160;&#160;&#160;&#160;Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Schedules and Exhibits referred to in this Agreement constitute the entire agreement between the Parties with respect to the subject matter hereof, and supersede all previous arrangements with respect to the subject matter hereof, whether written or oral, including the Clinical Development and Option Agreement.  Any amendment or modification to this Agreement will be made in writing signed by both Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.5&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any consent or notice required to be given or made under this Agreement by one of the Parties to the other will be in writing and (a) delivered by hand or (b) sent by internationally recognized overnight delivery service and will be deemed to have been properly served to the addressee upon receipt of such written communication, in any event to the following addresses&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.461%"><tr><td style="width:1.0%"></td><td style="width:42.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to KKC&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kyowa Kirin Co., Ltd.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1-9-2, Otemachi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chiyoda-ku, Tokyo 100-0004</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Japan</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Director of Business Development Department</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kyowa Kirin Co., Ltd.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1-9-2, Otemachi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chiyoda-ku, Tokyo 100-0004</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Japan</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Director of Legal Affairs Group, Legal and Intellectual Property Department</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to AEVI&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Aevi Genomic Medicine, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1500 Liberty Ridge Drive, Suite 321</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wayne, PA 19087</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Chief Executive Officer</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Troutman Pepper Hamilton Sanders LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Two Logan Square</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#38; Arch Streets</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Philadelphia, Pennsylvania 19103-2799</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Brian M. Katz</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.  Any such notice will be deemed to have been given&#58; (a)&#160;if personally delivered, when delivered&#59; (b) if sent by internationally-recognized overnight courier, on the Business Day of the sender during which the sender delivers the notice to the courier&#59; or (c)&#160;if sent by facsimile, when all pages of the notice are successfully transmitted (as shown by a report generated by the sender&#8217;s facsimile machine) during a Business Day of the sender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.6&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The failure of either Party to timely perform any obligation under this Agreement by reason of epidemic, earthquake, riot, civil commotion, fire, act of God, war, terrorist act, strike, flood, or governmental act or restriction, or other cause that is beyond the reasonable control of such Party, will not be deemed to be a breach of this Agreement, but will be excused to the extent and for the duration of such cause, and the affected Party will provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities) and will use its Commercially Reasonable Efforts to avoid or remove such cause, and will perform its obligation(s) with the utmost dispatch when the cause is removed.  If the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">performance of any such obligation under this Agreement is delayed owing to such a force majeure for any continuous period of more than one hundred eighty (180) days, the Parties will consult with respect to an equitable solution, including the possibility of the mutual termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.7&#160;&#160;&#160;&#160;Compliance with Export Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party will export any technology licensed to it by the other Party under this Agreement except in compliance with U.S. export laws and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.8&#160;&#160;&#160;&#160;Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is understood and agreed that the relationship between the Parties is that of independent contractors and that nothing in this Agreement will be construed as authorization for either KKC or AEVI to act as agent for the other.  Nothing herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties or any of their agents or employees for any purpose, including tax purposes, or to create any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party.  Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.9&#160;&#160;&#160;&#160;Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees to execute, acknowledge and&#47;or deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.10&#160;&#160;&#160;&#160;No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement has been prepared jointly and will not be strictly construed against either Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.11&#160;&#160;&#160;&#160;Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party recognizes that the other Party may perform some or all of its obligations under this Agreement through Affiliates to the extent permitted under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such other Party will remain responsible for the performance by its Affiliates as if such obligations were performed by such other Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.12&#160;&#160;&#160;&#160;Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, and the use of any gender will be applicable to all genders.  The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement.  The term &#8220;including&#8221; as used herein means including, without limiting the generality of any description that precedes such term, and will be deemed to be followed by the phrase &#8220;but not limited to,&#8221; &#8220;without limitation&#8221; or words of similar import regardless of whether such words are actually written there (and drawing no implication from the actual inclusion of such phrase in some instances after the word &#8220;including&#8221; but not others).  References to &#8220;Article&#8221;, &#8220;Articles&#8221;, &#8220;Section&#8221;, Sections&#8221;, &#8220;Exhibit&#8221; or &#8220;Exhibits&#8221; are references to the numbered Article(s), Section(s), or lettered Exhibit(s) of this Agreement, unless expressly stated otherwise.  Except where the context otherwise requires, (a)&#160;references to a particular law, rule or regulation mean such law, rule or regulation as in effect as of the relevant time, including all rules and regulations thereunder and any successor law, rule </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or regulation in effect as of the relevant time, and including the then-current amendments thereto&#59; (b) the word &#8220;or&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;and&#47;or&#8221;&#59; (c) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day&#59; (d) references to a particular person or entity include such person&#8217;s or entity&#8217;s successors and assigns to the extent not prohibited by this Agreement&#59; (e) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner&#59; and (f) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement (including any Exhibits).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.13&#160;&#160;&#160;&#160;No Implied Waivers&#59; Rights Cumulative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No failure on the part of KKC or AEVI to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, will impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor will any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.14&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties will substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions.  In case such valid provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one (1) or several provisions of this Agreement will not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.15&#160;&#160;&#160;&#160;No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no person or entity other than AEVI, KKC and their respective Affiliates and permitted assignees hereunder will be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly authorized officers as of the Effective Date.</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.070%"><tr><td style="width:1.0%"></td><td style="width:48.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.247%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">KYOWA KIRIN CO., LTD.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AEVI GENOMIC MEDICINE, LLC</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Masashi Miyamoto</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Michael F. Cola</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Masashi Miyamoto</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Michael F. Cola</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President and CEO</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Signature Page to License Agreement&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE 1.14</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMINO ACID SEQUENCE OF ANTI-LIGHT MAB</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE 1.45</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTE RATES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The following table sets forth the FTE Rates for AEVI FTEs&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.711%"><tr><td style="width:1.0%"></td><td style="width:60.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#47;Role</font></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FTE Rate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***$***)</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE 1.53</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">KKC IN-LICENSES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">License Agreement between La Jolla Institute for Immunology and Kyowa Kirin Co., Ltd. (***) (including the LIGHT Addendum between La Jolla Institute for Allergy and Immunology and Kyowa Kirin Co., Ltd., attached thereto).  This is the LJI Agreement referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***) Agreement between Bristol-Myers Squibb Company and Kyowa Kirin Co., Ltd. (***).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Letters between Kyowa Kirin Co., Ltd. and Sanofi (***), and sublicensing of rights to AEVI.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE 1.57</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">KKC PATENT RIGHTS</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#dbeef3;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="31" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(***)</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">65</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>q12021cercex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icd9744e41e064bd688cd6dcdef12262c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I,&#160;Michael Cola, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Cerecor&#160;Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center;text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 13, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Michael Cola</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael Cola</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s principal executive officer)</font></td></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>q12021cercex-312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i32f94b3f73624e2eb14fbe00a7e5d9b6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I,&#160;Schond Greenway, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q of Cerecor&#160;Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center;text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 13, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Schond L. Greenway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schond L. Greenway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s principal financial officer)</font></td></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>q12021cercex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iff285935895c4f04b0cb7968d150c67b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:0.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="margin-top:0.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:0.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="margin-top:0.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:0.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-top:0.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Cerecor Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael Cola, Chief Executive Officer of the Registrant, and I, Schond Greenway, Chief Financial Officer of the Registrant, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 13, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Michael Cola</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael Cola</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s principal executive officer)</font></td></tr></table></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 13, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Schond L. Greenway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schond L. Greenway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s principal financial officer)</font></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of section&#160;18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cerecor Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="text-align:center;text-indent:63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cerc-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4f7a87f1-b6d6-4918-8a41-8e0f9da38f3e,g:12909dcc-0657-4b99-8650-be04def8faa3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cerc="http://www.cerecor.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cerecor.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cerc-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cerc-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cerc-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cerc-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cerecor.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://www.cerecor.com/role/Business">
        <link:definition>2101101 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://www.cerecor.com/role/BusinessDetails">
        <link:definition>2402401 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AytuDivestiture" roleURI="http://www.cerecor.com/role/AytuDivestiture">
        <link:definition>2105103 - Disclosure - Aytu Divestiture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AytuDivestitureTables" roleURI="http://www.cerecor.com/role/AytuDivestitureTables">
        <link:definition>2306301 - Disclosure - Aytu Divestiture (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AytuDivestitureNarrativeDetails" roleURI="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails">
        <link:definition>2407402 - Disclosure - Aytu Divestiture - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails">
        <link:definition>2408403 - Disclosure - Aytu Divestiture - Summary of Liabilities of the Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AytuDivestitureSummaryofIncomeStatementDetails" roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails">
        <link:definition>2409404 - Disclosure - Aytu Divestiture - Summary of Income Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AytuDivestitureSummaryofCashFlowsDetails" roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails">
        <link:definition>2410405 - Disclosure - Aytu Divestiture - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.cerecor.com/role/Revenue">
        <link:definition>2111104 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetails" roleURI="http://www.cerecor.com/role/RevenueDetails">
        <link:definition>2412406 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.cerecor.com/role/NetLossPerShare">
        <link:definition>2113105 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.cerecor.com/role/NetLossPerShareTables">
        <link:definition>2314302 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNarrativeDetails" roleURI="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails">
        <link:definition>2415407 - Disclosure - Net Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofNetLossPerShareDetails" roleURI="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails">
        <link:definition>2416408 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>2417409 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetAcquisition" roleURI="http://www.cerecor.com/role/AssetAcquisition">
        <link:definition>2118106 - Disclosure - Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetAcquisitionDetails" roleURI="http://www.cerecor.com/role/AssetAcquisitionDetails">
        <link:definition>2419410 - Disclosure - Asset Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cerecor.com/role/FairValueMeasurements">
        <link:definition>2120107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cerecor.com/role/FairValueMeasurementsTables">
        <link:definition>2321303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2422411 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2423412 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>2124108 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>2325304 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>2426413 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails">
        <link:definition>2427414 - Disclosure - Accrued Expenses and Other Current Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructure" roleURI="http://www.cerecor.com/role/CapitalStructure">
        <link:definition>2128109 - Disclosure - Capital Structure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructureTables" roleURI="http://www.cerecor.com/role/CapitalStructureTables">
        <link:definition>2329305 - Disclosure - Capital Structure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructureNarrativeDetails" roleURI="http://www.cerecor.com/role/CapitalStructureNarrativeDetails">
        <link:definition>2430415 - Disclosure - Capital Structure - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStructureWarrantsDetails" roleURI="http://www.cerecor.com/role/CapitalStructureWarrantsDetails">
        <link:definition>2431416 - Disclosure - Capital Structure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.cerecor.com/role/StockBasedCompensation">
        <link:definition>2132110 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.cerecor.com/role/StockBasedCompensationTables">
        <link:definition>2333306 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2434417 - Disclosure - Stock Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>2435418 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails">
        <link:definition>2436419 - Disclosure - Stock Based Compensation - Stock Options With Service-based Vesting Conditions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockbasedCompensationAssumptionsDetails" roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails">
        <link:definition>2437420 - Disclosure - Stock Based Compensation - Stock-based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails">
        <link:definition>2438421 - Disclosure - Stock Based Compensation - Stock Options With Company's Market-based Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>2439422 - Disclosure - Stock Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cerecor.com/role/IncomeTaxes">
        <link:definition>2140111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.cerecor.com/role/IncomeTaxesDetails">
        <link:definition>2441423 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cerecor.com/role/Leases">
        <link:definition>2142112 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cerecor.com/role/LeasesTables">
        <link:definition>2343307 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cerecor.com/role/LeasesNarrativeDetails">
        <link:definition>2444424 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAssetsandLiabilitiesDetails" roleURI="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails">
        <link:definition>2445425 - Disclosure - Leases - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://www.cerecor.com/role/LeasesLeaseCostDetails">
        <link:definition>2446426 - Disclosure - Leases - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseMaturityDetails" roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails">
        <link:definition>2447427 - Disclosure - Leases - Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseMaturityDetails_1" roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1">
        <link:definition>2447427 - Disclosure - Leases - Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cerecor.com/role/CommitmentsandContingencies">
        <link:definition>2148113 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cerecor.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2449428 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" abstract="false" name="RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_OfficersMember" abstract="true" name="OfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LicenseAgreementSemiAnnualLicensePayment" abstract="false" name="LicenseAgreementSemiAnnualLicensePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_TRISPharmaMember" abstract="true" name="TRISPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LicenseAgreementInstallmentPayment" abstract="false" name="LicenseAgreementInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cerc_DebtInstrumentFutureAggregateDeferredPayments" abstract="false" name="DebtInstrumentFutureAggregateDeferredPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_UnderwritersUnitPurchaseOptionMember" abstract="false" name="UnderwritersUnitPurchaseOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" abstract="false" name="AssetAcquisitionContingentValueRightNumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_AssetAcquisitionContingentConsiderationLiability" abstract="false" name="AssetAcquisitionContingentConsiderationLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_RoyaltyAgreementPaymentReceived" abstract="false" name="RoyaltyAgreementPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" abstract="false" name="AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_TevaPharmaceuticalIndustriesLtd.Member" abstract="true" name="TevaPharmaceuticalIndustriesLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" abstract="false" name="AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_The2016PlanMember" abstract="true" name="The2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_EmployeeStockPurchasePlanESPPMember" abstract="true" name="EmployeeStockPurchasePlanESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="cerc_InventoryPeriodBeforeExpiration" abstract="false" name="InventoryPeriodBeforeExpiration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cerc_NumberOfClassOfStockAuthorized" abstract="false" name="NumberOfClassOfStockAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" abstract="false" name="LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" abstract="false" name="LicenseAgreementPotentialMilestonePaymentNumberTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" abstract="false" name="IssuanceOfSharesSharePursuantToRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cerc_ProceedsFromOptionOrWarrantExercises" abstract="false" name="ProceedsFromOptionOrWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" abstract="false" name="EmployeeConsultantsAndDirectorsStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" abstract="false" name="LicenseAgreementPotentialMilestonePaymentNumberOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_CommonStockWarrantsExpirationDateOfJune2024Member" abstract="true" name="CommonStockWarrantsExpirationDateOfJune2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cerc_AssetAcquisitionTransactionCosts" abstract="false" name="AssetAcquisitionTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_PotentialFutureRegulatoryMilestone" abstract="false" name="PotentialFutureRegulatoryMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" abstract="false" name="FairValueMeasurementsChangesInValuationTechniquesNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_ArmisticeMember" abstract="true" name="ArmisticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_IchorionMember" abstract="true" name="IchorionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" abstract="false" name="RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cerc_MajorCustomerNumberTwoMember" abstract="true" name="MajorCustomerNumberTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_CERC007AstraZenecaLicenseAgreementMember" abstract="true" name="CERC007AstraZenecaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_ArmisticePurchaseAgreementMember" abstract="true" name="ArmisticePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_AnnualBaseSalary" abstract="false" name="AnnualBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" abstract="false" name="LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_DeerfieldObligationMember" abstract="true" name="DeerfieldObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_NantahalaMember" abstract="true" name="NantahalaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cerc_NantahalaCapitalManagementLLCMember" abstract="true" name="NantahalaCapitalManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" abstract="false" name="OperatingLeasesRentExpenseAnnualIncreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_DebtInstrumentRemainingContingentConsiderationLiability" abstract="false" name="DebtInstrumentRemainingContingentConsiderationLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" abstract="false" name="LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_CERC611Member" abstract="true" name="CERC611Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_AssetAcquisitionDisclosureTextBlock" abstract="false" name="AssetAcquisitionDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cerc_CommonStockWarrantsExpirationDateOfMay2022Member" abstract="false" name="CommonStockWarrantsExpirationDateOfMay2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_ThirdAmended2016PlanMember" abstract="true" name="ThirdAmended2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_AssetAcquisitionDomain" abstract="true" name="AssetAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" abstract="true" name="NeurologicalClinicalAndPreclinicalStageCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_MillipredMember" abstract="true" name="MillipredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_KarbinalAgreementMember" abstract="true" name="KarbinalAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_CERC006AstellasLicenseAgreementMember" abstract="true" name="CERC006AstellasLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" abstract="false" name="FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_WarrantCommonStockMember" abstract="false" name="WarrantCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_MonthlyOperationPaymentsAdditionalTerm" abstract="false" name="MonthlyOperationPaymentsAdditionalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cerc_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cerc_CAPITALSTRUCTUREAbstract" abstract="true" name="CAPITALSTRUCTUREAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cerc_AssembledWorkforceMember" abstract="true" name="AssembledWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_ServiceBasedOptionsMember" abstract="true" name="ServiceBasedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_NumberOfPreclinicalTherapies" abstract="false" name="NumberOfPreclinicalTherapies" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_LicenseAgreementMilestonePaymentRecognized" abstract="false" name="LicenseAgreementMilestonePaymentRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_AeviGenomicMedicineIncMember" abstract="true" name="AeviGenomicMedicineIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_MajorCustomerNumberOneMember" abstract="true" name="MajorCustomerNumberOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_CapitalStockSharesAuthorized" abstract="false" name="CapitalStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cerc_DebtInstrumentContingentConsiderationPaid" abstract="false" name="DebtInstrumentContingentConsiderationPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cerc_PediatricPortfolioMember" abstract="true" name="PediatricPortfolioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_AccruedMedicaidRebates" abstract="false" name="AccruedMedicaidRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_ClinicalStageMember" abstract="true" name="ClinicalStageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" abstract="false" name="LicenseAgreementPercentOfNetProfitForInstallmentPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_AccruedSalesReturnsAndAllowances" abstract="false" name="AccruedSalesReturnsAndAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cerc_AssetAcquisitionCashandEquivalents" abstract="false" name="AssetAcquisitionCashandEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" abstract="false" name="StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cerc_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_StockholdersEquityNotePreferredStockConversionRatio" abstract="false" name="StockholdersEquityNotePreferredStockConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cerc_NumberOfProductsDeveloped" abstract="false" name="NumberOfProductsDeveloped" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_LesseeOperatingLeaseRentAbatementPeriod" abstract="false" name="LesseeOperatingLeaseRentAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" abstract="false" name="ClassOfWarrantOrRightPercentOwnershipThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" abstract="false" name="ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_MajorCustomerNumberThreeMember" abstract="true" name="MajorCustomerNumberThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" abstract="false" name="IssuanceOfSharesValuePursuantToRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_AccruedGeneralAndAdministrativeExpenses" abstract="false" name="AccruedGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationSalesReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_AssetAcquisitionAxis" abstract="true" name="AssetAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cerc_ProceedsFromRegisteredDirectOffering" abstract="false" name="ProceedsFromRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_A2016SecondAmendedPlanMember" abstract="true" name="A2016SecondAmendedPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" abstract="false" name="LesseeOperatingLeaseLiabilityAnnualBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" abstract="true" name="BusinessCombinationsAndAssetAcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cerc_StockOptionsWithMarketBasedVestingConditionsMember" abstract="true" name="StockOptionsWithMarketBasedVestingConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="cerc_ClassOfStockNumberOfClassesOfStockOutstanding" abstract="false" name="ClassOfStockNumberOfClassesOfStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" abstract="false" name="AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_LesseeOperatingLeaseNumberOfContracts" abstract="false" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" abstract="false" name="PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cerc_LesseeOperatingLeaseRemainingLeaseTeam" abstract="false" name="LesseeOperatingLeaseRemainingLeaseTeam" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cerc_CERC913Member" abstract="true" name="CERC913Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_CERC801CERC802AndCERC803Member" abstract="true" name="CERC801CERC802AndCERC803Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_CommonStockWarrantsNoExpirationMember" abstract="true" name="CommonStockWarrantsNoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_CERC002KKCLicenseAgreementMember" abstract="true" name="CERC002KKCLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LicenseAgreementMakeWholePaymentPerUnit" abstract="false" name="LicenseAgreementMakeWholePaymentPerUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" abstract="false" name="AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_MonthlyOperationPaymentsTerm" abstract="false" name="MonthlyOperationPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cerc_AYTUBioScienceIncMember" abstract="true" name="AYTUBioScienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cerc_LicenseObligationNoncurrent" abstract="false" name="LicenseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" abstract="false" name="AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cerc-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4f7a87f1-b6d6-4918-8a41-8e0f9da38f3e,g:12909dcc-0657-4b99-8650-be04def8faa3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cerecor.com/role/CoverPage" xlink:type="simple" xlink:href="cerc-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5b6f74a-c715-4bd1-a974-8d2bc2893646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0e1a0b9c-87d7-4f44-bbd2-868ab22f3e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d5b6f74a-c715-4bd1-a974-8d2bc2893646" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0e1a0b9c-87d7-4f44-bbd2-868ab22f3e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_75415e9b-fc9f-478e-ac11-2657ff707d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d5b6f74a-c715-4bd1-a974-8d2bc2893646" xlink:to="loc_us-gaap_CommonStockValue_75415e9b-fc9f-478e-ac11-2657ff707d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94310564-0472-405a-a622-4f9c5b37bc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d5b6f74a-c715-4bd1-a974-8d2bc2893646" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94310564-0472-405a-a622-4f9c5b37bc15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6ffe0885-e8b4-48fc-998d-bb692c966b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d5b6f74a-c715-4bd1-a974-8d2bc2893646" xlink:to="loc_us-gaap_PreferredStockValue_6ffe0885-e8b4-48fc-998d-bb692c966b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_266f6317-c6b7-49f0-a2d8-262bdf8107bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cdb05484-c387-4007-8f8c-cf2f86ffd22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_266f6317-c6b7-49f0-a2d8-262bdf8107bd" xlink:to="loc_us-gaap_Liabilities_cdb05484-c387-4007-8f8c-cf2f86ffd22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cea9fd1b-9aad-48a2-ad25-c3bccc75a468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_266f6317-c6b7-49f0-a2d8-262bdf8107bd" xlink:to="loc_us-gaap_StockholdersEquity_cea9fd1b-9aad-48a2-ad25-c3bccc75a468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f5b201b1-4fe5-4f4d-b90c-ff79dd129a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb2b39b6-ee2b-49cd-93a2-f32ede4e932f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b201b1-4fe5-4f4d-b90c-ff79dd129a72" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb2b39b6-ee2b-49cd-93a2-f32ede4e932f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_429a7ab4-6697-4cc2-b666-e2ecf2117799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b201b1-4fe5-4f4d-b90c-ff79dd129a72" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_429a7ab4-6697-4cc2-b666-e2ecf2117799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_92cbdbcd-9080-4031-a621-66a1f9530523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b201b1-4fe5-4f4d-b90c-ff79dd129a72" xlink:to="loc_us-gaap_Goodwill_92cbdbcd-9080-4031-a621-66a1f9530523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_10a10398-6cae-444d-8ef9-fe2eb8a6b92d" xlink:href="cerc-20210331.xsd#cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b201b1-4fe5-4f4d-b90c-ff79dd129a72" xlink:to="loc_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_10a10398-6cae-444d-8ef9-fe2eb8a6b92d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f5e236f7-a54f-4e80-87cd-f57df916d4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5b201b1-4fe5-4f4d-b90c-ff79dd129a72" xlink:to="loc_us-gaap_AssetsCurrent_f5e236f7-a54f-4e80-87cd-f57df916d4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_42e09a95-bfc1-44cc-98f0-23425342cc14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_08883045-0470-4d79-9ed5-40f7a36fbf2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42e09a95-bfc1-44cc-98f0-23425342cc14" xlink:to="loc_us-gaap_AccountsPayableCurrent_08883045-0470-4d79-9ed5-40f7a36fbf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_65337aa4-f908-4c77-8afd-0a446b9c6a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42e09a95-bfc1-44cc-98f0-23425342cc14" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_65337aa4-f908-4c77-8afd-0a446b9c6a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_92805459-72ec-41ae-87e2-ead82a04c0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42e09a95-bfc1-44cc-98f0-23425342cc14" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_92805459-72ec-41ae-87e2-ead82a04c0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd50870d-a324-4396-ac56-603c9ee3ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd50870d-a324-4396-ac56-603c9ee3ddae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_677cc5d4-1345-4fc8-8ee1-7d37f0d8f039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:to="loc_us-gaap_AccountsReceivableNet_677cc5d4-1345-4fc8-8ee1-7d37f0d8f039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_32c2bbd1-f772-43b6-aab0-bf2795b82c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_32c2bbd1-f772-43b6-aab0-bf2795b82c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_37a0bc57-9ff7-4a68-a405-4e96fe59f88e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:to="loc_us-gaap_InventoryNet_37a0bc57-9ff7-4a68-a405-4e96fe59f88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af435611-898a-4c5c-9147-5c32f9c52880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af435611-898a-4c5c-9147-5c32f9c52880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_95eab9bb-5b0c-4e49-82bd-4a785378414f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1225a246-df2a-451e-9ba4-dea5b8f5fbce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_95eab9bb-5b0c-4e49-82bd-4a785378414f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7b0b86bc-82b8-4e66-a2ab-673d680e9604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_33731c39-1c07-4d4c-84a5-4b52bdf99554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7b0b86bc-82b8-4e66-a2ab-673d680e9604" xlink:to="loc_us-gaap_LiabilitiesCurrent_33731c39-1c07-4d4c-84a5-4b52bdf99554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_18e986c9-a1de-4996-bef0-336d0e3266d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7b0b86bc-82b8-4e66-a2ab-673d680e9604" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_18e986c9-a1de-4996-bef0-336d0e3266d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_474f9848-f100-4178-9524-83b7b28f6855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7b0b86bc-82b8-4e66-a2ab-673d680e9604" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_474f9848-f100-4178-9524-83b7b28f6855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_5b302547-9bdf-4666-9aba-6e638865d917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7b0b86bc-82b8-4e66-a2ab-673d680e9604" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_5b302547-9bdf-4666-9aba-6e638865d917" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c33abe16-5b83-4564-85a9-00fd428a3bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_390e9b19-a49b-422d-bfa4-66bb280c5bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c33abe16-5b83-4564-85a9-00fd428a3bf0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_390e9b19-a49b-422d-bfa4-66bb280c5bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_cd1401ca-b6f3-4658-bc7e-060ae905580a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c33abe16-5b83-4564-85a9-00fd428a3bf0" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_cd1401ca-b6f3-4658-bc7e-060ae905580a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d9d7ca40-39b0-4f95-8d9c-bf2cb6b44407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b0cab99-69d4-4712-afae-bcd3611f786e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d9d7ca40-39b0-4f95-8d9c-bf2cb6b44407" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b0cab99-69d4-4712-afae-bcd3611f786e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4bf962bf-dac6-4abd-84a6-67daaaf42ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d9d7ca40-39b0-4f95-8d9c-bf2cb6b44407" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4bf962bf-dac6-4abd-84a6-67daaaf42ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_805f2939-d7cf-4e7b-a5ec-dc815d4dcbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_61360e0d-442c-4af1-8f56-212de7728971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_805f2939-d7cf-4e7b-a5ec-dc815d4dcbd3" xlink:to="loc_us-gaap_CostsAndExpenses_61360e0d-442c-4af1-8f56-212de7728971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a841a7a7-d1dc-431b-8950-da5f20b52362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_805f2939-d7cf-4e7b-a5ec-dc815d4dcbd3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a841a7a7-d1dc-431b-8950-da5f20b52362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c9876ab-b642-4b8d-992a-26b97973179b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_bd3086e5-762f-4b79-9d41-a98714019f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3c9876ab-b642-4b8d-992a-26b97973179b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_bd3086e5-762f-4b79-9d41-a98714019f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_288d7250-2c01-4128-bc6d-763be4359f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3c9876ab-b642-4b8d-992a-26b97973179b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_288d7250-2c01-4128-bc6d-763be4359f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f83a0ee0-8a48-4cc8-bf13-c04d30518443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_34b22ef0-4578-4da3-b34b-70f461eba68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f83a0ee0-8a48-4cc8-bf13-c04d30518443" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_34b22ef0-4578-4da3-b34b-70f461eba68b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_adecc030-7782-4fc2-aabe-58c5f082ba44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f83a0ee0-8a48-4cc8-bf13-c04d30518443" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_adecc030-7782-4fc2-aabe-58c5f082ba44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_975249f3-1685-4171-918e-fd21abbc599f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f83a0ee0-8a48-4cc8-bf13-c04d30518443" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_975249f3-1685-4171-918e-fd21abbc599f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9fda9d39-4758-47a1-b4fe-4bfe358e166a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9fda9d39-4758-47a1-b4fe-4bfe358e166a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2d775df3-76cb-46fe-bb6d-7c01981f4c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2d775df3-76cb-46fe-bb6d-7c01981f4c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f98a1973-7db9-4ff0-b59d-fa8bf4891352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f98a1973-7db9-4ff0-b59d-fa8bf4891352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f4a08615-fc2c-413c-ab6a-d6c5c53beb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f4a08615-fc2c-413c-ab6a-d6c5c53beb7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_99a1b78e-5edc-4b2b-b744-fb651e910a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:to="loc_us-gaap_SellingAndMarketingExpense_99a1b78e-5edc-4b2b-b744-fb651e910a17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a108fef4-70a2-48c1-962b-8be4fd63d3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d75ba5a-4180-4457-a236-fa4c650ae78a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a108fef4-70a2-48c1-962b-8be4fd63d3f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0be09c86-975c-4d0a-9650-936a595e6c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e737a88e-a6c0-4287-9f82-8bef80c0fe82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0be09c86-975c-4d0a-9650-936a595e6c16" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e737a88e-a6c0-4287-9f82-8bef80c0fe82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b2de6809-cf42-4b8d-8d74-34041d97a6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0be09c86-975c-4d0a-9650-936a595e6c16" xlink:to="loc_us-gaap_OperatingIncomeLoss_b2de6809-cf42-4b8d-8d74-34041d97a6d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8e483665-a3a4-42d3-bbbc-cab0277e5e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9f40bad5-824e-46b6-9e23-d3f1f2e5b925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_8e483665-a3a4-42d3-bbbc-cab0277e5e5f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9f40bad5-824e-46b6-9e23-d3f1f2e5b925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_bf2efdd7-80af-4071-92c7-b742986b6c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_8e483665-a3a4-42d3-bbbc-cab0277e5e5f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_bf2efdd7-80af-4071-92c7-b742986b6c06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_65e46884-8a3a-4213-bf02-fd46d07eeae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8689081-b4b3-4f09-87bc-eeca317526b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_65e46884-8a3a-4213-bf02-fd46d07eeae6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8689081-b4b3-4f09-87bc-eeca317526b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_974262a1-a851-4c7c-827f-7c9df8a6cad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_65e46884-8a3a-4213-bf02-fd46d07eeae6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_974262a1-a851-4c7c-827f-7c9df8a6cad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e4f839b-0be1-4330-8d17-4394713e8629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_65e46884-8a3a-4213-bf02-fd46d07eeae6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e4f839b-0be1-4330-8d17-4394713e8629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75897d99-bc1a-4131-9ece-12828576b4df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_577e09d1-2c8d-44b6-b45d-8f812a9910cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75897d99-bc1a-4131-9ece-12828576b4df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_577e09d1-2c8d-44b6-b45d-8f812a9910cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_57651002-ccd9-4157-a371-301b7f1143b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75897d99-bc1a-4131-9ece-12828576b4df" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_57651002-ccd9-4157-a371-301b7f1143b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_145a8040-4079-4d9d-972d-f49d1462c7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75897d99-bc1a-4131-9ece-12828576b4df" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_145a8040-4079-4d9d-972d-f49d1462c7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1bf93941-a32c-4d09-bd91-c659ca7960b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_NetIncomeLoss_1bf93941-a32c-4d09-bd91-c659ca7960b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3933a0a5-9691-4d94-82f3-0436ccf7c1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3933a0a5-9691-4d94-82f3-0436ccf7c1d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_02a55e0e-6c24-481c-ae97-3d2b8e1567d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_ShareBasedCompensation_02a55e0e-6c24-481c-ae97-3d2b8e1567d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ace3d5ca-a0cd-44ff-b24c-46da861ab871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ace3d5ca-a0cd-44ff-b24c-46da861ab871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad77c6a5-bda4-469b-bf5f-8cb8ce929b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad77c6a5-bda4-469b-bf5f-8cb8ce929b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_ecfeb302-42d4-40bc-ae03-1a8c6b86ed96" xlink:href="cerc-20210331.xsd#cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_ecfeb302-42d4-40bc-ae03-1a8c6b86ed96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f6b3098b-091a-447d-b87c-b4e96b174fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f6b3098b-091a-447d-b87c-b4e96b174fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_ee265bca-13d2-46e9-9d8e-e7dca149e224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_ee265bca-13d2-46e9-9d8e-e7dca149e224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_21b60dfe-ac2b-45cc-a5c7-ce0214e295a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_21b60dfe-ac2b-45cc-a5c7-ce0214e295a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db1c5899-08f1-42ee-b400-72e984fe3d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db1c5899-08f1-42ee-b400-72e984fe3d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0d364e87-b6c9-4ad4-9ad3-73004370eb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0d364e87-b6c9-4ad4-9ad3-73004370eb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3368e8c1-0134-45c5-90be-852d9e602c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3368e8c1-0134-45c5-90be-852d9e602c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_63fe2c27-5ae1-427b-9986-01ab656134b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_63fe2c27-5ae1-427b-9986-01ab656134b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IncreaseDecreaseInLeaseLiability_fe5972cb-d763-4469-bc70-d9f729b02708" xlink:href="cerc-20210331.xsd#cerc_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_cerc_IncreaseDecreaseInLeaseLiability_fe5972cb-d763-4469-bc70-d9f729b02708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_47e91ff6-1068-47c2-946a-c51cc97b5aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_47e91ff6-1068-47c2-946a-c51cc97b5aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_c796d587-a758-4849-b5a1-43aee55ecf95" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2575982-eceb-46e8-9bb9-9af2d8fb57dc" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_c796d587-a758-4849-b5a1-43aee55ecf95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d29664d9-f205-4c7a-96b0-211767a3ea77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromOptionOrWarrantExercises_f972482b-c374-479a-b7ec-7f7b2ec6fbbb" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromOptionOrWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d29664d9-f205-4c7a-96b0-211767a3ea77" xlink:to="loc_cerc_ProceedsFromOptionOrWarrantExercises_f972482b-c374-479a-b7ec-7f7b2ec6fbbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_13a513ec-82ca-46ba-9fb8-af66a1321720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d29664d9-f205-4c7a-96b0-211767a3ea77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_13a513ec-82ca-46ba-9fb8-af66a1321720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_c739add1-727b-4ba9-8675-910e08e68b7e" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d29664d9-f205-4c7a-96b0-211767a3ea77" xlink:to="loc_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_c739add1-727b-4ba9-8675-910e08e68b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromRegisteredDirectOffering_01cb67ca-b677-403a-bb4e-5d1e2ea1f9e3" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromRegisteredDirectOffering"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d29664d9-f205-4c7a-96b0-211767a3ea77" xlink:to="loc_cerc_ProceedsFromRegisteredDirectOffering_01cb67ca-b677-403a-bb4e-5d1e2ea1f9e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75c30c27-c509-4365-9554-4bddbbffde9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PaymentsForAssetAcquisitions_614ae890-814a-41a0-baa9-95105083067b" xlink:href="cerc-20210331.xsd#cerc_PaymentsForAssetAcquisitions"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75c30c27-c509-4365-9554-4bddbbffde9b" xlink:to="loc_cerc_PaymentsForAssetAcquisitions_614ae890-814a-41a0-baa9-95105083067b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c7439afc-5cf5-467a-9326-235dd47abf3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75c30c27-c509-4365-9554-4bddbbffde9b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c7439afc-5cf5-467a-9326-235dd47abf3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/Business" xlink:type="simple" xlink:href="cerc-20210331.xsd#Business"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/Business" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/BusinessDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#BusinessDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/BusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="cerc-20210331.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cerc-20210331.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestiture" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestiture"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AytuDivestiture" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_33f90dfd-035e-42a4-8235-84b4f87c26a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8a5ac4f6-33fe-45ed-97de-79cb14d6db68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_33f90dfd-035e-42a4-8235-84b4f87c26a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8a5ac4f6-33fe-45ed-97de-79cb14d6db68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofIncomeStatementDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_5c9f1d84-5c63-4551-a3f9-8da7e938e058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_214f2941-868b-4f93-8908-81a39b4005fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_5c9f1d84-5c63-4551-a3f9-8da7e938e058" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_214f2941-868b-4f93-8908-81a39b4005fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9670b105-cc5a-4269-8a11-d292641e62f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f9b90b07-dc4b-4ce3-997d-f6e8c51d62d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9670b105-cc5a-4269-8a11-d292641e62f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f9b90b07-dc4b-4ce3-997d-f6e8c51d62d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_0fa60390-4d31-413f-94b5-eb9efab43924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9670b105-cc5a-4269-8a11-d292641e62f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_0fa60390-4d31-413f-94b5-eb9efab43924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_38876a79-d394-44ff-a73b-027a7f9cced1" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9670b105-cc5a-4269-8a11-d292641e62f2" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_38876a79-d394-44ff-a73b-027a7f9cced1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_dbc9a28e-2201-4a8b-bbaf-3939f97b7ace" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_e86f7ddb-672b-48a7-9ba5-664c039043fb" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_dbc9a28e-2201-4a8b-bbaf-3939f97b7ace" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_e86f7ddb-672b-48a7-9ba5-664c039043fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofCashFlowsDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/Revenue" xlink:type="simple" xlink:href="cerc-20210331.xsd#Revenue"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/Revenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/RevenueDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#RevenueDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/RevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareScheduleofNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AssetAcquisition" xlink:type="simple" xlink:href="cerc-20210331.xsd#AssetAcquisition"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AssetAcquisition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AssetAcquisitionDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AssetAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AssetAcquisitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedSalesReturnsAndAllowances_7fecb910-d0cc-4882-ab70-ae357aeac5b8" xlink:href="cerc-20210331.xsd#cerc_AccruedSalesReturnsAndAllowances"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_cerc_AccruedSalesReturnsAndAllowances_7fecb910-d0cc-4882-ab70-ae357aeac5b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedMedicaidRebates_f361a571-76f9-4671-bbf5-d46b4d216e3d" xlink:href="cerc-20210331.xsd#cerc_AccruedMedicaidRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_cerc_AccruedMedicaidRebates_f361a571-76f9-4671-bbf5-d46b4d216e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0b252ec-b4ac-4329-9a75-c8ef8ad2f988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0b252ec-b4ac-4329-9a75-c8ef8ad2f988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedResearchAndDevelopment_85d6c28a-c70b-4bd0-b91d-2ff60dc246e2" xlink:href="cerc-20210331.xsd#cerc_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_cerc_AccruedResearchAndDevelopment_85d6c28a-c70b-4bd0-b91d-2ff60dc246e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_a78fbb18-b5e5-48f3-8884-e67d3d298f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_a78fbb18-b5e5-48f3-8884-e67d3d298f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedGeneralAndAdministrativeExpenses_03bd9374-85bc-440d-919b-fc8775687288" xlink:href="cerc-20210331.xsd#cerc_AccruedGeneralAndAdministrativeExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_cerc_AccruedGeneralAndAdministrativeExpenses_03bd9374-85bc-440d-919b-fc8775687288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_1d64d694-db2c-4f71-9cac-64e04c6ec84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_1d64d694-db2c-4f71-9cac-64e04c6ec84f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e0a76fe7-9664-4459-97fe-2fad9bb8f53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48b37e02-1077-4af6-adea-3e0a2877a39d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e0a76fe7-9664-4459-97fe-2fad9bb8f53d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructure" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructure"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CapitalStructure" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CapitalStructureTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CapitalStructureNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureWarrantsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CapitalStructureWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockbasedCompensationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cerc-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/Leases" xlink:type="simple" xlink:href="cerc-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e511bee6-a62a-4c63-a5ed-45e454c7dab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35232985-0a04-4c00-80cc-282994dd0871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e511bee6-a62a-4c63-a5ed-45e454c7dab5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35232985-0a04-4c00-80cc-282994dd0871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffa84a51-f2b3-4538-a7ec-d954752f597d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e511bee6-a62a-4c63-a5ed-45e454c7dab5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffa84a51-f2b3-4538-a7ec-d954752f597d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/LeasesLeaseCostDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/LeasesLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c85ade2c-8d98-4164-80bf-11843a31e4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e8e8bab3-d627-49fa-8aac-13125cd525ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c85ade2c-8d98-4164-80bf-11843a31e4e4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e8e8bab3-d627-49fa-8aac-13125cd525ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2ba1b1ac-9c6a-4a42-81a3-2470c5c36f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c85ade2c-8d98-4164-80bf-11843a31e4e4" xlink:to="loc_us-gaap_OperatingLeaseLiability_2ba1b1ac-9c6a-4a42-81a3-2470c5c36f5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_68262a71-7f8f-4cf5-8a47-cb8606409799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_68262a71-7f8f-4cf5-8a47-cb8606409799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0f18c0fb-1ea2-4200-86d9-79c87b678282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0f18c0fb-1ea2-4200-86d9-79c87b678282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c67bea45-5254-4b12-a6f1-fa25c9ce5a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c67bea45-5254-4b12-a6f1-fa25c9ce5a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09de9801-1f75-41c6-964a-1270220886eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09de9801-1f75-41c6-964a-1270220886eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3f27454a-3a49-4fd1-9b28-e0998aff95d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3f27454a-3a49-4fd1-9b28-e0998aff95d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_12efad8a-4905-45b0-ba8e-e94f9b2f2159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_12efad8a-4905-45b0-ba8e-e94f9b2f2159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_23814fdf-a5e0-45c6-ae99-6f14fa7aab63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9ee7071-d484-4105-a8d2-213ed04b11d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_23814fdf-a5e0-45c6-ae99-6f14fa7aab63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cerc-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.cerecor.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cerc-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4f7a87f1-b6d6-4918-8a41-8e0f9da38f3e,g:12909dcc-0657-4b99-8650-be04def8faa3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CoverPage" xlink:type="simple" xlink:href="cerc-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CoverPage" xlink:type="extended" id="idfaf911ead264c63bea418686e4b944f_CoverPage"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i7ef164ee3ab74de7beee29cefd98aed6_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i75eb1d091be54f40b624711ec80d33bc_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" id="i00fc892f333845449eed3684f4e3f0d8_CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_005681fd-0fbb-446f-a8ea-b6d2905bbe96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_RevenuesAbstract_005681fd-0fbb-446f-a8ea-b6d2905bbe96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ba29bc76-917b-46a1-aef8-a713d67d8213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_005681fd-0fbb-446f-a8ea-b6d2905bbe96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ba29bc76-917b-46a1-aef8-a713d67d8213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b84ce18-1c1e-427f-b24c-4adad3a54944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b84ce18-1c1e-427f-b24c-4adad3a54944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8585c897-c640-47e0-b544-9aaf518166e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8585c897-c640-47e0-b544-9aaf518166e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e8e9c060-121c-4f25-8a4d-8349251529a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e8e9c060-121c-4f25-8a4d-8349251529a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5da47cdc-a25f-424f-909b-5d5cfe03071f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5da47cdc-a25f-424f-909b-5d5cfe03071f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d6b7d877-048b-4d3a-afa6-7b1aecf1093c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d6b7d877-048b-4d3a-afa6-7b1aecf1093c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4939805c-e963-4e9f-b277-de2ac7b650b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4939805c-e963-4e9f-b277-de2ac7b650b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_88bc7780-842f-457d-9637-c4a15ca906a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_CostsAndExpenses_88bc7780-842f-457d-9637-c4a15ca906a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_391ad511-709e-411c-92f3-b2ee04586f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_OperatingIncomeLoss_391ad511-709e-411c-92f3-b2ee04586f60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2b35ad85-d153-4825-b29c-6e6fc4b98984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2b35ad85-d153-4825-b29c-6e6fc4b98984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_65b3000b-4c0f-40b2-9456-532373ff8d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_65b3000b-4c0f-40b2-9456-532373ff8d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_68b805c0-4b13-4e59-9d81-4d5928a14bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_68b805c0-4b13-4e59-9d81-4d5928a14bff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2a27edbb-77ab-4a89-8f5e-3991c0696888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2a27edbb-77ab-4a89-8f5e-3991c0696888" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d02bea6-4ce6-46c0-82df-ec2d9dba4f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d02bea6-4ce6-46c0-82df-ec2d9dba4f40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3645ce6b-6441-49a7-8478-1db66a2fdb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3645ce6b-6441-49a7-8478-1db66a2fdb85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_04efaa32-29f5-4a32-b550-e8ed4e9a30e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_04efaa32-29f5-4a32-b550-e8ed4e9a30e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_101f2d5b-5246-4131-98d1-c9744220b631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_101f2d5b-5246-4131-98d1-c9744220b631" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_185bf29b-bc1d-402f-85da-48507d73e1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_NetIncomeLoss_185bf29b-bc1d-402f-85da-48507d73e1c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1d702496-3d36-415c-930b-04234a55758b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1d702496-3d36-415c-930b-04234a55758b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5f607b89-4b19-438f-a996-ad5a098aa0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5f607b89-4b19-438f-a996-ad5a098aa0a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4c944449-77cb-442a-975d-97144749580b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4c944449-77cb-442a-975d-97144749580b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_a4e22dd9-06e0-4fc8-9999-4ad0ed6b1944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_a4e22dd9-06e0-4fc8-9999-4ad0ed6b1944" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7e0b0ae3-c94b-4812-8638-3ef90ae87b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_EarningsPerShareBasic_7e0b0ae3-c94b-4812-8638-3ef90ae87b9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1cc678c5-6deb-4b08-8a23-de35ef9456a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1cc678c5-6deb-4b08-8a23-de35ef9456a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ecb9707-57ca-4996-b5d0-30b42583c4e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:to="loc_us-gaap_ClassOfStockDomain_1ecb9707-57ca-4996-b5d0-30b42583c4e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:to="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3bd528ab-d655-4ab6-ae13-135603f99f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:to="loc_us-gaap_CommonStockMember_3bd528ab-d655-4ab6-ae13-135603f99f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_176077bb-915e-4003-b679-e06e081434a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:to="loc_us-gaap_PreferredStockMember_176077bb-915e-4003-b679-e06e081434a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:to="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:to="loc_srt_ProductsAndServicesDomain_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f8909d3a-d66d-46ce-ad1f-6e624dbd48ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:to="loc_srt_ProductsAndServicesDomain_f8909d3a-d66d-46ce-ad1f-6e624dbd48ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_156ba021-6ce6-43a4-864c-d8a9613890c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f8909d3a-d66d-46ce-ad1f-6e624dbd48ee" xlink:to="loc_us-gaap_ProductMember_156ba021-6ce6-43a4-864c-d8a9613890c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended" id="i0dd2419394bd48fd8a7f69399b0d28a6_CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69064a38-169d-42e6-88e0-761c30dd5ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69064a38-169d-42e6-88e0-761c30dd5ae4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7c4dae3d-03db-4af7-8fd3-e80013464058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_SharesOutstanding_7c4dae3d-03db-4af7-8fd3-e80013464058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05aa0f64-7590-49cc-943a-803b4d2ccfd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockholdersEquity_05aa0f64-7590-49cc-943a-803b4d2ccfd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbe0db29-1ab1-451f-a558-d937937e719e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbe0db29-1ab1-451f-a558-d937937e719e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f27a7c04-314d-4ad7-be6d-03e411da0bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f27a7c04-314d-4ad7-be6d-03e411da0bf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_65cb2058-17b5-4a48-84cd-3cecdfaf3cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_65cb2058-17b5-4a48-84cd-3cecdfaf3cc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_8375133a-6528-47ce-a3fa-5491aac8ecc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_8375133a-6528-47ce-a3fa-5491aac8ecc8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d104fbe4-a700-4203-bc8f-02b80848d55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d104fbe4-a700-4203-bc8f-02b80848d55c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f9dbdbae-4d7b-40a9-bba7-38c467c449d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f9dbdbae-4d7b-40a9-bba7-38c467c449d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_44fd1fc6-bc52-4e90-8ede-d133f6ef2919" xlink:href="cerc-20210331.xsd#cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_44fd1fc6-bc52-4e90-8ede-d133f6ef2919" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_c0b58bc4-8019-476a-9a30-2546e787aea0" xlink:href="cerc-20210331.xsd#cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_c0b58bc4-8019-476a-9a30-2546e787aea0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_e05ec94e-b4bf-4231-9526-b66079af6439" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_e05ec94e-b4bf-4231-9526-b66079af6439" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_98627d50-c3ba-49a5-8629-5276dd575ed2" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_98627d50-c3ba-49a5-8629-5276dd575ed2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_61c2afe6-87e0-4802-90da-c39f317f14fc" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_61c2afe6-87e0-4802-90da-c39f317f14fc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_ce22c9d2-a66b-421a-a2dd-114b2b989a69" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_ce22c9d2-a66b-421a-a2dd-114b2b989a69" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2e5a14e2-2281-45c0-9ac3-b7112fd668a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2e5a14e2-2281-45c0-9ac3-b7112fd668a0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de28f015-ed73-41d9-b572-82ac6d43709c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_NetIncomeLoss_de28f015-ed73-41d9-b572-82ac6d43709c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_75d5dee8-bdc6-4858-ab72-c87c9a9f2b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26a17759-42fd-43ff-a326-77c1b309c253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69064a38-169d-42e6-88e0-761c30dd5ae4" xlink:to="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5dd1ac17-d5da-4a62-a667-94918a20fd2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:to="loc_us-gaap_EquityComponentDomain_5dd1ac17-d5da-4a62-a667-94918a20fd2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:to="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95911307-f551-4f1c-80f1-7347be10f515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_CommonStockMember_95911307-f551-4f1c-80f1-7347be10f515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ac651eb2-af17-4ac3-85f9-b5a4798b14b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_PreferredStockMember_ac651eb2-af17-4ac3-85f9-b5a4798b14b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0daa83fc-0c31-4a18-8700-97f4cfb482f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0daa83fc-0c31-4a18-8700-97f4cfb482f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d5c0d495-e2c5-493b-ae77-f8d696c7c6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_RetainedEarningsMember_d5c0d495-e2c5-493b-ae77-f8d696c7c6f2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i6a7c28d769cc49b4a961dfbc6e2b889f_CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/Business" xlink:type="simple" xlink:href="cerc-20210331.xsd#Business"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/Business" xlink:type="extended" id="ib4d6824c790e423d84781e6dadff0f38_Business"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/BusinessDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#BusinessDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/BusinessDetails" xlink:type="extended" id="i1cb572eda9714f4588abd3dc51929583_BusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfProductsDeveloped_63ff4b68-7b0b-4e83-b34e-d322a32f1659" xlink:href="cerc-20210331.xsd#cerc_NumberOfProductsDeveloped"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_cerc_NumberOfProductsDeveloped_63ff4b68-7b0b-4e83-b34e-d322a32f1659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82935e93-9c4e-4811-ad9c-58b4d60124fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82935e93-9c4e-4811-ad9c-58b4d60124fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2f8fa2d8-a4c7-4027-81dd-79f6d2efa9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2f8fa2d8-a4c7-4027-81dd-79f6d2efa9d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_efd84377-d51a-4621-986e-9cce7ef4a320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_efd84377-d51a-4621-986e-9cce7ef4a320" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f2d3ade-49c7-4833-983f-aa026a4b1bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_NetIncomeLoss_0f2d3ade-49c7-4833-983f-aa026a4b1bbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a74159a-501b-4edb-96e1-a0869fc093f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a74159a-501b-4edb-96e1-a0869fc093f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b92a100-7dab-4523-a7a2-509bec622899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b92a100-7dab-4523-a7a2-509bec622899" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bb26d38e-5bb7-43ec-90b3-ee36d3856e81_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:to="loc_srt_ProductsAndServicesDomain_bb26d38e-5bb7-43ec-90b3-ee36d3856e81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:to="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_4055cd20-0048-42d0-87b5-1d15c81066e3" xlink:href="cerc-20210331.xsd#cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:to="loc_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_4055cd20-0048-42d0-87b5-1d15c81066e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClinicalStageMember_1f5d2c62-1c9c-4934-b264-679af6f920de" xlink:href="cerc-20210331.xsd#cerc_ClinicalStageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:to="loc_cerc_ClinicalStageMember_1f5d2c62-1c9c-4934-b264-679af6f920de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6fb78416-b660-4b52-9119-747546b3016e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6fb78416-b660-4b52-9119-747546b3016e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e82daab1-cd57-4534-923c-1e0f17018ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e82daab1-cd57-4534-923c-1e0f17018ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwrittenPublicOfferingMember_d54aeb59-bd9a-45e6-9d1f-9bad2f27e849" xlink:href="cerc-20210331.xsd#cerc_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e82daab1-cd57-4534-923c-1e0f17018ab1" xlink:to="loc_cerc_UnderwrittenPublicOfferingMember_d54aeb59-bd9a-45e6-9d1f-9bad2f27e849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3f703b27-884e-4c8f-905d-16d9a95e3ae5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3f703b27-884e-4c8f-905d-16d9a95e3ae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6ddc79e8-80f9-489c-8c01-8c69d949cd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6ddc79e8-80f9-489c-8c01-8c69d949cd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_327d6f86-b1a4-425c-9591-6a95dfd3dadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6ddc79e8-80f9-489c-8c01-8c69d949cd13" xlink:to="loc_us-gaap_WarrantMember_327d6f86-b1a4-425c-9591-6a95dfd3dadb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="cerc-20210331.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended" id="i4d1edd596cd643929105bf23426a1482_BasisofPresentationandSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cerc-20210331.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i742d1a9ba5aa4ba8bb7d536e8ce38bd8_BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestiture" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestiture"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AytuDivestiture" xlink:type="extended" id="iba57526f943b46bd8d489ba6e4404a29_AytuDivestiture"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AytuDivestitureTables" xlink:type="extended" id="i66ee96a3d13b4722b5d0ddde18b1e43d_AytuDivestitureTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails" xlink:type="extended" id="i93b04398a64646f9a7cbc96d7e73531f_AytuDivestitureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2a8fd509-7acd-43df-8390-dccecd054481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2a8fd509-7acd-43df-8390-dccecd054481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_355b459b-1adc-451a-b294-d1ba6f97ca84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_355b459b-1adc-451a-b294-d1ba6f97ca84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MonthlyOperationPaymentsTerm_389f9fb6-2cc1-40fa-bf6b-8efa8f0c4c05" xlink:href="cerc-20210331.xsd#cerc_MonthlyOperationPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_MonthlyOperationPaymentsTerm_389f9fb6-2cc1-40fa-bf6b-8efa8f0c4c05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MonthlyOperationPaymentsAdditionalTerm_f2d09ea0-00ed-4672-9833-0628e13dce1b" xlink:href="cerc-20210331.xsd#cerc_MonthlyOperationPaymentsAdditionalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_MonthlyOperationPaymentsAdditionalTerm_f2d09ea0-00ed-4672-9833-0628e13dce1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9e52a0d4-3ae2-4a5a-833a-417e880050b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_RepaymentsOfDebt_9e52a0d4-3ae2-4a5a-833a-417e880050b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentContingentConsiderationPaid_bde73ed8-f351-4e08-b1c6-447a0d331da0" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentContingentConsiderationPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DebtInstrumentContingentConsiderationPaid_bde73ed8-f351-4e08-b1c6-447a0d331da0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentRemainingContingentConsiderationLiability_98c897b1-f49c-4cd9-919c-990cee6c8c51" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentRemainingContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DebtInstrumentRemainingContingentConsiderationLiability_98c897b1-f49c-4cd9-919c-990cee6c8c51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_4e498dc9-23f9-4a04-8ecd-03537f61eb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_4e498dc9-23f9-4a04-8ecd-03537f61eb51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentFutureAggregateDeferredPayments_64484db5-23b3-4a3a-b12f-2fb135204385" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentFutureAggregateDeferredPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DebtInstrumentFutureAggregateDeferredPayments_64484db5-23b3-4a3a-b12f-2fb135204385" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_b0c44fb2-2d07-4f1e-882a-e77980550572" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_b0c44fb2-2d07-4f1e-882a-e77980550572" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_610d0927-9d84-43e4-9e56-349b67808fe6" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_610d0927-9d84-43e4-9e56-349b67808fe6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_83daf9a8-4f87-436d-9ce1-2d1e9646684e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_83daf9a8-4f87-436d-9ce1-2d1e9646684e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dda798ae-7474-468e-a9a2-ed2231acb846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dda798ae-7474-468e-a9a2-ed2231acb846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_9f03878a-d68d-480f-a3ae-45afff1362c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_dda798ae-7474-468e-a9a2-ed2231acb846" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_9f03878a-d68d-480f-a3ae-45afff1362c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b8847bfc-87ca-47a8-97dc-26527793b365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b8847bfc-87ca-47a8-97dc-26527793b365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_1eb442ca-906b-4f5f-a823-d5e557e0c594" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b8847bfc-87ca-47a8-97dc-26527793b365" xlink:to="loc_cerc_PediatricPortfolioMember_1eb442ca-906b-4f5f-a823-d5e557e0c594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9260e37c-bf1d-4a7d-acdf-121857e3a700_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9260e37c-bf1d-4a7d-acdf-121857e3a700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_09666fd3-d048-4cfd-9c13-6a4ad3f8f525" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_09666fd3-d048-4cfd-9c13-6a4ad3f8f525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember_148ddfe5-f20f-47e3-a50a-e33c323f9b3a" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09666fd3-d048-4cfd-9c13-6a4ad3f8f525" xlink:to="loc_cerc_AYTUBioScienceIncMember_148ddfe5-f20f-47e3-a50a-e33c323f9b3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f0b2381-cfa6-40f4-83cc-099d757887d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:to="loc_us-gaap_ClassOfStockDomain_5f0b2381-cfa6-40f4-83cc-099d757887d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_469627d8-8022-4367-86bf-604641059c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:to="loc_us-gaap_ClassOfStockDomain_469627d8-8022-4367-86bf-604641059c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7e09f454-7e55-4e20-8668-89cbe3f5ffea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_469627d8-8022-4367-86bf-604641059c92" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7e09f454-7e55-4e20-8668-89cbe3f5ffea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_955692ef-cec4-4970-86a8-7bc7aaec9e12_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_955692ef-cec4-4970-86a8-7bc7aaec9e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ebe0dc7-1220-4103-abe0-98841adad5b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ebe0dc7-1220-4103-abe0-98841adad5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember_452267fa-7c7d-4ddf-87c3-34697d07b0bf" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ebe0dc7-1220-4103-abe0-98841adad5b2" xlink:to="loc_cerc_AYTUBioScienceIncMember_452267fa-7c7d-4ddf-87c3-34697d07b0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19236b80-1bfa-4178-a4f4-d142aecb6f71_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:to="loc_srt_RangeMember_19236b80-1bfa-4178-a4f4-d142aecb6f71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:to="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a5c64ff-46b8-4b42-a14a-8cf6e9e26428" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:to="loc_srt_MaximumMember_4a5c64ff-46b8-4b42-a14a-8cf6e9e26428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_520b99f5-a344-47e3-a7bc-9cc513ad238e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:to="loc_srt_MinimumMember_520b99f5-a344-47e3-a7bc-9cc513ad238e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d9edc596-b3d5-47f6-8eab-f02c432510b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d9edc596-b3d5-47f6-8eab-f02c432510b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2d8431d2-6427-49ff-9e73-30cc2bd51a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2d8431d2-6427-49ff-9e73-30cc2bd51a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_360a9774-c984-4fab-9a5a-a71c53edef11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2d8431d2-6427-49ff-9e73-30cc2bd51a46" xlink:to="loc_us-gaap_SubsequentEventMember_360a9774-c984-4fab-9a5a-a71c53edef11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1e39293-a38b-4330-a186-1cf15b9c46c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1e39293-a38b-4330-a186-1cf15b9c46c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_67cde12e-a1f4-4221-8150-7c90210e230e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_67cde12e-a1f4-4221-8150-7c90210e230e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DeerfieldObligationMember_5e3797f7-1e94-4a4d-82ca-5f40c9d9ffa4" xlink:href="cerc-20210331.xsd#cerc_DeerfieldObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_67cde12e-a1f4-4221-8150-7c90210e230e" xlink:to="loc_cerc_DeerfieldObligationMember_5e3797f7-1e94-4a4d-82ca-5f40c9d9ffa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9056a97f-7e09-47b7-8c58-49590d992700_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:to="loc_dei_EntityDomain_9056a97f-7e09-47b7-8c58-49590d992700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fdc72299-3fa7-4b64-a4c4-444592c3c3b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:to="loc_dei_EntityDomain_fdc72299-3fa7-4b64-a4c4-444592c3c3b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember_88f73027-0780-4905-8d48-7239cf993f5d" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fdc72299-3fa7-4b64-a4c4-444592c3c3b3" xlink:to="loc_cerc_AYTUBioScienceIncMember_88f73027-0780-4905-8d48-7239cf993f5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" xlink:type="extended" id="id450971b6db44a6392e83381845de15d_AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d0bd33c8-6484-4a19-8b86-7cdd1cceb2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_2d89f1c4-d1a0-42e6-9d9a-b7257bc5178a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d0bd33c8-6484-4a19-8b86-7cdd1cceb2dd" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_2d89f1c4-d1a0-42e6-9d9a-b7257bc5178a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_2d89f1c4-d1a0-42e6-9d9a-b7257bc5178a" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9c455468-73f0-4b96-9ec5-dc3f15712cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9c455468-73f0-4b96-9ec5-dc3f15712cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dabfe980-5a35-49fc-9877-d10e780e6268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dabfe980-5a35-49fc-9877-d10e780e6268" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d0bd33c8-6484-4a19-8b86-7cdd1cceb2dd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4c11ddb-cff9-44fa-992c-468640e52cbd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4c11ddb-cff9-44fa-992c-468640e52cbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17bba1d-ec66-4e12-b3a4-fd8b0b96063a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17bba1d-ec66-4e12-b3a4-fd8b0b96063a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_b4687f2a-ebac-416c-982f-bd54456eebcb" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17bba1d-ec66-4e12-b3a4-fd8b0b96063a" xlink:to="loc_cerc_PediatricPortfolioMember_b4687f2a-ebac-416c-982f-bd54456eebcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c4c213c9-4ba3-4c15-a6f9-01ae8dc65353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c4c213c9-4ba3-4c15-a6f9-01ae8dc65353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_83864c13-240b-48cc-be19-352e00cebef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c4c213c9-4ba3-4c15-a6f9-01ae8dc65353" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_83864c13-240b-48cc-be19-352e00cebef2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofIncomeStatementDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails" xlink:type="extended" id="ic1e136f4f26545c9a50d26999dcec26b_AytuDivestitureSummaryofIncomeStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_624df991-3c52-40ee-bd20-81f15a017841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_624df991-3c52-40ee-bd20-81f15a017841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_45a7e008-541f-4bf8-9949-422f874b9f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_45a7e008-541f-4bf8-9949-422f874b9f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eadfbbf4-500f-4ce8-8b25-ed7d59500bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eadfbbf4-500f-4ce8-8b25-ed7d59500bd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_4a1e4ae5-8637-4b3a-99c2-04c7ef9ff5bb" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_4a1e4ae5-8637-4b3a-99c2-04c7ef9ff5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a55053c4-3603-43ae-a824-6aa2ab101158" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a55053c4-3603-43ae-a824-6aa2ab101158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_db394bd9-0258-476a-a4ce-35344833f4f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_db394bd9-0258-476a-a4ce-35344833f4f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4351984a-fa5a-4538-b0cb-48fb2e0c567a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4351984a-fa5a-4538-b0cb-48fb2e0c567a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59f7943a-3f40-42cc-9859-1cce868ffe45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59f7943a-3f40-42cc-9859-1cce868ffe45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_4b038243-e0a8-41c0-abf9-1ba0b46f59ba" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59f7943a-3f40-42cc-9859-1cce868ffe45" xlink:to="loc_cerc_PediatricPortfolioMember_4b038243-e0a8-41c0-abf9-1ba0b46f59ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_424a929c-d995-440d-a48e-e8e963a8d097_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_424a929c-d995-440d-a48e-e8e963a8d097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d51d9bb6-46b8-448e-9eca-54ff1a995eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d51d9bb6-46b8-448e-9eca-54ff1a995eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_d7906c49-e1fe-4ef3-9344-09ff8ac408e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d51d9bb6-46b8-448e-9eca-54ff1a995eaa" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_d7906c49-e1fe-4ef3-9344-09ff8ac408e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails" xlink:type="extended" id="ie33cf540cd874404b64eb7e7a2eaf069_AytuDivestitureSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3c1a4ac2-3212-4e2d-89ac-f013ae53abd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_aa9f78b1-cbb3-4ba7-aa77-b433b21a23dd" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3c1a4ac2-3212-4e2d-89ac-f013ae53abd2" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_aa9f78b1-cbb3-4ba7-aa77-b433b21a23dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3c1a4ac2-3212-4e2d-89ac-f013ae53abd2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e803647-8acf-4789-81fb-dfbbc50a1ec7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e803647-8acf-4789-81fb-dfbbc50a1ec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7627d4f-e6f5-458b-be47-0dab15c28873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7627d4f-e6f5-458b-be47-0dab15c28873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_edb02de2-4855-40e4-b674-77d6102f974d" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7627d4f-e6f5-458b-be47-0dab15c28873" xlink:to="loc_cerc_PediatricPortfolioMember_edb02de2-4855-40e4-b674-77d6102f974d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e9b01974-c2bc-475c-a7cc-d3b0f345f293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e9b01974-c2bc-475c-a7cc-d3b0f345f293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2a3f4671-d031-4bd2-a4cd-0f984fa8a602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e9b01974-c2bc-475c-a7cc-d3b0f345f293" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2a3f4671-d031-4bd2-a4cd-0f984fa8a602" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/Revenue" xlink:type="simple" xlink:href="cerc-20210331.xsd#Revenue"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/Revenue" xlink:type="extended" id="i2ac3ac7b51c944298f91ec75ce965b71_Revenue"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/RevenueDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#RevenueDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/RevenueDetails" xlink:type="extended" id="i92ec53a342504917ab641ee4ee00c4f9_RevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c7c62a35-e23e-4ec5-a31b-a9cf430600c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c7c62a35-e23e-4ec5-a31b-a9cf430600c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_7259d157-ba16-47d4-aa38-21defd14b074" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_7259d157-ba16-47d4-aa38-21defd14b074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementInstallmentPayment_70256d4f-4bc3-491b-93c5-b90ec605a1bc" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_cerc_LicenseAgreementInstallmentPayment_70256d4f-4bc3-491b-93c5-b90ec605a1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a343ea-68f2-47b3-8405-76634a2d2c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a343ea-68f2-47b3-8405-76634a2d2c51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_InventoryPeriodBeforeExpiration_a24697bd-a3d7-472f-9ce8-1ed8058dbbb6" xlink:href="cerc-20210331.xsd#cerc_InventoryPeriodBeforeExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_cerc_InventoryPeriodBeforeExpiration_a24697bd-a3d7-472f-9ce8-1ed8058dbbb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_39dce2ec-6e0e-4ad2-abf3-b239cb36f155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_39dce2ec-6e0e-4ad2-abf3-b239cb36f155" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a0d2355-0b83-4df6-acc0-8193d1f9b834_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a0d2355-0b83-4df6-acc0-8193d1f9b834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0990814-2565-4f94-a5f3-41d3f450e93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0990814-2565-4f94-a5f3-41d3f450e93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c56f0dcd-81e0-4b78-af5a-2d4737786ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0990814-2565-4f94-a5f3-41d3f450e93f" xlink:to="loc_us-gaap_SalesRevenueNetMember_c56f0dcd-81e0-4b78-af5a-2d4737786ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2601a634-66e9-45e7-96bb-f1a77bc13dd8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2601a634-66e9-45e7-96bb-f1a77bc13dd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b95d6d80-8acf-4583-8c33-099e691b62f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b95d6d80-8acf-4583-8c33-099e691b62f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_01358ff1-232a-47bc-a761-f34a4bf88281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b95d6d80-8acf-4583-8c33-099e691b62f9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_01358ff1-232a-47bc-a761-f34a4bf88281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f5357c41-96b8-4dc8-8841-46ccaf898c3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:to="loc_srt_NameOfMajorCustomerDomain_f5357c41-96b8-4dc8-8841-46ccaf898c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:to="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberOneMember_2f08dff0-ae5b-4b40-bb0e-0d6ff35c6e90" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:to="loc_cerc_MajorCustomerNumberOneMember_2f08dff0-ae5b-4b40-bb0e-0d6ff35c6e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberTwoMember_1effda4b-1f7f-493e-bcd8-88ced7f202d6" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:to="loc_cerc_MajorCustomerNumberTwoMember_1effda4b-1f7f-493e-bcd8-88ced7f202d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberThreeMember_2113421c-941a-4744-86b1-f49e61e05c0a" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:to="loc_cerc_MajorCustomerNumberThreeMember_2113421c-941a-4744-86b1-f49e61e05c0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89b1f3cc-76b0-420f-851a-a696e7de4eb3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:to="loc_srt_ProductsAndServicesDomain_89b1f3cc-76b0-420f-851a-a696e7de4eb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:to="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MillipredMember_e9a6078f-9cc6-47e2-9fe5-e2f3bf9b65dd" xlink:href="cerc-20210331.xsd#cerc_MillipredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:to="loc_cerc_MillipredMember_e9a6078f-9cc6-47e2-9fe5-e2f3bf9b65dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a165ff95-fa0e-4aa0-9b48-4634de82b01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:to="loc_us-gaap_ProductMember_a165ff95-fa0e-4aa0-9b48-4634de82b01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d0e65139-6a50-45e2-a43b-97d46e1d9c55_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:to="loc_us-gaap_RelatedPartyDomain_d0e65139-6a50-45e2-a43b-97d46e1d9c55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e9483e2d-5e2e-4456-8fb8-26c8a610b8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:to="loc_us-gaap_RelatedPartyDomain_e9483e2d-5e2e-4456-8fb8-26c8a610b8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_d592e5ef-06e3-4948-8e00-02f99912185c" xlink:href="cerc-20210331.xsd#cerc_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e9483e2d-5e2e-4456-8fb8-26c8a610b8a4" xlink:to="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_d592e5ef-06e3-4948-8e00-02f99912185c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_44b6b0cb-72d1-4234-bda0-e8cb16da290e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_44b6b0cb-72d1-4234-bda0-e8cb16da290e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3934d4f9-67fb-4a23-a238-2bb9a976b49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3934d4f9-67fb-4a23-a238-2bb9a976b49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c550cc5b-3293-4ace-89fc-88a5dc43cada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3934d4f9-67fb-4a23-a238-2bb9a976b49c" xlink:to="loc_us-gaap_SubsequentEventMember_c550cc5b-3293-4ace-89fc-88a5dc43cada" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/NetLossPerShare" xlink:type="extended" id="iec6ad988427b438aa4298d2c480f8fb8_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/NetLossPerShareTables" xlink:type="extended" id="ib4add199fd4a4d71a0359f6dd6523c9c_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended" id="i84798fadf31a404f9cbb5914a9ab8176_NetLossPerShareNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_99618869-eeda-4edb-a1f6-a5a624300954" xlink:href="cerc-20210331.xsd#cerc_ClassOfStockNumberOfClassesOfStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_99618869-eeda-4edb-a1f6-a5a624300954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_d7686f62-ba58-4745-8a93-b5cec3f2257d" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityNotePreferredStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_d7686f62-ba58-4745-8a93-b5cec3f2257d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_7dacfdd5-ecf2-4596-bc3a-14710f8dd6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_7dacfdd5-ecf2-4596-bc3a-14710f8dd6d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_fcdb3c0e-758c-4b2b-ac87-d5475b9b209a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_fcdb3c0e-758c-4b2b-ac87-d5475b9b209a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ab061c01-a08c-42b4-9874-212ff8504583_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:to="loc_us-gaap_ClassOfStockDomain_ab061c01-a08c-42b4-9874-212ff8504583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87b05f92-f009-449c-9697-6d9aab054017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:to="loc_us-gaap_ClassOfStockDomain_87b05f92-f009-449c-9697-6d9aab054017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_ac0e7e40-8ccd-4853-adf2-b1baf0accbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_87b05f92-f009-449c-9697-6d9aab054017" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_ac0e7e40-8ccd-4853-adf2-b1baf0accbd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c40a8233-2274-4195-9325-903eff91af9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:to="loc_us-gaap_EquityComponentDomain_c40a8233-2274-4195-9325-903eff91af9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:to="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_32f59285-739f-42d0-ade5-4beff0cd71e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:to="loc_us-gaap_PreferredStockMember_32f59285-739f-42d0-ade5-4beff0cd71e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8eee96a2-9114-4029-b726-e9a58806f749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:to="loc_us-gaap_CommonStockMember_8eee96a2-9114-4029-b726-e9a58806f749" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareScheduleofNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="extended" id="ia07210d1c323411a8d0eee6160357436_NetLossPerShareScheduleofNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:href="cerc-20210331.xsd#cerc_NumeratorAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:to="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e98e1635-01f8-4edb-91a3-95e04c233d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:to="loc_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e98e1635-01f8-4edb-91a3-95e04c233d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e867b061-03ed-4a8a-b8d4-34a1d0d151e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:to="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e867b061-03ed-4a8a-b8d4-34a1d0d151e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:href="cerc-20210331.xsd#cerc_DenominatorAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:to="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08f0e904-c479-46dd-97dc-96e96700a67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08f0e904-c479-46dd-97dc-96e96700a67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c44c6d3-4aa6-43b9-abce-e038cc8c0e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c44c6d3-4aa6-43b9-abce-e038cc8c0e23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_85971d3c-40cd-4f23-a977-75d3a6b8b47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_85971d3c-40cd-4f23-a977-75d3a6b8b47c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c8ff4270-0cd7-4b0d-98a5-09921d96169e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c8ff4270-0cd7-4b0d-98a5-09921d96169e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d71d8a8-e7cb-448e-aefc-2eeb5001fe66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d71d8a8-e7cb-448e-aefc-2eeb5001fe66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c7d84668-fc6c-4206-a412-b376242a5a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c7d84668-fc6c-4206-a412-b376242a5a34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6edd735a-4f85-449e-bf61-f35238145163_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:to="loc_us-gaap_ClassOfStockDomain_6edd735a-4f85-449e-bf61-f35238145163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:to="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e61bff1-eedb-43cb-ad3d-02036584bc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:to="loc_us-gaap_CommonStockMember_8e61bff1-eedb-43cb-ad3d-02036584bc4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ba7f747b-9460-43dd-b935-50deda174e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:to="loc_us-gaap_PreferredStockMember_ba7f747b-9460-43dd-b935-50deda174e6a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="ib55cd10a1e6547579bbaa6a9ea12bc58_NetLossPerShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b46fede-df0a-42f3-a860-7e68b312e404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b46fede-df0a-42f3-a860-7e68b312e404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15aae78e-a932-4f19-af9e-611d886b96aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15aae78e-a932-4f19-af9e-611d886b96aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a835a1e-4423-4b21-ba44-b4f100320bc7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a835a1e-4423-4b21-ba44-b4f100320bc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_aa5330ea-bd00-4195-a733-173ae1a7d96f" xlink:href="cerc-20210331.xsd#cerc_EmployeeConsultantsAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_aa5330ea-bd00-4195-a733-173ae1a7d96f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_WarrantCommonStockMember_ea8236c6-41ae-41bb-b7ac-042c6e709898" xlink:href="cerc-20210331.xsd#cerc_WarrantCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_cerc_WarrantCommonStockMember_ea8236c6-41ae-41bb-b7ac-042c6e709898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_324e7240-ab6f-4c0a-9251-1868df20bab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_324e7240-ab6f-4c0a-9251-1868df20bab8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwritersUnitPurchaseOptionMember_34f20453-7dc6-4a6c-8e47-a33a059e885a" xlink:href="cerc-20210331.xsd#cerc_UnderwritersUnitPurchaseOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_cerc_UnderwritersUnitPurchaseOptionMember_34f20453-7dc6-4a6c-8e47-a33a059e885a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:to="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d31fb6-5285-449a-9284-07bd28367f88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d31fb6-5285-449a-9284-07bd28367f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaMember_27fcbb2f-5642-4e05-adb6-8fd33305bb35" xlink:href="cerc-20210331.xsd#cerc_NantahalaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d31fb6-5285-449a-9284-07bd28367f88" xlink:to="loc_cerc_NantahalaMember_27fcbb2f-5642-4e05-adb6-8fd33305bb35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AssetAcquisition" xlink:type="simple" xlink:href="cerc-20210331.xsd#AssetAcquisition"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AssetAcquisition" xlink:type="extended" id="ie6a9f3ba160f4e5c99340bff80e6b719_AssetAcquisition"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AssetAcquisitionDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AssetAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AssetAcquisitionDetails" xlink:type="extended" id="ia023c0f8371d40b9b5e4040900878eff_AssetAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_4af6bf4a-73ae-4963-824b-6f199819a4f2" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_4af6bf4a-73ae-4963-824b-6f199819a4f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0df497dd-9bfa-4809-a730-94672ea0cb50" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0df497dd-9bfa-4809-a730-94672ea0cb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_24dd8429-ba22-4b0f-abfc-983cf14eb034" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_24dd8429-ba22-4b0f-abfc-983cf14eb034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_ad7db7cf-033b-43e8-82d0-406ee7cb3132" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_ad7db7cf-033b-43e8-82d0-406ee7cb3132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionTransactionCosts_79cd7d4d-7192-4b0a-b042-1466ab51d187" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionTransactionCosts_79cd7d4d-7192-4b0a-b042-1466ab51d187" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_aff3699d-a6b7-4210-a47b-800f75da4fc4" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_aff3699d-a6b7-4210-a47b-800f75da4fc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_d980e082-43b6-4d44-ae1f-8fe8d5af2997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_d980e082-43b6-4d44-ae1f-8fe8d5af2997" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionCashandEquivalents_a1ebecaf-6ddb-49f7-9fa0-fa3d19d019fd" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionCashandEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionCashandEquivalents_a1ebecaf-6ddb-49f7-9fa0-fa3d19d019fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_526043b7-a8f2-4052-9106-496d220184e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_526043b7-a8f2-4052-9106-496d220184e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4e46008-705e-4760-9022-9c1c2a67e276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4e46008-705e-4760-9022-9c1c2a67e276" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_6d0beb5a-2dda-49aa-84f8-12aa134cbe42_default" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:to="loc_cerc_AssetAcquisitionDomain_6d0beb5a-2dda-49aa-84f8-12aa134cbe42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_614e643a-e724-4898-94bf-8784b7420c17" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:to="loc_cerc_AssetAcquisitionDomain_614e643a-e724-4898-94bf-8784b7420c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_987e557c-023c-4782-88bd-54d84def03a2" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_AssetAcquisitionDomain_614e643a-e724-4898-94bf-8784b7420c17" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_987e557c-023c-4782-88bd-54d84def03a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0adeb030-630e-44f2-9a1f-0361b9fa04a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0adeb030-630e-44f2-9a1f-0361b9fa04a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_aacf28cd-08b4-476c-8d06-0a3825fe8a74" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0adeb030-630e-44f2-9a1f-0361b9fa04a6" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_aacf28cd-08b4-476c-8d06-0a3825fe8a74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1926359b-ef53-4e35-b14d-0bf3bbb50755_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1926359b-ef53-4e35-b14d-0bf3bbb50755_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7268edf4-6096-4fd4-9829-a18392315abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7268edf4-6096-4fd4-9829-a18392315abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssembledWorkforceMember_5b1b598d-308c-4da6-b04a-75b67b2f90ce" xlink:href="cerc-20210331.xsd#cerc_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7268edf4-6096-4fd4-9829-a18392315abd" xlink:to="loc_cerc_AssembledWorkforceMember_5b1b598d-308c-4da6-b04a-75b67b2f90ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/FairValueMeasurements" xlink:type="extended" id="ie5630c5677c9400a915a979189d884f3_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsTables" xlink:type="extended" id="ia32b13130500427cb8757ab91cab6614_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i00e8c2d843b2470ea5400efc9aee3138_FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988d538c-b125-49af-a149-42b9774e34a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb8d1d72-c705-4760-98c8-4980ff1286b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988d538c-b125-49af-a149-42b9774e34a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb8d1d72-c705-4760-98c8-4980ff1286b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988d538c-b125-49af-a149-42b9774e34a6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7e097b0-bfc0-43e6-8073-f3f7865fcf73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7e097b0-bfc0-43e6-8073-f3f7865fcf73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dfd078f9-be74-4834-bd2d-9b8e9f669cea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dfd078f9-be74-4834-bd2d-9b8e9f669cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_239c7f46-c9dd-4b16-ad72-f1eb2ef2c8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dfd078f9-be74-4834-bd2d-9b8e9f669cea" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_239c7f46-c9dd-4b16-ad72-f1eb2ef2c8b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7be14a59-b621-44ea-b0c7-f6776a9f7046_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7be14a59-b621-44ea-b0c7-f6776a9f7046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fa000095-ef36-4649-bb32-ba2addabe73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fa000095-ef36-4649-bb32-ba2addabe73f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f6600fc2-edd0-40b0-af54-7bfc9c37bf05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f6600fc2-edd0-40b0-af54-7bfc9c37bf05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e8f47391-4ac9-41c3-bf4e-f92d3acfbedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e8f47391-4ac9-41c3-bf4e-f92d3acfbedd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i78208b4f304f44f1b5a5df1fb4299763_FairValueMeasurementsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended" id="i237d92acd7f24415aa44766e19824013_AccruedExpensesandOtherCurrentLiabilities"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended" id="i3c591c671c9a49ee983c3c404d8cf9f1_AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended" id="i0bd3d2edd7aa4462b441e5bcc8e7aa83_AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" xlink:type="extended" id="ib4f71a127be4469aa17244e222586276_AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructure" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructure"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CapitalStructure" xlink:type="extended" id="i72219fec7cc84e12850e5aaf0e534887_CapitalStructure"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CapitalStructureTables" xlink:type="extended" id="iee8c6edb18fb4acd9a826035d7358214_CapitalStructureTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CapitalStructureNarrativeDetails" xlink:type="extended" id="i094ae9b9d2f74a20b34173fa9195911d_CapitalStructureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfClassOfStockAuthorized_5ec25a05-247a-4dc9-a797-6944f35ab954" xlink:href="cerc-20210331.xsd#cerc_NumberOfClassOfStockAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_NumberOfClassOfStockAuthorized_5ec25a05-247a-4dc9-a797-6944f35ab954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CapitalStockSharesAuthorized_4244b859-ce25-4ad1-b8c8-b8996af54995" xlink:href="cerc-20210331.xsd#cerc_CapitalStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_CapitalStockSharesAuthorized_4244b859-ce25-4ad1-b8c8-b8996af54995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_09ebc762-e38b-4212-91b0-820d9d8b4fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_09ebc762-e38b-4212-91b0-820d9d8b4fd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c6db43c7-759d-4a1b-abb3-a1b07d079da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c6db43c7-759d-4a1b-abb3-a1b07d079da8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5681845a-ab6b-467b-b207-d54258aca408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5681845a-ab6b-467b-b207-d54258aca408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4cda0a51-18ea-42c9-b94c-9367e3125c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4cda0a51-18ea-42c9-b94c-9367e3125c25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3d99f72f-8a49-47a8-aeeb-24f8f7172516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3d99f72f-8a49-47a8-aeeb-24f8f7172516" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25799aae-1535-4211-9221-118c5584010f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25799aae-1535-4211-9221-118c5584010f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7a36cb49-3367-44fc-84ea-3d2ca3fb4b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7a36cb49-3367-44fc-84ea-3d2ca3fb4b93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a3ebc70e-8123-4bcd-a1ce-d7f30a1df008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a3ebc70e-8123-4bcd-a1ce-d7f30a1df008" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_69a2a7e9-5612-42d7-8846-5bed42a46211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_69a2a7e9-5612-42d7-8846-5bed42a46211" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dcc1c59-45b3-4ff8-80c9-1bf2416ddad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dcc1c59-45b3-4ff8-80c9-1bf2416ddad3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_64cc0b78-111e-47a9-994b-aa75a6401bb8" xlink:href="cerc-20210331.xsd#cerc_ClassOfWarrantOrRightPercentOwnershipThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_64cc0b78-111e-47a9-994b-aa75a6401bb8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ad286b3d-b606-48e0-90fb-8cbabea5031e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ad286b3d-b606-48e0-90fb-8cbabea5031e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_f59d8073-c5a7-46ec-8288-93cdb1d7ed9d" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_f59d8073-c5a7-46ec-8288-93cdb1d7ed9d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_32c6a727-03f2-478b-b80c-7e9b341c9b40" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityNotePreferredStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_32c6a727-03f2-478b-b80c-7e9b341c9b40" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_8923ed39-90e4-49f7-aa19-24829442fa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_8923ed39-90e4-49f7-aa19-24829442fa5e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_b6902bca-173f-44be-ac4a-e38c91e12665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_b6902bca-173f-44be-ac4a-e38c91e12665" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_88967aba-2938-4e2d-bcbd-ffa95909e4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_88967aba-2938-4e2d-bcbd-ffa95909e4c1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f8af7e6e-32db-4ff9-a653-079e37c34c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f8af7e6e-32db-4ff9-a653-079e37c34c54" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db981226-fa54-47c2-bb91-469c9a8664a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db981226-fa54-47c2-bb91-469c9a8664a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwrittenPublicOfferingMember_41619f4a-71de-4985-9a4f-ec5877609484" xlink:href="cerc-20210331.xsd#cerc_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_cerc_UnderwrittenPublicOfferingMember_41619f4a-71de-4985-9a4f-ec5877609484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticePurchaseAgreementMember_7a96deb5-434a-439b-b058-8c0c896b1ecd" xlink:href="cerc-20210331.xsd#cerc_ArmisticePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_cerc_ArmisticePurchaseAgreementMember_7a96deb5-434a-439b-b058-8c0c896b1ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RegisteredDirectOfferingMember_88adaf94-a0dc-4481-8faa-9e27a6a3355c" xlink:href="cerc-20210331.xsd#cerc_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_cerc_RegisteredDirectOfferingMember_88adaf94-a0dc-4481-8faa-9e27a6a3355c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_279143f1-8b6d-422e-9c03-92c91b14d5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_us-gaap_PrivatePlacementMember_279143f1-8b6d-422e-9c03-92c91b14d5d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_76bf30d8-5617-4b8c-88a6-3897a1f93f55_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_76bf30d8-5617-4b8c-88a6-3897a1f93f55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aaeb801f-5973-4354-88f6-194a569045ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aaeb801f-5973-4354-88f6-194a569045ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b0038970-6ab0-46bb-82ce-73604789ee01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aaeb801f-5973-4354-88f6-194a569045ea" xlink:to="loc_us-gaap_WarrantMember_b0038970-6ab0-46bb-82ce-73604789ee01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e829add8-9395-4a22-b99d-22c511661337_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e829add8-9395-4a22-b99d-22c511661337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticeMember_30b4228e-1e22-4df1-8b1f-0684285de6ec" xlink:href="cerc-20210331.xsd#cerc_ArmisticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:to="loc_cerc_ArmisticeMember_30b4228e-1e22-4df1-8b1f-0684285de6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaMember_05f04862-7615-4665-9877-1602217dec42" xlink:href="cerc-20210331.xsd#cerc_NantahalaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:to="loc_cerc_NantahalaMember_05f04862-7615-4665-9877-1602217dec42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_OfficersMember_4000c17e-a373-4c40-8567-9a467d7d191b" xlink:href="cerc-20210331.xsd#cerc_OfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:to="loc_cerc_OfficersMember_4000c17e-a373-4c40-8567-9a467d7d191b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7bb4c3b9-5326-43a7-9031-28923b50463e_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:to="loc_dei_EntityDomain_7bb4c3b9-5326-43a7-9031-28923b50463e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5678f4f7-f71e-4f38-b6dc-8b8d218d4c55" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:to="loc_dei_EntityDomain_5678f4f7-f71e-4f38-b6dc-8b8d218d4c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaCapitalManagementLLCMember_50773223-e286-4230-8ba2-9b9f7e449635" xlink:href="cerc-20210331.xsd#cerc_NantahalaCapitalManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5678f4f7-f71e-4f38-b6dc-8b8d218d4c55" xlink:to="loc_cerc_NantahalaCapitalManagementLLCMember_50773223-e286-4230-8ba2-9b9f7e449635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9fee57fd-c12b-425f-b48a-44e37eff5b5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:to="loc_us-gaap_EquityComponentDomain_9fee57fd-c12b-425f-b48a-44e37eff5b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:to="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ebc8f600-1240-4a6e-b995-71c6a4e150df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:to="loc_us-gaap_CommonStockMember_ebc8f600-1240-4a6e-b995-71c6a4e150df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_5ebb668e-4f64-4b48-859f-8d4c58e3cfce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:to="loc_us-gaap_PreferredStockMember_5ebb668e-4f64-4b48-859f-8d4c58e3cfce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:to="loc_us-gaap_ClassOfStockDomain_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_872055ae-7a92-4c73-a43a-91a0a0e9981e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:to="loc_us-gaap_ClassOfStockDomain_872055ae-7a92-4c73-a43a-91a0a0e9981e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_eaf8a667-dbd3-4703-a2aa-177d12cb1c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_872055ae-7a92-4c73-a43a-91a0a0e9981e" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_eaf8a667-dbd3-4703-a2aa-177d12cb1c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_5866097b-7197-46bb-bbe0-4842708ad7fd_default" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:to="loc_cerc_AssetAcquisitionDomain_5866097b-7197-46bb-bbe0-4842708ad7fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_cfda0878-4c8e-4587-8708-f19957f9fd93" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:to="loc_cerc_AssetAcquisitionDomain_cfda0878-4c8e-4587-8708-f19957f9fd93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_7c4ee507-1fd6-4039-951e-81f2686ddb61" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_AssetAcquisitionDomain_cfda0878-4c8e-4587-8708-f19957f9fd93" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_7c4ee507-1fd6-4039-951e-81f2686ddb61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9374a5be-5f48-4bae-b5ee-f2065893fbaf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9374a5be-5f48-4bae-b5ee-f2065893fbaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1e1081f-2593-4bfe-80a6-15fcd2a8931d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1e1081f-2593-4bfe-80a6-15fcd2a8931d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7951b88a-4fe0-49ff-b2e6-1ceb1d2fb397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1e1081f-2593-4bfe-80a6-15fcd2a8931d" xlink:to="loc_us-gaap_SubsequentEventMember_7951b88a-4fe0-49ff-b2e6-1ceb1d2fb397" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureWarrantsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CapitalStructureWarrantsDetails" xlink:type="extended" id="i47d4463f2bf245ef94cc7451b69c8a5c_CapitalStructureWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5613558c-8a72-456c-8f5e-2419687ca372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5613558c-8a72-456c-8f5e-2419687ca372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5261616-101b-481e-b4ef-ba1d042ce058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5261616-101b-481e-b4ef-ba1d042ce058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_0a618498-ffc3-4a2b-8531-c1efe6dea818" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsExpirationDateOfMay2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:to="loc_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_0a618498-ffc3-4a2b-8531-c1efe6dea818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_bde60649-202c-40b5-b04a-b87be7835369" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsExpirationDateOfJune2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:to="loc_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_bde60649-202c-40b5-b04a-b87be7835369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsNoExpirationMember_bbec80bb-f555-429e-a336-486bce557c94" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsNoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:to="loc_cerc_CommonStockWarrantsNoExpirationMember_bbec80bb-f555-429e-a336-486bce557c94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bbb79ecc-a89f-4146-8c37-7b289c26e6e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:to="loc_us-gaap_ClassOfStockDomain_bbb79ecc-a89f-4146-8c37-7b289c26e6e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dbe650b-8aef-4d3f-bb7c-7c043ecfe315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:to="loc_us-gaap_ClassOfStockDomain_2dbe650b-8aef-4d3f-bb7c-7c043ecfe315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_94336139-ca32-44a3-9416-816df8c6a222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dbe650b-8aef-4d3f-bb7c-7c043ecfe315" xlink:to="loc_us-gaap_CommonClassAMember_94336139-ca32-44a3-9416-816df8c6a222" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensation" xlink:type="extended" id="i1215618240d64026bcc78b5fdc6bc3eb_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationTables" xlink:type="extended" id="ib86f518b78764677b16ef86c1cb244f1_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ic62e07e478bf46f2a9e71d421c546d57_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_a297c4da-cfa9-4fbf-a5a1-6f57f4ebf586" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_a297c4da-cfa9-4fbf-a5a1-6f57f4ebf586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e665137-73c4-47b3-a937-251b8760d509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e665137-73c4-47b3-a937-251b8760d509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_bd774fcb-4a50-4edf-9560-dd90419038ea" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_bd774fcb-4a50-4edf-9560-dd90419038ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f01488-c466-4d6d-91ee-195f39c5d18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f01488-c466-4d6d-91ee-195f39c5d18b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e662d2e-1fd6-4aa5-80c0-3f957122a166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e662d2e-1fd6-4aa5-80c0-3f957122a166" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f6cea95-2789-4b33-91bd-64af9c96f86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f6cea95-2789-4b33-91bd-64af9c96f86b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_f3cc06de-ddff-425d-b1a1-a48b3f361986" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_f3cc06de-ddff-425d-b1a1-a48b3f361986" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AnnualBaseSalary_c23f1c15-4589-4809-abfb-ca0474e209d3" xlink:href="cerc-20210331.xsd#cerc_AnnualBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_AnnualBaseSalary_c23f1c15-4589-4809-abfb-ca0474e209d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_41847abc-4a1c-4895-b99c-7fe88274b86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_41847abc-4a1c-4895-b99c-7fe88274b86b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88365d0a-a0ec-4ffb-bb3b-4638eeac794d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88365d0a-a0ec-4ffb-bb3b-4638eeac794d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_eadd3493-1efd-4aa3-8d74-a245637c3aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_eadd3493-1efd-4aa3-8d74-a245637c3aed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ebec49a1-1035-4dbc-8a1a-735984309aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ebec49a1-1035-4dbc-8a1a-735984309aca" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_747ef180-4305-4e4b-8c57-0a0e609b1785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_747ef180-4305-4e4b-8c57-0a0e609b1785" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_45d798de-0bda-40d9-855a-c88ea1957c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_45d798de-0bda-40d9-855a-c88ea1957c5b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2323e676-2c17-4917-a2e4-483c5d012e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2323e676-2c17-4917-a2e4-483c5d012e96" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722a0f57-d558-4e7f-8016-614dc5939957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722a0f57-d558-4e7f-8016-614dc5939957" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4f11f1a7-57ff-4e66-a7c8-a833b54ec58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4f11f1a7-57ff-4e66-a7c8-a833b54ec58e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_b7ccf9dc-240d-458b-b288-18eb16aaefbb" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_b7ccf9dc-240d-458b-b288-18eb16aaefbb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d92f27e-7418-4c17-a4af-b8ff0388c5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d92f27e-7418-4c17-a4af-b8ff0388c5f3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_94c4951a-a9bf-4e30-9d8c-0ba6f4d8773a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_94c4951a-a9bf-4e30-9d8c-0ba6f4d8773a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_67fe5273-e19a-40f1-9e34-0ebf4641c6f1" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_67fe5273-e19a-40f1-9e34-0ebf4641c6f1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ae60a276-8592-4afc-a8d1-10e51f5b256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ae60a276-8592-4afc-a8d1-10e51f5b256a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_56219023-7da1-4d88-8857-02ab981ed5be" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_56219023-7da1-4d88-8857-02ab981ed5be" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_eaa30ac6-cf00-4db3-a95f-ef0ad6692950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_eaa30ac6-cf00-4db3-a95f-ef0ad6692950" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d08af95b-0bc2-4212-ad4a-4e57d4b222aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:to="loc_us-gaap_PlanNameDomain_d08af95b-0bc2-4212-ad4a-4e57d4b222aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:to="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_The2016PlanMember_325af987-8398-4eb3-bc3a-d4056eff4218" xlink:href="cerc-20210331.xsd#cerc_The2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:to="loc_cerc_The2016PlanMember_325af987-8398-4eb3-bc3a-d4056eff4218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_A2016SecondAmendedPlanMember_95aa1435-8e84-40bf-8c08-4d6ea1799582" xlink:href="cerc-20210331.xsd#cerc_A2016SecondAmendedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:to="loc_cerc_A2016SecondAmendedPlanMember_95aa1435-8e84-40bf-8c08-4d6ea1799582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ThirdAmended2016PlanMember_684a72c4-02b9-47df-aefe-474e623eda01" xlink:href="cerc-20210331.xsd#cerc_ThirdAmended2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:to="loc_cerc_ThirdAmended2016PlanMember_684a72c4-02b9-47df-aefe-474e623eda01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_614266d6-2726-4e07-873b-d307de17e90c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_614266d6-2726-4e07-873b-d307de17e90c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_d65f5785-8630-4dc1-b6c9-f281a2f08262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_us-gaap_StockOptionMember_d65f5785-8630-4dc1-b6c9-f281a2f08262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember_8de00055-a962-4591-b0a0-b660fd02f185" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_cerc_ServiceBasedOptionsMember_8de00055-a962-4591-b0a0-b660fd02f185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_bb9be852-7a9d-46fc-b7fb-70bdf03e7220" xlink:href="cerc-20210331.xsd#cerc_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_bb9be852-7a9d-46fc-b7fb-70bdf03e7220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c7793cf7-4404-4675-9d36-f5a0b630612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_us-gaap_RestrictedStockMember_c7793cf7-4404-4675-9d36-f5a0b630612c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeStockPurchasePlanESPPMember_8cf35299-42cc-47a4-8e9d-79c7a954325d" xlink:href="cerc-20210331.xsd#cerc_EmployeeStockPurchasePlanESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_cerc_EmployeeStockPurchasePlanESPPMember_8cf35299-42cc-47a4-8e9d-79c7a954325d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b85deb60-3810-44fc-9bad-24e9bf8a654a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:to="loc_srt_RangeMember_b85deb60-3810-44fc-9bad-24e9bf8a654a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:to="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_efa07772-3bbe-4d51-a3a4-bf96df8871d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:to="loc_srt_MinimumMember_efa07772-3bbe-4d51-a3a4-bf96df8871d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_84d66b6a-1af4-4cac-9c88-256602bd570c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:to="loc_srt_MaximumMember_84d66b6a-1af4-4cac-9c88-256602bd570c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_12d3321a-9b71-4fdb-bc25-7dca90b0160d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:to="loc_us-gaap_GranteeStatusDomain_12d3321a-9b71-4fdb-bc25-7dca90b0160d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e58f0dd3-3c72-453f-95f6-014ba58e5920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:to="loc_us-gaap_GranteeStatusDomain_e58f0dd3-3c72-453f-95f6-014ba58e5920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_2d639206-80ea-477a-aa28-b3f5197cbed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_e58f0dd3-3c72-453f-95f6-014ba58e5920" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_2d639206-80ea-477a-aa28-b3f5197cbed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_415a64e6-67cb-4678-a5ae-17507a43bef7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_415a64e6-67cb-4678-a5ae-17507a43bef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d43f71f9-62cf-4f95-a83e-53d562446286" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_DirectorMember_d43f71f9-62cf-4f95-a83e-53d562446286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_e7b8d8c8-87fb-479b-b44b-f72e483333d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_ExecutiveOfficerMember_e7b8d8c8-87fb-479b-b44b-f72e483333d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_7cbfda55-498a-4308-a2e6-c4ec9887c554" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_ChiefExecutiveOfficerMember_7cbfda55-498a-4308-a2e6-c4ec9887c554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_19fce579-aab4-44df-be8b-0003ee804cc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_19fce579-aab4-44df-be8b-0003ee804cc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_62017505-1e55-42a3-91ac-b0451df8a3da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:to="loc_us-gaap_VestingDomain_62017505-1e55-42a3-91ac-b0451df8a3da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:to="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f3d59a60-5638-44de-bf75-2c43dec2f7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f3d59a60-5638-44de-bf75-2c43dec2f7a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e943c525-ed23-4690-ac9c-cc05e202a873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e943c525-ed23-4690-ac9c-cc05e202a873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a427357d-1e46-4ffa-9a75-0a30ebeb99c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a427357d-1e46-4ffa-9a75-0a30ebeb99c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bebef1ff-89bf-4e18-a621-80b42138a88c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bebef1ff-89bf-4e18-a621-80b42138a88c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_facf919b-750d-4bff-aed0-a3eaf5fa093b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_facf919b-750d-4bff-aed0-a3eaf5fa093b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeStockPurchasePlanESPPMember_b73c58f9-ff6d-4334-b9f4-db57606f21a7" xlink:href="cerc-20210331.xsd#cerc_EmployeeStockPurchasePlanESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_facf919b-750d-4bff-aed0-a3eaf5fa093b" xlink:to="loc_cerc_EmployeeStockPurchasePlanESPPMember_b73c58f9-ff6d-4334-b9f4-db57606f21a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i1348933131b54a289c9e3e4fbd6c1bb0_StockBasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28cdd192-47ae-41b2-9f39-985a36728067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f397671c-cad6-4b7b-9146-dbd4a2ed06bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28cdd192-47ae-41b2-9f39-985a36728067" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f397671c-cad6-4b7b-9146-dbd4a2ed06bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28cdd192-47ae-41b2-9f39-985a36728067" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1c0c8cad-1ebf-4b66-86bd-603293a04b79_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1c0c8cad-1ebf-4b66-86bd-603293a04b79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4b877a9-b413-41eb-a15b-29b3d7ec9d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4b877a9-b413-41eb-a15b-29b3d7ec9d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa45b764-f3bb-42e7-ab92-34d3b2260eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa45b764-f3bb-42e7-ab92-34d3b2260eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_6c3a951e-2f35-4812-bdaa-7678178465fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_6c3a951e-2f35-4812-bdaa-7678178465fd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" xlink:type="extended" id="i269a64fe56d14033a5c44e0c2d0df0a7_StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34e32a3a-1395-4188-b57f-353cf2d20bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34e32a3a-1395-4188-b57f-353cf2d20bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_913a53c7-20ad-4482-af75-6c6ca0300549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_913a53c7-20ad-4482-af75-6c6ca0300549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f4134e-acc9-430f-9df2-ce85addd2c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f4134e-acc9-430f-9df2-ce85addd2c34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f62bc41-8c70-445a-9916-2d00b3b83af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f62bc41-8c70-445a-9916-2d00b3b83af7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef29287c-117b-45ef-98cb-683ad49bff3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6833f7e9-5cb3-48c4-a70e-4b2af8837502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6833f7e9-5cb3-48c4-a70e-4b2af8837502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40b7fc22-6064-4f53-b33e-f00cf33541cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40b7fc22-6064-4f53-b33e-f00cf33541cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57128f07-4f42-450d-9f52-4f809a45a77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57128f07-4f42-450d-9f52-4f809a45a77e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4cb3e14c-1c9c-4d1a-a552-61aee04042e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4cb3e14c-1c9c-4d1a-a552-61aee04042e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a4edcaf-e58e-445c-8982-0d6722f7abd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a4edcaf-e58e-445c-8982-0d6722f7abd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5cb2737-fe18-46ad-97e5-df072f26b44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c75b3b71-97e5-493c-a53c-3724b364c6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c75b3b71-97e5-493c-a53c-3724b364c6aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_14b6415a-9fa1-4600-b9d0-ad8b669ce990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_14b6415a-9fa1-4600-b9d0-ad8b669ce990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_46f5aaa1-7ced-491b-9f68-72e0348d6d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_46f5aaa1-7ced-491b-9f68-72e0348d6d78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_cbb4b7f9-88fe-4160-a6eb-4e2694047c54" xlink:href="cerc-20210331.xsd#cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_cbb4b7f9-88fe-4160-a6eb-4e2694047c54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_959575af-0559-46e5-ae6c-7e224e39894d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_959575af-0559-46e5-ae6c-7e224e39894d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_b4025dbd-6018-4366-9805-aefac11d0e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_acb99aa1-0df7-49de-b1d4-1d6d8c149641" xlink:href="cerc-20210331.xsd#cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_acb99aa1-0df7-49de-b1d4-1d6d8c149641" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc38b99e-7fc2-42c6-b59c-b091f658f639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc38b99e-7fc2-42c6-b59c-b091f658f639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f67cccd8-f31c-4d5c-9ae0-71fb7fb91ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f67cccd8-f31c-4d5c-9ae0-71fb7fb91ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:to="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87ca125c-8885-4d01-bbf8-082a962cb7c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87ca125c-8885-4d01-bbf8-082a962cb7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcdcbf87-a6f9-4e96-b58e-787e04e266ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcdcbf87-a6f9-4e96-b58e-787e04e266ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember_6956a838-91fd-4950-b9e7-32dc5165e976" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcdcbf87-a6f9-4e96-b58e-787e04e266ca" xlink:to="loc_cerc_ServiceBasedOptionsMember_6956a838-91fd-4950-b9e7-32dc5165e976" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockbasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails" xlink:type="extended" id="ibb86fa85e3a747d2bb0b1673e5d2c51d_StockBasedCompensationStockbasedCompensationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ab37222a-1a07-4286-b13c-1ac74596e9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ab37222a-1a07-4286-b13c-1ac74596e9b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d99d22b4-609d-479e-a7fe-fc58416665a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d99d22b4-609d-479e-a7fe-fc58416665a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_73a3d98a-e5ba-40d4-bc03-8e60d7ebbca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_73a3d98a-e5ba-40d4-bc03-8e60d7ebbca4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_24b56805-3c80-4fca-801f-36829f8c9ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_24b56805-3c80-4fca-801f-36829f8c9ab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:to="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bbfb01e-1062-466b-9b2e-0d23d2814d27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bbfb01e-1062-466b-9b2e-0d23d2814d27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ba4ddb8-cf93-4be9-8241-af7c1e0c40d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ba4ddb8-cf93-4be9-8241-af7c1e0c40d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember_b8201867-46c7-4da3-8b64-fa5e3448b2d2" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ba4ddb8-cf93-4be9-8241-af7c1e0c40d5" xlink:to="loc_cerc_ServiceBasedOptionsMember_b8201867-46c7-4da3-8b64-fa5e3448b2d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:to="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_705677cf-5d99-445e-97fd-fa24d78024de_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:to="loc_srt_RangeMember_705677cf-5d99-445e-97fd-fa24d78024de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:to="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_593e735d-ab2c-4367-969c-40bee481f803" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:to="loc_srt_MinimumMember_593e735d-ab2c-4367-969c-40bee481f803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8aba2490-8477-471b-88ab-85a398107363" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:to="loc_srt_MaximumMember_8aba2490-8477-471b-88ab-85a398107363" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" xlink:type="extended" id="if98231afc7874c3ebdd98354d877809f_StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8f773b86-9026-4804-8333-149ef837efef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8f773b86-9026-4804-8333-149ef837efef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a23ca45f-013d-4bc4-8099-eebf2e893114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a23ca45f-013d-4bc4-8099-eebf2e893114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45f8f6ba-3aee-47da-915a-71f6af88e215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4dc359c6-b9ca-41b2-a8cd-4a3d3dbdb8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4dc359c6-b9ca-41b2-a8cd-4a3d3dbdb8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_83a6d293-66c9-44c7-9c24-502c8bb5e1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_83a6d293-66c9-44c7-9c24-502c8bb5e1ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96528cd2-2002-4eb4-9ae1-59a7eb7550e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96528cd2-2002-4eb4-9ae1-59a7eb7550e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_acbc48bd-dbe1-474f-a065-a4927fc070c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_14686489-f1ed-4e51-91f6-a8e8420e4681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_14686489-f1ed-4e51-91f6-a8e8420e4681" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7ece3a6-d887-4221-a55a-9d0cfa62ea35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_14686489-f1ed-4e51-91f6-a8e8420e4681" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7ece3a6-d887-4221-a55a-9d0cfa62ea35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f02a91dc-ee52-497f-bd5e-857d873521c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f02a91dc-ee52-497f-bd5e-857d873521c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_856476b4-9ebd-4af7-84e1-aee8f023b05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_856476b4-9ebd-4af7-84e1-aee8f023b05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:to="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_707483bb-03e9-43a7-92b6-3ec7de0932aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_707483bb-03e9-43a7-92b6-3ec7de0932aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3133478f-16d9-4907-bb48-4116c65518fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3133478f-16d9-4907-bb48-4116c65518fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_34ce07f2-491b-493a-bf5a-8e480adc5e0b" xlink:href="cerc-20210331.xsd#cerc_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3133478f-16d9-4907-bb48-4116c65518fd" xlink:to="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_34ce07f2-491b-493a-bf5a-8e480adc5e0b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i499f8e6a83b8412eb21915079b0da42b_StockBasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28308509-3f46-42f1-aa04-6de49ee651d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28308509-3f46-42f1-aa04-6de49ee651d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00a0b222-0abd-46fe-9bda-7b52baf2a2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00a0b222-0abd-46fe-9bda-7b52baf2a2fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e0746df3-f050-4b24-9508-19f2b1be94e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0dd97dfe-316c-4913-9726-02401a7a0e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0dd97dfe-316c-4913-9726-02401a7a0e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_93072781-e305-4c38-88b6-6e84e41f260a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_93072781-e305-4c38-88b6-6e84e41f260a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b19c27ea-3f89-47fe-8716-6116cf538ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:to="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2488381f-5508-4063-b8b0-7af411d239c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2488381f-5508-4063-b8b0-7af411d239c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd350d55-6892-442f-84d6-50bf9bbff72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd350d55-6892-442f-84d6-50bf9bbff72a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1cfc0a85-3dfd-496b-80e4-7c817bbac5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd350d55-6892-442f-84d6-50bf9bbff72a" xlink:to="loc_us-gaap_RestrictedStockMember_1cfc0a85-3dfd-496b-80e4-7c817bbac5f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cerc-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/IncomeTaxes" xlink:type="extended" id="ia4e65beddf0f4d8facc24ede43d04b19_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/IncomeTaxesDetails" xlink:type="extended" id="i3617e3873eee45d29ada92f5e6c29116_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/Leases" xlink:type="simple" xlink:href="cerc-20210331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/Leases" xlink:type="extended" id="i17f88a0b9ab14cd3a1c25ceb943325f8_Leases"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/LeasesTables" xlink:type="extended" id="i834d8167076e4b938a232688e6a8b396_LeasesTables"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i90e843045c09421eae02e2a4626d2667_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseNumberOfContracts_582503b5-87d0-42a7-8b59-afa9aff2e164" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseNumberOfContracts_582503b5-87d0-42a7-8b59-afa9aff2e164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_e5264a71-db10-43d0-89dc-35238a552845" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_e5264a71-db10-43d0-89dc-35238a552845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_db7d35af-1652-4caa-9df3-e5997c228751" xlink:href="cerc-20210331.xsd#cerc_OperatingLeasesRentExpenseAnnualIncreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_db7d35af-1652-4caa-9df3-e5997c228751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseRentAbatementPeriod_8879c5d1-d80f-4d8c-84fd-43c16e8729d3" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseRentAbatementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseRentAbatementPeriod_8879c5d1-d80f-4d8c-84fd-43c16e8729d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61fc7963-ec1e-44d5-b1f9-95b48dfd07f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61fc7963-ec1e-44d5-b1f9-95b48dfd07f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_498a0076-45b1-49c2-96d1-98c075332a0c" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_498a0076-45b1-49c2-96d1-98c075332a0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_265aceb6-a433-4054-a971-ed335aec7985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_265aceb6-a433-4054-a971-ed335aec7985" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseRemainingLeaseTeam_05500fa5-0576-4f46-9810-864d82746aa7" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseRemainingLeaseTeam"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseRemainingLeaseTeam_05500fa5-0576-4f46-9810-864d82746aa7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4654800a-fc70-412e-bb78-068a17c29957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4654800a-fc70-412e-bb78-068a17c29957" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9aef242-a414-4d68-bfe0-f84ab92a0b65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9aef242-a414-4d68-bfe0-f84ab92a0b65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03807777-1d9e-4f43-a9cb-8dc889eca890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03807777-1d9e-4f43-a9cb-8dc889eca890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_efd4704f-6599-4957-b880-1781c7340e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03807777-1d9e-4f43-a9cb-8dc889eca890" xlink:to="loc_us-gaap_BuildingMember_efd4704f-6599-4957-b880-1781c7340e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:to="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_601e44de-b6f0-4822-b2b4-0e1bbf9099e5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:to="loc_srt_SegmentGeographicalDomain_601e44de-b6f0-4822-b2b4-0e1bbf9099e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:to="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_96b673a3-fe39-43fb-a2d6-3af8d0d69f62" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:to="loc_stpr_MD_96b673a3-fe39-43fb-a2d6-3af8d0d69f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_98c335d1-67f3-48ca-893e-868ccc76b0d8" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:to="loc_stpr_PA_98c335d1-67f3-48ca-893e-868ccc76b0d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails" xlink:type="extended" id="if4d1a7cb07484c4dad4701fcd0a98e71_LeasesAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/LeasesLeaseCostDetails" xlink:type="extended" id="if3ab540992a14c2891cdd01ac2959ac4_LeasesLeaseCostDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/LeasesLeaseMaturityDetails" xlink:type="extended" id="ibbaf978f327b443faaa3e00e11c280e8_LeasesLeaseMaturityDetails"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cerc-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CommitmentsandContingencies" xlink:type="extended" id="id684d46a4ef64617862b3691dc770ece_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.cerecor.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ie50f3b2edf4b447c9ffff1a034337172_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_763e9fc6-6c8a-49d6-8fdf-b3b18b55e046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_763e9fc6-6c8a-49d6-8fdf-b3b18b55e046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementMakeWholePaymentPerUnit_2ae0e285-c694-445e-a790-a58ecbda9c9f" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementMakeWholePaymentPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementMakeWholePaymentPerUnit_2ae0e285-c694-445e-a790-a58ecbda9c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementSemiAnnualLicensePayment_e785e94e-a866-48ae-ad62-83ef3a874445" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementSemiAnnualLicensePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementSemiAnnualLicensePayment_e785e94e-a866-48ae-ad62-83ef3a874445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_24bfc38c-1868-4ebf-a1b6-48392e019f18" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_24bfc38c-1868-4ebf-a1b6-48392e019f18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementInstallmentPayment_f4a4d22b-6712-43ee-b33f-8c6a3140baf3" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementInstallmentPayment_f4a4d22b-6712-43ee-b33f-8c6a3140baf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_e489e46e-1b06-4082-a48f-be922f7e49a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_RevenueFromRelatedParties_e489e46e-1b06-4082-a48f-be922f7e49a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_9c0e2299-8c93-4c57-93a4-9434bee79804" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestonePaymentNumberOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_9c0e2299-8c93-4c57-93a4-9434bee79804" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_a8d04790-3092-4f89-95e8-b0cd4086dbe5" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_a8d04790-3092-4f89-95e8-b0cd4086dbe5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_183345dd-2299-461b-94b0-d7fa3a9bc0b1" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_183345dd-2299-461b-94b0-d7fa3a9bc0b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_92c539bb-69fc-4f3f-ad3e-b54a45499534" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_92c539bb-69fc-4f3f-ad3e-b54a45499534" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseObligationNoncurrent_c37df290-5d48-409b-8d90-5605211c58dc" xlink:href="cerc-20210331.xsd#cerc_LicenseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseObligationNoncurrent_c37df290-5d48-409b-8d90-5605211c58dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d6b08d-ea4b-4bbb-8bee-880dce90c1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d6b08d-ea4b-4bbb-8bee-880dce90c1ff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PotentialFutureRegulatoryMilestone_3d30f9dc-c1e1-4d95-afcd-f7e48c1ee001" xlink:href="cerc-20210331.xsd#cerc_PotentialFutureRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_PotentialFutureRegulatoryMilestone_3d30f9dc-c1e1-4d95-afcd-f7e48c1ee001" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementUpfrontFee_8debec2d-162b-4f07-b61d-e37749ce8ec2" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementUpfrontFee_8debec2d-162b-4f07-b61d-e37749ce8ec2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_8ea0ac86-b51f-4d75-bd7a-626f415f302e" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_8ea0ac86-b51f-4d75-bd7a-626f415f302e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementMilestonePaymentRecognized_7bf24a24-713c-4633-9490-f2c6a6104a73" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementMilestonePaymentRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementMilestonePaymentRecognized_7bf24a24-713c-4633-9490-f2c6a6104a73" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementPaymentReceived_afe8746b-2789-423b-9cf2-8cc173eee388" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_RoyaltyAgreementPaymentReceived_afe8746b-2789-423b-9cf2-8cc173eee388" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_c883fa24-962d-41ef-a413-fcbb91ebfb09" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_c883fa24-962d-41ef-a413-fcbb91ebfb09" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_9ff3e52f-16d0-41e2-ab74-3cc0da31ea63" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_9ff3e52f-16d0-41e2-ab74-3cc0da31ea63" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_7f5de0c9-6739-45eb-baa8-c4ac9649a69b" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightNumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_7f5de0c9-6739-45eb-baa8-c4ac9649a69b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_5e061ad4-2d61-4fe0-9729-08247d31dc8d" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_5e061ad4-2d61-4fe0-9729-08247d31dc8d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentConsiderationLiability_f6db0c44-ea44-4dfb-b0ee-fed67be388a4" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_AssetAcquisitionContingentConsiderationLiability_f6db0c44-ea44-4dfb-b0ee-fed67be388a4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfPreclinicalTherapies_1eec1fae-326c-428d-bb05-bce29702a1ff" xlink:href="cerc-20210331.xsd#cerc_NumberOfPreclinicalTherapies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_NumberOfPreclinicalTherapies_1eec1fae-326c-428d-bb05-bce29702a1ff" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_69b480ad-8d99-47dd-824d-3af0e506591e" xlink:href="cerc-20210331.xsd#cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_69b480ad-8d99-47dd-824d-3af0e506591e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_188c1f9a-7dc7-4eb4-a469-dc5574b78866_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_188c1f9a-7dc7-4eb4-a469-dc5574b78866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d93d58d4-a2df-48bc-9b92-b082133c0d5f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d93d58d4-a2df-48bc-9b92-b082133c0d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TRISPharmaMember_e2144d2f-4a16-4375-98d9-ba8cd8e89c02" xlink:href="cerc-20210331.xsd#cerc_TRISPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d93d58d4-a2df-48bc-9b92-b082133c0d5f" xlink:to="loc_cerc_TRISPharmaMember_e2144d2f-4a16-4375-98d9-ba8cd8e89c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e412a19-057b-40ea-ab73-f1e49e2670de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4e412a19-057b-40ea-ab73-f1e49e2670de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20a28d3e-256c-43fe-942c-b03ed6af67f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20a28d3e-256c-43fe-942c-b03ed6af67f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_KarbinalAgreementMember_1f58fd99-f967-4651-a4c0-ff411b0d1084" xlink:href="cerc-20210331.xsd#cerc_KarbinalAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20a28d3e-256c-43fe-942c-b03ed6af67f8" xlink:to="loc_cerc_KarbinalAgreementMember_1f58fd99-f967-4651-a4c0-ff411b0d1084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_04cea93f-e431-472d-a576-e3233ca6d031_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:to="loc_srt_ProductsAndServicesDomain_04cea93f-e431-472d-a576-e3233ca6d031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:to="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MillipredMember_91eaeb28-c1fd-4a43-98af-b0e2df246b8d" xlink:href="cerc-20210331.xsd#cerc_MillipredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_MillipredMember_91eaeb28-c1fd-4a43-98af-b0e2df246b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC611Member_7af7b349-8a2a-4ff7-8bdd-1fd77391a1cf" xlink:href="cerc-20210331.xsd#cerc_CERC611Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC611Member_7af7b349-8a2a-4ff7-8bdd-1fd77391a1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f0614a21-fda7-49fd-b7f2-d4cb81733098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_us-gaap_LicenseMember_f0614a21-fda7-49fd-b7f2-d4cb81733098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC002KKCLicenseAgreementMember_9472154e-d41b-449d-ba82-cf8e9ed15dbd" xlink:href="cerc-20210331.xsd#cerc_CERC002KKCLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC002KKCLicenseAgreementMember_9472154e-d41b-449d-ba82-cf8e9ed15dbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC006AstellasLicenseAgreementMember_01065913-8051-402c-ba96-d7e5a5a7b724" xlink:href="cerc-20210331.xsd#cerc_CERC006AstellasLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC006AstellasLicenseAgreementMember_01065913-8051-402c-ba96-d7e5a5a7b724" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC007AstraZenecaLicenseAgreementMember_d2412697-974a-46e7-8a7c-6a8f673750ae" xlink:href="cerc-20210331.xsd#cerc_CERC007AstraZenecaLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC007AstraZenecaLicenseAgreementMember_d2412697-974a-46e7-8a7c-6a8f673750ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC801CERC802AndCERC803Member_a6d4aa76-6087-4d34-90c4-0f6ff13378f9" xlink:href="cerc-20210331.xsd#cerc_CERC801CERC802AndCERC803Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC801CERC802AndCERC803Member_a6d4aa76-6087-4d34-90c4-0f6ff13378f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC913Member_da66c903-e93c-41de-bded-e44ec0bdc592" xlink:href="cerc-20210331.xsd#cerc_CERC913Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC913Member_da66c903-e93c-41de-bded-e44ec0bdc592" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dca96955-4c2a-435a-9add-dffbb84a7af8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:to="loc_us-gaap_RelatedPartyDomain_dca96955-4c2a-435a-9add-dffbb84a7af8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:to="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_3e9e2888-e5f3-463c-9d8b-1f653ffa2fcd" xlink:href="cerc-20210331.xsd#cerc_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:to="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_3e9e2888-e5f3-463c-9d8b-1f653ffa2fcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticeMember_80fdc6a1-4618-49e8-b39c-3a69e967a71b" xlink:href="cerc-20210331.xsd#cerc_ArmisticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:to="loc_cerc_ArmisticeMember_80fdc6a1-4618-49e8-b39c-3a69e967a71b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_72df747f-efe2-4cc0-a293-b903d8205b03_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_72df747f-efe2-4cc0-a293-b903d8205b03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a3a49e26-91c5-411f-aee3-064d8980aaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a3a49e26-91c5-411f-aee3-064d8980aaa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_43cb6871-d293-4894-9a65-3e72c85fe929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a3a49e26-91c5-411f-aee3-064d8980aaa3" xlink:to="loc_us-gaap_SubsequentEventMember_43cb6871-d293-4894-9a65-3e72c85fe929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_e7dd312f-3176-409a-904d-7e538e5cbf0e_default" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:to="loc_cerc_AssetAcquisitionDomain_e7dd312f-3176-409a-904d-7e538e5cbf0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:to="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_5617dce6-f04f-4e42-9fb6-532c7cb7e7ca" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_5617dce6-f04f-4e42-9fb6-532c7cb7e7ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IchorionMember_9d829814-1283-4d7d-9a70-5ee7867b5d51" xlink:href="cerc-20210331.xsd#cerc_IchorionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:to="loc_cerc_IchorionMember_9d829814-1283-4d7d-9a70-5ee7867b5d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:href="cerc-20210331.xsd#cerc_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneDomain_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8_default" xlink:href="cerc-20210331.xsd#cerc_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:to="loc_cerc_MilestoneDomain_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:href="cerc-20210331.xsd#cerc_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:to="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneOneMember_fd53a945-7558-474b-9330-e7b9b8ef5c2a" xlink:href="cerc-20210331.xsd#cerc_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:to="loc_cerc_MilestoneOneMember_fd53a945-7558-474b-9330-e7b9b8ef5c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneTwoMember_31015ef6-71fc-42ba-a4ad-a9fe40ec961e" xlink:href="cerc-20210331.xsd#cerc_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:to="loc_cerc_MilestoneTwoMember_31015ef6-71fc-42ba-a4ad-a9fe40ec961e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneThreeMember_c8dd393a-1fa6-48aa-a4e0-4941c98c0eb2" xlink:href="cerc-20210331.xsd#cerc_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:to="loc_cerc_MilestoneThreeMember_c8dd393a-1fa6-48aa-a4e0-4941c98c0eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3ced8a15-6ddf-4e7b-a649-bae6299fd396" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3ced8a15-6ddf-4e7b-a649-bae6299fd396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2c4edeb8-1647-49f4-ab04-e3f04c2c34e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3ced8a15-6ddf-4e7b-a649-bae6299fd396" xlink:to="loc_srt_ScenarioForecastMember_2c4edeb8-1647-49f4-ab04-e3f04c2c34e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ad2a903a-3604-4dc4-a7e6-3814b1539435_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:to="loc_dei_EntityDomain_ad2a903a-3604-4dc4-a7e6-3814b1539435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa44fa58-e5f1-4eee-9560-c346cb8f66c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:to="loc_dei_EntityDomain_fa44fa58-e5f1-4eee-9560-c346cb8f66c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_4b584c9d-67e6-453a-8818-a9c35833f2f6" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fa44fa58-e5f1-4eee-9560-c346cb8f66c5" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_4b584c9d-67e6-453a-8818-a9c35833f2f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cerc-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4f7a87f1-b6d6-4918-8a41-8e0f9da38f3e,g:12909dcc-0657-4b99-8650-be04def8faa3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_62fb6286-958c-4d3f-9af9-13a0039959f2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_05199354-d1a8-4938-ab85-bebb59856f78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f9a2e927-c592-4332-b8db-238c49f7dd4d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_ce233d79-06c9-4628-9657-05dc5e6a7edf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c39a392e-7b82-4423-bcd9-931512ab62e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ee73c71c-7c54-4687-9051-5bb56ae8c17c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8a3a9714-77f1-4a3e-8d6e-860b72c2577a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_961841e2-91dc-4c2a-862f-6ca964a64304_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f8d72268-331f-4aab-85b4-c44f2087f16d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ebff7d1b-36b1-448e-8945-de2c7bfab5b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_717c961e-8557-4218-a72d-e61fe64d21e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_8676c300-a77c-4b5c-b1a2-19e0b48ee50d_terseLabel_en-US" xlink:label="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Exercised, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Exercised, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="cerc-20210331.xsd#cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_b948e530-4682-4158-bc5a-77da27301726_terseLabel_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual amount of fair market value of the company's common stock that a participant may accrue the rights to purchase</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_label_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_documentation_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:to="lab_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b5678422-e574-49bf-99bd-fb00840a0cc2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3664917e-f719-4f39-866c-bed60bfe80bf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82672856-d4ba-456a-85e6-8e219d243f79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_e7f824d6-8bc5-49b7-8089-55691a7c4d2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_683b220d-f175-4cc2-8ec4-dc057071b8a0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_7e023ff3-f5e6-4896-9847-d27fe4f634a3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d6ffa904-847a-4ab4-834b-6927ecb14357_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_054017f7-4217-425f-b1e4-5989f386f953_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_6c2aadb8-36c7-4971-9a29-4e04a16b64a4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_03970e3f-2a34-4ce5-b974-86f591326508_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_185b2f36-2975-4a6c-b06f-98d3641e1e4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c02affc2-16ee-46ac-82ca-77cdf6ae9c62_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionTransactionCosts_4b4484d5-a7a2-40d9-ad15-88574d2aa547_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_cerc_AssetAcquisitionTransactionCosts_label_en-US" xlink:label="lab_cerc_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:label id="lab_cerc_AssetAcquisitionTransactionCosts_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionTransactionCosts" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionTransactionCosts" xlink:to="lab_cerc_AssetAcquisitionTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability_aa5088e9-b3df-4e76-a1d5-ad4799ba6df9_terseLabel_en-US" xlink:label="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining contingent consideration</link:label>
    <link:label id="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability_label_en-US" xlink:label="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Remaining Contingent Consideration, Liability</link:label>
    <link:label id="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability_documentation_en-US" xlink:label="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Remaining Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentRemainingContingentConsiderationLiability" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentRemainingContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DebtInstrumentRemainingContingentConsiderationLiability" xlink:to="lab_cerc_DebtInstrumentRemainingContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_94ccc5bd-5b20-45cf-aaf6-339d460d9e34_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ab561cb0-894e-4200-a972-de04f536c14d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs at December 31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_229b71ab-0a15-4914-bac5-4770b7fd2cdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs at March 31, 2021 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_c6a1f044-0135-4abe-9602-bed7a3ada8e6_terseLabel_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_label_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase To Shares Authorized As Percentage Of Outstanding Stock At End Of Preceding Year</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_documentation_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase To Shares Authorized As Percentage Of Outstanding Stock At End Of Preceding Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:to="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a2fa1c2a-1777-4212-8c96-c8a3f99de69b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e85ef03f-5c41-404a-bd72-a5e20d8e2d9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_77378729-2b9b-4ee2-a45d-5bd03542b5ec_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5b92f518-e3a9-4e56-a1e5-2742be0639e0_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae599699-95af-4b69-98c4-f4af6d2c514e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f5af88b7-6f67-4d09-8ac3-d3c186f2f522_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1ae9b908-672a-4a8e-85de-2ca4a4f5f42c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_37002d6e-3f00-45be-9e33-6eeced515575_terseLabel_en-US" xlink:label="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the components of accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="cerc-20210331.xsd#cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_EmployeeStockPurchasePlanESPPMember_5a39c8fd-e9ad-4083-ac13-109a8913cb18_terseLabel_en-US" xlink:label="lab_cerc_EmployeeStockPurchasePlanESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP)</link:label>
    <link:label id="lab_cerc_EmployeeStockPurchasePlanESPPMember_label_en-US" xlink:label="lab_cerc_EmployeeStockPurchasePlanESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) [Member]</link:label>
    <link:label id="lab_cerc_EmployeeStockPurchasePlanESPPMember_documentation_en-US" xlink:label="lab_cerc_EmployeeStockPurchasePlanESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeStockPurchasePlanESPPMember" xlink:href="cerc-20210331.xsd#cerc_EmployeeStockPurchasePlanESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_EmployeeStockPurchasePlanESPPMember" xlink:to="lab_cerc_EmployeeStockPurchasePlanESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4bf9ae74-9cd4-4a93-8dce-3b89e2ec43d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6fbbf231-4032-4e11-9fee-561836142574_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_822713b3-81ac-4a27-ae94-82bd1d237b23_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MajorCustomerNumberOneMember_e0f87029-364f-427d-a539-cca436899676_terseLabel_en-US" xlink:label="lab_cerc_MajorCustomerNumberOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number One</link:label>
    <link:label id="lab_cerc_MajorCustomerNumberOneMember_label_en-US" xlink:label="lab_cerc_MajorCustomerNumberOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number One [Member]</link:label>
    <link:label id="lab_cerc_MajorCustomerNumberOneMember_documentation_en-US" xlink:label="lab_cerc_MajorCustomerNumberOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberOneMember" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MajorCustomerNumberOneMember" xlink:to="lab_cerc_MajorCustomerNumberOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0ca4bb0b-4c2b-4b7f-8e60-e1e71ed7e196_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_73d94cb1-d294-46fe-acd9-881573212b96_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accumulated deficit) retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ac118be7-0438-44e9-a42b-42314a4d8271_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AccruedMedicaidRebates_90c1c1a1-9296-4066-a50d-b677cd06cb69_terseLabel_en-US" xlink:label="lab_cerc_AccruedMedicaidRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid rebates</link:label>
    <link:label id="lab_cerc_AccruedMedicaidRebates_label_en-US" xlink:label="lab_cerc_AccruedMedicaidRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Medicaid Rebates</link:label>
    <link:label id="lab_cerc_AccruedMedicaidRebates_documentation_en-US" xlink:label="lab_cerc_AccruedMedicaidRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Medicaid Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedMedicaidRebates" xlink:href="cerc-20210331.xsd#cerc_AccruedMedicaidRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AccruedMedicaidRebates" xlink:to="lab_cerc_AccruedMedicaidRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ArmisticePurchaseAgreementMember_3f1d8c8a-a13c-4bef-b38b-188fd09232e7_terseLabel_en-US" xlink:label="lab_cerc_ArmisticePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice Purchase Agreement</link:label>
    <link:label id="lab_cerc_ArmisticePurchaseAgreementMember_label_en-US" xlink:label="lab_cerc_ArmisticePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice Purchase Agreement [Member]</link:label>
    <link:label id="lab_cerc_ArmisticePurchaseAgreementMember_documentation_en-US" xlink:label="lab_cerc_ArmisticePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticePurchaseAgreementMember" xlink:href="cerc-20210331.xsd#cerc_ArmisticePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ArmisticePurchaseAgreementMember" xlink:to="lab_cerc_ArmisticePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e5d5a88d-a277-48fb-bfda-86f1bc3ef06d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_26671ec7-f3f6-4cc3-b7c0-6d2a0e2d2623_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_489c4cea-a96b-4848-8eca-e003c78d2f0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36208873-5f68-404d-9164-3bec43764a40_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7dd8c8e2-5e90-4bd8-b083-03c05902737d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_1562dd44-d880-4365-8c54-f74940cd34c8_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d461a93d-ec38-4c9d-b16d-f20ee5581104_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8821c91a-cb14-4a6d-8d55-295b9ac79668_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_c78ad327-69a3-4b7a-abc0-602b98b8ec57_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_52f01e92-91a6-45b6-b382-a9e7859c082a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_20df35e4-69a0-4e39-a0df-a21cf6c3b1a5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#8212;$0.001 par value; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; 1,257,143 shares issued and outstanding at March 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_A2016SecondAmendedPlanMember_fd729eae-f39f-41f1-9a8e-05c40ebc4153_terseLabel_en-US" xlink:label="lab_cerc_A2016SecondAmendedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Second Amended Plan</link:label>
    <link:label id="lab_cerc_A2016SecondAmendedPlanMember_label_en-US" xlink:label="lab_cerc_A2016SecondAmendedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Second Amended Plan [Member]</link:label>
    <link:label id="lab_cerc_A2016SecondAmendedPlanMember_documentation_en-US" xlink:label="lab_cerc_A2016SecondAmendedPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Second Amended Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_A2016SecondAmendedPlanMember" xlink:href="cerc-20210331.xsd#cerc_A2016SecondAmendedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_A2016SecondAmendedPlanMember" xlink:to="lab_cerc_A2016SecondAmendedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a2d8af7a-68ac-48f7-bac5-fd36f826e406_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_71c43b4d-e4aa-46cb-84c4-f1e453331e19_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share, continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ProceedsFromRegisteredDirectOffering_c78a0c53-ec39-418a-bee9-10b8e203c0c2_terseLabel_en-US" xlink:label="lab_cerc_ProceedsFromRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from registered direct offering, net</link:label>
    <link:label id="lab_cerc_ProceedsFromRegisteredDirectOffering_label_en-US" xlink:label="lab_cerc_ProceedsFromRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Registered Direct Offering</link:label>
    <link:label id="lab_cerc_ProceedsFromRegisteredDirectOffering_documentation_en-US" xlink:label="lab_cerc_ProceedsFromRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromRegisteredDirectOffering" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromRegisteredDirectOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ProceedsFromRegisteredDirectOffering" xlink:to="lab_cerc_ProceedsFromRegisteredDirectOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_f24f5e2e-6e6e-4d83-9399-4a4e11044852_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_e7338aaf-db2b-4148-b4ba-5fbc94a2312e_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share, discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_80432ba3-04e1-4e68-8744-2240619bfb1a_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d628cb27-3e97-4ee9-a8a1-128aa046a7f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_343172be-c260-41b5-85bf-184337ad2ef5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0cc97402-b1bc-45c7-b4a6-519031d83923_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_556c1304-c6c2-4e83-9654-7571e6585e2f_terseLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns disposed of</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_label_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Sales Returns</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_documentation_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" xlink:to="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_UnderwritersUnitPurchaseOptionMember_cb2a9543-159f-47de-b396-4dc78fa743ba_terseLabel_en-US" xlink:label="lab_cerc_UnderwritersUnitPurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters&#8217; unit purchase option</link:label>
    <link:label id="lab_cerc_UnderwritersUnitPurchaseOptionMember_label_en-US" xlink:label="lab_cerc_UnderwritersUnitPurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters Unit Purchase Option [Member]</link:label>
    <link:label id="lab_cerc_UnderwritersUnitPurchaseOptionMember_documentation_en-US" xlink:label="lab_cerc_UnderwritersUnitPurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information pertaining to the underwriter's unit purchase option that was offered as part of the IPO.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwritersUnitPurchaseOptionMember" xlink:href="cerc-20210331.xsd#cerc_UnderwritersUnitPurchaseOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_UnderwritersUnitPurchaseOptionMember" xlink:to="lab_cerc_UnderwritersUnitPurchaseOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1149ebb1-8727-4eae-ab66-9e5895989e42_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_14b9bf8a-9456-4b90-b2ff-c44c0119e769_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of asset acquisition</link:label>
    <link:label id="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Net</link:label>
    <link:label id="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionDomain_153b0305-61c3-4989-8097-75b1d554ed27_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_cerc_AssetAcquisitionDomain_label_en-US" xlink:label="lab_cerc_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_cerc_AssetAcquisitionDomain_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionDomain" xlink:to="lab_cerc_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_60c3e896-7758-4b5b-8563-dd1a74581914_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6cb7c22b-2f43-427c-8ad9-f8c9d482f732_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18b09f16-4465-41a7-8f47-5de3241e7d4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a22b574e-2579-42e5-9be0-d659d3c4e96b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1940d452-cdee-4767-b281-fa229887a9e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_eb0afe0d-c1ed-42a1-85e5-0b235f24a538_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_aa2d8b66-7b2a-42bb-825d-900d41e2155b_terseLabel_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares pursuant to common stock private placement, net of offering costs (in shares)</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_label_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, Private Placement</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_documentation_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:to="lab_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_73ce77eb-e7f5-4e49-b963-8ff1c2c363ed_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_59a05534-76c9-4f66-ae2e-a96256a626f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_cf78ebb7-8314-44ca-a4f4-5633a2cc39b6_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chairman of the Board</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_257679f8-c0a4-48ac-9d53-42b4f9147ee9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e0ce8661-966b-4b90-b754-3367c54a7bcd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares related to Aevi Merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_f0f8f412-8675-4d50-adf4-5415ed12b9af_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_label_en-US" xlink:label="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Equity Interest Issued Or Issuable, Number Of Shares</link:label>
    <link:label id="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Equity Interest Issued Or Issuable, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:to="lab_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83f84d1b-75de-40bf-b988-1e2e95bae81c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded From Computation of Diluted Weighted Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_5a495fe5-1a31-4654-9fb4-7b5f862501c7_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3e82fbe3-6508-4a9d-9242-00d268e26ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit_4d31c9e3-ca09-4ae8-8102-9aeb282c0d31_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make whole payment per unit (in dollars per share)</link:label>
    <link:label id="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit_label_en-US" xlink:label="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Make Whole Payment Per Unit</link:label>
    <link:label id="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Make Whole Payment Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementMakeWholePaymentPerUnit" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementMakeWholePaymentPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementMakeWholePaymentPerUnit" xlink:to="lab_cerc_LicenseAgreementMakeWholePaymentPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_2f78e190-cb53-4995-af4c-4bdf43e3bb3b_terseLabel_en-US" xlink:label="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Asset Acquisition Contingent Consideration Liability Operating Activities</link:label>
    <link:label id="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_documentation_en-US" xlink:label="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Asset Acquisition Contingent Consideration Liability Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:href="cerc-20210331.xsd#cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_b1a1b94e-447c-4b91-950a-819f3956fa44_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5bdf4ab4-cd9d-4da0-bc1c-ad6c15461894_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3b867e1e-f591-4c65-9f81-f32a6db5b637_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_55d1a428-383a-4615-bbf5-04e52f78921e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7c8272cf-fb4f-4549-9ca9-e113056c2e45_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b4766af4-3a56-4fde-8f68-50539c7fad73_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_83e4af2c-8e6e-4f09-95d8-796d09e1e316_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of payments received from sublicensing</link:label>
    <link:label id="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_label_en-US" xlink:label="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Payments Received From Sublicensing</link:label>
    <link:label id="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Payments Received From Sublicensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" xlink:to="lab_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fd74ad9b-8fde-4250-be6f-aa38cb4f5dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_b8c3cf3f-400d-481f-804e-991f39329865_terseLabel_en-US" xlink:label="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of classes of stock outstanding</link:label>
    <link:label id="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_label_en-US" xlink:label="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock, Number Of Classes Of Stock Outstanding</link:label>
    <link:label id="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_documentation_en-US" xlink:label="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock, Number Of Classes Of Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClassOfStockNumberOfClassesOfStockOutstanding" xlink:href="cerc-20210331.xsd#cerc_ClassOfStockNumberOfClassesOfStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ClassOfStockNumberOfClassesOfStockOutstanding" xlink:to="lab_cerc_ClassOfStockNumberOfClassesOfStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_e3ba06d2-e7e8-448d-a1c4-5a0fcbaf3db2_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of loan</link:label>
    <link:label id="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Liabilities Incurred</link:label>
    <link:label id="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_1f8ed493-ec7a-4600-900f-6d7600602cbb_terseLabel_en-US" xlink:label="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares pursuant to registered direct offering, net of offering costs</link:label>
    <link:label id="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_label_en-US" xlink:label="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Shares, Value, Pursuant To Registered Direct Offering</link:label>
    <link:label id="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_documentation_en-US" xlink:label="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Shares, Value, Pursuant To Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" xlink:href="cerc-20210331.xsd#cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" xlink:to="lab_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_75528cc7-d999-4921-ab93-d1b41c7cf717_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_ea0e11e3-bd4e-4519-ae1e-085bc06fc9b0_terseLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_label_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_documentation_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:to="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_6aad4674-cbc5-4f65-984d-c6039d2d051f_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone revenue threshold two</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_label_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Revenue Threshold Number Two</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Revenue Threshold Number Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" xlink:to="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9a8f757-fd49-454f-9607-e8225ed14514_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5b26d89f-e0b7-46fc-a8a3-f6d716baad72_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CERC006AstellasLicenseAgreementMember_6bb75bb8-8862-4a96-9ca9-507e83d0eee4_terseLabel_en-US" xlink:label="lab_cerc_CERC006AstellasLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-006 Astellas License Agreement</link:label>
    <link:label id="lab_cerc_CERC006AstellasLicenseAgreementMember_label_en-US" xlink:label="lab_cerc_CERC006AstellasLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-006 Astellas License Agreement [Member]</link:label>
    <link:label id="lab_cerc_CERC006AstellasLicenseAgreementMember_documentation_en-US" xlink:label="lab_cerc_CERC006AstellasLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-006 Astellas License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC006AstellasLicenseAgreementMember" xlink:href="cerc-20210331.xsd#cerc_CERC006AstellasLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CERC006AstellasLicenseAgreementMember" xlink:to="lab_cerc_CERC006AstellasLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AccruedSalesReturnsAndAllowances_989ce111-88d8-4d6d-9fec-43dbb12169c2_terseLabel_en-US" xlink:label="lab_cerc_AccruedSalesReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns and allowances</link:label>
    <link:label id="lab_cerc_AccruedSalesReturnsAndAllowances_label_en-US" xlink:label="lab_cerc_AccruedSalesReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns And Allowances</link:label>
    <link:label id="lab_cerc_AccruedSalesReturnsAndAllowances_documentation_en-US" xlink:label="lab_cerc_AccruedSalesReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns And Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedSalesReturnsAndAllowances" xlink:href="cerc-20210331.xsd#cerc_AccruedSalesReturnsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AccruedSalesReturnsAndAllowances" xlink:to="lab_cerc_AccruedSalesReturnsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da019111-1a96-4293-b68c-27627854df04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_51eacb0d-cce9-46ff-8436-79ab5fdad016_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f500308e-b5ac-4681-a06c-2664554adfc7_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_IchorionMember_0a7aa7d1-6e82-4e93-8f01-3e12754f7661_terseLabel_en-US" xlink:label="lab_cerc_IchorionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ichorion</link:label>
    <link:label id="lab_cerc_IchorionMember_label_en-US" xlink:label="lab_cerc_IchorionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ichorion [Member]</link:label>
    <link:label id="lab_cerc_IchorionMember_documentation_en-US" xlink:label="lab_cerc_IchorionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ichorion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IchorionMember" xlink:href="cerc-20210331.xsd#cerc_IchorionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_IchorionMember" xlink:to="lab_cerc_IchorionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_IncreaseDecreaseInLeaseLiability_fd94ac96-1506-4a71-9b56-a16c9998bc8c_terseLabel_en-US" xlink:label="lab_cerc_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net</link:label>
    <link:label id="lab_cerc_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_cerc_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liability</link:label>
    <link:label id="lab_cerc_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_cerc_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IncreaseDecreaseInLeaseLiability" xlink:href="cerc-20210331.xsd#cerc_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_IncreaseDecreaseInLeaseLiability" xlink:to="lab_cerc_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_500cd87c-8799-47a0-826e-c32e79e09d16_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone revenue threshold</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_label_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Revenue Threshold Number One</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Revenue Threshold Number One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" xlink:to="lab_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5b616436-6adf-4532-b0a3-3265df6e4674_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_741bff89-21cd-47ca-8a8f-84ac6c883489_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e55161cd-a91a-45ed-aaa5-83b758d18ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Computation of Basic and Diluted Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments_033adba8-53f0-4b9a-bc43-632b9075aa2b_terseLabel_en-US" xlink:label="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future aggregate deferred payments</link:label>
    <link:label id="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments_label_en-US" xlink:label="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Future Aggregate Deferred Payments</link:label>
    <link:label id="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments_documentation_en-US" xlink:label="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Future Aggregate Deferred Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentFutureAggregateDeferredPayments" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentFutureAggregateDeferredPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DebtInstrumentFutureAggregateDeferredPayments" xlink:to="lab_cerc_DebtInstrumentFutureAggregateDeferredPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f67d11b8-6c98-4607-8ab4-cb0e6f2f94e8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4992bf89-f588-4077-a15e-58d815b88827_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionCashandEquivalents_607ea384-bfcf-476d-93df-50f1dca2b809_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionCashandEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_cerc_AssetAcquisitionCashandEquivalents_label_en-US" xlink:label="lab_cerc_AssetAcquisitionCashandEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash and Equivalents</link:label>
    <link:label id="lab_cerc_AssetAcquisitionCashandEquivalents_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionCashandEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionCashandEquivalents" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionCashandEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionCashandEquivalents" xlink:to="lab_cerc_AssetAcquisitionCashandEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6b9b7cfe-7f25-48fe-857e-db4181786b81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock remaining for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_616c55c4-8f65-440b-bab6-d2dbf1141e87_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c6b6bc51-f2d7-4ef5-bd65-7466044d16c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares pursuant to common stock private placement, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4443be0f-bc51-4256-b1f2-700a10e0cfce_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4437f9d0-3494-42a6-8d1a-138ec9d1afff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0b83882c-2da4-4399-830c-901fce0f974e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_60c3c0d0-385b-46ce-aa5a-aea05028cf7c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_92e9b875-aed8-4605-b26d-aeb04b6f8173_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_be4161c2-5b8e-47c4-9934-2c5ca330e079_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7a50c9ba-e806-4552-a586-09dda579ff97_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_04cdb6cb-918e-4ae0-8697-3935567815f8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CAPITALSTRUCTUREAbstract_90345694-6b6b-4472-8147-43b093e415cf_terseLabel_en-US" xlink:label="lab_cerc_CAPITALSTRUCTUREAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAPITAL STRUCTURE</link:label>
    <link:label id="lab_cerc_CAPITALSTRUCTUREAbstract_label_en-US" xlink:label="lab_cerc_CAPITALSTRUCTUREAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAPITAL STRUCTURE [Abstract]</link:label>
    <link:label id="lab_cerc_CAPITALSTRUCTUREAbstract_documentation_en-US" xlink:label="lab_cerc_CAPITALSTRUCTUREAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definitions available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CAPITALSTRUCTUREAbstract" xlink:href="cerc-20210331.xsd#cerc_CAPITALSTRUCTUREAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CAPITALSTRUCTUREAbstract" xlink:to="lab_cerc_CAPITALSTRUCTUREAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_a7e1f142-6f48-45aa-b81f-9813b18c22fd_terseLabel_en-US" xlink:label="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability and unit purchase option liability</link:label>
    <link:label id="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_label_en-US" xlink:label="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment Of Warrants And Investor Rights Obligation</link:label>
    <link:label id="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_documentation_en-US" xlink:label="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of warrant liability and investor rights obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" xlink:href="cerc-20210331.xsd#cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" xlink:to="lab_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_3ac560f8-8edf-4570-a8ab-66972bf15761_terseLabel_en-US" xlink:label="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_label_en-US" xlink:label="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Consultants And Directors Stock Options [Member]</link:label>
    <link:label id="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_documentation_en-US" xlink:label="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:href="cerc-20210331.xsd#cerc_EmployeeConsultantsAndDirectorsStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="lab_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_0d883ddc-2a43-4430-ba8f-9c8683051eac_terseLabel_en-US" xlink:label="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants in underwritten public offering, net</link:label>
    <link:label id="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_f013eeda-08d6-4af9-af02-07baf8c109ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_03d60589-265c-4d0b-a749-d57753fddc09_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f0458933-ef48-4ddf-8045-97000327af7b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_5eb74f2b-6fb0-415f-80c9-6739ff32d411_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Activity, Fair value of options granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_83f7c772-fea0-4895-9aa2-3868d476b109_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_891bb922-ca16-41a3-bd40-e7dd2a3d6398_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_437dfe38-c516-429d-83fe-9adccacd5d0d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_4f4daf1a-79d2-41c6-a37d-88555b1dbe73_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares related to Aevi Merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_43deba62-aae7-49c4-a037-231c32c13ad6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_49f24c60-f4a7-4bc5-8813-d266852a1112_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70b18f7a-e49e-4be4-8867-7a3813ed9e09_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3eee36fc-acbf-4460-a85a-2654983e2b03_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_40213858-5a7c-4160-b764-b2a7f07e72d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MonthlyOperationPaymentsTerm_63b27fab-439d-4900-bdc9-63f536095cca_terseLabel_en-US" xlink:label="lab_cerc_MonthlyOperationPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of monthly commercial operation payments</link:label>
    <link:label id="lab_cerc_MonthlyOperationPaymentsTerm_label_en-US" xlink:label="lab_cerc_MonthlyOperationPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Operation Payments, Term</link:label>
    <link:label id="lab_cerc_MonthlyOperationPaymentsTerm_documentation_en-US" xlink:label="lab_cerc_MonthlyOperationPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Operation Payments, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MonthlyOperationPaymentsTerm" xlink:href="cerc-20210331.xsd#cerc_MonthlyOperationPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MonthlyOperationPaymentsTerm" xlink:to="lab_cerc_MonthlyOperationPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e890310d-4c44-42ca-9aad-19cbb66ac0e5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_68254cf6-15f6-4381-b962-a2f46ee5e219_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MilestoneDomain_188d3fdb-5ad8-4d94-a734-75b3223add39_terseLabel_en-US" xlink:label="lab_cerc_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_cerc_MilestoneDomain_label_en-US" xlink:label="lab_cerc_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_cerc_MilestoneDomain_documentation_en-US" xlink:label="lab_cerc_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneDomain" xlink:href="cerc-20210331.xsd#cerc_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MilestoneDomain" xlink:to="lab_cerc_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AccruedResearchAndDevelopment_0c288479-429b-494e-b0ed-c07bf2bb1cb6_terseLabel_en-US" xlink:label="lab_cerc_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_cerc_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_cerc_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_cerc_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_cerc_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedResearchAndDevelopment" xlink:href="cerc-20210331.xsd#cerc_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AccruedResearchAndDevelopment" xlink:to="lab_cerc_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_49afeab1-0c3d-4bd2-957f-bc0a3aabb05b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0d5b5c32-b3bb-482d-bfbe-06f6b7c695a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3c8b7142-7934-4ba2-bbfb-0d49602ae394_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3fa62c19-c39f-4944-8a5b-f6067e545769_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4717f80d-a4c0-4de3-9d58-c816295b1929_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_c595b767-442a-4ab6-96ed-163cce18bff5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_5da00aaa-ff40-44ee-bb82-5f5fa4d0e8fa_terseLabel_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Number Of Renewal Options</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_cerc_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1e1f96df-18d1-41ba-a44e-eaa1e1cfc9dc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_53fd80ae-e50f-4fea-9453-42a9b72eda8e_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_45963e1b-2786-4e70-b186-ffee7d22fbc6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NumberOfProductsDeveloped_bcc09be0-99c9-438a-812e-a437cbdb274b_terseLabel_en-US" xlink:label="lab_cerc_NumberOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products in development</link:label>
    <link:label id="lab_cerc_NumberOfProductsDeveloped_label_en-US" xlink:label="lab_cerc_NumberOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products Developed</link:label>
    <link:label id="lab_cerc_NumberOfProductsDeveloped_documentation_en-US" xlink:label="lab_cerc_NumberOfProductsDeveloped" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products Developed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfProductsDeveloped" xlink:href="cerc-20210331.xsd#cerc_NumberOfProductsDeveloped"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NumberOfProductsDeveloped" xlink:to="lab_cerc_NumberOfProductsDeveloped" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2fbc5ba9-922f-40a7-a763-8e1e360df76b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs at December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68c4e5f7-4cc7-4cdc-be2e-6a7774bedf9e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs at March 31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_433de78a-b422-4810-b1cf-8f2ec981ed8e_totalLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_label_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_documentation_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2548f92c-05a1-4f15-8d5b-ca0eeabb6465_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_2138e272-0080-4671-b081-3c2767de62c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_045349a7-4fd2-4837-9bee-61c5d6177eb1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of Investment in Aytu</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_f1156a2d-8c21-4eec-9341-e60f1bc7236d_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of Investment in Aytu</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_e18cebee-24d7-450a-b47c-7bda6ba7e087_terseLabel_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual base rent</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_label_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Annual Base Rent</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_documentation_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:to="lab_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b8dcf4a-507c-4b10-b358-965beacbb6e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2a129b9f-5436-4b13-ab4f-dc4fd40330e3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6dea24b-3665-41ef-b960-4f741fe96c41_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_0bdaa47b-5b53-46bb-b6f9-06d452123b7e_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_091cb327-1acf-44b4-9d35-e0e714d740d8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_1b526f3f-0965-4af0-97de-a0718dcc8e88_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dfeb65bf-a722-4c48-bfff-7d9d466aa86b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_083e0718-f6da-4f62-a673-57ddbd1cdce8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e37faaff-e174-417c-84b1-5148ade8d216_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_519f1163-2396-4cdc-9624-f24b5f972e69_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_PediatricPortfolioMember_957c51c6-543c-4746-859f-ce5f70c8a349_terseLabel_en-US" xlink:label="lab_cerc_PediatricPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Portfolio</link:label>
    <link:label id="lab_cerc_PediatricPortfolioMember_label_en-US" xlink:label="lab_cerc_PediatricPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Portfolio [Member]</link:label>
    <link:label id="lab_cerc_PediatricPortfolioMember_documentation_en-US" xlink:label="lab_cerc_PediatricPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Portfolio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_PediatricPortfolioMember" xlink:to="lab_cerc_PediatricPortfolioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_464d6b22-36e3-42c6-ae1a-f01cfb1ebd04_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6e562f21-b88a-40ac-aa5f-416049079459_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_35df5cdd-78fa-41dd-8986-2f83d8b66895_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less implied interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_b27f61b2-480c-40c7-b8f0-e307763e61d6_terseLabel_en-US" xlink:label="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after public launch to terminate agreement</link:label>
    <link:label id="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_label_en-US" xlink:label="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Period After Public Launch To Terminate Agreement</link:label>
    <link:label id="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_documentation_en-US" xlink:label="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Period After Public Launch To Terminate Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:to="lab_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_8d8e042f-bf4c-416b-b958-48ffd21cc1fb_terseLabel_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on stock price, threshold percentage</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_label_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Price Premium, Threshold Percentage</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_documentation_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Price Premium, Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" xlink:to="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MajorCustomerNumberThreeMember_3e6cb074-d85c-438e-a1aa-4d492e40e965_terseLabel_en-US" xlink:label="lab_cerc_MajorCustomerNumberThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Three</link:label>
    <link:label id="lab_cerc_MajorCustomerNumberThreeMember_label_en-US" xlink:label="lab_cerc_MajorCustomerNumberThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Three [Member]</link:label>
    <link:label id="lab_cerc_MajorCustomerNumberThreeMember_documentation_en-US" xlink:label="lab_cerc_MajorCustomerNumberThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberThreeMember" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MajorCustomerNumberThreeMember" xlink:to="lab_cerc_MajorCustomerNumberThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93956e4d-f632-40b0-b526-075dae2196dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1522d687-6120-44b5-9b94-4f46cd7f9364_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_04f2dbd3-ab93-4f6e-a54b-112c31bc0301_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c6472c2-240a-4227-acbf-fc57ed7827fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CERC007AstraZenecaLicenseAgreementMember_33ead8b5-8c0c-493f-a657-f384dfa6a571_terseLabel_en-US" xlink:label="lab_cerc_CERC007AstraZenecaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-007 AstraZeneca License Agreement</link:label>
    <link:label id="lab_cerc_CERC007AstraZenecaLicenseAgreementMember_label_en-US" xlink:label="lab_cerc_CERC007AstraZenecaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-007 AstraZeneca License Agreement [Member]</link:label>
    <link:label id="lab_cerc_CERC007AstraZenecaLicenseAgreementMember_documentation_en-US" xlink:label="lab_cerc_CERC007AstraZenecaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-007 AstraZeneca License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC007AstraZenecaLicenseAgreementMember" xlink:href="cerc-20210331.xsd#cerc_CERC007AstraZenecaLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CERC007AstraZenecaLicenseAgreementMember" xlink:to="lab_cerc_CERC007AstraZenecaLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_bc96e2d0-ca4a-4e08-b38d-cf215dafbc84_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, net of current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f9d723f8-707c-4c4f-9439-4605c5748860_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e8243593-67c0-47c3-91f0-c841535b614a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_285a0864-0603-4760-ae7a-e122fb55b6e3_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_1ea16e53-14e5-4323-84b2-03b27647e6c9_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share, discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_306c2a2d-c15e-46d5-b55b-a9bfca3ee8bb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_213d2a4d-1489-45a2-bb31-bc5723f04cf4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_827bc72e-1ded-420b-b1dd-f88f9b1c6579_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dc52152d-4732-4048-b2f5-57ca020163cd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_68e53cf7-bafb-43ee-b764-0e5dc8ee01f6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5c95a356-67de-4258-bd7e-282c7d729610_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber_a91053e7-b572-4f40-8ab2-e57f7b504efb_terseLabel_en-US" xlink:label="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of changes in valuation techniques</link:label>
    <link:label id="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber_label_en-US" xlink:label="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Changes In Valuation Techniques Number</link:label>
    <link:label id="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber_documentation_en-US" xlink:label="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of changes in valuation techniques during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" xlink:href="cerc-20210331.xsd#cerc_FairValueMeasurementsChangesInValuationTechniquesNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" xlink:to="lab_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e20125ad-a723-4d21-a51c-c5e33c2e2581_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_ca7b2f18-afba-4551-8696-926f6382b640_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_d0d63ed3-9739-43c1-ba2c-fbdca937aa16_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share, continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_b912437e-9235-42c9-b114-aba939b16f80_terseLabel_en-US" xlink:label="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent ownership threshold</link:label>
    <link:label id="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_label_en-US" xlink:label="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Percent Ownership Threshold</link:label>
    <link:label id="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_documentation_en-US" xlink:label="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Percent Ownership Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" xlink:href="cerc-20210331.xsd#cerc_ClassOfWarrantOrRightPercentOwnershipThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" xlink:to="lab_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AnnualBaseSalary_bfcd64e8-c375-4aad-9abf-8633162f3c61_terseLabel_en-US" xlink:label="lab_cerc_AnnualBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual base salary</link:label>
    <link:label id="lab_cerc_AnnualBaseSalary_label_en-US" xlink:label="lab_cerc_AnnualBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Base Salary</link:label>
    <link:label id="lab_cerc_AnnualBaseSalary_documentation_en-US" xlink:label="lab_cerc_AnnualBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AnnualBaseSalary" xlink:href="cerc-20210331.xsd#cerc_AnnualBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AnnualBaseSalary" xlink:to="lab_cerc_AnnualBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7181a66c-0b0a-4bb9-9189-6766d32abb97_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_RegisteredDirectOfferingMember_0ff9175c-a062-4270-82b9-eaef7f3f8e15_terseLabel_en-US" xlink:label="lab_cerc_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_cerc_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_cerc_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_cerc_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_cerc_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RegisteredDirectOfferingMember" xlink:href="cerc-20210331.xsd#cerc_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_RegisteredDirectOfferingMember" xlink:to="lab_cerc_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_22906424-8396-44e0-b8ac-41f148f2ad6f_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net profit for installment payments</link:label>
    <link:label id="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_label_en-US" xlink:label="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Net Profit For Installment Payment</link:label>
    <link:label id="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Net Profit For Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:to="lab_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef1ee274-f7f4-47be-b298-cb95228bbda0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b51bcabc-c911-472d-9fd5-aefbb360719b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NantahalaCapitalManagementLLCMember_131aafa4-934d-4cc6-8d54-23372a9e14c7_terseLabel_en-US" xlink:label="lab_cerc_NantahalaCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala Capital Management LLC</link:label>
    <link:label id="lab_cerc_NantahalaCapitalManagementLLCMember_label_en-US" xlink:label="lab_cerc_NantahalaCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala Capital Management LLC [Member]</link:label>
    <link:label id="lab_cerc_NantahalaCapitalManagementLLCMember_documentation_en-US" xlink:label="lab_cerc_NantahalaCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala Capital Management LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaCapitalManagementLLCMember" xlink:href="cerc-20210331.xsd#cerc_NantahalaCapitalManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NantahalaCapitalManagementLLCMember" xlink:to="lab_cerc_NantahalaCapitalManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_OfficersMember_6e6d37dd-b5a9-4cc4-b877-7243059abba3_terseLabel_en-US" xlink:label="lab_cerc_OfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers</link:label>
    <link:label id="lab_cerc_OfficersMember_label_en-US" xlink:label="lab_cerc_OfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers [Member]</link:label>
    <link:label id="lab_cerc_OfficersMember_documentation_en-US" xlink:label="lab_cerc_OfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_OfficersMember" xlink:href="cerc-20210331.xsd#cerc_OfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_OfficersMember" xlink:to="lab_cerc_OfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cf0532a-ac93-4b57-aa5f-9fbca34b1cc1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a8690977-1469-4795-96d3-a9e6c469ec4e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8e365a14-155a-4fda-91c3-d41f3e7f722d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_67672b09-e72a-40d4-984a-af559c157f13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a54fd14e-2be8-4e1f-85ab-b012918f1b94_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d62ecafc-503c-4693-85e6-29d80877ccb0_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2f919630-5184-486e-afdd-b5858506b58a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_566de681-ece6-481f-956a-a714008ed992_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_7e44b2a7-d06b-429b-a34a-0681cc7e98fc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (loss) income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1d7503b5-4356-46ae-a3cd-fda7f91d9f4b_terseLabel_en-US" xlink:label="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment And Operating Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</link:label>
    <link:label id="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_documentation_en-US" xlink:label="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment And Operating Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="cerc-20210331.xsd#cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_dd97f587-273d-415c-9a93-4580c0857fed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_WarrantCommonStockMember_5bd096d6-ecf9-472f-82e6-5acab1ce2826_terseLabel_en-US" xlink:label="lab_cerc_WarrantCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants on common stock</link:label>
    <link:label id="lab_cerc_WarrantCommonStockMember_label_en-US" xlink:label="lab_cerc_WarrantCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Common Stock [Member]</link:label>
    <link:label id="lab_cerc_WarrantCommonStockMember_documentation_en-US" xlink:label="lab_cerc_WarrantCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to warrant common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_WarrantCommonStockMember" xlink:href="cerc-20210331.xsd#cerc_WarrantCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_WarrantCommonStockMember" xlink:to="lab_cerc_WarrantCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam_05efe057-3c9b-4109-bdbe-a92b83ec92b4_terseLabel_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease team</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam_label_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Remaining Lease Team</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam_documentation_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Remaining Lease Team</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseRemainingLeaseTeam" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseRemainingLeaseTeam"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LesseeOperatingLeaseRemainingLeaseTeam" xlink:to="lab_cerc_LesseeOperatingLeaseRemainingLeaseTeam" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionDisclosureTextBlock_c3429566-fbef-472d-87e3-341cf246fb83_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_cerc_AssetAcquisitionDisclosureTextBlock_label_en-US" xlink:label="lab_cerc_AssetAcquisitionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Disclosure [Text Block]</link:label>
    <link:label id="lab_cerc_AssetAcquisitionDisclosureTextBlock_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDisclosureTextBlock" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionDisclosureTextBlock" xlink:to="lab_cerc_AssetAcquisitionDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_18c814a0-cee7-456a-a610-8cf1a5ba0009_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AYTUBioScienceIncMember_73660271-3c1a-42e9-b05d-a677d6f12818_terseLabel_en-US" xlink:label="lab_cerc_AYTUBioScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AYTU</link:label>
    <link:label id="lab_cerc_AYTUBioScienceIncMember_label_en-US" xlink:label="lab_cerc_AYTUBioScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AYTU BioScience, Inc [Member]</link:label>
    <link:label id="lab_cerc_AYTUBioScienceIncMember_documentation_en-US" xlink:label="lab_cerc_AYTUBioScienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AYTU BioScience, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AYTUBioScienceIncMember" xlink:to="lab_cerc_AYTUBioScienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CERC611Member_82d0500d-9442-4685-8d66-3e348b019274_terseLabel_en-US" xlink:label="lab_cerc_CERC611Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-611</link:label>
    <link:label id="lab_cerc_CERC611Member_label_en-US" xlink:label="lab_cerc_CERC611Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-611 [Member]</link:label>
    <link:label id="lab_cerc_CERC611Member_documentation_en-US" xlink:label="lab_cerc_CERC611Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-611 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC611Member" xlink:href="cerc-20210331.xsd#cerc_CERC611Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CERC611Member" xlink:to="lab_cerc_CERC611Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_addb1701-fa91-4b5f-bb77-c0be6c161081_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3145621c-920c-4246-a9f1-3baa7c6ab11d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_515b878a-b0c0-4ba9-b72e-df5350e22f6b_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of undistributed net (loss) income, continuing operations</link:label>
    <link:label id="lab_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Continuing Operation Earnings (Loss), Allocation to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_997e75c1-acdc-48c7-924e-a79e58923bb8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f31d56b1-804b-4097-8c93-a07573830258_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_74fd7537-b9cd-4f8b-bc74-3e0d96baed4c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_447e4e01-9246-40c8-bb36-acff45a9e9b7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_16592992-303f-4e4f-9ce0-d493c540f7f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares available (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ArmisticeMember_a3e3dbb4-7e70-4bed-88e8-3b923b8ba1af_terseLabel_en-US" xlink:label="lab_cerc_ArmisticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice</link:label>
    <link:label id="lab_cerc_ArmisticeMember_label_en-US" xlink:label="lab_cerc_ArmisticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice [Member]</link:label>
    <link:label id="lab_cerc_ArmisticeMember_documentation_en-US" xlink:label="lab_cerc_ArmisticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Armistice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticeMember" xlink:href="cerc-20210331.xsd#cerc_ArmisticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ArmisticeMember" xlink:to="lab_cerc_ArmisticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ClinicalStageMember_dc231891-4bdc-4c49-bb9c-579ba01a4fb7_terseLabel_en-US" xlink:label="lab_cerc_ClinicalStageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Stage</link:label>
    <link:label id="lab_cerc_ClinicalStageMember_label_en-US" xlink:label="lab_cerc_ClinicalStageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Stage [Member]</link:label>
    <link:label id="lab_cerc_ClinicalStageMember_documentation_en-US" xlink:label="lab_cerc_ClinicalStageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Stage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClinicalStageMember" xlink:href="cerc-20210331.xsd#cerc_ClinicalStageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ClinicalStageMember" xlink:to="lab_cerc_ClinicalStageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f81c61e5-df58-42f6-813d-04a2b27c62fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ddb7a11e-7c89-42be-9140-daa64f3f47e9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_eaf936b3-6ee3-44e3-8809-fca594fa7998_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MD_5a1773cb-3efb-4bb4-a569-02ef58bbf334_terseLabel_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maryland</link:label>
    <link:label id="lab_stpr_MD_label_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARYLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_73638b38-f129-45d5-a99b-6e547b558226_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6a9929ef-9db8-4d13-a0fa-8225fa0e4cc6_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f643c9cb-e519-4c99-bbfa-24e334471872_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37c2c7f3-10ea-456e-81fe-8d142435234a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f00c5d95-41f1-4ca8-bd0f-a5e80074d72e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_463c71f1-0c40-4429-88a4-2aa009b19458_terseLabel_en-US" xlink:label="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Structure</link:label>
    <link:label id="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity And Temporary Equity Note Disclosure [Text Block]</link:label>
    <link:label id="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_documentation_en-US" xlink:label="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Also include temporary equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:to="lab_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ee76b967-0bb9-434e-9224-1f0fbf2d492b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8138010b-1069-4566-a9d3-6dbefb1e2eff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_0c11d13f-a38c-4fe9-8705-09e88218e46e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_ba25b027-9de2-496a-8a99-f37601c21dfe_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1c12ce88-b05e-45db-92d0-968348129135_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_10da00f8-5480-495f-9a20-82153372c05c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_85da2299-2a8c-45ed-946a-0c2a02a95bb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MilestoneThreeMember_b142a3a7-8eba-4ed1-bc6e-134c06688ca1_terseLabel_en-US" xlink:label="lab_cerc_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_cerc_MilestoneThreeMember_label_en-US" xlink:label="lab_cerc_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_cerc_MilestoneThreeMember_documentation_en-US" xlink:label="lab_cerc_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneThreeMember" xlink:href="cerc-20210331.xsd#cerc_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MilestoneThreeMember" xlink:to="lab_cerc_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_275ad4ef-c1ed-49e8-921e-5903ba18aa80_terseLabel_en-US" xlink:label="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:href="cerc-20210331.xsd#cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="lab_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_c4d1f480-c907-41a5-bf2d-9e06f8268f91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_InventoryPeriodBeforeExpiration_efcfa201-9222-43d7-af71-96d08eafa85a_terseLabel_en-US" xlink:label="lab_cerc_InventoryPeriodBeforeExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period before expiration to be considered as inventory</link:label>
    <link:label id="lab_cerc_InventoryPeriodBeforeExpiration_label_en-US" xlink:label="lab_cerc_InventoryPeriodBeforeExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Period Before Expiration</link:label>
    <link:label id="lab_cerc_InventoryPeriodBeforeExpiration_documentation_en-US" xlink:label="lab_cerc_InventoryPeriodBeforeExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Period Before Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_InventoryPeriodBeforeExpiration" xlink:href="cerc-20210331.xsd#cerc_InventoryPeriodBeforeExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_InventoryPeriodBeforeExpiration" xlink:to="lab_cerc_InventoryPeriodBeforeExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DenominatorAbstract_1991758e-36a7-4370-b1aa-d7ac2f26e916_terseLabel_en-US" xlink:label="lab_cerc_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cerc_DenominatorAbstract_label_en-US" xlink:label="lab_cerc_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cerc_DenominatorAbstract_documentation_en-US" xlink:label="lab_cerc_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DenominatorAbstract" xlink:href="cerc-20210331.xsd#cerc_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DenominatorAbstract" xlink:to="lab_cerc_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_493edb49-8d88-4932-a35c-a1ebc867e5fa_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_5b5abdf4-a949-4b34-b756-527ea48e3b7b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum quantity required</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Minimum Quantity Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3efcd019-91ca-42f2-95c1-8eb7e63e2b76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_00d5d68e-7951-4a3f-91e5-79b96c90750e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_The2016PlanMember_333e71d9-8eef-4cba-83b9-5149f9b76333_terseLabel_en-US" xlink:label="lab_cerc_The2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_cerc_The2016PlanMember_label_en-US" xlink:label="lab_cerc_The2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2016 Plan [Member]</link:label>
    <link:label id="lab_cerc_The2016PlanMember_documentation_en-US" xlink:label="lab_cerc_The2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2016 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_The2016PlanMember" xlink:href="cerc-20210331.xsd#cerc_The2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_The2016PlanMember" xlink:to="lab_cerc_The2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_091be383-40fd-4556-81fd-fe2474c18649_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod_c59c9102-499c-4863-af7e-c191f8833b1c_terseLabel_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent abatement period</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod_label_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Abatement Period</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod_documentation_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseRentAbatementPeriod" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseRentAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LesseeOperatingLeaseRentAbatementPeriod" xlink:to="lab_cerc_LesseeOperatingLeaseRentAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio_102142fe-3981-4408-8dd4-b23bd30111e3_terseLabel_en-US" xlink:label="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock conversion ratio</link:label>
    <link:label id="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio_label_en-US" xlink:label="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity Note Preferred Stock Conversion Ratio</link:label>
    <link:label id="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio_documentation_en-US" xlink:label="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity Note Preferred Stock Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityNotePreferredStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio" xlink:to="lab_cerc_StockholdersEquityNotePreferredStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock_1b424ea9-b7e7-48b9-b6ca-1f519c406ba8_terseLabel_en-US" xlink:label="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Lessee</link:label>
    <link:label id="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities Lessee [Table Text Block]</link:label>
    <link:label id="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cerc-20210331.xsd#cerc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cerc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_RoyaltyAgreementPaymentReceived_191e941e-c98c-4959-8510-c8ce9099f3ac_terseLabel_en-US" xlink:label="lab_cerc_RoyaltyAgreementPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment received</link:label>
    <link:label id="lab_cerc_RoyaltyAgreementPaymentReceived_label_en-US" xlink:label="lab_cerc_RoyaltyAgreementPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Payment Received</link:label>
    <link:label id="lab_cerc_RoyaltyAgreementPaymentReceived_documentation_en-US" xlink:label="lab_cerc_RoyaltyAgreementPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementPaymentReceived" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_RoyaltyAgreementPaymentReceived" xlink:to="lab_cerc_RoyaltyAgreementPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_80486d5e-3d4d-4c34-ade6-da653023954c_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of undistributed net (loss) income, discontinued operations</link:label>
    <link:label id="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Discontinued Operation Earnings (Loss), Allocation to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e8e5d87e-d4b2-40f0-9c83-bad1b1b62524_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f382df0f-8d29-4063-bc9b-fc79b6eac9d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_77725160-6f00-458e-a765-030d6b411ac9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_fa964679-d426-44c0-9b7e-fca344968535_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0548a6cd-be2f-4f94-b7f6-bf13d689bb30_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_7ec19fff-019d-4ade-9afa-20680143b4aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_a9029cc5-c732-4aa2-941b-aa0beb217199_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4e504a9c-8798-4088-ae51-5d10a90e503e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7fb648cc-088f-4a3b-a259-ff2d16c2ffc1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a38c9faf-e6a7-4633-94f1-3467caf587b0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a4cd14e2-f3b3-444c-bb38-928f28a06444_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_c292603f-b424-456e-bccd-eeb55464c5eb_terseLabel_en-US" xlink:label="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net present value of royalty payments</link:label>
    <link:label id="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_label_en-US" xlink:label="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments</link:label>
    <link:label id="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_documentation_en-US" xlink:label="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:to="lab_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3b036f4e-35ae-4902-9050-90bc792c5653_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_60efaa88-f9f0-4bc2-9a27-b230ace38518_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_17eaf554-8ccd-4da9-9188-389f26681ede_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_52170d0f-3a2f-4aa4-b007-7018434d1d4e_terseLabel_en-US" xlink:label="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurological Clinical And Preclinical Stage Compounds</link:label>
    <link:label id="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_label_en-US" xlink:label="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurological Clinical And Preclinical Stage Compounds [Member]</link:label>
    <link:label id="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_documentation_en-US" xlink:label="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurological Clinical And Preclinical Stage Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" xlink:href="cerc-20210331.xsd#cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" xlink:to="lab_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_81ea8e7b-f3d7-4588-b2bf-39bce51e30ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions for Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d73cb905-c417-4b84-84f3-d2254ef9e186_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_449af337-3895-4ba3-a451-63faf2d91f29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DeerfieldObligationMember_61ea728e-2fc3-49fa-ad6f-e8f054bc4594_terseLabel_en-US" xlink:label="lab_cerc_DeerfieldObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Obligation</link:label>
    <link:label id="lab_cerc_DeerfieldObligationMember_label_en-US" xlink:label="lab_cerc_DeerfieldObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Obligation [Member]</link:label>
    <link:label id="lab_cerc_DeerfieldObligationMember_documentation_en-US" xlink:label="lab_cerc_DeerfieldObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Obligation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DeerfieldObligationMember" xlink:href="cerc-20210331.xsd#cerc_DeerfieldObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DeerfieldObligationMember" xlink:to="lab_cerc_DeerfieldObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d2f8f7cd-c2e2-4cb8-b7a3-d062a814a70e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fb3450f5-535a-42fd-ac5e-9f1426211f61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5239f94-9f49-45bc-a36a-400a915dbec5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ServiceBasedOptionsMember_48056530-a12a-475c-8423-a856afd020a6_terseLabel_en-US" xlink:label="lab_cerc_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Options</link:label>
    <link:label id="lab_cerc_ServiceBasedOptionsMember_label_en-US" xlink:label="lab_cerc_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Options [Member]</link:label>
    <link:label id="lab_cerc_ServiceBasedOptionsMember_documentation_en-US" xlink:label="lab_cerc_ServiceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ServiceBasedOptionsMember" xlink:to="lab_cerc_ServiceBasedOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_a6a9be1b-b0fc-472c-b7fe-81f77a9f7592_terseLabel_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants (in shares)</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Options And Warrants Exercised</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Options And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_e993c87c-9fed-40c7-9e79-a08f956b891e_negatedTerseLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in value of Guarantee</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_6db485f7-bd8b-47e9-8369-e9f73ca96f84_verboseLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in value of Guarantee</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_label_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_documentation_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:to="lab_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_9d625866-2de5-4bd4-bdd3-a4beafccc220_terseLabel_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_label_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_documentation_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the increase in the number of shares reserved for issuance under the incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:to="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5ae5663a-c9e6-42a0-ae28-1a40ab58f76d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_28154088-8d39-4f84-9950-213a893f0350_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember_3a7f29c1-9833-48d8-9850-8eed30af8d42_terseLabel_en-US" xlink:label="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Based Options</link:label>
    <link:label id="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember_label_en-US" xlink:label="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options With Market Based Vesting Conditions [Member]</link:label>
    <link:label id="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember_documentation_en-US" xlink:label="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options With Market Based Vesting Conditions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember" xlink:href="cerc-20210331.xsd#cerc_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember" xlink:to="lab_cerc_StockOptionsWithMarketBasedVestingConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dbe7ede0-e334-4cd7-ad88-359471e0940e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e2c975ca-d9ed-40ec-bc96-ed86f620c91c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_14bf18e6-f097-4a93-aad3-26315a54cd4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_35a69cfb-506d-4eba-a723-fbadca4fa286_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_63cb7ed6-4855-4858-8568-3a60db3947e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_PotentialFutureRegulatoryMilestone_3f8a615f-93bb-4921-a56d-ba75632b2f5f_terseLabel_en-US" xlink:label="lab_cerc_PotentialFutureRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future regulatory milestone</link:label>
    <link:label id="lab_cerc_PotentialFutureRegulatoryMilestone_label_en-US" xlink:label="lab_cerc_PotentialFutureRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Regulatory Milestone</link:label>
    <link:label id="lab_cerc_PotentialFutureRegulatoryMilestone_documentation_en-US" xlink:label="lab_cerc_PotentialFutureRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PotentialFutureRegulatoryMilestone" xlink:href="cerc-20210331.xsd#cerc_PotentialFutureRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_PotentialFutureRegulatoryMilestone" xlink:to="lab_cerc_PotentialFutureRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_96c9078a-cf0f-4683-a860-370b5c72be97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_45bae3e5-5553-4ee0-82f6-e32a102e39d0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NantahalaMember_8350e556-3538-4d01-b190-73f22e89cea1_terseLabel_en-US" xlink:label="lab_cerc_NantahalaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala</link:label>
    <link:label id="lab_cerc_NantahalaMember_label_en-US" xlink:label="lab_cerc_NantahalaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala [Member]</link:label>
    <link:label id="lab_cerc_NantahalaMember_documentation_en-US" xlink:label="lab_cerc_NantahalaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nantahala</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaMember" xlink:href="cerc-20210331.xsd#cerc_NantahalaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NantahalaMember" xlink:to="lab_cerc_NantahalaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_bb840781-45e9-4322-902e-335a36a2f41b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_8f555e49-c6e3-46f5-90fe-f532a4c1e85e_terseLabel_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual share reserve increase</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_label_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_documentation_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percent, applied to total number of outstanding shares of common stock on the last trading day in December of the prior year, by which the share reserve automatically increases on the first day of January of each calendar year beginning in 2016.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:to="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cc513b0c-3138-4227-a593-ed8060010ab8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_bc3cd1ac-dc2a-457d-9232-971715bdd658_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b41ec20d-bc68-4b6b-ac97-0180e03915ce_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member_d9a48384-3f7b-41aa-91db-0bcc8bfdbc9a_terseLabel_en-US" xlink:label="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva</link:label>
    <link:label id="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member_label_en-US" xlink:label="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceutical Industries Ltd. [Member]</link:label>
    <link:label id="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member_documentation_en-US" xlink:label="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceutical Industries Ltd. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member" xlink:href="cerc-20210331.xsd#cerc_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member" xlink:to="lab_cerc_TevaPharmaceuticalIndustriesLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a8de045b-8184-48bf-a71d-18e57d99526b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b45839e2-6d5e-4f31-b613-4012c296ceaa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_97ef5b4f-1850-4787-a49b-52fe572e44f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_564180cd-40b5-450d-bec4-eab5f4351a1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1fce3107-f81a-44b3-af6d-dc9c0178349e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_f5cdb098-d0e5-434f-a47b-5963ecbef7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ff5c1423-5f92-474a-a4e2-44a6f62067e7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f741c446-26af-43b3-a107-2cdc05c7cd55_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementInstallmentPayment_327d3e26-6616-4ac3-8846-94d238b66a32_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment payment</link:label>
    <link:label id="lab_cerc_LicenseAgreementInstallmentPayment_label_en-US" xlink:label="lab_cerc_LicenseAgreementInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Installment Payment</link:label>
    <link:label id="lab_cerc_LicenseAgreementInstallmentPayment_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementInstallmentPayment" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementInstallmentPayment" xlink:to="lab_cerc_LicenseAgreementInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b7bf10e0-2d68-4a77-9349-0b330ccb0989_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_6541c7ed-4dc1-480e-9d3d-d016f2d4e6ef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_37fb7362-e44b-4a28-999d-617a3c3e1119_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_533fe4e9-d4fb-43e8-af3f-cc500a01ac82_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_936a69eb-fb07-4f2a-aff5-9bdab1498544_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current portion</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_73bdb75a-545e-4eec-a823-980bac4a46d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7f8db421-6e96-40c5-a644-a826fcfee9c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_785d483b-ab44-45f5-aaa4-0a44ef38ecf1_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_label_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments</link:label>
    <link:label id="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" xlink:to="lab_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_916e4ccd-acf6-4033-8944-5d16a523dfcd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_34256ff6-6427-4433-9d04-49cc034d6a6a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c701297f-0a0c-4f7d-94b9-c595f8c7c3c3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6ba26f07-adc2-458f-ad00-effc221d1db0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_f625e368-4eb0-480d-8229-2727c0e7d515_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ddab2361-d823-4be0-b4e8-6cabf5c77e4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1516c366-4999-415f-95d9-1bd553e85b44_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aytu Divestiture</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_3fe248c3-7368-4618-b54e-08159defeff5_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value assigned to intangible asset at purchase</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2ecd428e-6b4c-4895-9722-1f25f4a5c453_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39d30507-814f-4aa0-9f39-885784eb2557_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4e4a4a90-6623-4930-b470-9de3f7bf8d8c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_68879c57-dccd-4427-8623-b98959abf008_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_label_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Payment Number One</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Payment Number One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestonePaymentNumberOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" xlink:to="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9be23cbb-2401-4f0d-b494-367c42f21761_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5db8ed72-3044-401f-bb72-9b92a9052195_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share of common stock, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2f358854-11b1-4872-bfab-13a30530b1e4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_86d6eb2c-34ea-4dec-9ff5-2fa98aa2b007_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_6bdcef1e-b2a5-405c-ade4-c360885b9e18_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_a1a03ff0-59aa-4d5e-9b35-9b77ac78e490_verboseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e12f675c-d9dc-4056-8731-560180d0b30f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_3384c06b-5e49-4fd3-9524-3c931d331767_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Liabilities of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_85f7ec13-de09-4cc2-b47f-34ae0aa3c8db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4657db36-0d74-4c2e-ac64-096c7f8e0f82_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrant, component of additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_PaymentsForAssetAcquisitions_2aa0ec8f-aa97-4447-a59e-411478369939_negatedTerseLabel_en-US" xlink:label="lab_cerc_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in merger with Aevi</link:label>
    <link:label id="lab_cerc_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_cerc_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:label id="lab_cerc_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_cerc_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PaymentsForAssetAcquisitions" xlink:href="cerc-20210331.xsd#cerc_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_PaymentsForAssetAcquisitions" xlink:to="lab_cerc_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_842e198b-1d2c-4ff3-9d03-920e5de1f298_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8aa3e47b-6da8-42d1-b210-39718889b258_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_87821f9e-c8e8-4d0f-9038-6f26973e8741_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_c4d26d88-6b64-4488-8e8c-738ec785b8da_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Award, Number of Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9ed6e6fc-4af0-4433-aaea-b878ed49a6c2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a7ae2255-9edd-4d08-b2fb-b7229290cb54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;$0.001 par value; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020; 89,104,816 and 75,004,127 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ccfed6ce-c54e-4182-9a27-b8b4dc66d682_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fb03c898-3427-4035-b499-7a7ff9de3fd6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MonthlyOperationPaymentsAdditionalTerm_d7a87437-a0d0-467e-84e6-dea1baaa3bf9_terseLabel_en-US" xlink:label="lab_cerc_MonthlyOperationPaymentsAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional duration of monthly commercial operation payments</link:label>
    <link:label id="lab_cerc_MonthlyOperationPaymentsAdditionalTerm_label_en-US" xlink:label="lab_cerc_MonthlyOperationPaymentsAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Operation Payments, Additional Term</link:label>
    <link:label id="lab_cerc_MonthlyOperationPaymentsAdditionalTerm_documentation_en-US" xlink:label="lab_cerc_MonthlyOperationPaymentsAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Operation Payments, Additional Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MonthlyOperationPaymentsAdditionalTerm" xlink:href="cerc-20210331.xsd#cerc_MonthlyOperationPaymentsAdditionalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MonthlyOperationPaymentsAdditionalTerm" xlink:to="lab_cerc_MonthlyOperationPaymentsAdditionalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d08f8c3d-2355-4707-a19e-5092a34d3697_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a3ab3d0c-7a02-42ae-a64c-0264cb156cf0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CERC002KKCLicenseAgreementMember_d1c99b61-6069-439a-a812-13475c4971b6_terseLabel_en-US" xlink:label="lab_cerc_CERC002KKCLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-002 KKC License Agreement</link:label>
    <link:label id="lab_cerc_CERC002KKCLicenseAgreementMember_label_en-US" xlink:label="lab_cerc_CERC002KKCLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-002 KKC License Agreement [Member]</link:label>
    <link:label id="lab_cerc_CERC002KKCLicenseAgreementMember_documentation_en-US" xlink:label="lab_cerc_CERC002KKCLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-002 KKC License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC002KKCLicenseAgreementMember" xlink:href="cerc-20210331.xsd#cerc_CERC002KKCLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CERC002KKCLicenseAgreementMember" xlink:to="lab_cerc_CERC002KKCLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DebtInstrumentContingentConsiderationPaid_715cc564-4654-4d20-ab80-9d624957a791_terseLabel_en-US" xlink:label="lab_cerc_DebtInstrumentContingentConsiderationPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid</link:label>
    <link:label id="lab_cerc_DebtInstrumentContingentConsiderationPaid_label_en-US" xlink:label="lab_cerc_DebtInstrumentContingentConsiderationPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Contingent Consideration Paid</link:label>
    <link:label id="lab_cerc_DebtInstrumentContingentConsiderationPaid_documentation_en-US" xlink:label="lab_cerc_DebtInstrumentContingentConsiderationPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Contingent Consideration Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentContingentConsiderationPaid" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentContingentConsiderationPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DebtInstrumentContingentConsiderationPaid" xlink:to="lab_cerc_DebtInstrumentContingentConsiderationPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_70aab292-a744-417c-ae85-02238950af6d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MillipredMember_908798e6-f402-4948-90ee-1c39fa43719d_terseLabel_en-US" xlink:label="lab_cerc_MillipredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millipred</link:label>
    <link:label id="lab_cerc_MillipredMember_label_en-US" xlink:label="lab_cerc_MillipredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millipred [Member]</link:label>
    <link:label id="lab_cerc_MillipredMember_documentation_en-US" xlink:label="lab_cerc_MillipredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Millipred [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MillipredMember" xlink:href="cerc-20210331.xsd#cerc_MillipredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MillipredMember" xlink:to="lab_cerc_MillipredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_fb4335f2-fa40-4f99-b4ef-b4c24ea43b68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e2a36cfa-a53a-46bf-a822-542ed467db3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6530cf7b-c19f-43ce-be2d-60015ed55f0c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_aba61348-9d09-4e09-b376-ec9cc40d04fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_82a02edc-7003-4051-b546-8afe82abc2be_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_af9ab49d-8f61-4fb4-bfcf-21bbdfde25f5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8d4a0699-12f9-4d7e-8620-c4a15565d7e7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2789a2a9-b4c9-4de4-9a0d-76d5875991c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_17be9524-a06e-450e-b0ff-62d6592954ff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_324e359f-9ace-4da7-a251-e33f909e8d7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4e37f183-18ae-4a35-98f3-ea0b7ec20d3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_85d0e3b8-4bf8-4436-ad1f-ed7fe04a1b84_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2f893918-5faa-4a15-a085-c443e54c573e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f4843201-d6df-440d-84de-7696eca96d8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ff6c3eee-3e95-4bd7-9152-9d3cc9119b5e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_052daae5-3778-4378-bc1e-b272e5eb47ae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3af2dc0b-a615-4651-bf77-2ef5ca90ee65_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0e87d9b1-8654-4c1e-857f-c59506e742f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NumeratorAbstract_1500071c-7840-48eb-9165-1d4606aa6738_terseLabel_en-US" xlink:label="lab_cerc_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cerc_NumeratorAbstract_label_en-US" xlink:label="lab_cerc_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cerc_NumeratorAbstract_documentation_en-US" xlink:label="lab_cerc_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumeratorAbstract" xlink:href="cerc-20210331.xsd#cerc_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NumeratorAbstract" xlink:to="lab_cerc_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MajorCustomerNumberTwoMember_610aed85-6936-47d0-8b34-c159f7dcc29a_terseLabel_en-US" xlink:label="lab_cerc_MajorCustomerNumberTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Two</link:label>
    <link:label id="lab_cerc_MajorCustomerNumberTwoMember_label_en-US" xlink:label="lab_cerc_MajorCustomerNumberTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Two [Member]</link:label>
    <link:label id="lab_cerc_MajorCustomerNumberTwoMember_documentation_en-US" xlink:label="lab_cerc_MajorCustomerNumberTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Number Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberTwoMember" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MajorCustomerNumberTwoMember" xlink:to="lab_cerc_MajorCustomerNumberTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_24321bb0-4be5-45f3-ad68-2336b2f28a7d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9d6ca651-f76e-4b1b-ae4d-f2e02e46a235_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e845ec8e-6427-484e-bf93-6a173a8bfa64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_723fb657-99d5-43c5-8e74-27b0c8a643ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f58318b2-9865-4531-9f21-f0b332626821_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_8d10c11c-9d64-4d79-87a7-e4cf9c3c7462_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment two</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_label_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Payment Number Two</link:label>
    <link:label id="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Milestone Payment Number Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" xlink:to="lab_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c17468cd-dbcb-4132-b21f-8733d2e0a1c8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_c6b68065-9afc-423c-b2fc-637863d5c4f5_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_65fad402-b34b-48c0-a6ce-62ccfbf5acb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_186d62a1-4dab-4c82-901c-c2a77f22d892_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LesseeOperatingLeaseNumberOfContracts_b4ddc996-bafe-4d2b-ade7-5138e2d7d2cb_terseLabel_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contracts</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseNumberOfContracts_label_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Number Of Contracts</link:label>
    <link:label id="lab_cerc_LesseeOperatingLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_cerc_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseNumberOfContracts" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LesseeOperatingLeaseNumberOfContracts" xlink:to="lab_cerc_LesseeOperatingLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3b4454d8-0aa0-4081-ac71-53cca545d2a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum portion of earning an employee may contribute to the ESPP Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_eb6d7638-035e-4cbf-bd19-ce74e68281da_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NumberOfClassOfStockAuthorized_1b2fe87b-02e4-4bd9-9c64-feffd583214b_terseLabel_en-US" xlink:label="lab_cerc_NumberOfClassOfStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of classes of stock authorized to issue</link:label>
    <link:label id="lab_cerc_NumberOfClassOfStockAuthorized_label_en-US" xlink:label="lab_cerc_NumberOfClassOfStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Of Stock Authorized</link:label>
    <link:label id="lab_cerc_NumberOfClassOfStockAuthorized_documentation_en-US" xlink:label="lab_cerc_NumberOfClassOfStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of classes of stock permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfClassOfStockAuthorized" xlink:href="cerc-20210331.xsd#cerc_NumberOfClassOfStockAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NumberOfClassOfStockAuthorized" xlink:to="lab_cerc_NumberOfClassOfStockAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20f23ae-047d-4b2f-b788-e6d7d6cf4819_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_2f00c26f-5cbe-47e6-bb1a-b05e54cf0ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_f038945e-223c-4b30-98e9-f5dc00dd0359_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_952660fb-92c1-47c2-a4be-bdcef08dae40_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_62ec3918-a97e-431e-b564-7cb4ae36469e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_282744d6-74c7-40a9-8f27-a9c0ad5b325c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_1985b45b-c415-46ba-8375-3b2c40d0688e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development, including transaction costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_c8755852-3dd4-4775-99fc-707b12c501ae_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_9b53a842-1465-48c7-8565-fa1bc2016bd6_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_6174d082-89db-49f6-b4cc-1eb1c48a9b38_terseLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_label_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_documentation_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:to="lab_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MilestoneAxis_85340086-d2a0-400d-80ae-df4ba99d4577_terseLabel_en-US" xlink:label="lab_cerc_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_cerc_MilestoneAxis_label_en-US" xlink:label="lab_cerc_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_cerc_MilestoneAxis_documentation_en-US" xlink:label="lab_cerc_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneAxis" xlink:href="cerc-20210331.xsd#cerc_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MilestoneAxis" xlink:to="lab_cerc_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3832b4f7-1d2d-4280-aabe-5ddc7b0812f3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_fe728a4c-1186-4627-ac25-2899f27f125b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_bafde1bb-1d7f-4be6-8388-f98cc1bbd11d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_607e8d7e-2f3f-4471-8a4e-181e7363af68_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_84a46805-9288-4df7-a5a2-0ba66c0b25af_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of option (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ce08cf4e-d7f7-4e94-a8cf-3af7708220d8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_fba39d79-037e-426f-b5da-75e5e5610600_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_df421231-cd9c-4c9a-b2de-47ec39a78d86_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_87d552cd-015d-47ad-9589-4816adee8c82_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_ee2af26b-bebb-4f6a-ba3e-f1f2ac512f4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07078d37-32c2-4909-b83d-06a3343b6ece_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0d11dc86-f973-4207-a453-44d5987a7a6b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 1, 2021 through December 31, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_13ccd387-11ec-4994-bd91-f3d64dda4079_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementMilestonePaymentRecognized_c36cbc20-2190-4bcd-8245-14de446dbd1b_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementMilestonePaymentRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment recognized</link:label>
    <link:label id="lab_cerc_LicenseAgreementMilestonePaymentRecognized_label_en-US" xlink:label="lab_cerc_LicenseAgreementMilestonePaymentRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Recognized</link:label>
    <link:label id="lab_cerc_LicenseAgreementMilestonePaymentRecognized_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementMilestonePaymentRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payment Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementMilestonePaymentRecognized" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementMilestonePaymentRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementMilestonePaymentRecognized" xlink:to="lab_cerc_LicenseAgreementMilestonePaymentRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3513342b-4730-49d5-867a-3180f1b55bb2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionContingentConsiderationLiability_43907ab1-935a-461a-a993-001af85599df_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_cerc_AssetAcquisitionContingentConsiderationLiability_label_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:label id="lab_cerc_AssetAcquisitionContingentConsiderationLiability_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentConsiderationLiability" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionContingentConsiderationLiability" xlink:to="lab_cerc_AssetAcquisitionContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0cd9fb7e-457a-439f-8200-3d4a973f5fdd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6a228261-5f2a-440c-b1d6-b5d7c4ef293c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6495e967-c6d7-4dfd-af96-925273c69f86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_275233e4-854e-41dd-bcc0-41b25bb835e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share of common stock, basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_UnderwrittenPublicOfferingMember_81b843fd-326e-4002-98ef-23746049dbc0_terseLabel_en-US" xlink:label="lab_cerc_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_cerc_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_cerc_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_cerc_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_cerc_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwrittenPublicOfferingMember" xlink:href="cerc-20210331.xsd#cerc_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_UnderwrittenPublicOfferingMember" xlink:to="lab_cerc_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3ae4419c-9497-4d98-bb27-22d059609452_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AccruedGeneralAndAdministrativeExpenses_25dd5ed0-d4c2-4813-b1d6-b0d5d61deb79_terseLabel_en-US" xlink:label="lab_cerc_AccruedGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_cerc_AccruedGeneralAndAdministrativeExpenses_label_en-US" xlink:label="lab_cerc_AccruedGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General And Administrative Expenses</link:label>
    <link:label id="lab_cerc_AccruedGeneralAndAdministrativeExpenses_documentation_en-US" xlink:label="lab_cerc_AccruedGeneralAndAdministrativeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for general and administrative expenses..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedGeneralAndAdministrativeExpenses" xlink:href="cerc-20210331.xsd#cerc_AccruedGeneralAndAdministrativeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AccruedGeneralAndAdministrativeExpenses" xlink:to="lab_cerc_AccruedGeneralAndAdministrativeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MilestoneTwoMember_45516bca-4e2f-4bee-865b-7360a5de8527_terseLabel_en-US" xlink:label="lab_cerc_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_cerc_MilestoneTwoMember_label_en-US" xlink:label="lab_cerc_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_cerc_MilestoneTwoMember_documentation_en-US" xlink:label="lab_cerc_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneTwoMember" xlink:href="cerc-20210331.xsd#cerc_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MilestoneTwoMember" xlink:to="lab_cerc_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_48be3926-2f62-4daa-beff-ef3604607d4c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_07a8f768-14be-46ad-a9ee-d14798355e0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_3448389e-bffe-42f9-84b5-f820c1cc1350_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transfers of assets from level 1 to level 2</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1ca1eaeb-da68-4d44-8492-52f0f1c13e85_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available under warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92d6bd2a-91ac-4db9-a059-1dc82549f98c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0c9b1bbd-edfc-4381-bf8c-73359d767d5f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ThirdAmended2016PlanMember_8330d147-a1d8-4a5f-afb1-baa46b256a87_terseLabel_en-US" xlink:label="lab_cerc_ThirdAmended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Third Amended Plan</link:label>
    <link:label id="lab_cerc_ThirdAmended2016PlanMember_label_en-US" xlink:label="lab_cerc_ThirdAmended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amended 2016 Plan [Member]</link:label>
    <link:label id="lab_cerc_ThirdAmended2016PlanMember_documentation_en-US" xlink:label="lab_cerc_ThirdAmended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amended 2016 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ThirdAmended2016PlanMember" xlink:href="cerc-20210331.xsd#cerc_ThirdAmended2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ThirdAmended2016PlanMember" xlink:to="lab_cerc_ThirdAmended2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_ac7dfd83-7d6f-47f6-b98b-724fa167e6f5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_ed4e328a-3dc8-46b9-9848-3af77bc875be_terseLabel_en-US" xlink:label="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration May 2022</link:label>
    <link:label id="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_label_en-US" xlink:label="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date Of May 2022 [Member]</link:label>
    <link:label id="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_documentation_en-US" xlink:label="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date Of May 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsExpirationDateOfMay2022Member" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsExpirationDateOfMay2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CommonStockWarrantsExpirationDateOfMay2022Member" xlink:to="lab_cerc_CommonStockWarrantsExpirationDateOfMay2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_8cf508c4-56fd-44c1-8b7f-65421717da58_verboseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, shares issued</link:label>
    <link:label id="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interests Issued And Issuable</link:label>
    <link:label id="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interests Issued And Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_MilestoneOneMember_aa08e9b1-bd7a-4fe6-8e45-9e47e23bc1d2_terseLabel_en-US" xlink:label="lab_cerc_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_cerc_MilestoneOneMember_label_en-US" xlink:label="lab_cerc_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_cerc_MilestoneOneMember_documentation_en-US" xlink:label="lab_cerc_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneOneMember" xlink:href="cerc-20210331.xsd#cerc_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_MilestoneOneMember" xlink:to="lab_cerc_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_3b44469f-92cc-4303-a45f-88878c8ad757_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_f81f0b9a-3db8-45a5-b760-13fce22bc29c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4a1148de-0b15-4bb5-acaa-c1fa817fe659_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_825b3b5d-e0ea-4cf5-aeca-c51968bce36b_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_label_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Value Right, Number Of Milestones</link:label>
    <link:label id="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Value Right, Number Of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightNumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:to="lab_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f7f2dbf5-4dec-43d3-be2d-21be1bbbc5cd_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_128aa65d-17a6-4c7c-a9d8-2d5b18a2b8fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1730ce88-01ac-4257-98d7-40ae07ba107e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_e0c1b4d7-078d-4839-83da-17b3b8ccfe66_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9b653a61-1b63-4378-9614-f37ca6376fdb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_65fd22bd-860f-4d6e-a53c-8b88dd1f8fea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1caad457-bb69-47b7-9ada-03b7110f37f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseObligationNoncurrent_fb8debce-7713-4bf5-bc3e-8e044e8d9803_terseLabel_en-US" xlink:label="lab_cerc_LicenseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations</link:label>
    <link:label id="lab_cerc_LicenseObligationNoncurrent_label_en-US" xlink:label="lab_cerc_LicenseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligation, Noncurrent</link:label>
    <link:label id="lab_cerc_LicenseObligationNoncurrent_documentation_en-US" xlink:label="lab_cerc_LicenseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseObligationNoncurrent" xlink:href="cerc-20210331.xsd#cerc_LicenseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseObligationNoncurrent" xlink:to="lab_cerc_LicenseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3f7466ba-cef9-4af7-aed0-f33926f0ffa8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_e682628e-014d-4566-bff8-7a01b3c9169d_terseLabel_en-US" xlink:label="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Asset Acquisitions [Abstract] [Abstract]</link:label>
    <link:label id="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_label_en-US" xlink:label="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Asset Acquisitions [Abstract]</link:label>
    <link:label id="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_documentation_en-US" xlink:label="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Asset Acquisitions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" xlink:href="cerc-20210331.xsd#cerc_BusinessCombinationsAndAssetAcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" xlink:to="lab_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_TRISPharmaMember_377f7bcc-1191-47af-9ace-e5472452fd25_terseLabel_en-US" xlink:label="lab_cerc_TRISPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRIS Pharma</link:label>
    <link:label id="lab_cerc_TRISPharmaMember_label_en-US" xlink:label="lab_cerc_TRISPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRIS Pharma [Member]</link:label>
    <link:label id="lab_cerc_TRISPharmaMember_documentation_en-US" xlink:label="lab_cerc_TRISPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRIS Pharma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TRISPharmaMember" xlink:href="cerc-20210331.xsd#cerc_TRISPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_TRISPharmaMember" xlink:to="lab_cerc_TRISPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e13d5775-f3ea-408a-bbfc-82dbc2e75f32_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock in underwritten public offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_df34f859-b6f2-47f6-8117-794e96b6c3c6_terseLabel_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_label_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Sales Return Reserve, Current</link:label>
    <link:label id="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_documentation_en-US" xlink:label="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Sales Return Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" xlink:to="lab_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ProceedsFromOptionOrWarrantExercises_56b069f4-2c59-4e08-a9ad-de39d6e10bfa_terseLabel_en-US" xlink:label="lab_cerc_ProceedsFromOptionOrWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and warrants</link:label>
    <link:label id="lab_cerc_ProceedsFromOptionOrWarrantExercises_label_en-US" xlink:label="lab_cerc_ProceedsFromOptionOrWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Option Or Warrant Exercises</link:label>
    <link:label id="lab_cerc_ProceedsFromOptionOrWarrantExercises_documentation_en-US" xlink:label="lab_cerc_ProceedsFromOptionOrWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Option Or Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromOptionOrWarrantExercises" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromOptionOrWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ProceedsFromOptionOrWarrantExercises" xlink:to="lab_cerc_ProceedsFromOptionOrWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_e08c8a6d-c8eb-42c4-a88d-747c9a8e8959_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_7326997f-3d61-4fae-82cd-3fa163ed65f7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_baa5837b-0a0b-4395-82b5-a3bfce496a05_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8f3279ed-ed6e-4934-b2b4-277c349e472a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9f4ba854-6e73-4e3a-985f-8ea8e53e53f6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13c15190-6be3-42b8-a372-bc3d21dfbe52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercises in period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_447f5c66-5f16-4a43-9ec9-d64b10490d7d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d49e6d9e-7388-4890-b391-e01a9dd4cfa5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net from continuing operations</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssetAcquisitionAxis_c2b52745-a29b-469f-84f7-3b29eeed283b_terseLabel_en-US" xlink:label="lab_cerc_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_cerc_AssetAcquisitionAxis_label_en-US" xlink:label="lab_cerc_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_cerc_AssetAcquisitionAxis_documentation_en-US" xlink:label="lab_cerc_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssetAcquisitionAxis" xlink:to="lab_cerc_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d073d2c5-8f9f-44c9-8b8f-015fe205c785_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fcc44c47-8989-4fe8-9b8a-847c285ab32d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_NumberOfPreclinicalTherapies_b2b9e30e-f4b3-46a6-8e0d-7488b005eea4_terseLabel_en-US" xlink:label="lab_cerc_NumberOfPreclinicalTherapies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of preclinical therapies</link:label>
    <link:label id="lab_cerc_NumberOfPreclinicalTherapies_label_en-US" xlink:label="lab_cerc_NumberOfPreclinicalTherapies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preclinical Therapies</link:label>
    <link:label id="lab_cerc_NumberOfPreclinicalTherapies_documentation_en-US" xlink:label="lab_cerc_NumberOfPreclinicalTherapies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preclinical Therapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfPreclinicalTherapies" xlink:href="cerc-20210331.xsd#cerc_NumberOfPreclinicalTherapies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_NumberOfPreclinicalTherapies" xlink:to="lab_cerc_NumberOfPreclinicalTherapies" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_9edfb351-192b-4767-8ad2-4e36321ecd3f_terseLabel_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares pursuant to common stock private placement, net of offering costs</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_label_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues, Private Placement</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_documentation_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues, Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:to="lab_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_30159ecd-eb33-4aae-aec4-5781d41ba130_terseLabel_en-US" xlink:label="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares pursuant to registered direct offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_label_en-US" xlink:label="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Shares, Share, Pursuant To Registered Direct Offering</link:label>
    <link:label id="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_documentation_en-US" xlink:label="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Shares, Share, Pursuant To Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" xlink:href="cerc-20210331.xsd#cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" xlink:to="lab_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_f46ff9a2-f86d-4830-9dd2-01909ef57e65_terseLabel_en-US" xlink:label="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase</link:label>
    <link:label id="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_label_en-US" xlink:label="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Annual Increase, Percent</link:label>
    <link:label id="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_documentation_en-US" xlink:label="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Annual Increase, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:href="cerc-20210331.xsd#cerc_OperatingLeasesRentExpenseAnnualIncreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:to="lab_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_56c9ee1d-84c7-431d-b291-738bb022a537_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acb41ddf-2e4d-42e7-8798-29798c8799d1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_cf4bd737-d5c6-421c-bd3b-9459ad1af88f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in Aevi Merger</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c0056e1b-ef42-478d-92bc-9fee132e4ccd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_acecde35-6858-44df-bee5-8dda7e4688a1_terseLabel_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Options And Warrants Exercised</link:label>
    <link:label id="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Options And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="lab_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_03fac731-a950-46a3-8719-3fceeb09bb86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_afecfa1b-c896-49f1-a017-506d1bf8f324_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AssembledWorkforceMember_677caff6-c80c-4a71-9a83-dd3dd75b69d5_terseLabel_en-US" xlink:label="lab_cerc_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce</link:label>
    <link:label id="lab_cerc_AssembledWorkforceMember_label_en-US" xlink:label="lab_cerc_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:label id="lab_cerc_AssembledWorkforceMember_documentation_en-US" xlink:label="lab_cerc_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssembledWorkforceMember" xlink:href="cerc-20210331.xsd#cerc_AssembledWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AssembledWorkforceMember" xlink:to="lab_cerc_AssembledWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_80bc9114-3df3-4c53-b7d3-753af08f81e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_0bde4b72-6201-4ad8-917b-873b0450dfe4_terseLabel_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation on service-based vesting conditions</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_label_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested, Granted in Period, Gross</link:label>
    <link:label id="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_documentation_en-US" xlink:label="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested, Granted in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" xlink:to="lab_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5d1041d0-366d-4ff3-a21e-48e300f4f6b4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CERC801CERC802AndCERC803Member_4bed83d5-d717-4a7f-abd0-4b25627e738b_terseLabel_en-US" xlink:label="lab_cerc_CERC801CERC802AndCERC803Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-801, CERC-802, and CERC-803</link:label>
    <link:label id="lab_cerc_CERC801CERC802AndCERC803Member_label_en-US" xlink:label="lab_cerc_CERC801CERC802AndCERC803Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-801, CERC-802, And CERC-803 [Member]</link:label>
    <link:label id="lab_cerc_CERC801CERC802AndCERC803Member_documentation_en-US" xlink:label="lab_cerc_CERC801CERC802AndCERC803Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-801, CERC-802, And CERC-803 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC801CERC802AndCERC803Member" xlink:href="cerc-20210331.xsd#cerc_CERC801CERC802AndCERC803Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CERC801CERC802AndCERC803Member" xlink:to="lab_cerc_CERC801CERC802AndCERC803Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_94a4c8b7-8dba-4a13-8af2-611d70ab7b00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_11491575-1f72-4122-bf36-3c00c9df00c8_terseLabel_en-US" xlink:label="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date Of June 2024</link:label>
    <link:label id="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_label_en-US" xlink:label="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date Of June 2024 [Member]</link:label>
    <link:label id="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_documentation_en-US" xlink:label="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants Expiration Date Of June 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsExpirationDateOfJune2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:to="lab_cerc_CommonStockWarrantsExpirationDateOfJune2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e713c250-9d2f-4239-91d3-1bf01e2672ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CERC913Member_f1fa1407-6557-4d1c-86fb-1b1b2f160d1b_terseLabel_en-US" xlink:label="lab_cerc_CERC913Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-913</link:label>
    <link:label id="lab_cerc_CERC913Member_label_en-US" xlink:label="lab_cerc_CERC913Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-913 [Member]</link:label>
    <link:label id="lab_cerc_CERC913Member_documentation_en-US" xlink:label="lab_cerc_CERC913Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CERC-913 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC913Member" xlink:href="cerc-20210331.xsd#cerc_CERC913Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CERC913Member" xlink:to="lab_cerc_CERC913Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_83a7a713-0bef-487c-8004-0742f70b2491_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f02a170f-8c5e-4d86-87d9-b147b5b6f7d0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_624dbc1b-b441-4745-84fc-af120f18ec59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fc58bc2a-6606-423d-b593-d1b956ef8965_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2596dfb-cb9f-4cd2-ae11-be04af232a0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e9ecccd-0540-4d23-8c0d-d2d936d75219_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c7f7817-b203-4122-a1d3-3c4253e32642_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_KarbinalAgreementMember_328dc7ff-d94b-4338-8c2f-923e00f83061_terseLabel_en-US" xlink:label="lab_cerc_KarbinalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karbinal Agreement</link:label>
    <link:label id="lab_cerc_KarbinalAgreementMember_label_en-US" xlink:label="lab_cerc_KarbinalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karbinal Agreement [Member]</link:label>
    <link:label id="lab_cerc_KarbinalAgreementMember_documentation_en-US" xlink:label="lab_cerc_KarbinalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karbinal Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_KarbinalAgreementMember" xlink:href="cerc-20210331.xsd#cerc_KarbinalAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_KarbinalAgreementMember" xlink:to="lab_cerc_KarbinalAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9929e3f0-960e-45d3-ae1c-484f8e306a63_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_40752d0b-cb76-4261-b06a-06c9d286361d_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share of common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0f01ccdc-200f-4350-8614-4f9cddd804d8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_044c6dc5-ab16-4449-9de4-29221dcccc94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transfers of assets from level 2 to level 1</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_88e63709-513e-456f-9559-522b5e244e37_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d9030267-2a10-4214-abac-b70db631bb6b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_eca52427-fc18-4f20-9972-f359bbd6c286_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_82c2637a-db67-4da8-98aa-448d9314a9a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_932d99a5-9cb0-4a3f-ae14-a34da569eb49_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_33f7aede-1117-4895-8893-73da364bb4ee_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_41915341-3950-40fe-83dc-43ffde531e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:to="lab_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_0de05d74-6c28-46c4-961d-1319c958467e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_30c0cc05-80f6-4be6-8a22-dd9c0476bfcc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_11f9c56f-aaa7-4606-a44a-ef4bce9a727d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7948ef63-8700-420f-b930-b3239d3c8690_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_74649181-1fda-44f5-99f6-1c4b1584d880_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_AeviGenomicMedicineIncMember_ca8a9768-6f66-4ce8-bc8f-4918fab802cc_terseLabel_en-US" xlink:label="lab_cerc_AeviGenomicMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aevi</link:label>
    <link:label id="lab_cerc_AeviGenomicMedicineIncMember_label_en-US" xlink:label="lab_cerc_AeviGenomicMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aevi Genomic Medicine Inc [Member]</link:label>
    <link:label id="lab_cerc_AeviGenomicMedicineIncMember_documentation_en-US" xlink:label="lab_cerc_AeviGenomicMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aevi Genomic Medicine Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_AeviGenomicMedicineIncMember" xlink:to="lab_cerc_AeviGenomicMedicineIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5cc56e73-cedd-48a4-b6f1-c80bf026d887_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d7a50fe4-eafa-4472-aec3-d423ce8564ca_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3cbafa8b-b24e-4354-95f7-96d5df00adde_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementUpfrontFee_af57ef21-3a8b-4c89-88ea-94f9a32d1b0b_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement fees</link:label>
    <link:label id="lab_cerc_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_cerc_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Fee</link:label>
    <link:label id="lab_cerc_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementUpfrontFee" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementUpfrontFee" xlink:to="lab_cerc_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_809a6e02-7e2f-45ba-9792-1cf17996890e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a4b4240f-ee35-4c28-81cb-5c695b755e72_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ac0d2a7-15c4-4416-a630-70a16bead161_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bc63ec51-3d33-49d7-852c-110968beb921_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_79fc58d8-64f2-4bd4-a223-a17e21805491_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_664220fc-c488-4236-80dd-c3d0b8ca6d4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_974cb539-81d4-4b1b-bd91-e2f5ea914918_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CapitalStockSharesAuthorized_854431fc-2eef-4a70-a73f-a69614cbd509_terseLabel_en-US" xlink:label="lab_cerc_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of capital stock authorized to issue (in shares)</link:label>
    <link:label id="lab_cerc_CapitalStockSharesAuthorized_label_en-US" xlink:label="lab_cerc_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock Shares Authorized</link:label>
    <link:label id="lab_cerc_CapitalStockSharesAuthorized_documentation_en-US" xlink:label="lab_cerc_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum number of capital stock, including common stock and preferred stock, solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CapitalStockSharesAuthorized" xlink:href="cerc-20210331.xsd#cerc_CapitalStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CapitalStockSharesAuthorized" xlink:to="lab_cerc_CapitalStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d14287ca-d827-45db-9880-e9cc22d40d8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_0f91ead9-d5ea-4348-8988-9b8d6ba5195d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_650b9172-3d59-4799-a410-a82b3d6a427d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_ab16a1d5-d445-491a-9985-d7367087384b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9967db4d-ae36-41d1-b3bd-5eb18acb41d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_19a3d2b4-18bc-40cc-a6d8-0c256242e9d8_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_55d22a6f-00cd-45e1-8c39-d392b4522ed7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_CommonStockWarrantsNoExpirationMember_74f465d9-3b74-4f16-abdb-a20f9248a573_terseLabel_en-US" xlink:label="lab_cerc_CommonStockWarrantsNoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration</link:label>
    <link:label id="lab_cerc_CommonStockWarrantsNoExpirationMember_label_en-US" xlink:label="lab_cerc_CommonStockWarrantsNoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration [Member]</link:label>
    <link:label id="lab_cerc_CommonStockWarrantsNoExpirationMember_documentation_en-US" xlink:label="lab_cerc_CommonStockWarrantsNoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants No Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsNoExpirationMember" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsNoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_CommonStockWarrantsNoExpirationMember" xlink:to="lab_cerc_CommonStockWarrantsNoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_38a5ae85-302e-400d-ab57-c20b052389f6_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_96d914d2-252e-4ac4-bfa4-47b4ba8967bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4cb95dc1-a39c-43e3-b8de-a349125060bb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cerc_LicenseAgreementSemiAnnualLicensePayment_45831e2a-7df0-42aa-b5ae-b6fb63a0f722_terseLabel_en-US" xlink:label="lab_cerc_LicenseAgreementSemiAnnualLicensePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Semi-annual license payment</link:label>
    <link:label id="lab_cerc_LicenseAgreementSemiAnnualLicensePayment_label_en-US" xlink:label="lab_cerc_LicenseAgreementSemiAnnualLicensePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Semi-Annual License Payment</link:label>
    <link:label id="lab_cerc_LicenseAgreementSemiAnnualLicensePayment_documentation_en-US" xlink:label="lab_cerc_LicenseAgreementSemiAnnualLicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Semi-Annual License Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementSemiAnnualLicensePayment" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementSemiAnnualLicensePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cerc_LicenseAgreementSemiAnnualLicensePayment" xlink:to="lab_cerc_LicenseAgreementSemiAnnualLicensePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4968d62c-0a59-4119-95c8-2a73934e6343_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8f022bb5-48de-4918-a839-27d5d7badb54_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_beff9242-7a76-4d19-92c3-c3f97fe3c501_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6de154ea-6a2a-42f7-a37f-ad1d2e9b329f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_42e3bda0-3dbd-421f-8287-1410e5537263_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_040f4990-8c1a-4b00-9c98-f78853d869d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_420ecb67-bf99-4989-a8f7-06c34d652460_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cerc-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4f7a87f1-b6d6-4918-8a41-8e0f9da38f3e,g:12909dcc-0657-4b99-8650-be04def8faa3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cerecor.com/role/CoverPage" xlink:type="simple" xlink:href="cerc-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a6916f10-dd83-44c2-9a99-163f539cded2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_DocumentType_a6916f10-dd83-44c2-9a99-163f539cded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e4cb20ec-bcf2-4db0-89a9-c80e631ba55f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_DocumentQuarterlyReport_e4cb20ec-bcf2-4db0-89a9-c80e631ba55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6f7fb462-d8fe-40df-bf89-1382b00c9fbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_DocumentPeriodEndDate_6f7fb462-d8fe-40df-bf89-1382b00c9fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_87821e6e-59dc-4fda-ad56-4830435b7667" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_DocumentTransitionReport_87821e6e-59dc-4fda-ad56-4830435b7667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ac300aa7-844e-4aa7-abea-2bc48bf29487" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityFileNumber_ac300aa7-844e-4aa7-abea-2bc48bf29487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_10f1280e-e867-4a49-8bad-b590ebfd8a89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityRegistrantName_10f1280e-e867-4a49-8bad-b590ebfd8a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_aab839e6-aa40-462a-91af-4c4fbfc1529d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityIncorporationStateCountryCode_aab839e6-aa40-462a-91af-4c4fbfc1529d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f3144dae-d996-414e-8cd3-dc935cb37b16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityTaxIdentificationNumber_f3144dae-d996-414e-8cd3-dc935cb37b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_86057d8f-c631-4350-a37e-e14b910ed20a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityAddressAddressLine1_86057d8f-c631-4350-a37e-e14b910ed20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_697f9f23-4028-47df-ad6c-d56725881fc3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityAddressCityOrTown_697f9f23-4028-47df-ad6c-d56725881fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7d0e8c88-7e8a-4be1-aea9-9bfd36ec0ebd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityAddressStateOrProvince_7d0e8c88-7e8a-4be1-aea9-9bfd36ec0ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ff999966-07ff-4c0e-874b-7927ce37b0d3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityAddressPostalZipCode_ff999966-07ff-4c0e-874b-7927ce37b0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bb58c4ca-ee27-4c8e-ba49-ec2b341d281e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_CityAreaCode_bb58c4ca-ee27-4c8e-ba49-ec2b341d281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d66908a5-0b25-4a76-8ff7-763ec07c0671" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_LocalPhoneNumber_d66908a5-0b25-4a76-8ff7-763ec07c0671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0b2ed3da-fb8d-4597-b663-8124004c44da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_Security12bTitle_0b2ed3da-fb8d-4597-b663-8124004c44da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0cd408e2-70c1-4f94-bce3-dc92e059c10a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_TradingSymbol_0cd408e2-70c1-4f94-bce3-dc92e059c10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_39c70dc2-bac4-4e69-b8ea-c381e149ed78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityCurrentReportingStatus_39c70dc2-bac4-4e69-b8ea-c381e149ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a79bcec3-8c2c-4a22-8349-03732e351774" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityInteractiveDataCurrent_a79bcec3-8c2c-4a22-8349-03732e351774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6ae1d82a-15ff-43e0-9c90-b58ff47b5e38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityFilerCategory_6ae1d82a-15ff-43e0-9c90-b58ff47b5e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_39a23707-7dd7-4265-a16f-844674f64d20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntitySmallBusiness_39a23707-7dd7-4265-a16f-844674f64d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fe581943-a2ab-42da-85a8-15c395285d6c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityEmergingGrowthCompany_fe581943-a2ab-42da-85a8-15c395285d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3683d730-0680-4066-b507-cfde334d9150" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityShellCompany_3683d730-0680-4066-b507-cfde334d9150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3b4a5ebb-9585-458a-96a7-bd9d832e2528" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3b4a5ebb-9585-458a-96a7-bd9d832e2528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e5cea361-d977-4675-aa5f-1c70405931e0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_EntityCentralIndexKey_e5cea361-d977-4675-aa5f-1c70405931e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_91c39b5a-93af-4b41-af41-1a355e7f7f70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_CurrentFiscalYearEndDate_91c39b5a-93af-4b41-af41-1a355e7f7f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7c242944-c2ec-492c-bf31-554a6178aacb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_DocumentFiscalYearFocus_7c242944-c2ec-492c-bf31-554a6178aacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b719c54e-80de-4056-b6f9-184de9e96860" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b719c54e-80de-4056-b6f9-184de9e96860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c0e12b4-2e1f-4916-82ef-94b100f2d80b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ffe91b89-6d99-4a4f-8424-a35525010b32" xlink:to="loc_dei_AmendmentFlag_5c0e12b4-2e1f-4916-82ef-94b100f2d80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7d28b9a6-8353-4a2a-bf64-9fc1a8415de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7d28b9a6-8353-4a2a-bf64-9fc1a8415de4" xlink:to="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a67eeb9-e246-4b18-ad9d-25c003bc6f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a67eeb9-e246-4b18-ad9d-25c003bc6f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_69ea4cb5-1e1f-42e2-80dc-8050d134b521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_AccountsReceivableNet_69ea4cb5-1e1f-42e2-80dc-8050d134b521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_121dcc2a-4ea7-4ab1-b57e-468e19449cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_121dcc2a-4ea7-4ab1-b57e-468e19449cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bfeccca4-aec0-47db-8958-da7cbdf4b178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_InventoryNet_bfeccca4-aec0-47db-8958-da7cbdf4b178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12d93583-0cf9-42ef-ab5e-a9ac59916a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12d93583-0cf9-42ef-ab5e-a9ac59916a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_b4201689-fdf4-4e1c-adac-8235ccf503c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_b4201689-fdf4-4e1c-adac-8235ccf503c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d3df4dd-a278-4d4f-9db7-26b5f9b15738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_875f7bf6-e9be-4ce9-afcf-bcb7e4308668" xlink:to="loc_us-gaap_AssetsCurrent_5d3df4dd-a278-4d4f-9db7-26b5f9b15738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_49f33cff-b5aa-4caf-97d4-dad3a1958491" xlink:href="cerc-20210331.xsd#cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:to="loc_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_49f33cff-b5aa-4caf-97d4-dad3a1958491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_85a110db-161a-4674-ba72-ce3acdd22f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_85a110db-161a-4674-ba72-ce3acdd22f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c07f1cf5-4ad6-4f5d-949e-ec83eaed9156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:to="loc_us-gaap_Goodwill_c07f1cf5-4ad6-4f5d-949e-ec83eaed9156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f0cbea8a-9dec-4a21-9e96-969ace990d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f0cbea8a-9dec-4a21-9e96-969ace990d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_facbeca9-c0ef-4f24-ba8c-ea509f67b78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26c12376-222a-4128-b77a-bb658a068ad9" xlink:to="loc_us-gaap_Assets_facbeca9-c0ef-4f24-ba8c-ea509f67b78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7d28b9a6-8353-4a2a-bf64-9fc1a8415de4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1fa5f3b9-2b3b-48d5-8fb9-6f9bab45deae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1fa5f3b9-2b3b-48d5-8fb9-6f9bab45deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ea682fe0-36d5-401b-b809-cb860ef5fe1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1fa5f3b9-2b3b-48d5-8fb9-6f9bab45deae" xlink:to="loc_us-gaap_AccountsPayableCurrent_ea682fe0-36d5-401b-b809-cb860ef5fe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fa566912-af3d-4a9c-ac05-feacf45242d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1fa5f3b9-2b3b-48d5-8fb9-6f9bab45deae" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fa566912-af3d-4a9c-ac05-feacf45242d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a8d0575-269d-4997-bc90-0c178d0395c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1fa5f3b9-2b3b-48d5-8fb9-6f9bab45deae" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a8d0575-269d-4997-bc90-0c178d0395c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b1335cb3-4997-482c-98e6-f45603bd5f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1fa5f3b9-2b3b-48d5-8fb9-6f9bab45deae" xlink:to="loc_us-gaap_LiabilitiesCurrent_b1335cb3-4997-482c-98e6-f45603bd5f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_789a5333-4910-42d2-a1de-1f53b057a557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_789a5333-4910-42d2-a1de-1f53b057a557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_542d91a9-b0f3-42bc-8c8c-8277ecdd9413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_542d91a9-b0f3-42bc-8c8c-8277ecdd9413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_005fd4d8-7be9-48ec-b4ec-5853e6981fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_005fd4d8-7be9-48ec-b4ec-5853e6981fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c46c44e2-c72d-4345-a256-d115fec44ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_Liabilities_c46c44e2-c72d-4345-a256-d115fec44ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7934dc03-b49b-4c87-8959-15e519eaaffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:to="loc_us-gaap_CommonStockValue_7934dc03-b49b-4c87-8959-15e519eaaffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b4f78591-5bb0-446b-8829-371db349c17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:to="loc_us-gaap_PreferredStockValue_b4f78591-5bb0-446b-8829-371db349c17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_94e8dd25-e5f4-48fb-9ff4-a363c1a1212d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_94e8dd25-e5f4-48fb-9ff4-a363c1a1212d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23907cf1-790b-4edc-8527-25f3fa09d7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23907cf1-790b-4edc-8527-25f3fa09d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_afb13e72-4d89-4da5-83c9-3cd8290b1146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_048a428e-37d8-415d-a31c-2436a7043df0" xlink:to="loc_us-gaap_StockholdersEquity_afb13e72-4d89-4da5-83c9-3cd8290b1146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a12ff0de-0d53-45da-abdf-6b829853e54c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9ae48a2-936d-4c06-9901-e57a91c674d1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a12ff0de-0d53-45da-abdf-6b829853e54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_40a75387-a4d7-4eb0-a552-eba996ad74a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_40a75387-a4d7-4eb0-a552-eba996ad74a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f994cf10-262f-4ffe-96be-155dafb0fe09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f994cf10-262f-4ffe-96be-155dafb0fe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b7a37e2b-0bd2-48ba-8cf4-cb9c7841dd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_CommonStockSharesIssued_b7a37e2b-0bd2-48ba-8cf4-cb9c7841dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98773535-1686-4471-adb1-af710c03acfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98773535-1686-4471-adb1-af710c03acfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8da8b6f4-eac8-4215-93b9-30f502d58cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8da8b6f4-eac8-4215-93b9-30f502d58cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eeacc8dd-b568-4aeb-990b-596b55d1e193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eeacc8dd-b568-4aeb-990b-596b55d1e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2f60aa7e-dff1-45d5-aef1-4c7be11fde0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2f60aa7e-dff1-45d5-aef1-4c7be11fde0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_52ee3937-91f1-4dfe-83e9-acdc80cd44d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e4b9b03-d27b-42f2-b5e6-174d128b7af9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_52ee3937-91f1-4dfe-83e9-acdc80cd44d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4b3a4912-50a9-4ca8-aa31-c470a7291ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b3a4912-50a9-4ca8-aa31-c470a7291ce9" xlink:to="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ecb9707-57ca-4996-b5d0-30b42583c4e9" xlink:to="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3bd528ab-d655-4ab6-ae13-135603f99f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:to="loc_us-gaap_CommonStockMember_3bd528ab-d655-4ab6-ae13-135603f99f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_176077bb-915e-4003-b679-e06e081434a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fe31fe0e-d3c3-4b11-ad60-90b9daaf780b" xlink:to="loc_us-gaap_PreferredStockMember_176077bb-915e-4003-b679-e06e081434a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:to="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f8909d3a-d66d-46ce-ad1f-6e624dbd48ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7ca5d9bf-9c53-4ce6-9027-bf95c2d43db2" xlink:to="loc_srt_ProductsAndServicesDomain_f8909d3a-d66d-46ce-ad1f-6e624dbd48ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_156ba021-6ce6-43a4-864c-d8a9613890c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f8909d3a-d66d-46ce-ad1f-6e624dbd48ee" xlink:to="loc_us-gaap_ProductMember_156ba021-6ce6-43a4-864c-d8a9613890c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee00ab68-201e-4a05-aa7f-c0cb226c84cd" xlink:to="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_005681fd-0fbb-446f-a8ea-b6d2905bbe96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_RevenuesAbstract_005681fd-0fbb-446f-a8ea-b6d2905bbe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ba29bc76-917b-46a1-aef8-a713d67d8213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_005681fd-0fbb-446f-a8ea-b6d2905bbe96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ba29bc76-917b-46a1-aef8-a713d67d8213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b84ce18-1c1e-427f-b24c-4adad3a54944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b84ce18-1c1e-427f-b24c-4adad3a54944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8585c897-c640-47e0-b544-9aaf518166e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8585c897-c640-47e0-b544-9aaf518166e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e8e9c060-121c-4f25-8a4d-8349251529a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e8e9c060-121c-4f25-8a4d-8349251529a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5da47cdc-a25f-424f-909b-5d5cfe03071f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5da47cdc-a25f-424f-909b-5d5cfe03071f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d6b7d877-048b-4d3a-afa6-7b1aecf1093c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d6b7d877-048b-4d3a-afa6-7b1aecf1093c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4939805c-e963-4e9f-b277-de2ac7b650b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4939805c-e963-4e9f-b277-de2ac7b650b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_88bc7780-842f-457d-9637-c4a15ca906a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15358b90-64c7-4072-9331-87a0d017b69b" xlink:to="loc_us-gaap_CostsAndExpenses_88bc7780-842f-457d-9637-c4a15ca906a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_391ad511-709e-411c-92f3-b2ee04586f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_OperatingIncomeLoss_391ad511-709e-411c-92f3-b2ee04586f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2b35ad85-d153-4825-b29c-6e6fc4b98984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2b35ad85-d153-4825-b29c-6e6fc4b98984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_65b3000b-4c0f-40b2-9456-532373ff8d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_65b3000b-4c0f-40b2-9456-532373ff8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_68b805c0-4b13-4e59-9d81-4d5928a14bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5db5231a-20e7-40de-8478-4b8442309deb" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_68b805c0-4b13-4e59-9d81-4d5928a14bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2a27edbb-77ab-4a89-8f5e-3991c0696888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2a27edbb-77ab-4a89-8f5e-3991c0696888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d02bea6-4ce6-46c0-82df-ec2d9dba4f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d02bea6-4ce6-46c0-82df-ec2d9dba4f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3645ce6b-6441-49a7-8478-1db66a2fdb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3645ce6b-6441-49a7-8478-1db66a2fdb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_04efaa32-29f5-4a32-b550-e8ed4e9a30e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_04efaa32-29f5-4a32-b550-e8ed4e9a30e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_101f2d5b-5246-4131-98d1-c9744220b631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_101f2d5b-5246-4131-98d1-c9744220b631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_185bf29b-bc1d-402f-85da-48507d73e1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_NetIncomeLoss_185bf29b-bc1d-402f-85da-48507d73e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3069c920-424c-4977-ba07-c84ca9eacaca" xlink:to="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1d702496-3d36-415c-930b-04234a55758b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1d702496-3d36-415c-930b-04234a55758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5f607b89-4b19-438f-a996-ad5a098aa0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5f607b89-4b19-438f-a996-ad5a098aa0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4c944449-77cb-442a-975d-97144749580b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4c944449-77cb-442a-975d-97144749580b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_a4e22dd9-06e0-4fc8-9999-4ad0ed6b1944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_a4e22dd9-06e0-4fc8-9999-4ad0ed6b1944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7e0b0ae3-c94b-4812-8638-3ef90ae87b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_EarningsPerShareBasic_7e0b0ae3-c94b-4812-8638-3ef90ae87b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1cc678c5-6deb-4b08-8a23-de35ef9456a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30d18365-bea2-4f7f-955e-fbb45dbf9a07" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1cc678c5-6deb-4b08-8a23-de35ef9456a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_de79251b-5905-4fdb-86f8-8c16472ba2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_de79251b-5905-4fdb-86f8-8c16472ba2fb" xlink:to="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5dd1ac17-d5da-4a62-a667-94918a20fd2a" xlink:to="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95911307-f551-4f1c-80f1-7347be10f515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_CommonStockMember_95911307-f551-4f1c-80f1-7347be10f515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ac651eb2-af17-4ac3-85f9-b5a4798b14b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_PreferredStockMember_ac651eb2-af17-4ac3-85f9-b5a4798b14b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0daa83fc-0c31-4a18-8700-97f4cfb482f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0daa83fc-0c31-4a18-8700-97f4cfb482f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d5c0d495-e2c5-493b-ae77-f8d696c7c6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_536e5f6b-c044-4798-8807-576b27d74e17" xlink:to="loc_us-gaap_RetainedEarningsMember_d5c0d495-e2c5-493b-ae77-f8d696c7c6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69064a38-169d-42e6-88e0-761c30dd5ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1270ece3-2092-44b9-9386-e35ad47daea1" xlink:to="loc_us-gaap_StatementLineItems_69064a38-169d-42e6-88e0-761c30dd5ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69064a38-169d-42e6-88e0-761c30dd5ae4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7c4dae3d-03db-4af7-8fd3-e80013464058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_SharesOutstanding_7c4dae3d-03db-4af7-8fd3-e80013464058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05aa0f64-7590-49cc-943a-803b4d2ccfd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockholdersEquity_05aa0f64-7590-49cc-943a-803b4d2ccfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbe0db29-1ab1-451f-a558-d937937e719e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbe0db29-1ab1-451f-a558-d937937e719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f27a7c04-314d-4ad7-be6d-03e411da0bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f27a7c04-314d-4ad7-be6d-03e411da0bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_65cb2058-17b5-4a48-84cd-3cecdfaf3cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_65cb2058-17b5-4a48-84cd-3cecdfaf3cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_8375133a-6528-47ce-a3fa-5491aac8ecc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_8375133a-6528-47ce-a3fa-5491aac8ecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d104fbe4-a700-4203-bc8f-02b80848d55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d104fbe4-a700-4203-bc8f-02b80848d55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f9dbdbae-4d7b-40a9-bba7-38c467c449d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f9dbdbae-4d7b-40a9-bba7-38c467c449d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_44fd1fc6-bc52-4e90-8ede-d133f6ef2919" xlink:href="cerc-20210331.xsd#cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering_44fd1fc6-bc52-4e90-8ede-d133f6ef2919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_c0b58bc4-8019-476a-9a30-2546e787aea0" xlink:href="cerc-20210331.xsd#cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering_c0b58bc4-8019-476a-9a30-2546e787aea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_e05ec94e-b4bf-4231-9526-b66079af6439" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_e05ec94e-b4bf-4231-9526-b66079af6439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_98627d50-c3ba-49a5-8629-5276dd575ed2" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_98627d50-c3ba-49a5-8629-5276dd575ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_61c2afe6-87e0-4802-90da-c39f317f14fc" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_61c2afe6-87e0-4802-90da-c39f317f14fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_ce22c9d2-a66b-421a-a2dd-114b2b989a69" xlink:href="cerc-20210331.xsd#cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_ce22c9d2-a66b-421a-a2dd-114b2b989a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2e5a14e2-2281-45c0-9ac3-b7112fd668a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2e5a14e2-2281-45c0-9ac3-b7112fd668a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de28f015-ed73-41d9-b572-82ac6d43709c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_NetIncomeLoss_de28f015-ed73-41d9-b572-82ac6d43709c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_75d5dee8-bdc6-4858-ab72-c87c9a9f2b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_SharesOutstanding_75d5dee8-bdc6-4858-ab72-c87c9a9f2b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_26a17759-42fd-43ff-a326-77c1b309c253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1ee1e1f-cdc2-40a7-857a-3c577641710e" xlink:to="loc_us-gaap_StockholdersEquity_26a17759-42fd-43ff-a326-77c1b309c253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="cerc-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2b7751ab-779f-4257-b264-ff8b06fe8653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2b7751ab-779f-4257-b264-ff8b06fe8653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b6dfa29-bbfb-4b53-89c2-9d88904c9f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2b7751ab-779f-4257-b264-ff8b06fe8653" xlink:to="loc_us-gaap_NetIncomeLoss_7b6dfa29-bbfb-4b53-89c2-9d88904c9f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2b7751ab-779f-4257-b264-ff8b06fe8653" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_282292ed-2150-4105-ac6a-101e890d8bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_282292ed-2150-4105-ac6a-101e890d8bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_92c7d24c-5d61-4ab6-8a99-50c46e59c491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_us-gaap_ShareBasedCompensation_92c7d24c-5d61-4ab6-8a99-50c46e59c491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_776cd13d-32d5-488f-9ca2-b5bbd89551a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_776cd13d-32d5-488f-9ca2-b5bbd89551a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8020d635-9603-40c8-a2d0-a65fd0cc6b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8020d635-9603-40c8-a2d0-a65fd0cc6b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_087c886b-34c8-4b5a-b8d7-d1d5a1b24d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_087c886b-34c8-4b5a-b8d7-d1d5a1b24d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_99cc6dd5-dfb2-48af-93cd-7607f065a7b6" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_99cc6dd5-dfb2-48af-93cd-7607f065a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_d9b86a49-44a0-49df-b5f9-d37d317d3eb7" xlink:href="cerc-20210331.xsd#cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation_d9b86a49-44a0-49df-b5f9-d37d317d3eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ed5a720-1689-4ecb-baf1-b2e22ceaa73a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce67bb14-930a-47de-af84-c1e1f5025fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ce67bb14-930a-47de-af84-c1e1f5025fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_367a32ba-c646-48d4-a920-316baea893c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_367a32ba-c646-48d4-a920-316baea893c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a8aeec97-ce81-495b-ab30-4bdf07eeb5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a8aeec97-ce81-495b-ab30-4bdf07eeb5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8851024e-1b00-44ea-b590-195893499269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8851024e-1b00-44ea-b590-195893499269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_89475c0a-36eb-4698-894d-968d27b7c825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_89475c0a-36eb-4698-894d-968d27b7c825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9871726c-75c0-4794-bd9c-38086105f800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9871726c-75c0-4794-bd9c-38086105f800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_6ec35ede-044e-4a7b-bab1-493ceb94c2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_6ec35ede-044e-4a7b-bab1-493ceb94c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IncreaseDecreaseInLeaseLiability_a2580afe-e5ea-465a-8fe6-cf4c88faccfa" xlink:href="cerc-20210331.xsd#cerc_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_429b7616-04c0-4052-a1a2-8d351f750db3" xlink:to="loc_cerc_IncreaseDecreaseInLeaseLiability_a2580afe-e5ea-465a-8fe6-cf4c88faccfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db4fe40-0c0d-4f93-9561-ff0995cf460d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2b7751ab-779f-4257-b264-ff8b06fe8653" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db4fe40-0c0d-4f93-9561-ff0995cf460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_74120f8c-b343-459f-8912-676ca9800ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_74120f8c-b343-459f-8912-676ca9800ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PaymentsForAssetAcquisitions_6475a804-30b6-4392-8330-2f12671f073a" xlink:href="cerc-20210331.xsd#cerc_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_74120f8c-b343-459f-8912-676ca9800ccd" xlink:to="loc_cerc_PaymentsForAssetAcquisitions_6475a804-30b6-4392-8330-2f12671f073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f167613f-5151-40d0-a802-3bcbfdd4e6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_74120f8c-b343-459f-8912-676ca9800ccd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f167613f-5151-40d0-a802-3bcbfdd4e6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af1c88b9-2eaf-47dd-882e-4bcfd72a8726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_74120f8c-b343-459f-8912-676ca9800ccd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af1c88b9-2eaf-47dd-882e-4bcfd72a8726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_ce7f5014-69d6-43df-b6e2-3f742076b531" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:to="loc_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants_ce7f5014-69d6-43df-b6e2-3f742076b531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromRegisteredDirectOffering_02ebc3b2-3457-45af-85d9-0a2537b98b98" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromRegisteredDirectOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:to="loc_cerc_ProceedsFromRegisteredDirectOffering_02ebc3b2-3457-45af-85d9-0a2537b98b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fdf22c25-6d65-47b2-a8df-8be032cd12ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fdf22c25-6d65-47b2-a8df-8be032cd12ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ProceedsFromOptionOrWarrantExercises_48687b6f-61c9-4233-b1f1-aa4cda3070b8" xlink:href="cerc-20210331.xsd#cerc_ProceedsFromOptionOrWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:to="loc_cerc_ProceedsFromOptionOrWarrantExercises_48687b6f-61c9-4233-b1f1-aa4cda3070b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_736fb9cd-d457-49ec-a063-793566fc66b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_76dc46d7-b192-4312-8323-8c93bbadba63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_736fb9cd-d457-49ec-a063-793566fc66b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1d808d8f-7e76-4289-b68d-bd74ba7e0dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1d808d8f-7e76-4289-b68d-bd74ba7e0dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_442d235c-8c98-46d2-8adf-cd9089878420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_442d235c-8c98-46d2-8adf-cd9089878420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_408245a6-101f-4b9c-8a6c-975b3759b7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_408245a6-101f-4b9c-8a6c-975b3759b7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_66d7ec1a-62a9-443e-ab2e-9bd28448443a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_66d7ec1a-62a9-443e-ab2e-9bd28448443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_7bb0473f-ba55-4608-886a-4d8e3d4bbd18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_66d7ec1a-62a9-443e-ab2e-9bd28448443a" xlink:to="loc_us-gaap_IncomeTaxesPaid_7bb0473f-ba55-4608-886a-4d8e3d4bbd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_368b93bf-01c3-4fa8-acda-d727d33c23f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_368b93bf-01c3-4fa8-acda-d727d33c23f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_1f376908-614c-48ed-86f6-54a082684b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_368b93bf-01c3-4fa8-acda-d727d33c23f3" xlink:to="loc_us-gaap_StockIssued1_1f376908-614c-48ed-86f6-54a082684b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7861b256-9bca-42d8-8380-b6544c6c58ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7861b256-9bca-42d8-8380-b6544c6c58ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d28798fa-79be-4ae1-867d-50d0f17cd943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d28798fa-79be-4ae1-867d-50d0f17cd943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_bb82ae2e-1a61-4077-a878-e179e3b38493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_bb82ae2e-1a61-4077-a878-e179e3b38493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd381b7f-2238-4183-896b-fc5b2bdf59fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d56ea55-c705-436f-bfee-b187ac6d4783" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd381b7f-2238-4183-896b-fc5b2bdf59fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/Business" xlink:type="simple" xlink:href="cerc-20210331.xsd#Business"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/Business" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d713779c-718d-4bdc-96e4-79403273e01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_82100945-947d-49af-9488-8c9a25fb08e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d713779c-718d-4bdc-96e4-79403273e01f" xlink:to="loc_us-gaap_NatureOfOperations_82100945-947d-49af-9488-8c9a25fb08e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/BusinessDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#BusinessDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80206250-1a57-4f0c-a7a7-492fb48fd312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80206250-1a57-4f0c-a7a7-492fb48fd312" xlink:to="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bb26d38e-5bb7-43ec-90b3-ee36d3856e81" xlink:to="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_4055cd20-0048-42d0-87b5-1d15c81066e3" xlink:href="cerc-20210331.xsd#cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:to="loc_cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember_4055cd20-0048-42d0-87b5-1d15c81066e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClinicalStageMember_1f5d2c62-1c9c-4934-b264-679af6f920de" xlink:href="cerc-20210331.xsd#cerc_ClinicalStageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf41b120-f8d9-459a-ad21-1e31da5e392d" xlink:to="loc_cerc_ClinicalStageMember_1f5d2c62-1c9c-4934-b264-679af6f920de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e82daab1-cd57-4534-923c-1e0f17018ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6fb78416-b660-4b52-9119-747546b3016e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e82daab1-cd57-4534-923c-1e0f17018ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwrittenPublicOfferingMember_d54aeb59-bd9a-45e6-9d1f-9bad2f27e849" xlink:href="cerc-20210331.xsd#cerc_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e82daab1-cd57-4534-923c-1e0f17018ab1" xlink:to="loc_cerc_UnderwrittenPublicOfferingMember_d54aeb59-bd9a-45e6-9d1f-9bad2f27e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6ddc79e8-80f9-489c-8c01-8c69d949cd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3f703b27-884e-4c8f-905d-16d9a95e3ae5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6ddc79e8-80f9-489c-8c01-8c69d949cd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_327d6f86-b1a4-425c-9591-6a95dfd3dadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6ddc79e8-80f9-489c-8c01-8c69d949cd13" xlink:to="loc_us-gaap_WarrantMember_327d6f86-b1a4-425c-9591-6a95dfd3dadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_956d31cd-7b4c-48f8-bd55-478e4fcebd45" xlink:to="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfProductsDeveloped_63ff4b68-7b0b-4e83-b34e-d322a32f1659" xlink:href="cerc-20210331.xsd#cerc_NumberOfProductsDeveloped"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_cerc_NumberOfProductsDeveloped_63ff4b68-7b0b-4e83-b34e-d322a32f1659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82935e93-9c4e-4811-ad9c-58b4d60124fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_82935e93-9c4e-4811-ad9c-58b4d60124fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2f8fa2d8-a4c7-4027-81dd-79f6d2efa9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2f8fa2d8-a4c7-4027-81dd-79f6d2efa9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_efd84377-d51a-4621-986e-9cce7ef4a320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_efd84377-d51a-4621-986e-9cce7ef4a320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f2d3ade-49c7-4833-983f-aa026a4b1bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_NetIncomeLoss_0f2d3ade-49c7-4833-983f-aa026a4b1bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a74159a-501b-4edb-96e1-a0869fc093f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a74159a-501b-4edb-96e1-a0869fc093f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b92a100-7dab-4523-a7a2-509bec622899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b5e49f19-47a4-46df-80f9-60ee38b9cde4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b92a100-7dab-4523-a7a2-509bec622899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="cerc-20210331.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ebcb1a45-f86d-4de7-bc9d-effdab5764bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0948fb92-6a2a-4663-989b-e92410379a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ebcb1a45-f86d-4de7-bc9d-effdab5764bc" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0948fb92-6a2a-4663-989b-e92410379a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cerc-20210331.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ddc6c876-190b-470a-bae9-32ee7d335e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_778560a3-c780-4697-b4ad-b7c786475c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddc6c876-190b-470a-bae9-32ee7d335e30" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_778560a3-c780-4697-b4ad-b7c786475c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestiture" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestiture"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AytuDivestiture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_18d4628c-98de-4398-aa15-19209d27ade1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d7a8059d-7eeb-45c8-9601-87accdea545a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_18d4628c-98de-4398-aa15-19209d27ade1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d7a8059d-7eeb-45c8-9601-87accdea545a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_87785d9a-2e7c-481c-95c2-6f7df49e5c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9a392acb-9c1c-4d78-a3e3-0ed507ad6ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_87785d9a-2e7c-481c-95c2-6f7df49e5c37" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9a392acb-9c1c-4d78-a3e3-0ed507ad6ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_958c4bef-b0a1-4ed1-9b50-bc713ecb9163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_958c4bef-b0a1-4ed1-9b50-bc713ecb9163" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dda798ae-7474-468e-a9a2-ed2231acb846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_83daf9a8-4f87-436d-9ce1-2d1e9646684e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dda798ae-7474-468e-a9a2-ed2231acb846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_9f03878a-d68d-480f-a3ae-45afff1362c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_dda798ae-7474-468e-a9a2-ed2231acb846" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_9f03878a-d68d-480f-a3ae-45afff1362c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b8847bfc-87ca-47a8-97dc-26527793b365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e1881e6e-1a42-40aa-9ac7-ef5ad2a186dd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b8847bfc-87ca-47a8-97dc-26527793b365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_1eb442ca-906b-4f5f-a823-d5e557e0c594" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b8847bfc-87ca-47a8-97dc-26527793b365" xlink:to="loc_cerc_PediatricPortfolioMember_1eb442ca-906b-4f5f-a823-d5e557e0c594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_09666fd3-d048-4cfd-9c13-6a4ad3f8f525" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9260e37c-bf1d-4a7d-acdf-121857e3a700" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_09666fd3-d048-4cfd-9c13-6a4ad3f8f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember_148ddfe5-f20f-47e3-a50a-e33c323f9b3a" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09666fd3-d048-4cfd-9c13-6a4ad3f8f525" xlink:to="loc_cerc_AYTUBioScienceIncMember_148ddfe5-f20f-47e3-a50a-e33c323f9b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_469627d8-8022-4367-86bf-604641059c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5f0b2381-cfa6-40f4-83cc-099d757887d6" xlink:to="loc_us-gaap_ClassOfStockDomain_469627d8-8022-4367-86bf-604641059c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7e09f454-7e55-4e20-8668-89cbe3f5ffea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_469627d8-8022-4367-86bf-604641059c92" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7e09f454-7e55-4e20-8668-89cbe3f5ffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ebe0dc7-1220-4103-abe0-98841adad5b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_955692ef-cec4-4970-86a8-7bc7aaec9e12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ebe0dc7-1220-4103-abe0-98841adad5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember_452267fa-7c7d-4ddf-87c3-34697d07b0bf" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3ebe0dc7-1220-4103-abe0-98841adad5b2" xlink:to="loc_cerc_AYTUBioScienceIncMember_452267fa-7c7d-4ddf-87c3-34697d07b0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_19236b80-1bfa-4178-a4f4-d142aecb6f71" xlink:to="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a5c64ff-46b8-4b42-a14a-8cf6e9e26428" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:to="loc_srt_MaximumMember_4a5c64ff-46b8-4b42-a14a-8cf6e9e26428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_520b99f5-a344-47e3-a7bc-9cc513ad238e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eee10af0-a29c-4a62-bf9e-018f3548234d" xlink:to="loc_srt_MinimumMember_520b99f5-a344-47e3-a7bc-9cc513ad238e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2d8431d2-6427-49ff-9e73-30cc2bd51a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d9edc596-b3d5-47f6-8eab-f02c432510b2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2d8431d2-6427-49ff-9e73-30cc2bd51a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_360a9774-c984-4fab-9a5a-a71c53edef11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2d8431d2-6427-49ff-9e73-30cc2bd51a46" xlink:to="loc_us-gaap_SubsequentEventMember_360a9774-c984-4fab-9a5a-a71c53edef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_67cde12e-a1f4-4221-8150-7c90210e230e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1e39293-a38b-4330-a186-1cf15b9c46c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_67cde12e-a1f4-4221-8150-7c90210e230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DeerfieldObligationMember_5e3797f7-1e94-4a4d-82ca-5f40c9d9ffa4" xlink:href="cerc-20210331.xsd#cerc_DeerfieldObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_67cde12e-a1f4-4221-8150-7c90210e230e" xlink:to="loc_cerc_DeerfieldObligationMember_5e3797f7-1e94-4a4d-82ca-5f40c9d9ffa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fdc72299-3fa7-4b64-a4c4-444592c3c3b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9056a97f-7e09-47b7-8c58-49590d992700" xlink:to="loc_dei_EntityDomain_fdc72299-3fa7-4b64-a4c4-444592c3c3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AYTUBioScienceIncMember_88f73027-0780-4905-8d48-7239cf993f5d" xlink:href="cerc-20210331.xsd#cerc_AYTUBioScienceIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fdc72299-3fa7-4b64-a4c4-444592c3c3b3" xlink:to="loc_cerc_AYTUBioScienceIncMember_88f73027-0780-4905-8d48-7239cf993f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_15788aea-2bba-4876-9e5e-1cb240ecd535" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2a8fd509-7acd-43df-8390-dccecd054481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2a8fd509-7acd-43df-8390-dccecd054481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_355b459b-1adc-451a-b294-d1ba6f97ca84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_355b459b-1adc-451a-b294-d1ba6f97ca84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MonthlyOperationPaymentsTerm_389f9fb6-2cc1-40fa-bf6b-8efa8f0c4c05" xlink:href="cerc-20210331.xsd#cerc_MonthlyOperationPaymentsTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_MonthlyOperationPaymentsTerm_389f9fb6-2cc1-40fa-bf6b-8efa8f0c4c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MonthlyOperationPaymentsAdditionalTerm_f2d09ea0-00ed-4672-9833-0628e13dce1b" xlink:href="cerc-20210331.xsd#cerc_MonthlyOperationPaymentsAdditionalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_MonthlyOperationPaymentsAdditionalTerm_f2d09ea0-00ed-4672-9833-0628e13dce1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9e52a0d4-3ae2-4a5a-833a-417e880050b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_RepaymentsOfDebt_9e52a0d4-3ae2-4a5a-833a-417e880050b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentContingentConsiderationPaid_bde73ed8-f351-4e08-b1c6-447a0d331da0" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentContingentConsiderationPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DebtInstrumentContingentConsiderationPaid_bde73ed8-f351-4e08-b1c6-447a0d331da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentRemainingContingentConsiderationLiability_98c897b1-f49c-4cd9-919c-990cee6c8c51" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentRemainingContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DebtInstrumentRemainingContingentConsiderationLiability_98c897b1-f49c-4cd9-919c-990cee6c8c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_4e498dc9-23f9-4a04-8ecd-03537f61eb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_4e498dc9-23f9-4a04-8ecd-03537f61eb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DebtInstrumentFutureAggregateDeferredPayments_64484db5-23b3-4a3a-b12f-2fb135204385" xlink:href="cerc-20210331.xsd#cerc_DebtInstrumentFutureAggregateDeferredPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DebtInstrumentFutureAggregateDeferredPayments_64484db5-23b3-4a3a-b12f-2fb135204385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_b0c44fb2-2d07-4f1e-882a-e77980550572" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns_b0c44fb2-2d07-4f1e-882a-e77980550572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_610d0927-9d84-43e4-9e56-349b67808fe6" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_23f42fbb-5044-4e0c-a6c3-b2349deb4129" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent_610d0927-9d84-43e4-9e56-349b67808fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5ed06909-0338-4d7c-8fae-66207f3fe209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5ed06909-0338-4d7c-8fae-66207f3fe209" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17bba1d-ec66-4e12-b3a4-fd8b0b96063a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4c11ddb-cff9-44fa-992c-468640e52cbd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17bba1d-ec66-4e12-b3a4-fd8b0b96063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_b4687f2a-ebac-416c-982f-bd54456eebcb" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d17bba1d-ec66-4e12-b3a4-fd8b0b96063a" xlink:to="loc_cerc_PediatricPortfolioMember_b4687f2a-ebac-416c-982f-bd54456eebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c4c213c9-4ba3-4c15-a6f9-01ae8dc65353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ce6192c2-49c5-4f0b-9ff6-2cf25eb208f8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c4c213c9-4ba3-4c15-a6f9-01ae8dc65353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_83864c13-240b-48cc-be19-352e00cebef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c4c213c9-4ba3-4c15-a6f9-01ae8dc65353" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_83864c13-240b-48cc-be19-352e00cebef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d0bd33c8-6484-4a19-8b86-7cdd1cceb2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_628562d2-5935-4cc4-a80f-74f4aa670df1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d0bd33c8-6484-4a19-8b86-7cdd1cceb2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_2d89f1c4-d1a0-42e6-9d9a-b7257bc5178a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d0bd33c8-6484-4a19-8b86-7cdd1cceb2dd" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_2d89f1c4-d1a0-42e6-9d9a-b7257bc5178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_2d89f1c4-d1a0-42e6-9d9a-b7257bc5178a" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9c455468-73f0-4b96-9ec5-dc3f15712cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9c455468-73f0-4b96-9ec5-dc3f15712cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dabfe980-5a35-49fc-9877-d10e780e6268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_124c6af3-c1f8-449e-ba8a-f73f46da410e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dabfe980-5a35-49fc-9877-d10e780e6268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofIncomeStatementDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9d398741-b6aa-4688-8f21-1b0725e4d42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9d398741-b6aa-4688-8f21-1b0725e4d42e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59f7943a-3f40-42cc-9859-1cce868ffe45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4351984a-fa5a-4538-b0cb-48fb2e0c567a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59f7943a-3f40-42cc-9859-1cce868ffe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_4b038243-e0a8-41c0-abf9-1ba0b46f59ba" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59f7943a-3f40-42cc-9859-1cce868ffe45" xlink:to="loc_cerc_PediatricPortfolioMember_4b038243-e0a8-41c0-abf9-1ba0b46f59ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d51d9bb6-46b8-448e-9eca-54ff1a995eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_424a929c-d995-440d-a48e-e8e963a8d097" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d51d9bb6-46b8-448e-9eca-54ff1a995eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_d7906c49-e1fe-4ef3-9344-09ff8ac408e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d51d9bb6-46b8-448e-9eca-54ff1a995eaa" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_d7906c49-e1fe-4ef3-9344-09ff8ac408e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cfc87724-5ec4-4ac5-91d0-9e7a632a54aa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_624df991-3c52-40ee-bd20-81f15a017841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_624df991-3c52-40ee-bd20-81f15a017841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_45a7e008-541f-4bf8-9949-422f874b9f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_45a7e008-541f-4bf8-9949-422f874b9f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eadfbbf4-500f-4ce8-8b25-ed7d59500bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_687efd13-a793-472b-ac62-b9193b68144f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_eadfbbf4-500f-4ce8-8b25-ed7d59500bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8068ce22-8b96-4ea5-b95c-e0050138ed97" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_4a1e4ae5-8637-4b3a-99c2-04c7ef9ff5bb" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_4a1e4ae5-8637-4b3a-99c2-04c7ef9ff5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a55053c4-3603-43ae-a824-6aa2ab101158" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_a55053c4-3603-43ae-a824-6aa2ab101158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_db394bd9-0258-476a-a4ce-35344833f4f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_7fcf55ae-6957-47b3-8992-d8f0b52ed084" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_db394bd9-0258-476a-a4ce-35344833f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AytuDivestitureSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fe3f0959-f4d5-4cdf-bbba-d5a95b83c283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fe3f0959-f4d5-4cdf-bbba-d5a95b83c283" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7627d4f-e6f5-458b-be47-0dab15c28873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e803647-8acf-4789-81fb-dfbbc50a1ec7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7627d4f-e6f5-458b-be47-0dab15c28873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PediatricPortfolioMember_edb02de2-4855-40e4-b674-77d6102f974d" xlink:href="cerc-20210331.xsd#cerc_PediatricPortfolioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7627d4f-e6f5-458b-be47-0dab15c28873" xlink:to="loc_cerc_PediatricPortfolioMember_edb02de2-4855-40e4-b674-77d6102f974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e9b01974-c2bc-475c-a7cc-d3b0f345f293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cd0180f9-7791-4e6b-bc64-77ac46cbcf6f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e9b01974-c2bc-475c-a7cc-d3b0f345f293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2a3f4671-d031-4bd2-a4cd-0f984fa8a602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e9b01974-c2bc-475c-a7cc-d3b0f345f293" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2a3f4671-d031-4bd2-a4cd-0f984fa8a602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3c1a4ac2-3212-4e2d-89ac-f013ae53abd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a6183c70-e842-484c-86a4-cfa52c3a8930" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3c1a4ac2-3212-4e2d-89ac-f013ae53abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_aa9f78b1-cbb3-4ba7-aa77-b433b21a23dd" xlink:href="cerc-20210331.xsd#cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3c1a4ac2-3212-4e2d-89ac-f013ae53abd2" xlink:to="loc_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee_aa9f78b1-cbb3-4ba7-aa77-b433b21a23dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/Revenue" xlink:type="simple" xlink:href="cerc-20210331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d16ace9c-71c2-4743-914b-50207a483cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a4626ca4-0b2e-4480-8a2d-8bda94322c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d16ace9c-71c2-4743-914b-50207a483cb3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a4626ca4-0b2e-4480-8a2d-8bda94322c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/RevenueDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#RevenueDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_90496ae3-3c89-4668-a890-6e73ed6029f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_90496ae3-3c89-4668-a890-6e73ed6029f4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0990814-2565-4f94-a5f3-41d3f450e93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0a0d2355-0b83-4df6-acc0-8193d1f9b834" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0990814-2565-4f94-a5f3-41d3f450e93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c56f0dcd-81e0-4b78-af5a-2d4737786ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0990814-2565-4f94-a5f3-41d3f450e93f" xlink:to="loc_us-gaap_SalesRevenueNetMember_c56f0dcd-81e0-4b78-af5a-2d4737786ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b95d6d80-8acf-4583-8c33-099e691b62f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2601a634-66e9-45e7-96bb-f1a77bc13dd8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b95d6d80-8acf-4583-8c33-099e691b62f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_01358ff1-232a-47bc-a761-f34a4bf88281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b95d6d80-8acf-4583-8c33-099e691b62f9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_01358ff1-232a-47bc-a761-f34a4bf88281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f5357c41-96b8-4dc8-8841-46ccaf898c3f" xlink:to="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberOneMember_2f08dff0-ae5b-4b40-bb0e-0d6ff35c6e90" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:to="loc_cerc_MajorCustomerNumberOneMember_2f08dff0-ae5b-4b40-bb0e-0d6ff35c6e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberTwoMember_1effda4b-1f7f-493e-bcd8-88ced7f202d6" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:to="loc_cerc_MajorCustomerNumberTwoMember_1effda4b-1f7f-493e-bcd8-88ced7f202d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MajorCustomerNumberThreeMember_2113421c-941a-4744-86b1-f49e61e05c0a" xlink:href="cerc-20210331.xsd#cerc_MajorCustomerNumberThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e36a0c10-9e6e-4f6e-a810-936b28daa01e" xlink:to="loc_cerc_MajorCustomerNumberThreeMember_2113421c-941a-4744-86b1-f49e61e05c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_89b1f3cc-76b0-420f-851a-a696e7de4eb3" xlink:to="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MillipredMember_e9a6078f-9cc6-47e2-9fe5-e2f3bf9b65dd" xlink:href="cerc-20210331.xsd#cerc_MillipredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:to="loc_cerc_MillipredMember_e9a6078f-9cc6-47e2-9fe5-e2f3bf9b65dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a165ff95-fa0e-4aa0-9b48-4634de82b01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a26bfffb-bf61-4b01-a232-f8cb23cd0d6f" xlink:to="loc_us-gaap_ProductMember_a165ff95-fa0e-4aa0-9b48-4634de82b01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e9483e2d-5e2e-4456-8fb8-26c8a610b8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d0e65139-6a50-45e2-a43b-97d46e1d9c55" xlink:to="loc_us-gaap_RelatedPartyDomain_e9483e2d-5e2e-4456-8fb8-26c8a610b8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_d592e5ef-06e3-4948-8e00-02f99912185c" xlink:href="cerc-20210331.xsd#cerc_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e9483e2d-5e2e-4456-8fb8-26c8a610b8a4" xlink:to="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_d592e5ef-06e3-4948-8e00-02f99912185c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3934d4f9-67fb-4a23-a238-2bb9a976b49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_44b6b0cb-72d1-4234-bda0-e8cb16da290e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3934d4f9-67fb-4a23-a238-2bb9a976b49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c550cc5b-3293-4ace-89fc-88a5dc43cada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3934d4f9-67fb-4a23-a238-2bb9a976b49c" xlink:to="loc_us-gaap_SubsequentEventMember_c550cc5b-3293-4ace-89fc-88a5dc43cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_314ee5d3-4865-45a2-aab5-f64e32c66010" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c7c62a35-e23e-4ec5-a31b-a9cf430600c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c7c62a35-e23e-4ec5-a31b-a9cf430600c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_7259d157-ba16-47d4-aa38-21defd14b074" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_7259d157-ba16-47d4-aa38-21defd14b074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementInstallmentPayment_70256d4f-4bc3-491b-93c5-b90ec605a1bc" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementInstallmentPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_cerc_LicenseAgreementInstallmentPayment_70256d4f-4bc3-491b-93c5-b90ec605a1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a343ea-68f2-47b3-8405-76634a2d2c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a343ea-68f2-47b3-8405-76634a2d2c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_InventoryPeriodBeforeExpiration_a24697bd-a3d7-472f-9ce8-1ed8058dbbb6" xlink:href="cerc-20210331.xsd#cerc_InventoryPeriodBeforeExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_cerc_InventoryPeriodBeforeExpiration_a24697bd-a3d7-472f-9ce8-1ed8058dbbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_39dce2ec-6e0e-4ad2-abf3-b239cb36f155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e2da130-576b-4d01-a319-867311342d77" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_39dce2ec-6e0e-4ad2-abf3-b239cb36f155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5826c60c-7634-467d-baa2-0e546631d457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2afb243d-ab5c-4018-bb2b-e570331bdcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5826c60c-7634-467d-baa2-0e546631d457" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2afb243d-ab5c-4018-bb2b-e570331bdcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88635b34-255b-4540-b766-2edd65d73aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_06b66139-ee20-4a07-98e9-1547cb6a7036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88635b34-255b-4540-b766-2edd65d73aa7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_06b66139-ee20-4a07-98e9-1547cb6a7036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b9020904-e147-4b0e-a010-c0711eff1e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88635b34-255b-4540-b766-2edd65d73aa7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b9020904-e147-4b0e-a010-c0711eff1e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_389d43a9-6880-467e-8f78-f3ea8169850d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_389d43a9-6880-467e-8f78-f3ea8169850d" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87b05f92-f009-449c-9697-6d9aab054017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab061c01-a08c-42b4-9874-212ff8504583" xlink:to="loc_us-gaap_ClassOfStockDomain_87b05f92-f009-449c-9697-6d9aab054017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_ac0e7e40-8ccd-4853-adf2-b1baf0accbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_87b05f92-f009-449c-9697-6d9aab054017" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_ac0e7e40-8ccd-4853-adf2-b1baf0accbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c40a8233-2274-4195-9325-903eff91af9c" xlink:to="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_32f59285-739f-42d0-ade5-4beff0cd71e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:to="loc_us-gaap_PreferredStockMember_32f59285-739f-42d0-ade5-4beff0cd71e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8eee96a2-9114-4029-b726-e9a58806f749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7dffb8ac-8657-4dfe-b63a-e2f5d2eb0096" xlink:to="loc_us-gaap_CommonStockMember_8eee96a2-9114-4029-b726-e9a58806f749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cf2631a8-77dc-4ee2-8889-39e032aa29d9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_99618869-eeda-4edb-a1f6-a5a624300954" xlink:href="cerc-20210331.xsd#cerc_ClassOfStockNumberOfClassesOfStockOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_cerc_ClassOfStockNumberOfClassesOfStockOutstanding_99618869-eeda-4edb-a1f6-a5a624300954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_d7686f62-ba58-4745-8a93-b5cec3f2257d" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityNotePreferredStockConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_d7686f62-ba58-4745-8a93-b5cec3f2257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_7dacfdd5-ecf2-4596-bc3a-14710f8dd6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_7dacfdd5-ecf2-4596-bc3a-14710f8dd6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_fcdb3c0e-758c-4b2b-ac87-d5475b9b209a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d870b8e6-7d04-48a4-9f8f-aa614365bec9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_fcdb3c0e-758c-4b2b-ac87-d5475b9b209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareScheduleofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7ac2c715-4711-4c7a-91f2-b89d90df76ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7ac2c715-4711-4c7a-91f2-b89d90df76ef" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6edd735a-4f85-449e-bf61-f35238145163" xlink:to="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e61bff1-eedb-43cb-ad3d-02036584bc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:to="loc_us-gaap_CommonStockMember_8e61bff1-eedb-43cb-ad3d-02036584bc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ba7f747b-9460-43dd-b935-50deda174e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6eccc8cd-96f9-416d-b854-bda52f4dc6ae" xlink:to="loc_us-gaap_PreferredStockMember_ba7f747b-9460-43dd-b935-50deda174e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_66857c2b-6d99-4170-92cd-2a977ecbfd67" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:href="cerc-20210331.xsd#cerc_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:to="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e98e1635-01f8-4edb-91a3-95e04c233d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:to="loc_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e98e1635-01f8-4edb-91a3-95e04c233d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e867b061-03ed-4a8a-b8d4-34a1d0d151e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_NumeratorAbstract_0a937a30-3476-46cf-8977-54f9f51cf7e9" xlink:to="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_e867b061-03ed-4a8a-b8d4-34a1d0d151e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:href="cerc-20210331.xsd#cerc_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_53dbda85-3aba-4b58-ac72-88011020e875" xlink:to="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08f0e904-c479-46dd-97dc-96e96700a67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08f0e904-c479-46dd-97dc-96e96700a67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c44c6d3-4aa6-43b9-abce-e038cc8c0e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c44c6d3-4aa6-43b9-abce-e038cc8c0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_85971d3c-40cd-4f23-a977-75d3a6b8b47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_85971d3c-40cd-4f23-a977-75d3a6b8b47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c8ff4270-0cd7-4b0d-98a5-09921d96169e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c8ff4270-0cd7-4b0d-98a5-09921d96169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d71d8a8-e7cb-448e-aefc-2eeb5001fe66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d71d8a8-e7cb-448e-aefc-2eeb5001fe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c7d84668-fc6c-4206-a412-b376242a5a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_DenominatorAbstract_492ec9eb-5f55-4857-b247-69145d386b1a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c7d84668-fc6c-4206-a412-b376242a5a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_56aac199-8ab1-4c1b-ad04-a88cb511c1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56aac199-8ab1-4c1b-ad04-a88cb511c1ad" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a835a1e-4423-4b21-ba44-b4f100320bc7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_aa5330ea-bd00-4195-a733-173ae1a7d96f" xlink:href="cerc-20210331.xsd#cerc_EmployeeConsultantsAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_cerc_EmployeeConsultantsAndDirectorsStockOptionsMember_aa5330ea-bd00-4195-a733-173ae1a7d96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_WarrantCommonStockMember_ea8236c6-41ae-41bb-b7ac-042c6e709898" xlink:href="cerc-20210331.xsd#cerc_WarrantCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_cerc_WarrantCommonStockMember_ea8236c6-41ae-41bb-b7ac-042c6e709898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_324e7240-ab6f-4c0a-9251-1868df20bab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_324e7240-ab6f-4c0a-9251-1868df20bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwritersUnitPurchaseOptionMember_34f20453-7dc6-4a6c-8e47-a33a059e885a" xlink:href="cerc-20210331.xsd#cerc_UnderwritersUnitPurchaseOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45f22418-c3f5-4f08-b3b3-90973b4d3a17" xlink:to="loc_cerc_UnderwritersUnitPurchaseOptionMember_34f20453-7dc6-4a6c-8e47-a33a059e885a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:to="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d31fb6-5285-449a-9284-07bd28367f88" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f81ec40e-02c0-4fe9-8ca5-c11f12fa42c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d31fb6-5285-449a-9284-07bd28367f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaMember_27fcbb2f-5642-4e05-adb6-8fd33305bb35" xlink:href="cerc-20210331.xsd#cerc_NantahalaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d31fb6-5285-449a-9284-07bd28367f88" xlink:to="loc_cerc_NantahalaMember_27fcbb2f-5642-4e05-adb6-8fd33305bb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b82aa26-930e-460b-96b4-0c06fa80249f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b46fede-df0a-42f3-a860-7e68b312e404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b46fede-df0a-42f3-a860-7e68b312e404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15aae78e-a932-4f19-af9e-611d886b96aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a479c321-ecf0-4546-ba2b-7e8bc3268efd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15aae78e-a932-4f19-af9e-611d886b96aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AssetAcquisition" xlink:type="simple" xlink:href="cerc-20210331.xsd#AssetAcquisition"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AssetAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_7f0157fb-67d3-4ce2-8604-4d8bcee42d95" xlink:href="cerc-20210331.xsd#cerc_BusinessCombinationsAndAssetAcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDisclosureTextBlock_a3d3881c-ae8c-44a0-9bed-b3eca2734c4c" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_7f0157fb-67d3-4ce2-8604-4d8bcee42d95" xlink:to="loc_cerc_AssetAcquisitionDisclosureTextBlock_a3d3881c-ae8c-44a0-9bed-b3eca2734c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AssetAcquisitionDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AssetAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AssetAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_67663b38-b92a-40e9-b376-6a7b9b96e62d" xlink:href="cerc-20210331.xsd#cerc_BusinessCombinationsAndAssetAcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract_67663b38-b92a-40e9-b376-6a7b9b96e62d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_614e643a-e724-4898-94bf-8784b7420c17" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionAxis_6d0beb5a-2dda-49aa-84f8-12aa134cbe42" xlink:to="loc_cerc_AssetAcquisitionDomain_614e643a-e724-4898-94bf-8784b7420c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_987e557c-023c-4782-88bd-54d84def03a2" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionDomain_614e643a-e724-4898-94bf-8784b7420c17" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_987e557c-023c-4782-88bd-54d84def03a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0adeb030-630e-44f2-9a1f-0361b9fa04a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6ba38ebf-21fa-41b7-828f-6a5ccfe1d0d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0adeb030-630e-44f2-9a1f-0361b9fa04a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_aacf28cd-08b4-476c-8d06-0a3825fe8a74" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0adeb030-630e-44f2-9a1f-0361b9fa04a6" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_aacf28cd-08b4-476c-8d06-0a3825fe8a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7268edf4-6096-4fd4-9829-a18392315abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1926359b-ef53-4e35-b14d-0bf3bbb50755" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7268edf4-6096-4fd4-9829-a18392315abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssembledWorkforceMember_5b1b598d-308c-4da6-b04a-75b67b2f90ce" xlink:href="cerc-20210331.xsd#cerc_AssembledWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7268edf4-6096-4fd4-9829-a18392315abd" xlink:to="loc_cerc_AssembledWorkforceMember_5b1b598d-308c-4da6-b04a-75b67b2f90ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46814f38-0b93-404a-b85d-b1ee86767263" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_4af6bf4a-73ae-4963-824b-6f199819a4f2" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable_4af6bf4a-73ae-4963-824b-6f199819a4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0df497dd-9bfa-4809-a730-94672ea0cb50" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_0df497dd-9bfa-4809-a730-94672ea0cb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_24dd8429-ba22-4b0f-abfc-983cf14eb034" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred_24dd8429-ba22-4b0f-abfc-983cf14eb034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_ad7db7cf-033b-43e8-82d0-406ee7cb3132" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_ad7db7cf-033b-43e8-82d0-406ee7cb3132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionTransactionCosts_79cd7d4d-7192-4b0a-b042-1466ab51d187" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionTransactionCosts_79cd7d4d-7192-4b0a-b042-1466ab51d187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_aff3699d-a6b7-4210-a47b-800f75da4fc4" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_aff3699d-a6b7-4210-a47b-800f75da4fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_d980e082-43b6-4d44-ae1f-8fe8d5af2997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_d980e082-43b6-4d44-ae1f-8fe8d5af2997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionCashandEquivalents_a1ebecaf-6ddb-49f7-9fa0-fa3d19d019fd" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionCashandEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_cerc_AssetAcquisitionCashandEquivalents_a1ebecaf-6ddb-49f7-9fa0-fa3d19d019fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_526043b7-a8f2-4052-9106-496d220184e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_526043b7-a8f2-4052-9106-496d220184e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4e46008-705e-4760-9022-9c1c2a67e276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41d370c4-b06a-4242-a8e6-c386c038bea5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4e46008-705e-4760-9022-9c1c2a67e276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1eab70a1-1168-4a1c-b51f-13f9a451dbfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e5b9890f-56c1-4c1a-82c1-b67b0ab53509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1eab70a1-1168-4a1c-b51f-13f9a451dbfb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e5b9890f-56c1-4c1a-82c1-b67b0ab53509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe54a217-7194-49e6-a964-5c0817aa882b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8708b367-9004-4a0b-ace8-fc835227e5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe54a217-7194-49e6-a964-5c0817aa882b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8708b367-9004-4a0b-ace8-fc835227e5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7a11a56-8590-4f7b-805c-a7897280f590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7a11a56-8590-4f7b-805c-a7897280f590" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dfd078f9-be74-4834-bd2d-9b8e9f669cea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f7e097b0-bfc0-43e6-8073-f3f7865fcf73" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dfd078f9-be74-4834-bd2d-9b8e9f669cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_239c7f46-c9dd-4b16-ad72-f1eb2ef2c8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dfd078f9-be74-4834-bd2d-9b8e9f669cea" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_239c7f46-c9dd-4b16-ad72-f1eb2ef2c8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7be14a59-b621-44ea-b0c7-f6776a9f7046" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fa000095-ef36-4649-bb32-ba2addabe73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fa000095-ef36-4649-bb32-ba2addabe73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f6600fc2-edd0-40b0-af54-7bfc9c37bf05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f6600fc2-edd0-40b0-af54-7bfc9c37bf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e8f47391-4ac9-41c3-bf4e-f92d3acfbedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cf2a9c8-3f14-4894-930c-4097fce8740c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e8f47391-4ac9-41c3-bf4e-f92d3acfbedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988d538c-b125-49af-a149-42b9774e34a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6bd28e72-190a-492a-af68-28881576a0c9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988d538c-b125-49af-a149-42b9774e34a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb8d1d72-c705-4760-98c8-4980ff1286b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988d538c-b125-49af-a149-42b9774e34a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fb8d1d72-c705-4760-98c8-4980ff1286b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ad0f848-48bb-4e08-b276-a466b33754c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber_67084e23-7b23-428e-816b-5830282a6c72" xlink:href="cerc-20210331.xsd#cerc_FairValueMeasurementsChangesInValuationTechniquesNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ad0f848-48bb-4e08-b276-a466b33754c5" xlink:to="loc_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber_67084e23-7b23-428e-816b-5830282a6c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_e0d0661a-f56d-4977-8217-114cec0857df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ad0f848-48bb-4e08-b276-a466b33754c5" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_e0d0661a-f56d-4977-8217-114cec0857df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_aa6169c3-bdce-4a59-9232-1685c48b4faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ad0f848-48bb-4e08-b276-a466b33754c5" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_aa6169c3-bdce-4a59-9232-1685c48b4faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_30fffbb0-6c13-48bf-ab61-bc621b371477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_70cb1a01-9d98-4828-b627-9da86d6f5a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_30fffbb0-6c13-48bf-ab61-bc621b371477" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_70cb1a01-9d98-4828-b627-9da86d6f5a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1f3e45a1-9a3a-462a-88ec-33f539845e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_4118d947-67fa-4352-8795-005c3f43ffbd" xlink:href="cerc-20210331.xsd#cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1f3e45a1-9a3a-462a-88ec-33f539845e30" xlink:to="loc_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_4118d947-67fa-4352-8795-005c3f43ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedResearchAndDevelopment_4ba654b2-18a0-4a48-9275-76d7348bb518" xlink:href="cerc-20210331.xsd#cerc_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_cerc_AccruedResearchAndDevelopment_4ba654b2-18a0-4a48-9275-76d7348bb518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7be94348-e428-4589-81ae-f307ca493f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7be94348-e428-4589-81ae-f307ca493f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedGeneralAndAdministrativeExpenses_e07b2e1a-ba0c-4226-bf10-06774008fcfe" xlink:href="cerc-20210331.xsd#cerc_AccruedGeneralAndAdministrativeExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_cerc_AccruedGeneralAndAdministrativeExpenses_e07b2e1a-ba0c-4226-bf10-06774008fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_6bdbb76d-f6d3-4061-815a-b7172f71b64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_6bdbb76d-f6d3-4061-815a-b7172f71b64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedSalesReturnsAndAllowances_7d60395d-5a1d-4040-88e8-59a37b25c7f0" xlink:href="cerc-20210331.xsd#cerc_AccruedSalesReturnsAndAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_cerc_AccruedSalesReturnsAndAllowances_7d60395d-5a1d-4040-88e8-59a37b25c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AccruedMedicaidRebates_6f8fb984-255f-432f-bb8d-064b3da50720" xlink:href="cerc-20210331.xsd#cerc_AccruedMedicaidRebates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_cerc_AccruedMedicaidRebates_6f8fb984-255f-432f-bb8d-064b3da50720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bf601f3e-9c96-4b4b-8bb2-b38f83ed0e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bf601f3e-9c96-4b4b-8bb2-b38f83ed0e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_64c7fcff-3bd2-4630-8fc3-5089e365d4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_64c7fcff-3bd2-4630-8fc3-5089e365d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_30ca1e38-63d3-43c9-b8a4-bb27ab9bb608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_77636fe8-4808-4cc3-a87a-2d4e7e3fb878" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_30ca1e38-63d3-43c9-b8a4-bb27ab9bb608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_824e095e-c145-4506-ac20-718a6cb4ac46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e536c911-613c-477d-aa28-b5d6d5c140a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_824e095e-c145-4506-ac20-718a6cb4ac46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e536c911-613c-477d-aa28-b5d6d5c140a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_InventoryPeriodBeforeExpiration_913cf0ab-4d08-4d9d-b966-dc88cf58e67d" xlink:href="cerc-20210331.xsd#cerc_InventoryPeriodBeforeExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_824e095e-c145-4506-ac20-718a6cb4ac46" xlink:to="loc_cerc_InventoryPeriodBeforeExpiration_913cf0ab-4d08-4d9d-b966-dc88cf58e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructure" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructure"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CapitalStructure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CAPITALSTRUCTUREAbstract_7087c4e2-9db0-4321-8714-065688d8fdf1" xlink:href="cerc-20210331.xsd#cerc_CAPITALSTRUCTUREAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_61a41726-2f0e-4e2c-8956-11d5fc112e85" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_CAPITALSTRUCTUREAbstract_7087c4e2-9db0-4321-8714-065688d8fdf1" xlink:to="loc_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock_61a41726-2f0e-4e2c-8956-11d5fc112e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CapitalStructureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CAPITALSTRUCTUREAbstract_9e21091d-67d9-4c35-914e-520c13a20e30" xlink:href="cerc-20210331.xsd#cerc_CAPITALSTRUCTUREAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_690fce27-3747-484c-879d-7b44a9fad3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_CAPITALSTRUCTUREAbstract_9e21091d-67d9-4c35-914e-520c13a20e30" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_690fce27-3747-484c-879d-7b44a9fad3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CapitalStructureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CAPITALSTRUCTUREAbstract_0d9b4535-f7da-4c4f-8159-c3ba4cbc3ddb" xlink:href="cerc-20210331.xsd#cerc_CAPITALSTRUCTUREAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_CAPITALSTRUCTUREAbstract_0d9b4535-f7da-4c4f-8159-c3ba4cbc3ddb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db981226-fa54-47c2-bb91-469c9a8664a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_UnderwrittenPublicOfferingMember_41619f4a-71de-4985-9a4f-ec5877609484" xlink:href="cerc-20210331.xsd#cerc_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_cerc_UnderwrittenPublicOfferingMember_41619f4a-71de-4985-9a4f-ec5877609484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticePurchaseAgreementMember_7a96deb5-434a-439b-b058-8c0c896b1ecd" xlink:href="cerc-20210331.xsd#cerc_ArmisticePurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_cerc_ArmisticePurchaseAgreementMember_7a96deb5-434a-439b-b058-8c0c896b1ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RegisteredDirectOfferingMember_88adaf94-a0dc-4481-8faa-9e27a6a3355c" xlink:href="cerc-20210331.xsd#cerc_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_cerc_RegisteredDirectOfferingMember_88adaf94-a0dc-4481-8faa-9e27a6a3355c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_279143f1-8b6d-422e-9c03-92c91b14d5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6f3e932-ebc6-45b0-a5dd-27c62a02b5af" xlink:to="loc_us-gaap_PrivatePlacementMember_279143f1-8b6d-422e-9c03-92c91b14d5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aaeb801f-5973-4354-88f6-194a569045ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_76bf30d8-5617-4b8c-88a6-3897a1f93f55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aaeb801f-5973-4354-88f6-194a569045ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b0038970-6ab0-46bb-82ce-73604789ee01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aaeb801f-5973-4354-88f6-194a569045ea" xlink:to="loc_us-gaap_WarrantMember_b0038970-6ab0-46bb-82ce-73604789ee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e829add8-9395-4a22-b99d-22c511661337" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticeMember_30b4228e-1e22-4df1-8b1f-0684285de6ec" xlink:href="cerc-20210331.xsd#cerc_ArmisticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:to="loc_cerc_ArmisticeMember_30b4228e-1e22-4df1-8b1f-0684285de6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaMember_05f04862-7615-4665-9877-1602217dec42" xlink:href="cerc-20210331.xsd#cerc_NantahalaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:to="loc_cerc_NantahalaMember_05f04862-7615-4665-9877-1602217dec42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_OfficersMember_4000c17e-a373-4c40-8567-9a467d7d191b" xlink:href="cerc-20210331.xsd#cerc_OfficersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9bb0d9e5-c371-4cae-9329-bbeb146efdc3" xlink:to="loc_cerc_OfficersMember_4000c17e-a373-4c40-8567-9a467d7d191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5678f4f7-f71e-4f38-b6dc-8b8d218d4c55" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7bb4c3b9-5326-43a7-9031-28923b50463e" xlink:to="loc_dei_EntityDomain_5678f4f7-f71e-4f38-b6dc-8b8d218d4c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NantahalaCapitalManagementLLCMember_50773223-e286-4230-8ba2-9b9f7e449635" xlink:href="cerc-20210331.xsd#cerc_NantahalaCapitalManagementLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5678f4f7-f71e-4f38-b6dc-8b8d218d4c55" xlink:to="loc_cerc_NantahalaCapitalManagementLLCMember_50773223-e286-4230-8ba2-9b9f7e449635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9fee57fd-c12b-425f-b48a-44e37eff5b5b" xlink:to="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ebc8f600-1240-4a6e-b995-71c6a4e150df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:to="loc_us-gaap_CommonStockMember_ebc8f600-1240-4a6e-b995-71c6a4e150df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_5ebb668e-4f64-4b48-859f-8d4c58e3cfce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc4de0c8-dd4c-4c0f-9d6b-f04ed5500425" xlink:to="loc_us-gaap_PreferredStockMember_5ebb668e-4f64-4b48-859f-8d4c58e3cfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_872055ae-7a92-4c73-a43a-91a0a0e9981e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e80fd1a9-5ebd-4f78-9a3b-03be1fe33ea5" xlink:to="loc_us-gaap_ClassOfStockDomain_872055ae-7a92-4c73-a43a-91a0a0e9981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_eaf8a667-dbd3-4703-a2aa-177d12cb1c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_872055ae-7a92-4c73-a43a-91a0a0e9981e" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_eaf8a667-dbd3-4703-a2aa-177d12cb1c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_cfda0878-4c8e-4587-8708-f19957f9fd93" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionAxis_5866097b-7197-46bb-bbe0-4842708ad7fd" xlink:to="loc_cerc_AssetAcquisitionDomain_cfda0878-4c8e-4587-8708-f19957f9fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_7c4ee507-1fd6-4039-951e-81f2686ddb61" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionDomain_cfda0878-4c8e-4587-8708-f19957f9fd93" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_7c4ee507-1fd6-4039-951e-81f2686ddb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1e1081f-2593-4bfe-80a6-15fcd2a8931d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9374a5be-5f48-4bae-b5ee-f2065893fbaf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1e1081f-2593-4bfe-80a6-15fcd2a8931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7951b88a-4fe0-49ff-b2e6-1ceb1d2fb397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1e1081f-2593-4bfe-80a6-15fcd2a8931d" xlink:to="loc_us-gaap_SubsequentEventMember_7951b88a-4fe0-49ff-b2e6-1ceb1d2fb397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a903b06e-5165-4e95-b94e-d9631bea16c7" xlink:to="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfClassOfStockAuthorized_5ec25a05-247a-4dc9-a797-6944f35ab954" xlink:href="cerc-20210331.xsd#cerc_NumberOfClassOfStockAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_NumberOfClassOfStockAuthorized_5ec25a05-247a-4dc9-a797-6944f35ab954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CapitalStockSharesAuthorized_4244b859-ce25-4ad1-b8c8-b8996af54995" xlink:href="cerc-20210331.xsd#cerc_CapitalStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_CapitalStockSharesAuthorized_4244b859-ce25-4ad1-b8c8-b8996af54995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_09ebc762-e38b-4212-91b0-820d9d8b4fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_09ebc762-e38b-4212-91b0-820d9d8b4fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c6db43c7-759d-4a1b-abb3-a1b07d079da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c6db43c7-759d-4a1b-abb3-a1b07d079da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5681845a-ab6b-467b-b207-d54258aca408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5681845a-ab6b-467b-b207-d54258aca408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4cda0a51-18ea-42c9-b94c-9367e3125c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4cda0a51-18ea-42c9-b94c-9367e3125c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3d99f72f-8a49-47a8-aeeb-24f8f7172516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3d99f72f-8a49-47a8-aeeb-24f8f7172516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25799aae-1535-4211-9221-118c5584010f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25799aae-1535-4211-9221-118c5584010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7a36cb49-3367-44fc-84ea-3d2ca3fb4b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_7a36cb49-3367-44fc-84ea-3d2ca3fb4b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a3ebc70e-8123-4bcd-a1ce-d7f30a1df008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a3ebc70e-8123-4bcd-a1ce-d7f30a1df008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_69a2a7e9-5612-42d7-8846-5bed42a46211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_69a2a7e9-5612-42d7-8846-5bed42a46211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dcc1c59-45b3-4ff8-80c9-1bf2416ddad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dcc1c59-45b3-4ff8-80c9-1bf2416ddad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_64cc0b78-111e-47a9-994b-aa75a6401bb8" xlink:href="cerc-20210331.xsd#cerc_ClassOfWarrantOrRightPercentOwnershipThreshold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold_64cc0b78-111e-47a9-994b-aa75a6401bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ad286b3d-b606-48e0-90fb-8cbabea5031e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ad286b3d-b606-48e0-90fb-8cbabea5031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_f59d8073-c5a7-46ec-8288-93cdb1d7ed9d" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares_f59d8073-c5a7-46ec-8288-93cdb1d7ed9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_32c6a727-03f2-478b-b80c-7e9b341c9b40" xlink:href="cerc-20210331.xsd#cerc_StockholdersEquityNotePreferredStockConversionRatio"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_cerc_StockholdersEquityNotePreferredStockConversionRatio_32c6a727-03f2-478b-b80c-7e9b341c9b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_8923ed39-90e4-49f7-aa19-24829442fa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_8923ed39-90e4-49f7-aa19-24829442fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_b6902bca-173f-44be-ac4a-e38c91e12665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_b6902bca-173f-44be-ac4a-e38c91e12665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_88967aba-2938-4e2d-bcbd-ffa95909e4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_88967aba-2938-4e2d-bcbd-ffa95909e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f8af7e6e-32db-4ff9-a653-079e37c34c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c8a51dc1-4aa9-431e-ba1b-b16127ea45b9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f8af7e6e-32db-4ff9-a653-079e37c34c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CapitalStructureWarrantsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CapitalStructureWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CapitalStructureWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CAPITALSTRUCTUREAbstract_a95877b3-0522-4bd1-8d28-2c9008012146" xlink:href="cerc-20210331.xsd#cerc_CAPITALSTRUCTUREAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_CAPITALSTRUCTUREAbstract_a95877b3-0522-4bd1-8d28-2c9008012146" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b6dcaf92-1e99-4572-b39c-0f9d3e5e076c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_0a618498-ffc3-4a2b-8531-c1efe6dea818" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsExpirationDateOfMay2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:to="loc_cerc_CommonStockWarrantsExpirationDateOfMay2022Member_0a618498-ffc3-4a2b-8531-c1efe6dea818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_bde60649-202c-40b5-b04a-b87be7835369" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsExpirationDateOfJune2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:to="loc_cerc_CommonStockWarrantsExpirationDateOfJune2024Member_bde60649-202c-40b5-b04a-b87be7835369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CommonStockWarrantsNoExpirationMember_bbec80bb-f555-429e-a336-486bce557c94" xlink:href="cerc-20210331.xsd#cerc_CommonStockWarrantsNoExpirationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_00c1eb04-aba6-4cc4-a525-96af307e2ef9" xlink:to="loc_cerc_CommonStockWarrantsNoExpirationMember_bbec80bb-f555-429e-a336-486bce557c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dbe650b-8aef-4d3f-bb7c-7c043ecfe315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bbb79ecc-a89f-4146-8c37-7b289c26e6e3" xlink:to="loc_us-gaap_ClassOfStockDomain_2dbe650b-8aef-4d3f-bb7c-7c043ecfe315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_94336139-ca32-44a3-9416-816df8c6a222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dbe650b-8aef-4d3f-bb7c-7c043ecfe315" xlink:to="loc_us-gaap_CommonClassAMember_94336139-ca32-44a3-9416-816df8c6a222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e4218335-ffb7-423f-8eb3-85c1acfe4e3c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5613558c-8a72-456c-8f5e-2419687ca372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5613558c-8a72-456c-8f5e-2419687ca372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5261616-101b-481e-b4ef-ba1d042ce058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8deae4ab-a825-4e21-8f14-064177db9db2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b5261616-101b-481e-b4ef-ba1d042ce058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_a9f43702-832c-472a-a43e-d05baa1b0a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ed5ea5df-abc1-45bb-a57f-f3e8b768f6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_a9f43702-832c-472a-a43e-d05baa1b0a86" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ed5ea5df-abc1-45bb-a57f-f3e8b768f6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_1bb0d645-8b6e-4d91-bf0f-4962fae21cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a5d417eb-3897-4266-aa5d-7199f6a38978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_1bb0d645-8b6e-4d91-bf0f-4962fae21cae" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a5d417eb-3897-4266-aa5d-7199f6a38978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_be4d074a-f109-4cf3-a4c2-e85f753639bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_1bb0d645-8b6e-4d91-bf0f-4962fae21cae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_be4d074a-f109-4cf3-a4c2-e85f753639bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_02b25fb9-e241-4295-907c-c4ed5ece432d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_1bb0d645-8b6e-4d91-bf0f-4962fae21cae" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_02b25fb9-e241-4295-907c-c4ed5ece432d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_83355603-3f6f-4033-a8f9-89049c7fbbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_1bb0d645-8b6e-4d91-bf0f-4962fae21cae" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_83355603-3f6f-4033-a8f9-89049c7fbbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_971439df-ca81-4bdc-aac0-5db7f091fcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_971439df-ca81-4bdc-aac0-5db7f091fcca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d08af95b-0bc2-4212-ad4a-4e57d4b222aa" xlink:to="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_The2016PlanMember_325af987-8398-4eb3-bc3a-d4056eff4218" xlink:href="cerc-20210331.xsd#cerc_The2016PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:to="loc_cerc_The2016PlanMember_325af987-8398-4eb3-bc3a-d4056eff4218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_A2016SecondAmendedPlanMember_95aa1435-8e84-40bf-8c08-4d6ea1799582" xlink:href="cerc-20210331.xsd#cerc_A2016SecondAmendedPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:to="loc_cerc_A2016SecondAmendedPlanMember_95aa1435-8e84-40bf-8c08-4d6ea1799582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ThirdAmended2016PlanMember_684a72c4-02b9-47df-aefe-474e623eda01" xlink:href="cerc-20210331.xsd#cerc_ThirdAmended2016PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fecac85e-c5e5-4888-a2af-ffc1ed4e901e" xlink:to="loc_cerc_ThirdAmended2016PlanMember_684a72c4-02b9-47df-aefe-474e623eda01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_614266d6-2726-4e07-873b-d307de17e90c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_d65f5785-8630-4dc1-b6c9-f281a2f08262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_us-gaap_StockOptionMember_d65f5785-8630-4dc1-b6c9-f281a2f08262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember_8de00055-a962-4591-b0a0-b660fd02f185" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_cerc_ServiceBasedOptionsMember_8de00055-a962-4591-b0a0-b660fd02f185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_bb9be852-7a9d-46fc-b7fb-70bdf03e7220" xlink:href="cerc-20210331.xsd#cerc_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_bb9be852-7a9d-46fc-b7fb-70bdf03e7220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c7793cf7-4404-4675-9d36-f5a0b630612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_us-gaap_RestrictedStockMember_c7793cf7-4404-4675-9d36-f5a0b630612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeStockPurchasePlanESPPMember_8cf35299-42cc-47a4-8e9d-79c7a954325d" xlink:href="cerc-20210331.xsd#cerc_EmployeeStockPurchasePlanESPPMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf053a48-59a8-481f-9e6b-0f4bab802e74" xlink:to="loc_cerc_EmployeeStockPurchasePlanESPPMember_8cf35299-42cc-47a4-8e9d-79c7a954325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b85deb60-3810-44fc-9bad-24e9bf8a654a" xlink:to="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_efa07772-3bbe-4d51-a3a4-bf96df8871d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:to="loc_srt_MinimumMember_efa07772-3bbe-4d51-a3a4-bf96df8871d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_84d66b6a-1af4-4cac-9c88-256602bd570c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60cab84f-a010-4587-8f99-eb17c3086a10" xlink:to="loc_srt_MaximumMember_84d66b6a-1af4-4cac-9c88-256602bd570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e58f0dd3-3c72-453f-95f6-014ba58e5920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_12d3321a-9b71-4fdb-bc25-7dca90b0160d" xlink:to="loc_us-gaap_GranteeStatusDomain_e58f0dd3-3c72-453f-95f6-014ba58e5920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_2d639206-80ea-477a-aa28-b3f5197cbed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_e58f0dd3-3c72-453f-95f6-014ba58e5920" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_2d639206-80ea-477a-aa28-b3f5197cbed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_415a64e6-67cb-4678-a5ae-17507a43bef7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d43f71f9-62cf-4f95-a83e-53d562446286" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_DirectorMember_d43f71f9-62cf-4f95-a83e-53d562446286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_e7b8d8c8-87fb-479b-b44b-f72e483333d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_ExecutiveOfficerMember_e7b8d8c8-87fb-479b-b44b-f72e483333d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_7cbfda55-498a-4308-a2e6-c4ec9887c554" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_ChiefExecutiveOfficerMember_7cbfda55-498a-4308-a2e6-c4ec9887c554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_19fce579-aab4-44df-be8b-0003ee804cc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2b6deba3-b406-460f-8237-b09a87c3cbaa" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_19fce579-aab4-44df-be8b-0003ee804cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_62017505-1e55-42a3-91ac-b0451df8a3da" xlink:to="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f3d59a60-5638-44de-bf75-2c43dec2f7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f3d59a60-5638-44de-bf75-2c43dec2f7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e943c525-ed23-4690-ac9c-cc05e202a873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e943c525-ed23-4690-ac9c-cc05e202a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a427357d-1e46-4ffa-9a75-0a30ebeb99c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b7397d52-4b8a-437c-b263-12f18bd0ba0b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a427357d-1e46-4ffa-9a75-0a30ebeb99c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_facf919b-750d-4bff-aed0-a3eaf5fa093b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bebef1ff-89bf-4e18-a621-80b42138a88c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_facf919b-750d-4bff-aed0-a3eaf5fa093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_EmployeeStockPurchasePlanESPPMember_b73c58f9-ff6d-4334-b9f4-db57606f21a7" xlink:href="cerc-20210331.xsd#cerc_EmployeeStockPurchasePlanESPPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_facf919b-750d-4bff-aed0-a3eaf5fa093b" xlink:to="loc_cerc_EmployeeStockPurchasePlanESPPMember_b73c58f9-ff6d-4334-b9f4-db57606f21a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b740685-8ddf-48fd-902a-8fbf119dfa15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_a297c4da-cfa9-4fbf-a5a1-6f57f4ebf586" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease_a297c4da-cfa9-4fbf-a5a1-6f57f4ebf586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e665137-73c4-47b3-a937-251b8760d509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e665137-73c4-47b3-a937-251b8760d509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_bd774fcb-4a50-4edf-9560-dd90419038ea" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent_bd774fcb-4a50-4edf-9560-dd90419038ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f01488-c466-4d6d-91ee-195f39c5d18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c4f01488-c466-4d6d-91ee-195f39c5d18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e662d2e-1fd6-4aa5-80c0-3f957122a166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e662d2e-1fd6-4aa5-80c0-3f957122a166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f6cea95-2789-4b33-91bd-64af9c96f86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f6cea95-2789-4b33-91bd-64af9c96f86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_f3cc06de-ddff-425d-b1a1-a48b3f361986" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross_f3cc06de-ddff-425d-b1a1-a48b3f361986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AnnualBaseSalary_c23f1c15-4589-4809-abfb-ca0474e209d3" xlink:href="cerc-20210331.xsd#cerc_AnnualBaseSalary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_AnnualBaseSalary_c23f1c15-4589-4809-abfb-ca0474e209d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_41847abc-4a1c-4895-b99c-7fe88274b86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_41847abc-4a1c-4895-b99c-7fe88274b86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88365d0a-a0ec-4ffb-bb3b-4638eeac794d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88365d0a-a0ec-4ffb-bb3b-4638eeac794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_eadd3493-1efd-4aa3-8d74-a245637c3aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_eadd3493-1efd-4aa3-8d74-a245637c3aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ebec49a1-1035-4dbc-8a1a-735984309aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ebec49a1-1035-4dbc-8a1a-735984309aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_747ef180-4305-4e4b-8c57-0a0e609b1785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_747ef180-4305-4e4b-8c57-0a0e609b1785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_45d798de-0bda-40d9-855a-c88ea1957c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_45d798de-0bda-40d9-855a-c88ea1957c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2323e676-2c17-4917-a2e4-483c5d012e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2323e676-2c17-4917-a2e4-483c5d012e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722a0f57-d558-4e7f-8016-614dc5939957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722a0f57-d558-4e7f-8016-614dc5939957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4f11f1a7-57ff-4e66-a7c8-a833b54ec58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4f11f1a7-57ff-4e66-a7c8-a833b54ec58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_b7ccf9dc-240d-458b-b288-18eb16aaefbb" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage_b7ccf9dc-240d-458b-b288-18eb16aaefbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d92f27e-7418-4c17-a4af-b8ff0388c5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d92f27e-7418-4c17-a4af-b8ff0388c5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_94c4951a-a9bf-4e30-9d8c-0ba6f4d8773a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_94c4951a-a9bf-4e30-9d8c-0ba6f4d8773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_67fe5273-e19a-40f1-9e34-0ebf4641c6f1" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum_67fe5273-e19a-40f1-9e34-0ebf4641c6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ae60a276-8592-4afc-a8d1-10e51f5b256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ae60a276-8592-4afc-a8d1-10e51f5b256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_56219023-7da1-4d88-8857-02ab981ed5be" xlink:href="cerc-20210331.xsd#cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear_56219023-7da1-4d88-8857-02ab981ed5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_eaa30ac6-cf00-4db3-a95f-ef0ad6692950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42fd6784-fab7-4515-b471-d2b468b617d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_eaa30ac6-cf00-4db3-a95f-ef0ad6692950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12e6c56e-b9b7-4c9d-a3e1-2954f4cbf458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12e6c56e-b9b7-4c9d-a3e1-2954f4cbf458" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1c0c8cad-1ebf-4b66-86bd-603293a04b79" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4b877a9-b413-41eb-a15b-29b3d7ec9d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d4b877a9-b413-41eb-a15b-29b3d7ec9d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa45b764-f3bb-42e7-ab92-34d3b2260eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa45b764-f3bb-42e7-ab92-34d3b2260eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_6c3a951e-2f35-4812-bdaa-7678178465fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c331c76d-afda-4bb1-a766-4902c719905a" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_6c3a951e-2f35-4812-bdaa-7678178465fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28cdd192-47ae-41b2-9f39-985a36728067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff62e0c6-faa3-48c5-9205-9c50bf6fb3b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28cdd192-47ae-41b2-9f39-985a36728067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f397671c-cad6-4b7b-9146-dbd4a2ed06bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28cdd192-47ae-41b2-9f39-985a36728067" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f397671c-cad6-4b7b-9146-dbd4a2ed06bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b38877b8-cc4f-42fe-a3da-bb9957ba97fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b38877b8-cc4f-42fe-a3da-bb9957ba97fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:to="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcdcbf87-a6f9-4e96-b58e-787e04e266ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_87ca125c-8885-4d01-bbf8-082a962cb7c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcdcbf87-a6f9-4e96-b58e-787e04e266ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember_6956a838-91fd-4950-b9e7-32dc5165e976" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcdcbf87-a6f9-4e96-b58e-787e04e266ca" xlink:to="loc_cerc_ServiceBasedOptionsMember_6956a838-91fd-4950-b9e7-32dc5165e976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ae0bf30-2ab8-41f7-8b95-c638529e25c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34e32a3a-1395-4188-b57f-353cf2d20bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34e32a3a-1395-4188-b57f-353cf2d20bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_913a53c7-20ad-4482-af75-6c6ca0300549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_913a53c7-20ad-4482-af75-6c6ca0300549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f4134e-acc9-430f-9df2-ce85addd2c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f4134e-acc9-430f-9df2-ce85addd2c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f62bc41-8c70-445a-9916-2d00b3b83af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f62bc41-8c70-445a-9916-2d00b3b83af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef29287c-117b-45ef-98cb-683ad49bff3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fa7b23d7-c09e-4216-8958-3bcb99dc2d24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef29287c-117b-45ef-98cb-683ad49bff3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6833f7e9-5cb3-48c4-a70e-4b2af8837502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6833f7e9-5cb3-48c4-a70e-4b2af8837502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40b7fc22-6064-4f53-b33e-f00cf33541cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40b7fc22-6064-4f53-b33e-f00cf33541cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57128f07-4f42-450d-9f52-4f809a45a77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57128f07-4f42-450d-9f52-4f809a45a77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4cb3e14c-1c9c-4d1a-a552-61aee04042e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4cb3e14c-1c9c-4d1a-a552-61aee04042e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a4edcaf-e58e-445c-8982-0d6722f7abd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a4edcaf-e58e-445c-8982-0d6722f7abd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5cb2737-fe18-46ad-97e5-df072f26b44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d0d57cb-0115-4657-99f0-7a09148bd4d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5cb2737-fe18-46ad-97e5-df072f26b44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c75b3b71-97e5-493c-a53c-3724b364c6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c75b3b71-97e5-493c-a53c-3724b364c6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_14b6415a-9fa1-4600-b9d0-ad8b669ce990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_14b6415a-9fa1-4600-b9d0-ad8b669ce990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_46f5aaa1-7ced-491b-9f68-72e0348d6d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_46f5aaa1-7ced-491b-9f68-72e0348d6d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_cbb4b7f9-88fe-4160-a6eb-4e2694047c54" xlink:href="cerc-20210331.xsd#cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue_cbb4b7f9-88fe-4160-a6eb-4e2694047c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_959575af-0559-46e5-ae6c-7e224e39894d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_959575af-0559-46e5-ae6c-7e224e39894d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_b4025dbd-6018-4366-9805-aefac11d0e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_3a9eb8bf-c96c-41ff-8b9c-34d1138eb198" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_b4025dbd-6018-4366-9805-aefac11d0e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_acb99aa1-0df7-49de-b1d4-1d6d8c149641" xlink:href="cerc-20210331.xsd#cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_acb99aa1-0df7-49de-b1d4-1d6d8c149641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_555e76f3-d672-4b76-8be9-9457e1469ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc38b99e-7fc2-42c6-b59c-b091f658f639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc38b99e-7fc2-42c6-b59c-b091f658f639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f67cccd8-f31c-4d5c-9ae0-71fb7fb91ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2289d20d-5ace-4f33-a28a-9bd7c56bc433" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f67cccd8-f31c-4d5c-9ae0-71fb7fb91ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockbasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34c20581-7042-4ac7-b56b-242f07a0782c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34c20581-7042-4ac7-b56b-242f07a0782c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:to="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ba4ddb8-cf93-4be9-8241-af7c1e0c40d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0bbfb01e-1062-466b-9b2e-0d23d2814d27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ba4ddb8-cf93-4be9-8241-af7c1e0c40d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ServiceBasedOptionsMember_b8201867-46c7-4da3-8b64-fa5e3448b2d2" xlink:href="cerc-20210331.xsd#cerc_ServiceBasedOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ba4ddb8-cf93-4be9-8241-af7c1e0c40d5" xlink:to="loc_cerc_ServiceBasedOptionsMember_b8201867-46c7-4da3-8b64-fa5e3448b2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:to="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_705677cf-5d99-445e-97fd-fa24d78024de" xlink:to="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_593e735d-ab2c-4367-969c-40bee481f803" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:to="loc_srt_MinimumMember_593e735d-ab2c-4367-969c-40bee481f803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8aba2490-8477-471b-88ab-85a398107363" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0eac1c2-0a9c-40b5-b24b-9542eb1683d6" xlink:to="loc_srt_MaximumMember_8aba2490-8477-471b-88ab-85a398107363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca0d63a2-3625-4188-bc36-325f5774caf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ab37222a-1a07-4286-b13c-1ac74596e9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ab37222a-1a07-4286-b13c-1ac74596e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d99d22b4-609d-479e-a7fe-fc58416665a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d99d22b4-609d-479e-a7fe-fc58416665a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_73a3d98a-e5ba-40d4-bc03-8e60d7ebbca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_73a3d98a-e5ba-40d4-bc03-8e60d7ebbca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_24b56805-3c80-4fca-801f-36829f8c9ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_968478e9-8230-438a-b415-76748a3e6f02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_24b56805-3c80-4fca-801f-36829f8c9ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f16ee0a1-b6c7-4063-9ab9-ab916764902f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f16ee0a1-b6c7-4063-9ab9-ab916764902f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:to="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3133478f-16d9-4907-bb48-4116c65518fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_707483bb-03e9-43a7-92b6-3ec7de0932aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3133478f-16d9-4907-bb48-4116c65518fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_34ce07f2-491b-493a-bf5a-8e480adc5e0b" xlink:href="cerc-20210331.xsd#cerc_StockOptionsWithMarketBasedVestingConditionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3133478f-16d9-4907-bb48-4116c65518fd" xlink:to="loc_cerc_StockOptionsWithMarketBasedVestingConditionsMember_34ce07f2-491b-493a-bf5a-8e480adc5e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e211c0d-6420-4392-aa0b-8796cafd9b30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8f773b86-9026-4804-8333-149ef837efef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8f773b86-9026-4804-8333-149ef837efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a23ca45f-013d-4bc4-8099-eebf2e893114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a23ca45f-013d-4bc4-8099-eebf2e893114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45f8f6ba-3aee-47da-915a-71f6af88e215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6e2fefc4-d585-4562-8440-f1271c1c4c3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45f8f6ba-3aee-47da-915a-71f6af88e215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4dc359c6-b9ca-41b2-a8cd-4a3d3dbdb8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4dc359c6-b9ca-41b2-a8cd-4a3d3dbdb8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_83a6d293-66c9-44c7-9c24-502c8bb5e1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_83a6d293-66c9-44c7-9c24-502c8bb5e1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96528cd2-2002-4eb4-9ae1-59a7eb7550e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96528cd2-2002-4eb4-9ae1-59a7eb7550e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_acbc48bd-dbe1-474f-a065-a4927fc070c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5750fd81-fb6d-4e35-b09f-27cb6b370492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_acbc48bd-dbe1-474f-a065-a4927fc070c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_14686489-f1ed-4e51-91f6-a8e8420e4681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_14686489-f1ed-4e51-91f6-a8e8420e4681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7ece3a6-d887-4221-a55a-9d0cfa62ea35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_14686489-f1ed-4e51-91f6-a8e8420e4681" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7ece3a6-d887-4221-a55a-9d0cfa62ea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266a034f-3bf6-49d6-8f14-70a8e9018cd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f02a91dc-ee52-497f-bd5e-857d873521c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f02a91dc-ee52-497f-bd5e-857d873521c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_856476b4-9ebd-4af7-84e1-aee8f023b05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_529ff60f-6e5a-432e-b68e-83550d176bc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_856476b4-9ebd-4af7-84e1-aee8f023b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ed0cd9c-aac2-4ebc-81f0-34b90d8de0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ed0cd9c-aac2-4ebc-81f0-34b90d8de0ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:to="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd350d55-6892-442f-84d6-50bf9bbff72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2488381f-5508-4063-b8b0-7af411d239c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd350d55-6892-442f-84d6-50bf9bbff72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1cfc0a85-3dfd-496b-80e4-7c817bbac5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd350d55-6892-442f-84d6-50bf9bbff72a" xlink:to="loc_us-gaap_RestrictedStockMember_1cfc0a85-3dfd-496b-80e4-7c817bbac5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7506c248-0cf4-4faf-92a4-5172fd827c72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28308509-3f46-42f1-aa04-6de49ee651d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28308509-3f46-42f1-aa04-6de49ee651d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00a0b222-0abd-46fe-9bda-7b52baf2a2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00a0b222-0abd-46fe-9bda-7b52baf2a2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e0746df3-f050-4b24-9508-19f2b1be94e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_6303e66b-cb41-43dd-9564-411991d6693c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e0746df3-f050-4b24-9508-19f2b1be94e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a843c003-644b-4db1-b5ba-7136db274a95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0dd97dfe-316c-4913-9726-02401a7a0e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0dd97dfe-316c-4913-9726-02401a7a0e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_93072781-e305-4c38-88b6-6e84e41f260a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_93072781-e305-4c38-88b6-6e84e41f260a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b19c27ea-3f89-47fe-8716-6116cf538ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ef8614c-6aa8-4901-9374-984ac46bc87e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b19c27ea-3f89-47fe-8716-6116cf538ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cerc-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ea38c9e-27b8-4fd7-b05b-c091f692dd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_edaa3e60-d83f-438e-a536-fc941a7ba93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ea38c9e-27b8-4fd7-b05b-c091f692dd1c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_edaa3e60-d83f-438e-a536-fc941a7ba93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a69bd55-7021-4ec4-a945-7fcb805b7636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f804c57a-debe-47f5-a3af-b1e7a00c74d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a69bd55-7021-4ec4-a945-7fcb805b7636" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f804c57a-debe-47f5-a3af-b1e7a00c74d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/Leases" xlink:type="simple" xlink:href="cerc-20210331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9777e8e3-537d-49b7-b1fe-4ae7a8cf4adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8524b094-58a9-4b08-a108-f4ad13c045ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9777e8e3-537d-49b7-b1fe-4ae7a8cf4adc" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8524b094-58a9-4b08-a108-f4ad13c045ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesTables" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_97979206-d6be-4589-abae-ac00a7029da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetsAndLiabilitiesLesseeTableTextBlock_37eb3988-aacd-4b9c-954a-57acf81182fd" xlink:href="cerc-20210331.xsd#cerc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_97979206-d6be-4589-abae-ac00a7029da5" xlink:to="loc_cerc_AssetsAndLiabilitiesLesseeTableTextBlock_37eb3988-aacd-4b9c-954a-57acf81182fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_afc36ca8-8d02-4f3d-a5ce-6fc4989e1152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_97979206-d6be-4589-abae-ac00a7029da5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_afc36ca8-8d02-4f3d-a5ce-6fc4989e1152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b0123ff3-ceb2-4a22-ba63-e7c8cd1b6c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_97979206-d6be-4589-abae-ac00a7029da5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b0123ff3-ceb2-4a22-ba63-e7c8cd1b6c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dc09a47a-d62b-4bfb-bbfb-c26b049a8d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc09a47a-d62b-4bfb-bbfb-c26b049a8d2a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03807777-1d9e-4f43-a9cb-8dc889eca890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9aef242-a414-4d68-bfe0-f84ab92a0b65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03807777-1d9e-4f43-a9cb-8dc889eca890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_efd4704f-6599-4957-b880-1781c7340e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03807777-1d9e-4f43-a9cb-8dc889eca890" xlink:to="loc_us-gaap_BuildingMember_efd4704f-6599-4957-b880-1781c7340e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:to="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_601e44de-b6f0-4822-b2b4-0e1bbf9099e5" xlink:to="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_96b673a3-fe39-43fb-a2d6-3af8d0d69f62" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:to="loc_stpr_MD_96b673a3-fe39-43fb-a2d6-3af8d0d69f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_98c335d1-67f3-48ca-893e-868ccc76b0d8" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_PA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c5275ed5-324e-4661-875f-7f5232c569f0" xlink:to="loc_stpr_PA_98c335d1-67f3-48ca-893e-868ccc76b0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbb58aa7-7770-4a36-b500-71e7fdb45fe4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseNumberOfContracts_582503b5-87d0-42a7-8b59-afa9aff2e164" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseNumberOfContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseNumberOfContracts_582503b5-87d0-42a7-8b59-afa9aff2e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_e5264a71-db10-43d0-89dc-35238a552845" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent_e5264a71-db10-43d0-89dc-35238a552845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_db7d35af-1652-4caa-9df3-e5997c228751" xlink:href="cerc-20210331.xsd#cerc_OperatingLeasesRentExpenseAnnualIncreasePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent_db7d35af-1652-4caa-9df3-e5997c228751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseRentAbatementPeriod_8879c5d1-d80f-4d8c-84fd-43c16e8729d3" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseRentAbatementPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseRentAbatementPeriod_8879c5d1-d80f-4d8c-84fd-43c16e8729d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61fc7963-ec1e-44d5-b1f9-95b48dfd07f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61fc7963-ec1e-44d5-b1f9-95b48dfd07f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_498a0076-45b1-49c2-96d1-98c075332a0c" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseNumberOfRenewalOptions_498a0076-45b1-49c2-96d1-98c075332a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_265aceb6-a433-4054-a971-ed335aec7985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_265aceb6-a433-4054-a971-ed335aec7985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LesseeOperatingLeaseRemainingLeaseTeam_05500fa5-0576-4f46-9810-864d82746aa7" xlink:href="cerc-20210331.xsd#cerc_LesseeOperatingLeaseRemainingLeaseTeam"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_cerc_LesseeOperatingLeaseRemainingLeaseTeam_05500fa5-0576-4f46-9810-864d82746aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4654800a-fc70-412e-bb78-068a17c29957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8f1e55e-b72a-4cf7-99c9-9a9f86370826" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4654800a-fc70-412e-bb78-068a17c29957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_47e39b75-9133-4e87-ba22-aa4acefac588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_47e39b75-9133-4e87-ba22-aa4acefac588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3e7f6809-b4b3-4733-ac29-9eb61404aa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3e7f6809-b4b3-4733-ac29-9eb61404aa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c9eff76c-4b8f-46a4-91e0-2d25c1c985db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c9eff76c-4b8f-46a4-91e0-2d25c1c985db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ea0c11c-556a-45ba-871d-b72b448b8bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ea0c11c-556a-45ba-871d-b72b448b8bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e62962af-1344-4bf9-83e1-ea17e1d6fa29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_e62962af-1344-4bf9-83e1-ea17e1d6fa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0b6fe90-99d4-469d-a2de-ebd7d3d08bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0b6fe90-99d4-469d-a2de-ebd7d3d08bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e05f9e7c-b108-42aa-99b7-50e0444ad1f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ba98bda-7bd1-44c5-8d1f-6e80c7b85513" xlink:to="loc_us-gaap_OperatingLeaseLiability_e05f9e7c-b108-42aa-99b7-50e0444ad1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3b3a3d58-e01a-41e5-8ee2-18b4e81a0623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ab32d5e9-2faf-4062-bd41-114021729da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b3a3d58-e01a-41e5-8ee2-18b4e81a0623" xlink:to="loc_us-gaap_OperatingLeaseCost_ab32d5e9-2faf-4062-bd41-114021729da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/LeasesLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_632a6fed-da5a-45b4-9531-1563bcca166b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_632a6fed-da5a-45b4-9531-1563bcca166b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_27c84c71-ca0c-4dcf-be6b-8129903522b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_27c84c71-ca0c-4dcf-be6b-8129903522b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d08a520d-d312-4b19-bc5c-5ed344790615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d08a520d-d312-4b19-bc5c-5ed344790615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f391d1c9-b420-4b9d-9a23-83063decb3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f391d1c9-b420-4b9d-9a23-83063decb3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7d5a177f-6827-497b-88f4-6bbe87d542c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7d5a177f-6827-497b-88f4-6bbe87d542c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_34c5007b-58fa-4a28-a2f4-e5edc1f18d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_34c5007b-58fa-4a28-a2f4-e5edc1f18d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3d42b5df-d202-4efb-9cca-560c2ee9e932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3d42b5df-d202-4efb-9cca-560c2ee9e932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_450ac954-2e76-4853-8a9c-3f7a766fc72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_450ac954-2e76-4853-8a9c-3f7a766fc72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6dd38149-5734-434b-9634-bc8ee8c4d553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6dd38149-5734-434b-9634-bc8ee8c4d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5a39462e-2de3-4ae0-8ba6-eeee308c7b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6ff921da-54fd-4494-a965-3d71714d7639" xlink:to="loc_us-gaap_OperatingLeaseLiability_5a39462e-2de3-4ae0-8ba6-eeee308c7b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1" xlink:type="simple" xlink:href="cerc-20210331.xsd#LeasesLeaseMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cerecor.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cerc-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ac49269-0a9e-4bf9-be4a-216bbe0c53d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6737c418-a7f6-41f3-9350-cc52f2f0918a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ac49269-0a9e-4bf9-be4a-216bbe0c53d8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6737c418-a7f6-41f3-9350-cc52f2f0918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cerecor.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cerc-20210331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cerecor.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b14a2e53-09e3-4800-ac73-4a11ab345880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b14a2e53-09e3-4800-ac73-4a11ab345880" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d93d58d4-a2df-48bc-9b92-b082133c0d5f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_188c1f9a-7dc7-4eb4-a469-dc5574b78866" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d93d58d4-a2df-48bc-9b92-b082133c0d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TRISPharmaMember_e2144d2f-4a16-4375-98d9-ba8cd8e89c02" xlink:href="cerc-20210331.xsd#cerc_TRISPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d93d58d4-a2df-48bc-9b92-b082133c0d5f" xlink:to="loc_cerc_TRISPharmaMember_e2144d2f-4a16-4375-98d9-ba8cd8e89c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20a28d3e-256c-43fe-942c-b03ed6af67f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e412a19-057b-40ea-ab73-f1e49e2670de" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20a28d3e-256c-43fe-942c-b03ed6af67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_KarbinalAgreementMember_1f58fd99-f967-4651-a4c0-ff411b0d1084" xlink:href="cerc-20210331.xsd#cerc_KarbinalAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_20a28d3e-256c-43fe-942c-b03ed6af67f8" xlink:to="loc_cerc_KarbinalAgreementMember_1f58fd99-f967-4651-a4c0-ff411b0d1084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_04cea93f-e431-472d-a576-e3233ca6d031" xlink:to="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MillipredMember_91eaeb28-c1fd-4a43-98af-b0e2df246b8d" xlink:href="cerc-20210331.xsd#cerc_MillipredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_MillipredMember_91eaeb28-c1fd-4a43-98af-b0e2df246b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC611Member_7af7b349-8a2a-4ff7-8bdd-1fd77391a1cf" xlink:href="cerc-20210331.xsd#cerc_CERC611Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC611Member_7af7b349-8a2a-4ff7-8bdd-1fd77391a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f0614a21-fda7-49fd-b7f2-d4cb81733098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_us-gaap_LicenseMember_f0614a21-fda7-49fd-b7f2-d4cb81733098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC002KKCLicenseAgreementMember_9472154e-d41b-449d-ba82-cf8e9ed15dbd" xlink:href="cerc-20210331.xsd#cerc_CERC002KKCLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC002KKCLicenseAgreementMember_9472154e-d41b-449d-ba82-cf8e9ed15dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC006AstellasLicenseAgreementMember_01065913-8051-402c-ba96-d7e5a5a7b724" xlink:href="cerc-20210331.xsd#cerc_CERC006AstellasLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC006AstellasLicenseAgreementMember_01065913-8051-402c-ba96-d7e5a5a7b724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC007AstraZenecaLicenseAgreementMember_d2412697-974a-46e7-8a7c-6a8f673750ae" xlink:href="cerc-20210331.xsd#cerc_CERC007AstraZenecaLicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC007AstraZenecaLicenseAgreementMember_d2412697-974a-46e7-8a7c-6a8f673750ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC801CERC802AndCERC803Member_a6d4aa76-6087-4d34-90c4-0f6ff13378f9" xlink:href="cerc-20210331.xsd#cerc_CERC801CERC802AndCERC803Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC801CERC802AndCERC803Member_a6d4aa76-6087-4d34-90c4-0f6ff13378f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_CERC913Member_da66c903-e93c-41de-bded-e44ec0bdc592" xlink:href="cerc-20210331.xsd#cerc_CERC913Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9cdba97b-ff59-43b4-be9d-71d6dad9cfe4" xlink:to="loc_cerc_CERC913Member_da66c903-e93c-41de-bded-e44ec0bdc592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dca96955-4c2a-435a-9add-dffbb84a7af8" xlink:to="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_3e9e2888-e5f3-463c-9d8b-1f653ffa2fcd" xlink:href="cerc-20210331.xsd#cerc_TevaPharmaceuticalIndustriesLtd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:to="loc_cerc_TevaPharmaceuticalIndustriesLtd.Member_3e9e2888-e5f3-463c-9d8b-1f653ffa2fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_ArmisticeMember_80fdc6a1-4618-49e8-b39c-3a69e967a71b" xlink:href="cerc-20210331.xsd#cerc_ArmisticeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_36165e12-f338-408c-ab1d-71b66ad2e213" xlink:to="loc_cerc_ArmisticeMember_80fdc6a1-4618-49e8-b39c-3a69e967a71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a3a49e26-91c5-411f-aee3-064d8980aaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_72df747f-efe2-4cc0-a293-b903d8205b03" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a3a49e26-91c5-411f-aee3-064d8980aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_43cb6871-d293-4894-9a65-3e72c85fe929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a3a49e26-91c5-411f-aee3-064d8980aaa3" xlink:to="loc_us-gaap_SubsequentEventMember_43cb6871-d293-4894-9a65-3e72c85fe929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionAxis_e7dd312f-3176-409a-904d-7e538e5cbf0e" xlink:to="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_5617dce6-f04f-4e42-9fb6-532c7cb7e7ca" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_5617dce6-f04f-4e42-9fb6-532c7cb7e7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_IchorionMember_9d829814-1283-4d7d-9a70-5ee7867b5d51" xlink:href="cerc-20210331.xsd#cerc_IchorionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_AssetAcquisitionDomain_da16985e-7c2b-4c93-98ef-a83bd757972b" xlink:to="loc_cerc_IchorionMember_9d829814-1283-4d7d-9a70-5ee7867b5d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:href="cerc-20210331.xsd#cerc_MilestoneAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:href="cerc-20210331.xsd#cerc_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_MilestoneAxis_4c4ad6c1-0c5a-4b50-aaa7-0aee78505af8" xlink:to="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneOneMember_fd53a945-7558-474b-9330-e7b9b8ef5c2a" xlink:href="cerc-20210331.xsd#cerc_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:to="loc_cerc_MilestoneOneMember_fd53a945-7558-474b-9330-e7b9b8ef5c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneTwoMember_31015ef6-71fc-42ba-a4ad-a9fe40ec961e" xlink:href="cerc-20210331.xsd#cerc_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:to="loc_cerc_MilestoneTwoMember_31015ef6-71fc-42ba-a4ad-a9fe40ec961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_MilestoneThreeMember_c8dd393a-1fa6-48aa-a4e0-4941c98c0eb2" xlink:href="cerc-20210331.xsd#cerc_MilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cerc_MilestoneDomain_8581d949-0ba6-47ac-b20b-226f28e4dfd0" xlink:to="loc_cerc_MilestoneThreeMember_c8dd393a-1fa6-48aa-a4e0-4941c98c0eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3ced8a15-6ddf-4e7b-a649-bae6299fd396" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_dd0c0d1a-ec0b-4b18-9246-eb019b99da6e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3ced8a15-6ddf-4e7b-a649-bae6299fd396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2c4edeb8-1647-49f4-ab04-e3f04c2c34e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3ced8a15-6ddf-4e7b-a649-bae6299fd396" xlink:to="loc_srt_ScenarioForecastMember_2c4edeb8-1647-49f4-ab04-e3f04c2c34e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa44fa58-e5f1-4eee-9560-c346cb8f66c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ad2a903a-3604-4dc4-a7e6-3814b1539435" xlink:to="loc_dei_EntityDomain_fa44fa58-e5f1-4eee-9560-c346cb8f66c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AeviGenomicMedicineIncMember_4b584c9d-67e6-453a-8818-a9c35833f2f6" xlink:href="cerc-20210331.xsd#cerc_AeviGenomicMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fa44fa58-e5f1-4eee-9560-c346cb8f66c5" xlink:to="loc_cerc_AeviGenomicMedicineIncMember_4b584c9d-67e6-453a-8818-a9c35833f2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6fd3d7bb-b2f4-4a5e-809b-96d5a106d276" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_763e9fc6-6c8a-49d6-8fdf-b3b18b55e046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired_763e9fc6-6c8a-49d6-8fdf-b3b18b55e046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementMakeWholePaymentPerUnit_2ae0e285-c694-445e-a790-a58ecbda9c9f" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementMakeWholePaymentPerUnit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementMakeWholePaymentPerUnit_2ae0e285-c694-445e-a790-a58ecbda9c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementSemiAnnualLicensePayment_e785e94e-a866-48ae-ad62-83ef3a874445" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementSemiAnnualLicensePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementSemiAnnualLicensePayment_e785e94e-a866-48ae-ad62-83ef3a874445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_24bfc38c-1868-4ebf-a1b6-48392e019f18" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment_24bfc38c-1868-4ebf-a1b6-48392e019f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementInstallmentPayment_f4a4d22b-6712-43ee-b33f-8c6a3140baf3" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementInstallmentPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementInstallmentPayment_f4a4d22b-6712-43ee-b33f-8c6a3140baf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_e489e46e-1b06-4082-a48f-be922f7e49a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_RevenueFromRelatedParties_e489e46e-1b06-4082-a48f-be922f7e49a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_9c0e2299-8c93-4c57-93a4-9434bee79804" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestonePaymentNumberOne"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne_9c0e2299-8c93-4c57-93a4-9434bee79804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_a8d04790-3092-4f89-95e8-b0cd4086dbe5" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne_a8d04790-3092-4f89-95e8-b0cd4086dbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_183345dd-2299-461b-94b0-d7fa3a9bc0b1" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo_183345dd-2299-461b-94b0-d7fa3a9bc0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_92c539bb-69fc-4f3f-ad3e-b54a45499534" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo_92c539bb-69fc-4f3f-ad3e-b54a45499534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseObligationNoncurrent_c37df290-5d48-409b-8d90-5605211c58dc" xlink:href="cerc-20210331.xsd#cerc_LicenseObligationNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseObligationNoncurrent_c37df290-5d48-409b-8d90-5605211c58dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d6b08d-ea4b-4bbb-8bee-880dce90c1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d6b08d-ea4b-4bbb-8bee-880dce90c1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PotentialFutureRegulatoryMilestone_3d30f9dc-c1e1-4d95-afcd-f7e48c1ee001" xlink:href="cerc-20210331.xsd#cerc_PotentialFutureRegulatoryMilestone"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_PotentialFutureRegulatoryMilestone_3d30f9dc-c1e1-4d95-afcd-f7e48c1ee001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementUpfrontFee_8debec2d-162b-4f07-b61d-e37749ce8ec2" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementUpfrontFee_8debec2d-162b-4f07-b61d-e37749ce8ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_8ea0ac86-b51f-4d75-bd7a-626f415f302e" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing_8ea0ac86-b51f-4d75-bd7a-626f415f302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_LicenseAgreementMilestonePaymentRecognized_7bf24a24-713c-4633-9490-f2c6a6104a73" xlink:href="cerc-20210331.xsd#cerc_LicenseAgreementMilestonePaymentRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_LicenseAgreementMilestonePaymentRecognized_7bf24a24-713c-4633-9490-f2c6a6104a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementPaymentReceived_afe8746b-2789-423b-9cf2-8cc173eee388" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementPaymentReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_RoyaltyAgreementPaymentReceived_afe8746b-2789-423b-9cf2-8cc173eee388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_c883fa24-962d-41ef-a413-fcbb91ebfb09" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement_c883fa24-962d-41ef-a413-fcbb91ebfb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_9ff3e52f-16d0-41e2-ab74-3cc0da31ea63" xlink:href="cerc-20210331.xsd#cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments_9ff3e52f-16d0-41e2-ab74-3cc0da31ea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_7f5de0c9-6739-45eb-baa8-c4ac9649a69b" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightNumberOfMilestones"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones_7f5de0c9-6739-45eb-baa8-c4ac9649a69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_5e061ad4-2d61-4fe0-9729-08247d31dc8d" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments_5e061ad4-2d61-4fe0-9729-08247d31dc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_AssetAcquisitionContingentConsiderationLiability_f6db0c44-ea44-4dfb-b0ee-fed67be388a4" xlink:href="cerc-20210331.xsd#cerc_AssetAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_AssetAcquisitionContingentConsiderationLiability_f6db0c44-ea44-4dfb-b0ee-fed67be388a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_NumberOfPreclinicalTherapies_1eec1fae-326c-428d-bb05-bce29702a1ff" xlink:href="cerc-20210331.xsd#cerc_NumberOfPreclinicalTherapies"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_NumberOfPreclinicalTherapies_1eec1fae-326c-428d-bb05-bce29702a1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_69b480ad-8d99-47dd-824d-3af0e506591e" xlink:href="cerc-20210331.xsd#cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_86f36c56-9f01-4841-8067-73a04b145506" xlink:to="loc_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities_69b480ad-8d99-47dd-824d-3af0e506591e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cerc-20210331_g1.jpg
<TEXT>
begin 644 cerc-20210331_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0/!9X# 2(  A$! Q$!_\0
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M ./4?\/!/B?_ 'K'_OY=?_'J^9Z*/[,P?_/M!]<Q'\[/IC_AX)\3_P"]8_\
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MHK[V=>'Q5:4FI2Z/\CC_ /AX)\3_ .]8_P#?RZ_^/4?\/!/B?_>L?^_EU_\
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M '\NO_CU'_#P3XG_ -ZQ_P"_EU_\>KYGHH_LS!_\^T'US$?SL^F/^'@GQ/\
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M_#P3XG_WK'_OY=?_ !ZOF>BC^S,'_P ^T'US$?SL^F/^'@GQ/_O6/_?RZ_\
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M^N8C^=GTQ_P\$^)_]ZQ_[^77_P >H_X>"?$_^]8_]_+K_P"/5\ST4?V9@_\
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M117><H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VW_P $LO\
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M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?8_P/\
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MX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?&+5]<_:"UW5=*^+_P .['4[/0K73R+RSEM= U51)(TD)E>9SF,R9#J?FW8
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M&^,?^N&L_P#H@U^:=>%EW\?$_P"(]/%_PJ/H%%%%>Z>8%%%% !1110 4444
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M9;^5[7QO7EY?_#G_ (I?F=F*^*/^%?D%%%%>H<84444 %%%% !1110 4444
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M98^G)1]D[WE%=5I*^J[[>AK#"3U=31)2?3=*]GV^9\=T5]:Q?L*Z):>*-/\
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M?M!:IX#_ &5;[PM\/[3X3^&?%EC/HJW6I:MK%OF_NGD+IF*YP3&0R%L@$#<
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M8I;&<8R*J6.P\9.+EM?H[:*[UM;04<+5DKI=NR>KLM-]6?)%%>Z2? ;X>_\
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M\"O^4?7QH_["2_\ H-K7F9A_#A_BC^:.W"_'+T?Y'QO1117IG$%%%% 'TO\
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MGW[5GAKPOKGP#^%'Q,T?PMI/A+5]<$EO?V>AVRVUK(0"=PC7@89&P>3AL$G
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MXJ^-Z\_#9?A9U*RE#:5E]R.JMBJT84VI;K]6?9'_  \Z\;?]"9X5_P"_4_\
M\<H_X>=>-O\ H3/"O_?J?_XY7QO17H?V7@_^?:_$Y?KE?^8^R/\ AYUXV_Z$
MSPK_ -^I_P#XY1_P\Z\;?]"9X5_[]3__ !ROC>BC^R\'_P ^U^(?7*_\Q]D?
M\/.O&W_0F>%?^_4__P <H_X>=>-O^A,\*_\ ?J?_ ..5\;T4?V7@_P#GVOQ#
MZY7_ )C[(_X>=>-O^A,\*_\ ?J?_ ..4?\/.O&W_ $)GA7_OU/\ _'*^-Z*/
M[+P?_/M?B'URO_,?9'_#SKQM_P!"9X5_[]3_ /QRC_AYUXV_Z$SPK_WZG_\
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M7_T9+7Y^?M3>/O"_Q#^(-EJ'A#;#HT.G16R6*Z?%:BR*L^80T9(F SGS.^[
MZ5^@?[ /_)"],_ZY+_Z,EKPLZJ2JX.G.4;-O;Y/^O\SU<#35/$SA%W5O\OZ_
MR/@C]LK_ )+MJO\ UPB_D:\/KW#]LK_DNVJ_]<(OY&O#Z^@R_P#W2EZ(\G%?
MQY^K"OI[]C7XJ>!O ?AGXJ:'XU\2?\(TGB;3(["UNOL,]W@E)T9ML2G[OF*<
M$C/K7S#1717HQQ%*5&6TO\[F=&K*A4C5ANG<^O/"'Q2^$G[+?@;Q0_P_\57_
M ,1/'VO6C6,6I-I<FGVUC&?XMLOS9!.[@MN**/E&379_"S]KK0[CX$^%/"Q^
M)UW\(O$GA^,6DMS_ ,(Z-8@OX%&$(78Q4XV]UP<\,,8^$**XJF74JJ;J-N3:
M=W;I>VEK6U>ENIM'%2IM<B22OIKUM?K?HNNEM#[!T?\ :KTK0_VN](\77'B_
M5/%'A9=.&B:AK.IZ=%;O)"P9F9(((EQ&LI5@"I? (.>*E^.O[4/@W3OB%\)8
M/AM(VI^"?!,RZ@T,<$MN)I6E^= LBJ=P0'#8QF4^]?'-%..7T5.G/^3TL]]T
METN["EBJDHSATG_P-O5))[GZ-^*OVQ/"VI:M=>(-,^/FN:5HTEN)$\'6G@^!
M[R.39_JUNYH&C^]_>+#D_-C%>%-^T)X<TO\ 9=^&FC6VH_;_ !MX>\6#7+K3
M'@E4%%GGD!,NS8<[TX#$_-TX-?+-%12RRC124;Z-/I]F]M4KO?6]WYFLL=5G
M>_5-=>JMWT\K'W=JWQ4_9_\ $WQVTSXW7/CK5K'4K>&*YE\)G19VF>YCCV(/
M/ \L<!?ER02/O &M[X=>-O#GQD_9]^/OB3Q?+=^'_#FM^(TDFFLHQ--:1D6R
MPL5_CVD1E@.2 V.U?GG77:+\6/%?A_X?ZUX(T_5?L_AC695GOK'[/$WG.I4@
M[RI=?N+]UATK"IE<>11IR=U9*[V2DFTK+RTO?9&M+'-5HU*BZW=MW9-+RZ^1
M]0Z]\>?AEX)\*?!CX=>$O$-UXBT3PWXEM-;U?Q#/I\UNH"3L[[8F7?UD=L '
M 4#+$FK?@O\ :-^'FD_MS>,_B%=^(/*\(:AIWD6VH_8K@^8_DVRX\L1^8.8W
M'*CI[BOB6BNEY?2DI*4FW)23>FO/:[VMT5NASRQ<VHQLK1Y;;_9O;KYNY]+?
M!KXQ>$?"?P!^-GAS5-6^RZUXB _LNU^S3/\ :.''WE0JO4?>(KZ!F_;0\.^.
MM!\-W]K\9=0^%-Y;VJ0ZKH/_  BJ:H)Y%^\T4QB8)GD DD8VY4'.?SHHI5LM
MHUINI)N[MV>RMLTUMWZCCC*D4TNKD^OVI<SZWWV\C[!T_P#:.\(WW@#]H:VU
M/Q-?7>K^+'0:0^I6.VXO42,QJ7^SQ"&,X"_W1^M<AKWQD\*3?L:^ _!5MJ7G
M^+-)\0-?W6F_9Y5V1>9<,&\PIL.1(G 8GGIP:^;:*UA@:4)*46]'!]/L*RZ?
M?^A'UF?*XM;\_P#Y.VW^>GZGU%^VG\0/AK\:=2TOQUX6\87%UKSVEM83^')M
M*FB,"+YKM(T[ (2"RKM7/<@D5\NT45OA\/'#4_90;:7<RJU76ES26OY_UY!7
MVW_P2R_Y*/XU_P"P3'_Z.%?$E?;?_!++_DH_C7_L$Q_^CA7'FO\ N53T_5'1
M@O\ >('SI^U%_P G%?$?_L.W7_HPUY?7J'[47_)Q7Q'_ .P[=?\ HPUY?7;A
M_P"##T7Y'-5_B2]6%%%%=!D%%%% !7T]\3/V&]3^&_P/'CU_$J7VIV]M:76H
M^'UL=CV:3X',HE;=M)P?D&<,>U><_LK_  S/Q8^/'A30Y(O-L%N1>WO&5\B'
MYV#>S8"?\#%?H#X9T^W\<?&KXL:=JWQ \$:[X>\:6']F6N@Z7KRW&H6_D1L@
M'D;0 =AE9MI)!'?&1X>98RIAW&-)ZI<S\TFM/GK]QZ.#HQJMRJ+W;J/S?7Y?
MKL?E-17WE\#=8UCX _LC_&"[6TMI/$7ASQ0]M']JB$B0W ^SPB4*PP2I8L,]
MP*Z'X ^(8IOV=_%WQ<U/Q=;^%_'.LZNT>I^,?^$>&IRV:+Y:B,6\:X56 !)Q
MMR^2.F+J9BX\\E"\8M).^[ERM:6VU_R3;T%@W[BD[.5].W+>_7R_SM;7\[**
M_0[Q39Z9\9_C?\']9\ W&E:WXK^PW4NJ:_KGAFZL["^6%$470@D5/-=6=BH1
MSM;9E@ *WOBE)!\0OV2_B@^M>.+?XH7>AW6;?5!X<_LK[!/&Z Q1\8DQ\PWK
MV<@DYK*6:<BBY0U>ZUNO>Y?Y?GKR]MRX8)5)\L9^CTWM>SU_*_?8_-.BBBO>
M/+"BBB@ HHHH _2S]D'_ ),-\8_]<-9_]$&OS3K]+/V0?^3#?&/_ %PUG_T0
M:_-.O"R[^/B?\1Z>+_A4?0****]T\P^H_@+\?-!^&?[+?Q*\.+XENM"\;ZE=
M^?I*V27"2GY(EW+-&NU#\K=6!_.O'O /Q(O)OC5X,\4^,M>O]233]7LKBZU#
M49Y;J5((YU=CD[F( !.!GV%>>T5S4\/"G5G66\OT5M#:5:4J4:717_%W/I'Q
MY^T!H.F_ML3?%/0)&UWP]#?V\RO'$\3S1"UCAEVK(%(8?/C<!R!VYKUO3/BI
M\ ? _P <-=^-6G>.=4UG5;N*:XM_"<>C3Q2)<RIM?,[@1D<MQD 9ZM@"OA.B
MN667TW",(R:Y8\MU;6/9Z>72QM]:ES2E))\S4K:VNFVGOYGZ8> _'&D>'_V:
M_!?B#Q;>Z+X9N->UZ\U:W'B3P_/K\37$MQ+)&]O'#(C0D!LJQ]3W.3RL>O)^
MS;^T]XWU?XL>,[>_D\5>&3+9:G;:?,HD+2*B0^3&',6T1$#)(P 2V2:^5/ '
M[6/Q8^%_AR'0?#?C">QTB GR;66UM[D19.2%,L;%1G)P#CDUP7CCQYX@^)/B
M*XUWQ/JUQK.K3@![BX89"CHJ@8"J.RJ !GI7GK*Y^UJ7:4)<RTWL]DKK2WJT
M]-#J^N1]E&Z]]6?E=._?5>5OF>Y_L6?%KP/\*=<\62^*[N/0]4OK 0Z/XBDT
MPWXTZ4;PQ\M06YW(>!@[,$C->P_&?]I[P-XL\!?#O2O^%AW'C77-%\6V6HZC
MJD^B26!EMXR[/*L2QA0JA@H49<XZ'K7P;17I5L!2K5E7DW=6[=/E?UL]?4Y*
M>)G3INE%:._XJS_X%]C[9M/VC/AY%^WI>?$5O$&/!LEAY"ZE]BN.7^R+'CR_
M+\S[X(^[[]*XGX3_ !J\&^&?"O[2%GJ6L?9KGQ=;S1Z(GV69OM;-]KP,JA"?
MZV/[^W[WL:^7**C^SJ7)R7=N50Z;*7-VWNON+^N5.=SLKMJ7S45'\E]X4445
MZAPA7V1\"O\ E'U\:/\ L)+_ .@VM?&]?9'P*_Y1]?&C_L)+_P"@VM>9F'\.
M'^*/YH[<+\<O1_D?&]%%%>F<04444 %%%% !7LG[*7P+LOV@/B@V@:IJ-QIF
MDV=A+J-W+:!?.:-&1=J%@0"6D7D@\ \5]8?%3Q[XI_9OD^#'A/X4Z7;1^&]6
MM8)+AX;".8ZQ,Q0,COM)W,I#%E(8[^N!7I7@FZC\"_MD>._"?AMX-/T"^\-#
MQ!>Z9;0QA$U'?&GF9"Y4E"&*@X)<DC)KYVOF4_92E"-KJ=G?7W-[JVG==]G8
M]2C@U*<8R?\ (WZ2VL_P?;I=JQ^9GQ-A\%0^+)D\ 3ZU<>' B^6^OK$+G?\
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MOVB]:^*D'Q!U&YN/$,+0OI_]BW"Q:>613(\C[-TFYHU " X+'.1R/SUHK/\
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M* G8"1D8P">/=-5'./PR<5KO:_\ D3'#*7(E+5J[TVV1\/:-\$]=USX,:_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_6?\
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MOZE_X"2?_$T?\*Y\4?\ 0OZE_P" DG_Q-=GU[#?\_%]YA]7J_P K.=HKHO\
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M]"_J7_@))_\ $T?7L-_S\7WA]7J_RLYVBNB_X5SXH_Z%_4O_  $D_P#B:/\
MA7/BC_H7]2_\!)/_ (FCZ]AO^?B^\/J]7^5G.T5T7_"N?%'_ $+^I?\ @))_
M\31_PKGQ1_T+^I?^ DG_ ,31]>PW_/Q?>'U>K_*SG:*Z+_A7/BC_ *%_4O\
MP$D_^)H_X5SXH_Z%_4O_  $D_P#B:/KV&_Y^+[P^KU?Y6?4'_!+W_DO/B'_L
M6I__ $JM:^0KS_C[G_WV_G7U'^Q%XF;X#_%/5]>\5:)KD6GW.C2V,9M=-EE;
MS&G@<9 '3$;<_2OGVX^'OB>2XE=?#^IX9B1_H<GK_NUYU'%4%BZLW-6:CU]3
MJG1J.A"*CJF_T.9HKHO^%<^*/^A?U+_P$D_^)H_X5SXH_P"A?U+_ ,!)/_B:
M]'Z]AO\ GXOO.7ZO5_E9SM%=%_PKGQ1_T+^I?^ DG_Q-'_"N?%'_ $+^I?\
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MO"8  SJUH#[CSDXKFJZ;X7_\E+\)?]A>T_\ 1R5A6_A2]&;T/XL/5?F?H/\
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M(/\ GC'_ -\"C[)!_P \8_\ O@5-10!#]D@_YXQ_]\"C[)!_SQC_ .^!4U%
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M78$/V.#_ )X1_P#? H^QP?\ /"/_ +X%34478$/V.#_GA'_WP*/L<'_/"/\
M[X%34478$/V.#_GA'_WP*/L<'_/"/_O@5-11=@0_8X/^>$?_ 'P*/L<'_/"/
M_O@5-11=@0_8X/\ GA'_ -\"C['!_P \(_\ O@5-11=@,CACASL14SUV@"GU
MD^)/%6E^$;&.\U:Z^R6TD@A5_+=\L02!A03T4_E7-_\ "\/!/_0:_P#)6?\
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M 4444 %%%% !1110 4444 %%%% !73?"_P#Y*7X2_P"PO:?^CDKF:Z;X7_\
M)2_"7_87M/\ T<E8UOX4O1FU#^+#U7YGZ&4445^1'[(%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!;TW_7M_N_U%:=9FF_Z]O\ =_J*TZPGN=-/
MX0HHHK,U"BBB@ HHHH **** "BBB@ HHHH **;(XC1F;.%&3@$G\JR?"/B[2
MO'7AZTUS1+HWFEW88PSF)XMX5BI^5U##E3U':@#8K2T'_C\?_KF?YBLVM+0?
M^/Q_^N9_F*SJ? S2G\:-ZBBBO./1"BBB@ HHHH **:LBR9*L&P<'!SSZ4Z@
MHHHH **** "BBB@ HHHH **** "BBJ.EZYINN?:_[.U"UU#[).UK<?99ED\F
M9?O1OM)VN,C*GD9H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y1^TE_R(UC_P!A&/\ ]%2U\W5](_M)?\B-8_\
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MA21F.\;< @CAFXYKG_VO/'NI_#WX'ZO?:/.]IJ-U+%8Q7,1P\0D;YF4]CM#
M'MG-6='\?ZI\:QJ'A]?!_C;P)I4UHWF:]?!=-NX9-R[5@'S$DC=\W;'3FN*^
M+O[,.HWWP=\2Z3H_BOQ5XOU69X+NVM_$NJBZ :%F)6(E5"EE9ASU(7I6-6[C
M9[:?=?4VI64KK?\ 6VAYI\2_A[8_LTP?"SQIX6GO;76;J]AMM9DDNY)!J =
M[^8I)'.'&!@<CN,UT^E^$;#]IK]H3XE6?C(W=]H'A?R[#3M/CNGBBAD)93+A
M2,MF-CSQR,Y  JIXBM_%_P"T9)\-?"UQX#U[PQ9Z%<PW>MZCK=H8("8U"E82
M?]8&&['?+#C&36Q##XF_9[^/'C[7(_!6O>+?#WBI5NK67P_;&Y:.<$MLD /R
M#<[C)[8(!YK65N=W^'W[?=&W_MUOP,HWY-/BM&_WN_Z7(_V7[*X^*7PO\5^
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MAZ_.]OD9RMRR45_+_P"EK\MSS[_A:G@[XO?M3_#[_A%];M]>MK;1=5BNO(#
M)O6/ .0.H!_*L;XG_LU_#+1?C5\(M(LO"%C;Z;K%UJ*7]NK2;9UCM2Z _-V;
MGBO6/&F@ZG=?M/?#?58=.NIM+M-(U2*XO8X6:&%W$>Q7<#"EL' )YP<4[XK:
M#J6I?'/X,W]II]U=6.GW6IM>74,+/%;A[0JAD8#" MP,XR>*4;+V=O/_ -*D
M5._[V_;_ -LB>@^"/ /A_P"&^AKHWAK2X=(TQ9&E%M"6*[V^\>23SBO*;O\
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M;>P90[*@R%)_#GFS^S3K&CZ)\6/B1X$\*:O'J_@O3TM-0TM+>\^U1632*1/
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MLK!1112&%<EX3_Y&SQ;_ -=X?_0#76UR7A/_ )&SQ;_UWA_] - 'YZ?M"?\
M)4-1_P!U?ZUYO7I'[0G_ "5#4?\ =7^M>;U^WY7_ +C1_P *_(_!\V_W^O\
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M_P"BI:^;J^D?VDO^1&L?^PC'_P"BI:^;J_0,E_W1>K/SG//]\?H@HHHKW3P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KV;X._!TZH8==UV'%EP]M9R#_7>CL/[OH._TZGP=
M^#IU0PZ[KL.++A[:SD'^N]'8?W?0=_IU^@0 H  P*^4S3-.6]"@]>K_1'U^4
MY3S6Q&(6G1?JP "@ # I:**^-/M@HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7A/\ Y&SQ;_UWA_\
M0#76UR7A/_D;/%O_ %WA_P#0#0!^>G[0G_)4-1_W5_K7F]>D?M"?\E0U'_=7
M^M>;U^WY7_N-'_"OR/P?-O\ ?Z_^)_F%%%%>H>4%%%% !1110 4444 %%%%
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MZU'_ ,"VKK:* .2_X5KIG_/UJ/\ X%M1_P *UTS_ )^M1_\  MJZVB@#DO\
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M .2_X5KIG_/UJ/\ X%M1_P *UTS_ )^M1_\  MJZVB@#DO\ A6NF?\_6H_\
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M1]!>//B-IOP[_P"$?_M*&ZF_MO5H-&M_LJ*VV:7=M9]S#"#:<D9/3@U/I7Q
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M9;)M?=&Y]H:9XV\.ZUI5SJ>G:]IE_IMJ&:>\M;R.2&( 9)=U8A<#DY-0VWQ
M\+WE_:6-OXDTB>]O(UEMK:._B:29",AD4-E@1R"*^,?AO=-_PDOQRAC?PZ('
M\)SN\?A'<-+++$ #$&]-S9[9+8XJ#Q1\-_#=I^S-\+=7@TFWAU;4-7MX[J_C
M&)YED\T,K/UQ\BX&<#'&*:FW9]^7_P F;7Z&?(E=7[_@D_UL?;NC>,-!\17-
MU;Z3K>G:G<6IQ<16=W',\)SC#A22OXU27XF>$'^Q%?%>B,+UBEKC48?W[!MI
M"?-\Q#<<=^*\*MO".C> ?VPM#L/#NG6^C6-SX7D::WLT$:.0T@R0.I^1,GJ2
M,GFO&-'\ ^'I_P!C7Q1XFDTJWDU^/4_W>HNF9HP+B) JMU5<.V0.#GFH]KI?
MLO\ V[E_X)4:5WR]VE]ZN?=-KXPT&^UN?1K;6].N-7@!,NGQ7<;7$>.NZ,'<
M/Q%5]2^('A?1]632[_Q)I%CJ;D!;*YOXHYF)Z (6!Y^E?,VL^"-#\"_$3]GJ
MZT'38-+N;[<MW/;KM>XS%$29&ZN3YC\G)P<=*\M^+7BS3/%&C^/YK'P_X%T%
M(M5EBD&H/))XAN)O-!:6$]E)SD<*!N':KE-Q^3:?R:7ZBA3Y[-;-+\;_ .1]
MA^+/V@/!O@KX@Z=X0U;44MK^[C:22Z>:%+:SPI8"=VD!C+ #:,<[E]:=I/CK
MQ!J'QHU'P[Y>AR>%H=,2\@G@O4:_:1MG+1"0L$.XX8H!T^8YQ7SGXBL_#</Q
M6^!^K>*K;2ETK4/#BG4;K5(HO)N)%MBJF8N,,03& 6Z?+76ZE+<Q_M%?$N30
M/^/M? VZP^RC^/RX_+V8]\8Q[42DZ:N];.7X*7^6A*BI62TNHO[VO\SZ%_X6
M#X6_MS^Q?^$ET?\ MC?Y?]G_ &^+[1N_N^7NW9]L58U+QEH&BW4UKJ&N:;87
M,$'VJ6&YNXXWCAW;?,8,00F2!N/&>*^&+@?#*;]E&U%J--E^(TDR8V;3JANC
M<<_]--FS./X>G>O4)O"-KXP_:B\'V'B_3XM4EB\'0SW-M>+O1KA=P)=3PV&+
M<'(S5)MOEZWMY?"WI]P<JMS>7SW2_7\&?4.C:YIOB+3X[[2=0M=4LI"0ES9S
M+-&V.#AE)!J[7SQ^R;8P:+KWQ:TFR3[/IUEXEECM[9?N1*"XPH[<*H_ 5]#U
M46I14EU2?WJY$ERR<>S:^YEO3?\ 7M_N_P!16G69IO\ KV_W?ZBM.L9[F]/X
M0KSSXY?&33O@CX)?7+RV?4+J:5;:RL(VVM<3,"0N<'  !).#TZ$D5Z'7RQ^W
MA;3V>E_#_P 0/$\VDZ3K2O>*JY !VE2?^^&'U(K&717M=I?>[&\>KM>R;^Y'
M>>$?$?QUNKW1[[7O#/A)=$O98_M%C97,T=_91,1EW+DQL5!R57DXP*Y#2/C1
M\7?B%\4_'7ACP?:>"H+7PW=F#S-<2\#NA=E4YB<@GY3G@5]!V_B_0[K2M/U.
M/5[(V&H%%M+@W"!)V<@(J$GEB2  .<\5\>_"SX9_\+(_:(^,L?\ PE?B;PO]
MEU'=O\-ZC]C:;=+)Q(=K;@,<>F33U]KR6TM+\+?E^HM/9N=^L?QO^9ZE\:OC
M1\1?A'X7\"0R6GA>Y\6:[?M9715+EK%#N 0Q_.K@89<DYZ' I^B_'#Q[X/\
MC!H/@7XDZ3X?SK\9-AJ7AMYO+5QGY764ECR,=L9'7MQ'[:&AW&EZ5\'](M=5
MNY+J#55MHM4OB+BX+@1*LTA.!(^<,<XR<U7\,:;JGAG]K_2[#XIZS-XKU5[
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M6EH/_'X__7,_S%8U/@9M3^-&]115;4=0@TG3[J]NI!#:VT332R-T5%!+$_0
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M/CM/X9^'_@>[@T@:[XT\706XTW1;5_*26=X5DD8LV=D2;LDG.!CZUN?M%?\
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M>BBJE)RU>Y,8J.BV/*/VDO\ D1K'_L(Q_P#HJ6OFZOI']I+_ )$:Q_[",?\
MZ*EKYNK[[)?]T7JS\[SS_?'Z(****]T\ **** "BBB@ HHHH **** "BBB@
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MH2"!M*#&1RG0BL#]H[XKZ!\3=2\):7I%_<7MMHT'V>?Q!?0LDERS; 9"H&[
MVECP"23@>OA=%<D,MI0Q'UE-WNWTT;5GTO\ )NR.R69UI8;ZK9)64;ZWLG?O
M;?K:[/>_VJ_C)I'Q)N_#FE>'=3EU71]+M29+N2)XC-.V%)*NJG(51SC^,UX)
M1175A<+3P=%4:>R_74Y,7BJF-K.M4W=MMM%;S"NF^%__ "4OPE_V%[3_ -')
M7,UTWPO_ .2E^$O^PO:?^CDK:M_"EZ,QH?Q8>J_,_0RBBBOR(_9#"_X0/PS_
M &?J%C_PCND_8M1E\^]MOL,7EW,F0=\B[<.V0#ELG(JU=>%]&OI--DN=)L;A
M]-8-8M+;(QM2  #$2/D. /NXZ"M.B@=V9UMX:TBSU"_O[?2K*"^U  7ES';H
MLER , 2,!E\#CG-4_P#A _#/]@#0_P#A'=)_L16WC3?L,7V8-G.?+V[<Y)/3
MO6[12\@NS!L_ /AC35F6T\.:3:K-;&RE6&QB020'K$V%Y3D_*>.>E2S>"O#U
MQI-GI4N@Z9)IEFZR6UD]G&88'7.UD3;M4C)P0.,FMFBF!GR>'M*FUJ+6)-,L
MY-7BB,$=^UNAG2,Y)028W!>3QG')JI'X&\-Q:#-H:>']+319FWR::ME$+9VR
M&RT>W:3D Y(Z@5MT4K(+LS+CPOHUY/IL\^D6,\VF?\>,DELC-:< ?NB1\G
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M+>0AXUMMH"!T;(^;D[3VVYJG\!;6&R_;6^--O;Q1P016=JD<42A510L(  '
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M57 ]2.?YCWNBIEG&+E%QNE\BXY+@XR4K-V\R.WMXK.WC@@C6&&-0B1H,*H'
M 'I4E%%>(>[L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:ZVB@#DO[2\8_P#0&L/_  )-']I>,?\ H#6'_@2:ZVB@#DO[2\8_] :P_P#
MDT?VEXQ_Z UA_P"!)KK:* .2_M+QC_T!K#_P)-']I>,?^@-8?^!)KK:* .2_
MM+QC_P! :P_\"31_:7C'_H#6'_@2:ZVB@#DO[2\8_P#0&L/_  )-']I>,?\
MH#6'_@2:ZVB@#DO[2\8_] :P_P# DT?VEXQ_Z UA_P"!)KK:* .2_M+QC_T!
MK#_P)-']I>,?^@-8?^!)KK:* .2_M+QC_P! :P_\"31_:7C'_H#6'_@2:ZVB
M@#DO[2\8_P#0&L/_  )-']I>,?\ H#6'_@2:ZVB@#DO[2\8_] :P_P# DT?V
MEXQ_Z UA_P"!)KK:* .2_M+QC_T!K#_P)-']I>,?^@-8?^!)KK:* .2_M+QC
M_P! :P_\"31_:7C'_H#6'_@2:ZVB@#DO[2\8_P#0&L/_  )-']I>,?\ H#6'
M_@2:ZVB@#DO[2\8_] :P_P# DT?VEXQ_Z UA_P"!)KK:* .2_M+QC_T!K#_P
M)-']I>,?^@-8?^!)KK:* .2_M+QC_P! :P_\"31_:7C'_H#6'_@2:ZVB@#DO
M[2\8_P#0&L/_  )-']I>,?\ H#6'_@2:ZVB@#DO[2\8_] :P_P# DT?VEXQ_
MZ UA_P"!)KK:* .2_M+QC_T!K#_P)-']I>,?^@-8?^!)KK:* .2_M+QC_P!
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M_'_ZYG^8K-K2T'_C\?\ ZYG^8K.I\#-*?QHWJ***\X]$**** "BBB@ HHHH
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M"?\ )4-1_P!U?ZUYO7[?E?\ N-'_  K\C\'S;_?Z_P#B?YA1117J'E!1110
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M^+1,WRI/[_2Z7YO[DSZKJGJ^L6'A_3;C4=4OK;3=/MUWS7=Y,L44:YQEG8@
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MKR2>S3_!-_H$G[K:W37YI?J>T?$#XH>%OA;IL%]XHU>+2H+B3R8%*/++,_\
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M5M+6[7W7O^5O5H^RO$GQ&TWPMXQ\)^&KN&ZDOO$DEQ%9R0HIB0PQ>:_F$L"
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M7_87M/\ T<E8UOX4O1FU#^+#U7YGZ&4445^1'[(%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!;TW_7M_N_U%:=9FF_Z]O\ =_J*TZPGN=-/X0KS
M;X]?!6R^.7@H:-/=MIM_;3"ZL;]%W&&4 CD9&5()!Y'8]J])HK)KF5F;)N+N
MCQ/PGX>^/,-UI%CKWB7P@-(LY8S<WUC;3R7]Y$I&Y&#J(U+@8+* 1G(KD=(^
M"_Q=^'OQ3\=>)_!]WX*GM?$EV9O+UQ[PNB!V91B)  ?F.>37TU13^US==?QM
M_D+IR]-/P/G_ .+'P7\=_%S2?AW-J=WX=MM=T+5/MVI"T>=;5TWJ0(=R,Q.U
M1PV.<\UJ?$;X)ZYJGQR\'_$;PG=Z?975@/LVKQ7CNGVJWSC"[4;+;&<?-CHG
M/%>V44;--=[_ (6_(.CB^UOQO^9\^:]\!?&7A#XK:KX[^%VMZ/9SZT/^)GH^
MOQR&UD;.2X:,%LEOFQP02><'%=WX7\!Z]XDT>[B^+*>&O%4LEPLUMI]MIHDL
M[/"E?D\X%F8Y/+<C.!7I%%**Y8\O1?@-MM\W4\3^,?[.-KXNT'P__P (0NF>
M$-:\.W_]HZ;Y%HL5J9"5+!UC7C)1#D _=Z&JO@?X(^*]4^*C_$'XEZEH]]JU
MO8G3[#3M"27[+#&P8,Q,H#$D,_'^V>>@'NU%"2U_K=6?X!?^OG?\]3Y2A_9C
M^)?AKPMXA^'_ (;\4>'XO &L732M/>Q3'4;:)\;XT"C8<A0#D\\XVYKT'XH_
M!'6M0^ 5G\-O MY96,:)#:S7&IRNF^!?F?E$;YG8#/ &"U>V44.*<>5^7X;#
MYK2YEY_CN<[\._!EK\// ^A^&[/!ATVU2#>!C>P'SO\ 5FRWXUT5%%7*3DVW
MU,XI122"M+0?^/Q_^N9_F*S:TM!_X_'_ .N9_F*QJ? S:G\:-ZBBBO./1/*_
MBI\(;CXJ>/\ P3+JJ:;>>"=$>XO+W3+Q3(UY<LFR$&,H4*+EB<GJ<8K"^*/[
M-&C:A8:+J'P[\/\ AOPGXLT;5;;4K:\@LDLTD5&_>12/#&6*LI/&",@5[C15
M1DXVMT=_G>_]>6@I)2O?JK?(\X^'OPYU/PG\3/B1XCO)[22R\2W%G-:1P.QD
MC$,'EL) 5 !)Z8)X].E<1I'[.>K?\*2^(_@?4-2LH;OQ-JVH:A:W5J7D2)9G
M5X@X95.05&X#/7@FO?J*GI;RM\M/\D-:-/SO\]?\V>#^)/A;\2/B#\*]-T#Q
M)<>%X-9L-7T^ZCDTR2X\AK>W=&<L73=YC;6P H7H,]Z]XHHJY2<KW[W^=DOT
M(C%1M;HK?+5_J>7^'_A=JFD_$CXI^()KBS:R\50V4=E&CN9(S#;-$WF K@98
MY&TMQZ=*X[X-^"OC3\+_  KX9\*2P> [K1-+"02W*7UZ;EH=Y+E08 N_!.,X
M&<5] T4HOET]%]VWYCDN;\?QM_D@KYS\5?#_ .-VO?%+PYXPBA\ 1MX?2\AM
M+=[^^Q+'.H7,G[CA@ .AQFOHRBDM'S?UKH4]58\8\>?#'QS>>.O#7Q!\*W^@
MQ>*K+2FTJ_TW5A,;"9'8.YCD0>8I#@X)7D8R!R#9^&OPO\50?$S5OB%XZO='
M?7[K3DTBVL- 67[+!;K)YA+/* SN6QV 'X\>O44U+EV\_E>]_P W]Y+C??R^
M=K6_)?<><_%?X<:EXZ\1?#R_L)[6&'P[KJ:I=+<.RL\0B=,1X4Y;+#@X'7FC
M4OASJ5Y\?=%\<)/:C2;+0;C2Y(6=O/,KS*X(&W;MPIR=V<]J]&HI1;CMY_BN
M5_@.2YM_+\'?\SP+Q3\#_&-XOQH;1=1TJVN/'!LXK*6::53;PI#Y4YDQ&<,5
M+;0N<Y&2*ZD_LP_#'_A$_P"Q/^$'\/;OL7V/[?\ V5!]ISLV>;YFS=O_ (MV
M<YYS7JE%+[/+Y)?)*R'U4O5_>[L^9X_V??B3'X9^$L4/B31+3Q#X&^V)]N82
MW$4Z,GEP)L**2"@"/RI )*DD"NT\"_"_QE?_ !4_X6!\0[[1&U*RT]M,TO3?
M#XE:W@1V#22L\H#%VQC&, >M>R45ISMMR>^OX[_?<CD5E%;:?@[K[F%%%%9E
MA1110 4444 %%%% !1110!Y#J_P-B\<?&R_\5^,K#1=?\.VVDQZ=H^EWD(N?
M+<OOFFDCD38&SA5(+''ITJKJ'[/MIX>^+7@OQAX!TO0?#,&GBXM-:L[6W%HM
MY:RJ,;5BCPSJP!&['UXKVBBJC)QM;I^M[_?=DRBI7OU_2UOR1X)I'PG^)/PA
MU/6K?X;:CX9U#PKJEY+J":7XF^T1/I\TARZQ20AM\9/.& QZ]2=KP+\&?$6A
MOXO\3ZQXFMY_B/XCMQ!_:EK:9M--1%(BBAB<Y9%8Y.XY; SZGV&BE>RMY6^7
M]?,=M;^=_G_7R/GWQ1\*OBM\7+73_#OCS4_"-GX5AO(;N\FT!+DWE[Y3AT3;
M*-L0) R06([>E7=>^'OQ/T+XT>*/&7@L>$KFRUNQL[5HM>NKJ.2,PJPR!%$1
M@EO[W;M7NM%/F?3S_%6?X"Y5K\OP=U^)Y3\,/A+K.C>,]5\=^-M8M=;\9:C:
MI8J-/@:*ST^U5MWDP!B6(+?,6;D^G7/JU%%)NXTK!1112&%%%% !1110!Y1^
MTE_R(UC_ -A&/_T5+7S=7TC^TE_R(UC_ -A&/_T5+7S=7Z!DO^Z+U9^<YY_O
MC]$%%%%>Z> %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5K>%_"
M^H>+]8BT[3HO,F?EF/"QKW9CV H\+^%]0\7ZQ%IVG1>9,_+,>%C7NS'L!7U;
MX$\":?X#T=;2T7S+A\-<73#YI6_H!V';ZY->/F&81P<>6.LWLOU9[66Y;/&S
MYI:06[_1!X$\":?X#T=;2T7S+A\-<73#YI6_H!V';ZY-=+117Y]4J2JR<YN[
M9^CTZ<:4%""LD%%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=\6--FU3P3>Q)X
MQD\!VZLLEUK<1C1H8 ?G DD.V,D<;^U?-'P/\1:Y8_M27/AKPC\0=<^)GP[3
M33+J6H:M??VA':S%6*JEP!MSN"XV8!#,.=I(^D_B]K,VB^#9I1X*G\?6,LBP
MWVCVR1RR-;D'<PBDXEP0OR=\^U?,'P_\!ZCXL_:@\/>,/ _PTUCX4^$=.M63
M5?[4LAI@O20XV+;*=ISE>G'RY."!G2C\;737\NOEMMUVUN9UO@\]/SZ>?KT^
M1J?#V\\7?M=>./&FI3>.O$'@OP/H=\=.TZR\+W0M)YV&?WDDN"3P%)!S]_ Q
MCG=^!OCCQ=X%_:(\2?!SQ/XANO%VG0V0U'2=5U##7:IA&V2/U;ASR>Z<8!P.
M;^&,?B[]D?QMXWT>\\ ^)/&/A#6M0;4=,U#PK9_;'3.?D>,$;?E*@Y(Y3C(.
M:SO@KXRA\2_ME>)?$WCBWF\"Z[>:?%8Z#X?UB)H9IXV"@-N("E\)]W.29"!G
M;5T]7%1VY=?7E^^_-^%^A%33F;WYM/2_Y<OX^9]4?$OP/JGC[2K73M.\7:IX
M0@$^^[N-'"+=3Q[2/+25@?*^8@[@">,=Z^8/@/\ $#Q3X)_:!^)_@VX\5ZOX
MY\&>';">\-WK%P;F>&2,(=OFG^+ET('!*YP,5[/^U9X^\;>!_AN8_ 'AW5-<
MU_4Y#:+<:9:27+6*%26F*HI.>RYX!.>V#YC^S#8Z/HOA6[\ P?#WXA:1J^OV
MLYU;Q1XDT'[-!-,8FR6D,C$#DA%]3SR2:QCS<M24>S5N[MO\OS-I\MX*7=?)
M7_7\CSJ'5/B+XS_9[UWX[?\ "RO$6F:[;WDEQ::)9W6S2X[=)A&8V@QACUY/
M7 R"237T!=>&]6^/GP\\-^+Y_B+X@\#:7<:##>2V?AV9;3;<%"\DLDV"S(,@
M;.!A<YYKY]TC3OB/X;_9YUKX$GX9>(KOQ#<7<EM;ZS#; Z48'F$AD:XSM!^]
M@=.1D@\5TW[0UOXZ\+^ _ WP>T+PUXHO_#$.F6L6OZ[X;TN6\DF11M>"+&%R
M2I8AF&0RCID':HDTXT]FX\O_ ("[O\OGYF4&U+FGNN;F^]6_6WEY'4?L5^.O
M'_Q2^#?BJWO_ !')->V=XUEI/B*_M_M+C* DL&(\W:2"-QS\V"3C%+^SEJOB
M>S_:B^*?A;6_&&M>*;/2[. Q'4[@E!(WELS)$N(X^6(PJC XYKO?@OX\T7P]
M\,]2L/#_ ,,/'?AK2_#%HLD>GZIHGDW>H$ABWD+O/G2DJ2W(Y8>M>+?!_P :
M:YI/[47C?Q?>?"_XA6VC^+/LUI:/-X?D0VQS&I><EMJ(-I)(+8%7\6(=EIRO
M[[*WWZD/2AY\R^Z]W]VA]M4445RG2%%%% !1110 4444 %<EX3_Y&SQ;_P!=
MX?\ T UUM<EX3_Y&SQ;_ -=X?_0#0!^>G[0G_)4-1_W5_K7F]>D?M"?\E0U'
M_=7^M>;U^WY7_N-'_"OR/P?-O]_K_P")_F%%%%>H>4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5TWPO\ ^2E^$O\ L+VG_HY*YFNF^%__ "4O
MPE_V%[3_ -')6-;^%+T9M0_BP]5^9^AE%%%?D1^R!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 6]-_U[?[O]16G69IO^O;_ '?ZBM.L)[G33^$*
M***S-0HHHH **** "BBB@ HHHH **** "BBB@ K2T'_C\?\ ZYG^8K-K2T'_
M (_'_P"N9_F*SJ? S2G\:-ZBBBO./1"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /*/VDO^1&L?^PC'_Z*EKYNK[HHKZ#!9M]3I>RY
M+_.WZ'SF.R?Z[6]K[2WRO^I\+T5]T45W_P"L'_3K\?\ @'G_ .KO_3W_ ,E_
MX)\+T5]T44?ZP?\ 3K\?^ '^KO\ T]_\E_X)\+T5]T44?ZP?].OQ_P" '^KO
M_3W_ ,E_X)\+T5]T44?ZP?\ 3K\?^ '^KO\ T]_\E_X)\+T5]T44?ZP?].OQ
M_P" '^KO_3W_ ,E_X)\+T5]T44?ZP?\ 3K\?^ '^KO\ T]_\E_X)\+T5]T44
M?ZP?].OQ_P" '^KO_3W_ ,E_X)\+T5]T44?ZP?\ 3K\?^ '^KO\ T]_\E_X)
M\+UK>%_"^H>+]8BT[3HO,F?EF/"QKW9CV K[2HJ)9_)Q:C3L_7_@%QX=BI)R
MJW7I_P $YKP)X$T_P'HZVEHOF7#X:XNF'S2M_0#L.WUR:Z6BBOEZE2563G-W
M;/K*=.-*"A!62"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]2
M\/:5K5Q97&H:99W]Q8RB>UEN;=)&MY!T>,L"5;W&#6A10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<EX3_P"1L\6_]=X?_0#76UR7A/\ Y&SQ;_UW
MA_\ 0#0!\(?&SP3KOB#XA7UYIVFS7=JRJ%ECQ@XS[UP?_"K_ !5_T [K\A_C
M75_'S5KVS^)6H107EQ!&%7"1RLH[]@:\[_X2#5/^@E=_]_V_QK]@RU8OZG2Y
M)1MRKH_\S\7S.6#^NUN>,K\SV:[^AL_\*O\ %7_0#NOR'^-'_"K_ !5_T [K
M\A_C6-_PD&J?]!*[_P"_[?XT?\)!JG_02N_^_P"W^->ERXW^:'W/_P"2/,YL
M#_+/[U_\B;/_  J_Q5_T [K\A_C1_P *O\5?] .Z_(?XUC?\)!JG_02N_P#O
M^W^-'_"0:I_T$KO_ +_M_C1RXW^:'W/_ .2#FP/\L_O7_P B;/\ PJ_Q5_T
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MUS)$^JVJLCS,58&9001GD5C6CC?9RO*.SZ/_ .2-J,L#[6-HSW75?_(GW?\
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M;?\ ?E?\* ,K_A8'AW_H+6_YG_"C_A8'AW_H+6_YG_"M7^QM/_Y\;;_ORO\
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MG_"C_A8'AW_H+6_YG_"M7^QM/_Y\;;_ORO\ A1_8VG_\^-M_WY7_  H RO\
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M6_YG_"C_ (6!X=_Z"UO^9_PK5_L;3_\ GQMO^_*_X4?V-I__ #XVW_?E?\*
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M *"UO^9_PH_X6!X=_P"@M;_F?\*U?[&T_P#Y\;;_ +\K_A1_8VG_ //C;?\
M?E?\* ,K_A8'AW_H+6_YG_"C_A8'AW_H+6_YG_"M7^QM/_Y\;;_ORO\ A1_8
MVG_\^-M_WY7_  H RO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PK5_L;3_\
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M+6_YG_"C_A8'AW_H+6_YG_"M7^QM/_Y\;;_ORO\ A1_8VG_\^-M_WY7_  H
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M8'AW_H+6_P"9_P */^%@>'?^@M;_ )G_  K5_L;3_P#GQMO^_*_X4?V-I_\
MSXVW_?E?\* ,K_A8'AW_ *"UO^9_PK,\"W]OJ7B3Q3<6LJS0R30E77H1L(_H
M:ZC^QM/_ .?&V_[\K_A7-^#H4@\4^*TC18T6:$!5& /D- 'Y[_M"?\E0U'_=
M7^M>;UZ1^T)_R5#4?]U?ZUYO7[?E?^XT?\*_(_!\V_W^O_B?YA1117J'E!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %=-\+_\ DI?A+_L+VG_H
MY*YFNF^%_P#R4OPE_P!A>T_]')6-;^%+T9M0_BP]5^9^AE%%%?D1^R!1110
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MG_\ B*/^%X>"?^@U_P"2L_\ \17RC17I?V%AOYI?>O\ (\S_ %@Q7\L?N?\
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MA<3%AE^<+P$8@A00'6OK&GO&,EU5Q;2<>V@5I:#_ ,?C_P#7,_S%9M:6@_\
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MKRBOGC]I'Q98>!_C%\%M9U,S?8[>[U0%+:%II9&:TV(B(H)9F9E4 =217?\
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MVMMY&[G)Z5Z'16KGJVEU;^]17Z&<8623[)?<V_U/G_P6#_PO3]H3C_EUTO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@##\:^))_"7AF]U6UT:_\07, 41:;IJ!IYV9@H R
M0  6R2>B@GM7BGAG]J[4E^+^F?#SQW\/;SP-JNK1A]/E.I17R2YW;=QC4!<[
M2."V#P<=:]S\3>)M,\&^'[_6]9O(]/TNQB,T]Q,<*BC^9/0 <DD 5\K_  ;\
M,ZQ^TI\<4^-NNV4FE>$])4VOAFPF&)+@*6 F;V!9F]V( R%R;I6<_>V6_DO+
MS;V(J74+K?IY_P# 2W/9OA[\=O\ A//C%X\\"?V)]A_X1<Q_\3#[7YGVG?\
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MLJ7_ ')8,TQ"CD*O%?,WCK7M-N_^";OAFUANX9+J:6WLXX58%VG2Z9G0#KN
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MV_*_]QH_X5^1^#YM_O\ 7_Q/\PHHHKU#R@HHHH **** "BBB@ HHHH ****
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MW#?RR^Y?YA_J_BOYH_>_\CY1HKZN_P"%'^"?^@+_ .34_P#\71_PH_P3_P!
M7_R:G_\ BZ/[=PW\LON7^8?ZOXK^:/WO_(^4:*^KO^%'^"?^@+_Y-3__ !='
M_"C_  3_ - 7_P FI_\ XNC^W<-_++[E_F'^K^*_FC][_P CY1HKZN_X4?X)
M_P"@+_Y-3_\ Q='_  H_P3_T!?\ R:G_ /BZ/[=PW\LON7^8?ZOXK^:/WO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '/^// 6A?$SPQ=>'O$MA_:6CW10S6WG21;MK!E^9&5A@@'@UYI
MH/[&/P<\,ZWI^KZ;X/\ LVHV%Q'=6TW]IWC[)$8,K8:8@X(!P017M=%.,G%W
MB["DE)6EJ<IX>^%OA?PKXPU[Q5I>E_9=>UW;_:-WY\K^?MZ?(S%5_P" @4>'
M_A;X8\*^,=>\5:7I8M=>UW;_ &C=^?*WG[?N_(S%5_X"!75T4)M6MT5OEV]
M>M[]=?GW.!^*/P'\"_&A]/?QEH?]L-IX<6Q^USP>7OV[O]4ZYSM'7/2L_P"&
M_P"S3\-OA'K5QJ_A3PV-+U"XMFM)96O;F<-$S*S+MED9>2J]L\5Z=10FXJR!
MI2=V>2Z3^RA\)="\6)XDL?!-C#JR2^>CF25H8WSD,L+.8U(/(PHQVQ3_ !_^
MRQ\+_BAXFN/$/B?PQ_:>L7"HDES_ &A=1;@JA5&V.55X ':O5Z*+O3R"RU\S
MR[2/V9?AKH/@76?!UCX;\CPWK$J37UE]NN6\YT*E3O,A=<%%^ZPZ5F^$_P!D
M'X2>!O$FGZ_HGA/[%JUA*)K:X_M*[DV..,[7E*GKW!KV.BGS23YD]1<L;<MM
M HHHJ2@HHHH **** "BBB@ KDO"?_(V>+?\ KO#_ .@&NMKDO"?_ "-GBW_K
MO#_Z : /ST_:$_Y*AJ/^ZO\ 6O-Z^]8?@5X<\>-/JNIP)-=M*\9=HP20IP.]
M2?\ #+'@S_GSB_[\C_&OT+!\28?#8>G1E"3<4ET_S/SC&\,XG$XFI6C.*4FW
MUZ_(^!J*^^?^&6/!G_/G%_WY'^-'_#+'@S_GSB_[\C_&NO\ UJPW_/N7X?YG
M%_JEBO\ GY'\?\CX&HK[Y_X98\&?\^<7_?D?XT?\,L>#/^?.+_OR/\:/]:L-
M_P ^Y?A_F'^J6*_Y^1_'_(^!J*^^?^&6/!G_ #YQ?]^1_C1_PRQX,_Y\XO\
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M<:+BT[GHU%>?_P!B:Q_T,U]_WRM']B:Q_P!#-??]\K7*=1Z!17G_ /8FL?\
M0S7W_?*T?V)K'_0S7W_?*T >@45Y_P#V)K'_ $,U]_WRM']B:Q_T,U]_WRM
M'H%%>?\ ]B:Q_P!#-??]\K1_8FL?]#-??]\K0!Z!17G_ /8FL?\ 0S7W_?*T
M?V)K'_0S7W_?*T >@45Y_P#V)K'_ $,U]_WRM']B:Q_T,U]_WRM 'H%%>?\
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M,U]_WRM 'H%%>?\ ]B:Q_P!#-??]\K1_8FL?]#-??]\K0!Z!17G_ /8FL?\
M0S7W_?*T?V)K'_0S7W_?*T >@45Y_P#V)K'_ $,U]_WRM']B:Q_T,U]_WRM
M'H%%>?\ ]B:Q_P!#-??]\K1_8FL?]#-??]\K0!Z!17G_ /8FL?\ 0S7W_?*T
M?V)K'_0S7W_?*T >@45Y_P#V)K'_ $,U]_WRM']B:Q_T,U]_WRM 'H%%>?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K.\"_\C%XH_Z[0_\ H!K1K.\"_P#(Q>*/
M^NT/_H!H ^9O%W[0&K_#K7KK1;6W,T4;&3?YBKDL<G@H?YUC?\-=:_\ \^1_
M[_I_\:KA/CG_ ,E&U#Z+_6N K\OQ^<X^CBJE.G4LDVEHO\C]WRGAG*<3@*%:
MK1O*44V^:6[7DSWK_AKK7_\ GR/_ '_3_P"-4?\ #76O_P#/D?\ O^G_ ,:K
MP6BN'^WLQ_Y^_A'_ "/5_P!4LE_Y\?\ DT__ )(]Z_X:ZU__ )\C_P!_T_\
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M#_X")1Y.O_\ 0P'_ ,!$K2HH]M/N'U:EV,WR=?\ ^A@/_@(E'DZ__P!# ?\
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M*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P
M$_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)
MU[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X
M0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\
MBJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H
M:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O
M^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6
MB@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\
M $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;
M_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#B
MO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^
M*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P
M$_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)
MU[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X
M0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\
MBJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H
M:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O
M^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6
MB@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\
M $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;
M_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#B
MO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^
M*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P
M$_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)
MU[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X
M0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\
MBJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H
M:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O
M^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6
MB@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\
M $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;
M_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#B
MO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^
M*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P
M$_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)
MU[_H:V_\ $_^*H_X0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X
M0G7O^AK;_P  $_\ BJ[6B@#BO^$)U[_H:V_\ $_^*H_X0G7O^AK;_P  $_\
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MS#W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NC^&O_)1?"O\
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MP!;&!GKR!7GWP!U!O%GQ0\$^$_$6I2W7A#0YKR[\--/"474)$D(CR2>0NUF
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M( /R,!N.#C.1G%9J-VUVU+YM$^^GS/HZBOG*X_; M7^ VD^-K+1Q/K^J7O\
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M&<9&<CFO._%VM?&KX>^.O!ND/XST;7G\9--9>7<Z0L%OI,Z()#)%L.^50NX
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M*&P,@'G KYL^ W[3GA#PW\*M$M_'/C5GUZ:ZO!+)>&>ZDC4WDJ1^=(%;REP
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M+7P3^)&H_M":/\3? =WX5$FGZ5_9XMO$4ER 6/FACMA3D;9./F'(Z5H?#OX
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M\3_B3X)_L>TMY_AQH,CV$<MYJWBO5WM[2>ZY$D-M$&$F 0"&?LP[@UL_LO\
MQQNOCU\/;G6=0L+:PU.POY-.NEL9"]O(Z*C;XR23M(<=STZFO-_B=^S)XX\7
M?%"Q\=6S>!=?OY]'AT_4-.\564UQ96\R@;Y;:/#9YR5#XQDYSGCO/V4_@?K/
MP&\&Z]HNM7NG7TM[K,U_#)IH98_*:.-5!0JNP_(?E&0,@ FB/+RRYM]?OYO\
MOZN*7-S1Y=M/_2?\_P"K'ME%%%8FP4444 %%%% !7)>$_P#D;/%O_7>'_P!
M-=;7)>$_^1L\6_\ 7>'_ - - 'P7\<_^2C:A]%_K7 5W_P <_P#DHVH?1?ZU
MP%?BN:?[[6_Q/\S^GLB_Y%>&_P $?R"BBBO,/="BBB@ HHHH **** "BBB@
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M . 5+"NS46DG;\(V?^9\M^-;'PO;?'OX3:IXKM=(32=2\.B34+G58HO(N)A
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M"EM>:K(0TDZS31>:1W=4=5<^[ YKT73M.M=(L;>RL;:*SL[=!%#;P($CC0#
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M'CPQVMCA\Y'Z32:Y\3O'WQT^(?A+0O&$'A?P_H/V"6.[_LR"[G5I;<-Y*JX
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M !1110 4444 %%%% !1110!B>,?&FA_#_P /W&M^(]3M](TJWQYES<-A<DX
M ZDGL "37)_#7]HKX=?%[4I].\)>)[?5+^%/,>U:&6"0J."RK*BE@,C)7.,B
MNF\>PS-X6O)[3PW;^+=1M0+BSTFYDCB6:93E,22 JC ]&(XKY#\%ZU?ZG^W#
M8:S\1O#TWP^\0W&F-;Z-I,)2ZAO/W;J6DND;#-C>!A<<*"1@;KII2EROS_+\
M=>B(J-QCS+^M?PTZL^E?B/\ M&?#CX2Z@EAXJ\56NFW[*&^R)'+<3*#T+)$K
M,H/;(&:WOA[\4O"?Q6TE]2\)ZY:ZU:1MLD,!*O$W8.C ,A/^T!FOFO\ 81L[
M?Q-X@^*GC#5HTN?%<^NO;RSS#=)#%RVQ2>@))&!V0#M2^!;&#PG_ ,%"?%NF
MZ%$MIIVH:$+J_M;< 1^:5B;<5' )8Y^KGUJHQ3<8O=J_X<UONZ]Q2D]6MD[?
MCRW^_I^)],>/OB3X8^%VA_VOXJUFVT73R_EK)<$DNV"=J*H+,< G"@GBLCX8
M_'3P)\9/M8\'^(H-8DM0#-#Y4D,J*> WER*K;<\9QBND\42:%ING-K6OK91V
MFD!KP7EXBD6N%(:16(^4[21D<\X[U\:_ G3;_P ;?$[XO_'+2;*31O#L^GWE
MOI&Y-C7<@129=O\ VR#'_:?&20:RC;WW+9)O[ME\V:2O[O+NVE_G]R/HG6/V
MK?A-H'BZ3PU?^-;&#5XY?(DC\N5HHY,X*M,$,:D'@Y88/7%;/Q*^/G@#X0M:
MIXM\36NE372>9# $DGE=,X#[(E9MN0?FQC@^E?(G@G0=.O/^";OB6ZFM8I;J
M:6XO9)F4%VG2Z55<GKN  &?3ZU[IX?\ B/X<^&/[+/A;QUXK@MIK]O#=K9J\
ML2FYO28OW=N"1E@Q)..@!9NF:TJ0]FI=7&WSNGM\U;J9PE[22ML[_*S6_P G
MY'KW@_XH^$_'GA-O$VA:]9WVA)N\V]W^6D.T982!\&,@8)# <$&LOP%\=? G
MQ0U_4]%\*^(H-;U#34\RY6VBD\M5)V[ED*A'&?[K&O%OV'?@K=>&_@UK$GBW
M2H?(\5W(N_[%O(0\:VVT! Z-D?-R=I[;<U3^ MK#9?MK?&FWMXHX((K.U2.*
M)0JHH6$  #@"K<$JSI^3?S26GWLGG?LE4_O)?)MZ_<CZRHHHK V"BBB@ HHH
MH **** "N2\)_P#(V>+?^N\/_H!KK:Y+PG_R-GBW_KO#_P"@&@#X+^.?_)1M
M0^B_UK@*[_XY_P#)1M0^B_UK@*_%<T_WVM_B?YG]/9%_R*\-_@C^04445YA[
MH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !71_#7_DHOA7_ +"M
MK_Z.6N<KH_AK_P E%\*_]A6U_P#1RUM1_BQ]4<N*_@5/1_D?>]?+/[3WQ@^(
M/@7XG6>G>$-42WL;?1/[7N;)[2*43A)G$F69"P&Q>Q' />OJ:O!?&?@N^U[]
MJS0[N;2+NX\/2>&+BRNKP6[&W!<S QM)C:&(8<9SS7['3=IIVO:_X1=OQ/YM
MK:TVEI=QVWUDK_@6?C!\:[ZW^%OA:]\%W"1^(/%\UO#I;M&LOE!P&D<JP(.T
M<'(.":R/@I^T%>M\#;?Q1XUFO==U.;59=.@CTRP5[BY<#<B+'&JKG ;G@<=<
MUP/P#^$/B^S^)4UGXGL+Q= \#V]Y;Z)+<6[I'</-(V'C8C#_ "ECQG'RBL[P
MOH?Q-\(_LW:39:/I7B/29F\0RMJT&FVK1ZF+,X^:%& ;)(X(]NV:[.2G:48]
M;->2;M;[E=^IPJ=6\92OI=/S:5V_/71>A[C#\?-*^('A?QSI^G6FN>&?$FD:
M3/<O8:Q:FTNXAY1*R* QQ@E>X(R#7A7BSXS>*=-_9M^&UK;WOB8ZIK4W^F:_
M:!I)7C$\JF%9RV[SCA<+U(7KBK'PU\#^)!X^^(>I/HGC9M/U'PE<PV5UXN1I
M;Z=R%41NP&-Y*G$?WL 5HZIX%\2R?LX_!S3%\/:JVI6.O0S7=F+*0S6\8EF)
M>1-N47!!R0!R*J-.G&45W</SDG^ES-U*M1-]HS_*#7ZI'J5E\;M"^%_ACPQH
M=Q;^-O$GB"^MFN(M)N[3[5K8C+,=UPN5 (Y'7.%]JVK#]I3PCJ7PZUWQA!'J
M1MM#<1ZAILENL=[;N6"A61F"YR?[V.#SD$5Q'CJU\0?#']I"3X@)X3U;Q9X?
MU+2%T]O["M_M-S:R*0?]7D'!V#G@?,><C!XBZ^'7BW6OAG\;/%%QX;O]/O/%
MTT$FGZ#Y)>\\N.7.YHUR0Q#=,9^4GIBL&HSBYOKK\^:UONU.A2J4YJFNC2VZ
M<M[W]=/PW/7)/VKO"D7A>\\2/H_B./08)[>"/4)=/$<5SYI<;H2SC>J%#NQR
M., U7C_:^\%_VH^G3:9XFM+N2)9K"&?2'#ZFK'"?9T!+-N[%@H/K7._';P?K
M.J?LN^$]'TW1+Z[U&W&F"2PM;5WECVQ@/F-1D8/7CCO6YXU\,ZI=?M1_#75H
M-*O)M+M-+NH[B^CMV:"%BD@57<#:I.1@$]ZOV=+F:Z7DM^BC?\7_ $S-U:ZB
MI?W8O;JY6M\D=/X3_:)\*>+/"/B#7T34M-CT&3RM1L;^T*W<#9P 8U+9).0
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M +/^R11,QE3R(#&_F J ,D\8)XZXKT6BGS/IY_C;_)$\J_+\ HHHJ2PHHHH
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M<G*3NV%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX^G_ -P_S%9]:&B?\?3_ .X?YBKA\2,ZGP,VZ***[3S@HHHH **** "BBB@
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MS73R9MI7=A6 ;@]&R/:N2U+]FWX:ZQXM?Q+>>%;:?5I+@7DC--*())A_RT>
M/Y3/GG<4)/>O2Z*$W%W7]?U8&E)684444AA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<E
MX3_Y&SQ;_P!=X?\ T UUM<EX3_Y&SQ;_ -=X?_0#0!\%_'/_ )*-J'T7^M<!
M7?\ QS_Y*-J'T7^M<!7XKFG^^UO\3_,_I[(O^17AO\$?R"BBBO,/="BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z#X=JTGC_PRJ/Y;MJ=L%?&=
MI\U<''?%<_71_#7_ )*+X5_["MK_ .CEK:A_%AZK\SEQ7^[U/1_D?;O]DZO_
M -!P_P#@*O\ C1_9.K_]!P_^ J_XUM45^Q<[_I(_F_V<?/[W_F8O]DZO_P!!
MP_\ @*O^-']DZO\ ]!P_^ J_XUM44<[_ *2#V<?/[W_F8O\ 9.K_ /0</_@*
MO^-']DZO_P!!P_\ @*O^-;5%'._Z2#V<?/[W_F8O]DZO_P!!P_\ @*O^-']D
MZO\ ]!P_^ J_XUM44<[_ *2#V<?/[W_F8O\ 9.K_ /0</_@*O^-']DZO_P!!
MP_\ @*O^-;5%'._Z2#V<?/[W_F8O]DZO_P!!P_\ @*O^-']DZO\ ]!P_^ J_
MXUM44<[_ *2#V<?/[W_F8O\ 9.K_ /0</_@*O^-']DZO_P!!P_\ @*O^-;5%
M'._Z2#V<?/[W_F8O]DZO_P!!P_\ @*O^-']DZO\ ]!P_^ J_XUM44<[_ *2#
MV<?/[W_F8O\ 9.K_ /0</_@*O^-']DZO_P!!P_\ @*O^-;5%'._Z2#V<?/[W
M_F9EGH^LM*0FOE#CK]D0_P!:N_V'KO\ T,9_\ D_QK0T_P#US?[O]16C6L9.
MQRU()2_X+.>_L/7?^AC/_@$G^-']AZ[_ -#&?_ )/\:Z&BJYF9\J_ILY[^P]
M=_Z&,_\ @$G^-']AZ[_T,9_\ D_QKH:*.9ARK^FSGO[#UW_H8S_X!)_C1_8>
MN_\ 0QG_ , D_P :Z&BCF8<J_ILY[^P]=_Z&,_\ @$G^-']AZ[_T,9_\ D_Q
MKH:*.9ARK^FSGO[#UW_H8S_X!)_C1_8>N_\ 0QG_ , D_P :Z&BCF8<J_ILY
M[^P]=_Z&,_\ @$G^-']AZ[_T,9_\ D_QKH:*.9ARK^FSGO[#UW_H8S_X!)_C
M1_8>N_\ 0QG_ , D_P :Z&BCF8<J_ILY[^P]=_Z&,_\ @$G^-6]+\/\ B"2X
M81^*#$VW[WV&,]Q[UK5H:)_Q]/\ [A_F*N,GS(SJ17*S-_X1GQ-_T-[?^"Z/
M_&C_ (1GQ-_T-[?^"Z/_ !KK:*ZS@.2_X1GQ-_T-[?\ @NC_ ,:/^$9\3?\
M0WM_X+H_\:ZVB@#DO^$9\3?]#>W_ (+H_P#&C_A&?$W_ $-[?^"Z/_&NMHH
MY+_A&?$W_0WM_P""Z/\ QH_X1GQ-_P!#>W_@NC_QKK:* .2_X1GQ-_T-[?\
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M\3?]#>W_ (+H_P#&C_A&?$W_ $-[?^"Z/_&NMHH Y+_A&?$W_0WM_P""Z/\
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MZ/\ QH_X1GQ-_P!#>W_@NC_QKK:* .2_X1GQ-_T-[?\ @NC_ ,:/^$9\3?\
M0WM_X+H_\:ZVB@#DO^$9\3?]#>W_ (+H_P#&C_A&?$W_ $-[?^"Z/_&NMHH
MY+_A&?$W_0WM_P""Z/\ QH_X1GQ-_P!#>W_@NC_QKK:* .2_X1GQ-_T-[?\
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MN K\5S3_ 'VM_B?YG]/9%_R*\-_@C^04445YA[H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !71_#7_ )*+X5_["MK_ .CEKG*Z/X:_\E%\*_\
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M_H*V7_@0G^->!T4?VA/^4/['I_SL]\_X272/^@K9?^!"?XT?\)+I'_05LO\
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M'I_SL]\_X272/^@K9?\ @0G^-'_"2Z1_T%;+_P "$_QKP.BC^T)_RA_8]/\
MG9[Y_P )+I'_ $%;+_P(3_&C_A)=(_Z"ME_X$)_C7@=%']H3_E#^QZ?\[/?/
M^$ETC_H*V7_@0G^-'_"2Z1_T%;+_ ,"$_P :\#HH_M"?\H?V/3_G9[Y_PDND
M?]!6R_\  A/\:/\ A)=(_P"@K9?^!"?XUX'11_:$_P"4/['I_P [/?/^$ETC
M_H*V7_@0G^-'_"2Z1_T%;+_P(3_&O Z*/[0G_*']CT_YV>^?\)+I'_05LO\
MP(3_ !J6WUS3KR98K>_M9Y6Z1QS*S'\ :^?J?#,]O*DD;M'(AW*RG!!'<4+,
M)7UB)Y/"VDV?1=%<CX(\;IX@B%I=E8]10?02@=Q[^H_$>W75[%.I&I'FCL?.
M5J,Z$W":U"BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBL[7O
M$6E>%=+EU+6M3L]'TZ(@27E_<)!"F3@9=R ,D@=>] &C17->&OB9X/\ &ET]
MMX?\5Z)KMRB[FATW48;AU7U(1B0*T--\5:)K.J:AIFGZQ87VI:>0MY9VUTDD
MUL3T$B*24)P?O =*=F*Z-6BBBD,**** "BJFK:K:Z%I5YJ5]+Y%E9PO<3R[2
MVR-%+,V "3@ ]*S?!'C?1/B-X8LO$/AV]_M'1[P,8+GRGBW[6*GY74,.5(Y'
M:CN&UK]3=HKA9OCQ\-+6:2&;XB>%(I8V*/&^MVP96!P007X(-='X9\8:#XTL
M7O?#VMZ=KUG'(8GN-,NX[B-7 !*ED) ."#CW%.SM<5U>QKT5E:WXJT3PU)91
MZOK%AI4E]*+>U2^NDA-Q(>B1AB-S<C@9/-:M(845R_C?XG>&OAS)HT?B+4_[
M.?6+Q;"Q'D22>=.W1/D4[?JV![UT-]?6^FV<]W>3Q6MI;QM+-/.X2.-%&69F
M/   ))/2CI?H'6Q/17&:9\:OA[K5]%9:=X\\,W]Y,=L=O:ZQ;R2.?0*KDD_2
MNSIV:%=,****0PHHHH **** "N2\)_\ (V>+?^N\/_H!KK:Y+PG_ ,C9XM_Z
M[P_^@&@#X+^.?_)1M0^B_P!:X"N_^.?_ "4;4/HO]:X"OQ7-/]]K?XG^9_3V
M1?\ (KPW^"/Y!1117F'NA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %='\-?^2B^%?^PK:_^CEKG*Z/X:_\E%\*_P#85M?_ $<M;4?XL?5'+BOX
M%3T?Y'WO1117Z^?SF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M:T__ %S?[O\ 45HUG:?_ *YO]W^HK1K6.QR5/B"BO!_''QY\3ZI\5)OAS\,M
M%T[5-<L8O.U/4]:D=;*S&!\I$>&8_,O0]3C!YQ#XZ^+7Q0^%OP@\5>(/$^A>
M'$UO3);9;*XT^666QNUDD".3&S+(I7/<C.X>AK;E?*I=]O/6QS\ZYG%=-_+2
MY[]17B7PO\0?&[Q8GAS6]83P!'X8U&**[F2Q%\+U870, H8E _(ZDCK7':?\
M;?B_X\^*'C[PSX-L/!@MO#%R8A_;"7:RS+N95 9'VECM/4*.15NFU)PZJ_X6
M_P R%6BXJ?1V_'8^GJ*\)^&/[4=CXG^#_B'QCXDL/[&NO#<KVVIVMNV]6D &
MWR\_WBP4 G@]R.:R?"?Q0^.GQ!T"'Q;H?A'PG;>';K][9Z5J-W.NH7$.>&60
M8C&X="P'KC&*/92NT^EM>FNWW[C]K&R:ZW]=-_N/HRBH[=Y)+>)Y8_)E907C
MW;MIQR,]\5\X:M\?OB)XN\9^.],^'NC^&UTWP:6COIO$,DWFW+KOW")8R O,
M;@;N. <C.*S2NVNVOR+<DDGWT^;/I.BOG"3]KK_BP.C>.(]!#^(-7O#I=II/
MFGRWN0Q4MNQG9@9]<D#/>KGASXX>//"WQ<T'P/\ $W2-!MV\00&33K_P_)-Y
M:2#/[N02$DG(QD8 )'4'C7V,^9QZ[>NE]/D9>WARJ73?TUMK\SZ#HKYS^,'[
M0'C[X=^/?"^FIX6TK3]!UC6!ID5S?W#7%Q<QB1%,R)&RK$"'X#%CZ@=*]+^,
MWQFT;X.>&9M1O;BQGU+]V;?29[]+::Y5I41F0$$D*&+'"G[O;K6:@W&,E]IV
M7KI_F:>TBG)/I_7Z'H-%8MGX@M?%WA^6]\*ZWIE\L@9+?4(6%[;+(..1'(N[
M!ZJ'!]Q7E'[+^J>*]:L?%LVNZ['JEI;>(=0LTCEMIO/5TD7[LDEPX6( D+$%
M^7^\>XHMWOI97_+_ #"4DK-:W=OP;_0]QK0T3_CZ?_</\Q6?6AHG_'T_^X?Y
MBB'Q(53X&;=%%%=IYP4444 >':!_R>3XL_[%"R_]*9*Q/%\5IX"_;$\(ZGIZ
M+8Q^(]"OQKGE_*DJVZB1)G ZL,8W=<#%;?B[X>?$G3OC?J7CGP5_PBMS;7^C
M0:7)!KUS<Q.K1R.Y8"*)ACYAW]>*U_AS\)=>M?'EWX_\>ZQ9:QXLEL_[/M+;
M2H7CL=-M]VYDBWDL[,>2[8/:KAHHN^RE^/-;\TR)ZN:[\OX<M_R:,?Q=^TYX
M.\0?#CQO/X$\3VNL:_I>AW5_'%;J^Z/:F!)RHZ,RU%\)9K#X+_L^^#;O2/"V
ML^*9M4M8+N]/A^VCGN9YYHO->>4NZ9&3C))(^4=*]MU33;;6M-N]/O85N+.Z
MB>":%^CHP*LI]B":\*\+_#7XO_"'3?\ A&_!>M>%?$/A2W+#3E\4"YBN[*,G
M(B+0AA*JY.,[3VX& $FO>2TO;\+W7SNON]!M/W6];7_&UG\K/[_4Z+0OBU;_
M !#^$NL^)O!WV7P=)%>2V]Q<^*H4ACM)$=5GEE6-RK$#)&7&2 "0*\\^%WQJ
MU)OCAHOA%/BCIOQ3TC6+.Z>26UL8+:33YX5#C!AX9'&X#.3QUK1;]EW6F^ -
MYX,DU[3YM?N-:.OM*ULXL7F,PE\ATR6:(D8SUZ''%;>E_#'XC:U\8O!GC+Q3
M/X7L]/T"VO+5=+T1IV*B6(*'#R(N[)'W<*%"C&XFKCRJ6O\ 7N__ "6FGK>Q
M$N9QT[_^W?\ R.OX6N8?P/OM1TWX8_%.ZTK4-+TF]C\9:JRW^M$BTME\V/?)
M)@C.U=Q ) ) !(&369\.?C9J4?QO\.>%8_BII?Q4TK7(+L3_ &6P@MY-.FA3
MS%93#PR.-P&XD\=36U??LTZWJOPA\;^$YM5L+>_UCQ/<:_9R+OEMRAF26.*=
M2JG!V88#(&01G&*TK'X8?$CQ!\6/ GBSQ//X4L--\-)=Q+I6AM<-@30;-ZO(
MBYY"_)A0H'5B:5.WN\W9+_R3_/Y];V'4O[W+WD__ "9_I_5S*\'ZU\3_ (Z+
MK_B;P[XZM?!NAVNJ7&GZ5I8T:&\%RD#[3)<.YWC>P/"%<#UKGO$/@OQKJ/[7
M=M#;?$2?2;Z;PG)<I<6^DVL@MX1=(K6RK(IW*6^;>V7[9Q77:)\*_BG\+;K7
MM)\ ZIX4E\*ZE?S:C;-KR7'VK3GF.Z1$6,;)%!R5R5Z\UK^/OAGX\_X6=H'C
MKP;J&@3ZK;Z-)HM_;Z\LT<,B-(LGFQ^4"=VX?=.!CC-%-\KIORU]>1I_^3?U
M:X37,IKS_#F3_+Y_.QF7'B3Q[\6OBCXN\.^%/%L7@G0_"9@M)[V/3(;VYOKJ
M2/>PQ+E411@<#).>?3FY/CA\0M+^%_Q*L)8[?5O'/@O4H;"74K*R+)+:RE&%
MY]G!Y98R[%!Q\OIFNOU3X7?$'P7\2/$7BKX=7_AR>W\2B&34])\1">...XC3
M8)H9(@Q^8=5(_'TG\*_"'QKX)\)^(;_3?$FF3_$77M375K^\NK-O[/E( 46H
M4'>L00;0X.[O[5*MRZ]E_P"!75_.WQ;=+=2M;Z=_PL[>5]M^M^AG:!\5$\+_
M  E\7>/%^)4/Q2TRPL1<0(+.VMI()@K?NW\D+C>2@VNH9<'DYKRT_M-:AX<T
MO0/$C_%S0_%VH7-S;KJ?@VUL8(XXXYG576VD4>;OBW=79@VT\5Z1H7[.6L>)
M;[XB:IX[ET.PN_%VEII,EEX6CD\B-5W$7#M(%,DNXCG:!A>^:V/!_ASXXZ';
MZ/H5[K'@J71K#RH'UB."Z>_GMTP.83B-9&48+;R!DG%:QY>>[_N_K=?ETOVU
M1G+FY++S_)6?Y]?7<]LHHHK V"BBB@ HHHH **** "BBOGFQ^)'QB\:>*?'T
M'A.#P7_9OAG5I--BM=5@NUN+G:BO_K$EV D-C.W&>U'5^2O\M%^H/17^7Y_Y
M'T-17A-K^U1977P7T#QC%H-Q<^(-<NSI5CX;AE'F37X=D,0D(P$!4DN1P.V>
M*O0WG[04*Q7L^G_#VXB+!Y-)AEO(YPG]P7!)0N/78%J^1W:?H3S*Q[117SU^
MTI^T-XE^"OBSPK:Z1I.GZEI-S;3W^K"X60SI;PR1"0PE7 !"R,?F5NE>S>(_
M&VE^&O ]_P"*[BX5M(M+%K\S*>'C";QM]<C&/J*AZ0]H]M?P_P"&?W%+6?LU
MOI^-G^J^\WZ*\(_9W^.WB7XD>&O&6I>,-'M-/N="G4K9Z1#*TGE-;K.$*LS%
MI &QQC)XQ5KX4?&KQ9XZ^+NN>&]>\+Q>%M-@TB'5;&UN&+W^R25D4SX;8A(7
M/E@97."2<UHX24N1[VO^%_R(YUR\W2]OQM^9[;117BVN?%CQEXO^(FM>#_AI
MIVBN?#XC&KZYXA:9K6.9QE;>*.(AG<#DG< .GIG-:NR+>BNSVFBO$?'?Q*^)
M'PO^"?B[Q)XBTWPV_B#2?+:RDTYYY+*Y1G1<M&Q61"-QXW'M@UF^)OB1\8_A
M3H;>*?%.C^$_$_A>U59-0C\-BYM[ZVB)&Z55F9U<*.2,@_09(=O,F^VF]_P/
MH"BO*?B+\=(?#^F^%(/"FG?\)7XC\7 -HEBLHBC>+8':>5R/DC52">,GIZD0
M:/<?'6SU;3I-9MO .I:5),BWD&EO>07$,98!G1Y"RN5!)P0N<>]-1=[/3H',
MK76O7Y'KM%%%24%%%% '%?%C_D7;;_K[7_T!Z\FKUGXL?\B[;?\ 7VO_ * ]
M>35\YCOXS/L\J_W9>K"BBBO//8"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** 'PS/;RI)&[1R(=
MRLIP01W%>N^"/&Z>((A:796/44'T$H'<>_J/Q'MX_3X9GMY4DC=HY$.Y64X(
M([BNJA7E0E=;'#BL+#%0Y9;]&?1=%<CX(\;IX@B%I=E8]10?02@=Q[^H_$>W
M75]+3J1J1YH['Q%:C.A-PFM0HHHK0Q"BBB@ HHHH **** "BBB@ HHHH ***
M* "OG3]O[_DV77_^OJS_ /1Z5]%UY1^T]\*-6^-7P?U/PIHES96FHW4T$B2Z
M@[I" DJN<E%8] <<5$M;>J_-%Q=K^C_)GR-:_P#"(_$SXG_!1/@QHXAUG1F@
ME\1:KI6F/9P1(HBW^<=BAFPLH+$?-N R<UZ'I7CS4?"?C#]I77?!WA308/$?
MA^>WG,\BW4AOH]\C2F53/M#!49AY809Z@U];^$])ET'PKHVF3LCSV5E#;2-&
M25+)&JDC(!QD>E>5?"OX&ZIX/^*'Q<U_69M/O-'\97$3VUO;N[2+&!*'64,@
M R)!]TMWKJJ2UDH]I6?FW'\--CDA&T(N2ZPNO)7O\]=SD_$/[5&KWWA'X.S>
M$;+3;KQ%X\N8XI;>\222*V1<+<$!74_*YX))X4]:1OCU\4?B=XR\9:?\*M \
M,R:-X5N&L[B\\1RS[[V=<[DA6(@*<J0-W'0DC.*Q?V>?V/?$7PJ^*T6O>(-:
MT[5?#^BPW4/A^UMY)'E@\Z0G<X:-54[&?."W+>U:L?P#^*OPO\9>-+WX6^(/
M#"Z'XJN6O9[;Q'%/YME,Q8LT)C!#'YCC=QP 0<9,SY7K#K=KR;:LGZ)/RNRX
M\Z5GTLO5:W:]6UYV1XU^TC\:M=^.W[*VF>(;;3].TG3X=9%EK=G,TC7,=XA!
MB\@CY3&0Q+;N1D 9P37TEKWC3XK^"OAAIMUJ<'@)/$,UR8[C4[C49;31[&WV
MYC>3S2)'8D8(4]\]*XS5OV,YA^S'-\-]-UZ*37I;]=7FU*[1EAFNLC<"!EE3
M;P#R>,XYQ4GQ5_9]^)7Q>\)^";G7;[P=<^+/#=_).VFO%<MHU[$P0*)007)&
MSGY<'>1Q5-QLXK^;](W:^::]";2<HR?1/\W:_P K?,R?"/[1FN?$[1OB[X+\
M1KX:OM0T?P]<W<6K^$;II]/N8VA((5F9B2"Z\YZY! Q7H/[$7_)L/@O_ '+C
M_P!*9:X7X:_LJ^+_  MXF^(>L:C-X1L_^$H\.2Z7#8^';>2TM;6X<* %B\O
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MC575R3A2"IZ_6MWPC\)_"G@2^UZ[T/2%L9==E\[45\Z22.=LL<['8JOWVX4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJH_Q8^J)Q7\"IZ/\C[WHHHK]?/YS"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH M:?\ ZYO]W^HK1K.T_P#US?[O]16C6L=CDJ?$%%%%69!1110
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M_P#LZ/J=?^7\4']I87^?\'_D><45Z/\ \*?_ .HM_P"2W_V='_"G_P#J+?\
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M_P#U%O\ R6_^SH^IU_Y?Q0?VEA?Y_P '_D><45Z/_P *?_ZBW_DM_P#9T?\
M"G_^HM_Y+?\ V='U.O\ R_B@_M+"_P _X/\ R/.**]'_ .%/_P#46_\ );_[
M.I['X200W4<ESJ#7,*G+1+#LW>V=QIK!U[_#^*$\RPJ5^;\'_D8'@?P0^O2+
M=W:LFGJ>!T,I]![>I_R/7(HD@C2.-%2-1M55& !Z411)!&D<:*D:C:JJ, #T
MI]>Y0H1H1LMSY7%8J>*GS2VZ(****Z3B"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#C/C!X#O_B=\.M8\,:=K\WAFXU&-8FU*&'S
M62/<"Z[=RY#*"I^8<,:\F^$_[-?Q"^$=MH^E:5\88AX8L;E9IM)B\)6D?VE-
MX:1&FWE\L,C>22./05]&4549.#;74F45-)/H>4_#WX$_\('\8O'GCO\ MO[=
M_P )28_^)?\ 9/+^S;/^FF\[\_[JT?#WX%#P'\8O'GCL:V;[_A*/+_XE_P!E
M\O[-L_Z:;SOS_NKBO5J*(R<;6Z*R]!M*5[]7?YGB7[2_[.NH?M"V>AV4/C*3
MPU8:=*\\MI_9XNXKJ0[=C.ID0?+AN#D?,:N^!_@_XUTZ'4-+\;?$F/QOX7N]
M-DT[^Q4\.6VFH@8!=P>)B<! R[<8^;V%>P44EI%PZ/\ 4'K)2ZH^6[']B.Z_
MLO3O"FJ_$O5-5^&NGWOVVW\,-811OG<6"/<AMS+ECD;0.20%/-;'Q8_93U_X
MA_%RP\=:7\1O[ ETN*./3+"?0H[^*R*K@L@DE"9+?-G9D''/ KZ,HJN>5T[[
M:_/;\B>2.JMOI^-_S/+M(^'_ ,2K/P+K.EWWQ7_M'Q)=2HUCX@_X1RVB^PH"
MNY/LX;9)N 898\;O:N"^$?[+WC3X5>/]2\2+\6/[2BUJ]%[K=E_PCD,7]H-E
MSC?YK>5R['Y .O2OHZBA2:ES+?\ X;_)>NX.*<>5[?U_7D%%%%06%%%% !11
M10 4444 %<EX3_Y&SQ;_ -=X?_0#76UR7A/_ )&SQ;_UWA_] - 'P7\<_P#D
MHVH?1?ZUP%=_\<_^2C:A]%_K7 5^*YI_OM;_ !/\S^GLB_Y%>&_P1_(*Z/PC
M\1/$/@2WU.'0]0^PQ:G$(;M?)CD\Q & 'SJ<?>;D8/-<Y7K_ .S_ /"70/B=
M!XIN=?N=2M[?1[:.X4::\:NP(D+ [U8'A..G6N;"TZE6KR4G9V?6VEG?\+G7
MF-;#X?#2JXJ/-!6NK7ZI+3UL<)X9^(WB+P?H^K:5I.HFVT[58_+O+=H8Y5E4
MJ5/WU.WAB,K@]/05NZ'^T!\0/#F@P:+I_B2>#3H$\N*,PQ.R+V4.R%@!V&>!
MP*[;1?@UX%^*VBZD?AYK6LQ:_8QF<Z5X@2+=.@X^5HP .<#.3@D9 SFN/E\"
M^'H_@NOB3S=<'B079@>(V4GV #S",>;Y>W=MP<>9G/&*[W#&X=<T:C2Y;IJ6
MCC>UEKT;VZ=CRGB,LQ4G&I1O)R2:<-5)K1NZVLM)?B4(?C9XTM]?UG6X]:VZ
MGK$*P7T_V6']ZBJ% V[,+@ #*@&L#PGXRUKP+JZZGH.HS:;>JI3S(L$,IZJR
MD$,.!P01D#TI9/!/B*'1AJ\F@:I'I)4.+]K.00%3T/F;=N#D<YINA^"_$'B>
M&271]"U+5HHVVN]C9R3*IZX)4'!KBY\5SK67,M5O=7UT]6>JJ>!C3E:,%%V3
MVMHK)/T6B3V6AN^-?C1XT^(FGQV/B#79;ZS1Q((%BCA0L.A(C5=V/?-<A9WE
MQIUU#=6L\EM<PL'CFA<HZ,.A!'(/O5RU\,:Q?:P^DVVDWUQJJ%@UC%;.TZE?
MO90#<,=^.*DNO".NV*6+W.BZC;I?G;:-+:R*+@\<1Y'SGD=,]16<I5ZDO:RN
MWWU_,TI1PN'C["DHQ7962U\D=VO[3WQ.2U6W'BF7RU7:&-K;E\?[YCW9]\YK
ME?"_Q.\4^#=;N]7TC6[FUU&\):YF8B3SR222X<$,<DG)!/)KU/X)_!2#5;/Q
MG_PFGAJ_MKBSTW[38B^2>U8-B3+ 97=RJ]<BO&]#\(Z[XH\W^QM%U#5O*QYG
MV&UDFV9Z9V@XKNJRQR=.I*<G)IM:NZU:?IM]QY6'_LN4J]"E2@HQY>;2*C*Z
MNO7Y]3H/$WQJ\:^,+W3+K5]=ENY=-G6ZM1Y,2)'*I!5]BJ%)&.X/?UJ!OBUX
ML;QTOC$ZMGQ&J[1>_9XN!L,>-FS9]TD?=_6L6U\)ZY?:M-I=MHVH7&IP@M+9
M16KM-&!C)9 -PQD=1WJ23P7XAAFT^)]"U-)=0&ZS1K.0-<@ $F,;?G&"#\N>
MM<WM<7)\ZE*][WN]]OOZ?@=ZP^ IKV:A!*S5K1^%ZM6[/=]&:OAWXM>+O">O
M:CK.DZU-9ZAJ,C2W;JB,DSLQ8LT94IG)...,G&,TSQM\5?%?Q%DM7\0ZS-J'
MV4DPKL2)$)[A451GWQFL;7/#.L>&9HX=8TJ^TF:1=R1WUL\+,/4!@,BLVLY5
MZZC[&4W9=+NWW&T,+A)36)A3BY=))*]MM_P.\UKX[>.O$4.E1:EK\EVFEW,=
MY:;[>'*31@A')"98C)^]G.>:HK\6O%T?C:;Q='K4L7B&90LMY''&N]0H4*R!
M=A&%7@KC@'K7(T4WB\1)\SJ2O>^[WVOZV%' 82$7&-&*5FOA6SU:VV;U:.K\
M<_%3Q5\2?LP\1ZO)J*VV3%'Y<<2*3C)VHJC/'4C-<I116$YRJ2<YN[?5G32H
MT\/!4Z,5&*Z)67W(*Z/X:_\ )1?"O_85M?\ T<M<Y71_#7_DHOA7_L*VO_HY
M:NC_ !8^J,\5_ J>C_(^]Z***_7S^<PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** +6G_P"N;_=_J*T:SM/_ -<W^[_45HUK'8Y*GQ!1115F0444
M4 %%%% !1110 4444 %%%% !1110 5H:)_Q]/_N'^8K/K0T3_CZ?_</\Q5P^
M)&=3X&;=%%%=IYP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*76RNVWV2/J?Q!JDOQLT'Q#/X>UW7?">NZ=I;6^I^&-2BQ9^65;<I5AA689
M?[P ' KF?C!KVO\ @;X7_"JW\$75YIVF7%JLC2Z:"IGG*1LJN5')8LYVG[QS
MD'%>.Z[^T%\0?$FA3:/J/B6>;3YD\N6-88HV=>ZLZH&(/?)Y[U!X1^.GCKP+
MI"Z7HGB&:UL%)*020Q3!,]0OF*VT=\# R2>]==3-:%3G5Y)R2]Y+6ZDWHN;1
M.^MGNKVZ'%0R#%T.1V@XPDVH-MJSC;67)=M/57B[+2_4^LM0AM_^&D_ MQ(D
M<6M3Z%.U\JC#9"G:6'UWC\/:N!^#_BB_\:_M/:Y'KNH2WL>EF^_LRUE<^5;L
MLBQCRTZ*?+!Z=>37SU8_%3Q7I_C)O%<6LS-X@8,IO9D24X(P1M=2H&. ,8';
M%9=EXNUC3?$__"16M_+;:U]H:Y^UQ85O,8DL< 8P<G(Q@@D8Q2><TW5IS46D
MIRDUZO3U:W]1T^&JL:,Z4IIMTE!/6Z=Y-]-(ZV[VZ'UE\%O%/C+Q%8_%:/Q)
M->7%G;K.L7VI3MAFVR;XD)Z  )\HX''3/,%KJF@^"?V;_!5VUYXGTW3YV$MQ
M=^$GB24W!W;A,[_P[@5Q_L@'M7@U]^T?\1]2:8W'B:619K=[5X_LT 0QM]X;
M0F,_[6-WO67X+^-'C3X>6#V6@:]-8V;-O^SM%',@/<J)%8+GOC&:FGFE&G%0
MO)VBH\S2;NI<VW-L]M_O,Y\/8JI*52T(WE&7+%M1TBXO7ET?5/E?4^G_  +X
MVTWQ]^T1I>I66CZMI<A\.2)+)K%LL,ETHD79( K$,,9&[OC':O+_  '\;M6T
M[XS:YK/B&/5/$&GV\=U"1:*9?[-B:5 9$3HB#8BGIU[GKYE#\:O&L/C!_%*Z
M[*VNM ;;[5)#$^(B<[%0J549YX YSZFLKPM\0O$/@KQ!/K>BZF]CJ<X999E1
M&WAB&8%6!4C(!Z=JQ>:_O*<XR:2<V]%KS6MI>SZWU5KZ,ZZ?#SA&K&48M2A&
M*5WI:]_>Y;I:JSMTU70]8_:*\,W</A/PKX@M?%^H>*O#%V\OV'^V 3=0LX#'
M+D!G4[.X&W QUKP6NF\<?$OQ-\2+BWG\1ZM+J3VZE8E9$C1,]<(@"@G R<9X
M'I7,UX^,JPKUY5*2:B]K[[?/\W;8^ERO#UL)A8T:[3DK[;:MOLKON[*[UL%%
M%%<9ZH4444 %='\-?^2B^%?^PK:_^CEKG*Z/X:_\E%\*_P#85M?_ $<M;4?X
ML?5'+BOX%3T?Y'WO1117Z^?SF%%%>4_M%?%^\^$OA.Q;1[2.^\1:Q=K8:=#-
MDH)&ZNP!&0.!C/5A3BG)J*W8I248N4MD>K45Y/X)\*?%C0M:TZ^\2^/M,\0:
M4ZL=1TYM*CMO(^0D&&5!E\-M^^!QGO6->?M@>"K6:>9--\1W>@6]Q]EE\26^
MF%]-1\XQYF[/Y+SVS6GLVWRQ=_0Q]LDN::Y?4]QHKRSQK^T=X6\#^)-.T.>V
MU;5+[4M/74; :3:"Y%TK,52.,!MQ=L$CC&!UH\/?M)^#=>\"Z[XI>2]TJTT.
M3R=0L]1M_+NH),X5"@)R6/  /7(.,&E[.7+S6T_X-OST+]K#FY;Z_P# O^6I
MZG17C/A']J/1?&'C:P\+0^$O%^GZE>1^>IU#3$B1(2,B9_WI81G^]C'(J*\_
M:V\%V>I3H++7KC1+>Z^QS^)(-.+:9%+G&UI=V>I[+],BJ]C4NE8CV]*W-S:'
MM=%>4^,OVD?#/@OQC)X7ET_6]5UG[)'>6]OI%D+DW:OR%B"MDL%!8Y &!U[5
MQGQ.^-VA_$+]GO5?$NAZ_K_A>*WO8K:XFL+<#4+:3S%!C*><@Y##)$G0]^12
M5.;L[:-K\7;\QNM!75]4F_N5_P CZ)HKYQ\:?M*ZO\/_ (H>%O"4'AK5]>TR
M6P5[J>+36EOKYO)W![4"0*^#C?D'!#^E=SXT_:*T;P7J$MDWASQ5K-Q:VZ7-
M\-)THRK8HR!QYS%E53M.3@G%-TI*S6S)C7A)M=5;\3U6BOG/XL?%0^(KKX*Z
MSX4UJ]@T?7-=1)1;RO#Y\>Y5:.501D [@5.1UKZ,J94W%7?=K[K?YE0JQJ2:
MCV3^^_\ D%%%%9FPV2UN[P!+.^^P2#DR>4),CTP?P_*H_P"P]=_Z&,_^ 2?X
MUH:?_KF_W?ZBM&MX-I'%5BG(Y[^P]=_Z&,_^ 2?XT?V'KO\ T,9_\ D_QKH:
M*OF9ERK^FSGO[#UW_H8S_P" 2?XT?V'KO_0QG_P"3_&NAHHYF'*OZ;.>_L/7
M?^AC/_@$G^-']AZ[_P!#&?\ P"3_ !KH:*.9ARK^FSGO[#UW_H8S_P" 2?XT
M?V'KO_0QG_P"3_&NAHHYF'*OZ;.>_L/7?^AC/_@$G^-']AZ[_P!#&?\ P"3_
M !KH:*.9ARK^FSGO[#UW_H8S_P" 2?XT?V'KO_0QG_P"3_&NAHHYF'*OZ;.>
M_L/7?^AC/_@$G^-']AZ[_P!#&?\ P"3_ !KH:*.9ARK^FSGO[#UW_H8S_P"
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M !KK:* .2_X1KQ-_T-Y_\%T?^-'_  C7B;_H;S_X+H_\:ZVB@#DO^$:\3?\
M0WG_ ,%T?^-'_"->)O\ H;S_ ."Z/_&NMHH Y+_A&O$W_0WG_P %T?\ C1_P
MC7B;_H;S_P""Z/\ QKK:* .2_P"$:\3?]#>?_!='_C1_PC7B;_H;S_X+H_\
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MZFR/JZC&T'Z?^ <B_P SYL^#.JVEY\6(6\9ZGXP?QGJ&E2:9HS>)= 33(O(
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M>_\ \CR_\$^:OB]I>O>&?BU\*_'%MX8UCQ%INDV$MK>6^C6IGN(V:-E'R?\
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M "/3J***]H^8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSKX_?%X?
MWX9:AXO.E'6OLLL,0LQ<>1O\R0)G?M;&,YZ'I7HM?.G[?W_)LNO_ /7U9_\
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M.,C + D!< C%?0OQP\-_#OX6^ ? G@/2?#&LZQ;:YJ+R6/AG2=;DM;?4)F1
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M "*\-_@C^04445YA[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** /C[]L#PWJ?B#XQ^%9]$DDCUW1/#M[K>GF-B"9K>>*3;QUW*&7'O7K?Q
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M-2%]8Z5I[:A/9M+&BHDGDY4'/OV/I73*WM5R?!=V[?#*QA&_LVI?%I?[U?\
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MVC[^W;Z].^KZ?"*HJ:]I\CX;,)495FZ/S[7\@HHHKL/-"BBB@ HHHH ****
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M%%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '%?%C_D7;;_ *^U_P#0'KR:O6?BQ_R+MM_U]K_Z ]>35\YCOXS/L\J_
MW9>K"BBBO//8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***7KP* #KP*]/\!^ _L?EZEJ4?\ I'WH
M8&'W/]H^_MV^O0\!^ _L?EZEJ4?^D?>A@8?<_P!H^_MV^O3OJ]O"82W[RI\D
M?+YAF'->C1>G5_Y!1117L'S@4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <W\1/'^C_"_P9JGB?79S!IFGQ^9(57<SDD!44=V9B /
MK7R5^SWK6@?%SXQ-\7O'OC#PY9Z]</\ 8?#7A7^UK<SVL9)1-T>[=O.XA5QD
MEV; RH'V3KWA[2O%.ERZ;K6F6>KZ=-@R6=_ D\+X((RC @X(!Y':N9L/@A\.
M=+OK>]LO 'A>SO+>198;BWT:V22)U.596"9!! ((Z8JZ;49.3^7EW^9%1.4>
M5?/S[?(^4?!/PO\ ^%G?M;_&FW_X2WQ3X3^RRPR>;X7U+[$\V<#;(=K;@,<#
MWK?_ &2_#O\ PB/[3_QHT?\ M34M:^QI;Q_;]7N//NIOFSNDDP-QYZX[5]7Z
M?X3T/2-8O]6L=&T^RU74,?;+ZWM4CGN<=/,<#<^/<FET_P *:)I.L7^KV.CZ
M?9ZKJ&/ME];VJ1SW..GF.!N?'N354Y\B@NT7'Y]Q3ASN3[RO_P  \M_:A_:&
MM/@'X*26$1W/B?5"T&E6LI CWC :60G ")N!.2,D@>I'B?PU^&OA^U^ 'Q-L
M=.\9:'XV^*/BC2;J^U1=*U*"ZE#;6(C4(Q) 9^6Z%G],5]:>*/A_X7\<&W/B
M/PWI'B V^X0G5+"*Y\K=C=MWJ<9P,X]!5?PS\+_!O@N_>^\/>$M"T*]>,Q-<
MZ9IL-O(R$@E2R*"1D X]A6:MR2B]Y75_+M_GW-+OGC);+6WG_6Q\)^)_B=X;
M\1_L'^&/!&FZK;WGB^>XM[!=$A<-=B1;DMS&/F"D 8;&"6 KU+]H_P"-$GAO
MP_X>^"6AZOI^D^)=1T^WLM7UC4KE;:UTVV,05\R.0-S*#TY"]/F85]/6?PV\
M(Z?X@?7;7PMHMMKCL6;4H=.A2Y8GJ3*%W$GZU6\0?"7P-XLU.34M;\&>']9U
M&0!7N]0TN">5@!@ NZ$G XZUI*49M\RTD^9_=MZ=_N,HQ<;<K^%67WWOZG&?
M Y/AM\)?@_#I_A_QCH=]H.D$?VAK2ZE T/VAR-SRR!MJ%B0 ">FT<UXM^R%X
MZ\-K\<?C;&?$.E"36O$&_3%-[%F^7S;@Y@&[]X,$'Y<]17T_9_"OP7I^A7NB
M6OA#0;;1KUE>ZTZ'3($MYV!!!>,+M8C P2#T%5M)^#/P_P! U*WU'3/ OAK3
MM0MVWPW5II%O%+$WJKJ@(/N#1SIU)3EU5OR?Z:>0N1^S4%T=_NO_ )ZG9444
M5D;!1110 4444 %%%% !7)>$_P#D;/%O_7>'_P! -=;7)>$_^1L\6_\ 7>'_
M - - 'P7\<_^2C:A]%_K7 5W_P <_P#DHVH?1?ZUP%?BN:?[[6_Q/\S^GLB_
MY%>&_P $?R"BBBO,/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Z/X:_\E%\*_P#85M?_ $<M<Y71_#7_ )*+X5_["MK_ .CEK:C_ !8^J.7%
M?P*GH_R/O>BBBOU\_G,\6UK]G6]L/&6I^)O 'C6\\"7VJMOU"W2RCO;6=\YW
M^4Y #9).>>IQC)JAI?[+?V'X;^-O#=QXLFOM3\63K<WFK26*JJR!]Q*PJXZG
M/&[O7O%%:>TER\O3^F8^QAS<]M=_GWMM<^7?VPO"]EHOP#\*Z4TTEQK6G75G
M8Z9-$FUYI%CV-QD[054G&3R%KT+5/V==*\2? _0/ =S<2Z=+I<4,L%]; ;X;
MI02T@'?+,^1D=>HZU[!15^VERM=7+F^9'L(*:ET4>6WE_6AXO=?L\ZEXN\'Z
MSH?CSQ[J/BW[<D2V\RVD=HMF8R65UC4D,Y)P6/)''O4/A_\ 9SU1_%'A_5_&
MWCV\\:Q>'COTNSDL([5(G&,/(59C(PPIR><@9)Z5[=125::=T_P7W^3\QO#T
MY;K\7]WFO+8\,\2?LWZOXT\06K>(/B'J&J^%K34SJ=OHTMA%YL;[BP3[5G>4
M&2,8Z<#& :\\_:/\ Z=X^_:<^'>CVX<WE[ 'U:-!\IM(I"ZEOKMD'/HM?6U%
M.G6E3E&7\O\ E;_+[A5,/&I"<?YK7^^_^?WGGOB+X2+KWQ>\+^.!JGV<:':3
M6O\ 9XM]WG>8K#/F;AMQNZ;3TKRB^_8UOY?#.J^%;3XC7=IX2N[DWD6EG2HG
M*2[@09)=P:0#'W?EZ ]J^F:*B-24=%_6M_SU+E1A)MM;_P"5ORT/'/'7[/\
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M/^A9A_\  ]*/[<\6?]"S#_X'I0!UM%<E_;GBS_H68?\ P/2C^W/%G_0LP_\
M@>E '6T5R7]N>+/^A9A_\#TH_MSQ9_T+,/\ X'I0!UM%<E_;GBS_ *%F'_P/
M2C^W/%G_ $+,/_@>E '6T5R7]N>+/^A9A_\  ]*/[<\6?]"S#_X'I0!UM%<E
M_;GBS_H68?\ P/2C^W/%G_0LP_\ @>E '6T5R7]N>+/^A9A_\#TH_MSQ9_T+
M,/\ X'I0!OZMHMGKENL%]#Y\2OO"[F7Y@",\$=B:R?\ A7?A[_H'_P#D:3_X
MJJW]N>+/^A9A_P# ]*/[<\6?]"S#_P"!Z5G*G"3O**?R-HUZM-<L)-+U+/\
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M ('I1_;GBS_H68?_  /2CV-+^5?<'UJO_P _'][+/_"N_#W_ $#_ /R-)_\
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M<\6?]"S#_P"!Z4?VYXL_Z%F'_P #TH]C2_E7W!]:K_\ /Q_>RS_PKOP]_P!
M_P#\C2?_ !5'_"N_#W_0/_\ (TG_ ,55;^W/%G_0LP_^!Z4?VYXL_P"A9A_\
M#TH]C2_E7W!]:K_\_'][+/\ PKOP]_T#_P#R-)_\51_PKOP]_P! _P#\C2?_
M !55O[<\6?\ 0LP_^!Z4?VYXL_Z%F'_P/2CV-+^5?<'UJO\ \_'][+/_  KO
MP]_T#_\ R-)_\51_PKOP]_T#_P#R-)_\55;^W/%G_0LP_P#@>E']N>+/^A9A
M_P# ]*/8TOY5]P?6J_\ S\?WLL_\*[\/?] __P C2?\ Q5'_  KOP]_T#_\
MR-)_\55;^W/%G_0LP_\ @>E']N>+/^A9A_\  ]*/8TOY5]P?6J__ #\?WLL_
M\*[\/?\ 0/\ _(TG_P 51_PKOP]_T#__ "-)_P#%56_MSQ9_T+,/_@>E']N>
M+/\ H68?_ ]*/8TOY5]P?6J__/Q_>RS_ ,*[\/?] _\ \C2?_%4?\*[\/?\
M0/\ _(TG_P 55;^W/%G_ $+,/_@>E']N>+/^A9A_\#TH]C2_E7W!]:K_ //Q
M_>RS_P *[\/?] __ ,C2?_%5/9>!]$T^ZCN(+!5FC.59I';!]<$D5G_VYXL_
MZ%F'_P #TH_MSQ9_T+,/_@>E"HTUJHK[A/$UVK.;^]G6T5R7]N>+/^A9A_\
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M_A(/&?\ T*<'_@Q2CE8<R.SKDO"?_(V>+?\ KO#_ .@&H?\ A(/&?_0IP?\
M@Q2H?A]<7ESKWB>2^M5L[II82\*R!PIVMQD=>,?G2:L-.Y\+_'/_ )*-J'T7
M^M<!7?\ QS_Y*-J'T7^M<!7XIFG^^UO\3_,_I_(O^17AO\$?R"BBBO,/="BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z/X:_\ )1?"O_85M?\
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M_P <_P#DHVH?1?ZUP%?BN:?[[6_Q/\S^GLB_Y%>&_P $?R"BBBO,/="BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z/X:_\E%\*_P#85M?_ $<M
M<Y71_#7_ )*+X5_["MK_ .CEK:C_ !8^J.7%?P*GH_R/O>BBBOU\_G,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"UI_P#KF_W?ZBM&L[3_ /7-
M_N_U%:-:QV.2I\044459D%%%% !1110 4444 %%%% !1110 4444 %:&B?\
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MSQ(K-A7@25 IR2>1D@CVKU6H+Z^MM+LKB\O+B*TM+>-I9KB=PD<:*,LS,>
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M_P -1WAS]I#2[OX9^*/%?B+2;KPW=>%[J6PU?2#(MQ+%<(5 CC<8$F\N@4\
MD^G-1V?QT\0Z3KGANW\:> 9?"FE>(KE;*PU!-4CNS'<."8HKB,(OE,P! P7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\,=#GT?2);IM.>\GO(H+AU86WFN7:*/"C$88L0#DC)YKJ**-@"BBB@ HHHH
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MENEZ'SE17T;_ ,,8:_\ \_3?E%_\<H_X8PU__GZ;\HO_ (Y7#_8&8_\ /O\
M%?YGJ_ZW9-_S^_\ )9?Y'SE17T;_ ,,8:_\ \_3?E%_\<H_X8PU__GZ;\HO_
M (Y1_8&8_P#/O\5_F'^MV3?\_O\ R67^1\Y45]&_\,8:_P#\_3?E%_\ '*/^
M&,-?_P"?IORB_P#CE']@9C_S[_%?YA_K=DW_ #^_\EE_D?.5%?1O_#&&O_\
M/TWY1?\ QRC_ (8PU_\ Y^F_*+_XY1_8&8_\^_Q7^8?ZW9-_S^_\EE_D?.5%
M?1O_  QAK_\ S]-^47_QRC_AC#7_ /GZ;\HO_CE']@9C_P ^_P 5_F'^MV3?
M\_O_ "67^1\Y45]&_P##&&O_ //TWY1?_'*/^&,-?_Y^F_*+_P".4?V!F/\
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M[-\5?] */_P,3_&CV,^P?6:7<L457_LWQ5_T H__  ,3_&C^S?%7_0"C_P#
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M/^A9A_\  ]*/[<\6?]"S#_X'I0!UM%<E_;GBS_H68?\ P/2C^W/%G_0LP_\
M@>E '6T5R7]N>+/^A9A_\#TH_MSQ9_T+,/\ X'I0!UM%<E_;GBS_ *%F'_P/
M2C^W/%G_ $+,/_@>E '6T5R7]N>+/^A9A_\  ]*/[<\6?]"S#_X'I0!UM%<E
M_;GBS_H68?\ P/2C^W/%G_0LP_\ @>E '6T5R7]N>+/^A9A_\#TH_MSQ9_T+
M,/\ X'I0!UM%<E_;GBS_ *%F'_P/2C^W/%G_ $+,/_@>E '6T5R7]N>+/^A9
MA_\  ]*/[<\6?]"S#_X'I0!UM%<E_;GBS_H68?\ P/2C^W/%G_0LP_\ @>E
M'6T5R7]N>+/^A9A_\#TH_MSQ9_T+,/\ X'I0!UM%<E_;GBS_ *%F'_P/2C^W
M/%G_ $+,/_@>E '6T5R7]N>+/^A9A_\  ]*/[<\6?]"S#_X'I0!UM%<E_;GB
MS_H68?\ P/2C^W/%G_0LP_\ @>E '6T5R7]N>+/^A9A_\#TH_MSQ9_T+,/\
MX'I0!UM%<E_;GBS_ *%F'_P/2C^W/%G_ $+,/_@>E '6T5R7]N>+/^A9A_\
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M/_@>E '6T5R7]N>+/^A9A_\  ]*/[<\6?]"S#_X'I0!UM%<E_;GBS_H68?\
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M4444 %%%4=(U[3?$$$TVEZC:ZE##,]O))9SK*J2H<.C%2<,IX(/(H O4444
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MHJC-KVFV^L6^DRZA:QZK<1--#8O.HGDC4@,ZIG<5!(R0,#- %ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BJ,.O:;<:Q<:3%J%K+JMO&
MLTUBDZF>*-LA79,[@IP<$C!Q5Z@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \<^
M)7[2'AGP7XF\,:3:>*O##O<ZS_9^LQW&HQ&2PA$4A9F D'E$.BJ2XP,XQDBO
M4]!\0Z5XITN'4]%U*SU?39MWEWEA.D\+X)4[74D'!!!P>H-8'CKP!_PFFL>$
M+[[?]C_X1_51J?E^3YGGXBDCV9W#;_K,YYZ8QS77U2MR:[W_  LOUN$OB5MK
M?J_^ ?/GP=\,Z1\=%\3^,O&^EV?B>1];O-/TRQU:!;FWTZU@D\M4BB<%%=BF
MYW RQQDX K(M?%M]\$=>^,_A_0]LVC>']#A\1:+I]XSRPV3-')O@4;@1#O0$
M1J0%R0,9KO/#WP_\8_"G7/$*^$(=#USPSK-]+JJZ?J]]-83V%Q+@RJDL<$XE
MC9@6 *H5)QEJI7?P-UC5?!OQ)GU+4+&Z\<^-;!K266-6CLK-1"4AMT."[(A9
MLR%=S$YVCA0FVJ?N_P OXV_/FUO^.NKC9U/>_F_"_P#EI;_(SM:^+WC[PO\
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M2^%>J:/)\"?A==:S:V>MZ99ZA<M=*;K[(S(HPT3PSVTQF4,< ,N%9R?0^K_
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M@!@5=^&_A3XC_#OPSI/@]?\ A&]2TC2PEI;Z]/=7"W)M$(VA[,1;3($&S(N
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M24?R][^K&GI?QB^)?B;PC\0?$FGP>%[2S\)ZEJ-K';7%M<2R:C';'=MW"91
MVP8W8D#,?NH!\WJ<.O>)?''AGP]J_A272=(M=3L8[][G5[>6\>/>BLL0@1X<
M\,<R&48VXV-NRO)^#?@YK7AWX:_$GP]<W5@][XDU+5;RTDBD<QHETN(Q(2@(
M(_BP#CL36'JWP'U^:T^'27%EX>\8V'A[0UTR\\-Z]=2QZ>]R$11=Q_N)0S@!
MU&^+[K9!!J(VLD^T?OL^;\;?\-<N5^9M=Y?==<OX7_X>QQOQB\>>)OB%^S/X
M_6^_LO3M2\/ZP^CZIY-K)+%>>5<0[9(,R@PYWH2'\SH1WR/1?B-XAUOPC_PK
M&WUZ#PWXGOM2\56UF+HZ.\*VB,C$20H\\I29<'$F[H?NUB:/^S9JT'P5^(?@
MN>?1-,NO$.IS:E8KI$+QV=KGRFCBV%054/%M.W/R\CG@=5XT^'OB[XB1?#RY
MU"#1=*O_  ]XCM]5O(;6_FN(I((T8'RW:!"7);[I4 ?WC51LG%/O%O\ \EO^
M*>QF[VD_*:7X\O\ 3$L_'7CCXC:UXP3P7)X?TG2_#][)I,4VMV<]V^H7D: R
M_P"KFB\B-694SB0G#' Q@\O/^T=XA\0:?\,)/#>BZ=:WWBO4+W3+ZTU:5W%E
M-;JX<J\>-P5T)P5^=0!\A;<.ETKP#XY^&NL^,#X/70=8TKQ#J$NKQ)K5[/:R
M:?=2C$HQ'#+Y\98*P&Z,CE<]#67I_P"SM>^'9_A/'IVI6]Y#X5U"\U#5;JZW
M1RWDMPC[WC10P&9')VEAA<#)Q2A:T>;^[?U^U\M_PY>I4KWE;^];TUY?GM^-
MSJ?A_P"/?$%Q\2/%'@?Q0=-N]0TNUM=1M=1TFVDMHI[>;<I5XGEE*NKQMR'(
M((X&.?3*\C\0:1-\.?B)XX^*.I7EG#H/_".6]JB$NTPEA>5SN4+@AMZ@88DG
MC XKL_A?JGB76_A_H6H>+[&UTSQ)=6PFO+.S5ECA9B2% 9F((4KD$G!S1\44
M^O7[W;\%J5\,K='M]RO^+/DZXNOAU9ZG\>;OQKX9_M;4%\030VFI'19)3 6A
MC2)1?^7Y=L?,(P7E3:2#QUKZ.\#Z3\1=,^%/A#2[C4=+;Q1'91IJ>JZMYM[L
M8*#]Q'0SL?NEC*O.6^?H:7@_X+RV:_%6R\1-:7FE>,M5GNDBMV9F6WDA6,J^
MY0 _!/&1TYKD9O@;XVO/ _PYTO6I]"\7/X7>>&_T75+N:/3]6@V%+:25O)?,
MD0$9VO$ZDECG.#0G[BB^T/PCK^._?39)B:?.Y+O/\7=?EIV^8_6OC[XJ\,_#
MWXLSWUEI-QXH\"SQQI<00RI97J2*CQN8C(70[7P5\P\C(/:MKQ5\7/$_PW^&
M,?BGQ/\ V M_J\UK;:;IRE[:WL)9R<"ZNWE82(@.6=4C^XV!R".1_P"&9O$'
M_"OOBYHEM#X7T.7QBUO)I]AI(DBLK+8BAD;$0Z$'YE3YC\VU,[1ZE\3_ (6W
M?CSP#I6EV6HQZ9KVC7-IJ6GWCH9(5NK<@J'4$%D;YE/<!LX.,$=M+_W+_P#M
MVWZ?(->G]ZW_ +;\OZ9R?@/X]'5/BII_@VZ\4^$?&D>J6$MU:ZCX3.S[--$<
MO#-&;B?AD(97##[C#;WK/_:\?2%C^%J^(6LAH#>,+0WRZF4^RF(1R[O-W_+M
MQG.[BO5O"]SXYO+]3XBT[P_I5E'$0R:7?SWTD\AQ@AGAA$2C#<8D+;ARNWYL
M7XO?#G4O'VJ> ;G3Y[6%- \16^KW0N792\,:N"J;5.6^88!P/>GIS0\FO_2O
M\OZN)7Y)^:?_ *3;\7^9Y7X7\0>&?!GQ2\6>)/ "6P^&.F>&7NM9_L%4&ER:
MA&P=!!L(B,WDCYRF?X W)HL?VIY[9?"FJW_BCP'JEIKE_!:W/AK1;K?J6F1W
M#8C8R_:&$QCRGF#R8_XL=.?H'QEX7M?&WA'6?#]ZSI::I:2V<K1G#*KH5)'N
M,YKBO &D?$KPQH^A^'-13PS=6&F+':OKR75P;BYMX_E4FS\H*DK(%!/GLJL2
MV& VD@U>TNEOFKMR_1=TMNH232NNM_EHDOU?:^YG1_$+QIXV\7>,+3P?;Z+#
MI/A>X6PE75XI7EU.Z"+)+%'(D@%NH5E7>R2G<<[<#!\B^$OBR30?A'\"89=#
MTJ]EU;Q/<VKMJ5N)Y+$F6Y8R0,"-D@QC?SP3QS7KMK\.?&7@KQIXSO/"<VB2
MZ5XKN8[YY=4DE2;3+GRQ'*ZQ)&1<J0J,%,D7((W8.:Y?P]^SOXCT?P?\)=)F
MU'3;BY\(^()=5OIM\@$\3-.1Y?[OE_WJY!"CKSTR0LN6_P#<O]_O?+^EU"=_
M>M_>M]SY?Z[WOT.R^+/BCX@^!_#/B'Q7I[^&SI6C1-=#2+BVN)I[N"/YG/VD
M2QK"[+NPOE2 $#YFSQY_XTNO$OB;]H+X3ZIHVJ:3IJ:AHE_<V*7VE2W)MU:&
M!I%EVW,?F$Y&"NS;CG=4?CG]FOQ!XH_X6#;S:5X/\177B"XGFTWQ1XADEEO]
M,B>,;+=(C ^U8VW*K),H 8/L)!5NYUKX6^)+/5OAIK^A_P!E7^K>%M/ETVYL
M=0NY;:"=)($1F25(9&#*T8(RF"">AI4[:2?]7C)/\;?IH5*^J7G^#C;\+^??
M4K+\1?'NO?&[Q%X#T@>'[*PT>PLKV76+RSFG;=*K;HQ LZ9W-RK;P$"$$.6&
M,1OC;'X'O?C7JDOAO37D\/ZE96T*Z9"+>YU2::*-8Q/(2=S;G50V/E7L<5WG
MA7X<ZKH_QL\9>,[J6S_L_6]/L+6&"&1VE22$.'W90#;EA@@DGN!7':M^SG?^
M)/\ A;D%]J=M9Q>+=0L[_3+BVWR26KV\:;6E0A1]]!P&.1W!I:=>SO\ ^!K;
M_MV]N@>G=?=RO_V[?J>D^#X?'T%Y$?%-[X<OK26UW.NDV4]K);7&5^0>9-*)
MDP6^;]V1M'RG=\OF/QVT'3/%'Q^^"NE:UIUIJ^F3'6&ELK^!9X9"MM&5+(P*
MG!Y&1Q7IW@^?Q]<7D0\4V/ARPM([7;(=(O;BZDN+C*_./,AB$2 !_E_>$[A\
MPVG=S?Q4^'_B77?B-\/_ !=X<BTJ\?PT;X366J7LMH)A<1+&"LB0RXQM).5I
M[3BWMK^3M^@M>5KK;]#E]=T6R^"GQI^'R>$8DT70O%=S<Z=J7A^S'EV32+!O
MCN8X%&V.0>6%9E W C/K7/:7\>+SPS\,+W5K31O#OA[[1XXN-"EOTM'BTZQ0
MSE3>W2*X+,<89MZ LPRRBO4-+\ >(?$WQ"TOQAXSETVU;1(YH](T/2)7N(8'
ME0+)<27$B1M(Y7<H41J$!/+$YK&^'OPU\9?#7P;J^GVD7AW6;B_\07^HRV5[
M<31PS6MP[%4\T1,4<9&08G4@%>,[@+9<W;_VZ.GW7]$_(?\ A_KW9:_?;U:\
MQ?'/QDU'X;_#C3-4U'4O#&J:AK5_%8:5K$,[6FE.LJETNIMSOLC10Q(61]X5
M<,N_"UOAW\=GU[XG2^#)?$GA/QFUQI;ZE9:IX7<QQJR.%>">/SY]I^96#!N0
M&^7CG!T_]F75['PC</87FD>'_$</BC_A*=*TVP1WTFQD5=BVN,(QC=!AW5%P
M7)"<8/K.GQ^.-=@U&WUN'1?#D$MH\$#:/?3WTXF88$OF/# $"?W=K%B0=R[<
M,:)-[O\ ^U5O+25]M[?RBUNET_\ MG?SUC;?;IJCD?%?CSQW\.M9\(W.N_\
M"/:CHVO:Q#I$]AIMK/'<6#SAO+9;AY2LZJPP3Y,18<@+T$'A_P"+?B#Q=\5/
M$WANSOO#>D/H=^ML/#NJ1R_VG?VX5&>Z202 (A#Y7$,@. "R[LC@],_9B\0I
M%X'6?0O!%EJF@:O:ZCJ'B:"6:?4]8\N3=([R-;JR.^2Q#/("V!E0,UW'Q4^%
M/BGXK:CIUG?V'A>VM-/U:*]M/$\,LW]J6L"2K+Y<4)B(20[%1G$^" 6V#A14
M5'F5WI=_=[NOG]K1ZOU2)?-9^B^_WM/RVV]+F5XH_:(EF\8>+='TKQ?X%\'K
MX>?[&J^+9MT^HW7EASL07,/E1 L$WG>2=W VX/J7PC^(EO\ %CX;Z%XLM[?[
M(FI0>8]OY@D\J16*.H8 ;@&5L' R,' Z5R>F^ _&/P[\;^+-3\*1:+KNB^)+
ML:E-8:O?S6,MG=;%1RDB03B1'"@X*J5(ZD5Z?HZWZ:7;#59+:;4=@\][.-HX
M2_?8K,Q ^I_PJ%;D7?3[^OX_+:VY;OSOMK]W3\/U/G+X'?"GP;\0;CXLW'B3
MPMI&MWC>-=4MA>7EG')<)'E,*DI&],9."I!!Y&#4.A_'"_\ A3X(\<:;J-^N
MNW.@>*O^$>TC4-<O=BE9@KQ&[N&ZK$&;<_+$)VZUV'@GP+\2/AK=>-XM(T_P
MMJ=OKVOWFLVMY>ZQ<PO )B-JO MHP;;MR0)1GID=:74_V<YY/AS)IMIXA\SQ
MC_;R^*3KMQ;;8I]25PP+PJWRQ%0(PH8[5QU(Y(NT8WVY8I_^2W^Y*7WZ":UE
M;?FD_D^:WR;Y?NU*GA']H*2X^(]OX4G\1^$_'HU#3)[VTNO!YV/%-!\SV\L1
MN)\[U(*/N7E6!7O6M\!_BIKWQ:TN'7)M3\,7%G*LGVS0]/CE2_T=]S>7%.S2
M-YCX4A@8X><LN0,'L]!G\?WTS_VU9>&]%B2W95^P7EQJ+2SD#:QW16_EHN#E
M?G+;@-R;<MQ&G_"OQ'KGQ@T'QQKNF^&_#]UI5I<0W$^@7$L]QJSR(L:B=G@B
MVQH%W*I,A!P 1C));->3_7_@+OL^XM;7_KI_P7VW78Y#P!\:-4F^%?P^@T'0
MO#^AZWXJUR\TV!+>S>/3;)(IIVEE,".&=BD9.T.NYW)+ <&Y+\:/'_A_2OC-
M-JTOAN^NO UN&M!9:9<0QW+/ )D>0M<O@8R&C'(.#OKA=6^%&J^%]+^"_P ,
MK_5[.UUA]9U745N4:Z-EQYTJ$/%+;R^<HF78%9>=YS@#=TEEX8U#5-/^+/P6
MLDT6?5IM)6\;7[5;I%DGN@P"7K32W,IE^7<&,C$IC"@**J6L9N.[O;Y6_*S^
M_P!"H_Q%S;7U^<G^?N_U>_80_%3QQH<GPZU;Q%#H#Z)XONX+![#3H)A<6$L\
M1>%O/:0K,,J0P\I,9X+8R>A^*GB#XA>$?#WB+Q-I4GAM=,T:WDNUTNZM;B>>
M\AC7>Y-P)8UA8J& 7RI "H.X[L+#XL^%>K:]X<^%VGV]Q9)-X7U?3K^]:1W"
MR1P0LCB/"G+$L,;MHQU(K@?''[..O^)[[Q^L^D^$/$TOB&25M-\1>(WEEOM(
MB:+:L$41@<!4;<59)4P6W%21M*J/67)T;MZ>[;\WOV]!4[^[S]E?UUO^FW^8
MSQQJ/B3Q?\;/@CK.C:EI>EQZII>HW=C%?:7+<FVWVD+R"4K<Q^;D, -NS;@Y
MWUU%Y\3(O"?QF\9Q:MIFD>5H?@^'5KK6+6R,=[/M>3=$7+G]W\I*H<X)ZFK6
MI_"CQ)8?\*HU;1CI5]K7@RRDL+BROKJ6WMKE);5879)EBD92K1J1F/D$YP:7
M6/@C>^+/B5XQUG5IK6+1/$7A2/0'AMIG:>*3>Y=AE "H#\'.21RHHJ::4^G/
M^/,U^:"E=Q3J;OEO]\;_ *F3JGQ8^(7A7X<Z;\2=:L]!?PW-Y%W?>'[2WF%]
M96<Q 5A=-+LED0.C,ODH#\P## )T8_B-XZ\5_&'QIX-\/'P]IVGZ#;V-RFJ:
MC:SW+MY\3-Y9B26,-DC._>NT+C:Y;*TKSX4^/O%/P[TSX<>(+C05\-P""TO]
M=L[F9KV_LX2"JBU:$)"\@2,,WG2!<O@'(QUW@WX;ZCX;^,GC_P 5S36C:7K]
MOIT-I#$[&:,V\;J^\%0 "6&,$]\XJI<O,[;:V]-+?KOKWTL1'GY4WOI?UNK_
M (7VTVMK<R_!_P 7/$WC#X-6WB?2?",6N^*$N7L;K1;?4$M(C+%.T,SI+*"
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M-YI[22R!(D01 B8B,E3^[/W0W4<UUU))U923T=__ $N+^6B.>C&T8)]&K_\
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MEY8WFFW5J&EEM)+>- KR(0H/[R,':&.1W!KO?"EQ\1;BYL8_$EAX9L+:&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!E^(O"^B^,--.GZ]I%AK=@7$AM=1MDN(MPZ-M<$9&>N*3PWX4T
M3P;IYL- T?3]#L2YE-KIMJEO%O. 6VH ,G Y]A6K11L 4444 %%%% !1110
M4444 %%%% '.>*/AOX2\;7$-QXB\+:+K]Q"GEQ2ZII\-RT:YSM4NI(&><"MV
MSLX-/M(+6U@CMK:!%BBAA0(D:*,*JJ.     *FHHZ6#K<**** "BBB@#/C\/
MZ7'KDNLIIMFFL2P"VDU!8$%P\0.X1F3&XJ#SMSC-:%%% !1110 4444 %%%%
M !1110 4444 9\/A_2[?6I]8BTVSCU>XB6":_2!!/)&IRJ-)C<5!Z G K0HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)&DT;QR(L
MD;@JRL,@@]01571]'T_P_IMOIVEV-MINGVZ[(;2SA6**-<YPJ*  /H*N44 %
M%%% !1110!#>6<&H6DUK=01W-K.C1RPS('21",%64\$$'!!INGZ=::186]C8
M6L-E96T:Q06UO&(XXD48554#"@ 8 ' JQ10!1M-"TVPU*^U&VT^UMM0O]GVN
M[A@59;C8-J>8X&7VC@9)P.E7J** "BBB@ HHHH **** "BBB@ HHHH ****
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M0^/OC1?Z/\1]7\)OK?ASP596-A#<07/B2TEO9M9,H.5M8EGAW%"I4A3(S,0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&8GE1VKP+7K>XF\(_M#^#+W5M8U#2?#EI]LTV2YU6Y:XC$U@TIA>;S/,EC#
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M=$O]7CN9%NY;2 F\>0R!MP+6YC4G)^_@]:(QYFK=;?\ I7*_N>X2ER7OY_\
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M+VYMKN'[3<V>R;RS*8F>)G:,)G.<,-V,XI1CS*/G;\7I^:82ERW\K_@K_P#
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MZ?1K'Y6_\EV^XG2:OWO_ .3;_><%KGPBM-0\8S^*='U[6/"6NW=NMK?7.CM
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M_73]?U/-_#\=[)\5/";>!%\<+H4:W'_"12>+)-4%J83'^Z5%U$[C-Y@!!A'
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MC>WR6A\J>/=#L9/@7\9]#DM(M3T/PGX@2V\/R7B"<V",;<R00NP)54+N@P>
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MXATN\FDT.5)=+^VZO>72V)4%0(5EF81KC ** IVKD':N)@U&IS=+K[KZ_P#
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MRY4D]=_G[_-KZK1[[]4%KMO;5?+W.7\]5^AY=X+^#OB#PK\3?#NMZ/X5\(^
M]#M[:>TU>T\/ZK-,=1C*?N2\9LX59XY!G>QW89N>QG_:>86EW\*K^\8+H=IX
MQLGOF<_NTR'6)W]A(5Y/3BO0O"OPG\-^#KRWNM/AU"::UB,%L=3U>\OQ;(0
M1"MQ*XBR  =@&0,=*Z+6M#T_Q)I5SIFK6-OJ6G72>7/:W40DBD7T92,&G*6L
M6M;-/[G?S_X!,8^[)/2Z:^]6\BS=2M#;RR(AD9$+!!_$0.E?*?A'P3X:\=?L
MPZE\0-?CBG\:75I>ZM-XHD)&H6-U%)(8Q#/]^%8C$BJBD !<8Y.?>=!^#/A7
MP[?6%W;V^I7<FG_\>4>J:S>W\-J0NT-%%/,Z1L%RH90" 2 0":KWGP%\#7U[
M=3RZ/*(+NZ6]N=,CU"YCTZXG!4^9)9+(+=R616.Z,[B,G)YK-I:I.U^O5>GY
M_)?+1/5-K;IW_K]3Q#3M-7XH?&KX4/XPM/MTE[\/C>7]C<<0W$IDB8K-&,+(
MNX[MC KD*<<"JG@_X;>&]9T'XY65_I4-[8>&]2U"VT.SN"7ATI/(\[_14)Q
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MQ%;6\:Q11KT55   ^@%;2DI<\EW:7H_>?XO\+&48M<D7KHF_5+E7X?HSYO\
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MX/\ #_A>R^+^O:/X8TF#6]'\1:M%IUQ;Z?$LT")"A6&-@N53DC:..3QS7*>
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M)-]X1T/1?^"><^IZ?HVGV&I:CH=HU[>VMJD<UR1<)@R.H#.>3U)ZU]I]>#7
M)\!_!*>$]7\,?V9=-X=U3'VC2WU2[:W0"0R8A0RX@&\DXBV \=@*F.BDN_+^
M%_SO^!=]8/M?\;?E;\3S?Q+X-T?X9_%CX.WWARR33K[5+NZT[4[M"3-J,36C
M2'[3(3NF;>BL&<DY&<URWAOP'K'Q(\*?&C1=$N[>"Z;XA3326][))';7T*"W
M:2VF:,%A'(H*G .>F,$U]*ZQX+T;7]2T+4+^S\^[T.9KC3Y/-=?)D9#&3@,
MWRL1ALCGUK(;X.^$OL>K6R:9) NJ:F=9N9;>]N(IOMA !FCE5P\384#]VRC!
M(Z$YKFU;]?\ TJ+_ $>GGYLPC!J,8^E_NDG^:U\O)',? +7M&NH_$>B67@L_
M#W6])N(1JWA^&2-[6&22,,CP&(^659 "2JH21\PSR<GP5_HW[6OQ)2_XN[G0
M]+ETXR=3;*9%EV9_A\TC..]>G^#O .A^ K:[AT6T>!KR<W-U<7%S+<W%Q(1C
M?)-*S2.<  ;F. ,#BH?&'PU\.>.[C3[K6+!GO]/9FL]0L[F6TO+?<"K".XA9
M)%5@2"H;![@T.2YE+R_3I\_PT+Y?<<?ZWN>;?$W_ (F'[3GP>MK']Y?V-OJM
MY>A.L5HT"QAG] TA4#W!K@M!E2W_ &2/C%YKK'MO_$2-O.,,9I< ^YR/S%>F
M:[^S=IR:G!KO@_Q%K?A#Q9&Z[]8-]-J1O(\@&*Z2YD?SD"@[06^0X(Z8.YKG
M[/G@'Q)=ZO-J.AO<1ZM*T]]9?;[E+.>9HQ&9FMED$7FX _>!-X8!@=PS46_=
MN/=27WR3^[IZFD9.,U*VS3^Y-?K]UC@;>_\ !^I>%_AMX>U;P==?$+7G\,VM
MW#H<<4,\$-N(D4W#I=2QVX;=\@8GS/F('!->.:PL]Y^S;J^C$ZCI%I8?$E=,
MLK5[A?M&FVXNX]D*.C,JF/<<;68 C@D 5]8:M\&O">L?V*9+&[M)]&L_[/L;
MK3=3NK*XBM\*/*,T,J.Z?*O#,1D9ZU!!\"? MKX9?P]#H"0Z,VIKK!M([B95
M^UJRL) 0^1RBG:#MXZ<FM^>+J<[VO?\ \G3_ "7WOL<ZA)4U#JE;_P D:_-_
M=YGE/[1'PA\#Z#X5\"V]AX0T2WC/B_2X'*Z?%ND2295E#MMR^]54/N)W8&[-
M'Q1T%6^,7@;X?Z3X7T&\\*QZ/>:E#X9OISIVEW%PLJ#+)';RK(45F81E-N7+
M=0,^]>+O!^D>.]"FT?7+/[;I\K(YC\QXV5T8,CJZ$,C*P!#*001UK(UCX2^&
M/$&D:5I^HVEY>#2I#+8WTFIW1O[=R>62\\SSP3T/[SD8!X %9QDU:_=O[XI?
M@]5^FYI*-V[=DON=_P 5H_UV/G+XL?#_ ,1_#S]G7XPQ7]MI.B^'KV2VN](T
M31;^6YBTXF6/SU0O!%L1G <*JX!9L =3TGQ^^'^@> ?@SH<&BZ;!:RW'B'1F
MN[S8#<WL@N%_>SRXW2R$EB68DY8^M>QW7P;\(W_A'5?#5YIT]_I6K%6O_MFH
M7,]Q<E2I7?</(9FV[5 R_ &!QQ6QXL\#:)XXTFWTS6[+[;8V]Q#=QQ>:\>V6
M)@T;91@3@@'!.#WS51ERRB^SB_E&W^7S)E&\6O*7WR1\Y>./&=Q^SWXT^*^G
M6BLD?BC3EU[P_$.C:G(ZVLR)ZL99()".PR:]^^$_@.#X8_#?P]X7MSO&G6B1
M22?\])3\TC_\"<L?QKBOBS\,KWXC?&#X7W4FCI+H'ANXN-5NM3>2/*S!5$,*
MINW'+JKD[<?(.<U[%41=J:77;Y1NH_FUYI)EM7J7Z;_-VO\ E?U;1\-Z./%-
MK^S3XNN5O[23P0?$6H1ZU8V=DR:FMBUVRW+Q7+2-'G:2=IASMW88'!KTGQI;
MCQ7\9O"'A#2]$T7Q5X0L_"2ZGINC:YJ,EOI\[&41++@6\XG9(@H4.N%$A88-
M>[:%\-_#GAKPS?\ A[3M-6'1[^2XEN;5I9)!(TY)ER68GYBQX!P,\8K+NO@I
MX.N]$\/Z6VERPP^'X_*TJYMK^X@O+--NS9'<I()@I7@C?@@#.<"G%I<J?2W_
M *2X_@]5ZO;04HWO;K?_ -*3_%:/Y;GSM\7/ _B3X:_LY^.K;5'T[1=(EUZQ
MO=&L-'U"2XCTJ)KF$O&DDD,6U1(&=0%VKN. *[KQAX-T/X5_%WX0W'A*TCT[
M4M6O[C3M1>#)FU2U-LSO)<L#F=E=4?S'R=QR3UK9^.WP7?5O@?J_A?P?I4FH
M7U]?6MS*EY>F::Z*SQL[RSW$A:0B-,?.Y.U54< "N[\,_!WPCX/UJ/5M,TN1
M;^&$VUK)=7D]RMG"3S%;)*[+;IVVQ!1@ 8P *J,DM?/[THQ7X[-]=12C?3R_
M-O7Y;V]#Q;X:^!?#'Q<^&/BSQ=XRLX-1\37&H:DLVJ78S=:0()I%ACMY#\UN
M(U56 0KR23UKD]+M9OBUXD_9K/C SW[7^AZA/>QS-@7RK%&RB9?XT<*C,IX;
M/.037T7K'P*\%:[J&H7=UI4Z?VC*)K^TM=1NK:SO7&/FGMHY%AF)P-Q=&W 8
M;-;]YX#T&^\2:'KTNGK_ &KHD4L&GS)(Z+;QRJ%=0BD*05 '(.,<8I0DHVOY
M?A&2_-K[NI4DY7\[_C)/\$G_ , \+\2?"7P,W[4?A+36\&>'FTZ3PQ>2/9G2
MH/)9HY85C8ILP2J_*#C@<"O3?VB/$FI>"_@;XSU?17:WU&TTV0P2Q#YH2<*7
M7'0J"6SVQ70>+/ASH/C:^TV^U2WN1?Z:7^R7MA?W%E/$' #J)('1BK #*DX.
M!Q707=G;ZA9S6EU!'<VLR&*6&90Z2(1@JP/!!'!!ZU$FY4U#M?\ %M_K;Y%1
MM&IS]-/P27Z'S7\3?A_X;^%_P]\(>*O!=I#8^*HM4TV.#5[08N]6^T3(LJ3R
M?>G\U69CO+<\]J3P%\,_#/Q#^,7QU7Q+I,&N0QZG;10V]\/-AA+V:;I(XVRJ
MRX 'F ;@!@$#.?7]!^!_@WPWJ6GWUEIMRTFFEC807FIW5U;6)(QFW@EE:.$@
M< HJX!(&!Q6_H?@C1/#>L:]JNG67V>_UR9+C4)O-=O/D1 BG#,0N% &% %.;
MYHS2W:E;ROR__(O[]C.,6E%=K?.RE_FONW.&_98UB]U[]G_P9>:A<R7ET;5X
MFFF8L[+'*\:Y)Y)VJ.:X+X2V/BZ[^*WQI;P[K>BZ5;CQ&@ECU31IKUF;[-'R
MK)=0A1CL0?K7O7@_PAI'@+PW9:#H5I]ATFS#+!;^8\FP,Q8_,Y+'EB>3WIGA
M_P $Z+X5U/7-0TNR^RWFMW(O+^3S7?SI0H0-AF(7Y0!A0![5<IIU)S[I_C)/
M]!\ON1BNC7Y-?J>0WND6/Q*_:2U3P[XQMK;6]+T/P]:W=CI%Y#OLYIY9)%FN
MO(<LK,H"H"=VT,<')S7COQ5MSHWPQ^-7A'3+F>/POHWB+24TI8Y#BQ:9X))H
M(3_ J.<A1PN[@"OK3Q9\,_#WC34+/4-2M)TU.S5HX-1TZ^GL;M$;[T?G0.DF
MP]2A;;G!QD52G^#/@VY\#OX0DT53H$DZW,ML)Y0\TPD$GFR2A_,=RZ@EF8EL
M<DU,9)<M^G_R:E^2M_P!R3=VOZ]VWYZ_\$\?_:(^&_A[PCX)\!Z/H>GKH\%Y
MXTTF.YN-/)@N9V+,AE>9,.TI'_+0G=GG.:CD^%OA2S_:BM_"EKH=I:>%;WPH
M=2O=!MT\NQO;B*Z$<<D\ ^24J)&^^#DA2<E01[[XJ\$Z+XVATV+6K+[:FG7T
M.I6H\UX_+N(CF-_E89P3T.0>X-#^"=%D\:1>+6LL^(([%M-2\\U^+=G$A39N
MV_> .<9]\41E9W?=O[X)+[FK^704HW^'LE]TFW]Z=CS#]F&;[+9_$30X-T>E
MZ'XNOK'3[7<2EM;A8W$48/W4!=L*.!GC%,_:ZTVSA^!_BF_CM($OIWTZ*6Z6
M-1+(B7T116;&2%+L0#TW'U->I>&?!.B^#IM8ET>R^R/J]\^I7I\UW\VX<*&?
MYF.W(5>%P..E8_CSX0^&OB8&3Q%'JEY;,B(]G#K5[;6S[6WJ6ABF6,L&P=Q7
M/ YX%3?6#?3EO\K7^]H?+I)=V_Q=U]QPO[03+;_$+X*75PF;%/%!B=V.$65[
M:58L^^[I[U#X\:;_ (:J\#3V5M)?W&G^&=4N9[6V*"5T+1+&H+LJY9^!N8#/
M4CK7H]Y\*_#>J>$9O#.I6MUJ^D2OYI75-1N;R97SD,L\LC2HRD94JP*GD8J?
MPG\.= \%75Y=Z9:SMJ%X%6XU#4+V>^NY%485#/.[R;!V3=M!)(&2:J+4?DW^
M,>7_ ((2O+YI+[I<W_ /&OVGM?U?Q)\!?$1O/"6M>';2UNK"6[74I;.3[1;"
MZ0S "VN)>%49;=MX/?!Q[+X[U;2['X<:]J-Y-"-'32YI9)<CRS%Y1.0?0CI]
M:Z"\LX-0M)K6Z@CN;6=&CEAF0.DB$8*LIX((."#7FMW^S3\/K[27TB?2]0ET
M1MV-';7+\V$>XD_);>?Y28))7:HVG!7! QG)<T)0[_JDOT_,N+Y9QGO;_.__
M  _R[!^S#I]_I7[/O@*UU.-XKQ-*B)CD&&52-R CL=I7BO4*\N\(? N'1VTP
M^)/$&I>-Y-!OWO/#]WJ[D76GJR!2DDB,/M!^]\T@X! QP*]1K:K)3G*:ZN_W
M_P!?\$QIQ<(*#Z*W]?U\@HHHK(U"BBB@ HHHH **** "BBB@ HHHH **** "
MBL;6/&&CZ#?Z997UZ(KK4KO[#:QJC2%YO+:38=H.WY%9LM@8'7D5:U#7+#2]
M+DU&YNHX[)(6G,P.X%%0N2H&2WRJ3QG@4;*[V'K>Q?HJAH>O6'B32[34=.N!
M<6EU#'<1/M*L4=0Z$JP#+E2#@@'FK]-IIV9*::N@HJCI.NZ;KT=Q)IFH6NHI
M;SO;3-:3K*(IDX>-BI.&7NIY%7J0PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BJ.K:[IOA^&&;5-0M=-AFF2WBDNYUB5Y7.$C4L1EF/  Y-7J
M "BBB@ HHHH ***I:IK6GZ''!)J-_:Z>EQ.EM"UU,L8DE<X2-2Q&68\!1R>U
M %VBJ-IKNFW^I7VG6VH6MSJ%AL^UVD,ZM+;[QN3S$!RFX<C(&1TJ]0 451TC
M7M-\0033:7J-KJ4,,SV\DEG.LJI*APZ,5)PRG@@\BKU !1110 4444 %%%%
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M/$$=T8KN6+4]/BN+DS;<LMU*6=)WC9F1' &$4 5R7[//PI\$W'CCXK22^#]
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M1Y>;>^NII2%>=.DB(J<(V1N.<9 KUGPM)XCGM[B7Q)!I=E.[_N;/2YY+A8D
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M:W/J)O!XYU*2:;5KB,7 D1&S 6B;8 F5E=0J[0N&R/HKXE?\DY\5?]@JZ_\
M1+UE4?+0;6^OY+];[ZFE-<U:SVO^K_2QXO#\<_B!:?!_0/BGJ=AX?B\/7'V6
M2^T6""=KL6\KK&;B.?S2H.Y@XB,;87@R$\UVS>//%?CCX@>)/#W@V71=*L?#
M:Q17FI:Q9S7IN;J5!(L4<4<T.Q40Y9RS9+ !1@D^4_#3X>>-_BA^S?X$\)7U
MUHMMX0NK:RN+K4X)91?O9IME%L+?9L#%E5#-YOW<GR\\5ZE'\/\ Q;X#^(7B
MKQ!X/CT?6-/\3>3/=:;K-]-9&TN8HQ&)(Y$AFWJZ@94JN"HP3G ZZL5&<H]G
M*WX6O_Y-\_*QS4VY0B_)7_'\=K^7]X\F^,GC[Q!\2O@?#.ZZ=H>JZ/XMM='U
MFS:W>Z1KR*]A59('$J$19(?:RDD-MRI&X^E_$CXOZI\,[KPKX:U3Q#X5L_$&
MM-/++K^J0M8Z9:6\14L?)>Y+/(V]55?.&3EB0!@T]2_9ZU*X^#>J:%'JUK<>
M+M1UE?$MQ>RHT=I+?"X2;R\#<RPX18P>6 &<=JV_%G@'Q=K_ (@\'^.+&/1M
M.\8:$+BWFTF2^FFL+RUF*AX_M/DJZ, BN&\DX;@@CFH35E%][O\ \!CMY<R?
MR^1H[WNNUE_X%)Z_]NOKU.';]IZ^C\$?%.:TO_#/B76_!UK'>VVJ:,S/IU]%
M*"4R@F=D92K*RB4\X.1G%=/'\4/&WA[6/A[<>)(M!DT;Q?<BR-GIL$PN-.FD
MA,L.9WD*SJ=I5L11XR",XYUOB%X-\:_%#X2>,O#NI1Z#I.I:M:&UL;>UNI[B
M&+CEI9VB0MD]EA&W'5L\2>,OA?JOB*'X8);7%FA\+ZK;7UYYKN/,2.!XV$>%
M.6RPQNVC'>A6OKWBOEKS/\A:VT[2^^RM^-SB/A+8^+1^T1\7#)K>BM!'=Z6;
MY%T>8-.AM,H(F^U'RB%X)82;CR O2MSX*>*-=\9?#.\N?#^D^&?#][_;U_:-
MY-I)':Q(DSJ9S C9FE8@;AYD>2Q;<,8._HO@7Q#X5^,GBGQ%81Z9?Z!XG6R>
M[-Q=R075G)!$T1\N,0NLJLNP\NA!W=>*\\@_9T\4VGPTL=!:[TC47M_%-QK=
MWH]Q<S1Z?JMK),[BWG<1D\;E;!C==R $$<U$=DG_ "I?.\4_/O\ +8I^6][_
M (2_6QJ:Q\0/$-_I?QA\$^)TTVYO]%\/M>P:GI4$EO%<03V\N%:%Y)"CJR,/
MOD$$=._<_L\_\D'^'G_8 L?_ $0E>>^%OV?-9T?4/B5=QZ9X4\,V_BC0DTVT
MTGP^'6"UF59E)=O)0.#YBDN$4\D;?E!;UOX5^%KOP/\ #3PKX=OY(9;W2M,M
MK*>2W8M&SQQJK%20"1D<9 /M5:)2[OE_#G_S1&KDNRYOQY/UN?-?P%TWX;ZK
M;>*5\4^!E\0ZW+XMU-/M\W@ZXU)=IN"%#7*VSH /=_E[XKUK5/B'XTU'XZ:G
M\/O#J:#86%GHMOJAU/4;::=XB\CH4\E)8Q(#M4#YDV\G+<+53X8^"?B-\*+'
M7=,L]'\+ZW:7VMWNJ0W4^OW-K($GE+A6C%C( 0.N&-=+H_PYU6S^/6L^.9Y;
M,:;?:#;:8MO'([3+-'*SL2"@&S#<'.?84EM!/9+\>7_,J6\VMV]/_ _\CS:R
M^/7Q!U#X4^(O' L?#=K#X3GN+74K%H[B1M3>VDQ.T$GF+]F4J/DWK,<GG &6
MZ/QU^T%!I_BS0O#MAK_AGPF;[2DUNXUCQ7,IA2%R5BABB$T7F2LPR3Y@"JI.
M&R,5].^ ^OV?P)^(O@I[S33JGB.]U2YM)EED\A%N7+1B0[-P(!YPI]LUI?\
M"J/%'A3Q5X:\6>&9M*OM4M= A\/ZKI6I7$MO;W,<8W)+%.D<C(ZN,8,1#*Q^
MZ10K-KF\OO<7?_R:WIZ7'*ZOR^?W*2M_Y+?S?K8XO4?VJ-7B^#WB/Q!I4&@Z
M_P"(- \00:+(]A,SZ?J"R2QA986#DH'23 RS!6!R6 KN_&'CSQOX)T_POIEW
M+H-YXH\4:O'IUK+%931V6GJ8VDD,BF=GN"JHX!4Q;B1D)S1\5OAWXQ^+'PO?
M1[Q]#T[69-5M+Q(8)YGMX889XW*&8QAI'(1CN\M!\P7'&XX'[3VGMXJ\4_"K
MPQ#J TZYO]9FN(Y+D3"VS#;.06:":&3S0SJ8PKJ<@G(QRU;16U<E]UHW^]W]
M.F@G?5K91?WWE;[E;UZCM+^-/BKPOJGQ7/C2?1+[3O ]K#.!HFG36TEWYL/F
MH2TES($. 5*8/)!W8X.3I/[35Q;ZQX,.H^*_ 6OP>(KZ+3Y]%\.W.Z^TMYO]
M4QD^T.)U4X1SY4?+ CTIGAOPC#J6J?$;X*ZE_9]R=0TA=1NO$6DQW(G\R8E
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M!:2X(9!CMB(1C';%..J?-T_5:?=:3?G84M.5+K^CNW\[Q7I<SM>_Y/(\*_\
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M!U[0M4OY]5M5UK4)[*:PFF8M+$?+@F$T>[# Y1AN8'/#5A:W^S9J.H?#'3O
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M-,?QEXJU>UU6^EW2)9P"&2+;!&VTNRI''@,5!9B20N<#Z$IZ<NN^G_I,;_\
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MJ>GW"[)K2\A66*1<YPR,"",@=15F&&.VACAAC6**-0B1HH"JH&  !T %/HH
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>cerc-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cerc="http://www.cerecor.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cerc-20210331.xsd" xlink:type="simple"/>
    <context id="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i457f29798d7f4a138d9ba9c629c704fb_I20210511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="idedefda4bb914378b63f3c9b8b6ee172_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66f50cdd8bac484bb18c5e75cf2515ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6051bdc503c644b88a48cbfbf8982a59_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i89b6277e47054b73b39ed0e390870309_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i97014661c9674a1aa49d94115f232a8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i888ee0d094224a8c9d478400fe2c9087_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2cf49ee253f4aa884cbc90462dfac03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6f1b44d7eb742ad8b64d152e535816f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i690cbeed41364aeabc936a485830713d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0527fb21cb6e422a81b0d2b896ce2a12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i84b59ac211a5411c8a1466475097bdbd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1824d4fdd18644d08279a67df7329d8f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ief11578c5a3d4120889bfb43d5e8c59e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4f7f7fe58b1947a1af4d75615be3a866_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3698e2a15da04d2582ead896c9da1bdb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8858464917a44129a19e5fd629e46e2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5248b004c3024ef7844b36f897f76171_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbd4365662c24c30b28e21ce069efe37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icc41f7eca88947c9a35e4be0dc501644_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3aed8d010f6b4643ab5cf935d95e3ddb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic5b1d9aca4484c4d8668324b0b5763d2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i293bef8c2ab840b6bfc576a532a95a7e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icca7fddb46cc489688e478d5cee8ffe0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7acefac7b962485a8c15861ff10d0200_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i60933515d1434308883ae1bb020e0a13_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i628f57f6215a46b79ad5e7d53f734b1a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:NeurologicalClinicalAndPreclinicalStageCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iec8d13d67faf489fa328978709bcf27a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:ClinicalStageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e92ff68bdc846f39796a8688fdb85c6_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i2d9f33420b794d6b82ec040bbdcda9ac_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="icb32bfec45e942d4a910555a806195f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a0d41b8169040d484988356bf9f4cdb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66052a9dae424dca80a7f82db41f4f83_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i625aa7d5128448528ad08b7663090142_D20210501-20210506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="i1a2b8460cb924cb9b2aea21da6564fbf_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id606c2359deb445f9a0a8ae38b02ddb5_D20190101-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i0e29f50e08944917829774bcbe7aff76_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="iec26640aabfa4148bdbe5fd031d0b667_D20191101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i763dfef39718433ead8376b849f71b21_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cerc:DeerfieldObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AYTUBioScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i7d85ed913ebe404ab54475135f67de89_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if5751c8b6986481696dc10ecdf31864b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5bc1c0e3c3fc4ff5b491ac78fb641632_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99b8c7fd991847e8837bd5a30646756a_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="if834bd2acf0f4a6cbbc998c9d3a0ec9d_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="i0c24c03ec1214b87aa2626d83a326856_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cerc:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icf18c62a06294fc58da61652b71d9234_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cerc:MajorCustomerNumberOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i927b204af3c04c0bbd2188ed6a3eb0cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cerc:MajorCustomerNumberTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i15c7116f8756475caf3bf460b774b112_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cerc:MajorCustomerNumberThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie67565b970d24f429f156729cd22f735_D20210401-20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:MillipredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cerc:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="i014f146895fb4927a75a9cdec07aaa18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2105f80d294440588767dee094560b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i629fbb798db048ea9b95506876d74823_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3df572689a424ea28bc48c6a42dbc0bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:WarrantCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id922871740784b9b88673ef935b11162_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:WarrantCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia9167fb87d13406f85d22cdf0ee9c556_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieb2884fecf704a3ab359a11213837e2f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53a62490f94c4f49b56fb7acc1da3613_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:UnderwritersUnitPurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7e8caa450d984e75b7af9b3d66541996_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cerc:UnderwritersUnitPurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i50329ad27a3d4d858d5e36be03888359_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:NantahalaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i1b37c73849e9467f95d35e15bd0b8503_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idc103a37d52c4b8d9aab7c7d78bd8dab_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i950a8c7a799e4212b6120485b875cc33_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cerc:AssembledWorkforceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3a8340a3cbf64f1ab5d3614c69eea675_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i00fa8b9a9a0a48da86b188ca05a629de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1a66b18e75cf45d289497fdebf1a0e33_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8bf61356e0974feb98765a9f2a41e09d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9358ce44d144a59aa2cf6bce55c55b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i590b811c4dca4dbca6d871776b523532_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d38bb42b8534eff87ac8d23d0d697ea_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:ArmisticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie87e47a24f4a454290d837ab00a53c08_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:NantahalaCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i11a884079f7b4e2db9df7f885c73462d_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:NantahalaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i3d4b3944edc64b9eab3475e9c9ce4eb4_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:NantahalaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i30ffa7aeea1749d0b4cdf2eac8066e73_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i83186431d6e54ca9af494baa43072af0_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="i04419c05a564471cafd04ce10e0ea363_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:ArmisticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="id4830d434af540fab7f362a2f6851391_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:OfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="i79d25c29ccea491bb940f8ab428a1a67_D20200317-20200317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:ArmisticePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="i5666247a03f94008beee4c2791508959_D20200206-20200206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-06</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="i3b1d24a349414177befd56fcc3bbf5f0_D20200206-20200206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:ArmisticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-06</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="idc18b2fcdebb49ae970fee17a9b37770_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cerc:CommonStockWarrantsExpirationDateOfMay2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb3043f210a045168b002098fa42b497_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cerc:CommonStockWarrantsExpirationDateOfJune2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7278c7eb9d8c4d468fdc7b1b16998399_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cerc:CommonStockWarrantsNoExpirationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib7d433fb05b0421e829cbc118f401dfb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iffb1f30979714ea79f95d4802ff984ef_I20181226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-26</instant>
        </period>
    </context>
    <context id="ie34e5b7882f4464fb323bd265625bb05_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i87335e7fb2f644479af541532f926a9d_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i6cd83eb2a4284855bc679909757c91ed_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i6d9884fb9a86405fb7c325756d06accd_I20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-27</instant>
        </period>
    </context>
    <context id="i1a57959625a746b382f212a041c26d2b_I20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-27</instant>
        </period>
    </context>
    <context id="id78630f60e5b4ecca96e7de37d2b0ede_I20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-27</instant>
        </period>
    </context>
    <context id="ie6a48ca344334551b7645592e589572f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d3edf5294c94a15b1515cb8bac0fbf5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0f7987a16d51476399f00aba786832f0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9ec411596a6843a496aa5fc4c66a5283_D20181227-20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-27</startDate>
            <endDate>2018-12-27</endDate>
        </period>
    </context>
    <context id="i6063b66d7fe140e18f3cd8924bb75c11_D20181226-20181226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-26</startDate>
            <endDate>2018-12-26</endDate>
        </period>
    </context>
    <context id="icf49c9a4875b435fb1444f3db3551e0d_D20160518-20160518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-18</startDate>
            <endDate>2016-05-18</endDate>
        </period>
    </context>
    <context id="i95616c1bb6fd48dba5535428036866f9_I20160518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-18</instant>
        </period>
    </context>
    <context id="i6364a4c535f944fc8d6272cec44a6605_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ib80218def2434edb83018969f2462fd9_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:A2016SecondAmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i4a4f6b0df275417caf8e9588d5879953_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:ThirdAmended2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i29e9f70e9f7b4f01be2ea582e6fc1273_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31f47b2beb7b41178e355e797e2f3729_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a4bbd01132947da84d8a776d5a0b90e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c13bb871c0f4896b5ef4d28dafbd2d6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63645a96f5bd4cfea3a83a7db78ff588_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0ee83b81d1c04985a8e197982cd1072c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cerc:The2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id696367226144fa4b944f70aa62c42fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9100bedc06f0427a92077cbcaacfb3bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i060be613e08b4af9bfd9b2dc947d28f0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i44363498ae0d4459991baef00bff6710_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i754b22e1563e4e3aa874036b82bf942c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75ba6fbf1c5441209f70f012cc625abf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i91e623503adb43afb6fb5459058e0547_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1461faa4f454dce8429a63ea92a7a06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9171628f1093474caf84d9d7559dbe75_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8030e840d448409f8fe845f94ea3abbb_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12e73acc1c964f5888c9864531a2b698_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3af98390081b4750881153e96552c18c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1da3c9dfb0d14dec942761d660b32921_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f071b1803cb487eab728baa86ce1d1b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e2f493114e24792b6ab7231ebc4f3a2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42e5c0a81c6c46b5bee3450a25f025e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7429f77f36e348619c1595052db52037_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6388e36dd5e54d04841bac2d0313519d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3a18d4e138304f578791e2ee584457c9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25979dec2f3d4ac2862b695cf3514d3f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7e8cecccd934890847824b3ae4a7ef0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i36b6d96bcc1749caadd5b13f2bf8889b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6185a21763b4022bb98a98a1f7511a0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:StockOptionsWithMarketBasedVestingConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i088e1fb0e42744319b8607076b983489_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie43534f2ad884d3c93e916333b4e6fe3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4809744336f94a308a12efafbd45bd1e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e67ffefb48e414f85fa6311d88d3fde_D20160405-20160405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-05</startDate>
            <endDate>2016-04-05</endDate>
        </period>
    </context>
    <context id="i0bfcb4e632484858beac101b5287566c_I20160405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-05</instant>
        </period>
    </context>
    <context id="i830174ed95fc44a1bd5ebc384320dfc9_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i4e1a839c0c2f4008a983a171019b82d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icbc7327a9c14482fb8f5db8aaf0f48d9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cerc:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i09cca0b1b8484ffda61d0f7e6de54442_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c920d35386546eb9e87448a6e1d8613_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cerc:TRISPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cerc:KarbinalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic7d61bbf3f01410cbe5cb14793b039dc_D20200101-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:MillipredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cerc:TevaPharmaceuticalIndustriesLtd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i4a82b49fc85849e9b165488476f66b9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC611Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cerc:ArmisticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC611Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i3b0da54fc099444480f1290196a28e52_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC611Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="iaa172516dbef43d4a1c0924d5edda6d8_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i66d40f7899394f23b9dadb48b6bcfb61_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i1fe9f3116d8e45d4a2a1a175df1addb6_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC002KKCLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="if09f167c7bc048a9bc324012285069cf_I20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC002KKCLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="ia883540f2ef34a27a1304fff4fc68648_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC002KKCLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC006AstellasLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7017084953a4b4da0c861f92df38447_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC007AstraZenecaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic249f77612fd40feb83d3691de9d3623_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC007AstraZenecaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a16536d275e465da455b4c203c89422_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ic77ef76142994d109c2c47014a1f6c8d_I20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-03</instant>
        </period>
    </context>
    <context id="i14700ec8a6124480982805c40bb35d5b_I20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-03</instant>
        </period>
    </context>
    <context id="i196aed014b0d4c248e5addc0ece06d67_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cerc:AeviGenomicMedicineIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5971bb063e474274b182039d0516e79b_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC801CERC802AndCERC803Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6b3a6dd6de704eda88270dee17a54df9_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cerc:CERC913Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i88d92807dcac45b09cb550ee806b75f2_D20200203-20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="i7386371b6dd84a49af329b3ccfa42f9a_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="if8b8acd95e6a4be8b07437719d50a52d_D20180901-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12f98b2dbe45438893e30257af07b4bc_D20180901-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="iab022d6245a44ee3a9b76763b77c8a31_D20180901-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cerc:MilestoneAxis">cerc:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="ib7287b6670b3448ea1ab4049c76715ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cerc:AssetAcquisitionAxis">cerc:IchorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>cerc:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="class_of_stock">
        <measure>cerc:class_of_stock</measure>
    </unit>
    <unit id="change">
        <measure>cerc:change</measure>
    </unit>
    <unit id="contract">
        <measure>cerc:contract</measure>
    </unit>
    <unit id="renewal_option">
        <measure>cerc:renewal_option</measure>
    </unit>
    <unit id="unit">
        <measure>cerc:unit</measure>
    </unit>
    <unit id="milestone">
        <measure>cerc:milestone</measure>
    </unit>
    <unit id="therapy">
        <measure>cerc:therapy</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl80LTEtMS0xLTA_a4ca7b07-bde3-4b76-88a7-7022c432aff9">0001534120</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl81LTEtMS0xLTA_12a446d1-04f9-4fc6-aca4-4f4cd540e017">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl8xMy0xLTEtMS0w_f8a72044-f0da-4ddd-950c-58c1b5d2dc53">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl8xNC0xLTEtMS0w_e5baed66-5d20-44f9-b241-4404cef05d59">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80L2ZyYWc6NmI5YTliYzc4MmQzNDYzNzgxNjE1YWE2Y2VmYzU5NTYvdGFibGU6NzhkNmU2OGY5ZTc3NGU4MjhkNmM5NDBhZTU0MDE3MzYvdGFibGVyYW5nZTo3OGQ2ZTY4ZjllNzc0ZTgyOGQ2Yzk0MGFlNTQwMTczNl8xNS0xLTEtMS0w_b45e9211-3c52-4f79-b3f4-dac9e4fef92f">false</dei:AmendmentFlag>
    <cerc:StockholdersEquityNotePreferredStockConversionRatio
      contextRef="i1b37c73849e9467f95d35e15bd0b8503_D20181201-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80Ni9mcmFnOmY2NzI5YWViODg0NzQyYWU4ZDBiNzg0ZjllNWMzOWJmL3RleHRyZWdpb246ZjY3MjlhZWI4ODQ3NDJhZThkMGI3ODRmOWU1YzM5YmZfMjQ_fda18e8e-6984-4b34-bae8-440d91748156"
      unitRef="number">0.20</cerc:StockholdersEquityNotePreferredStockConversionRatio>
    <cerc:StockholdersEquityNotePreferredStockConversionRatio
      contextRef="i9ec411596a6843a496aa5fc4c66a5283_D20181227-20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82MS9mcmFnOjBlYjI2MWJkYThiMTRmODI4M2UxMzM4OWE2OTI4OGYzL3RleHRyZWdpb246MGViMjYxYmRhOGIxNGY4MjgzZTEzMzg5YTY5Mjg4ZjNfNDE_34b33294-5753-4c0c-92bf-4392c5a9ebc4"
      unitRef="number">0.20</cerc:StockholdersEquityNotePreferredStockConversionRatio>
    <cerc:StockholdersEquityNotePreferredStockConversionRatio
      contextRef="i014f146895fb4927a75a9cdec07aaa18_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82MS9mcmFnOjBlYjI2MWJkYThiMTRmODI4M2UxMzM4OWE2OTI4OGYzL3RleHRyZWdpb246MGViMjYxYmRhOGIxNGY4MjgzZTEzMzg5YTY5Mjg4ZjNfNDE_d22b0db5-540e-46d7-ac08-bcb4a363c166"
      unitRef="number">0.20</cerc:StockholdersEquityNotePreferredStockConversionRatio>
    <cerc:StockholdersEquityNotePreferredStockConversionRatio
      contextRef="i6063b66d7fe140e18f3cd8924bb75c11_D20181226-20181226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82MS9mcmFnOjBlYjI2MWJkYThiMTRmODI4M2UxMzM4OWE2OTI4OGYzL3RleHRyZWdpb246MGViMjYxYmRhOGIxNGY4MjgzZTEzMzg5YTY5Mjg4ZjNfNDE_ea330e8f-1b31-4682-a9b2-545bfb371583"
      unitRef="number">0.20</cerc:StockholdersEquityNotePreferredStockConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9a4bbd01132947da84d8a776d5a0b90e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4MQ_63efab90-69fc-42af-b1b9-73b3e29c5cf7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i63645a96f5bd4cfea3a83a7db78ff588_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg2Nw_e865b985-b902-43d4-a27a-a09d25dc86dc">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38">us-gaap:AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8">us-gaap:AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl84ODEvZnJhZzozY2YwOWQ0MGUzNWM0ZjhjYjhmN2FhMTY3ODRhZDhiMS90YWJsZTpmZWY3NGUwYjg2NTc0YTAyOWJhNWUxNWJkNmYyYWUxZi90YWJsZXJhbmdlOmZlZjc0ZTBiODY1NzRhMDI5YmE1ZTE1YmQ2ZjJhZTFmXzAtMS0xLTEtNDE4OQ_3a6d4a46-c7e1-4097-b14c-015836148d34">cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl84ODEvZnJhZzozY2YwOWQ0MGUzNWM0ZjhjYjhmN2FhMTY3ODRhZDhiMS90YWJsZTpmZWY3NGUwYjg2NTc0YTAyOWJhNWUxNWJkNmYyYWUxZi90YWJsZXJhbmdlOmZlZjc0ZTBiODY1NzRhMDI5YmE1ZTE1YmQ2ZjJhZTFmXzAtMS0xLTEtNDE4OQ_c51d4dfc-b33c-4c8e-9134-b97e55bae4b6">cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzUz_b4fb192b-aebb-4f56-8d63-aa0eb20e060d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NWYxNjJjODNlMjFiNDRlZGExYTIxOGFiYmE2NTRmMzMvdGFibGVyYW5nZTo1ZjE2MmM4M2UyMWI0NGVkYTFhMjE4YWJiYTY1NGYzM18wLTAtMS0xLTA_f1d9c3a4-2bbf-4eff-8a18-fa668b506fdc">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NWYxNjJjODNlMjFiNDRlZGExYTIxOGFiYmE2NTRmMzMvdGFibGVyYW5nZTo1ZjE2MmM4M2UyMWI0NGVkYTFhMjE4YWJiYTY1NGYzM18xLTAtMS0xLTAvdGV4dHJlZ2lvbjpiZDg2OTQ4ZjdjZDc0MmZmYmY4MjYxYTU4NGNhNGUwM18zNQ_013d636a-4e16-492a-908b-7c21eb6b1d00">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NWYxNjJjODNlMjFiNDRlZGExYTIxOGFiYmE2NTRmMzMvdGFibGVyYW5nZTo1ZjE2MmM4M2UyMWI0NGVkYTFhMjE4YWJiYTY1NGYzM18zLTAtMS0xLTA_47869884-ec2b-49e8-b4a5-d7b8787c1fad">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU0_bef06f51-3882-4848-afdf-424d1bf0357d">001-37590</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU2_153cfdf9-8932-4828-a1f9-a3aed160256a">CERECOR INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8wLTAtMS0xLTAvdGV4dHJlZ2lvbjpjMGQ0NzE0OWNmZDE0MWQxYTRiOWI1M2U2OTE0MDBlYl81_2c266157-a113-484d-a6fc-7c6c1b05658c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8wLTEtMS0xLTAvdGV4dHJlZ2lvbjo0ODg5MjdiZjU3NmY0MWViYWZjNjRlZjNmMWRjNGJlM181_34102b2d-bb34-4869-8027-c756904ae3f2">45-0705648</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV81_3d3a1a45-314e-495d-aeea-3f049d6cd366">540 Gaither Road, Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV84_81411c67-43b2-46db-88a0-2c918ad1f268">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV8xMg_cdb35bec-a4a9-47bd-b117-705087a62e47">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjphMjliZmE4NDYyZWY0YmQzYWExMjNjYzI2ZjYxMjMwYV8xNQ_b1f5571b-3337-4a86-9877-ecc6ebbce5cc">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTEtMS0xLTAvdGV4dHJlZ2lvbjo4NjUzOTc3YTc0OWE0NTQ5OTdmMzE3ODVjNjExZmYzYV82_4971dbd2-cbcb-4c26-a959-b6b3a15fefb4">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NTIxNDAzMTFmOGZlNGUyNDg1NmY1ZWM3YjVlNjU3NjEvdGFibGVyYW5nZTo1MjE0MDMxMWY4ZmU0ZTI0ODU2ZjVlYzdiNWU2NTc2MV8xLTEtMS0xLTAvdGV4dHJlZ2lvbjo4NjUzOTc3YTc0OWE0NTQ5OTdmMzE3ODVjNjExZmYzYV8xMA_f3386e0b-febe-4a79-a0f6-3fc9e2e6e99e">522-8707</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6N2FjYjg0ZDE5YzQwNGVkYmE0ZjE1MzVmNDE1ZDIwMTQvdGFibGVyYW5nZTo3YWNiODRkMTljNDA0ZWRiYTRmMTUzNWY0MTVkMjAxNF8xLTAtMS0xLTA_5a878026-9207-46a5-a790-5a6e3ac22774">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6N2FjYjg0ZDE5YzQwNGVkYmE0ZjE1MzVmNDE1ZDIwMTQvdGFibGVyYW5nZTo3YWNiODRkMTljNDA0ZWRiYTRmMTUzNWY0MTVkMjAxNF8xLTEtMS0xLTA_76aa721c-cb69-4c7b-a726-abffa81298e4">CERC</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU3_59fcc410-3485-4ff7-a6ef-c5a71f569efb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzU4_0572975d-cb80-4b0f-9115-e80197a7e9d2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NzhiODQ4NDRhNjQ5NDJkMTkwMzI5YjgxZjc5ODQ3OTUvdGFibGVyYW5nZTo3OGI4NDg0NGE2NDk0MmQxOTAzMjliODFmNzk4NDc5NV8xLTAtMS0xLTM1L3RleHRyZWdpb246M2RmNzUwMGVjNmQwNDBjY2IyYThjZjJiZGZmNTk2MzdfNDk0NzgwMjMyNTA0NA_c97475ac-53f6-41de-a210-d0ff689236e3">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NzhiODQ4NDRhNjQ5NDJkMTkwMzI5YjgxZjc5ODQ3OTUvdGFibGVyYW5nZTo3OGI4NDg0NGE2NDk0MmQxOTAzMjliODFmNzk4NDc5NV8xLTItMS0xLTAvdGV4dHJlZ2lvbjo1M2FmZDFlNDFkOTc0MGYxYmNhOWM3MmYwYmY5MzY0Yl8zMA_82192efa-9819-46d4-8a19-6fa7605d8592">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGFibGU6NzhiODQ4NDRhNjQ5NDJkMTkwMzI5YjgxZjc5ODQ3OTUvdGFibGVyYW5nZTo3OGI4NDg0NGE2NDk0MmQxOTAzMjliODFmNzk4NDc5NV8yLTAtMS0xLTAvdGV4dHJlZ2lvbjplNWJlMmE0NjA0ODY0NDUxOGE5YjgyMjg4OWJmMjdmOF8yOA_855be068-cef5-4d93-b738-d1943bc84b0b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF80OTQ3ODAyMzI2ODM0_b384f063-8207-4350-92d9-992c4ad1ef8b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i457f29798d7f4a138d9ba9c629c704fb_I20210511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xL2ZyYWc6MjRhYzg4NjJiNmYwNGJlYWI3NTYzOTYwOGUyY2NkZTAvdGV4dHJlZ2lvbjoyNGFjODg2MmI2ZjA0YmVhYjc1NjM5NjA4ZTJjY2RlMF8xNzEz_fc1c065f-9b94-41dd-80da-c94068739be9"
      unitRef="shares">95471843</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNC0yLTEtMS0w_8a950d83-195a-4acb-9ede-e3d38995a51c"
      unitRef="usd">38292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNC00LTEtMS0w_b6575cd3-faa2-45e9-b3c0-135aac86c792"
      unitRef="usd">18919000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNS0yLTEtMS0w_771d6283-7057-4e96-9464-a19b71ffbf38"
      unitRef="usd">3130000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNS00LTEtMS0w_8078b57d-191b-493c-911b-8ee5a9281f39"
      unitRef="usd">2177000</us-gaap:AccountsReceivableNet>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNi0yLTEtMS0w_8d54d2a9-81f1-4634-8fdb-57034a237812"
      unitRef="usd">2056000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNi00LTEtMS0w_d5a35113-ffe8-4a4f-b63a-53b81ee50ec8"
      unitRef="usd">2208000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNy0yLTEtMS0w_7de96452-f8df-4495-abbe-47c07a9be069"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfNy00LTEtMS0w_5450113a-d8b3-4485-8434-52bb32637065"
      unitRef="usd">3000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOC0yLTEtMS0w_443c7d88-d8be-4ae8-8708-44acc28559d2"
      unitRef="usd">2465000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOC00LTEtMS0w_dcdf5263-327b-44c9-a40a-606ac65c50b4"
      unitRef="usd">2660000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOS0yLTEtMS0w_2d8c2550-b93f-4246-887e-a715f57732f4"
      unitRef="usd">153000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfOS00LTEtMS0w_524aad90-5024-4966-87ea-27b556701a03"
      unitRef="usd">38000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTItMi0xLTEtMA_93e5dabf-dfd7-4b4d-989c-f5d26294af42"
      unitRef="usd">46096000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTItNC0xLTEtMA_2cab460e-c3fa-4d42-b5de-77a4ebbb3a0f"
      unitRef="usd">26005000</us-gaap:AssetsCurrent>
    <cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTMtMi0xLTEtMA_e0604595-215a-4657-9893-d92a5032e0bb"
      unitRef="usd">1530000</cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTMtNC0xLTEtMA_77d5e91c-0b7b-486a-b473-725ae4c228c5"
      unitRef="usd">1607000</cerc:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTQtMi0xLTEtMA_7b60a041-6f97-426e-9339-4faae8d61a24"
      unitRef="usd">1161000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTQtNC0xLTEtMA_8381b89f-5e32-446a-a0a5-89fd03f8089d"
      unitRef="usd">1585000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTUtMi0xLTEtMA_1e749be3-9a7a-4e2f-9488-546950420967"
      unitRef="usd">14409000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTUtNC0xLTEtMA_373257f9-357e-4c92-a192-68568f1f0bc3"
      unitRef="usd">14409000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTYtMi0xLTEtMA_c509aa71-f1c3-4b13-91c7-fbd7c7a932d3"
      unitRef="usd">149000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTYtNC0xLTEtMA_998dd4ef-3410-4d00-ae69-455f6aa0ad58"
      unitRef="usd">149000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTctMi0xLTEtMA_3944ae0c-22cc-4c5c-94f0-e2fd2556e801"
      unitRef="usd">63345000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMTctNC0xLTEtMA_d7c10c92-0165-4ab3-910d-8404f414fa90"
      unitRef="usd">43755000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjAtMi0xLTEtMA_683cb0e2-58b4-4ba3-ae75-10a4a3a12d75"
      unitRef="usd">11913000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjAtNC0xLTEtMA_64b5e9f7-50c4-4b23-9894-7c295362a3e6"
      unitRef="usd">2574000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjEtMi0xLTEtMA_f2f71bf2-0354-430b-9f46-9f2f0f129539"
      unitRef="usd">14238000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjEtNC0xLTEtMA_3139cf80-9302-4132-8f11-9387fbf66ee4"
      unitRef="usd">11310000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjMtMi0xLTEtMA_c635481e-29b0-4757-8d1e-0399c64f2281"
      unitRef="usd">209000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjMtNC0xLTEtMA_64997439-124a-4e6f-8b70-bc95e8894030"
      unitRef="usd">1341000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjQtMi0xLTEtMA_79ba5a42-703f-4a5e-af88-766e3137c2cf"
      unitRef="usd">26360000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjQtNC0xLTEtMA_054ef17d-7eef-498b-93b5-64ac36df0ec4"
      unitRef="usd">15225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjUtMi0xLTEtMA_871638a3-5c6f-4371-9a1c-b363fd0920ec"
      unitRef="usd">2000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjUtNC0xLTEtMA_3308f81b-3252-4652-806b-d339d984c9ec"
      unitRef="usd">2000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjYtMi0xLTEtMA_8860fe69-96c9-4b26-aae6-282e6d8916fb"
      unitRef="usd">111000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjYtNC0xLTEtMA_d34dfe09-02d2-4685-8eac-e68669f9fe6b"
      unitRef="usd">90000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjctMi0xLTEtMA_8fa66867-ae03-4bfb-95f7-5e50f804f1d9"
      unitRef="usd">1719000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjctNC0xLTEtMA_cb6fbe10-4258-46a8-8b3d-6b1c6910e37b"
      unitRef="usd">1878000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjktMi0xLTEtMA_b76b9b45-5542-4fe0-bf52-38e24eec925d"
      unitRef="usd">30190000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMjktNC0xLTEtMA_745fd749-0efd-4463-8ca7-e64bc5edf592"
      unitRef="usd">19193000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzE3_791960c8-ee74-4910-9db7-2278cd1aaa3c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzE3_d0d290ad-b632-41c2-8213-7dc38b70a605"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzMx_50dbcd2d-fe58-42cd-b58a-e758223a1433"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzMx_a356e564-a28a-4cb8-a791-0a47f8aad027"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzk3_4bcb252e-fa17-4fe8-955d-e74e83291f91"
      unitRef="shares">89104816</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzk3_68157309-a849-4346-ac58-a5c95f04cbf6"
      unitRef="shares">89104816</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzEwNA_b2a5849f-f23c-4e0f-82c0-4f5b143dcc3b"
      unitRef="shares">75004127</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM1ZGI2ZDkxNDhkYzQxYzA5ZTdiOWZjMDhjODFhMjkxXzEwNA_c81f2aad-d940-4c2f-99ae-df7808bc5ef6"
      unitRef="shares">75004127</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtMi0xLTEtMA_bf8c42eb-9836-41b0-a602-3b90c45c7a8c"
      unitRef="usd">89000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzEtNC0xLTEtMA_ee119997-89bb-4e3e-98df-39ad60d0c8e6"
      unitRef="usd">75000</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzIx_d1a111ff-694a-41ce-a574-44e39a1d3d1b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzIx_e9e34be5-76c5-4e4f-82d2-ae2af23a9edd"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzM1_360b8c10-fb5f-4e5f-bb17-6122658ac1fd"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzM1_7be50919-1449-4624-9632-b5bc5b60d5a0"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_0e3b1688-9051-4bba-860a-a765932dc5e3"
      unitRef="shares">1257143</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_26e93e0d-121e-4dec-bcb7-52005605dbfa"
      unitRef="shares">1257143</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_ab7b44cd-98a3-4aa7-8652-4d38fcf36089"
      unitRef="shares">1257143</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjM2OTEzOWQyZTUzMTRlNTFiOTlkNTQxMzJmOGYyOTRhXzEwMQ_c3e79afe-af79-4b5c-adfa-6a4736dbd8d6"
      unitRef="shares">1257143</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItMi0xLTEtMA_54fa29be-8d7f-41cd-a0b5-e523ab446d2c"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzItNC0xLTEtMA_69bdce94-3610-4263-8942-5cc2686998ff"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzMtMi0xLTEtMA_09a0956c-9ce0-46f1-b200-6f2781726d57"
      unitRef="usd">241535000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzMtNC0xLTEtMA_9e7316dc-c936-4ae6-a62a-e93e50196770"
      unitRef="usd">202276000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzQtMi0xLTEtMA_66b8bb8f-a7c2-4f8e-b2e6-aeab3707567e"
      unitRef="usd">-208470000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzQtNC0xLTEtMA_4d6cf7f3-01a0-4138-ae85-074b3990f382"
      unitRef="usd">-177790000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzUtMi0xLTEtMA_02cb0604-85f7-4222-8be0-9605b7608401"
      unitRef="usd">33155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzUtNC0xLTEtMA_6429ea63-1e1b-41a0-a0cf-9c59c8d55322"
      unitRef="usd">24562000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzYtMi0xLTEtMA_69757674-a641-46b6-9aa3-e1186c0ae238"
      unitRef="usd">63345000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xNi9mcmFnOmVhNTZmZjZiZTA0YjQ1MzZiODU4N2QxMDA3OTYyYTllL3RhYmxlOmM4M2I1ODM5ZDE2NDQ4ODY4ZTBhOWFiMTJiMWIzMTQzL3RhYmxlcmFuZ2U6YzgzYjU4MzlkMTY0NDg4NjhlMGE5YWIxMmIxYjMxNDNfMzYtNC0xLTEtMA_9381ad5f-2971-49f6-88c7-64de53c64c27"
      unitRef="usd">43755000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66f50cdd8bac484bb18c5e75cf2515ca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNC0yLTEtMS0w_2c8be31f-9e9c-4fea-9dd3-e1698c35e610"
      unitRef="usd">473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6051bdc503c644b88a48cbfbf8982a59_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNC00LTEtMS0w_f0813d51-55ea-4ce8-b7f3-f4cb427fa425"
      unitRef="usd">2754000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNi0yLTEtMS0w_590d111a-edcd-4ab7-8547-bb2dddd4b9b9"
      unitRef="usd">473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfNi00LTEtMS0w_612bb52a-8204-4f0c-9b5a-d90345d40f5b"
      unitRef="usd">2754000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfOS0yLTEtMS0w_c6149be6-0654-46c0-ab4d-d2cd186d7b4f"
      unitRef="usd">77000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfOS00LTEtMS0w_4db293ab-cc22-4b43-a1a4-c19161de776e"
      unitRef="usd">66000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTAtMi0xLTEtMA_a03a6deb-5b86-4453-a16a-0ec0866e7598"
      unitRef="usd">25206000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTAtNC0xLTEtMA_2436ffb2-5201-4b98-a562-7a194f0647c2"
      unitRef="usd">4768000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTEtMi0xLTEtMA_d9dd12ef-37f9-4376-ba97-409dfcd7ee06"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTEtNC0xLTEtMA_a9617214-39b4-4c4f-9c23-3147520bf9df"
      unitRef="usd">25549000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTItMi0xLTEtMA_4abbfc8b-a4da-4c6f-90fa-2f3edb2960ad"
      unitRef="usd">4911000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTItNC0xLTEtMA_ea7d6327-6b08-457f-9715-ebae6eead8fd"
      unitRef="usd">2676000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTMtMi0xLTEtMA_3e4709b4-5268-4e51-9647-1bc794c42bf8"
      unitRef="usd">435000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTMtNC0xLTEtMA_39be4bd8-8779-40f2-a37d-93f44dbba27d"
      unitRef="usd">677000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTQtMi0xLTEtMA_d4cb5607-5866-49fb-a48b-4f7acccbba72"
      unitRef="usd">424000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTQtNC0xLTEtMA_0d7da33f-131d-4cf5-bdbd-edc5bf3d0f11"
      unitRef="usd">431000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTYtMi0xLTEtMA_583b0af3-8b08-441e-b1d5-037281e370ed"
      unitRef="usd">31053000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTYtNC0xLTEtMA_c3602322-c02e-48e2-ab15-86b0210d0266"
      unitRef="usd">34167000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTctMi0xLTEtMA_e57ca779-d4e0-440e-b5eb-ca07a227967f"
      unitRef="usd">-30580000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTctNC0xLTEtMA_6ccb930c-626b-4056-bb7d-39bab04af0b8"
      unitRef="usd">-31413000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktMi0xLTEtMA_7f6d7424-8ea2-47ca-bb0b-18f4dc299c93"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktNC0xLTEtMA_cb0495f1-6e68-4408-b975-05ef9fb251b1"
      unitRef="usd">7080000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktMi0xLTEtMjQyNw_fb5527fb-cf1f-4e92-8794-d42fe1da8ef3"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMTktNC0xLTEtMjQyNw_961e1283-ae5f-4100-8ac2-d591e0bb95df"
      unitRef="usd">11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtMi0xLTEtMjQyOQ_49d9e084-e519-4ee6-9ce7-bf1cee183705"
      unitRef="usd">17000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtNC0xLTEtMjQyOQ_f90e75f8-d415-42ed-9355-1f70dc6f2ece"
      unitRef="usd">10000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtMi0xLTEtMA_22c82cb7-2cdc-4b0e-9e84-1bc6101a63b6"
      unitRef="usd">17000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjEtNC0xLTEtMA_21fcd62a-e010-43ce-80bb-655d1c8d48d0"
      unitRef="usd">7101000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjItMi0xLTEtMA_b8e65fa1-32d4-4c17-a72b-8955917574a7"
      unitRef="usd">-30563000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjItNC0xLTEtMA_ea59cea2-b6a8-4418-abef-3033b856c9c9"
      unitRef="usd">-24312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjMtMi0xLTEtMA_72b90d4c-52d3-41ff-b4d1-a113c024b29e"
      unitRef="usd">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjMtNC0xLTEtMA_68099313-b32b-45d2-8f4a-92113e0b34f8"
      unitRef="usd">-2157000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjQtMi0xLTEtMA_dd0e93a4-6c75-4665-931d-fc24d255d9db"
      unitRef="usd">-30574000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjQtNC0xLTEtMA_70d2d27f-b8b5-4547-9a8b-a84d38290d4d"
      unitRef="usd">-22155000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjUtMi0xLTEtMA_f044c3b6-058a-4b3b-9741-698a4199709b"
      unitRef="usd">-106000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjUtNC0xLTEtMA_3eff5c4d-4e0f-4632-8917-760206387629"
      unitRef="usd">1038000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjYtMi0xLTEtMA_96692009-5b79-421d-ab0e-178210f47a53"
      unitRef="usd">-30680000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjYtNC0xLTEtMA_1762d37c-33f4-425a-bf4c-fad6d726fd03"
      unitRef="usd">-21117000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktMi0xLTEtMA_2011e9a7-a1b4-4ec9-a376-7d71eb007b8f"
      unitRef="usdPerShare">-0.32</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktMi0xLTEtMA_70792f2e-a14e-4f05-b1eb-e27b1807480a"
      unitRef="usdPerShare">-0.32</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktNC0xLTEtMA_b6e10e14-88f3-4466-9df8-37c34821dc33"
      unitRef="usdPerShare">-0.36</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMjktNC0xLTEtMA_dc010ad0-0e53-47b3-993d-9162c8118f37"
      unitRef="usdPerShare">-0.36</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtMi0xLTEtMA_79936e63-aab8-4e8c-a642-8588543acc53"
      unitRef="usdPerShare">-0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtMi0xLTEtMA_7a78a974-54b1-4f2f-ba60-968d0be438c0"
      unitRef="usdPerShare">-0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtNC0xLTEtMA_10e77e86-f50b-41d2-92cc-63a9327357b9"
      unitRef="usdPerShare">0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzAtNC0xLTEtMA_42cfb0c1-97da-4558-b849-08b79f3ff884"
      unitRef="usdPerShare">0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtMi0xLTEtMA_59a599f0-ce4b-4ec0-8bed-0d2e4842d00c"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtMi0xLTEtMA_5ddee8b4-4a22-45d1-954c-4b1ed0ffd49f"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtNC0xLTEtMA_a937b330-94a4-4566-b874-bb8ac6e5963a"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzEtNC0xLTEtMA_f7dcb4d1-40bc-4324-8ba1-1b106c7a93a0"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtMi0xLTEtMA_0bc9d3d8-7dc2-4da9-8f22-94057e57e560"
      unitRef="usdPerShare">-1.61</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtMi0xLTEtMA_269cedb8-247b-497b-b72a-a5f11ca3740b"
      unitRef="usdPerShare">-1.61</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtMi0xLTEtMA_d4ee7f77-e951-4d31-9d91-96f549d58e4d"
      unitRef="usdPerShare">-1.61</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtNC0xLTEtMA_53049003-d4da-4099-b8e0-acb1b98fad9d"
      unitRef="usdPerShare">-1.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtNC0xLTEtMA_6491b092-cfd9-441c-9567-ddc97afc09b5"
      unitRef="usdPerShare">-1.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzQtNC0xLTEtMA_b70cc2fa-183d-4310-a30a-6a5b5aba53be"
      unitRef="usdPerShare">-1.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtMi0xLTEtMA_6e121168-330f-460d-a4eb-d1a06c39d982"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtMi0xLTEtMA_95f19155-c0f7-4a98-bc60-4eb65bb24ec3"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtMi0xLTEtMA_c5597371-6a5c-4270-ace3-122912449367"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtNC0xLTEtMA_ab867d2e-aca4-4f6f-8854-2133be067c12"
      unitRef="usdPerShare">0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtNC0xLTEtMA_eec64f17-803d-41c7-b21f-a8c1dffa814b"
      unitRef="usdPerShare">0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzUtNC0xLTEtMA_fde5db28-6897-4e9f-8045-564bf481263e"
      unitRef="usdPerShare">0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtMi0xLTEtMA_0823dec6-1c6f-4490-969f-6eaa9aa31b71"
      unitRef="usdPerShare">-1.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtMi0xLTEtMA_318314b3-599a-4ab2-b18f-6c401d10622b"
      unitRef="usdPerShare">-1.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtNC0xLTEtMA_7c5b2d2e-738a-446d-ad46-9572426e2084"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8xOS9mcmFnOjNkMWNiYTZjZjVhMzRhNzBhYjVhNWNlMzI0MGMyZjRhL3RhYmxlOmEwNDRmZmNmOTVhMzRmOTdiOTI1M2QyZWEwNWQ3Zjk4L3RhYmxlcmFuZ2U6YTA0NGZmY2Y5NWEzNGY5N2I5MjUzZDJlYTA1ZDdmOThfMzYtNC0xLTEtMA_a4fe51ab-222e-49d5-ac92-3cf5c5b6994d"
      unitRef="usdPerShare">-1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="i97014661c9674a1aa49d94115f232a8e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0xLTEtMS01MTYw_a299804e-20fd-4440-8012-c15efebbcb2d"
      unitRef="shares">75004127</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i97014661c9674a1aa49d94115f232a8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0zLTEtMS01MTYw_72d719f4-0c82-4830-a472-56425a72d917"
      unitRef="usd">75000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i888ee0d094224a8c9d478400fe2c9087_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy01LTEtMS01MTYw_ef43976b-489d-4fc4-acaf-1969215b2cc3"
      unitRef="shares">1257143</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i888ee0d094224a8c9d478400fe2c9087_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy03LTEtMS01MTYw_2f86666d-07d5-45f6-b074-2db69e2872e5"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2cf49ee253f4aa884cbc90462dfac03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy05LTEtMS01MTYw_30085b6c-d75b-41d2-aea3-8156d521e950"
      unitRef="usd">202276000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6f1b44d7eb742ad8b64d152e535816f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0xMS0xLTEtNTE2MA_20c8b522-29ee-4857-bef1-2b7f9c323514"
      unitRef="usd">-177790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfMy0xMy0xLTEtNTE2MA_780bd65d-c986-4125-96f6-37067199601a"
      unitRef="usd">24562000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC0xLTEtMS01MTY4_43812fbb-5168-4abc-8b2e-de74335ce022"
      unitRef="shares">13971889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC0zLTEtMS01MTcz_ca229cf6-82b3-43d8-8962-db880a134eda"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC05LTEtMS01MTc1_96e33f3d-f99d-4167-add6-4280329ed3e2"
      unitRef="usd">37639000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNC0xMy0xLTEtNTE3Nw_0a49c246-2716-4a0b-8880-0d1680320d8f"
      unitRef="usd">37653000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cerc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
      contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNS0xLTEtMS01MTU4_b1764741-8d44-4a4e-bf83-3ac2bcb4c3f7"
      unitRef="shares">128800</cerc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNS05LTEtMS01MTU4_967714c4-f145-483b-b878-af19e630d631"
      unitRef="usd">172000</cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNS0xMy0xLTEtNTE1OA_1bdf02f4-1252-4271-8974-c3e2ed5ad0d9"
      unitRef="usd">172000</cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ia1a370c7c21c45b2a3001d2f6dcd959b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNi05LTEtMS01MTU4_3c3d4b5f-d54d-4057-91a8-aff62ebd2141"
      unitRef="usd">1448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNi0xMy0xLTEtNTE1OA_ee72faae-dd8d-44af-a953-14fe4481ebb1"
      unitRef="usd">1448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="i690cbeed41364aeabc936a485830713d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNy0xMS0xLTEtNTE1OA_8cba46a3-c0ee-4e39-b53f-9628b36ad8a5"
      unitRef="usd">-30680000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfNy0xMy0xLTEtNTE1OA_e61f3ee5-e0ed-4e78-b98a-3cc9ca235e34"
      unitRef="usd">-30680000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i0527fb21cb6e422a81b0d2b896ce2a12_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0xLTEtMS01MTU4_1426d368-b90d-40be-a47a-2e1877579b6d"
      unitRef="shares">89104816</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0527fb21cb6e422a81b0d2b896ce2a12_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0zLTEtMS01MTU4_ff5e2612-c3b1-4429-82a3-8f8848961e08"
      unitRef="usd">89000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i84b59ac211a5411c8a1466475097bdbd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC01LTEtMS01MTU4_8f0b1e90-1d01-4956-be14-bb194f93913b"
      unitRef="shares">1257143</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i84b59ac211a5411c8a1466475097bdbd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC03LTEtMS01MTU4_6f65f118-a136-496c-b417-779cdf5815b6"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1824d4fdd18644d08279a67df7329d8f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC05LTEtMS01MTU4_4efc1fd0-6e84-4d4c-b563-88484b2d3952"
      unitRef="usd">241535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief11578c5a3d4120889bfb43d5e8c59e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0xMS0xLTEtNTE1OA_62d4b94d-b0d0-4832-a505-b67486255243"
      unitRef="usd">-208470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjFhMGYwOTBlYTJjMTQ5ZTdhYTcwN2Q0Nzk2N2Y2NjI0L3RhYmxlcmFuZ2U6MWEwZjA5MGVhMmMxNDllN2FhNzA3ZDQ3OTY3ZjY2MjRfOC0xMy0xLTEtNTE1OA_7898c5b7-b057-4aab-ac21-f5b6e095908e"
      unitRef="usd">33155000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4f7f7fe58b1947a1af4d75615be3a866_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0xLTEtMS0w_ce938281-4e63-4f87-82a7-fcf88dcb899d"
      unitRef="shares">44384222</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4f7f7fe58b1947a1af4d75615be3a866_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0zLTEtMS0w_270b8122-c8c2-4ebb-8033-a8f6764b938f"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i3698e2a15da04d2582ead896c9da1bdb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy01LTEtMS0w_fde048ad-18dd-4ede-9603-c57fbb81d7f8"
      unitRef="shares">2857143</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3698e2a15da04d2582ead896c9da1bdb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy03LTEtMS0w_101a0a3e-9cfe-4769-a897-d61db0520b6c"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8858464917a44129a19e5fd629e46e2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy05LTEtMS0w_f749db90-818d-4154-94c8-c416441f5285"
      unitRef="usd">135239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5248b004c3024ef7844b36f897f76171_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0xMS0xLTEtMA_8a90961f-3028-4e2b-a747-0246fba74470"
      unitRef="usd">-114291000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbd4365662c24c30b28e21ce069efe37_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfMy0xMy0xLTEtMA_ebc43e72-a80e-4c26-bbb1-92c7b11ac619"
      unitRef="usd">20995000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0xLTEtMS0yNDg1_8573d531-4b29-45cc-9b4d-37ec11d8aa1b"
      unitRef="shares">8000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0zLTEtMS0yNDg1_4156bf63-5bb8-4313-8eb4-b04ef36b3317"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="icc41f7eca88947c9a35e4be0dc501644_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC01LTEtMS0yNDg5_3571d8dd-8277-4067-853d-0b1e214c8f5b"
      unitRef="shares">-1600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="icc41f7eca88947c9a35e4be0dc501644_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC03LTEtMS0yNDg5_f075b8ad-0e34-48fc-a2f0-30b8fd52c45c"
      unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC05LTEtMS0yNDg1_6e7bc185-d26a-4059-821c-b085da3baf5b"
      unitRef="usd">-6000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0xMy0xLTEtMjQ4NQ_70d62690-6ccc-46c7-90d4-51e9a735575f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xLTEtMS0yNDg1_6878c079-38bd-46ca-88a6-9973f7b11e81"
      unitRef="shares">3893361</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0zLTEtMS0yNDg1_308acea9-1b87-4298-ab94-9ad852169c7c"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS05LTEtMS0yNDg1_8d93ab15-5b53-4904-a409-4159d075cd04"
      unitRef="usd">15492000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xMy0xLTEtMjQ4NQ_e6ab747d-926a-42bc-9cd6-bda457258856"
      unitRef="usd">15496000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <cerc:IssuanceOfSharesSharePursuantToRegisteredDirectOffering
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xLTEtMS0yNDg1_20b1a02e-c369-43ca-93c2-59b633ed827a"
      unitRef="shares">1306282</cerc:IssuanceOfSharesSharePursuantToRegisteredDirectOffering>
    <cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0zLTEtMS0yNDg1_614714ec-af1b-4cd1-9dfd-fce19ea4fa17"
      unitRef="usd">1000</cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering>
    <cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering
      contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi05LTEtMS0yNDg1_8ef032e6-0a9f-4026-8266-510eacd05c22"
      unitRef="usd">5135000</cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering>
    <cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xMy0xLTEtMjQ4NQ_e69939e5-9dc2-41fd-a99a-d62f8ea8faa2"
      unitRef="usd">5136000</cerc:IssuanceOfSharesValuePursuantToRegisteredDirectOffering>
    <cerc:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy0xLTEtMS0yNDg1_b5ba4035-02a4-4331-a452-8fe1ea7f0336"
      unitRef="shares">1951219</cerc:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement>
    <cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy0zLTEtMS0yNDg1_c0c52a67-176f-4b4f-a98c-8827eb0aaaae"
      unitRef="usd">2000</cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement>
    <cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement
      contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy05LTEtMS0yNDg1_43e49205-a618-4119-9360-da72d81cedf7"
      unitRef="usd">3886000</cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement>
    <cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNy0xMy0xLTEtMjQ4NQ_b7ffc2d8-3940-43e3-bc10-13f3eb55abde"
      unitRef="usd">3888000</cerc:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement>
    <cerc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfOC0xLTEtMS0yNDg1_76c8c999-eda7-4939-a2a4-f11b5717380b"
      unitRef="shares">25168</cerc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC05LTEtMS0w_8745f6ac-6451-41f7-9215-d30c86e501ca"
      unitRef="usd">74000</cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNC0xMy0xLTEtMA_72fa2019-ae19-4018-968c-4d4cd3d0d38f"
      unitRef="usd">74000</cerc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ia685868db71942a9af4841c18c2bfcfb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfOS05LTEtMS0yNDg3_4c9b0398-c0fb-4064-a743-a1b9630bc1e7"
      unitRef="usd">1116000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfOS0xMy0xLTEtMjQ4Nw_60f3c792-63dc-4a99-8df9-a20d9f2055c8"
      unitRef="usd">1116000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="i3aed8d010f6b4643ab5cf935d95e3ddb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xMS0xLTEtMA_28edd4f3-c032-4df2-986a-7e4db354ae83"
      unitRef="usd">-21117000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNS0xMy0xLTEtMA_f0634f12-e08b-4d7e-8445-2b762f6eab72"
      unitRef="usd">-21117000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic5b1d9aca4484c4d8668324b0b5763d2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xLTEtMS0w_dff3ffef-ceeb-43aa-b6a7-1198a0a1decb"
      unitRef="shares">59560252</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic5b1d9aca4484c4d8668324b0b5763d2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0zLTEtMS0w_4e5f2160-b428-42e1-851c-a582cbf2981c"
      unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i293bef8c2ab840b6bfc576a532a95a7e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi01LTEtMS0w_e767626e-0c8f-42a3-8648-e3f723b5f33b"
      unitRef="shares">1257143</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i293bef8c2ab840b6bfc576a532a95a7e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi03LTEtMS0w_c5d3a0e2-fc3b-441c-a5ec-190c55ddeec2"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icca7fddb46cc489688e478d5cee8ffe0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi05LTEtMS0w_dcb55d8f-78c3-48fb-8517-2819fbfcd539"
      unitRef="usd">160936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7acefac7b962485a8c15861ff10d0200_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xMS0xLTEtMA_8b40d2e3-91f2-4be1-aba0-fe5cd1d43ea4"
      unitRef="usd">-135408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yNS9mcmFnOmVmMjMyNzVhNGZiMzQzMjU4NTYzOGM1ZjFjM2FmMDRmL3RhYmxlOjdjYWYwNmQ4NmRjNzQ3MjNiMmFiMmNlNmQwYTM3YzgwL3RhYmxlcmFuZ2U6N2NhZjA2ZDg2ZGM3NDcyM2IyYWIyY2U2ZDBhMzdjODBfNi0xMy0xLTEtMA_9b014c0c-431d-473f-ba50-6b411a6c1d45"
      unitRef="usd">25588000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMy0yLTEtMS0w_96692009-5b79-421d-ab0e-178210f47a53"
      unitRef="usd">-30680000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMy00LTEtMS0w_1762d37c-33f4-425a-bf4c-fad6d726fd03"
      unitRef="usd">-21117000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNS0yLTEtMS0w_c5caf297-3e18-4666-8c97-f685364c4708"
      unitRef="usd">451000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNS00LTEtMS0w_2eb9a827-c0b7-4842-b02e-969ad61c6a94"
      unitRef="usd">453000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNy0yLTEtMS0w_665d1e99-5939-420d-a925-be8e63adb65d"
      unitRef="usd">1448000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNy00LTEtMS0w_f61f8f35-3f7e-4773-bbc1-71ae6d3abc68"
      unitRef="usd">1116000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOC0yLTEtMS0w_0b59399e-f234-4073-9efa-9527be721ae1"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOC00LTEtMS0w_76ca9a67-892b-4c0a-8a28-ea5813597d45"
      unitRef="usd">25549000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOS0yLTEtMS0w_119660d3-56af-49a5-8017-9c74e0b1b447"
      unitRef="usd">21000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfOS00LTEtMS0w_cf884b2d-7099-4f5e-a571-81c72ace7ad9"
      unitRef="usd">21000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTEtMi0xLTEtMA_df357639-cfa9-43eb-bf68-db81f34ec1a8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTEtNC0xLTEtMA_b6912478-3db8-4634-8ffb-acf30e45badb"
      unitRef="usd">7080000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTItMi0xLTEtMjc4_e213f011-5036-4fe1-93c5-fd4cd50fa93d"
      unitRef="usd">0</cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee>
    <cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTItNC0xLTEtMjc4_b53498c0-f744-48a7-b3f9-94892c482559"
      unitRef="usd">1755000</cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee>
    <cerc:FairValueAdjustmentOfWarrantsAndInvestorRightsObligation
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTMtMi0xLTEtMA_04a2e791-c0f6-426e-a08a-6f82e089b3ac"
      unitRef="usd">0</cerc:FairValueAdjustmentOfWarrantsAndInvestorRightsObligation>
    <cerc:FairValueAdjustmentOfWarrantsAndInvestorRightsObligation
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTMtNC0xLTEtMA_d9f4d9fc-a200-4e36-94c8-92e68e941ee2"
      unitRef="usd">-11000</cerc:FairValueAdjustmentOfWarrantsAndInvestorRightsObligation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTYtMi0xLTEtMA_0f063c1f-848a-49ff-8505-03491c781858"
      unitRef="usd">953000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTYtNC0xLTEtMA_dd20b427-644a-410e-9ccf-c66dea17a107"
      unitRef="usd">696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTctMi0xLTEtMA_8ceb14cf-65d1-4164-bd66-93516fc1ee0c"
      unitRef="usd">-152000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTctNC0xLTEtMA_a9c3a6af-367a-4c99-a2c8-1268580e43f8"
      unitRef="usd">1963000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTgtMi0xLTEtMA_0b208bb9-df3b-4749-b10d-49e46c9a711c"
      unitRef="usd">-3000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTgtNC0xLTEtMA_fa96c7c6-9e61-4185-be26-a79ff749b5dd"
      unitRef="usd">-5000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTktMi0xLTEtMA_f77b5af6-f371-497f-9521-e2b2202f056b"
      unitRef="usd">-195000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMTktNC0xLTEtMA_6a0b8ad3-69e9-43a4-b5b3-d7ac9150e777"
      unitRef="usd">-23000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjAtMi0xLTEtMA_056c188e-375e-4609-84d9-d6da761bc29e"
      unitRef="usd">9339000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjAtNC0xLTEtMA_b76952f3-26ed-4068-91d7-71a0e99d5cea"
      unitRef="usd">251000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjEtMi0xLTEtMA_1c0811b5-0eb4-4b6a-8893-7d92b412efb6"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjEtNC0xLTEtMA_cd4fc6c9-296c-4f56-8a4a-f8c845a0c302"
      unitRef="usd">-551000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjItMi0xLTEtMA_8a974e1e-7ffd-4b6d-9e52-408c52548665"
      unitRef="usd">1724000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjItNC0xLTEtMA_48ac87f3-c088-4f65-9659-1ce432191bc2"
      unitRef="usd">-142000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <cerc:IncreaseDecreaseInLeaseLiability
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjQtMi0xLTEtMA_2a1d2d8d-e85e-4ee3-b880-367135c11ada"
      unitRef="usd">-16000</cerc:IncreaseDecreaseInLeaseLiability>
    <cerc:IncreaseDecreaseInLeaseLiability
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjQtNC0xLTEtMA_aae93992-5bb8-4a85-96d3-139f17bc8bd1"
      unitRef="usd">158000</cerc:IncreaseDecreaseInLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjUtMi0xLTEtMA_c4593d4c-d06c-44c9-9739-4a9a65a2a17f"
      unitRef="usd">-18316000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjUtNC0xLTEtMA_3030c5d1-864d-4610-905e-3e7f36f79a16"
      unitRef="usd">-5739000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cerc:PaymentsForAssetAcquisitions
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjgtMi0xLTEtMA_447dde79-cd2a-4d37-b548-a7eed57e5dac"
      unitRef="usd">0</cerc:PaymentsForAssetAcquisitions>
    <cerc:PaymentsForAssetAcquisitions
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjgtNC0xLTEtMA_23f123b6-2811-4b37-87cb-9e0ba3526ec2"
      unitRef="usd">1251000</cerc:PaymentsForAssetAcquisitions>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjktMi0xLTEtMA_f0e228c2-c5b2-42ba-b874-02ffa65beb33"
      unitRef="usd">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMjktNC0xLTEtMA_85bf9d9a-dc27-4b61-a2a3-ca2862c759b8"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzAtMi0xLTEtMA_b4f8ad6a-31fe-469a-8374-dbba74a9f9dd"
      unitRef="usd">-21000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzAtNC0xLTEtMA_39eaf5a2-61fb-449d-8eda-86dd80eb4fca"
      unitRef="usd">-1251000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cerc:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzItMi0xLTEtMA_1f405b95-7a30-4b4c-99c7-185dd4099439"
      unitRef="usd">37653000</cerc:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <cerc:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzItNC0xLTEtMA_fa9272b5-5f34-44ac-b18c-6347f495d8eb"
      unitRef="usd">0</cerc:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <cerc:ProceedsFromRegisteredDirectOffering
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzMtMi0xLTEtMA_ab5e2ab4-47b2-46fe-8c17-cfe2de987535"
      unitRef="usd">0</cerc:ProceedsFromRegisteredDirectOffering>
    <cerc:ProceedsFromRegisteredDirectOffering
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzMtNC0xLTEtMA_a6db07ba-3342-4e69-958f-a0af44bec625"
      unitRef="usd">5136000</cerc:ProceedsFromRegisteredDirectOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzQtMi0xLTEtMA_01e07918-2670-4b8c-a3a5-e526c935befb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzQtNC0xLTEtMA_66970af9-dc09-45ec-aae3-a62209aeb5dc"
      unitRef="usd">3888000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <cerc:ProceedsFromOptionOrWarrantExercises
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzUtMi0xLTEtMA_e454466c-8aca-4c23-be40-67906c74cbde"
      unitRef="usd">172000</cerc:ProceedsFromOptionOrWarrantExercises>
    <cerc:ProceedsFromOptionOrWarrantExercises
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfMzUtNC0xLTEtMA_9af9b646-c77d-4613-b466-df6f3c7fbb88"
      unitRef="usd">74000</cerc:ProceedsFromOptionOrWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDAtMi0xLTEtMA_fb3cdc63-88b9-4475-8d35-bcc1a7617a37"
      unitRef="usd">37825000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDAtNC0xLTEtMA_02209069-5976-4f23-9e19-9dcbba62136f"
      unitRef="usd">9098000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDEtMi0xLTEtMA_1089ec6e-54c7-4e28-903c-a7f46c46eba3"
      unitRef="usd">19488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDEtNC0xLTEtMA_69847ca8-7c38-4f12-9a3e-a516ca133c00"
      unitRef="usd">2108000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDItMi0xLTEtMA_c9bb3b97-3468-4da7-b55c-cbaf624b0d11"
      unitRef="usd">19106000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifbd4365662c24c30b28e21ce069efe37_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDItNC0xLTEtMA_dd86c64e-15fd-49d4-b8ec-c3cd35f160fa"
      unitRef="usd">3729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDMtMi0xLTEtMA_804034aa-8cc1-4b88-a727-8523b531db89"
      unitRef="usd">38594000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDMtNC0xLTEtMA_48e38221-e838-46fb-a44b-38b5638d94ab"
      unitRef="usd">5837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDYtMi0xLTEtMA_156ede2c-a639-4e1b-baec-ce7a0a24cdfa"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDYtNC0xLTEtMA_a5c49a79-f004-4ea5-ab98-01125396df6e"
      unitRef="usd">316000</us-gaap:IncomeTaxesPaid>
    <us-gaap:StockIssued1
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDgtMi0xLTEtMA_cd76de10-8442-49af-81b7-f079a7e3bb61"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOmY0M2JlZjBkODFlNjQ2M2E4M2I5MzViNTVmOWM2MTk4L3RhYmxlcmFuZ2U6ZjQzYmVmMGQ4MWU2NDYzYTgzYjkzNWI1NWY5YzYxOThfNDgtNC0xLTEtMA_74fb3fed-ae58-46c0-baa8-2f7bc59fd6f3"
      unitRef="usd">15496000</us-gaap:StockIssued1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfMy0yLTEtMS0w_8a950d83-195a-4acb-9ede-e3d38995a51c"
      unitRef="usd">38292000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfMy00LTEtMS0w_d2b6b665-681f-4e0f-9398-39de1a5b9805"
      unitRef="usd">5659000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNC0yLTEtMS0w_2d8c2550-b93f-4246-887e-a715f57732f4"
      unitRef="usd">153000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNC00LTEtMS0w_39c96523-da41-4dad-888e-d48f2b45e0e0"
      unitRef="usd">65000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNS0yLTEtMS0w_c509aa71-f1c3-4b13-91c7-fbd7c7a932d3"
      unitRef="usd">149000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNS00LTEtMS0w_410fa61c-7962-42a7-b071-0947236dc69f"
      unitRef="usd">113000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNi0yLTEtMS0w_33eda749-a58a-4f17-9117-c82c5c77960e"
      unitRef="usd">38594000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8yMi9mcmFnOjRiZGU1OWI3NDEyYTRjY2Y5ZDAyNDUwYjNiYTkzYjgwL3RhYmxlOjJiNTZjM2ZiMjI2MzQ2NjZhYWM4ZDk2OTc2Yzg1YmI5L3RhYmxlcmFuZ2U6MmI1NmMzZmIyMjYzNDY2NmFhYzhkOTY5NzZjODViYjlfNi00LTEtMS0w_62ddaa6e-7286-42e8-8286-fee312b74956"
      unitRef="usd">5837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNzA5OA_448e783c-c36f-4292-b4b2-2f1fa67462af">Business &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Cerecor Inc. (the &#x201c;Company&#x201d; or &#x201c;Cerecor&#x201d;) is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases. The Company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company&#x2019;s rare disease pipeline includes CERC-801, CERC-802 and CERC-803 (&#x201c;CERC-800 compounds&#x201d;), which are in development for therapies for congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor in development for the treatment of complex lymphatic malformations. The Company is also developing two monoclonal antibodies, CERC-002 and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for the treatment of severe pediatric-onset Crohn&#x2019;s disease and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still&#x2019;s disease (adult onset Still&#x2019;s disease and systemic juvenile idiopathic arthritis) and multiple myeloma. CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher (&#x201c;PRV&#x201d;) upon approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company continues to explore strategic alternatives for its non-core assets, including its commercialized product, Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;, an oral prednisolone indicated across a wide variety of inflammatory conditions, and for its neurology pipeline assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cerecor was incorporated and commenced operation in 2011 and completed its initial public offering in October 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company closed an underwritten public offering of 13,971,889 shares of its common stock and 1,676,923 pre-funded warrants for net proceeds of approximately $37.7&#160;million (see Note 9 for additional information). As of March 31, 2021, Cerecor had $38.3&#160;million in cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company&#x2019;s resources between investing in the Company&#x2019;s existing pipeline assets and acquisitions or in-licensing of new assets. For the three months ended March 31, 2021, Cerecor generated a net loss of $30.7&#160;million and negative cash flows from operations of $18.3&#160;million. As of March 31, 2021, Cerecor had an accumulated deficit of $208.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its core research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy at least one year after the date the condensed consolidated financial statements included herein were issued. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To mitigate these conditions and to meet the Company&#x2019;s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive financings, (ii) federal and/or private grants, (iii) other out-licensing or strategic alliances/collaborations of its current pipeline assets, and (iv) out-licensing or sale of its non-core assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report were issued. &lt;/span&gt;&lt;/div&gt;Over the long term, the Company&#x2019;s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any PRVs it receives.</us-gaap:NatureOfOperations>
    <cerc:NumberOfProductsDeveloped
      contextRef="i628f57f6215a46b79ad5e7d53f734b1a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDk0NzgwMjM0Njk5Mw_fa49fc62-8b5c-402d-abd0-3f611f688948"
      unitRef="product">2</cerc:NumberOfProductsDeveloped>
    <cerc:NumberOfProductsDeveloped
      contextRef="iec8d13d67faf489fa328978709bcf27a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDk0NzgwMjM0Njk5Ng_3cc27e2b-0612-4867-98ec-ae4f1ef1acba"
      unitRef="product">4</cerc:NumberOfProductsDeveloped>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7e92ff68bdc846f39796a8688fdb85c6_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNTQ5NzU1ODE2MDc2Nw_73cdf724-1ce1-473b-9d10-695a37805515"
      unitRef="shares">13971889</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2d9f33420b794d6b82ec040bbdcda9ac_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNTQ5NzU1ODE2MDc5MA_92fa76f7-4cf7-4650-abd5-9cb8459bb84e"
      unitRef="shares">1676923</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNTQ5NzU1ODE2MDgwMQ_957ae941-b933-45f1-a082-60b684ede504"
      unitRef="usd">37700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDk0NzgwMjM0OTEwMQ_3d4ce3ae-7a08-4f87-acf6-96af47caa56f"
      unitRef="usd">38300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfMzg5OA_505e853a-deca-4ffe-b4e4-43d9e7cdfaab"
      unitRef="usd">-30700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfMzk0NA_bce31e4b-9532-40bf-b1c2-e27cc33b12d7"
      unitRef="usd">-18300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zMS9mcmFnOmQ5MzlhMjE1MTVmMjQzYTk4MDU3MDEyZjY1YjMzNjBiL3RleHRyZWdpb246ZDkzOWEyMTUxNWYyNDNhOTgwNTcwMTJmNjViMzM2MGJfNDAxMw_fa08797f-a851-4e38-9915-0dd0f214eeac"
      unitRef="usd">-208500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNC9mcmFnOjRiZWQ3M2IwZjJiZDRjODU5ZmM4MGY3YzY3NThiYzExL3RleHRyZWdpb246NGJlZDczYjBmMmJkNGM4NTlmYzgwZjdjNjc1OGJjMTFfNjgyNg_5c1b194f-6cb2-4a31-8149-b61e70c17197">Basis of Presentation and Significant Accounting Policies&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2020 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2020 audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, there were no significant changes to the Company&#x2019;s summary of significant accounting policies contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 8, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNC9mcmFnOjRiZWQ3M2IwZjJiZDRjODU5ZmM4MGY3YzY3NThiYzExL3RleHRyZWdpb246NGJlZDczYjBmMmJkNGM4NTlmYzgwZjdjNjc1OGJjMTFfNjgwNA_2f55fef4-f840-4475-863b-cc07db54d01d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#x2019;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2020 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2020 audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfOTM1NQ_e121e825-a586-43c2-b20c-35f169b60b42">Aytu Divestiture&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Sale of Pediatric Portfolio and Related Commercial Infrastructure to Aytu BioScience&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company closed on an asset purchase agreement to sell the Company&#x2019;s rights, title and interest in assets relating to certain commercialized products (the &#x201c;Pediatric Portfolio&#x201d;) and the corresponding commercial infrastructure to Aytu BioScience, Inc. (&#x201c;Aytu&#x201d;). Aytu paid consideration of $4.5&#160;million in cash and approximately 9.8&#160;million shares of Aytu convertible preferred stock, and assumed certain of the Company&#x2019;s liabilities, including the Company&#x2019;s payment obligations to Deerfield CSF, LLC (&#x201c;Deerfield&#x201d;) and certain other liabilities primarily related to contingent consideration and sales returns. Steve Boyd, Chief Investment Officer of Armistice Capital, LLC, a significant stockholder of the Company, serves on each company&#x2019;s board of directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cerecor retains all rights to Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Pursuant to a transition services agreement entered into between Aytu and Cerecor upon the divestiture close date, Aytu managed Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercial operations for 18 months (post November 1, 2019). In May 2021, the Company entered into an amended transition services agreement in which Aytu will continue to manage Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s commercial operations for an additional two months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the sale of the Pediatric Portfolio to Aytu, the Pediatric Portfolio met all conditions to be classified as discontinued operations.  Therefore, the accompanying condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and as of December 31, 2020 reflect the operations, net of taxes, and related assets and liabilities of the Pediatric Portfolio as  discontinued operations. Refer to the &#x201c;Discontinued Operations&#x201d; section below for more information, including Cerecor&#x2019;s continuing involvement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deerfield Guarantee &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the closing date of the Aytu Divestiture on November 1, 2019, Aytu assumed the Company&#x2019;s debt obligation to Deerfield and the contingent consideration liability related to future royalties on Avadel Pharmaceuticals PLC&#x2019;s (&#x201c;Avadel&#x201d;) pediatric products. In conjunction with the closing of this transaction, the Company entered into a guarantee in favor of Deerfield, which guarantees the payment of the assumed liabilities to Deerfield, which included the debt obligation and includes the contingent consideration related to future royalties on Avadel&#x2019;s pediatric products (collectively referred to as the &#x201c;Guarantee&#x201d;).   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aytu publicly reported that it had paid the $15.0&#160;million balloon payment to Deerfield before it came due in June 2020 and the fixed monthly payments to Deerfield ended in January 2021, thus satisfying the debt obligation. Of the contingent consideration, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.2&#160;million was paid to Deerfield prior to the Aytu Divestiture and therefore, as of November 1, 2019, Aytu was responsible for the remaining $9.3&#160;million. Aytu is required to pay an amount equal to at least $0.1&#160;million per month. Cerecor&#x2019;s Guarantee will end upon the earlier of (i) February 5, 2026, or (ii) upon $12.5&#160;million in aggregate deferred payments has been paid to Deerfield. Cerecor is required to make a payment under the Guarantee upon demand by Deerfield if all or any part of the fixed payments and/or deferred payments are not paid by Aytu when due or upon breach of a covenant. The remaining minimum commitments payable as most recently publicly reported by Aytu was $7.3&#160;million as of June 30, 2020, which represents Cerecor&#x2019;s estimated maximum potential future payments under the Guarantee. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Guarantee, which relates to the Company&#x2019;s obligation to make future payments if Aytu defaults, was determined at the time of the Aytu Divestiture as the difference between (i) the estimated fair value of the assumed payments using Cerecor&#x2019;s estimated cost of debt and (ii) the estimated fair value of the assumed payments using Aytu&#x2019;s estimated cost of debt. Subsequent to the close of the Aytu Divestiture, at each reporting period, the value of the Guarantee is determined based on the expected credit loss of the Guarantee with changes recorded in (loss) income from discontinued operations, net of tax within the consolidated statements of operations and comprehensive loss. We considered key drivers of cost of debt both at Aytu and Cerecor, including but not limited to, recent financings, cash position, operating cash flows and trends and Aytu&#x2019;s ability to meet its financial commitments. Based on these facts, the Company concluded that the expected credit loss of the Guarantee was de minimis as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the liabilities of the discontinued operations as of March 31, 2021 and December 31, 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 related to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed&#160;$2.0 million&#160;and are less than&#160;$2.8 million&#160;(in other words, Aytu will only assume $0.8 million of such returns). Therefore, Cerecor is liable for future sales returns of the Pediatric Portfolio sold prior to November 1, 2019 in excess of the $0.8 million assumed by Aytu. As of March 31, 2021, the Company estimated future returns on sales of the Pediatric Portfolio made prior to the transaction close date to be $0.2&#160;million, which was recognized within accrued expenses and other current liabilities from discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company&#x2019;s estimate of sales returns related to the Pediatric Portfolio is included within discontinued operations on the statement of operations and comprehensive loss and is shown within product revenue, net in the table summarizing the results of discontinued operations below.  In future periods, as additional information becomes available, the Company expects to recognize expense (or a benefit) related to actual sales returns of the Pediatric Portfolio in excess (or less than) the returns reserve recorded, which will be recognized within discontinued operations. The Company expects this involvement to continue until sales returns are no longer accepted on sales of the Pediatric Portfolio made prior to November 1, 2019, which in line with the products&#x2019; return policies, returns on these products may be accepted through the second quarter of 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of discontinued operations for the three months ended March 31, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in value of Guarantee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no non-cash operating items from discontinued operations for the three months ended March 31, 2021 and no non-cash investing items from the discontinued operations for the three months ended March 31, 2021 and 2020. The significant non-cash operating item from the discontinued operations for the three months ended March 31, 2020 is contained below (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in value of Guarantee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="icb32bfec45e942d4a910555a806195f9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2NTE4Mg_a480395e-cf9d-488d-aadf-1e9d89dbcedf"
      unitRef="usd">4500000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i5a0d41b8169040d484988356bf9f4cdb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2NTE4NA_8ba051a5-d1e3-4554-98f1-92bdc30395fa"
      unitRef="shares">9800000</us-gaap:InvestmentOwnedBalanceShares>
    <cerc:MonthlyOperationPaymentsTerm
      contextRef="i66052a9dae424dca80a7f82db41f4f83_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfMTg0OQ_5ce5e6f3-6c1f-4e1f-bfe9-952cc60c3af2">P18M</cerc:MonthlyOperationPaymentsTerm>
    <cerc:MonthlyOperationPaymentsAdditionalTerm
      contextRef="i625aa7d5128448528ad08b7663090142_D20210501-20210506"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2NTIwNQ_ef92713f-8c1e-44ca-a236-fbfb670ede98">P2M</cerc:MonthlyOperationPaymentsAdditionalTerm>
    <us-gaap:RepaymentsOfDebt
      contextRef="i1a2b8460cb924cb9b2aea21da6564fbf_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfMzU3MQ_237cc7ee-2a0a-417f-a13c-992a9c56a31c"
      unitRef="usd">15000000.0</us-gaap:RepaymentsOfDebt>
    <cerc:DebtInstrumentContingentConsiderationPaid
      contextRef="id606c2359deb445f9a0a8ae38b02ddb5_D20190101-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ1MA_525e4732-312a-4c58-8609-55caff2ccbf5"
      unitRef="usd">3200000</cerc:DebtInstrumentContingentConsiderationPaid>
    <cerc:DebtInstrumentRemainingContingentConsiderationLiability
      contextRef="i0e29f50e08944917829774bcbe7aff76_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ2NA_76e9d99b-d554-41ab-b2e6-8ca876ff9142"
      unitRef="usd">9300000</cerc:DebtInstrumentRemainingContingentConsiderationLiability>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="iec26640aabfa4148bdbe5fd031d0b667_D20191101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ3OA_b3d917b8-0125-44dd-a744-5aa0b4c70950"
      unitRef="usd">100000</us-gaap:DebtInstrumentPeriodicPayment>
    <cerc:DebtInstrumentFutureAggregateDeferredPayments
      contextRef="i763dfef39718433ead8376b849f71b21_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDQ5Mg_41ca1177-afa2-434a-b6fb-27de9803c8f8"
      unitRef="usd">12500000</cerc:DebtInstrumentFutureAggregateDeferredPayments>
    <cerc:DebtInstrumentRemainingContingentConsiderationLiability
      contextRef="i7d85ed913ebe404ab54475135f67de89_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDUwNw_86b3b5b6-6064-4db8-89d6-b5e735d0561b"
      unitRef="usd">7300000</cerc:DebtInstrumentRemainingContingentConsiderationLiability>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfOTM1Ng_8be03e11-5872-46bd-8847-78f7e468dfce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the liabilities of the discontinued operations as of March 31, 2021 and December 31, 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes the results of discontinued operations for the three months ended March 31, 2021 and 2020 (in thousands): &lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in value of Guarantee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no non-cash operating items from discontinued operations for the three months ended March 31, 2021 and no non-cash investing items from the discontinued operations for the three months ended March 31, 2021 and 2020. The significant non-cash operating item from the discontinued operations for the three months ended March 31, 2020 is contained below (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in value of Guarantee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="if5751c8b6986481696dc10ecdf31864b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTAtMi0xLTEtMA_55c8572b-34b7-454d-9bd1-d72cc386cae0"
      unitRef="usd">209000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="i5bc1c0e3c3fc4ff5b491ac78fb641632_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTAtNC0xLTEtMA_c7228248-5465-47dd-90f0-c919052c1b86"
      unitRef="usd">1342000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if5751c8b6986481696dc10ecdf31864b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTEtMi0xLTEtMA_36456d8c-25a1-492d-9e18-dadb2bdc80de"
      unitRef="usd">209000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5bc1c0e3c3fc4ff5b491ac78fb641632_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmMyMGIyOGJlODE2NDRkMzQ4M2FjYmY0YzJjMzM5YzEwL3RhYmxlcmFuZ2U6YzIwYjI4YmU4MTY0NGQzNDgzYWNiZjRjMmMzMzljMTBfMTEtNC0xLTEtMA_5edf3816-6505-4541-b524-ac3323e77bc4"
      unitRef="usd">1342000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns
      contextRef="i99b8c7fd991847e8837bd5a30646756a_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzIzNA_931a5a8f-0907-4a3b-892e-801ebbe2a91f"
      unitRef="usd">2000000.0</cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns>
    <cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns
      contextRef="if834bd2acf0f4a6cbbc998c9d3a0ec9d_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzI1NQ_7e17db09-cec9-46be-b0b0-1927a78f7fde"
      unitRef="usd">2800000</cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns>
    <cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns
      contextRef="i0c24c03ec1214b87aa2626d83a326856_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzI5Nw_3a55d0fa-876e-46f7-bc1e-d12340851495"
      unitRef="usd">800000</cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns>
    <cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns
      contextRef="i0c24c03ec1214b87aa2626d83a326856_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNzQ0OA_24a95818-89f7-44d0-8de4-81842da2458d"
      unitRef="usd">800000</cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturns>
    <cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent
      contextRef="if5751c8b6986481696dc10ecdf31864b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RleHRyZWdpb246ODY0ZmFmZmVlOTZmNDNiYTg3M2Y4N2ZjMDY5YjhhYWRfNTQ5NzU1ODE2MDUyMQ_6ae96b2a-1831-481b-9090-c7540b6ee79f"
      unitRef="usd">200000</cerc:DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMy0yLTEtMS0w_29bc8c45-6f89-4633-aa04-27c5d090961c"
      unitRef="usd">-5000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMy00LTEtMS0w_c67a82ec-a75c-4837-942d-74bb7b4d6447"
      unitRef="usd">-717000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNS0yLTEtMS04ODEz_91480f6a-f019-4bc9-ad5e-3fc9d4683668"
      unitRef="usd">101000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNS00LTEtMS04ODEz_95b7f7cc-9a63-4689-aff8-9d6222d8d2a3"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNi0yLTEtMS04ODEx_a4a02a49-8bb8-4875-80a5-dc9156318bce"
      unitRef="usd">101000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfNi00LTEtMS04ODEx_defe751b-4002-423b-b9ae-9e020eac85cd"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTQtMi0xLTEtMA_a482e17d-2d8a-4143-aadc-1a5cc02ea861"
      unitRef="usd">0</cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee>
    <cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTQtNC0xLTEtMA_22b40548-c824-4ed0-b65c-7b1e7966170a"
      unitRef="usd">1755000</cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee>
    <cerc:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTYtMi0xLTEtMA_e13ecea6-60d8-45e1-812b-29463945a50b"
      unitRef="usd">0</cerc:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <cerc:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTYtNC0xLTEtMA_7b11c4d4-513e-4ac3-bf77-714c3c7f4fa8"
      unitRef="usd">1755000</cerc:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTctMi0xLTEtMA_17d1a532-5ce3-4074-8a53-73012572222f"
      unitRef="usd">-106000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOjJlYTc4NzVmMDQ2OTRmODk5MjQxM2IxOWEzZDM3ODY4L3RhYmxlcmFuZ2U6MmVhNzg3NWYwNDY5NGY4OTkyNDEzYjE5YTNkMzc4NjhfMTctNC0xLTEtMA_c1ee367b-332d-4d71-b76b-d31ecd43f8a8"
      unitRef="usd">1038000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee
      contextRef="i5784318d54aa43969df750e98d7fd10e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmE5MjYyMTRhZTBiMTRhMmJiMmJmZGI4MzYzMDUxN2I1L3RhYmxlcmFuZ2U6YTkyNjIxNGFlMGIxNGEyYmIyYmZkYjgzNjMwNTE3YjVfNy0yLTEtMS0w_2041c2c4-a820-4ace-b34b-63900863173e"
      unitRef="usd">0</cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee>
    <cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee
      contextRef="i76e2457246514f529ed6d4dd8846e26c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl8zNy9mcmFnOjg2NGZhZmZlZTk2ZjQzYmE4NzNmODdmYzA2OWI4YWFkL3RhYmxlOmE5MjYyMTRhZTBiMTRhMmJiMmJmZGI4MzYzMDUxN2I1L3RhYmxlcmFuZ2U6YTkyNjIxNGFlMGIxNGEyYmIyYmZkYjgzNjMwNTE3YjVfNy00LTEtMS0w_7aecad03-b88f-471e-b73a-13c7306bf8b8"
      unitRef="usd">1755000</cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfMjMyNA_60bf368f-073d-483b-afd6-b978965c323c">Revenue&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates substantially all of its revenue from sales of Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an oral prednisolone indicated across a wide variety of inflammatory conditions, which is considered a prescription drug. The Company sells its prescription drug in the United States primarily through wholesale distributors and specialty contracted pharmacies. Wholesale distributors account for substantially all of the Company&#x2019;s net product revenues and trade receivables. The Company also earns revenue from sales of its prescription drug directly to retail pharmacies. For the three months ended March 31, 2021, the Company&#x2019;s three largest customers accounted for approximately 67%, 18%, and 15% of the Company&#x2019;s total net product revenues from sale of prescription drugs from continuing operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license and supply agreement for the Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#x201c;Teva&#x201d;), which expires on September 30, 2023. As part of a prior amendment to extend the contract to its current term, Cerecor agreed to pay Teva fifty percent of the net profit of the Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product following each calendar quarter, subject to a $0.5&#160;million quarterly minimum payment, which was set to begin on April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#x2019;s board of directors and also serves as the Chairman of Teva&#x2019;s board of directors.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of prescription drugs was $0.5&#160;million and $2.8&#160;million for the three months ended March 31, 2021 and 2020, respectively. During the first quarter of 2021, the Company&#x2019;s inventory on hand became short-dated (which the Company considers inventory within six months of expiration) due to manufacturing delays. The Company recorded a full allowance of $2.9&#160;million for returns on the sale of short-dated inventory given the high likelihood of return. The Company received the delayed inventory lot in April 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf18c62a06294fc58da61652b71d9234_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0Nzg1Mw_d94d776b-9555-4cbd-9a25-6c2f9dc297e1"
      unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i927b204af3c04c0bbd2188ed6a3eb0cf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0Nzg1OA_779821f4-f186-4d98-bf13-78e12ecefd41"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i15c7116f8756475caf3bf460b774b112_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0Nzg2Mw_6c9b315b-dc71-40b0-acff-09ba819acfe6"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <cerc:LicenseAgreementPercentOfNetProfitForInstallmentPayment
      contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDMxMw_09761cb4-adbd-49b0-9cac-7e20b609d5f0"
      unitRef="number">0.50</cerc:LicenseAgreementPercentOfNetProfitForInstallmentPayment>
    <cerc:LicenseAgreementInstallmentPayment
      contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDI3Mg_5ab2dd0b-c712-4e83-959e-d328c3b4963c"
      unitRef="usd">500000</cerc:LicenseAgreementInstallmentPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66f50cdd8bac484bb18c5e75cf2515ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDI4Ng_e6423489-3f49-4462-9277-1b336e65bb3b"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6051bdc503c644b88a48cbfbf8982a59_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0NDMwMA_989dc130-f7f3-4a05-bf76-76394db0019a"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cerc:InventoryPeriodBeforeExpiration
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNDk0NzgwMjMzNDU4OQ_09c2184c-7d36-4c08-b513-cfc88b8a433f">P6M</cerc:InventoryPeriodBeforeExpiration>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80MC9mcmFnOmIxZDhjZDM2NGYwZDRkNDNhODQ5MTQwN2Y1ODY3OWQzL3RleHRyZWdpb246YjFkOGNkMzY0ZjBkNGQ0M2E4NDkxNDA3ZjU4Njc5ZDNfNTQ5NzU1ODE0ODQ2MA_f1c3d9d8-fb35-49db-a123-0607efca78b7"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzA0NQ_3e2dd843-4de0-486c-b98c-7d5da66cffa5">Net Loss Per Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes earnings per share (&#x201c;EPS&#x201d;) using the two-class method. The two-class method of computing EPS is an earnings allocation formula that determines EPS for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two classes of stock outstanding, common stock and preferred stock. The preferred stock outstanding as of March 31, 2021 has the same rights and preferences as the Company&#x2019;s common stock, other than being non-voting, and is convertible into shares of common stock on a 1-for-5 ratio.  Under the two-class method, the convertible preferred stock is considered a separate class of stock for EPS purposes and therefore basic and diluted EPS is provided below for both common stock and preferred stock. In April 2021, Armistice Capital Master Fund Ltd. (an affiliate of Armistice Capital, LLC and collectively &#x201c;Armistice&#x201d;), which is a significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, converted the remaining 1,257,143 shares of convertible preferred stock into 6,285,715 shares of Cerecor&#x2019;s common stock. Refer to Note 9 for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EPS for common stock and EPS for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. In applying the two-class method, undistributed earnings are allocated to common stock and preferred stock based on the weighted average shares outstanding during the period, which assumes the convertible preferred stock has been converted to common stock. The weighted average number of common shares outstanding as of March 31, 2021 includes the weighted average effect of the pre-funded warrants issued in connection with the January 2021 underwritten public offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock (refer to Note 9 for more information).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net (loss) income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the &#x201c;treasury stock method&#x201d; when dilutive; and (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the &#x201c;treasury stock method&#x201d; when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net (loss) income per share of common stock and preferred stock for the three months ended March 31, 2021 and 2020 (in thousands, except share and per share amounts):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allocation of undistributed net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,576,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,576,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allocation of undistributed net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,934,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,934,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March&#160;31, 2021 and 2020, as they could have been anti-dilutive:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,944,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,712,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants on common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024,708&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underwriters&#x2019; unit purchase option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;1 The above table excludes 1,676,923 pre-funded warrants. See the &#x201c;Q1 2021 Financing&#x201d; in Note 9 for more information.</us-gaap:EarningsPerShareTextBlock>
    <cerc:ClassOfStockNumberOfClassesOfStockOutstanding
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNDk0NzgwMjMzMzY1Nw_98ffdf0d-a6ea-4f69-a77e-7473fc4d6611"
      unitRef="class_of_stock">2</cerc:ClassOfStockNumberOfClassesOfStockOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i014f146895fb4927a75a9cdec07aaa18_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNTQ5NzU1ODE0Njc0NA_d76b7444-2ae3-4c55-9d76-a3a5689851c4"
      unitRef="shares">1257143</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="ifc5f85fcc1e248a78caf6d745147bdc1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNTQ5NzU1ODE0Njc1NQ_6f26535c-ecc3-44ad-bf37-67dae6238d89"
      unitRef="shares">6285715</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzA0Mg_641f69b2-f14d-484a-932e-8d8f41e0a910">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net (loss) income per share of common stock and preferred stock for the three months ended March 31, 2021 and 2020 (in thousands, except share and per share amounts):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allocation of undistributed net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,576,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,576,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allocation of undistributed net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,934,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,934,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS0yLTEtMS0w_6e3b38d5-1c98-436f-bbd3-19f2cf9698bf"
      unitRef="usd">-28548000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS00LTEtMS0w_5115eb30-8418-4a39-bbf2-e1752b8e84fd"
      unitRef="usd">-99000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS02LTEtMS0w_a6c59989-60fa-47fd-8d58-624e7394e0a3"
      unitRef="usd">-2026000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNS04LTEtMS0w_481cee85-2265-4de0-9aa5-d626d39f9e9a"
      unitRef="usd">-7000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy0yLTEtMS0w_1704d63a-0de1-4301-b7c8-9d5a305ced05"
      unitRef="shares">88576559</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy0yLTEtMS0w_5f6651f0-5953-4728-9059-7ea1b4f264d0"
      unitRef="shares">88576559</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy00LTEtMS0w_2d1d0d48-dbc4-48c3-94dc-21397dfb74de"
      unitRef="shares">88576559</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy00LTEtMS0w_91867ca1-2e4a-436e-9f06-8a3166a48031"
      unitRef="shares">88576559</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy02LTEtMS0w_4314b865-0f8d-4dff-ae49-aa0e5275325f"
      unitRef="shares">1257143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy02LTEtMS0w_bdb1ec35-e733-4309-813f-6583442bb215"
      unitRef="shares">1257143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy04LTEtMS0w_2e17e817-938b-4745-9925-a44bd5e962e3"
      unitRef="shares">1257143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfNy04LTEtMS0w_c9664b7e-5ea2-405e-949d-5b7bbc3a6d2b"
      unitRef="shares">1257143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC0yLTEtMS0w_2011e9a7-a1b4-4ec9-a376-7d71eb007b8f"
      unitRef="usdPerShare">-0.32</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC0yLTEtMS0w_70792f2e-a14e-4f05-b1eb-e27b1807480a"
      unitRef="usdPerShare">-0.32</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC00LTEtMS0w_79936e63-aab8-4e8c-a642-8588543acc53"
      unitRef="usdPerShare">-0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC00LTEtMS0w_7a78a974-54b1-4f2f-ba60-968d0be438c0"
      unitRef="usdPerShare">-0.00</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC02LTEtMS0w_0bc9d3d8-7dc2-4da9-8f22-94057e57e560"
      unitRef="usdPerShare">-1.61</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC02LTEtMS0w_269cedb8-247b-497b-b72a-a5f11ca3740b"
      unitRef="usdPerShare">-1.61</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC02LTEtMS0w_d4ee7f77-e951-4d31-9d91-96f549d58e4d"
      unitRef="usdPerShare">-1.61</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC04LTEtMS0w_6e121168-330f-460d-a4eb-d1a06c39d982"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC04LTEtMS0w_95f19155-c0f7-4a98-bc60-4eb65bb24ec3"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="ie3b2b725f6ae485f8b76bcbba42363ea_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjllYWQxNTc2YjE5YzQ3OTdhMmM5NWE4NDQ0MThmYjM2L3RhYmxlcmFuZ2U6OWVhZDE1NzZiMTljNDc5N2EyYzk1YTg0NDQxOGZiMzZfOC04LTEtMS0w_c5597371-6a5c-4270-ace3-122912449367"
      unitRef="usdPerShare">-0.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS0yLTEtMS0w_096a2327-7b0b-4950-8f18-b0eebb4def5b"
      unitRef="usd">-19205000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS00LTEtMS0w_faaa0990-671d-4f69-bfd8-311a3c2dc0d2"
      unitRef="usd">900000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS02LTEtMS0w_9a28ce45-d0a0-4ff6-a97a-e8bd0994b454"
      unitRef="usd">-2950000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNS04LTEtMS0w_b15c50e2-5eb0-4d47-b811-bbf45405496d"
      unitRef="usd">138000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy0yLTEtMS0w_4d5d8ecb-5307-46cc-bfb7-bdf73ba8cf14"
      unitRef="shares">53934760</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy0yLTEtMS0w_5c7d1bf0-5055-4770-b9e9-93c0cec87402"
      unitRef="shares">53934760</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy00LTEtMS0w_19bc7312-8adc-437a-b772-4b043d841d89"
      unitRef="shares">53934760</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy00LTEtMS0w_659efc54-192a-4a9c-a70d-33110ba7b07b"
      unitRef="shares">53934760</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy02LTEtMS0w_19813e7b-7684-4fba-bf6c-4f50dd863671"
      unitRef="shares">1657143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy02LTEtMS0w_743556cd-3746-4ad1-8ce0-2d87bb3e1ef5"
      unitRef="shares">1657143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy04LTEtMS0w_3c4890fd-307e-4eed-b32d-b7a62ae233c5"
      unitRef="shares">1657143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfNy04LTEtMS0w_5da18fc4-3cbb-4265-8a1e-fc3eba7585b6"
      unitRef="shares">1657143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC0yLTEtMS0w_b6e10e14-88f3-4466-9df8-37c34821dc33"
      unitRef="usdPerShare">-0.36</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC0yLTEtMS0w_dc010ad0-0e53-47b3-993d-9162c8118f37"
      unitRef="usdPerShare">-0.36</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC00LTEtMS0w_10e77e86-f50b-41d2-92cc-63a9327357b9"
      unitRef="usdPerShare">0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i91291938fe214166b2ead6b0d662a8df_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC00LTEtMS0w_42cfb0c1-97da-4558-b849-08b79f3ff884"
      unitRef="usdPerShare">0.02</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC02LTEtMS0w_53049003-d4da-4099-b8e0-acb1b98fad9d"
      unitRef="usdPerShare">-1.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC02LTEtMS0w_6491b092-cfd9-441c-9567-ddc97afc09b5"
      unitRef="usdPerShare">-1.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC02LTEtMS0w_b70cc2fa-183d-4310-a30a-6a5b5aba53be"
      unitRef="usdPerShare">-1.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC04LTEtMS0w_ab867d2e-aca4-4f6f-8854-2133be067c12"
      unitRef="usdPerShare">0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC04LTEtMS0w_eec64f17-803d-41c7-b21f-a8c1dffa814b"
      unitRef="usdPerShare">0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i5ddf25135bc245ce896b98d29df67d82_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOmZkNTIxNjMzNjBkMTRkNDk5MTVlZWY5MGQxMzM5ZmVlL3RhYmxlcmFuZ2U6ZmQ1MjE2MzM2MGQxNGQ0OTkxNWVlZjkwZDEzMzlmZWVfOC04LTEtMS0w_fde5db28-6897-4e9f-8045-564bf481263e"
      unitRef="usdPerShare">0.08</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzAzOQ_04d2b70f-04a0-4a80-9ff7-b98f172c5f5f">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March&#160;31, 2021 and 2020, as they could have been anti-dilutive:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,944,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,712,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants on common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024,708&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underwriters&#x2019; unit purchase option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;1 The above table excludes 1,676,923 pre-funded warrants. See the &#x201c;Q1 2021 Financing&#x201d; in Note 9 for more information.</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfMzA1MA_941d80a5-c751-49c7-8381-b5285e270c57">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March&#160;31, 2021 and 2020, as they could have been anti-dilutive:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,944,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,712,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants on common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024,708&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underwriters&#x2019; unit purchase option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;1 The above table excludes 1,676,923 pre-funded warrants. See the &#x201c;Q1 2021 Financing&#x201d; in Note 9 for more information.</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib2105f80d294440588767dee094560b3_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfMy0yLTEtMS0w_a39b7a32-2351-4ea5-b130-997ea308bc78"
      unitRef="shares">12944891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i629fbb798db048ea9b95506876d74823_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfMy00LTEtMS0w_ce4095fe-01cb-46af-85bc-534cb0477b72"
      unitRef="shares">7712680</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3df572689a424ea28bc48c6a42dbc0bc_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNC0yLTEtMS0w_a57eaaa1-f85a-43e9-ade7-acc9cbdf8f23"
      unitRef="shares">4002380</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id922871740784b9b88673ef935b11162_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNC00LTEtMS0w_3f7c0213-95ec-4383-b035-e26101de94ee"
      unitRef="shares">4024708</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia9167fb87d13406f85d22cdf0ee9c556_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNS0yLTEtMS0w_7f37fff6-a473-48fe-b940-99cb4347878e"
      unitRef="shares">155833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb2884fecf704a3ab359a11213837e2f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNS00LTEtMS0w_65b25185-3980-49bd-9bc3-61d4917471b0"
      unitRef="shares">267500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i53a62490f94c4f49b56fb7acc1da3613_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNi0yLTEtMS0yNTcz_623a3d27-aff3-48f7-850a-c75aeea37165"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7e8caa450d984e75b7af9b3d66541996_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RhYmxlOjU5NjRlM2QxZmNiMzRjODFiMTBkNGJjOGUxNWJmOWVhL3RhYmxlcmFuZ2U6NTk2NGUzZDFmY2IzNGM4MWIxMGQ0YmM4ZTE1YmY5ZWFfNi00LTEtMS0yNTcz_f1041bac-a286-49d8-b6ef-1ab6902e3a7f"
      unitRef="shares">40000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i50329ad27a3d4d858d5e36be03888359_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80My9mcmFnOjk1MWNhNzE2YmYyYTRiMDA4OTM1ZjY1YzQ1NjJkMDI2L3RleHRyZWdpb246OTUxY2E3MTZiZjJhNGIwMDg5MzVmNjVjNDU2MmQwMjZfNDk0NzgwMjMzMzI1OQ_de258652-7fa5-4c48-b693-f782970abea9"
      unitRef="shares">1676923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <cerc:AssetAcquisitionDisclosureTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNDU2Ng_08c0837f-9796-4b23-a77d-4a42be12017d">Asset Acquisition&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Aevi Merger&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, the Company consummated its merger with Aevi Genomic Medicine Inc. (&#x201c;Aevi&#x201d;), in which Cerecor acquired the rights to CERC-002, CERC-006 and CERC-007 (the &#x201c;Merger&#x201d; or the &#x201c;Aevi Merger&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger consideration included (i) stock valued at approximately $15.5 million, resulting in the issuance of approximately 3.9&#160;million shares of Cerecor common stock to Aevi stockholders, (ii) forgiveness of $4.1&#160;million the Company had loaned Aevi prior to the Merger closing, (iii) contingent value rights for up to an additional $6.5&#160;million in subsequent payments based on certain development milestones (discussed further in Note 13), and (iv) transaction costs of $1.5&#160;million. &lt;/span&gt;&lt;/div&gt;The Company recorded this transaction as an asset purchase as opposed to a business combination because management concluded that substantially all the value received was related to one group of similar identifiable assets, which was the in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) for two early phase therapies. The Company considered these pipeline assets similar due to similarities in the risks of development, stage of development, regulatory pathway, patient populations and economics of commercialization. The fair value of $25.5&#160;million (consisting primarily of $24.0&#160;million IPR&amp;amp;D, $0.3&#160;million of cash and $0.9&#160;million of assembled workforce) was immediately recognized as acquired in-process research and development expense in the Company&#x2019;s consolidated statement of operations and comprehensive loss because the IPR&amp;amp;D asset has no alternate use due to the stage of development. The assembled workforce asset was recorded to intangible assets and will be amortized over an estimated useful life of two years.</cerc:AssetAcquisitionDisclosureTextBlock>
    <cerc:AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfMjA5NQ_b0b85f74-ce18-4c5e-a3c6-122289111d1d"
      unitRef="usd">15500000</cerc:AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <cerc:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM0NA_8a0a97e4-9a08-4813-b97c-f5583bad1f6d"
      unitRef="shares">3900000</cerc:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares>
    <cerc:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred
      contextRef="idc103a37d52c4b8d9aab7c7d78bd8dab_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM1Nw_d4067cc5-e0f1-4d0d-ac9d-38a801cebac6"
      unitRef="usd">4100000</cerc:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred>
    <cerc:AssetAcquisitionContingentValueRightRightToReceiveContingentPayments
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM3MQ_b211ff25-3f15-4674-9ee0-14ab9687f213"
      unitRef="usd">6500000</cerc:AssetAcquisitionContingentValueRightRightToReceiveContingentPayments>
    <cerc:AssetAcquisitionTransactionCosts
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTM4NQ_388ae954-a10c-4d78-9c7e-2b2d7c6872cc"
      unitRef="usd">1500000</cerc:AssetAcquisitionTransactionCosts>
    <cerc:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTI4Ng_eb10289c-fedb-43f7-95c0-e29aac2c6953"
      unitRef="usd">25500000</cerc:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTMwMQ_5ce519f2-65b8-44f8-a90d-40308d261e10"
      unitRef="usd">24000000.0</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <cerc:AssetAcquisitionCashandEquivalents
      contextRef="if3e4c692d8be4db69e27560b083bebe4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTMxNg_92746faa-211f-4bef-ab79-815b4807398d"
      unitRef="usd">300000</cerc:AssetAcquisitionCashandEquivalents>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i950a8c7a799e4212b6120485b875cc33_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfNTQ5NzU1ODE1MTMzMA_306d6366-c905-4575-81d2-7f2f4bafe91a"
      unitRef="usd">900000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i950a8c7a799e4212b6120485b875cc33_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl80OS9mcmFnOjA4MmMxZDU1MjhkMjRkMGRhMTk3MTdlNTZkZmU3OGVhL3RleHRyZWdpb246MDgyYzFkNTUyOGQyNGQwZGExOTcxN2U1NmRmZTc4ZWFfMzM1Mw_019f8bfc-19ec-422b-a7d8-3ece044dd7dd">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNjgyMA_386faede-29ad-47d0-b55a-309d9449d05b">Fair Value Measurements &lt;div style="text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC No. 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three&#x2011;level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;1&#x2014;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;2&#x2014;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model&#x2011;derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;3&#x2014;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:99pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Investments in money market funds are reflected in cash and cash equivalents on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December&#160;31, 2020, the Company&#x2019;s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities. The carrying amounts reported in the accompanying condensed consolidated financial statements approximate their respective fair values because of the short-term nature of these accounts.&lt;/span&gt;&lt;/div&gt;No changes in valuation techniques or inputs occurred during the three months ended March 31, 2021 and 2020. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the three months ended March 31, 2021 and 2020.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNjgyNA_437388c5-f475-47f0-840c-f0399cdf2e53">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;active&#160;markets&#160;for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;observable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;unobservable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;identical&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Investments in money market funds are reflected in cash and cash equivalents on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3a8340a3cbf64f1ab5d3614c69eea675_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjE2NGFmZjBiN2UzYjRiYmViM2FiMWE4MDczNWUzZmI2L3RhYmxlcmFuZ2U6MTY0YWZmMGI3ZTNiNGJiZWIzYWIxYTgwNzM1ZTNmYjZfNy0yLTEtMS0w_ebb113ec-d0d6-48a1-942d-61fe77a4f941"
      unitRef="usd">37008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i00fa8b9a9a0a48da86b188ca05a629de_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjE2NGFmZjBiN2UzYjRiYmViM2FiMWE4MDczNWUzZmI2L3RhYmxlcmFuZ2U6MTY0YWZmMGI3ZTNiNGJiZWIzYWIxYTgwNzM1ZTNmYjZfNy00LTEtMS0w_7226da4b-93ee-4c92-9139-b919dd248b84"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1a66b18e75cf45d289497fdebf1a0e33_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjE2NGFmZjBiN2UzYjRiYmViM2FiMWE4MDczNWUzZmI2L3RhYmxlcmFuZ2U6MTY0YWZmMGI3ZTNiNGJiZWIzYWIxYTgwNzM1ZTNmYjZfNy02LTEtMS0w_b6d2c569-1613-4bab-9c7e-4249c1970d29"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8bf61356e0974feb98765a9f2a41e09d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjkxYzQ1YWQxYTdjODRhZmU4YmZjYzg5ZDQ5ODA3YjBhL3RhYmxlcmFuZ2U6OTFjNDVhZDFhN2M4NGFmZThiZmNjODlkNDk4MDdiMGFfNy0yLTEtMS0w_f1d1076d-3cf6-47cc-b121-ef23dd9d455a"
      unitRef="usd">17503000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9358ce44d144a59aa2cf6bce55c55b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjkxYzQ1YWQxYTdjODRhZmU4YmZjYzg5ZDQ5ODA3YjBhL3RhYmxlcmFuZ2U6OTFjNDVhZDFhN2M4NGFmZThiZmNjODlkNDk4MDdiMGFfNy00LTEtMS0w_c1a183f3-a0e5-4629-8616-6826292084b9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i590b811c4dca4dbca6d871776b523532_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RhYmxlOjkxYzQ1YWQxYTdjODRhZmU4YmZjYzg5ZDQ5ODA3YjBhL3RhYmxlcmFuZ2U6OTFjNDVhZDFhN2M4NGFmZThiZmNjODlkNDk4MDdiMGFfNy02LTEtMS0w_8297e605-736f-4272-ae5e-743aa663cf46"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <cerc:FairValueMeasurementsChangesInValuationTechniquesNumber
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDA5Ng_38692bd8-944a-4523-bc4a-a1d5bb37388f"
      unitRef="change">0</cerc:FairValueMeasurementsChangesInValuationTechniquesNumber>
    <cerc:FairValueMeasurementsChangesInValuationTechniquesNumber
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDA5Ng_ee34b814-1017-4cf3-a1bd-4b6ed778179e"
      unitRef="change">0</cerc:FairValueMeasurementsChangesInValuationTechniquesNumber>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_0f51ddc3-7ef7-4fbf-a940-a60961826c9f"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_25aa4641-c04b-48c8-9d89-4957e2f4b7e7"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_9885874c-2ff5-4935-8ba2-3e649313ff30"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="i60933515d1434308883ae1bb020e0a13_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81Mi9mcmFnOjQwOTJjM2M3MjM3YzQ3YjViNjBhZDQ3NTU4YjU3ZGVlL3RleHRyZWdpb246NDA5MmMzYzcyMzdjNDdiNWI2MGFkNDc1NThiNTdkZWVfNTQ5NzU1ODE1NDEwNQ_f74f0ace-86cb-436e-9db9-fb934f934fcd"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfODY3_140c4000-f79e-4785-b240-e51ec2be1ca0">Accrued Expenses and Other Current Liabilities  &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $2.5&#160;million increase in the research and development accrual as of March 31, 2021 was driven by an increase in manufacturing activities for CERC-002 to support the program&#x2019;s clinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021, the Company&#x2019;s inventory on hand became short-dated (which the Company considers inventory within six months of expiration) due to manufacturing delays. The Company records a full allowance for the returns on the sale of short-dated inventory given the high likelihood of return, which was the main driver of the increase in sales returns and allowances as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfODcw_03fe7ea4-59a9-4602-8fce-e8912b2ccf2e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <cerc:AccruedResearchAndDevelopment
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMi0yLTEtMS0w_998af465-752b-4f66-b908-b24227bb89ba"
      unitRef="usd">7393000</cerc:AccruedResearchAndDevelopment>
    <cerc:AccruedResearchAndDevelopment
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMi00LTEtMS0w_78034d3f-a61b-4216-8106-44d4b4e726d4"
      unitRef="usd">4939000</cerc:AccruedResearchAndDevelopment>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMy0yLTEtMS0w_460df067-067c-4975-b368-c4620984d811"
      unitRef="usd">1697000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMy00LTEtMS0w_3c655a31-aa00-4fb4-85e7-f14d49f4d7ca"
      unitRef="usd">3119000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cerc:AccruedGeneralAndAdministrativeExpenses
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNC0yLTEtMS0w_476366d9-dc32-42d3-83ed-35859610205b"
      unitRef="usd">966000</cerc:AccruedGeneralAndAdministrativeExpenses>
    <cerc:AccruedGeneralAndAdministrativeExpenses
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNC00LTEtMS0w_2e4bcc0c-a552-40d8-ad75-4a95689e62eb"
      unitRef="usd">771000</cerc:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNS0yLTEtMS0w_a7d7057a-bbd0-49a9-81b3-ebba44725b1d"
      unitRef="usd">93000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNS00LTEtMS0w_9a185921-2e19-40d0-8ad8-fe0fa5970b88"
      unitRef="usd">31000</us-gaap:AccruedMarketingCostsCurrent>
    <cerc:AccruedSalesReturnsAndAllowances
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNi0yLTEtMS0w_1b5bfddf-79d1-45ab-a9ed-a11613304b54"
      unitRef="usd">3630000</cerc:AccruedSalesReturnsAndAllowances>
    <cerc:AccruedSalesReturnsAndAllowances
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNi00LTEtMS0w_c89c480c-114a-47ca-b481-19ccef87cabd"
      unitRef="usd">1794000</cerc:AccruedSalesReturnsAndAllowances>
    <cerc:AccruedMedicaidRebates
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNy0yLTEtMS0w_cd37333c-0a95-4121-9504-b650d3a83ca4"
      unitRef="usd">83000</cerc:AccruedMedicaidRebates>
    <cerc:AccruedMedicaidRebates
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfNy00LTEtMS0w_d45736f7-804f-468d-9275-448d78e35068"
      unitRef="usd">119000</cerc:AccruedMedicaidRebates>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOC0yLTEtMS0w_f7538dac-cf4c-4c84-bfc8-432168bd73e2"
      unitRef="usd">357000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOC00LTEtMS0w_db39670c-9641-46ce-add4-8036f083506a"
      unitRef="usd">426000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOS0yLTEtMS0w_91583f05-a259-4b32-a5e5-bdcc783cc164"
      unitRef="usd">19000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfOS00LTEtMS0w_cf321830-4438-4853-98db-6626e5a06057"
      unitRef="usd">111000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMTAtMi0xLTEtMA_086b72d9-5cef-4193-a734-d2262a9c80f6"
      unitRef="usd">14238000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RhYmxlOmQyYTBkZDM4NDM0MDRmNjA5M2UzOGZiMTI4YTJhNjY4L3RhYmxlcmFuZ2U6ZDJhMGRkMzg0MzQwNGY2MDkzZTM4ZmIxMjhhMmE2NjhfMTAtNC0xLTEtMA_5cd3bdf8-9dd1-4e78-ade5-5a02bd1dad4a"
      unitRef="usd">11310000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfNDk0NzgwMjMzMDY2NQ_1ce2d687-0cd2-47db-a3c0-9852ea6f4fde"
      unitRef="usd">2500000</us-gaap:ResearchAndDevelopmentExpense>
    <cerc:InventoryPeriodBeforeExpiration
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81NS9mcmFnOmNiNWQ1YTE1OTM4ZjRkNWI5N2E0Nzg5OTI1MDgzNTM1L3RleHRyZWdpb246Y2I1ZDVhMTU5MzhmNGQ1Yjk3YTQ3ODk5MjUwODM1MzVfNDk0NzgwMjMzMDQwNg_09c2184c-7d36-4c08-b513-cfc88b8a433f">P6M</cerc:InventoryPeriodBeforeExpiration>
    <cerc:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNjg0Mw_30354ebf-0d48-467f-92e1-ce76a7347029">Capital Structure &lt;div style="text-align:justify;text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Company&#x2019;s amended and restated certificate of incorporation, the Company is authorized to issue two classes of stock, common stock and preferred stock. At March 31, 2021, the total number of shares of capital stock the Company was authorized to issue was 205,000,000 of which 200,000,000 was common stock and 5,000,000 was&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preferred stock. All shares of common and&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preferred stock have a par value of $0.001 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Q1 2021 Financing &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company closed an underwritten public offering of 13,971,889 shares of its common stock and 1,676,923 pre-funded warrants for net proceeds of $37.7&#160;million. Armistice, which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, participated in the offering by purchasing 2,500,000 shares of common stock, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC (collectively, &#x201c;Nantahala&#x201d;), which beneficially owned greater than 5% of the Company&#x2019;s outstanding common stock at the time of the offering and, therefore, were considered a related party pursuant to the Company&#x2019;s written related person transaction policy, purchased 1,400,000 shares of common stock, on the same terms as all other investors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nantahala also purchased the pre-funded warrants to purchase up to an aggregate of 1,676,923 shares of common stock at a purchase price of $2.599, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-funded warrants are exercisable at any time after their original issuance at the option of each holder, in such holder&#x2019;s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. A holder will not be entitled to exercise any portion of any pre-funded warrant if the holder&#x2019;s ownership of the Company&#x2019;s common stock would exceed 9.99% following such exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of certain fundamental transactions, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind of amounts of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the pre-funded warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-funded warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and pre-funded warrants, of which $4.4&#160;million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, the Company closed an underwritten public offering of 15,180,000 shares of its common stock for net proceeds of approximately $35.4&#160;million. Armistice participated in the offering by purchasing 2,000,000 shares of common stock, on the same terms as all other investors. Additionally, certain of the Company&#x2019;s officers participated in the offering by purchasing an aggregate of 110,000 shares of common stock, on the same terms as all other investors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2020, the Company entered into a securities purchase agreement with Armistice pursuant to which the Company sold 1,951,219 shares of the Company&#x2019;s common stock for net proceeds of approximately $3.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 6, 2020, the Company closed a registered direct offering with certain institutional investors for the sale by the Company of 1,306,282 shares of the Company&#x2019;s common stock for net proceeds of approximately $5.1 million.  Armistice participated in the offering by purchasing 1,256,282 shares of common stock from the Company, on the same terms as all other investors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Aevi Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, under the terms of the Aevi Merger noted above in Note 6, the Company issued approximately 3.9 million shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the following common stock warrants were outstanding:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;underlying&#160;warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;per&#160;share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676,923&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,679,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 26, 2018, the Company filed a Certificate of Designation of Preferences of Series B Non-Voting Convertible Preferred Stock (&#x201c;Series B Convertible Preferred Stock&#x201d; or &#x201c;convertible preferred stock&#x201d;) of Cerecor Inc. (the &#x201c;Certificate of Designation of the Series B Preferred Stock&#x201d;) classifying and designating the rights, preferences and privileges of the Series B Convertible Preferred Stock. The Certificate of Designation of the Series B Convertible Preferred Stock authorized 2,857,143 shares of convertible preferred stock. The Series B Convertible Preferred Stock converts to shares of common stock on a 1-for-5 ratio and has the same rights, preferences, and privileges as common stock other than it holds no voting rights. During the first quarter of 2020, Armistice converted 1,600,000 shares of Series B Convertible Preferred Stock into 8,000,000 shares of Cerecor&#x2019;s common stock. In April 2021, Armistice converted the remaining 1,257,143 shares of Series B Convertible Preferred Stock into 6,285,715 shares of Cerecor&#x2019;s common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;December 2018 Armistice Private Placement&lt;/span&gt;&lt;/div&gt;On December 27, 2018, the Company entered into a series of transactions as part of a private placement with Armistice. The transactions were considered one transaction for accounting purposes. As part of the transaction, the Company exchanged common stock warrants issued on April 27, 2017 to Armistice for the  purchase of up to 14,285,714 shares of the Company&#x2019;s common stock at an exercise price of $0.40 per share (the &#x201c;original warrants&#x201d;) for like-kind warrants to purchase up to 2,857,143 shares of the Company&#x2019;s Series B Convertible Preferred Stock with an exercise price of $2.00 per share (the &#x201c;exchanged warrants&#x201d;). Armistice immediately exercised the exchanged warrants and acquired an aggregate of 2,857,143 shares of the convertible preferred stock, which it has since converted into 14,285,715 shares of Cerecor common stock. Net proceeds of the transaction were approximately $5.7 million for the year ended December 31, 2018. In order to provide Armistice an incentive to exercise the exchanged warrants, the Company also entered into a securities purchase agreement with Armistice in December 2018 pursuant to which the Company issued warrants for 4,000,000 shares of common stock of the Company with a term of 5.5 years and an exercise price of $12.50 per share (the &#x201c;incentive warrants&#x201d;).</cerc:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock>
    <cerc:NumberOfClassOfStockAuthorized
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTQy_8454d057-9980-46e6-bffb-0563507771a2"
      unitRef="class_of_stock">2</cerc:NumberOfClassOfStockAuthorized>
    <cerc:CapitalStockSharesAuthorized
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMzA1_92c97e96-6bdc-4a3e-bb66-c79a9a172a71"
      unitRef="shares">205000000</cerc:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMzE3_118252f4-32f1-44da-96e2-9a3b8295a4c9"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMzQx_90f6f1e3-e6d3-40cc-9973-c31030aaed08"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDI3_84e12528-86d5-46de-a139-c61755b577ce"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDI3_f886796e-aade-44bf-a74b-cc99cc8628af"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODU5MA_05249c2f-9d5e-4970-adcb-43db9ba3301d"
      unitRef="shares">13971889</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2d9f33420b794d6b82ec040bbdcda9ac_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYwMg_d4d129a6-815a-4046-8f63-32b2f84f2cb9"
      unitRef="shares">1676923</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i552b4a0366c948bf8c45af4a70ecd1c5_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYxMw_fe29fd4d-0d8c-40bd-b7b6-ae750361919c"
      unitRef="usd">37700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2d38bb42b8534eff87ac8d23d0d697ea_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYyOA_e54c3c46-6340-438e-937e-5a8d8fa94687"
      unitRef="shares">2500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="ie87e47a24f4a454290d837ab00a53c08_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODY1MA_2ab5fbe9-7849-423a-bb86-4a79aa8085e6"
      unitRef="number">0.05</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i11a884079f7b4e2db9df7f885c73462d_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE0ODYzOQ_02b1b615-0f3c-49ae-8610-def6303ed70a"
      unitRef="shares">1400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i50329ad27a3d4d858d5e36be03888359_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc3MQ_4bd97359-0c93-40cf-8be6-cea9ba3f7f53"
      unitRef="shares">1676923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i3d4b3944edc64b9eab3475e9c9ce4eb4_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc5MA_3554178d-9e57-4370-806f-0d39528b8036"
      unitRef="usdPerShare">2.599</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i30ffa7aeea1749d0b4cdf2eac8066e73_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc4Mg_5fce869a-63dc-4e28-b185-0573231e23fb"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cerc:ClassOfWarrantOrRightPercentOwnershipThreshold
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1Mzc5OA_c3ceb0a4-9ab0-41ae-845b-fabc198d617d"
      unitRef="number">0.0999</cerc:ClassOfWarrantOrRightPercentOwnershipThreshold>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1MzgwNQ_4304c5cd-67c1-493e-981c-b9c87efb6512"
      unitRef="usd">4400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i83186431d6e54ca9af494baa43072af0_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTI5MA_a4ed1926-ee8b-48d0-a475-1dda982f40b5"
      unitRef="shares">15180000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i83186431d6e54ca9af494baa43072af0_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTUwOA_c420faaf-8377-4c3e-b1dc-00f53d3d4888"
      unitRef="usd">35400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i04419c05a564471cafd04ce10e0ea363_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTU2Ng_edc9bb5b-03e3-4e53-b26c-908846d07856"
      unitRef="shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id4830d434af540fab7f362a2f6851391_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTc0Mw_7f1136c3-4e4e-4676-9b2d-3b4bb36a7bbe"
      unitRef="shares">110000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i79d25c29ccea491bb940f8ab428a1a67_D20200317-20200317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMTk2Mw_0cb84194-e801-4fc3-92d6-cb5cf48f669d"
      unitRef="shares">1951219</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i79d25c29ccea491bb940f8ab428a1a67_D20200317-20200317"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjAzNw_472f007a-7070-4957-b035-855c12bd43c7"
      unitRef="usd">3900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5666247a03f94008beee4c2791508959_D20200206-20200206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjIwNQ_e007da4b-fa32-4d7b-bfd7-cdeb59f19026"
      unitRef="shares">1306282</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5666247a03f94008beee4c2791508959_D20200206-20200206"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjI3OQ_68bb03ee-d6b5-4e99-b63c-de898d6f52a0"
      unitRef="usd">5100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3b1d24a349414177befd56fcc3bbf5f0_D20200206-20200206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjMzNw_ce5fc6e6-9072-4de3-9229-3796d0c47622"
      unitRef="shares">1256282</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <cerc:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares
      contextRef="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjUzNg_3f1e12a1-8458-4e5e-86b9-a47d53a7ec29"
      unitRef="shares">3900000</cerc:AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNjg0Ng_81d4e3d6-8736-4262-bb75-5ebc3d8f5c30">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the following common stock warrants were outstanding:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;underlying&#160;warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;per&#160;share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676,923&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,679,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="idc18b2fcdebb49ae970fee17a9b37770_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0wLTEtMS0w_edc873e4-262f-4dbb-903f-7163148b319e"
      unitRef="shares">2380</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idc18b2fcdebb49ae970fee17a9b37770_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0yLTEtMS0w_73fc2706-3905-4004-a584-462ff4198925"
      unitRef="usdPerShare">8.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibb3043f210a045168b002098fa42b497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0wLTEtMS05MTkz_86292866-eb1c-4083-9eb9-b42529cd91a4"
      unitRef="shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibb3043f210a045168b002098fa42b497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0yLTEtMS05MTk1_03631345-2071-41ec-96d4-f421d475e0ae"
      unitRef="usdPerShare">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7278c7eb9d8c4d468fdc7b1b16998399_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0wLTEtMS0yOTA3_20caa62b-df13-44bd-80ca-1ac9ac675890"
      unitRef="shares">1676923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7278c7eb9d8c4d468fdc7b1b16998399_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfMy0yLTEtMS0yOTE5_388f3033-09f9-444a-bd32-be406eac8019"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ib7d433fb05b0421e829cbc118f401dfb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RhYmxlOjY0NjI5NTg5MzRhYjRiMGQ4MGNmZTdmYTZmNTk4Mjg0L3RhYmxlcmFuZ2U6NjQ2Mjk1ODkzNGFiNGIwZDgwY2ZlN2ZhNmY1OTgyODRfNS0wLTEtMS0w_2b46576a-5a05-425c-b42b-06f5d6ee423a"
      unitRef="shares">5679303</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iffb1f30979714ea79f95d4802ff984ef_I20181226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfMjc0ODc3OTA4NTYyOA_03ca97e6-7cd5-4392-b2e6-e5f3fddef22f"
      unitRef="shares">2857143</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ie34e5b7882f4464fb323bd265625bb05_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc1Ng_a9fa6f0f-00f6-4a5c-9e4a-1b7f82daa993"
      unitRef="shares">1600000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i2fdbe1b95f57454eacaf51de2d7cef4a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc2Nw_7a8f0685-baa3-47a4-86f1-399249c2cf17"
      unitRef="shares">8000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i87335e7fb2f644479af541532f926a9d_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc3OA_7dd04445-a742-4744-a04b-bd352ea7cc6e"
      unitRef="shares">1257143</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i6cd83eb2a4284855bc679909757c91ed_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk0NzgwMjM0NDc4OQ_4f1e2a10-0b83-458b-8002-8ebce6817d0d"
      unitRef="shares">6285715</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6d9884fb9a86405fb7c325756d06accd_I20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDkxNw_f50178a6-8f6c-40a4-9226-db7685f5a4b5"
      unitRef="shares">14285714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6d9884fb9a86405fb7c325756d06accd_I20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNDk4MQ_f98d93cd-09cd-4822-bff6-9801077f5373"
      unitRef="usdPerShare">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1a57959625a746b382f212a041c26d2b_I20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTA2MQ_4da9c2a5-e963-4e9c-8038-6584519bb0e8"
      unitRef="shares">2857143</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1a57959625a746b382f212a041c26d2b_I20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTE2OA_ba0eb358-c778-4134-95c0-8d3390993659"
      unitRef="usdPerShare">2.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id78630f60e5b4ecca96e7de37d2b0ede_I20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTI5NA_c596d5c4-5412-4785-b135-ccafad47ee30"
      unitRef="shares">2857143</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="ie6a48ca344334551b7645592e589572f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTQ5NzU1ODE1ODY4OA_1e78ac3d-acb4-41b4-8304-1b62f9ed3c33"
      unitRef="shares">14285715</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i1d3edf5294c94a15b1515cb8bac0fbf5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTM5Mg_caaa824e-edfa-464f-bea4-00943c9a93aa"
      unitRef="usd">5700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i0f7987a16d51476399f00aba786832f0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTY1Nw_cd42b029-320c-4928-b1bc-dc604ea25feb"
      unitRef="shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i0f7987a16d51476399f00aba786832f0_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTcxMw_0787b8e4-d8df-41d7-9eac-5d5207103f57">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0f7987a16d51476399f00aba786832f0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl81OC9mcmFnOjYzZmI5OGI0NTEwZTQ5ZjNhODMwNTBmYjRlZjZhY2E3L3RleHRyZWdpb246NjNmYjk4YjQ1MTBlNDlmM2E4MzA1MGZiNGVmNmFjYTdfNTc0MQ_796e991b-4710-4b08-9519-ddd047b385a6"
      unitRef="usdPerShare">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MTM_2d5f4a24-56e4-40e2-88c8-9d249e1b2bbf">Stock-Based Compensation &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2016, the Company&#x2019;s board of directors adopted the 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) as the successor to the 2015 Omnibus Plan (the &#x201c;2015 Plan&#x201d;). The 2016 Plan was approved by the Company&#x2019;s stockholders and became effective on May 18, 2016 (the &#x201c;2016 Plan Effective Date&#x201d;). Upon the 2016 Plan Effective Date, the 2016 Plan reserved and authorized up to 600,000 additional shares of common stock for issuance, as well as 464,476 unallocated shares remaining available for grant of new awards under the 2015 Plan. An Amended and Restated 2016 Equity Incentive Plan (the &#x201c;2016 Amended Plan&#x201d;) was approved by the Company&#x2019;s stockholders in May 2018, which increased the share reserve by an additional 1.4 million shares. A Second Amended and Restated 2016 Equity Incentive Plan (the &#x201c;2016 Second Amended Plan&#x201d;) was approved by the Company&#x2019;s stockholders in August 2019, which increased the share reserve by an additional 850,000 shares. A Third Amended and Restated Equity Incentive Plan (the &#x201c;2016 Third Amended Plan&#x201d;) was approved by the Company&#x2019;s stockholders in June 2020 which increased the share reserve by an additional 2,014,400 shares. During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year by an amount equal to 4% of the total number of outstanding shares of common &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock of the Company on the last trading day in December of the prior calendar year. As of March&#160;31, 2021, there were 2,728,771 shares available for future issuance under the 2016 Third Amended Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants expire after ten years. Employee options typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4MQ_63efab90-69fc-42af-b1b9-73b3e29c5cf7"&gt;three&lt;/span&gt; or four years. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. Options granted to directors typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg2Nw_e865b985-b902-43d4-a27a-a09d25dc86dc"&gt;one&lt;/span&gt; or three years. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company&#x2019;s stock-based awards is amortized ratably over the individuals&#x2019; service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options, restricted stock units and employee stock purchase plan shares. The amount of stock-based compensation expense recognized for the three months ended March&#160;31, 2021 and 2020 was as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock options with service-based vesting conditions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted awards that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. A summary of option activity for the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,830,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,467,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company granted its newly appointed Chief Financial Officer options with service-based vesting conditions to purchase 0.5&#160;million shares of common stock as an inducement option grant, pursuant to NASDAQ Listing Rule 5635(c)(4). In January 2021, the Company granted 2.7&#160;million options with service-based vesting conditions to its employees as part of its annual stock option award. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, our Chief Executive Officer entered into an amended employment agreement in which his salary in cash was reduced to $35,568 (the &#x201c;Reduction&#x201d;), which represents the minimum exempt annual salary. In consideration for the Reduction, on a quarterly basis, the Company grants stock options, which vest immediately, for the purchase of a number of shares of the Company&#x2019;s common stock with a total value (based on the Black-Scholes valuation methodology) based on a pro rata total annual value of the foregone salary. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. As of March&#160;31, 2021, the aggregate intrinsic value of options outstanding was $1.6 million.  The aggregate intrinsic value of options currently exercisable as of March&#160;31, 2021 was $0.7 million. There were&#160;1,137,239&#160;options that vested during the three months ended March 31, 2021 with a weighted average exercise price of&#160;$3.96 per share. The total grant date fair value of shares which vested during the three months ended March 31, 2021&#160;was&#160;$2.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense of $1.3 million related to stock options with service-based vesting conditions for the three months ended March 31, 2021. At March 31, 2021, there was $16.1 million of total unrecognized &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based compensation assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Service-based options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0% - 75.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of option (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36% - 1.12%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock options with market-based vesting conditions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s market-based option activity for the three months ended March 31, 2021 (in thousands except, for share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) The aggregate intrinsic value in the above table represents the total pre-tax amount that a participant would receive if the option had been exercised on the last day of the respective fiscal period. Options with a market value less than its exercise value are not included in the intrinsic value amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2020, the Company granted its recently appointed Chairman of the Board an option to purchase 1,000,000 shares of Company common stock with market-based vesting conditions. 500,000 of the shares vested immediately on the date of grant with an exercise price of the closing stock price on the date of grant of $2.51. 250,000 of the shares vest upon the Company&#x2019;s common stock reaching a 50% premium to the stock price on June 18, 2020 and has an exercise price of the stock at that time and 250,000 of the shares vest upon the Company&#x2019;s common stock reaching a 75% premium to the stock price on June 18, 2020 and has an exercise price of the stock at that time. Each vesting tranche represents a unique requisite service period and therefore the compensation cost for each vesting tranche is recognized on a straight-line basis over its respective vesting period. The Company recognized stock-based compensation expense of $0.1 million related to stock options with market-based vesting conditions for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, the second tranche of 250,000 shares and the third tranche of 250,000 shares both vested upon the Company&#x2019;s stock price reaching a 50% and 75% premium to the stock price on June 18, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of the restricted stock units using the stock price on the date of the grant. The restricted shares typically vest annually over a four-year period beginning on the first anniversary of the award. The following table summarizes the Company&#x2019;s restricted stock unit (&#x201c;RSU&#x201d;) activity for the three months ended March 31, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized expense of less than $6 thousand related to RSUs for the three months ended March 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2016, the Company&#x2019;s board of directors approved the 2016 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP was approved by the Company&#x2019;s stockholders and became effective on May 18, 2016 (the &#x201c;ESPP Effective Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company&#x2019;s board of directors. Under the ESPP, eligible employees may purchase stock at 85% of the lower of the fair market value of a share of the Company&#x2019;s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to 15% of their earnings during the offering period. The Company&#x2019;s board of directors may establish a maximum number of shares of the Company&#x2019;s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 of the fair market value of the Company&#x2019;s common stock for each calendar year in which such right is outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the ESPP Effective Date, the Company reserved and authorized up to 500,000 shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP shall automatically increases by a number equal to the lesser of (i) 1% of the total number of shares of the Company&#x2019;s capital stock outstanding on December 31 of the preceding calendar year, and (ii) 500,000 shares of the Company&#x2019;s common stock, or (iii) a number of shares of the Company&#x2019;s common stock as determined by the Company&#x2019;s board of directors or compensation committee. The number of shares were increased by 500,000 on January 1, 2021. As of March&#160;31, 2021, 1,925,308 shares remained available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 718-50,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Employee Share Purchase Plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the ability to purchase shares of the Company&#x2019;s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#x2019;s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $34 thousand for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease
      contextRef="icf49c9a4875b435fb1444f3db3551e0d_D20160518-20160518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDQy_e43ecbcf-8ee9-43f2-9caa-b39649a6e567"
      unitRef="shares">600000</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i95616c1bb6fd48dba5535428036866f9_I20160518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTA0_879fc212-b269-40da-bafd-003da758c5db"
      unitRef="shares">464476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease
      contextRef="i6364a4c535f944fc8d6272cec44a6605_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNzc1_b41e95ba-e7dd-4711-aa12-2fc4339746c2"
      unitRef="shares">1400000</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease
      contextRef="ib80218def2434edb83018969f2462fd9_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTg3_201a31cf-4a80-41e2-87c1-31aa63c5b73f"
      unitRef="shares">850000</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease
      contextRef="i4a4f6b0df275417caf8e9588d5879953_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTE4OQ_29a798f4-6214-4110-86e5-61cb625f3451"
      unitRef="shares">2014400</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTM3NA_4d86936d-945b-4525-ba99-8cc33c9fe4fe"
      unitRef="number">0.04</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i29e9f70e9f7b4f01be2ea582e6fc1273_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTUzNw_828941e6-e581-492e-a39c-552e5c5f88a6"
      unitRef="shares">2728771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i31f47b2beb7b41178e355e797e2f3729_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY0MA_1be079c4-a197-4121-b99f-1027519be1c6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0c13bb871c0f4896b5ef4d28dafbd2d6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4Nw_f7123f55-19d0-45ae-ba2f-b7c2382357dd">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0ee83b81d1c04985a8e197982cd1072c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg3Mw_27fef0c8-76b1-4060-96fd-d9be84745c4c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MDQ_a8283835-7fe7-460b-a152-15f19a0f1b0a">The amount of stock-based compensation expense recognized for the three months ended March&#160;31, 2021 and 2020 was as follows (in thousands):&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id696367226144fa4b944f70aa62c42fe_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMi0yLTEtMS0w_e506bc12-073b-41f0-a16a-000baf187eb6"
      unitRef="usd">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9100bedc06f0427a92077cbcaacfb3bc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMi00LTEtMS0w_aad9e85b-a349-4d6f-8f3a-0ef57e18e0fc"
      unitRef="usd">382000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i060be613e08b4af9bfd9b2dc947d28f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMy0yLTEtMS0w_2ea4cc85-4522-4f84-a92f-b0572a9e8a66"
      unitRef="usd">1045000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i44363498ae0d4459991baef00bff6710_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfMy00LTEtMS0w_a86e9ee6-06f0-488d-9b94-8db7b510517e"
      unitRef="usd">680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i754b22e1563e4e3aa874036b82bf942c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNC0yLTEtMS0w_ca918ad2-7554-4f4e-abb7-b9ad0af6dc01"
      unitRef="usd">105000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75ba6fbf1c5441209f70f012cc625abf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNC00LTEtMS0w_c0a4b042-3117-4b70-a473-b8ed7ed0c18a"
      unitRef="usd">55000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNy0yLTEtMS0w_4cad3993-0d3c-4666-93af-90c6ea53381f"
      unitRef="usd">1448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjJiYWViODQxN2I0MzRjZmFiMTcxYjYwMTE1MDJiZDM0L3RhYmxlcmFuZ2U6MmJhZWI4NDE3YjQzNGNmYWIxNzFiNjAxMTUwMmJkMzRfNy00LTEtMS0w_a34e2484-70e8-440b-9341-047798e981c5"
      unitRef="usd">1117000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MTA_2821d224-4dc3-4b1f-91fd-83c3de8fd032">A summary of option activity for the three months ended March 31, 2021 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,830,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,467,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s market-based option activity for the three months ended March 31, 2021 (in thousands except, for share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;(1) The aggregate intrinsic value in the above table represents the total pre-tax amount that a participant would receive if the option had been exercised on the last day of the respective fiscal period. Options with a market value less than its exercise value are not included in the intrinsic value amount.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i91e623503adb43afb6fb5459058e0547_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi0yLTEtMS0w_2134024c-d93f-49b2-ad7b-0e8ee39350d8"
      unitRef="shares">8830674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i91e623503adb43afb6fb5459058e0547_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi00LTEtMS0w_34414dfd-a26c-4e51-b42b-762568b2951f"
      unitRef="usdPerShare">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i91e623503adb43afb6fb5459058e0547_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi02LTEtMS0w_2d2af87f-01f4-493a-9a49-8ac46512b16c"
      unitRef="usdPerShare">2.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia1461faa4f454dce8429a63ea92a7a06_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMi04LTEtMS0w_b2f8e254-5f4b-4a36-b5c7-5961f884d2c7">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMy0yLTEtMS0w_7f76776b-5774-4410-b3ed-af32a0740fc4"
      unitRef="shares">3467817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMy00LTEtMS0w_bfbcaf72-2af8-4994-8a98-da1c89718b91"
      unitRef="usdPerShare">3.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfMy02LTEtMS0w_5753f65f-ed05-4951-b3ad-b575be64c372"
      unitRef="usdPerShare">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNC0yLTEtMS0w_f6a6f07c-1aba-4a7f-b5d3-69fe612295e4"
      unitRef="shares">128800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNC00LTEtMS0w_60be77ef-4c22-45b8-a64e-2f5c37dd9768"
      unitRef="usdPerShare">1.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cerc:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNC02LTEtMS0w_04124337-bce1-473f-9053-77beea09e571"
      unitRef="usdPerShare">1.00</cerc:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNS0yLTEtMS0w_9047555a-ed1b-4c81-906c-bc7e5cb0af81"
      unitRef="shares">224800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNS00LTEtMS0w_95533b2a-b46d-4aa4-8c01-92b847d90674"
      unitRef="usdPerShare">3.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNS02LTEtMS0w_8106944d-1190-4c6e-a59c-8c69bec85dc5"
      unitRef="usdPerShare">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy0yLTEtMS0w_fcab7797-bfcd-4c1a-a19d-2a1e34fc6ab4"
      unitRef="shares">11944891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy00LTEtMS0w_28c7b0b5-1bf8-4ace-851a-ef0f156c1204"
      unitRef="usdPerShare">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy02LTEtMS0w_44ccd370-b44e-45d7-adee-ff7f5e090c99"
      unitRef="usdPerShare">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfNy04LTEtMS0w_6df1a7b1-3988-4cf3-aa4f-ae3ad840c264">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS0yLTEtMS0w_13b9bf17-a6bd-4428-91dd-209dfdd46049"
      unitRef="shares">3914889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS00LTEtMS0w_9e9639bc-1f3e-4ae2-a67f-17aeea87eb6a"
      unitRef="usdPerShare">4.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <cerc:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS02LTEtMS0w_7794f089-5b04-4d11-b395-13e3f0d13d3b"
      unitRef="usdPerShare">2.53</cerc:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjk5MDVjNDU5MDg1ODQ1MDdiNjk0YmE3MmY1Nzk2NzJlL3RhYmxlcmFuZ2U6OTkwNWM0NTkwODU4NDUwN2I2OTRiYTcyZjU3OTY3MmVfOS04LTEtMS0w_42ad3df5-678d-4693-9109-85b934a4f941">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8030e840d448409f8fe845f94ea3abbb_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1MTE0NA_40aaba9a-45bc-406a-a638-dc099cb28809"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1MjkxMQ_fa2db1d1-dab6-429b-9691-2164e298038b"
      unitRef="usd">2700000</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross>
    <cerc:AnnualBaseSalary
      contextRef="i12e73acc1c964f5888c9864531a2b698_D20200301-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMzIxOA_ff210a92-861b-4af9-8dc9-eb96eaf37ed3"
      unitRef="usd">35568</cerc:AnnualBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDA2NA_c3bedbda-6fbc-44e0-861b-30f1701c7e6b"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDE2MQ_f9345a1a-9ba9-4141-b789-47ee22704357"
      unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDE3Ng_5ab112a2-bdfe-4414-8688-7689fd657f3f"
      unitRef="shares">1137239</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDI2MA_9910be71-c412-4feb-9482-d06052e320d3"
      unitRef="usdPerShare">3.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDM1NA_1c764cc5-cd28-4914-ae98-04174a7a9ebe"
      unitRef="usd">2800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDQxOA_42dc0b84-df34-490d-ac8f-1b0a5afd0e97"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9171628f1093474caf84d9d7559dbe75_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNDU5NQ_895b001b-14ff-4f98-a619-1e4dce81ef26"
      unitRef="usd">16100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjU5NzA2OTc3ODkzNA_fd1e5274-8d65-4866-bf00-3eda16d98ac3">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1NTM1OA_31169520-8c33-4af6-9c58-8449563295d3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the three months ended March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Service-based options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0% - 75.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of option (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36% - 1.12%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5cac8f2a539c49a89921227598dfba41_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMS0yLTEtMS04OTA5_59b9afc5-7495-4b91-97d0-dfbdf5c782c5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3af98390081b4750881153e96552c18c_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMi0yLTEtMS05NzA2L3RleHRyZWdpb246OGJiMGM1NGJmYzIwNDM1ZGFkMDU0YWMzZDU4NGJjYTZfNDk0NzgwMjMyNTAxNA_f2b7f0ee-6138-4cd8-acaf-faf687e2a97d"
      unitRef="number">0.730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1da3c9dfb0d14dec942761d660b32921_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMi0yLTEtMS05NzA2L3RleHRyZWdpb246OGJiMGM1NGJmYzIwNDM1ZGFkMDU0YWMzZDU4NGJjYTZfNDk0NzgwMjMyNTAzMA_3bf0472e-82b0-4193-9234-eb0637481db5"
      unitRef="number">0.756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i6f071b1803cb487eab728baa86ce1d1b_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMy0yLTEtMS05NzMyL3RleHRyZWdpb246MDkwOGM3MmU0ZTlmNDZiZGEzMzU2MmZhYTIwOWMwZDhfNDk0NzgwMjMyNTAwOQ_5e221f03-c15f-4efa-a221-7cf88db91b4d">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i1e2f493114e24792b6ab7231ebc4f3a2_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfMy0yLTEtMS05NzMyL3RleHRyZWdpb246MDkwOGM3MmU0ZTlmNDZiZGEzMzU2MmZhYTIwOWMwZDhfNDk0NzgwMjMyNTAxNg_b93bc29a-e23d-495f-b3ef-c08f29d161b7">P6Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3af98390081b4750881153e96552c18c_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfNC0yLTEtMS05NzQwL3RleHRyZWdpb246N2Y1OTRiODAwZTdiNDlhOWFiY2YzNjE0MGI0YWU4NjFfNDk0NzgwMjMyNTAxNA_7f11e326-2d68-468a-b1b2-de5e07a13b50"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1da3c9dfb0d14dec942761d660b32921_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjQwY2Y4NTRhNGJiMzQ2YzE4YzJmMTU3ZWFmMmQwY2I5L3RhYmxlcmFuZ2U6NDBjZjg1NGE0YmIzNDZjMThjMmYxNTdlYWYyZDBjYjlfNC0yLTEtMS05NzQwL3RleHRyZWdpb246N2Y1OTRiODAwZTdiNDlhOWFiY2YzNjE0MGI0YWU4NjFfNDk0NzgwMjMyNTAyMg_68b3747e-3f61-4651-ac5d-656ae155a0c7"
      unitRef="number">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi0yLTEtMS0w_7423361a-d974-41aa-857c-e031655357e6"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi00LTEtMS0w_77e751e5-0195-44f0-87c5-68724797c0dd"
      unitRef="usdPerShare">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i42e5c0a81c6c46b5bee3450a25f025e4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi02LTEtMS0w_b272a53a-5801-4c5c-ae83-d87cd9317c0d">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMi04LTEtMS0zMDIx_570801e7-9630-427d-b803-67a91a3bdeca"
      unitRef="usd">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMy0yLTEtMS0w_9a19cf01-3c8d-49a5-9170-a5db6c0b6eb5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfMy00LTEtMS0w_7a62ab8e-4a5d-4d77-b516-02bc84c2d0be"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNS0yLTEtMS0w_df193d93-0871-4a75-8449-7cfbc6d7a308"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNS00LTEtMS0w_e9fd5daf-6d7c-4bff-919b-8c5adeaa315a"
      unitRef="usdPerShare">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNS02LTEtMS0w_d7d21735-d4d5-4ea0-a0ed-10280f9e1a8c">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i7429f77f36e348619c1595052db52037_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNC04LTEtMS05NjAy_138b138e-c75a-4af9-94a2-212a877f9913"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNy0yLTEtMS0w_2b989a47-b440-4896-97be-d948c1b8970b"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ibc0352e97bad4fd0a1ff25ff1642f181_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOmRiYjc4ZDc4YmFmYjQ4MDM5OTEzYzkyNDU5ODdmM2IxL3RhYmxlcmFuZ2U6ZGJiNzhkNzhiYWZiNDgwMzk5MTNjOTI0NTk4N2YzYjFfNy04LTEtMS0w_c3b386a7-1556-40c6-885a-cc2fb24fe1ba"
      unitRef="usd">255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6388e36dd5e54d04841bac2d0313519d_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTgyMw_c9395b13-77f6-49e9-9e60-9af2ef3e823b"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i3a18d4e138304f578791e2ee584457c9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTg5NQ_d27f65df-e6d0-4bf4-bc66-99cead933ba2"
      unitRef="shares">500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i3a18d4e138304f578791e2ee584457c9_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjAyNg_53d019e5-bad9-41b8-92fa-1ee09dcc5dfd"
      unitRef="usdPerShare">2.51</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i25979dec2f3d4ac2862b695cf3514d3f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjAzMQ_bc968361-6132-4ba7-b9e8-7e56fb59cc8f"
      unitRef="shares">250000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage
      contextRef="i25979dec2f3d4ac2862b695cf3514d3f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjA5Ng_d0d845db-7cb7-441e-8ce8-90961cd68e99"
      unitRef="number">0.50</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="if7e8cecccd934890847824b3ae4a7ef0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjIwNQ_63a57890-c7d9-45d5-91e2-ae1f8a35501d"
      unitRef="shares">250000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage
      contextRef="if7e8cecccd934890847824b3ae4a7ef0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNjI3MA_86762340-d038-4d7a-bc2c-9649b5f79c55"
      unitRef="number">0.75</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a9e0c59c06f4f5eb6c5554b5897485b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA5OTUxMTY0MjYyMQ_72edbaf2-ab5d-462e-872e-7f88e9266c10"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i36b6d96bcc1749caadd5b13f2bf8889b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1MjkzNA_c4833fde-0772-45ec-a59a-67ab2a0ad61a"
      unitRef="shares">250000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ie6185a21763b4022bb98a98a1f7511a0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1Mjk0Mw_810b3ddf-f537-4a8c-87b5-d2387d17e7fa"
      unitRef="shares">250000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage
      contextRef="i36b6d96bcc1749caadd5b13f2bf8889b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1Mjk1Mg_10db5196-17c6-434c-b290-7ed47b67c7ac"
      unitRef="number">0.50</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage
      contextRef="ie6185a21763b4022bb98a98a1f7511a0_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNTQ5NzU1ODE1Mjk1Nw_cc9ff62c-5ab3-4b38-ace0-feb640dd70b8"
      unitRef="number">0.75</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA1OTY_d9943618-a36c-4918-b419-da77e6743e0f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA2MTI_8b0d54f2-9f31-4ae4-8b55-a02bc23c6319">The following table summarizes the Company&#x2019;s restricted stock unit (&#x201c;RSU&#x201d;) activity for the three months ended March 31, 2021: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie43534f2ad884d3c93e916333b4e6fe3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMi0yLTEtMS0w_a49f8013-0d98-4776-9735-0a99e13ea1bf"
      unitRef="shares">155833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie43534f2ad884d3c93e916333b4e6fe3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMi00LTEtMS0w_9fea017b-cf53-4190-b39a-c4a3ed5aceb5"
      unitRef="usdPerShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMy0yLTEtMS0w_0a175bbd-a7c0-49d5-bb91-786bdd241813"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfMy00LTEtMS0w_6a2067a5-7223-4021-aaf3-39d948af74c5"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4809744336f94a308a12efafbd45bd1e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfNC0yLTEtMS0w_921149a3-80c1-4646-910d-a04f295989d7"
      unitRef="shares">155833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4809744336f94a308a12efafbd45bd1e_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RhYmxlOjYxZTAwODliYzVkNjQ4YWVhMDA4NjY0MWU4OGUwNjhlL3RhYmxlcmFuZ2U6NjFlMDA4OWJjNWQ2NDhhZWEwMDg2NjQxZTg4ZTA2OGVfNC00LTEtMS0w_ab1e7afe-f1f8-42d6-b234-f532c09c2308"
      unitRef="usdPerShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i088e1fb0e42744319b8607076b983489_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfNzkyNg_af901bd8-e058-46af-b834-10c99cc0980a"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i4e67ffefb48e414f85fa6311d88d3fde_D20160405-20160405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfODU1OQ_5c11792b-5226-40b8-82dd-26b11b2a05e0"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i0bfcb4e632484858beac101b5287566c_I20160405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfODc1NQ_013018a9-9b47-42a4-b38b-e77be219b1c4"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <cerc:ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum
      contextRef="i4e67ffefb48e414f85fa6311d88d3fde_D20160405-20160405"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTEwMw_8c4126ef-5838-4972-b8c0-e50d8fbc81cf"
      unitRef="usd">25000</cerc:ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0bfcb4e632484858beac101b5287566c_I20160405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTI5Mw_a6a93db9-b481-43c1-b667-f2b380441062"
      unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear
      contextRef="i0bfcb4e632484858beac101b5287566c_I20160405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTUxOA_df98f98e-72ea-4f16-bbbb-b3c3766b7cbd"
      unitRef="number">0.01</cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0bfcb4e632484858beac101b5287566c_I20160405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTY1MA_81810605-fdea-4439-b8f2-91f8f33dd4c3"
      unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="i830174ed95fc44a1bd5ebc384320dfc9_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTg2Ng_d68909d5-ffc2-4110-8304-31a7b9d3b782"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4e1a839c0c2f4008a983a171019b82d6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfOTkwMA_d0303835-f0a7-4b90-bb14-43aa6037e1f6"
      unitRef="shares">1925308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icbc7327a9c14482fb8f5db8aaf0f48d9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTA1MTM_3f78cd55-d8c9-4adc-98af-cbe32b41fd9d"
      unitRef="usd">34000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82Ny9mcmFnOmIwZWQ5ZjZiZWQ1NTQ0NWU4M2M1ZmM2ZDEyMTk5ODlmL3RleHRyZWdpb246YjBlZDlmNmJlZDU1NDQ1ZTgzYzVmYzZkMTIxOTk4OWZfMTA1NQ_54b1566d-7e2b-46e3-8edb-904783f8fc23">Income Taxes The Company recognized minimal income tax expense for the three months ended March 31, 2021 and an income tax benefit of $2.2&#160;million for the three months ended March 31, 2020. The tax benefit recognized for the three months ended March 31, 2020 was a result of a tax law change signed into law as part of the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;), which allowed the Company to carry back certain losses for taxes paid in fiscal year 2017. Due to the full valuation allowance against the Company&#x2019;s deferred tax assets and the current year losses, minimal tax expense was recognized for the three months ended March 31, 2021.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82Ny9mcmFnOmIwZWQ5ZjZiZWQ1NTQ0NWU4M2M1ZmM2ZDEyMTk5ODlmL3RleHRyZWdpb246YjBlZDlmNmJlZDU1NDQ1ZTgzYzVmYzZkMTIxOTk4OWZfNTQ5NzU1ODE0MzEyNw_77a033d9-050c-4826-a05c-12f0b2c47165"
      unitRef="usd">-2200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE5NA_5088731d-782c-47d7-a4c3-b1f9796a8f84">Leases &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently occupies two leased properties, both of which serve as administrative office space. The Company determined that both leases are operating leases based on the lease classification test performed at lease commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual base rent for the Company&#x2019;s office located in Rockville, Maryland is $161,671, subject to annual 2.5% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of 12 months following the Company&#x2019;s date of occupancy. The lease has an initial term of 10 years from the date the Company makes its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease two&#160;times, each for a period of five years, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. As of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lease commencement date, it was not reasonably certain that the Company will exercise the renewal periods or early terminate the lease and therefore the end date of the lease for accounting purposes is January 31, 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a sublease for additional administrative office space in Chesterbrook, Pennsylvania in May 2020 (the &#x201c;Chesterbrook Lease&#x201d;). The annual base rent under the Chesterbrook Lease is $280,185. The lease expires in November 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining term of the operating leases at March 31, 2021 was 7.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the leased property is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease right-of-use (&#x201c;ROU&#x201d;) assets are included in property and equipment and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our condensed consolidated balance sheets. The Company utilized a weighted average discount rate of 7.4% to determine the present value of the lease payments.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three  months ended March 31, 2021 and 2020 were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Includes short-term leases, which are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a maturity analysis of the operating lease liabilities as of March 31, 2021 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 1, 2021 through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less implied interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cerc:LesseeOperatingLeaseNumberOfContracts
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNDk_96db3681-62d5-41fa-bb78-a2297e59028e"
      unitRef="contract">2</cerc:LesseeOperatingLeaseNumberOfContracts>
    <cerc:LesseeOperatingLeaseLiabilityAnnualBaseRent
      contextRef="i09cca0b1b8484ffda61d0f7e6de54442_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMzM4_495b6bc9-bdba-47e5-833f-e7080cb272e2"
      unitRef="usd">161671</cerc:LesseeOperatingLeaseLiabilityAnnualBaseRent>
    <cerc:OperatingLeasesRentExpenseAnnualIncreasePercent
      contextRef="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMzYw_2f1681a3-51ba-4f70-9812-5cd5438d15bb"
      unitRef="number">0.025</cerc:OperatingLeasesRentExpenseAnnualIncreasePercent>
    <cerc:LesseeOperatingLeaseRentAbatementPeriod
      contextRef="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNDY5_b83d8e91-6918-4926-a197-a49491159ad3">P12M</cerc:LesseeOperatingLeaseRentAbatementPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i09cca0b1b8484ffda61d0f7e6de54442_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNTQ5_09e0a73b-22e7-49b1-b548-a443241248d8">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cerc:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i71579a40f3f648f2884a610845bdfd3a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNzAw_5acaaf72-9643-42a0-b38d-845378c06c35"
      unitRef="renewal_option">2</cerc:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i09cca0b1b8484ffda61d0f7e6de54442_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfNzMx_35da7232-781d-4a60-9804-a367d4fd5515">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cerc:LesseeOperatingLeaseLiabilityAnnualBaseRent
      contextRef="i5c920d35386546eb9e87448a6e1d8613_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMTMwNQ_0ddcea26-f219-4c08-a4d2-a185a5cd6b98"
      unitRef="usd">280185</cerc:LesseeOperatingLeaseLiabilityAnnualBaseRent>
    <cerc:LesseeOperatingLeaseRemainingLeaseTeam
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMTQzMw_0b26cfa4-714b-4f54-8b9e-e57fca447d10">P7Y8M12D</cerc:LesseeOperatingLeaseRemainingLeaseTeam>
    <cerc:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE5MA_512656cd-abe5-4699-b487-b8c667bfd169">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the leased property is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cerc:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfMi0yLTEtMS0w_bc4db5c8-4f00-4542-b742-99daaf9813e9"
      unitRef="usd">846000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfMi00LTEtMS0w_4dd91736-91d0-458a-af96-1223e2a480bf"
      unitRef="usd">917000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0yLTEtMS0w_95666a30-b990-4b20-89a6-ad89201e3b5b"
      unitRef="usd">357000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC00LTEtMS0w_038991fd-484c-434a-abdd-c5dd15eecab6"
      unitRef="usd">426000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0yLTEtMS0w_2dfe9606-f320-45c9-8efc-70986b792bbb"
      unitRef="usd">1018000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS00LTEtMS0w_ab0f13d3-4d4e-4e1a-b873-c6f920e6b9d5"
      unitRef="usd">1038000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNi0yLTEtMS0w_63b51834-389b-4734-b83f-b1072381270f"
      unitRef="usd">1375000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5e9d7284c81d439f86d5e0c7bbbc8cdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNi00LTEtMS0w_7544f934-fba7-42ed-94e4-8a480b79f8d3"
      unitRef="usd">1464000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMTg0OQ_1462c418-3539-4507-8443-6e0440b039c9"
      unitRef="number">0.074</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE5Mg_fcc329ad-0722-4322-a6d2-8cb5b0bcf13b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the three  months ended March 31, 2021 and 2020 were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;*Includes short-term leases, which are immaterial.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjllMzUxOGUwODRkMjRlZThiMTQ4MTQ3YzY2ZDRkZWViL3RhYmxlcmFuZ2U6OWUzNTE4ZTA4NGQyNGVlOGIxNDgxNDdjNjZkNGRlZWJfMi0yLTEtMS0w_b7a454d3-9f2d-467f-bf93-54ebee3889b3"
      unitRef="usd">95000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i89b6277e47054b73b39ed0e390870309_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjllMzUxOGUwODRkMjRlZThiMTQ4MTQ3YzY2ZDRkZWViL3RhYmxlcmFuZ2U6OWUzNTE4ZTA4NGQyNGVlOGIxNDgxNDdjNjZkNGRlZWJfMi00LTEtMS0w_910fa71d-5881-4bcc-85ce-8ccbb4989739"
      unitRef="usd">55000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RleHRyZWdpb246ZWI1MjkxOWI0ODA1NGQ4MmFjMzFlZjYxMDM1MDU0NTBfMjE4Nw_841cc030-429e-4611-a8e8-daa06cd9f560">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a maturity analysis of the operating lease liabilities as of March 31, 2021 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 1, 2021 through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less implied interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMi0yLTEtMS0w_17044292-3211-4cd6-91ae-8c0108c86385"
      unitRef="usd">314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMy0yLTEtMS0w_36be97b7-0877-462e-ac8f-deb610985a02"
      unitRef="usd">174000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNC0yLTEtMS0w_21b82e0a-2522-43d4-b20c-17a480a232e9"
      unitRef="usd">178000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNS0yLTEtMS0w_966bc1da-4689-4337-aeaf-11d7d7311f42"
      unitRef="usd">183000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNi0yLTEtMS0w_24405fc9-468b-47e2-9d1c-35cec6d0f383"
      unitRef="usd">187000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfNy0yLTEtMS0w_6d879e98-0d21-4d39-8e2f-8a4c03134868"
      unitRef="usd">192000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfOC0yLTEtMS0w_2200361c-f11d-4d86-8cc9-f28dc5819a89"
      unitRef="usd">621000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfOS0yLTEtMS0w_0f0ac636-2d96-4453-b16e-4338b1e60a56"
      unitRef="usd">1849000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMTAtMi0xLTEtMA_e53afad5-9f94-463e-84d1-864be2a92244"
      unitRef="usd">474000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="idedefda4bb914378b63f3c9b8b6ee172_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOmFhM2Q0YjZiMTBmMTRlNWRiNzY1Y2U1ZDU1Y2ViOWQxL3RhYmxlcmFuZ2U6YWEzZDRiNmIxMGYxNGU1ZGI3NjVjZTVkNTVjZWI5ZDFfMTEtMi0xLTEtMA_7834044a-f76c-4760-948b-ad6d155c7945"
      unitRef="usd">1375000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTkyMA_4ec079df-2ae4-49d2-8d56-e64e9bbe3b49">Commitments and Contingencies &lt;div style="text-indent:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation - General&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Karbinal Royalty Make-Whole Provision &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, in connection with the acquisition of Avadel&#x2019;s pediatric products, the Company entered into a supply and distribution agreement (the &#x201c;Karbinal Agreement&#x201d;) with TRIS Pharma Inc. (&#x201c;TRIS&#x201d;). As part of the Karbinal Agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of&#160;70,000&#160;units through 2033. The Company was required to pay TRIS a royalty make whole payment (&#x201c;Make-Whole Payments&#x201d;) of&#160;$30&#160;for each unit under the&#160;70,000&#160;units annual minimum sales commitment through 2033.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a part of the Aytu Divestiture, which closed on November 1, 2019, the Company assigned all payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the &#x201c;TRIS Obligations&#x201d;) to Aytu.&#160; However, under the original license agreement, the Company could ultimately be liable for the TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Millipred License and Supply Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License and Supply Agreement for Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with Watson Laboratories, Inc., which is now part of Teva. Pursuant to the License and Supply Agreement, the Company is required to make license payments of $75,000 in February and August of each year through April 2021 and purchases inventory on an ad-hoc basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a prior amendment to extend the contract to its current term, Cerecor agreed to pay Teva fifty percent of the net profit of the Millipred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product following each calendar quarter, subject to a $0.5&#160;million quarterly minimum payment, which was set to begin on April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#x2019;s board of directors and also serves as the Chairman of Teva&#x2019;s board of directors.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Possible Future Milestone Proceeds for Out-Licensed Compounds&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CERC-611 License Assignment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company entered into an assignment of license agreement (the &#x201c;Assignment Agreement&#x201d;) with ES Therapeutics, LLC (&#x201c;ES Therapeutics&#x201d;), a wholly-owned subsidiary of Armistice, which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board. Pursuant to the Assignment Agreement, the Company assigned and transferred its rights, title, interest, and obligations with respect to CERC-611 to ES Therapeutics. The Company initially licensed the compound from Eli Lilly Company (&#x201c;Lilly&#x201d;) in September 2016. Under the Assignment Agreement, Armistice paid the Company an upfront payment of $0.1 million.  The Company recognized the payment as license and other revenue in 2019. The Assignment Agreement also provides for: (a) a $7.5 million milestone payment to the Company upon cumulative net sales of licensed products reaching $750.0 million; and (b) a $12.5 million milestone payment to the Company upon cumulative net sales of licensed products reaching $1.3 billion. The Assignment Agreement also releases the Company of obligations related to CERC-611, including the $1.3 million contingent payment to Lilly upon the first subject dosage of CERC-611 in a multiple ascending dose study and from additional potential future payments due to Lilly upon achievement of certain development and commercialization milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CERC-501 Sale to Janssen&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company sold its worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;) in exchange for initial gross proceeds of $25.0 million. There is a potential future $20.0 million regulatory milestone payment to the Company upon acceptance of an NDA for any indication. The terms of the agreement provide that Janssen will assume ongoing clinical trials and be responsible for any new development and commercialization of CERC-501. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Possible Future Milestone Payments for In-Licensed Compounds &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to license and development agreements with various third parties, which contain future milestone payments and other future payment obligations (discussed further below). The Company recognizes a liability (and related expense) for each milestone if and when such milestone is probable and can be reasonably estimated. As typical in the biotechnology industry, each milestone has its own unique risks that the Company evaluates when determining the probability of achieving each milestone and the probability of success evolves over time as the programs progress and additional information is obtained. The Company considers numerous factors when evaluating whether a given milestone is probable including (but not limited to) the regulatory pathway, development plan, ability to dedicate sufficient funding to reach a given milestone and the probability of success. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CERC-002 KKC License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. (&#x201c;KKC&#x201d;) for exclusive worldwide rights to develop, manufacture and commercialize CERC-002, KKC&#x2019;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the &#x201c;KKC License Agreement&#x201d;). The KKC License Agreement replaces the Amended and Restated Clinical Development and Option Agreement between the Company and KKC dated May 28, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the KKC License Agreement, the Company paid KKC an upfront license fee equal to $10.0&#160;million. The Company will also pay KKC milestone payments based on achievement of certain success-based regulatory milestones that equal, for each of three separate indications of CERC-002, mid-teen millions of dollars or less depending on the territory to which the regulatory milestone achievement relates. In addition, the Company will pay KKC (a) royalties during a country-by-country royalty term agreement equal to mid-teens percentage of the net sales of CERC-002 by the Company, (b) sales milestone payments aggregating up to $75&#160;million tied to achievement of annual net sales targets, and (c) a double digit percentage (less than 30%) of the payments that the Company receives from sublicensing of its rights under the KKC License Agreement, subject to certain exclusions. Subject to the option described below that allows, upon exercise, KKC to develop, manufacture and commercialize CERC-002 in Japan, the Company will be responsible for the development and commercialization of CERC-002 in all indications worldwide. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted KKC an option to exclude Japan from the scope of the worldwide rights granted to the Company such that, upon exercise of the option, KKC can develop, manufacture and commercialize CERC-002 in Japan. Upon exercise of the Option, KKC will be required to (a) reimburse the Company for a pre-agreed percentage of certain of its costs incurred to develop CERC-002 as a condition to KKC accessing the Company&#x2019;s data that would be required to be included in an application for marketing authorization, (b) pay the Company for its services (such as transfer of data and regulatory support), (c) pay for all further development of CERC-002 in Japan and (d) pay any royalty due to the Company&#x2019;s licensors on sales of CERC-002 in Japan. KKC will also have the right to purchase CERC-002 from the Company for use in Japan. No other amounts would be payable by KKC to the Company such as license fees, royalties and milestone payments. The option will expire if KKC does not exercise it within a set number of days after the FDA accepts for filing a Biologics License Application for a pre-defined indication of CERC-002. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the upfront license fee of $10.0&#160;million within research and development expenses for the three months ended March 31, 2021 and made the payment in April 2021. The Company has not recognized any liabilities related to the milestones outlined in the KKC License Agreement as of March 31, 2021. The Company will continue to monitor the milestones at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CERC-006 Astellas License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly owned subsidiary of Astellas Pharma, Inc. (&#x201c;Astellas&#x201d;), for the worldwide development and commercialization of the novel, second generation mTORC1/2 inhibitor (which we refer to as CERC-006). Under the terms of the license agreement, the Company paid Astellas an upfront license fee of $0.5&#160;million and Astellas will be eligible to receive milestone payments of up to $5.5&#160;million based upon the achievement of specified development and regulatory milestones. Upon commercialization, Astellas will be entitled to a tiered, single-digit royalty on worldwide annual net sales. Cerecor is fully responsible for the development and commercialization of the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, the Company accrued a $0.5&#160;million milestone payment due to Astellas upon confirmation from the FDA that an initial signal finding study may proceed in the United States given the Company concluded it was probable the Company will begin such study in 2021.  The Company will continue to monitor the remaining milestones at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CERC-007 AstraZeneca License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an exclusive global license to develop and commercialize a Phase 2-ready fully human, anti-IL-18 monoclonal antibody (which we refer to as CERC-007) from Medimmune Limited, a subsidiary of AstraZeneca plc (&#x201c;AstraZeneca&#x201d;). Up to $162&#160;million may be due to AstraZeneca upon achievement of certain development and sales-related milestones, in addition to a tiered low double-digit royalty on global annual product sales. Cerecor is fully responsible for the development and commercialization of the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2020, Cerecor recognized a $1.5&#160;million milestone payment to AstraZeneca within research and development expenses, which was due upon initiation of the first proof-of-concept study which uses CERC-007. The Company made such payment in the first quarter of 2021. The Company will continue to monitor the remaining milestones at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Related Party and Acquisition Related Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CERC-006 Royalty Agreement with Certain Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to Cerecor entering into the Aevi Merger, in July 2019, Aevi entered into a royalty agreement with Mike Cola, Cerecor&#x2019;s current Chief Executive Officer, Joseph J. Grano, Jr., Kathleen Jane Grano, Joseph C. Grano, The Grano Children&#x2019;s Trust, Joseph C. Grano, trustee and LeoGroup Private Investment Access, LLC on behalf of Garry A. Neil, Cerecor&#x2019;s current Chief Scientific Officer (collectively, the &#x201c;Investors&#x201d;) in exchange for a one-time aggregate payment of $2.0 million (the &#x201c;Royalty Agreement&#x201d;). Collectively, the Investors will be entitled to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of Astellas&#x2019; second generation mTORC1/2 inhibitor, CERC-006. At any time beginning three years after the date of the first public launch of CERC-006, Cerecor may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments.&#160;A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cerecor assumed this Royalty Agreement upon closing of the Aevi Merger and it is recorded as a royalty obligation within the Company&#x2019;s accompanying condensed consolidated balance sheet as of March 31, 2020.  Because there is a significant related party relationship between the Company and the Investors, the Company treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which would result in a corresponding increase in the liability balance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Aevi Merger Possible Future Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the consideration for the Aevi Merger includes two future contingent development milestones worth up to an additional $6.5 million. The first milestone is the enrollment of a patient in a Phase 2 study related to CERC-002 for use in pediatric onset Crohn&#x2019;s disease, CERC-006 (any indication) or CERC-007 (any indication) prior to February 3, 2022. If this milestone is met, the Company is required to make a milestone payment of $2.0 million. The second milestone is the receipt of a NDA approval for either CERC-006 or CERC-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $4.5 million. All milestones are payable in either shares of the Company&#x2019;s common stock or cash, at the election of the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated.  As of the consummation of the Merger on February 3, 2020 and as of March 31, 2021, no contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ichorion Asset Acquisition Possible Future Milestone Payments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company acquired Ichorion Therapeutics, Inc. including acquiring three compounds for inherited metabolic disorders known as CDGs (CERC-801, CERC-802 and CERC-803) and one other preclinical compound. Consideration for the transaction included shares of Cerecor common stock and three future contingent development milestones for the acquired compounds worth up to an additional&#160;$15.0 million. The first milestone is the first product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $6.0&#160;million. The second milestone is the second product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $5.0&#160;million. The third milestone is a protide molecule being approved by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $4.0&#160;million. All milestones are payable in either shares of the Company&#x2019;s common stock or cash, at the election of the Company. &lt;/span&gt;&lt;/div&gt;The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated. As of March 31, 2021, no contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired
      contextRef="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTg3Nw_94fc9c39-ac07-4e61-8c5c-f941bc7f63fb"
      unitRef="unit">70000</us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired>
    <cerc:LicenseAgreementMakeWholePaymentPerUnit
      contextRef="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTk5Mw_c9e81c9d-f814-47a0-bf88-5cb7ca173470"
      unitRef="usdPerShare">30</cerc:LicenseAgreementMakeWholePaymentPerUnit>
    <us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired
      contextRef="i12f4c3bd01e848c199aa81e15a7ed990_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMjAyMA_797474cb-a0d6-4fe4-b6c0-389a38dd6a6f"
      unitRef="unit">70000</us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired>
    <cerc:LicenseAgreementSemiAnnualLicensePayment
      contextRef="ic7d61bbf3f01410cbe5cb14793b039dc_D20200101-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjU5NzA2OTc3OTcxOQ_673e6288-e0e7-42f2-a852-29305dee3c6a"
      unitRef="usd">75000</cerc:LicenseAgreementSemiAnnualLicensePayment>
    <cerc:LicenseAgreementPercentOfNetProfitForInstallmentPayment
      contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTA5OTUxMTY2MDg3Nw_09761cb4-adbd-49b0-9cac-7e20b609d5f0"
      unitRef="number">0.50</cerc:LicenseAgreementPercentOfNetProfitForInstallmentPayment>
    <cerc:LicenseAgreementInstallmentPayment
      contextRef="ie67565b970d24f429f156729cd22f735_D20210401-20210401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTA5OTUxMTY2MDk3OA_5ab2dd0b-c712-4e83-959e-d328c3b4963c"
      unitRef="usd">500000</cerc:LicenseAgreementInstallmentPayment>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i4a82b49fc85849e9b165488476f66b9c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzI3MQ_45dd81e5-ce20-43c8-94af-949336976532"
      unitRef="usd">100000</us-gaap:RevenueFromRelatedParties>
    <cerc:LicenseAgreementPotentialMilestonePaymentNumberOne
      contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzQzNw_ff882fa8-ee63-4fb5-83fb-c561516f4ad0"
      unitRef="usd">7500000</cerc:LicenseAgreementPotentialMilestonePaymentNumberOne>
    <cerc:LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne
      contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzUyOQ_fb3ddd45-96a2-422e-b2ff-6e92285f0d39"
      unitRef="usd">750000000.0</cerc:LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne>
    <cerc:LicenseAgreementPotentialMilestonePaymentNumberTwo
      contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzU0Mw_d650a8f8-48d4-438b-8914-324d9bf42cf8"
      unitRef="usd">12500000</cerc:LicenseAgreementPotentialMilestonePaymentNumberTwo>
    <cerc:LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo
      contextRef="i8cdc22b182b946dd9a44780f5421d750_D20190801-20190831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzYzNQ_9093c134-b966-444c-acd9-718cf6e02c67"
      unitRef="usd">1300000000</cerc:LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo>
    <cerc:LicenseObligationNoncurrent
      contextRef="i3b0da54fc099444480f1290196a28e52_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMzczNg_1d02602f-9e94-448c-8f49-22c947e4a1e1"
      unitRef="usd">1300000</cerc:LicenseObligationNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa172516dbef43d4a1c0924d5edda6d8_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDMzMQ_639d8a1d-5895-4a97-b076-3c561203299b"
      unitRef="usd">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cerc:PotentialFutureRegulatoryMilestone
      contextRef="i66d40f7899394f23b9dadb48b6bcfb61_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDM2NA_826d7365-856d-4b24-bf91-b5b4976688ec"
      unitRef="usd">20000000.0</cerc:PotentialFutureRegulatoryMilestone>
    <cerc:LicenseAgreementUpfrontFee
      contextRef="i1fe9f3116d8e45d4a2a1a175df1addb6_D20210325-20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3Mjg5Nw_0f093e3a-764c-4363-a1d2-c7d224eddc75"
      unitRef="usd">10000000.0</cerc:LicenseAgreementUpfrontFee>
    <cerc:LicenseAgreementPotentialMilestonePaymentNumberOne
      contextRef="i1fe9f3116d8e45d4a2a1a175df1addb6_D20210325-20210325"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTQ5NzU1ODE2OTczNA_998c2649-dba9-4858-94fb-3bbb326459ad"
      unitRef="usd">75000000</cerc:LicenseAgreementPotentialMilestonePaymentNumberOne>
    <cerc:LicenseAgreementPercentOfPaymentsReceivedFromSublicensing
      contextRef="if09f167c7bc048a9bc324012285069cf_I20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDk0NzgwMjM1NzQ4NA_42441b10-478a-4fc1-8583-7d8182cdfa3e"
      unitRef="number">0.30</cerc:LicenseAgreementPercentOfPaymentsReceivedFromSublicensing>
    <cerc:LicenseAgreementUpfrontFee
      contextRef="ia883540f2ef34a27a1304fff4fc68648_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTQ5NzU1ODE2NjI5Mg_e596512d-d849-4e6e-8cf9-955d664ef501"
      unitRef="usd">10000000.0</cerc:LicenseAgreementUpfrontFee>
    <cerc:LicenseAgreementUpfrontFee
      contextRef="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3MjkyMw_efdc6f5f-5742-4d91-b22f-799fd4b818f9"
      unitRef="usd">500000</cerc:LicenseAgreementUpfrontFee>
    <cerc:LicenseAgreementPotentialMilestonePaymentNumberOne
      contextRef="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3MjkzNw_8e8a1a69-8a4a-418f-8eeb-a362182e8887"
      unitRef="usd">5500000</cerc:LicenseAgreementPotentialMilestonePaymentNumberOne>
    <cerc:LicenseAgreementMilestonePaymentRecognized
      contextRef="i4a955cc8d4f94528b4f0de7eefdf2c6b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTA5OTUxMTY1MzkwOA_af2f6997-8ab7-4be1-b21c-29ece9412c9a"
      unitRef="usd">500000</cerc:LicenseAgreementMilestonePaymentRecognized>
    <cerc:LicenseAgreementPotentialMilestonePaymentNumberOne
      contextRef="ic7017084953a4b4da0c861f92df38447_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA0NzMxMzk3Mjk2NQ_87416eac-6f2d-4bb4-ae85-d32e78129133"
      unitRef="usd">162000000</cerc:LicenseAgreementPotentialMilestonePaymentNumberOne>
    <cerc:LicenseAgreementMilestonePaymentRecognized
      contextRef="ic249f77612fd40feb83d3691de9d3623_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTQ5NzU1ODE3MTM1OA_18a74a7f-2fd5-4245-9dd7-e2a83d7ecb5e"
      unitRef="usd">1500000</cerc:LicenseAgreementMilestonePaymentRecognized>
    <cerc:RoyaltyAgreementPaymentReceived
      contextRef="i2a16536d275e465da455b4c203c89422_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTU0OA_630601d0-19fc-438a-a955-0d80a0526b8a"
      unitRef="usd">2000000.0</cerc:RoyaltyAgreementPaymentReceived>
    <cerc:RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement
      contextRef="i2a16536d275e465da455b4c203c89422_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNTgwOA_4ab143fb-faa0-4e19-825d-8fa864edb003">P3Y</cerc:RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement>
    <cerc:RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments
      contextRef="i2a16536d275e465da455b4c203c89422_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNjA1NA_fe461645-ae35-47da-98fb-0f87f0f08d1c"
      unitRef="number">0.75</cerc:RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments>
    <cerc:AssetAcquisitionContingentValueRightNumberOfMilestones
      contextRef="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDk0NzgwMjM1NzU0MQ_4ee375fd-0907-40a0-8185-67950c4d4dc1"
      unitRef="milestone">2</cerc:AssetAcquisitionContingentValueRightNumberOfMilestones>
    <cerc:AssetAcquisitionContingentValueRightRightToReceiveContingentPayments
      contextRef="i556181792d4d4140b8cf8b6d6c6be371_D20200203-20200203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNzMzMg_28c07a6c-535a-4460-80ef-25c7921a19c9"
      unitRef="usd">6500000</cerc:AssetAcquisitionContingentValueRightRightToReceiveContingentPayments>
    <cerc:AssetAcquisitionContingentConsiderationLiability
      contextRef="ic77ef76142994d109c2c47014a1f6c8d_I20200203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNzYwMg_8d69cf6f-0f35-4f6f-9f50-968237fb8acd"
      unitRef="usd">2000000.0</cerc:AssetAcquisitionContingentConsiderationLiability>
    <cerc:AssetAcquisitionContingentConsiderationLiability
      contextRef="i14700ec8a6124480982805c40bb35d5b_I20200203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNzgyMQ_22d698f2-560f-404f-bead-f3f3eba7a256"
      unitRef="usd">4500000</cerc:AssetAcquisitionContingentConsiderationLiability>
    <cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities
      contextRef="i196aed014b0d4c248e5addc0ece06d67_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfMTQ4NDM0MDcwMDc0ODU_a243afed-a676-4301-9822-9cb79b2f6ba3"
      unitRef="usd">0</cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <cerc:NumberOfPreclinicalTherapies
      contextRef="i5971bb063e474274b182039d0516e79b_D20180901-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfODUyMg_24577fad-41c9-400f-9fdc-3b1170cad4ed"
      unitRef="therapy">3</cerc:NumberOfPreclinicalTherapies>
    <cerc:NumberOfPreclinicalTherapies
      contextRef="i6b3a6dd6de704eda88270dee17a54df9_D20180901-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfODYyMQ_91694c10-8ac9-4cbb-8122-425c36f48910"
      unitRef="therapy">1</cerc:NumberOfPreclinicalTherapies>
    <cerc:AssetAcquisitionContingentValueRightNumberOfMilestones
      contextRef="i88d92807dcac45b09cb550ee806b75f2_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfNDk0NzgwMjM1OTgwMA_339c45c2-fc89-4988-adf0-d6def3249a36"
      unitRef="milestone">3</cerc:AssetAcquisitionContingentValueRightNumberOfMilestones>
    <cerc:AssetAcquisitionContingentConsiderationLiability
      contextRef="i7386371b6dd84a49af329b3ccfa42f9a_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfODgzMQ_d35d4a9b-dfe5-46e9-aebc-68d525ae62ed"
      unitRef="usd">15000000.0</cerc:AssetAcquisitionContingentConsiderationLiability>
    <cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities
      contextRef="if8b8acd95e6a4be8b07437719d50a52d_D20180901-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTA0MQ_dd0f9866-4ab8-4c60-9bca-42149ec8bbb8"
      unitRef="usd">6000000.0</cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities
      contextRef="i12f98b2dbe45438893e30257af07b4bc_D20180901-20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTI0NQ_b3224efa-c3bb-49d8-9153-06663075a475"
      unitRef="usd">5000000.0</cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities
      contextRef="iab022d6245a44ee3a9b76763b77c8a31_D20180901-20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTQzNA_b2de801b-1ca4-47c2-aa07-127047aba6dd"
      unitRef="usd">4000000.0</cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
    <cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities
      contextRef="ib7287b6670b3448ea1ab4049c76715ed_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83My9mcmFnOmMzZjdhYzA3MGY3NzRmODZhMjIxMGNhMWE5M2JmZTFkL3RleHRyZWdpb246YzNmN2FjMDcwZjc3NGY4NmEyMjEwY2ExYTkzYmZlMWRfOTc0Mw_02a32b36-2b98-447c-8586-b490fce94d92"
      unitRef="usd">0</cerc:PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136865288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CERECOR INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0705648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">540 Gaither Road, Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">522-8707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CERC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,471,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828215658712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 38,292<span></span>
</td>
<td class="nump">$ 18,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">3,130<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,465<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, current portion</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,096<span></span>
</td>
<td class="nump">26,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,161<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,409<span></span>
</td>
<td class="nump">14,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,345<span></span>
</td>
<td class="nump">43,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,913<span></span>
</td>
<td class="nump">2,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">14,238<span></span>
</td>
<td class="nump">11,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,360<span></span>
</td>
<td class="nump">15,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty obligation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability, net</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,190<span></span>
</td>
<td class="nump">19,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;$0.001 par value; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020; 89,104,816 and 75,004,127 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;$0.001 par value; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; 1,257,143 shares issued and outstanding at March 31, 2021 and December 31, 2020</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">241,535<span></span>
</td>
<td class="nump">202,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(208,470)<span></span>
</td>
<td class="num">(177,790)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">33,155<span></span>
</td>
<td class="nump">24,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 63,345<span></span>
</td>
<td class="nump">$ 43,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment And Operating Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828215208888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">89,104,816<span></span>
</td>
<td class="nump">75,004,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">89,104,816<span></span>
</td>
<td class="nump">75,004,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,257,143<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,257,143<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137977608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 2,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">25,206<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,911<span></span>
</td>
<td class="nump">2,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">31,053<span></span>
</td>
<td class="nump">34,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income (loss)</a></td>
<td class="num">(30,580)<span></span>
</td>
<td class="num">(31,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of Investment in Aytu</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net from continuing operations</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">7,101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before taxes</a></td>
<td class="num">(30,563)<span></span>
</td>
<td class="num">(24,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(2,157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(30,574)<span></span>
</td>
<td class="num">(22,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">(Loss) income from discontinued operations, net of tax</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,680)<span></span>
</td>
<td class="num">(21,117)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 2,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income per share of common stock, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="num">(0.32)<span></span>
</td>
<td class="num">(0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="nump">(0.00)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="nump">(0.00)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share of common stock, basic (in dollars per share)</a></td>
<td class="num">(0.32)<span></span>
</td>
<td class="num">(0.34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">(0.32)<span></span>
</td>
<td class="num">(0.34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income per share of common stock, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="num">(1.61)<span></span>
</td>
<td class="num">(1.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="num">(1.61)<span></span>
</td>
<td class="num">(1.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share of common stock, basic (in dollars per share)</a></td>
<td class="num">(1.62)<span></span>
</td>
<td class="num">(1.70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137871512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;stock</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,384,222<span></span>
</td>
<td class="nump">2,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 20,995<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 135,239<span></span>
</td>
<td class="num">$ (114,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares related to Aevi Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,893,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of shares related to Aevi Merger</a></td>
<td class="nump">15,496<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering', window );">Issuance of shares pursuant to registered direct offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering', window );">Issuance of shares pursuant to registered direct offering, net of offering costs</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement', window );">Issuance of shares pursuant to common stock private placement, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement', window );">Issuance of shares pursuant to common stock private placement, net of offering costs</a></td>
<td class="nump">3,888<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,117)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,560,252<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2020</a></td>
<td class="nump">25,588<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">160,936<span></span>
</td>
<td class="num">(135,408)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,004,127<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">24,562<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">202,276<span></span>
</td>
<td class="num">(177,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock in underwritten public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,971,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net</a></td>
<td class="nump">37,653<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,285,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,104,816<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2021</a></td>
<td class="nump">$ 33,155<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 241,535<span></span>
</td>
<td class="num">$ (208,470)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Shares, Share, Pursuant To Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Shares, Value, Pursuant To Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, New Issues, Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Stock Options And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues, Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Stock Options And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137359016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (30,680)<span></span>
</td>
<td class="num">$ (21,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development, including transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of Investment in Aytu</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee', window );">Change in value of Guarantee</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation', window );">Change in fair value of warrant liability and unit purchase option liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(953)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">152<span></span>
</td>
<td class="num">(1,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">9,339<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_IncreaseDecreaseInLeaseLiability', window );">Lease liability, net</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,316)<span></span>
</td>
<td class="num">(5,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PaymentsForAssetAcquisitions', window );">Net cash paid in merger with Aevi</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and pre-funded warrants in underwritten public offering, net</a></td>
<td class="nump">37,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ProceedsFromRegisteredDirectOffering', window );">Proceeds from registered direct offering, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of shares pursuant to common stock private placement, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ProceedsFromOptionOrWarrantExercises', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">37,825<span></span>
</td>
<td class="nump">9,098<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">19,488<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">19,106<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">38,594<span></span>
</td>
<td class="nump">5,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock in Aevi Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">38,292<span></span>
</td>
<td class="nump">5,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, current</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 38,594<span></span>
</td>
<td class="nump">$ 5,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability and investor rights obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ProceedsFromOptionOrWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Option Or Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ProceedsFromOptionOrWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ProceedsFromRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ProceedsFromRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136727480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business</a></td>
<td class="text">Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cerecor Inc. (the &#8220;Company&#8221; or &#8220;Cerecor&#8221;) is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases. The Company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company&#8217;s rare disease pipeline includes CERC-801, CERC-802 and CERC-803 (&#8220;CERC-800 compounds&#8221;), which are in development for therapies for congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor in development for the treatment of complex lymphatic malformations. The Company is also developing two monoclonal antibodies, CERC-002 and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for the treatment of severe pediatric-onset Crohn&#8217;s disease and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still&#8217;s disease (adult onset Still&#8217;s disease and systemic juvenile idiopathic arthritis) and multiple myeloma. CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher (&#8220;PRV&#8221;) upon approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company continues to explore strategic alternatives for its non-core assets, including its commercialized product, Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, and for its neurology pipeline assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cerecor was incorporated and commenced operation in 2011 and completed its initial public offering in October 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed an underwritten public offering of 13,971,889 shares of its common stock and 1,676,923 pre-funded warrants for net proceeds of approximately $37.7&#160;million (see Note 9 for additional information). As of March 31, 2021, Cerecor had $38.3&#160;million in cash and cash equivalents. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company&#8217;s resources between investing in the Company&#8217;s existing pipeline assets and acquisitions or in-licensing of new assets. For the three months ended March 31, 2021, Cerecor generated a net loss of $30.7&#160;million and negative cash flows from operations of $18.3&#160;million. As of March 31, 2021, Cerecor had an accumulated deficit of $208.5&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its core research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy at least one year after the date the condensed consolidated financial statements included herein were issued. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate these conditions and to meet the Company&#8217;s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive financings, (ii) federal and/or private grants, (iii) other out-licensing or strategic alliances/collaborations of its current pipeline assets, and (iv) out-licensing or sale of its non-core assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements in this Quarterly Report were issued. </span></div>Over the long term, the Company&#8217;s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any PRVs it receives.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133314696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2020 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2020 audited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, there were no significant changes to the Company&#8217;s summary of significant accounting policies contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 8, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136721464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Aytu Divestiture<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Aytu Divestiture</a></td>
<td class="text">Aytu Divestiture<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Sale of Pediatric Portfolio and Related Commercial Infrastructure to Aytu BioScience</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company closed on an asset purchase agreement to sell the Company&#8217;s rights, title and interest in assets relating to certain commercialized products (the &#8220;Pediatric Portfolio&#8221;) and the corresponding commercial infrastructure to Aytu BioScience, Inc. (&#8220;Aytu&#8221;). Aytu paid consideration of $4.5&#160;million in cash and approximately 9.8&#160;million shares of Aytu convertible preferred stock, and assumed certain of the Company&#8217;s liabilities, including the Company&#8217;s payment obligations to Deerfield CSF, LLC (&#8220;Deerfield&#8221;) and certain other liabilities primarily related to contingent consideration and sales returns. Steve Boyd, Chief Investment Officer of Armistice Capital, LLC, a significant stockholder of the Company, serves on each company&#8217;s board of directors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cerecor retains all rights to Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to a transition services agreement entered into between Aytu and Cerecor upon the divestiture close date, Aytu managed Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial operations for 18 months (post November 1, 2019). In May 2021, the Company entered into an amended transition services agreement in which Aytu will continue to manage Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s commercial operations for an additional two months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the sale of the Pediatric Portfolio to Aytu, the Pediatric Portfolio met all conditions to be classified as discontinued operations.  Therefore, the accompanying condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and as of December 31, 2020 reflect the operations, net of taxes, and related assets and liabilities of the Pediatric Portfolio as  discontinued operations. Refer to the &#8220;Discontinued Operations&#8221; section below for more information, including Cerecor&#8217;s continuing involvement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Guarantee </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the closing date of the Aytu Divestiture on November 1, 2019, Aytu assumed the Company&#8217;s debt obligation to Deerfield and the contingent consideration liability related to future royalties on Avadel Pharmaceuticals PLC&#8217;s (&#8220;Avadel&#8221;) pediatric products. In conjunction with the closing of this transaction, the Company entered into a guarantee in favor of Deerfield, which guarantees the payment of the assumed liabilities to Deerfield, which included the debt obligation and includes the contingent consideration related to future royalties on Avadel&#8217;s pediatric products (collectively referred to as the &#8220;Guarantee&#8221;).   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aytu publicly reported that it had paid the $15.0&#160;million balloon payment to Deerfield before it came due in June 2020 and the fixed monthly payments to Deerfield ended in January 2021, thus satisfying the debt obligation. Of the contingent consideration, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.2&#160;million was paid to Deerfield prior to the Aytu Divestiture and therefore, as of November 1, 2019, Aytu was responsible for the remaining $9.3&#160;million. Aytu is required to pay an amount equal to at least $0.1&#160;million per month. Cerecor&#8217;s Guarantee will end upon the earlier of (i) February 5, 2026, or (ii) upon $12.5&#160;million in aggregate deferred payments has been paid to Deerfield. Cerecor is required to make a payment under the Guarantee upon demand by Deerfield if all or any part of the fixed payments and/or deferred payments are not paid by Aytu when due or upon breach of a covenant. The remaining minimum commitments payable as most recently publicly reported by Aytu was $7.3&#160;million as of June 30, 2020, which represents Cerecor&#8217;s estimated maximum potential future payments under the Guarantee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Guarantee, which relates to the Company&#8217;s obligation to make future payments if Aytu defaults, was determined at the time of the Aytu Divestiture as the difference between (i) the estimated fair value of the assumed payments using Cerecor&#8217;s estimated cost of debt and (ii) the estimated fair value of the assumed payments using Aytu&#8217;s estimated cost of debt. Subsequent to the close of the Aytu Divestiture, at each reporting period, the value of the Guarantee is determined based on the expected credit loss of the Guarantee with changes recorded in (loss) income from discontinued operations, net of tax within the consolidated statements of operations and comprehensive loss. We considered key drivers of cost of debt both at Aytu and Cerecor, including but not limited to, recent financings, cash position, operating cash flows and trends and Aytu&#8217;s ability to meet its financial commitments. Based on these facts, the Company concluded that the expected credit loss of the Guarantee was de minimis as of March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the liabilities of the discontinued operations as of March 31, 2021 and December 31, 2020 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 related to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed&#160;$2.0 million&#160;and are less than&#160;$2.8 million&#160;(in other words, Aytu will only assume $0.8 million of such returns). Therefore, Cerecor is liable for future sales returns of the Pediatric Portfolio sold prior to November 1, 2019 in excess of the $0.8 million assumed by Aytu. As of March 31, 2021, the Company estimated future returns on sales of the Pediatric Portfolio made prior to the transaction close date to be $0.2&#160;million, which was recognized within accrued expenses and other current liabilities from discontinued operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s estimate of sales returns related to the Pediatric Portfolio is included within discontinued operations on the statement of operations and comprehensive loss and is shown within product revenue, net in the table summarizing the results of discontinued operations below.  In future periods, as additional information becomes available, the Company expects to recognize expense (or a benefit) related to actual sales returns of the Pediatric Portfolio in excess (or less than) the returns reserve recorded, which will be recognized within discontinued operations. The Company expects this involvement to continue until sales returns are no longer accepted on sales of the Pediatric Portfolio made prior to November 1, 2019, which in line with the products&#8217; return policies, returns on these products may be accepted through the second quarter of 2022.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of discontinued operations for the three months ended March 31, 2021 and 2020 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no non-cash operating items from discontinued operations for the three months ended March 31, 2021 and no non-cash investing items from the discontinued operations for the three months ended March 31, 2021 and 2020. The significant non-cash operating item from the discontinued operations for the three months ended March 31, 2020 is contained below (in thousands). </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133217288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates substantially all of its revenue from sales of Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral prednisolone indicated across a wide variety of inflammatory conditions, which is considered a prescription drug. The Company sells its prescription drug in the United States primarily through wholesale distributors and specialty contracted pharmacies. Wholesale distributors account for substantially all of the Company&#8217;s net product revenues and trade receivables. The Company also earns revenue from sales of its prescription drug directly to retail pharmacies. For the three months ended March 31, 2021, the Company&#8217;s three largest customers accounted for approximately 67%, 18%, and 15% of the Company&#8217;s total net product revenues from sale of prescription drugs from continuing operations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license and supply agreement for the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product with a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;), which expires on September 30, 2023. As part of a prior amendment to extend the contract to its current term, Cerecor agreed to pay Teva fifty percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $0.5&#160;million quarterly minimum payment, which was set to begin on April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#8217;s board of directors and also serves as the Chairman of Teva&#8217;s board of directors.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of prescription drugs was $0.5&#160;million and $2.8&#160;million for the three months ended March 31, 2021 and 2020, respectively. During the first quarter of 2021, the Company&#8217;s inventory on hand became short-dated (which the Company considers inventory within six months of expiration) due to manufacturing delays. The Company recorded a full allowance of $2.9&#160;million for returns on the sale of short-dated inventory given the high likelihood of return. The Company received the delayed inventory lot in April 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136731816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes earnings per share (&#8220;EPS&#8221;) using the two-class method. The two-class method of computing EPS is an earnings allocation formula that determines EPS for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two classes of stock outstanding, common stock and preferred stock. The preferred stock outstanding as of March 31, 2021 has the same rights and preferences as the Company&#8217;s common stock, other than being non-voting, and is convertible into shares of common stock on a 1-for-5 ratio.  Under the two-class method, the convertible preferred stock is considered a separate class of stock for EPS purposes and therefore basic and diluted EPS is provided below for both common stock and preferred stock. In April 2021, Armistice Capital Master Fund Ltd. (an affiliate of Armistice Capital, LLC and collectively &#8220;Armistice&#8221;), which is a significant </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, converted the remaining 1,257,143 shares of convertible preferred stock into 6,285,715 shares of Cerecor&#8217;s common stock. Refer to Note 9 for more information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPS for common stock and EPS for preferred stock is computed by dividing the sum of distributed earnings and undistributed earnings for each class of stock by the weighted average number of shares outstanding for each class of stock for the period. In applying the two-class method, undistributed earnings are allocated to common stock and preferred stock based on the weighted average shares outstanding during the period, which assumes the convertible preferred stock has been converted to common stock. The weighted average number of common shares outstanding as of March 31, 2021 includes the weighted average effect of the pre-funded warrants issued in connection with the January 2021 underwritten public offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock (refer to Note 9 for more information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net (loss) income per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units, which are included under the &#8220;treasury stock method&#8221; when dilutive; and (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the &#8220;treasury stock method&#8221; when dilutive. Because the impact of these items is generally anti-dilutive during periods of net loss, there is no difference between basic and diluted loss per common share for periods with net losses. In periods of net loss, losses are allocated to the participating security only if the security has not only the right to participate in earnings, but also a contractual obligation to share in the Company&#8217;s losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net (loss) income per share of common stock and preferred stock for the three months ended March 31, 2021 and 2020 (in thousands, except share and per share amounts):&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"><tr><td style="width:1.0%"/><td style="width:45.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,576,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,576,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.00)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"><tr><td style="width:1.0%"/><td style="width:45.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,934,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,934,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March&#160;31, 2021 and 2020, as they could have been anti-dilutive:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,944,891</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,712,680</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants on common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002,380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024,708</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,833</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underwriters&#8217; unit purchase option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></td></tr></table>1 The above table excludes 1,676,923 pre-funded warrants. See the &#8220;Q1 2021 Financing&#8221; in Note 9 for more information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133186184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract', window );"><strong>Business Combinations and Asset Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionDisclosureTextBlock', window );">Asset Acquisition</a></td>
<td class="text">Asset Acquisition<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company consummated its merger with Aevi Genomic Medicine Inc. (&#8220;Aevi&#8221;), in which Cerecor acquired the rights to CERC-002, CERC-006 and CERC-007 (the &#8220;Merger&#8221; or the &#8220;Aevi Merger&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger consideration included (i) stock valued at approximately $15.5 million, resulting in the issuance of approximately 3.9&#160;million shares of Cerecor common stock to Aevi stockholders, (ii) forgiveness of $4.1&#160;million the Company had loaned Aevi prior to the Merger closing, (iii) contingent value rights for up to an additional $6.5&#160;million in subsequent payments based on certain development milestones (discussed further in Note 13), and (iv) transaction costs of $1.5&#160;million. </span></div>The Company recorded this transaction as an asset purchase as opposed to a business combination because management concluded that substantially all the value received was related to one group of similar identifiable assets, which was the in-process research and development (&#8220;IPR&amp;D&#8221;) for two early phase therapies. The Company considered these pipeline assets similar due to similarities in the risks of development, stage of development, regulatory pathway, patient populations and economics of commercialization. The fair value of $25.5&#160;million (consisting primarily of $24.0&#160;million IPR&amp;D, $0.3&#160;million of cash and $0.9&#160;million of assembled workforce) was immediately recognized as acquired in-process research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss because the IPR&amp;D asset has no alternate use due to the stage of development. The assembled workforce asset was recorded to intangible assets and will be amortized over an estimated useful life of two years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_BusinessCombinationsAndAssetAcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations and Asset Acquisitions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_BusinessCombinationsAndAssetAcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136724536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC No. 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three&#8209;level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1&#8212;inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2&#8212;inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model&#8209;derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.&#160;</span></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3&#8212;inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.</span></div><div style="text-align:justify;text-indent:99pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:55.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:55.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investments in money market funds are reflected in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December&#160;31, 2020, the Company&#8217;s financial instruments included cash and cash equivalents, restricted cash, accounts receivable, other receivables, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities. The carrying amounts reported in the accompanying condensed consolidated financial statements approximate their respective fair values because of the short-term nature of these accounts.</span></div>No changes in valuation techniques or inputs occurred during the three months ended March 31, 2021 and 2020. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the three months ended March 31, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133127816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities  <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $2.5&#160;million increase in the research and development accrual as of March 31, 2021 was driven by an increase in manufacturing activities for CERC-002 to support the program&#8217;s clinical development. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company&#8217;s inventory on hand became short-dated (which the Company considers inventory within six months of expiration) due to manufacturing delays. The Company records a full allowance for the returns on the sale of short-dated inventory given the high likelihood of return, which was the main driver of the increase in sales returns and allowances as of March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133303432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_CAPITALSTRUCTUREAbstract', window );"><strong>CAPITAL STRUCTURE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock', window );">Capital Structure</a></td>
<td class="text">Capital Structure <div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s amended and restated certificate of incorporation, the Company is authorized to issue two classes of stock, common stock and preferred stock. At March 31, 2021, the total number of shares of capital stock the Company was authorized to issue was 205,000,000 of which 200,000,000 was common stock and 5,000,000 was</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock. All shares of common and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock have a par value of $0.001 per share. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Q1 2021 Financing </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed an underwritten public offering of 13,971,889 shares of its common stock and 1,676,923 pre-funded warrants for net proceeds of $37.7&#160;million. Armistice, which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board, participated in the offering by purchasing 2,500,000 shares of common stock, on the same terms as all other investors. Certain affiliates of Nantahala Capital Management LLC (collectively, &#8220;Nantahala&#8221;), which beneficially owned greater than 5% of the Company&#8217;s outstanding common stock at the time of the offering and, therefore, were considered a related party pursuant to the Company&#8217;s written related person transaction policy, purchased 1,400,000 shares of common stock, on the same terms as all other investors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nantahala also purchased the pre-funded warrants to purchase up to an aggregate of 1,676,923 shares of common stock at a purchase price of $2.599, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants are exercisable at any time after their original issuance at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. A holder will not be entitled to exercise any portion of any pre-funded warrant if the holder&#8217;s ownership of the Company&#8217;s common stock would exceed 9.99% following such exercise. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of certain fundamental transactions, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind of amounts of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the pre-funded warrants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-funded warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return. The Company valued the pre-funded warrants at issuance, concluding that their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and pre-funded warrants, of which $4.4&#160;million was allocated to the pre-funded warrants and recorded as a component of additional paid-in capital.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Financings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company closed an underwritten public offering of 15,180,000 shares of its common stock for net proceeds of approximately $35.4&#160;million. Armistice participated in the offering by purchasing 2,000,000 shares of common stock, on the same terms as all other investors. Additionally, certain of the Company&#8217;s officers participated in the offering by purchasing an aggregate of 110,000 shares of common stock, on the same terms as all other investors.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2020, the Company entered into a securities purchase agreement with Armistice pursuant to which the Company sold 1,951,219 shares of the Company&#8217;s common stock for net proceeds of approximately $3.9 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2020, the Company closed a registered direct offering with certain institutional investors for the sale by the Company of 1,306,282 shares of the Company&#8217;s common stock for net proceeds of approximately $5.1 million.  Armistice participated in the offering by purchasing 1,256,282 shares of common stock from the Company, on the same terms as all other investors. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, under the terms of the Aevi Merger noted above in Note 6, the Company issued approximately 3.9 million shares of common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the following common stock warrants were outstanding:&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">underlying&#160;warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676,923</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679,303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Preferred Stock </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2018, the Company filed a Certificate of Designation of Preferences of Series B Non-Voting Convertible Preferred Stock (&#8220;Series B Convertible Preferred Stock&#8221; or &#8220;convertible preferred stock&#8221;) of Cerecor Inc. (the &#8220;Certificate of Designation of the Series B Preferred Stock&#8221;) classifying and designating the rights, preferences and privileges of the Series B Convertible Preferred Stock. The Certificate of Designation of the Series B Convertible Preferred Stock authorized 2,857,143 shares of convertible preferred stock. The Series B Convertible Preferred Stock converts to shares of common stock on a 1-for-5 ratio and has the same rights, preferences, and privileges as common stock other than it holds no voting rights. During the first quarter of 2020, Armistice converted 1,600,000 shares of Series B Convertible Preferred Stock into 8,000,000 shares of Cerecor&#8217;s common stock. In April 2021, Armistice converted the remaining 1,257,143 shares of Series B Convertible Preferred Stock into 6,285,715 shares of Cerecor&#8217;s common stock.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2018 Armistice Private Placement</span></div>On December 27, 2018, the Company entered into a series of transactions as part of a private placement with Armistice. The transactions were considered one transaction for accounting purposes. As part of the transaction, the Company exchanged common stock warrants issued on April 27, 2017 to Armistice for the  purchase of up to 14,285,714 shares of the Company&#8217;s common stock at an exercise price of $0.40 per share (the &#8220;original warrants&#8221;) for like-kind warrants to purchase up to 2,857,143 shares of the Company&#8217;s Series B Convertible Preferred Stock with an exercise price of $2.00 per share (the &#8220;exchanged warrants&#8221;). Armistice immediately exercised the exchanged warrants and acquired an aggregate of 2,857,143 shares of the convertible preferred stock, which it has since converted into 14,285,715 shares of Cerecor common stock. Net proceeds of the transaction were approximately $5.7 million for the year ended December 31, 2018. In order to provide Armistice an incentive to exercise the exchanged warrants, the Company also entered into a securities purchase agreement with Armistice in December 2018 pursuant to which the Company issued warrants for 4,000,000 shares of common stock of the Company with a term of 5.5 years and an exercise price of $12.50 per share (the &#8220;incentive warrants&#8221;).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_CAPITALSTRUCTUREAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definitions available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_CAPITALSTRUCTUREAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Also include temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828131773864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2016, the Company&#8217;s board of directors adopted the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) as the successor to the 2015 Omnibus Plan (the &#8220;2015 Plan&#8221;). The 2016 Plan was approved by the Company&#8217;s stockholders and became effective on May 18, 2016 (the &#8220;2016 Plan Effective Date&#8221;). Upon the 2016 Plan Effective Date, the 2016 Plan reserved and authorized up to 600,000 additional shares of common stock for issuance, as well as 464,476 unallocated shares remaining available for grant of new awards under the 2015 Plan. An Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016 Amended Plan&#8221;) was approved by the Company&#8217;s stockholders in May 2018, which increased the share reserve by an additional 1.4 million shares. A Second Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016 Second Amended Plan&#8221;) was approved by the Company&#8217;s stockholders in August 2019, which increased the share reserve by an additional 850,000 shares. A Third Amended and Restated Equity Incentive Plan (the &#8220;2016 Third Amended Plan&#8221;) was approved by the Company&#8217;s stockholders in June 2020 which increased the share reserve by an additional 2,014,400 shares. During the term of the 2016 Third Amended Plan, the share reserve will automatically increase on the first trading day in January of each calendar year by an amount equal to 4% of the total number of outstanding shares of common </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock of the Company on the last trading day in December of the prior calendar year. As of March&#160;31, 2021, there were 2,728,771 shares available for future issuance under the 2016 Third Amended Plan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants expire after ten years. Employee options typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTY4MQ_63efab90-69fc-42af-b1b9-73b3e29c5cf7">three</span> or four years. Employees typically receive a new hire option grant, as well as an annual grant in the first or second quarter of each year. Options granted to directors typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl82NC9mcmFnOmQyMzI5ODkzMTAzNjRiY2Q5NDE0OTI4NDRhZGU5MTk3L3RleHRyZWdpb246ZDIzMjk4OTMxMDM2NGJjZDk0MTQ5Mjg0NGFkZTkxOTdfMTg2Nw_e865b985-b902-43d4-a27a-a09d25dc86dc">one</span> or three years. Directors may elect to receive stock options in lieu of board compensation, which vest immediately. For stock options granted to employees and non-employee directors, the estimated grant date fair market value of the Company&#8217;s stock-based awards is amortized ratably over the individuals&#8217; service periods, which is the period in which the awards vest. Stock-based compensation expense includes expense related to stock options, restricted stock units and employee stock purchase plan shares. The amount of stock-based compensation expense recognized for the three months ended March&#160;31, 2021 and 2020 was as follows (in thousands):&#160;</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with service-based vesting conditions</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted awards that contain service-based vesting conditions. The compensation cost for these options is recognized on a straight-line basis over the vesting periods. A summary of option activity for the three months ended March 31, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:39.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,830,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,467,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company granted its newly appointed Chief Financial Officer options with service-based vesting conditions to purchase 0.5&#160;million shares of common stock as an inducement option grant, pursuant to NASDAQ Listing Rule 5635(c)(4). In January 2021, the Company granted 2.7&#160;million options with service-based vesting conditions to its employees as part of its annual stock option award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, our Chief Executive Officer entered into an amended employment agreement in which his salary in cash was reduced to $35,568 (the &#8220;Reduction&#8221;), which represents the minimum exempt annual salary. In consideration for the Reduction, on a quarterly basis, the Company grants stock options, which vest immediately, for the purchase of a number of shares of the Company&#8217;s common stock with a total value (based on the Black-Scholes valuation methodology) based on a pro rata total annual value of the foregone salary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. As of March&#160;31, 2021, the aggregate intrinsic value of options outstanding was $1.6 million.  The aggregate intrinsic value of options currently exercisable as of March&#160;31, 2021 was $0.7 million. There were&#160;1,137,239&#160;options that vested during the three months ended March 31, 2021 with a weighted average exercise price of&#160;$3.96 per share. The total grant date fair value of shares which vested during the three months ended March 31, 2021&#160;was&#160;$2.8 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense of $1.3 million related to stock options with service-based vesting conditions for the three months ended March 31, 2021. At March 31, 2021, there was $16.1 million of total unrecognized </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation cost related to unvested service-based vesting condition awards. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 3.1 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the three months ended March 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service-based options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0% - 75.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of option (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36% - 1.12%</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options with market-based vesting conditions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s market-based option activity for the three months ended March 31, 2021 (in thousands except, for share amounts): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:39.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate intrinsic value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The aggregate intrinsic value in the above table represents the total pre-tax amount that a participant would receive if the option had been exercised on the last day of the respective fiscal period. Options with a market value less than its exercise value are not included in the intrinsic value amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, the Company granted its recently appointed Chairman of the Board an option to purchase 1,000,000 shares of Company common stock with market-based vesting conditions. 500,000 of the shares vested immediately on the date of grant with an exercise price of the closing stock price on the date of grant of $2.51. 250,000 of the shares vest upon the Company&#8217;s common stock reaching a 50% premium to the stock price on June 18, 2020 and has an exercise price of the stock at that time and 250,000 of the shares vest upon the Company&#8217;s common stock reaching a 75% premium to the stock price on June 18, 2020 and has an exercise price of the stock at that time. Each vesting tranche represents a unique requisite service period and therefore the compensation cost for each vesting tranche is recognized on a straight-line basis over its respective vesting period. The Company recognized stock-based compensation expense of $0.1 million related to stock options with market-based vesting conditions for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the second tranche of 250,000 shares and the third tranche of 250,000 shares both vested upon the Company&#8217;s stock price reaching a 50% and 75% premium to the stock price on June 18, 2020, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of the restricted stock units using the stock price on the date of the grant. The restricted shares typically vest annually over a four-year period beginning on the first anniversary of the award. The following table summarizes the Company&#8217;s restricted stock unit (&#8220;RSU&#8221;) activity for the three months ended March 31, 2021: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized expense of less than $6 thousand related to RSUs for the three months ended March 31, 2021.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2016, the Company&#8217;s board of directors approved the 2016 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by the Company&#8217;s stockholders and became effective on May 18, 2016 (the &#8220;ESPP Effective Date&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees can purchase common stock through accumulated payroll deductions at such times as are established by the administrator. The ESPP is administered by the compensation committee of the Company&#8217;s board of directors. Under the ESPP, eligible employees may purchase stock at 85% of the lower of the fair market value of a share of the Company&#8217;s common stock (i) on the first day of an offering period or (ii) on the purchase date. Eligible employees may contribute up to 15% of their earnings during the offering period. The Company&#8217;s board of directors may establish a maximum number of shares of the Company&#8217;s common stock that may be purchased by any participant, or all participants in the aggregate, during each offering or offering period. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 of the fair market value of the Company&#8217;s common stock for each calendar year in which such right is outstanding.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the ESPP Effective Date, the Company reserved and authorized up to 500,000 shares of common stock for issuance under the ESPP. On January 1 of each calendar year, the aggregate number of shares that may be issued under the ESPP shall automatically increases by a number equal to the lesser of (i) 1% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, and (ii) 500,000 shares of the Company&#8217;s common stock, or (iii) a number of shares of the Company&#8217;s common stock as determined by the Company&#8217;s board of directors or compensation committee. The number of shares were increased by 500,000 on January 1, 2021. As of March&#160;31, 2021, 1,925,308 shares remained available for issuance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 718-50,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Employee Share Purchase Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ability to purchase shares of the Company&#8217;s common stock at the lower of the offering date price or the purchase date price represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, stock-based compensation expense is determined based on the option&#8217;s grant-date fair value and is recognized over the requisite service period of the option. The Company used the Black-Scholes valuation model and recognized stock-based compensation expense of $34 thousand for the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136725096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The Company recognized minimal income tax expense for the three months ended March 31, 2021 and an income tax benefit of $2.2&#160;million for the three months ended March 31, 2020. The tax benefit recognized for the three months ended March 31, 2020 was a result of a tax law change signed into law as part of the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), which allowed the Company to carry back certain losses for taxes paid in fiscal year 2017. Due to the full valuation allowance against the Company&#8217;s deferred tax assets and the current year losses, minimal tax expense was recognized for the three months ended March 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828131826728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently occupies two leased properties, both of which serve as administrative office space. The Company determined that both leases are operating leases based on the lease classification test performed at lease commencement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent for the Company&#8217;s office located in Rockville, Maryland is $161,671, subject to annual 2.5% increases over the term of the lease. The applicable lease provided for a rent abatement for a period of 12 months following the Company&#8217;s date of occupancy. The lease has an initial term of 10 years from the date the Company makes its first annual fixed rent payment, which occurred in January 2020. The Company has the option to extend the lease two&#160;times, each for a period of five years, and may terminate the lease as of the sixth anniversary of the first annual fixed rent payment, upon the payment of a termination fee. As of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease commencement date, it was not reasonably certain that the Company will exercise the renewal periods or early terminate the lease and therefore the end date of the lease for accounting purposes is January 31, 2030. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a sublease for additional administrative office space in Chesterbrook, Pennsylvania in May 2020 (the &#8220;Chesterbrook Lease&#8221;). The annual base rent under the Chesterbrook Lease is $280,185. The lease expires in November 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining term of the operating leases at March 31, 2021 was 7.7 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leased property is as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease right-of-use (&#8220;ROU&#8221;) assets are included in property and equipment and the lease liabilities are included in accrued expenses and other current liabilities and other long-term liabilities in our condensed consolidated balance sheets. The Company utilized a weighted average discount rate of 7.4% to determine the present value of the lease payments.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three  months ended March 31, 2021 and 2020 were as follows (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Includes short-term leases, which are immaterial. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a maturity analysis of the operating lease liabilities as of March 31, 2021 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2021 through December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less implied interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133798776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation - General</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business. The Company currently does not believe that the resolution of such matters will have a material adverse effect on its financial position or results of operations except as otherwise disclosed in this report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Karbinal Royalty Make-Whole Provision </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, in connection with the acquisition of Avadel&#8217;s pediatric products, the Company entered into a supply and distribution agreement (the &#8220;Karbinal Agreement&#8221;) with TRIS Pharma Inc. (&#8220;TRIS&#8221;). As part of the Karbinal Agreement, the Company had an annual minimum sales commitment, which is based on a commercial year that spans from August 1 through July 31, of&#160;70,000&#160;units through 2033. The Company was required to pay TRIS a royalty make whole payment (&#8220;Make-Whole Payments&#8221;) of&#160;$30&#160;for each unit under the&#160;70,000&#160;units annual minimum sales commitment through 2033.&#160; </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the Aytu Divestiture, which closed on November 1, 2019, the Company assigned all payment obligations, including the Make-Whole Payments, under the Karbinal Agreement (collectively, the &#8220;TRIS Obligations&#8221;) to Aytu.&#160; However, under the original license agreement, the Company could ultimately be liable for the TRIS Obligations to the extent Aytu fails to make the required payments. The future Make-Whole Payments to be made by Aytu are unknown as the amount owed to TRIS is dependent on the number of units sold.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Millipred License and Supply Agreement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License and Supply Agreement for Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Watson Laboratories, Inc., which is now part of Teva. Pursuant to the License and Supply Agreement, the Company is required to make license payments of $75,000 in February and August of each year through April 2021 and purchases inventory on an ad-hoc basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a prior amendment to extend the contract to its current term, Cerecor agreed to pay Teva fifty percent of the net profit of the Millipred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product following each calendar quarter, subject to a $0.5&#160;million quarterly minimum payment, which was set to begin on April 1, 2021. In May 2021, the Company and Teva entered into an amendment in which the net profit split will be delayed until July 1, 2021. Dr. Sol Barer is the Chairman of Cerecor&#8217;s board of directors and also serves as the Chairman of Teva&#8217;s board of directors.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Proceeds for Out-Licensed Compounds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-611 License Assignment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into an assignment of license agreement (the &#8220;Assignment Agreement&#8221;) with ES Therapeutics, LLC (&#8220;ES Therapeutics&#8221;), a wholly-owned subsidiary of Armistice, which is a significant stockholder of the Company and whose chief investment officer, Steven Boyd, currently serves on the Board. Pursuant to the Assignment Agreement, the Company assigned and transferred its rights, title, interest, and obligations with respect to CERC-611 to ES Therapeutics. The Company initially licensed the compound from Eli Lilly Company (&#8220;Lilly&#8221;) in September 2016. Under the Assignment Agreement, Armistice paid the Company an upfront payment of $0.1 million.  The Company recognized the payment as license and other revenue in 2019. The Assignment Agreement also provides for: (a) a $7.5 million milestone payment to the Company upon cumulative net sales of licensed products reaching $750.0 million; and (b) a $12.5 million milestone payment to the Company upon cumulative net sales of licensed products reaching $1.3 billion. The Assignment Agreement also releases the Company of obligations related to CERC-611, including the $1.3 million contingent payment to Lilly upon the first subject dosage of CERC-611 in a multiple ascending dose study and from additional potential future payments due to Lilly upon achievement of certain development and commercialization milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-501 Sale to Janssen</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company sold its worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) in exchange for initial gross proceeds of $25.0 million. There is a potential future $20.0 million regulatory milestone payment to the Company upon acceptance of an NDA for any indication. The terms of the agreement provide that Janssen will assume ongoing clinical trials and be responsible for any new development and commercialization of CERC-501. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Possible Future Milestone Payments for In-Licensed Compounds </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to license and development agreements with various third parties, which contain future milestone payments and other future payment obligations (discussed further below). The Company recognizes a liability (and related expense) for each milestone if and when such milestone is probable and can be reasonably estimated. As typical in the biotechnology industry, each milestone has its own unique risks that the Company evaluates when determining the probability of achieving each milestone and the probability of success evolves over time as the programs progress and additional information is obtained. The Company considers numerous factors when evaluating whether a given milestone is probable including (but not limited to) the regulatory pathway, development plan, ability to dedicate sufficient funding to reach a given milestone and the probability of success. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-002 KKC License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company entered into a license agreement with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) for exclusive worldwide rights to develop, manufacture and commercialize CERC-002, KKC&#8217;s first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody for all indications (the &#8220;KKC License Agreement&#8221;). The KKC License Agreement replaces the Amended and Restated Clinical Development and Option Agreement between the Company and KKC dated May 28, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the KKC License Agreement, the Company paid KKC an upfront license fee equal to $10.0&#160;million. The Company will also pay KKC milestone payments based on achievement of certain success-based regulatory milestones that equal, for each of three separate indications of CERC-002, mid-teen millions of dollars or less depending on the territory to which the regulatory milestone achievement relates. In addition, the Company will pay KKC (a) royalties during a country-by-country royalty term agreement equal to mid-teens percentage of the net sales of CERC-002 by the Company, (b) sales milestone payments aggregating up to $75&#160;million tied to achievement of annual net sales targets, and (c) a double digit percentage (less than 30%) of the payments that the Company receives from sublicensing of its rights under the KKC License Agreement, subject to certain exclusions. Subject to the option described below that allows, upon exercise, KKC to develop, manufacture and commercialize CERC-002 in Japan, the Company will be responsible for the development and commercialization of CERC-002 in all indications worldwide. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted KKC an option to exclude Japan from the scope of the worldwide rights granted to the Company such that, upon exercise of the option, KKC can develop, manufacture and commercialize CERC-002 in Japan. Upon exercise of the Option, KKC will be required to (a) reimburse the Company for a pre-agreed percentage of certain of its costs incurred to develop CERC-002 as a condition to KKC accessing the Company&#8217;s data that would be required to be included in an application for marketing authorization, (b) pay the Company for its services (such as transfer of data and regulatory support), (c) pay for all further development of CERC-002 in Japan and (d) pay any royalty due to the Company&#8217;s licensors on sales of CERC-002 in Japan. KKC will also have the right to purchase CERC-002 from the Company for use in Japan. No other amounts would be payable by KKC to the Company such as license fees, royalties and milestone payments. The option will expire if KKC does not exercise it within a set number of days after the FDA accepts for filing a Biologics License Application for a pre-defined indication of CERC-002. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the upfront license fee of $10.0&#160;million within research and development expenses for the three months ended March 31, 2021 and made the payment in April 2021. The Company has not recognized any liabilities related to the milestones outlined in the KKC License Agreement as of March 31, 2021. The Company will continue to monitor the milestones at each reporting period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-006 Astellas License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly owned subsidiary of Astellas Pharma, Inc. (&#8220;Astellas&#8221;), for the worldwide development and commercialization of the novel, second generation mTORC1/2 inhibitor (which we refer to as CERC-006). Under the terms of the license agreement, the Company paid Astellas an upfront license fee of $0.5&#160;million and Astellas will be eligible to receive milestone payments of up to $5.5&#160;million based upon the achievement of specified development and regulatory milestones. Upon commercialization, Astellas will be entitled to a tiered, single-digit royalty on worldwide annual net sales. Cerecor is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, the Company accrued a $0.5&#160;million milestone payment due to Astellas upon confirmation from the FDA that an initial signal finding study may proceed in the United States given the Company concluded it was probable the Company will begin such study in 2021.  The Company will continue to monitor the remaining milestones at each reporting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-007 AstraZeneca License Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive global license to develop and commercialize a Phase 2-ready fully human, anti-IL-18 monoclonal antibody (which we refer to as CERC-007) from Medimmune Limited, a subsidiary of AstraZeneca plc (&#8220;AstraZeneca&#8221;). Up to $162&#160;million may be due to AstraZeneca upon achievement of certain development and sales-related milestones, in addition to a tiered low double-digit royalty on global annual product sales. Cerecor is fully responsible for the development and commercialization of the program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, Cerecor recognized a $1.5&#160;million milestone payment to AstraZeneca within research and development expenses, which was due upon initiation of the first proof-of-concept study which uses CERC-007. The Company made such payment in the first quarter of 2021. The Company will continue to monitor the remaining milestones at each reporting period. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party and Acquisition Related Contingent Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERC-006 Royalty Agreement with Certain Related Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to Cerecor entering into the Aevi Merger, in July 2019, Aevi entered into a royalty agreement with Mike Cola, Cerecor&#8217;s current Chief Executive Officer, Joseph J. Grano, Jr., Kathleen Jane Grano, Joseph C. Grano, The Grano Children&#8217;s Trust, Joseph C. Grano, trustee and LeoGroup Private Investment Access, LLC on behalf of Garry A. Neil, Cerecor&#8217;s current Chief Scientific Officer (collectively, the &#8220;Investors&#8221;) in exchange for a one-time aggregate payment of $2.0 million (the &#8220;Royalty Agreement&#8221;). Collectively, the Investors will be entitled to an aggregate amount equal to a low-single digit percentage of the aggregate net sales of Astellas&#8217; second generation mTORC1/2 inhibitor, CERC-006. At any time beginning three years after the date of the first public launch of CERC-006, Cerecor may exercise, at its sole discretion, a buyout option that terminates any further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments.&#160;A majority of the independent members of the board of directors and the audit committee of Aevi approved the Royalty Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cerecor assumed this Royalty Agreement upon closing of the Aevi Merger and it is recorded as a royalty obligation within the Company&#8217;s accompanying condensed consolidated balance sheet as of March 31, 2020.  Because there is a significant related party relationship between the Company and the Investors, the Company treated its obligation to make royalty payments under the Royalty Agreement as an implicit obligation to repay the funds advanced by the Investors. As the Company makes royalty payments in accordance with the Royalty Agreement, it will reduce the liability balance. At the time that such royalty payments become probable and estimable, and if such amounts exceed the liability balance, the Company will impute interest accordingly on a prospective basis based on such estimates, which would result in a corresponding increase in the liability balance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aevi Merger Possible Future Milestone Payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the consideration for the Aevi Merger includes two future contingent development milestones worth up to an additional $6.5 million. The first milestone is the enrollment of a patient in a Phase 2 study related to CERC-002 for use in pediatric onset Crohn&#8217;s disease, CERC-006 (any indication) or CERC-007 (any indication) prior to February 3, 2022. If this milestone is met, the Company is required to make a milestone payment of $2.0 million. The second milestone is the receipt of a NDA approval for either CERC-006 or CERC-007 from the FDA on or prior to February 3, 2025. If this milestone is met, the Company is required to make a milestone payment of $4.5 million. All milestones are payable in either shares of the Company&#8217;s common stock or cash, at the election of the Company.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated.  As of the consummation of the Merger on February 3, 2020 and as of March 31, 2021, no contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ichorion Asset Acquisition Possible Future Milestone Payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company acquired Ichorion Therapeutics, Inc. including acquiring three compounds for inherited metabolic disorders known as CDGs (CERC-801, CERC-802 and CERC-803) and one other preclinical compound. Consideration for the transaction included shares of Cerecor common stock and three future contingent development milestones for the acquired compounds worth up to an additional&#160;$15.0 million. The first milestone is the first product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $6.0&#160;million. The second milestone is the second product being approved for marketing by the FDA on or prior to December 31, 2021. If this milestone is met, the Company is required to make a milestone payment of $5.0&#160;million. The third milestone is a protide molecule being approved by the FDA on or prior to December 31, 2023. If this milestone is met, the Company is required to make a milestone payment of $4.0&#160;million. All milestones are payable in either shares of the Company&#8217;s common stock or cash, at the election of the Company. </span></div>The contingent consideration related to the development milestones will be recognized if and when such milestones are probable and can be reasonably estimated. As of March 31, 2021, no contingent consideration related to the development milestone has been recognized. The Company will continue to monitor the development milestones at each reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133547928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December&#160;31, 2020 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December&#160;31, 2020 audited consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136718088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Aytu Divestiture (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summary of Liabilities of Discontinued Operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the liabilities of the discontinued operations as of March 31, 2021 and December 31, 2020 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes the results of discontinued operations for the three months ended March 31, 2021 and 2020 (in thousands): <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no non-cash operating items from discontinued operations for the three months ended March 31, 2021 and no non-cash investing items from the discontinued operations for the three months ended March 31, 2021 and 2020. The significant non-cash operating item from the discontinued operations for the three months ended March 31, 2020 is contained below (in thousands). </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of Guarantee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133319560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the Computation of Basic and Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net (loss) income per share of common stock and preferred stock for the three months ended March 31, 2021 and 2020 (in thousands, except share and per share amounts):&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"><tr><td style="width:1.0%"/><td style="width:45.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,576,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,576,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.00)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.777%"><tr><td style="width:1.0%"/><td style="width:45.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discontinued Operations</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,934,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,934,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded From Computation of Diluted Weighted Shares Outstanding</a></td>
<td class="text">The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three months ended March&#160;31, 2021 and 2020, as they could have been anti-dilutive:&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,944,891</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,712,680</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants on common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002,380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024,708</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,833</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underwriters&#8217; unit purchase option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></td></tr></table>1 The above table excludes 1,676,923 pre-funded warrants. See the &#8220;Q1 2021 Financing&#8221; in Note 9 for more information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828217551912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:55.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:55.901%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">active&#160;markets&#160;for</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">observable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">unobservable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">identical&#160;assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in money market funds*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investments in money market funds are reflected in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828131793400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828131760168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_CAPITALSTRUCTUREAbstract', window );"><strong>CAPITAL STRUCTURE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Common Stock Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the following common stock warrants were outstanding:&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise&#160;price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">underlying&#160;warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676,923</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679,303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_CAPITALSTRUCTUREAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definitions available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_CAPITALSTRUCTUREAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828134150200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text">The amount of stock-based compensation expense recognized for the three months ended March&#160;31, 2021 and 2020 was as follows (in thousands):&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text">A summary of option activity for the three months ended March 31, 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:39.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,830,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,467,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s market-based option activity for the three months ended March 31, 2021 (in thousands except, for share amounts): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:39.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate intrinsic value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div>(1) The aggregate intrinsic value in the above table represents the total pre-tax amount that a participant would receive if the option had been exercised on the last day of the respective fiscal period. Options with a market value less than its exercise value are not included in the intrinsic value amount.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions for Options</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the assumptions used to compute stock-based compensation expense for stock options with service-based vesting conditions granted under the Black-Scholes valuation model for the three months ended March 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service-based options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0% - 75.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of option (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36% - 1.12%</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity</a></td>
<td class="text">The following table summarizes the Company&#8217;s restricted stock unit (&#8220;RSU&#8221;) activity for the three months ended March 31, 2021: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs&#160;Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133074936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets and Liabilities Lessee</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the leased property is as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e394686b-0d6d-4dac-9a39-2d39317b6d38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNC0wLTEtMS0w_e5054d1d-628c-491a-bf72-ffb338f61ba8">Accrued expenses and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_3192a58e-06c8-4d26-a10e-35ea51699aea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3YmIyNTdkNzkzYjRjMTNiZGMyZjUyNDdmOGU4MTlmL3NlYzpjN2JiMjU3ZDc5M2I0YzEzYmRjMmY1MjQ3ZjhlODE5Zl83MC9mcmFnOmViNTI5MTliNDgwNTRkODJhYzMxZWY2MTAzNTA1NDUwL3RhYmxlOjhmY2I1NzAzNzI1ZDQ0YmZhNTRkMDlmM2I2MTNlY2I2L3RhYmxlcmFuZ2U6OGZjYjU3MDM3MjVkNDRiZmE1NGQwOWYzYjYxM2VjYjZfNS0wLTEtMS0w_ab4d4f0e-9f39-4307-935d-22214802e863">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three  months ended March 31, 2021 and 2020 were as follows (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>*Includes short-term leases, which are immaterial.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a maturity analysis of the operating lease liabilities as of March 31, 2021 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:1.0%"/><td style="width:70.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2021 through December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less implied interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138052488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,971,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,292<span></span>
</td>
<td class="nump">$ 5,659<span></span>
</td>
<td class="nump">$ 18,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,680)<span></span>
</td>
<td class="num">(21,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,316)<span></span>
</td>
<td class="num">$ (5,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (208,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (177,790)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="nump">15,180,000<span></span>
</td>
<td class="nump">13,971,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 37,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember', window );">Neurological Clinical And Preclinical Stage Compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumberOfProductsDeveloped', window );">Number of products in development | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_ClinicalStageMember', window );">Clinical Stage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumberOfProductsDeveloped', window );">Number of products in development | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_NumberOfProductsDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products Developed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_NumberOfProductsDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_ClinicalStageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_ClinicalStageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138590072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Aytu Divestiture - Narrative (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 06, 2021</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DebtInstrumentRemainingContingentConsiderationLiability', window );">Remaining contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cerc_DeerfieldObligationMember', window );">Deerfield Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DebtInstrumentContingentConsiderationPaid', window );">Contingent consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cerc_DeerfieldObligationMember', window );">Deerfield Obligation | AYTU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DebtInstrumentRemainingContingentConsiderationLiability', window );">Remaining contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cerc_AYTUBioScienceIncMember', window );">AYTU | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_MonthlyOperationPaymentsTerm', window );">Duration of monthly commercial operation payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cerc_AYTUBioScienceIncMember', window );">AYTU | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_MonthlyOperationPaymentsAdditionalTerm', window );">Additional duration of monthly commercial operation payments</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cerc_AYTUBioScienceIncMember', window );">AYTU | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember', window );">Pediatric Portfolio | Deerfield Obligation | AYTU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DebtInstrumentFutureAggregateDeferredPayments', window );">Future aggregate deferred payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Pediatric Portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns', window );">Sales returns disposed of</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent', window );">Sales return reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns', window );">Sales returns disposed of</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns', window );">Sales returns disposed of</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DebtInstrumentContingentConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Contingent Consideration Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DebtInstrumentContingentConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DebtInstrumentFutureAggregateDeferredPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Future Aggregate Deferred Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DebtInstrumentFutureAggregateDeferredPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DebtInstrumentRemainingContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Remaining Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DebtInstrumentRemainingContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Sales Return Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_MonthlyOperationPaymentsAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly Operation Payments, Additional Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_MonthlyOperationPaymentsAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_MonthlyOperationPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly Operation Payments, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_MonthlyOperationPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cerc_DeerfieldObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cerc_DeerfieldObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cerc_AYTUBioScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cerc_AYTUBioScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_AYTUBioScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_AYTUBioScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cerc_AYTUBioScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cerc_AYTUBioScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137750392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Aytu Divestiture - Summary of Liabilities of the Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 1,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember', window );">Pediatric Portfolio | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 1,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828221146184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Aytu Divestiture - Summary of Income Statement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee', window );">Change in value of Guarantee</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember', window );">Pediatric Portfolio | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Product revenue, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Sales and marketing</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee', window );">Change in value of Guarantee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense', window );">Total other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">(Loss) income from discontinued operations, net of tax</a></td>
<td class="num">$ (106)<span></span>
</td>
<td class="nump">$ 1,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828134149640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Aytu Divestiture - Summary of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee', window );">Change in value of Guarantee</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,755)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember', window );">Pediatric Portfolio | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee', window );">Change in value of Guarantee</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,755)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cerc_PediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138024008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 2,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_InventoryPeriodBeforeExpiration', window );">Period before expiration to be considered as inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss', window );">Allowance for returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_MillipredMember', window );">Millipred | Teva | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment', window );">Percent of net profit for installment payments</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementInstallmentPayment', window );">Installment payment</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 2,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue | Customer Concentration Risk | Major Customer Number One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue | Customer Concentration Risk | Major Customer Number Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue | Customer Concentration Risk | Major Customer Number Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_InventoryPeriodBeforeExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Period Before Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_InventoryPeriodBeforeExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percent Of Net Profit For Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_MillipredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_MillipredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cerc_TevaPharmaceuticalIndustriesLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cerc_TevaPharmaceuticalIndustriesLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cerc_MajorCustomerNumberOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cerc_MajorCustomerNumberOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cerc_MajorCustomerNumberTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cerc_MajorCustomerNumberTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cerc_MajorCustomerNumberThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cerc_MajorCustomerNumberThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137361976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2018</div></th>
<th class="th"><div>Dec. 26, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>class_of_stock </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ClassOfStockNumberOfClassesOfStockOutstanding', window );">Number of classes of stock outstanding | class_of_stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,285,715<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">14,285,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockholdersEquityNotePreferredStockConversionRatio', window );">Preferred stock conversion ratio</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ClassOfStockNumberOfClassesOfStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Stock, Number Of Classes Of Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ClassOfStockNumberOfClassesOfStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockholdersEquityNotePreferredStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Note Preferred Stock Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockholdersEquityNotePreferredStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138033720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common&#160;stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic', window );">Allocation of undistributed net (loss) income, continuing operations</a></td>
<td class="num">$ (28,548)<span></span>
</td>
<td class="num">$ (19,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic', window );">Allocation of undistributed net (loss) income, discontinued operations</a></td>
<td class="num">$ (99)<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic (in shares)</a></td>
<td class="nump">88,576,559<span></span>
</td>
<td class="nump">53,934,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares, diluted (in shares)</a></td>
<td class="nump">88,576,559<span></span>
</td>
<td class="nump">53,934,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net loss per share, continuing operations (in dollars per share)</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Basic net loss per share, discontinued operations (in dollars per share)</a></td>
<td class="nump">(0.00)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net loss per share, continuing operations (in dollars per share)</a></td>
<td class="num">(0.32)<span></span>
</td>
<td class="num">(0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net loss per share, discontinued operations (in dollars per share)</a></td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic', window );">Allocation of undistributed net (loss) income, continuing operations</a></td>
<td class="num">$ (2,026)<span></span>
</td>
<td class="num">$ (2,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic', window );">Allocation of undistributed net (loss) income, discontinued operations</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic (in shares)</a></td>
<td class="nump">1,257,143<span></span>
</td>
<td class="nump">1,657,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares, diluted (in shares)</a></td>
<td class="nump">1,257,143<span></span>
</td>
<td class="nump">1,657,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net loss per share, continuing operations (in dollars per share)</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Basic net loss per share, discontinued operations (in dollars per share)</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net loss per share, continuing operations (in dollars per share)</a></td>
<td class="num">(1.61)<span></span>
</td>
<td class="num">(1.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net loss per share, discontinued operations (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) from continuing operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) from discontinued operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137982216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cerc_NantahalaMember', window );">Nantahala</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">12,944,891<span></span>
</td>
<td class="nump">7,712,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_WarrantCommonStockMember', window );">Warrants on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">4,002,380<span></span>
</td>
<td class="nump">4,024,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">155,833<span></span>
</td>
<td class="nump">267,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_UnderwritersUnitPurchaseOptionMember', window );">Underwriters&#8217; unit purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_NantahalaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_NantahalaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_WarrantCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_WarrantCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_UnderwritersUnitPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cerc_UnderwritersUnitPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138060792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred', window );">Forgiveness of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Consideration transferred, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares', window );">Shares issued (in shares)</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments', window );">Contingent consideration</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Fair value of asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Fair value assigned to intangible asset at purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionCashandEquivalents', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi | Assembled Workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionCashandEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash and Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionCashandEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Equity Interests Issued And Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Equity Interest Issued Or Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cerc_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cerc_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137936840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market funds</a></td>
<td class="nump">$ 37,008<span></span>
</td>
<td class="nump">$ 17,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828134249736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>change</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>change</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber', window );">Number of changes in valuation techniques | change</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Amount of transfers of assets from level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Amount of transfers of assets from level 2 to level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_FairValueMeasurementsChangesInValuationTechniquesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of changes in valuation techniques during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_FairValueMeasurementsChangesInValuationTechniquesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133043160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AccruedResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">$ 7,393<span></span>
</td>
<td class="nump">$ 4,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AccruedGeneralAndAdministrativeExpenses', window );">General and administrative</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Sales and marketing</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AccruedSalesReturnsAndAllowances', window );">Sales returns and allowances</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AccruedMedicaidRebates', window );">Medicaid rebates</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 14,238<span></span>
</td>
<td class="nump">$ 11,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for general and administrative expenses..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AccruedMedicaidRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Medicaid Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AccruedMedicaidRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AccruedSalesReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Returns And Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AccruedSalesReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828136727480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_InventoryPeriodBeforeExpiration', window );">Period before expiration to be considered as inventory</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_InventoryPeriodBeforeExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Period Before Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_InventoryPeriodBeforeExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828123613256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 27, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>class_of_stock </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumberOfClassOfStockAuthorized', window );">Number of classes of stock authorized to issue | class_of_stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_CapitalStockSharesAuthorized', window );">Number of shares of capital stock authorized to issue (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,971,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold', window );">Percent ownership threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrant, component of additional paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,285,715<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">14,285,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,285,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_StockholdersEquityNotePreferredStockConversionRatio', window );">Preferred stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cerc_NantahalaCapitalManagementLLCMember', window );">Nantahala Capital Management LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cerc_NantahalaMember', window );">Nantahala</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">15,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,971,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Armistice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Nantahala</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_ArmisticePurchaseAgreementMember', window );">Armistice Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_RegisteredDirectOfferingMember', window );">Registered Direct Offering | Armistice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,256,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Preferred Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,143<span></span>
</td>
<td class="nump">2,857,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Equity Interest Issued Or Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of capital stock, including common stock and preferred stock, solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ClassOfWarrantOrRightPercentOwnershipThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Percent Ownership Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ClassOfWarrantOrRightPercentOwnershipThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_NumberOfClassOfStockAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of classes of stock permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_NumberOfClassOfStockAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_StockholdersEquityNotePreferredStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Note Preferred Stock Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_StockholdersEquityNotePreferredStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cerc_NantahalaCapitalManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cerc_NantahalaCapitalManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_NantahalaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_NantahalaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cerc_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_ArmisticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_ArmisticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_OfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_OfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_ArmisticePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cerc_ArmisticePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cerc_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137856008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Structure - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">5,679,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsExpirationDateOfMay2022Member', window );">Common Stock Warrants Expiration May 2022 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">2,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsExpirationDateOfJune2024Member', window );">Common Stock Warrants Expiration Date Of June 2024 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsNoExpirationMember', window );">Common Stock Warrants No Expiration | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available under warrant (in shares)</a></td>
<td class="nump">1,676,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsExpirationDateOfMay2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsExpirationDateOfMay2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsExpirationDateOfJune2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsExpirationDateOfJune2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsNoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cerc_CommonStockWarrantsNoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828124085832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>May 18, 2016</div></th>
<th class="th"><div>Apr. 05, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent', window );">Annual share reserve increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,448,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,117,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_EmployeeStockPurchasePlanESPPMember', window );">Employee Stock Purchase Plan (ESPP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remaining for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,925,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,925,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum portion of earning an employee may contribute to the ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum', window );">Maximum annual amount of fair market value of the company's common stock that a participant may accrue the rights to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear', window );">Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Increase in shares available (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember', window );">Service Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross', window );">Share-based compensation on service-based vesting conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,137,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember', window );">Service Based Options | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember', window );">Service Based Options | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AnnualBaseSalary', window );">Annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember', window );">Market Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember', window );">Market Based Options | Chairman of the Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember', window );">Market Based Options | Chairman of the Board | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Options vested, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember', window );">Market Based Options | Chairman of the Board | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage', window );">Premium on stock price, threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember', window );">Market Based Options | Chairman of the Board | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage', window );">Premium on stock price, threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_EmployeeStockPurchasePlanESPPMember', window );">Employee Stock Purchase Plan (ESPP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease', window );">Increase in number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remaining for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,728,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,728,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember', window );">2016 Plan | Equity Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember', window );">2016 Plan | Equity Option | Minimum | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember', window );">2016 Plan | Equity Option | Minimum | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember', window );">2016 Plan | Equity Option | Maximum | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember', window );">2016 Plan | Equity Option | Maximum | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_A2016SecondAmendedPlanMember', window );">2016 Second Amended Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease', window );">Increase in number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cerc_ThirdAmended2016PlanMember', window );">2016 Third Amended Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease', window );">Increase in number of shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,014,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Base Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase To Shares Authorized As Percentage Of Outstanding Stock At End Of Preceding Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the increase in the number of shares reserved for issuance under the incentive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent, applied to total number of outstanding shares of common stock on the last trading day in December of the prior year, by which the share reserve automatically increases on the first day of January of each calendar year beginning in 2016.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Price Premium, Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Vested, Granted in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cerc_EmployeeStockPurchasePlanESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cerc_EmployeeStockPurchasePlanESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cerc_EmployeeStockPurchasePlanESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cerc_EmployeeStockPurchasePlanESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cerc_The2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cerc_The2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cerc_A2016SecondAmendedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cerc_A2016SecondAmendedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cerc_ThirdAmended2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cerc_ThirdAmended2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138206408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137235400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock Options With Service-based Vesting Conditions (Details) - Service Based Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, beginning of period (in shares) | shares</a></td>
<td class="nump">8,830,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,467,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercises in period (in shares) | shares</a></td>
<td class="num">(128,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares) | shares</a></td>
<td class="num">(224,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, ending of period (in shares) | shares</a></td>
<td class="nump">11,944,891<span></span>
</td>
<td class="nump">8,830,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">3,914,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of period (in dollars per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeitures (in dollars per share)</a></td>
<td class="nump">3.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending of period (in dollars per share)</a></td>
<td class="nump">3.81<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">4.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Option Activity, Fair value of options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of period (in dollars per share)</a></td>
<td class="nump">2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of period (in dollars per share)</a></td>
<td class="nump">2.34<span></span>
</td>
<td class="nump">$ 2.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Exercised, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828221106696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock-based Compensation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term of option (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember', window );">Service Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember', window );">Service Based Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term of option (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember', window );">Service Based Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">75.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term of option (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cerc_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137483624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock Options With Company's Market-based Option Activity (Details) - Market Based Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, beginning of period (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, ending of period (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of period (in dollars per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending of period (in dollars per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable aggregate intrinsic value</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cerc_StockOptionsWithMarketBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828138572040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Restricted Stock Units (Details) - Restricted Stock Awards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>Restricted Stock Award, Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs at December 31, 2020 (in shares) | shares</a></td>
<td class="nump">155,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs at March 31, 2021 (in shares) | shares</a></td>
<td class="nump">155,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested RSUs at December 31, 2020 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested RSUs at March 31, 2021 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828137978760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="nump">$ 2,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828221707768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>renewal_option </div>
<div>contract</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LesseeOperatingLeaseNumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LesseeOperatingLeaseRemainingLeaseTeam', window );">Remaining lease team</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 161,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent', window );">Annual rent increase</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LesseeOperatingLeaseRentAbatementPeriod', window );">Rent abatement period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term of contract</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 280,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LesseeOperatingLeaseRemainingLeaseTeam">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Remaining Lease Team</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LesseeOperatingLeaseRemainingLeaseTeam</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LesseeOperatingLeaseRentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Abatement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LesseeOperatingLeaseRentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_OperatingLeasesRentExpenseAnnualIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Rent Expense, Annual Increase, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_OperatingLeasesRentExpenseAnnualIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828133073800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Property and equipment, net</a></td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 1,018<span></span>
</td>
<td class="nump">$ 1,038<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,375<span></span>
</td>
<td class="nump">$ 1,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828131867320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828215321288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">April 1, 2021 through December 31, 2021</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less implied interest</a></td>
<td class="num">(474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 1,375<span></span>
</td>
<td class="nump">$ 1,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139828122896392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">16 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1">64 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>therapy</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>unit </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473,000<span></span>
</td>
<td class="nump">$ 2,754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PotentialFutureRegulatoryMilestone', window );">Potential future regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_RoyaltyAgreementPaymentReceived', window );">Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement', window );">Period after public launch to terminate agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments', window );">Percentage of net present value of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember', window );">Aevi | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_IchorionMember', window );">Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_IchorionMember', window );">Ichorion | Milestone One | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_IchorionMember', window );">Ichorion | Milestone Two | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_AssetAcquisitionAxis=cerc_IchorionMember', window );">Ichorion | Milestone Three | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_MillipredMember', window );">Millipred | Teva | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementSemiAnnualLicensePayment', window );">Semi-annual license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment', window );">Percent of net profit for installment payments</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementInstallmentPayment', window );">Installment payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC611Member', window );">CERC-611</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne', window );">Potential milestone revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo', window );">Potential milestone payment two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo', window );">Potential milestone revenue threshold two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseObligationNoncurrent', window );">License obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC611Member', window );">CERC-611 | Armistice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC002KKCLicenseAgreementMember', window );">CERC-002 KKC License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementUpfrontFee', window );">License agreement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing', window );">Percent of payments received from sublicensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC006AstellasLicenseAgreementMember', window );">CERC-006 Astellas License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementUpfrontFee', window );">License agreement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementMilestonePaymentRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC007AstraZenecaLicenseAgreementMember', window );">CERC-007 AstraZeneca License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementMilestonePaymentRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC801CERC802AndCERC803Member', window );">CERC-801, CERC-802, and CERC-803 | Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumberOfPreclinicalTherapies', window );">Number of preclinical therapies | therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cerc_CERC913Member', window );">CERC-913 | Ichorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_NumberOfPreclinicalTherapies', window );">Number of preclinical therapies | therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cerc_TRISPharmaMember', window );">TRIS Pharma | Karbinal Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired', window );">Minimum quantity required | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cerc_LicenseAgreementMakeWholePaymentPerUnit', window );">Make whole payment per unit (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionContingentValueRightNumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Value Right, Number Of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionContingentValueRightNumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementMakeWholePaymentPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Make Whole Payment Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementMakeWholePaymentPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementMilestonePaymentRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementMilestonePaymentRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percent Of Net Profit For Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percent Of Payments Received From Sublicensing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Milestone Payment Number One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPotentialMilestonePaymentNumberOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Milestone Payment Number Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Milestone Revenue Threshold Number One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Milestone Revenue Threshold Number Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementSemiAnnualLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Semi-Annual License Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementSemiAnnualLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_LicenseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_LicenseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_NumberOfPreclinicalTherapies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Preclinical Therapies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_NumberOfPreclinicalTherapies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Asset Acquisition Contingent Consideration Liability Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_PotentialFutureRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Regulatory Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_PotentialFutureRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_RoyaltyAgreementPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_RoyaltyAgreementPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Period After Public Launch To Terminate Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cerc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cerc_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cerc_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionAxis=cerc_AeviGenomicMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_MilestoneAxis=cerc_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_MilestoneAxis=cerc_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_MilestoneAxis=cerc_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_MilestoneAxis=cerc_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_AssetAcquisitionAxis=cerc_IchorionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_AssetAcquisitionAxis=cerc_IchorionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cerc_MilestoneAxis=cerc_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cerc_MilestoneAxis=cerc_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_MillipredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_MillipredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cerc_TevaPharmaceuticalIndustriesLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cerc_TevaPharmaceuticalIndustriesLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_CERC611Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_CERC611Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cerc_ArmisticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cerc_ArmisticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_CERC002KKCLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_CERC002KKCLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_CERC006AstellasLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_CERC006AstellasLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_CERC007AstraZenecaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_CERC007AstraZenecaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_CERC801CERC802AndCERC803Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_CERC801CERC802AndCERC803Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cerc_CERC913Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cerc_CERC913Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cerc_TRISPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cerc_TRISPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cerc_KarbinalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cerc_KarbinalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@_K=/09YXL6T#>0K?R.3 $9:N S]G!3IVP9)M]>U^W;ORAU@A*PB9&T(QT$
MA2*].%Z0K_ =>4[J<X=+]ER;?.&A7H/'SB0/H%>R$'K%M;$!22OSIL[_0O;,
M'73YJ]PEM;BXW$SZW[=A%&&SEU9E@.)&_A&N')!3);=AXM<G%-=\O,/0JMI
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M8:JIXL2LN-%RDQ\Z+:36,LXOUX('0ID/X/U22GV\,?^@/+<<_0=02P,$%
M  @ <CFM4N)>\Q^T!0  (A<  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6RM6&UOVS80_BN$5PP;X,0B]68WCH$VP;I^&!8D[?:9EFB;J"2Z)!W'^_4[
MRHIDBQ2= OV06++OCL\=>??<<;X7\IO:,*;12UE4ZG:TT7K[?C)1V8:55%V+
M+:O@EY60)=7P*M<3M96,YK5264Q($"23DO)JM)C7WSW(Q5SL=,$K]B"1VI4E
ME8>/K!#[VQ$>O7[QR-<;;;Z8+.9;NF9/3'_=/DAXF[16<EZR2G%1(<E6MZ,/
M^/U=&!B%6N(?SO;JY!D95Y9"?#,OG_/;46 0L8)EVIB@\/',[EA1&$N XWMC
M=-2N:11/GU^M_U$[#\XLJ6)WHOB7YWIS.YJ.4,Y6=%?H1['_DS4.Q<9>)@I5
M_T?[1C88H6RGM"@;94!0\NKX25^:0)PHX&A @30*Y*T*8:,0UHX>D=5NW5--
M%W,I]D@::;!F'NK8U-K@#:_,-CYI";]RT-.+.U'EL"DL1_"D1,%SJN'E(RUH
ME3'T9 PK=(6^/MVCW][]CMXA7J$O&[%3M,K5?*(!@[$TR9KU/A[7(P/K_47E
M-0KQ&)& 8(?ZG5_]GF6M>G"N/@'/6_=)ZSZI[85#[N^D9)5&5"GP\[W'8MA:
M#&N+T9!%JC8(8H,R\\"^[_@S+6 )9ZR.II+:E$FXYT4X)3,RGSR?AL26PM,9
MGK529SBC%F?DQ?DAR\0.8$$N9@PP+@LV1A73+IA'2_$I3!P&/92V$,%IZ@89
MMR!C+\B_]8;)$X3.(,;VPD&<]- YA$@P=:-+6G2)%]WGZADV5LC#8. 2:]5^
MU&R)T TJ;4&E7E /DFTISQ%[V9J\5O59%'4<L[/#[L*;VE&*DK@'V2&4)($;
M];1%/?6B?F1*2YZ9TF/R9MQBW0IIRKT+[-3"@>.PA]66"0<V?=8BG7F1?A&:
M%F\(Y<Q:.4J"6?]8VE(D"8+8#1$'75$/+AP"X'FI#_7FFQJT!>;5@\>TL=8+
M9?^HNJ228"##\0D!X0M9I&FUYI#=332'86(; $YP'Z9#*IX.A;0C"DR\,#\)
MD>]Y43B!$7O)* IF?627Q,ZA=8R#_91C)0_$#XG56W*HL7P.R<+M%SI'W?$/
M]A/0,9&&$PC;A)*$8=2O1@ZQ*$SCH?WNF ?';^H,"DZ7O.":,V][@#O2P'[6
M:(EW2P^&TYR^V[2 \0SWJYM#C,1I-.!ZQR#83R& 4.Z8ET).HN+$;W,$CLA)
MZ6WP.\1PB >X!'=D@OULXM@[DP\Y5YFH-*^,<Z9 4I,6;@=LXB!V/CL8*(SP
M /J.8/"/,,RE2+L8)$RLVFV+X9B0@2PA'=$0/]$\B@,M@&?$LN!K.E1EB,T<
M,&;V,5Z2.H?8\0OQ\\L]6S$(98XT?6FC.=RR$1?)]#G&(30; GHRBO@9YMCL
M%J):7VDFRTL[3QQLDN+^&75)3=.!'HATE$/\E',\HY<0VKP1!GAF[;N#7F"\
M&>B#24<P)/)6\"<MLF\;4>1,JE]_F<(T<E/W0OK@*^2D8PCB'T[N1%F*"BFS
M3&V?W+P+KH, 0V67"*:^';N!.348!\<_I#94FFJZTQLA^7]P)*E&,!!GFW8B
MKDLM#+FL7,)9>!UT;]!T-L9!-)[BI)9(8S 8C3%)7XURI4Q5JROU3BMHJ7)>
MK=^ZP!AF++5E]95*<7#NI3U 3:VS9LND0Q6FHTOBITN89YK\]0<Z_AEAQF/@
MSS&.PI\35F<@'=3>CZ-/Y#R,':>3"YR>Y]R49\A:,QY>\0IZQ2V'+':"= V"
M,!+TFR^77$!(F@S [1B<^!D<6I!=N2OJNZB<K7C&W<7:9N K&.NCU*HQ#D&<
MINE@U>[8FKR%K=5@K7'"MMDX#'%L1=?![5&<$#?DL"/MT$_:5O&N3^^/N= L
M<7HIY>K.'6*N[GQR<H%I;H\AN=:\4JA@*] +KE.(@3Q>R!Y?M-C6=YI+H;4H
MZ\<-HP#=",#O*R'TZXNY)FVOQ1?_ U!+ P04    " !R.:U2_M)!PN8"  #G
M"0  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)U676_:,!3]*U:TAU;J
MB!,(@0HBM535]C )%6U[F/9@$D.L.G9F&^CZZW?MI!F4CT!Y(+9SS[GG7-NQ
M1QNIGG5.J4$O!1=Z[.7&E+>^K].<%D1W9$D%O%E(51 #7;7T=:DHR1RHX'Z(
M<=\O"!->,G)C4Y6,Y,IP)NA4(;TJ"J+^WE,N-V,O\-X&GM@R-W; 3T8E6=(9
M-=_+J8*>W[!DK*!",RF0HHNQ=Q?<3@)L 2[B!Z,;O=5&ULI<RF?;^9J-/6P5
M44Y38RD(/-9T0CFW3*#C3TWJ-3DM<+O]QO[HS(.9.=%T(OE/EIE\[ T\E-$%
M67'S)#=?:&THLGRIY-K]HTT5VX\]E*ZTD44-!@4%$]63O-2%V ($O2. L :$
MYP*Z-:#KC%;*G*T'8D@R4G*#E(T&-MMPM7%H<,.$G<:94?"6 <XD$RDRF!2:
M(6AIR5E&#'3N"2<BI6AFB36ZFA)%A<FI82GAU^@S^H1\I',8U2/?@ [+YJ=U
MSOLJ9W@DYS>B.J@;W* 0A\$!^.0T_(&F#1SOPGUPWY0@;$H0.K[N$;Z9 <NP
M,@V2"_3(!!AGA*.IU,RMM%]W<VT4K+??)Y)UFV1=EZQWM-Y% 9PPK^GS#2J)
M0FO"5Q1=,8$RR3E1&I545;6]/E3;BC]V_':3KA/<P1CJN-XN85O4COA>([YW
M@?AJ^A%9F5PJ]@JKQIJH1@\JK\BC+4WPL:E^[]2?$[GC(&H<1)<[8%JOVM5'
M>YH&PP#W!D'_G?C]P#C"N!>$\6'M_49[_W+M\&76AHB,B66;@?ZY!O8#3QN(
M&P/Q20-3^$)3I:#4>\N_6?(7;(3XK(W0%K7C9- X&5SFY.*],-BK<71P)[3'
M[1@8-@:&'S)PWE88[HD*PB@.>MUWXMOC=L0'^/^AA3\D_X+=4&=H-W%&8.7"
MWSJ%[14(CKDE$QIQN@ D[L1 H:I;1=4QLG0'\UP:..9=,X>;&%4V -XOI#1O
M'7O6-W>[Y!]02P,$%     @ <CFM4D<5HG1+!@  Z!T  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6S%65UOVS84_2N$5PP)T,0B*<E.EAA(W'4+L&Y!
MTF[/C$7;0B31)6DGW:\?*<FB(W[$+E+L);'DR\MS+LES2//BB?%'L:14@N>R
MJ,3E8"GEZGPX%+,E+8DX92M:J6_FC)=$JD>^&(H5IR2K&Y7%$$51.BQ)7@TF
M%_6[6SZY8&M9Y!6]Y4"LRY+P;]>T8$^7 SC8OKC+%TNI7PPG%RNRH/=4?EG=
M<O4T[+)D>4DKD;,*<#J_'%S!\VF,=(,ZXN^</HF=ST!3>6#L43_<9)>#2".B
M!9U)G8*H?QLZI46A,RD<7]ND@ZY/W7#W\S;[QYJ\(O- !)VRXI\\D\O+P7@
M,CHGZT+>L:??:4LHT?EFK!#U7_#4QD8#,%L+R<JVL4)0YE7SGSRWA=AIH/*X
M&Z"V >HWB#T-<-L UT0;9#6M#T22R05G3X#K:)5-?ZAK4[=6;/)*#^.]Y.K;
M7+63DRFK,C4H- /JDV!%GA&I'NZE^J=&2PK YN"O%>5$5UT 4NG(4DV9I1[+
M#05_,"' T9>*K+-<-3T&)^#+_0=P].X8O -Y!3XOV5JH9N)B*!5@W>UPUH*[
M;L A#S@,/K%*+@7X58',7K8?*J(=6[1E>XV""3\1?@HP? ]0A* #SW3_YE$
M#NZ*C^M\V)/OCFYHM:;B/) K[G+%=:[8D^LSDZ10"ZO)^!Y45+H*WB1)ZR1Z
MB6\F\0A?##>[1;!CT"B)NZ 7\)(.7A*DVDZA:@'H\TI/N"#IM,N:!DE/F9!Z
M@JXXR]8S"00IJ'.>-6F2'4JC48^U'9*F;LZC#MTHB.Z."DKX;%DOFDR-3,%6
M>DVY (ZLWE&"HK2'T8Z*1^G8C7+<H1P'45[-OJYSKM9\7IVH.LZH6L[\ .1C
M"U/40VU'H"2)S]RPSSK89T'8O]%*S:BB1D@RI8RYD'J&;:@+Y)E=N#,(>SCM
M()2./', 1D9@HR#0>STG:YC*)Q^I7@-.)8QLB#CI(70$I3L3^27"'0N X1E0
M,B[S?VN%WRY/)T1H0T1Q'Z(C"$,/1&0@HCW4C5DBXH2)+ 081DE?Y5QA,4Q]
MU32:#O%!4/-JQDH*C@KED\=.O-@"<H*C9-Q?1LXX&$/L06R< \9A;99+REN<
M(56&1NQA$M;E):D65+O_G.0<;$BQIEJG;ZH-%5(KB?[NZIM<.PN2O"HICI!1
MM%.QE[B-G<"PG^Q6PHG,-@D+F1T"?=/?& D,.\E-):G29!F"9GL#[%N<*\97
M,V,?,.P?[7S?J5R]^0!SSDHP4_NWO%KK=<"Z3:03OFT2-GP[9@0C7W&-D<"P
MD]0;6#]:\$#5:8D"29X]>F/[AEZ_J24XCCBDM!&Y"2#C,"CL,#>-PBB 6UT$
M1P_*'N>Y= H.LEW$\D)'S F"B4<=D?$:%/::5XKMA&L[BJ[OJ.\\KCBD,"<>
MS,9\4-A\CC3HXZV0U^"S7+3XU<;)P&]FOA(Z-19.*K;GG$!KE^>(@A'V;/.0
M,284-J8_%31M0DY@3@]*+0]RQ2$(H6]>& ]"X>/+;;N#;P\PCO/+R\3&BE#X
MX+'/&0L9@T!A@]CSE-5F"1^S'$'^<Q8R7H'"7J%.YR6K?OX)IM$O0K+98XBX
M47DT#I913YYF"[-=!VK2 [$DO#;V6=TIJ/M[KW]7R6?-V2$OUI)FP>(;H49A
MH9ZZ%&/;VY':4&2L* @7!II;_II>QKMS.#K%J#\\[C#/>0 ;M<9AM?:P:"MU
M (^VG[-7>'C"?#R,DN.PDG_P2>"AXX%MW>[+3ANRRR$ZC3S&B8VPX["P>RE\
MQV#8FFV10(>0V/D-Z759?W'&>'UE'D +[S?'W&$>+</&%7#8%0[B]AV#%N_'
MSAWF8V>L"8=/2;><SBGG]<^M89W&QJ!P^C_I-#8.A%]SH#?1Z;:7%V6'IVE_
MI^H.&WFV2]@X'@Z?:]Y.I\?[\7"&>7D8U\1AUWP[G3YS+8/(XF&'J2@/C=C8
M9ARVS3?4ZMCIB!811UB B/'-..R;/U2O8]LH]5SK*YH[S+.)CXV?QF$__<%R
MW?8^?HV<,ZQ/;KAS9U92OJBO$H7"N*YD<Z'4O>VN*Z_J2[K>^VMX/FTN'4V:
MY@[T$^&+O!*@H'.5,CH=*3O@S;5B\R#9JKZ9>V!2LK+^N*0DHUP'J._GC,GM
M@^Z@N]R=_ =02P,$%     @ <CFM4APZ)+$\!@  -QP  !@   !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6R]65MOVS84_BN$5ZP)4-<BJ6OG!&B<!.U#AZ!I
MMX=A#XQ$QT)ET17IN/WW.Y0=R2(IV4F[YB'6Y1SJ.Q?R^RA--Z+Z(A><*_1M
M693R;+10:O5F,I'I@B^9?"U6O(0[<U$MF8+3ZGXB5Q5G6>VT+";$\\+)DN7E
MZ'Q:7[NISJ=BK8J\Y#<5DNOEDE7?+W@A-F<C/'J\\#&_7RA]87(^7;%[?LO5
MY]5-!6>39I0L7_)2YJ)$%9^?C=[B-]?4TPZUQ5\YW\B]8Z1#N1/BBSYYGYV-
M/(V(%SQ5>@@&/P]\QHM"CP0XONX&'37/U([[QX^C7]?!0S!W3/*9*/[.,[4X
M&\4CE/$Y6Q?JH]B\X[N  CU>*@I9_T>;G:TW0NE:*K'<.0."95YN?]FW72+V
M'##M<2 [!W*L ]TY4-,A[''P=PZ^X4"B'H=@YQ"8#GU!ASN'L,[]-EEUIB^9
M8N?32FQ0I:UA-'U0EZOVA@3GI>ZL6U7!W1S\U/E,E!GT"<\0'$E1Y!E3<'*K
MX <:2$DDYFBV8.4]ER@OX89(ORQ$D?'JI4177]>Y^HY./I=LG>7@>(K&Z//M
M)3IY<8I>:/M/"[&6K,SD=*( KG[H)-U!N]A"(SW0/@G%"H?;;-AM)I9+4?[^
M&PZ]/Z1&ZQCB<GB(&^AN7E5U'MP#7 T/\#:#;,#$805:L3S3B4C9*G?'<WU@
MK#1=+]=%71:8,GF:J^X@$RAY4W?2U)W4H_H]HUZP@I4I1TPAM>#HCM_G99F7
M]^@$L,H%J[@\U3<O>?H:4?P*$0\GKF)L'Q/4C]'+V,.Y[]/8)X1,)P_[*;<-
M21Q$V*>-72<0V@1"GQ?($> OMD.'^YB\) FZR&>VE>\;P=DFM&MQ95M@&A":
M=,VN;;,QQCY)L#M+?I,EOW:D/5EZ7Z; .Y*C$\A)?71JS&;Y\G$V__-1% 6"
M=7O#JNS?@5X+FH<'@R6"E>4!'J")1 F4UO,3U5-SO]M<S158/1-[]9^1?MMN
M#-._8]A!'C;(PV.1PS*X:I:%+7@C&%>#A18P _HLM H>&\'9%F-C;EW9CQF'
M[LBC)O)H,/+W4J[K>05Q;PL$.F*["$'8;_E#CC[PZIY7ATH86=!HG% :]C1T
MW."+?PX^5U5B"Q,._"0T*A/;T]Y(NWL<XHXL:2)+GAK9:EWI:TJ'5L$")Q77
M79CE%>@SL(.NA!7O%2JY/FLN0'=*(/ #!4KL(*@7DK@G#.RURL+[I8$X%81G
MH0\P-2NYL^HLOD8IW0,%/3G84U?X1W+060M75?X #8Q6!4MK[?7,@NX@=2J:
M!)C@I">:5C/@8='P?T3CK*JM%6@<QV95B<W>9E6= _4LC;B5''A8<UQ]XU6:
MRVT>ZFC%2LL]B4#I(J#-BI5'U(G:BBC 8=R#KJ5Z[/\$=,Z\^Q:BR%SSAFVZ
MD%N!@(<50JU#QGJ'F.DN@FVS9!JR$Z1-]ACCT(1YP*H+M-4#>%@0_ DM7 CI
MSIZ#A0D\-#(DWF&[+KB6LO$P9QM2F$.U#37_@56/@IAXSIZTZ3I(@M C@2GG
M'9:8#.AYW#(['J9V1QA'0+_ -AN3(+!7#9O6@\2,S;:Q^,+!_:&7F-1S[; ;
M Z_X7M\T;V4"'M8)S]C!]=3<5@!1X'D^)I&9%X=6&*HY:;4"&=8*1^[BW)4G
M-G<3/PB-CIT16P5$QE;OTF%C5M[U-(^0R*R\PVZ,HRA*>O8DI!45!/_ZS1S9
M>W/P9!4 1QWR!S3K$G!LJEPI7H)*N"OR]$>5*K'9'-,DPG'<HVQ(R^ADF-&/
MB$F3)^P QW,=V1[+'Q.KLVMM^J=1&%"S:QTO#DQ.=@]%^[+2*@DRK"2>OW$G
MMDH(Z]<]/8J:M%*!#$N%GZ.]B$,>D#CN>U] 6H% A@7"\\47L64!CDQ!>\"H
M"[H5#F18.#Q%?A$'[_M^;.(\8-4%VDH#,BP-AN07<3 M;&1CSUR7#]IUP;6$
M3)Y$R ?D%W:VI4VP<8(]/S;U[:7#<I"*:4O%]$E4[)!?+N@7U&9.2G%@O4NU
MS6)3?CEL3!)VF! ?!]1XW+7#;DR\V(_,:D_V/J'H3VH0+T@0B0H^!T_O=029
MKK9?J;8G2JSJKRIW0BFQK \7G $/: .X/Q="/9[H#S7-M\+S_P!02P,$%
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M&S$!,8*G,3MZYJ1IYEP%L5^%P"-FT".D?EW;R;',!3DORZ!-/F_B)9X.^XR
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MPQDTY%8 WJ^E-*\W]@/=&?CM_P%02P,$%     @ <CFM4C1XD+E:"0  !18
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M;!>!@"[GWI5VR'R?=''NTY>KB]W9&_26-A)Z5&B,UX!PS<NB4"ZL;>Y=34,
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M*\:)5Z-4(?U%=(U\Z%NX&%TM/TOY1,,+\'SID++N@@\8OOR>_A=02P,$%
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M+RPQF+6D*'85]RWLVZI1U,O@)A' [0^MS9-1"H&8\74B'ZAY&GP,<A$%9"F
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M:2LTCVV,^.#8)R:I3CLNBGSJ@QQK2QX*#T.??+K@]MBX6*LH0I3BD]CST-:
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M\AHE;K@UD,7CV02*.,MF\#,)-1->@55TQ;BKLGLK8#8>PV22P3T3QY30P_6
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MTF[R7X2!]Z0>/AO(VY83%8$;,DT'DU$$.HSBL+%JY\??6ED:IGY9T]<+:J=
MYQNE[&GC''3?0\N_ 5!+ P04    " !R.:U22ZD3.3L*  #D'0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6RM66UOVS@2_BM$+GM( =6QY3BQVS1
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MUM!6 >:6EE(B\(H;@;J.D<=G4C?-&RJ(21@!D2M E/Z '(-J'>.F*I%52/;
M8/3:S"K55N)9Z/J(+0N,&U5>5P B5[R;P2-4Z4$"H,Q N[#+*93;X.$N(\^L
MR4..!$TZ(J.:Q""S&Q^=U?P&7DD-<X/*IR:EYDP8U)]Y0*%AU*9UXT1I*QOU
MEH'$2-;R&7M2;\=V)[4DC+\'2#]DP*T<A.AE;0<\<!^R]8<\0Z"=+&%=3H<8
M'8@:9]5N3I"K*+.2V:8)KBADSSZWUV AEY?HB#AMYFC<\4PQ6]1#@(71&-F*
M$#\->OSP<!XC!)I0I?FJ2+(J<'_-%PA3)U&/ZIHN2VAQKW/NJ\+C32A'C$ =
MSX1YMY]OPX;$,2\%[@\A4L.[;\#;53G:3%S'9[VS9CX(\UJ[=RUPK\D\J3;I
M^H 9#F=[CR:E_F:&<N*?&**J0HE!F#;[__<4-8H&X]WN\\$4M6]&ZC@$,!X/
M1QM$.A/3SXTK_5_6"%^W6-+8T=320[-#F,/<SRC[H$T>_"K5X=IPDC"XV.=;
M! O/)KJ@0M:IP)L>7$*O,()1'>DZHS._A$#N2G8@,;3[D]$@B@?=J?J'_/.4
M^.A--N$!$]^JJ>4S@//' IAJ-G1G@U.-W/$;?[!MC6>I%FA?U>G3HME2.N?^
M=+VU"0\WP_YY%(_C7VSMJ#?XB\D 'XQV-=O6HJ&U6M>?R@ZUU.*#LG/<[OIB
MV/B":2/,S2RHAJ6[#H6!/#0U2ZI5XB,NR9?;1VR.*L V-IU .&#:S@G2GPU]
M'CABVW34V[WW5DO6.1YX(3[NEN0WV_/CF_M2AR/# $2VYGAK!&[F3FZQXF@X
M[HMC,>Z=CZ$@GVK%XJPELV,QP"C<#WR-9V>=D?I8A%&6 RU^*49X,D%,#@$!
MW(5HH<;GKCV&"XC 9:_19; 1,>?/8+R-_$QGG#ZWV\>AKQ4=6LEF\@ER%2HP
M^^ SXA"_;N#+XOD?QI/1CZEQ4I_FM.L>>;D^Z*%>H5Z5=%[>.6=L3H5(*5A
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MDMNX%?T55,=.M:O8:E%[>ZMJ>WHF3F7&CMN>>4CE 2(A"64N,D%:5KX^YUX
M7+3UXDQ>NB4*N/MR+L"7F[SX8E9*E>)[FF3FU=FJ+-?/+R]-M%*I-+U\K3+\
MLLB+5);X6BPOS;I0,N9-:7(YZ/<GEZG4V=GKE_SL0_'Z95Z5B<[4AT*8*DUE
ML7VCDGSSZBP\\P\^ZN6JI >7KU^NY5+=JO+S^D.!;Y<UE5BG*C,ZST2A%J_.
MKL/G;T:TGA?\KM7&M#X+TF2>YU_HR[OXU5F?!%*)BDJB(/'OFWJKDH0(08RO
MCN99S9(VMC][ZC^S[M!E+HUZFR=_Z+A<O3J;G8E8+625E!_SS=^4TV=,]*(\
M,?Q7;.S:2?],1)4I\]1MA@2ISNQ_^=W9H;5A=FS#P&T8L-R6$4OYDRSEZY=%
MOA$%K08U^L"J\FX(IS-RRFU9X%>-?>7KVS*/OH@WT"L6;_,4OC:2S/7RL@1U
M6G,9.4IO+*7!$4I#\6N>E2LC;K)8Q=W]EY"J%FW@17LS.$GP5UGTQ# ,Q* _
M"$_0&]:J#IG>\)BJ*UFHBSFK^D%N$5FEN"X*F2T5?0[$;WD62;,2-]_)#$K\
MZWINR@)Q\^\3W$<U]Q%S'YTR],7]#/TX2K!3.!$W7RM=;L6[+()."'CQ(9&9
M>)^)ZW6A$S$.>%D@RI7BW3+;_O4OLT$X?6'$/)=%+/*%B'6!K,D+(V2<KTLP
MHN4GZ)_3[T1GT'_!R^@I?P]?/!/2\'Y319$R)B]$F7N"8_$^S?2\,@?IC#MT
M>N*3EX(7;T!7KM=%_@T"SK<'53)DK%6>Q(J4R;!.13)50BT6B@N"@.%^E5L1
MSJQE#JLB;NKU2#/52/1YC?UE1ZSNTF#GUT(959# )(RLRE5>Z/_@:[4FJTSZ
M_:#?[\/LL2:?RD08"EM#7HGR- 4W5DF@'@MM3"7AB( LO$%EH_^CR2@832>B
MPN8DCR1YS]$H%)5IG2V%_"9U(N>)8CI+)$%)'#)44;E!$!ALA\D:+Y'L/7&-
M,$*NQ$[\C\J43/\AD>$)="+DP:[4UFN@"+]M5CI:X5&$MF1<L++*WMI$$K*T
MK!KV1BBG24)Y8ZT#[<2MBG+H]<,Z[M#Y856OJR5: 8EP]2AM9V,;5HVFGU:Z
M.*+H/77L4OAA%?]>911J@_YC]!L$_1!1W]+PIZJ@.*>]I2I2"NXZ#_<E#PXP
MV6C*IPH-&-4U0BYM:YF$R_F%+N 5M(B8>,5RRXK(K *\(8Y*0A%L!2-9B*W"
M'R=ZFE?(./6U@O!(^]%3+V"9EWB45>D<V8=GP%%P2\8,CE0"M],9V,N6R'W1
M?E*1\H1I#3H"LK\C(&*#.:#Y0G;??=D^L,V&_@R"Z6 63*>A%ZA;3!9566&5
MKTW=0G+(^#WQ?LW]B\N0$>K[&NU'R$5)^U3&<L&E-^DZR;<*UN?EZ"G;M7/,
M-\2N0+01GX)6()8^\:<V)ME1RD8;PE[Q8\J!6'T#3%TS-'@B!E<S_!W.!N(7
ME:D"?N&:'0.&:0(&G!QAT!^-Q636%[>PH^TQ@+=?5$F&#_MC,1Z+3^Q5=I<#
M(%&[<3\!E=%HQO_#<"HL*/-J;G2Y$A23.O+PA?0E\E1EM%WUJ14"*^0?&Y-2
MVY;S<B5+6EZB =Q)S#;:CHA1#@N3>^%(T[A 4U.)\F7&/8Q0MB#+$!2^(-Q"
MB!EKG&M4S6NM$'HQ5R(W#G"PKQND3B7(\7-.3:TKU2%7@@=T7N3H>!OSW 64
M$>];V?-;G5,N;/]@Q$XF@G080!!XJHBTX;Q X$)&5Q+V5MJ&&:-<BH74A?@F
MD^KDAJ;SD@\(4W+F4V4ZUR["GP&&)YPR<%6=JD[%OI@%LV$_F$Q'%).]JS$%
M:&\X$=/>5/SBG#T,1I-I,$,(T9JA73,8 -%:S6)Q'B)W9_W^,PJVWG#$_U W
M,>(LE"8:YX/!R*\8]J93IC'JMX7;,7X8!E<C[+D*><LLM**-Q*Q7L^;RL+]U
M&%RA<,]F5]@RZ@VO>.=X*":]/AJ06UU7H#K ?7!KE M@%E0 M)M<\[.W*ZT6
MXF>=05H-([]?+.#-XH'IA**\KL"<JGV_-][!"GLUF!I>AA(;5Q$/$SZ46="
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M0! %S: 7-#E"';5Q50XKKPFN^$S"S]X:,#O;"I+0[=Z=HYGNAD[[MLX*55N
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M8OX02(2Y(*]_!28)V.3U'"Q,^-F:3MP;,4E*$E5ZMC>GG/@>HM O$]B!8EC
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M ;'*4R>=DD5>,@B6A7*V2R43;V29:,3:.H!92$IYW>H-%Y<Q#"Q5!R71N@:
MJEN(R\OE%/IMU^<"!>SM.L^YW.*2,-2SGJ=%SI##><;[('W!JX*? CHZC65S
M?%;4C2@)2PPEBOVG%./1= A-WO##Q5)=PC2TP%L 0FNJ,60_'D,(43F&B^O:
M%?DU'-4#1U0RS9A,)C5;QG@ P\W&U9M_*XUJ%+Y;#2-PPO&0H38."8H\1G(1
MQ>;IP\%7V5F@,H;C'45^=YJX-9QB0WY)E.E^CJPSJL11N+.9@12_O#SGS0FF
MY9"KBPY+=*D-R#]D+A_44B0&U3!! ";W)6:N-C4Y259 9"@*\ P))+FON/^
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M"?51\MOV);?K.GO\[LWKGSZKP\^_O+I\M7QPI,JZJK."'8F>KVJD64;*HDA
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MSQ\^72Q/"#BV=L6*/?1G302[!'_$CMJHQ:.4L8^Z0[]S.LS4/8I\"W^7)O5
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M\#3J47)5D?'*&N&HN!TL)A^65WP^'OA3T=Z?K 5GLK7V@1\^Y[>#,0=$FK+
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M947_$M3.@<Y72MG=QA'T?Z?Y'U!+ P04    " !R.:U2S_>7/J<"  !F!0
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MP+(\%)4=+;;%)GXI-!P)BN8&#I)4F@!XOA)"'SKF7% ?32?_ 5!+ P04
M" !R.:U2*JJH2/L$  #D&   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6S565UOXC@4_2L6FH=6ZI+8X:LCBM26Z;2K[0PJVUVM5OM@$@-6DYBQ'2C2
M_/B]#FD,;6+HJOM 'YK8R;GW^MZ3XP_Z*R&?U)PQC9Z3.%47C;G6B\^>I\(Y
M2ZAJB@5+X<E4R(1J:,J9IQ:2T2@');%'?+_C)92GC4$_[QO)05]D.N8I&TFD
MLB2A<GW%8K&Z:.#&2\<#G\VUZ? &_06=L3'3CXN1A)976HEXPE+%18HDFUXT
M+O'GVZ!E /D;?W"V4EOWR QE(L23:=Q%%PW?1,1B%FIC@L)ER:Y9'!M+$,>/
MPFBC]&F V_<OUF_RP<-@)E2Q:Q'_R2,]OVCT&BAB4YK%^D&L;EDQH+:Q%XI8
MY?_1JGC7;Z P4UHD!1@B2'BZN=+G(A%; !S4 $@!(*\!K1I 4 ""0P&M M Z
M%- N .U# 9T"T#D4T"T W4,!O0+0RZN[*4=>RR'5=-"78H6D>1NLF9N<$#D:
M2LA3P]VQEO"4 TX/+M<Z0T.@C])<9Y*A7] W*B4UC$(G0Z8IC]4I]#Z.A^CD
MTRE2<RJ90CQ%]SR.@7[J#'W:;O8]#7$9ZUY8Q'"UB8'4Q'!/U\COG"'B$UR!
MOG:COXEE$_G8P/%Y!7SHAO^:I4T4^+EWOP+^Q0W_'FJ UWN_<<.'+'3"O^X)
MGJ8O\,K4W>Y+O*R#>\"CDDRD)!/)[04U]N[24"0,C375#/1-GZ$K&M,TA*Y<
MAVD:H<LHXD:U: RT4V$L5&;X-%F;YD(HZ/\J1;8 6H&Y.(MX.LO?%*GF:<8B
M]'W!##^!:NCOWR "= ?>U#^.^(,R_B"/OU43_P,S:F\<;KS-8 SF5O&H<%G%
MKXU-[.=&S5RQ''2;0=];5D32*B-I.2,9,B:GG,4PVDG,9Q6^=\RV2[/MHRQ0
MIXR_XTS+=4U9T(+RJ.KC[;RM3= DU;7IED%TG4&,F.0BXB$X79LD5GVVW;=^
M_2:N]MLK_?;>S0GT$UW^]?NC([7GI?7SHZ0&]NU,YN_)ST3#<JJ^*L/"0&>K
M*KA=712\-8'BCQ>-Z\+H#D/.FX&__5?#%VSE&!-G:(8:P)![^LR3+'$EV2HD
M#HZ3)E99\1YIS0K-$%.4@,=YO(9R)0F3(8?(Q,)J2DZDJ@7-S1X?N+<QK5P1
M6]'&[7>4$>[&V42Q'YDAVI?E&Z[O>K'2BCO'65FKR]@MS%O111]0Y*L][L@!
M-;;:CMWB7M08)K@EDYI/8H9&L(MC4D+2QEJ$3RXW5N3Q<:H\L2I/W"I_EYJ]
MBHD=G<"N8[,=.:WZ1@M#&.](;.\0B256_8E;_4<LXE1+6 V,A-13 5L@*.-_
MFZK)UCK[.!?:Q,XCQ+W4OLGRW2:=S22#_#!SWK AN^.+O"Z,[I04DV;-'$[L
MG$#VS G5PSXK4@6=H".0N3&%[_(GJBBZ*RE6Z,EQ+L^)G42(>X$^DB)D+%)H
M*D6"E$D79(XJQ:KG45*Q0&_5UM/.!,0MS:9."M:"P#$8962+6$FJ[EM2^<U>
M30Q6T8E;T;=C@(MB<LFJMNB%F5=[A9H]"K%*3\[_9TH?M'(,K' '_E&2.[!:
M'[BU_EVL*FSML(K4L2JPRA^XE_0?4U;8K^PIZ]:1R7%N" (K_H%;_-]7UM:;
M+>3K3]7;.HTUY__W5,XX6([9%#!^LPN3@-P<J6\:6BSR ]J)T%HD^>V<4=@]
MFA?@^50(_=(P9[[E#QN#?P%02P,$%     @ <CFM4H7D+JF, @  !0<  !D
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M#8X][C+#R124#<#[:RG-R\(^H)EU9[\ 4$L#!!0    ( '(YK5(.B!J R (
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M-!7: +Y/.5>;B;[H%)?S_C]02P,$%     @ <CFM4M=P\L)#!   0A,  !D
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M,SP#!6Q+TTA]Y<=?64'(R?)M>"3U)SH66,M FU0J'A?!4$$<)ODW_5Y,1"T
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M$\!6=29;@Q06>J*SM9@M101K+B^X9X=I1@&/(BIJX$YRQ<!>?8E:(YLTJ/7
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M$]C_(K^PR5\4/^@[CT>N%(_UXY[1@(D, /U;SM7+2S9 >6TV_Q=02P,$%
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M=,,U^YJRO#(BH@U-*LDTHPI]7E--6*Z^@)$RQFKN:O#"<+E).^.JF=$_,V.
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MYL27.:GXCG?P7>$:!<0M3*EG2BNF]+^&'>RRQ;M!]7^IL(OZIJ1^8\?/*SH
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M_NO@.%#;FJNV,\C2T%"TS5 \T@O7]N&Y2-T+54TT2FUSZ?8@:U.ZH@$%^VN
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MFTIX0,V(P&B ]7%8'!>8,3M&@Z=_**\RUMYEQ%L0HP.#JQD^HO@:7'T<%8O
MW#'Y4@HY ]\7<A7P&M77..D?2)LBT#@:X&V*-Z]1/P?M%D6 M"@"C:\!#HQ%
M:+ZO(SXZ,H$&RN! 7A,/-) &XU^F>Y/(? K:+US FCI.*S33VJ]3Y"^[;BE?
M14E&-FP)DL:1!#=>_EBJO!#IMOC!RGTJ1!H7']>,+AB7 ^#^,DW%_D+^!J;Z
MR=KI_P%02P,$%     @ <CFM4N+!]77[ @  - H  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&ULS59+;^(P$/XK5M1#*VV;%Z]6@ 2TNUMI*Z'2[AY6
M>S#)0*PF-FL;:/_]CIT04@C1'GKH)?%CYO,W\R7CZ6^%?%$)@":O6<K5P$FT
M7MVXKHH2R*BZ$BO@N+,0,J,:IW+IJI4$&ENG+'4#S^NX&67<&?;MVE0.^V*M
M4\9A*HE:9QF5;V-(Q7;@^,YNX9$M$VT6W&%_19<P _V\FDJ<N25*S#+@B@E.
M)"P&SLB_F?BA<; 6/QEL565,3"AS(5[,Y#X>.)YA!"E$VD!0?&U@ FEJD)#'
MWP+4*<\TCM7Q#OVK#1Z#F5,%$Y'^8K%.!D[/(3$LZ#K5CV+['8J V@8O$JFR
M3[(M;#V'1&NE158X(X.,\?Q-7XM$5!P0I]XA*!R"0X?6"8>P<+"9<W-F-JQ;
MJNFP+\662&.-:&9@<V.],1K&C8PS+7&7H9\>SK2(7L@8$Q&3B<CPZU#4YO>2
MV*W+^?'6W:L9 SF_!4U9JB[0^'EV2\[/+L@989P\)6*M*(]5W]7(T9SD1@6?
M<<XG.,$G) ^"ZT21.QY#_-[?Q=C* (-=@..@$?"!RBL2^E](X 5^#9_)_[M[
M#73",M^AQ0M/Y3NA$NJ2.I*2\B7@'Z+)_(U4[:;TS2Z/ME3&Y/</A"3W&C+U
MIX%0JR34LH1:)P@]"4U3HBI:1Q5:=0+F>!V+9ZK$9NBW6KV^NZEFM<;(][NE
MT3NJ[9)JNY'J(RB@,DH(?EKXJVZP!JU,8AJRT"FA.Y]#EFY)J/O!LN1X[4K&
M@^M#58YMPEY0+TJO)-IK)/H-.$BD:C2A,58HIK2DIC8W9.&Z!+_^'++XWKY>
M>A\L3 %8S;KOM=H'TM18=7I>O39^I;K[C6QG- 5EM<%+^@4TX\NF+ 1[W."3
M"+,OK'[XT<*$QT7*.]+EV*C=/I#%K=R_&<BE;4L4GK_F.K^IRM6R]1G9"_]@
M?6Q:(GNO[V'R?@KOH27CBJ2P0$COJHL?BLQ;E'RBQ<K>\G.AL6>PPP3;.I#&
M /<70NC=Q!Q0-HK#?U!+ P04    " !R.:U2J):[L&$$   I$@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-BYX;6RMF%UOXC@4AO^*A?9B*K4D=@*$$2"5
MMK.[%[-;3;73:Y,<P&H2L[:!5MH?OW8<$MHDGK0S-Y /G]>/3WQ>QYD=N7B2
M6P"%GK,TE_/!5JG=9\^3\18R*H=\![F^L^8BHTJ?BHTG=P)H4@1EJ4=\?^QE
ME.6#Q:RX=B\6,[Y7*<OA7B"YSS(J7I:0\N-\@ >G"]_89JO,!6\QV]$-/(#Z
M9W<O])E7J20L@UPRGB,!Z_G@&G^^(6,34+3XSN HSXZ1&<J*\R=S\F<R'_B&
M"%*(E9&@^N\ -Y"F1DES_%N*#JH^3>#Y\4G]2S%X/9@5E7##TT>6J.U\$ U0
M FNZ3]4W?OP#R@&-C%[,4UG\HF/9UA^@>"\5S\I@39"QW/[3YS(19P%!5P I
M TC?@* ,"(J!6K)B6+=4T<5,\",2IK56,P=%;HIH/1J6F\?XH(2^RW2<6CPH
M'C^AI4Y$@FYXIF>'I$5^KY"]]??.G$KTR-06/8 XL!BN5D7[[R 5RS<Z+D^8
M;?7I%A1EJ;PP\;9Q*5[JS#REJ4W?7EP2+BTAZ2 ,T%>>JZU$=WD"24O\C3L>
M$X> I]-5Y8R<<K8D3L6O5 Q1@"\1\0G^#7E(;JD :7_; -URMQ!7<KY;[A5N
M4#WBH- /.O3_VF<K$(BOT0\EPTHR+"3##LDE36D>PR5:P8;EN9D$6GX'@O$$
M?6)YV=,%^J^U3YMDV\6HZ,*XS6$118$_GH0S[]#"-JK81DZVWP7-%?3'&#4P
M@G \B?"D'6-<88R=&*>Z@6<0,9,@D>9Y9X;&#;0K3*+(]]O1)A7:Q(FF_6\-
M3.UUK[U1)DT40L).E*A"B?I-)- 6\J%9%#7 ,)Z&833%%9DMPF9#YW2;5B.8
M.D=P9Y\O7:70FWG:G')3'$;1M!T%^[69^\Y2?RQ6+3WYZ0&$7H6KV8=VPEBQ
MSJW%<G@ /ELZL/OA=11_PM.4"EGW=M'J^E8\.L_"<#KJ2 &IH4CO\N\)8@6G
MKT""+I#:=7'09V*\#R5HH.!AT#%#<>W6V&W7;PN^)TS8DI=)ARWBVIZQVY_O
MVBJ])]&HA2AZ6^AEJYX3J_9S[#;TMX7>$WG<0 Z'05>AUPZ.)\Y"MZL+NC8O
MP4R]7*(OE ETH.D>3&9YN?AL;#&XJKUV:OP#J_ZY:H\:>2##8-R1A]I\L=M]
M/U#MTQ800MI!2.V\Q/_EU5Y*OEJ[.CAJ3R9N3RY+_7T<N"4E':9#:B,F;B/6
M=?ZAF4*:=DS./;!\I2:-(N^>3Z0V;=++M-]9Y*7H:YA1T %3VS8)W[>:"S ;
M<U."L=[1"+T%WM,4*1!9 ?L"&O7"M<&I39JX3;I\+VL=K#LRLAB(H,SNNO3^
M*Z$O[?LBM]2DE(J<4J]'6-LYZ6WGK:-T1X\M6AN)=[89ST!LBF\44C^Q?:[L
MOKRZ6GT'N2YV_U[=W'Y$T1M-[;D2I;#6H?YPHO,E['<)>Z+XKMC:K[A2/"L.
MMT 3$*:!OK_F7)U.3 ?5UZ'%_U!+ P04    " !R.:U2[:C1/RL#  !3#
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M3H9P<[-;*+ZVD^2"*SV7VLM"_]< 80ST\R7GZK P#NI_+Y/_ %!+ P04
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M1AJ< +>L\(T"90-POY32[ TK,+YZV2]02P,$%     @ <CFM4J^B=-5  P
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M0?V6Y$F(.X@T8DS,.07U>Y(1S'\"9I?<Q/%0@1FH(#;0L^%XWZ@Q)OJJA-A
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MG[*^&[/\ZQ?H[36M==D<\EGWE<+D$U!+ 0(4 Q0    ( '(YK5('04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ <CFM4E<-1\?M    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ <CFM4IE<G",0!@  G"<  !,
M         ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !R
M.:U2DGBZ]!,%  ##%   &               @($,"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ <CFM4N)>\Q^T!0  (A<  !@
M         ("!50T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( '(YK5+^TD'"Y@(  .<)   8              " @3\3  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !R.:U21Q6B=$L&  #H'0
M&               @(%;%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ <CFM4APZ)+$\!@  -QP  !@              ("!W!P  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '(YK5+;[2-B= <
M  \?   8              " @4XC  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !R.:U2-'B0N5H)   %%@  &               @('X
M*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ <CFM4N(&
MPBT<!0  LPP  !@              ("!B#0  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( '(YK5+ZALU7K L  &$B   8
M  " @=HY  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !R
M.:U2:0 +Z%L%  !_#   &0              @(&\10  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '(YK5(^BUQUY@<  .,5   9
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M970Q-2YX;6Q02P$"% ,4    " !R.:U2_?F B#0.  !5+P  &0
M    @(%::P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M '(YK5(&# ?-"@,  .<&   9              " @<5Y  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ <CFM4H83[X<^!@  [@X  !D
M             ("!!GT  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !R.:U2%]@W-G85   B00  &0              @(%[@P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( '(YK5)\DU<ML@0
M "0+   9              " @2B9  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ <CFM4K+'%\!Q P  WP@  !D              ("!
M$9X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !R.:U2
M 0^5)CD$   1"P  &0              @(&YH0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( '(YK5*9PG^^30,   P(   9
M      " @2FF  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ <CFM4@1Y?%7Z @  J08  !D              ("!K:D  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !R.:U2S_>7/J<"  !F!0
M&0              @('>K   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( '(YK5(JUW<I= 4  /(.   9              " @;RO  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ <CFM4N=^H^*K
M P  WP@  !D              ("!9[4  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !R.:U2)*S=XO8#  "F#@  &0
M@(%)N0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '(Y
MK5(JJJA(^P0  .08   9              " @7:]  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ <CFM4H7D+JF, @  !0<  !D
M         ("!J,(  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !R.:U2M>C@>8X#  #W"@  &0              @(%KQ0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( '(YK5(.B!J R (  &\'
M   9              " @3#)  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ <CFM4AKC9'&, P    X  !D              ("!+\P
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !R.:U2\Y^:
MLS(#  "H"P  &0              @('RSP  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( '(YK5+7</+"0P0  $(3   9
M  " @5O3  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M<CFM4LSIW]66 P  % X  !D              ("!U=<  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !R.:U2= GD.%0#   1"P  &0
M            @(&BVP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( '(YK5+0V#P=K (  ),(   9              " @2W?  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ <CFM4FR>A^&( @
MK08  !D              ("!$.(  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !R.:U22-&%%$$#  #_"0  &0              @('/
MY   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '(YK5*]
MQ<*.9 (  %0%   9              " @4?H  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ <CFM4G*09S2("   N2\  !D
M     ("!XNH  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '(YK5+MJ-$_*P,  %,,   9              "
M@48( 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ <CFM
M4GFJ?:2N P  R0P  !D              ("!J L! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !R.:U2\$ES>\L"  !3"   &0
M        @(&-#P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( '(YK5(MD\><+ (   $%   9              " @8\2 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ <CFM4J^B=-5  P  \0H
M !D              ("!\A0! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !R.:U2),2TD_X"   Z"@  &0              @(%I& $
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( '(YK5+@=C]*
M*0(  /@$   9              " @9X; 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ <CFM4@IY&'G% @  >P@  !D
M ("!_AT! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !R
M.:U2\"B.NQ8(   ++0  &0              @('Z( $ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( '(YK5(L?T,Z* ,   P3   -
M          "  4<I 0!X;"]S='EL97,N>&UL4$L! A0#%     @ <CFM4I>*
MNQS     $P(   L              ( !FBP! %]R96QS+RYR96QS4$L! A0#
M%     @ <CFM4MR2QXUA!   820   \              ( !@RT! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( '(YK5*\ =;!X $  .P@   :
M      "  1$R 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( '(YK5(4U''DT $  *T@   3              "  2DT 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     _ #\ ,!$  "HV 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>184</ContextCount>
  <ElementCount>380</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Aytu Divestiture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AytuDivestiture</Role>
      <ShortName>Aytu Divestiture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AssetAcquisition</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Capital Structure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CapitalStructure</Role>
      <ShortName>Capital Structure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Aytu Divestiture (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AytuDivestitureTables</Role>
      <ShortName>Aytu Divestiture (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/AytuDivestiture</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/NetLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Capital Structure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CapitalStructureTables</Role>
      <ShortName>Capital Structure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/CapitalStructure</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/Business</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Aytu Divestiture - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AytuDivestitureNarrativeDetails</Role>
      <ShortName>Aytu Divestiture - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Aytu Divestiture - Summary of Liabilities of the Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails</Role>
      <ShortName>Aytu Divestiture - Summary of Liabilities of the Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Aytu Divestiture - Summary of Income Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails</Role>
      <ShortName>Aytu Divestiture - Summary of Income Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Aytu Divestiture - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails</Role>
      <ShortName>Aytu Divestiture - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/Revenue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Net Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/NetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Asset Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AssetAcquisitionDetails</Role>
      <ShortName>Asset Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/AssetAcquisition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Accrued Expenses and Other Current Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Capital Structure - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CapitalStructureNarrativeDetails</Role>
      <ShortName>Capital Structure - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Capital Structure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CapitalStructureWarrantsDetails</Role>
      <ShortName>Capital Structure - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Stock Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Stock Based Compensation - Stock Options With Service-based Vesting Conditions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails</Role>
      <ShortName>Stock Based Compensation - Stock Options With Service-based Vesting Conditions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Stock Based Compensation - Stock-based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock Based Compensation - Stock-based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Stock Based Compensation - Stock Options With Company's Market-based Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails</Role>
      <ShortName>Stock Based Compensation - Stock Options With Company's Market-based Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Stock Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/IncomeTaxes</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Leases - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Leases - Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/LeasesLeaseMaturityDetails</Role>
      <ShortName>Leases - Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cerc-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cerecor.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cerecor.com/role/CommitmentsandContingencies</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cerc-20210331.htm">cerc-20210331.htm</File>
    <File>cerc-20210331.xsd</File>
    <File>cerc-20210331_cal.xml</File>
    <File>cerc-20210331_def.xml</File>
    <File>cerc-20210331_lab.xml</File>
    <File>cerc-20210331_pre.xml</File>
    <File>kkclicenseagreement_redact.htm</File>
    <File>q12021cercex-311.htm</File>
    <File>q12021cercex-312.htm</File>
    <File>q12021cercex-321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cerc-20210331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cerc-20210331.htm": {
   "axisCustom": 2,
   "axisStandard": 31,
   "contextCount": 184,
   "dts": {
    "calculationLink": {
     "local": [
      "cerc-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cerc-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cerc-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cerc-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cerc-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cerc-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 536,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 8,
    "http://www.cerecor.com/20210331": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 17
   },
   "keyCustom": 80,
   "keyStandard": 300,
   "memberCustom": 43,
   "memberStandard": 39,
   "nsprefix": "cerc",
   "nsuri": "http://www.cerecor.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cerecor.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Revenue",
     "role": "http://www.cerecor.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Net Loss Per Share",
     "role": "http://www.cerecor.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:AssetAcquisitionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Asset Acquisition",
     "role": "http://www.cerecor.com/role/AssetAcquisition",
     "shortName": "Asset Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:AssetAcquisitionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Fair Value Measurements",
     "role": "http://www.cerecor.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Capital Structure",
     "role": "http://www.cerecor.com/role/CapitalStructure",
     "shortName": "Capital Structure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Stock Based Compensation",
     "role": "http://www.cerecor.com/role/StockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Income Taxes",
     "role": "http://www.cerecor.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Leases",
     "role": "http://www.cerecor.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148113 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cerecor.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Aytu Divestiture (Tables)",
     "role": "http://www.cerecor.com/role/AytuDivestitureTables",
     "shortName": "Aytu Divestiture (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.cerecor.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cerecor.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Capital Structure (Tables)",
     "role": "http://www.cerecor.com/role/CapitalStructureTables",
     "shortName": "Capital Structure (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - Leases (Tables)",
     "role": "http://www.cerecor.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cerc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i7e92ff68bdc846f39796a8688fdb85c6_D20210101-20210131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Business (Details)",
     "role": "http://www.cerecor.com/role/BusinessDetails",
     "shortName": "Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i628f57f6215a46b79ad5e7d53f734b1a_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "cerc:NumberOfProductsDeveloped",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i7d85ed913ebe404ab54475135f67de89_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cerc:DebtInstrumentRemainingContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Aytu Divestiture - Narrative (Details)",
     "role": "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
     "shortName": "Aytu Divestiture - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i7d85ed913ebe404ab54475135f67de89_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cerc:DebtInstrumentRemainingContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Aytu Divestiture - Summary of Liabilities of the Discontinued Operations (Details)",
     "role": "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails",
     "shortName": "Aytu Divestiture - Summary of Liabilities of the Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "if5751c8b6986481696dc10ecdf31864b_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Aytu Divestiture - Summary of Income Statement (Details)",
     "role": "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
     "shortName": "Aytu Divestiture - Summary of Income Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i5784318d54aa43969df750e98d7fd10e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cerc:DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Aytu Divestiture - Summary of Cash Flows (Details)",
     "role": "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
     "shortName": "Aytu Divestiture - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Revenue (Details)",
     "role": "http://www.cerecor.com/role/RevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:ClassOfStockNumberOfClassesOfStockOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_of_stock",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Net Loss Per Share - Narrative (Details)",
     "role": "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails",
     "shortName": "Net Loss Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:ClassOfStockNumberOfClassesOfStockOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_of_stock",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Net Loss Per Share - Schedule of Net Loss Per Share (Details)",
     "role": "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ie217a4dcec4d4aa09dfa029b4abba62b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i0f7987a16d51476399f00aba786832f0_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Net Loss Per Share - Anti-dilutive Securities (Details)",
     "role": "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib2105f80d294440588767dee094560b3_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idc103a37d52c4b8d9aab7c7d78bd8dab_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cerc:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Asset Acquisition (Details)",
     "role": "http://www.cerecor.com/role/AssetAcquisitionDetails",
     "shortName": "Asset Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idc103a37d52c4b8d9aab7c7d78bd8dab_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cerc:AssetAcquisitionConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i3a8340a3cbf64f1ab5d3614c69eea675_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i3a8340a3cbf64f1ab5d3614c69eea675_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "cerc:FairValueMeasurementsChangesInValuationTechniquesNumber",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:FairValueMeasurementsChangesInValuationTechniquesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "change",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "cerc:FairValueMeasurementsChangesInValuationTechniquesNumber",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:FairValueMeasurementsChangesInValuationTechniquesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "change",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cerc:AccruedResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cerc:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cerc:AccruedResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Accrued Expenses and Other Current Liabilities - Narrative (Details)",
     "role": "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:NumberOfClassOfStockAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_of_stock",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Capital Structure - Narrative (Details)",
     "role": "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
     "shortName": "Capital Structure - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:NumberOfClassOfStockAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_of_stock",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i0f7987a16d51476399f00aba786832f0_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Capital Structure - Warrants (Details)",
     "role": "http://www.cerecor.com/role/CapitalStructureWarrantsDetails",
     "shortName": "Capital Structure - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib7d433fb05b0421e829cbc118f401dfb_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Stock Based Compensation - Narrative (Details)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "id696367226144fa4b944f70aa62c42fe_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i91e623503adb43afb6fb5459058e0547_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Stock Based Compensation - Stock Options With Service-based Vesting Conditions (Details)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails",
     "shortName": "Stock Based Compensation - Stock Options With Service-based Vesting Conditions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i5cac8f2a539c49a89921227598dfba41_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i0f7987a16d51476399f00aba786832f0_I20181231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Stock Based Compensation - Stock-based Compensation Assumptions (Details)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails",
     "shortName": "Stock Based Compensation - Stock-based Compensation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i5cac8f2a539c49a89921227598dfba41_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i55bbfa0aaaa94da78a45d2f33ba4725f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Stock Based Compensation - Stock Options With Company's Market-based Option Activity (Details)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
     "shortName": "Stock Based Compensation - Stock Options With Company's Market-based Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ibc0352e97bad4fd0a1ff25ff1642f181_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ie43534f2ad884d3c93e916333b4e6fe3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Stock Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ie43534f2ad884d3c93e916333b4e6fe3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i4f7f7fe58b1947a1af4d75615be3a866_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)",
     "role": "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i4f7f7fe58b1947a1af4d75615be3a866_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Income Taxes (Details)",
     "role": "http://www.cerecor.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.cerecor.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cerc:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cerc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Leases - Assets and Liabilities (Details)",
     "role": "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails",
     "shortName": "Leases - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cerc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Leases - Lease Cost (Details)",
     "role": "http://www.cerecor.com/role/LeasesLeaseCostDetails",
     "shortName": "Leases - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Leases - Lease Maturity (Details)",
     "role": "http://www.cerecor.com/role/LeasesLeaseMaturityDetails",
     "shortName": "Leases - Lease Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "idedefda4bb914378b63f3c9b8b6ee172_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "i66d40f7899394f23b9dadb48b6bcfb61_D20170801-20170831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cerc:PotentialFutureRegulatoryMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Business",
     "role": "http://www.cerecor.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Aytu Divestiture",
     "role": "http://www.cerecor.com/role/AytuDivestiture",
     "shortName": "Aytu Divestiture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cerc-20210331.htm",
      "contextRef": "ib5faf784b6744cb8b078aa60fd6b93c2_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 90,
   "tag": {
    "cerc_A2016SecondAmendedPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Second Amended Plan [Member]",
        "label": "2016 Second Amended Plan [Member]",
        "terseLabel": "2016 Second Amended Plan"
       }
      }
     },
     "localname": "A2016SecondAmendedPlanMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_AYTUBioScienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AYTU BioScience, Inc [Member]",
        "label": "AYTU BioScience, Inc [Member]",
        "terseLabel": "AYTU"
       }
      }
     },
     "localname": "AYTUBioScienceIncMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_AccruedGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for general and administrative expenses..",
        "label": "Accrued General And Administrative Expenses",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AccruedMedicaidRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Medicaid Rebates",
        "label": "Accrued Medicaid Rebates",
        "terseLabel": "Medicaid rebates"
       }
      }
     },
     "localname": "AccruedMedicaidRebates",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development.",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AccruedSalesReturnsAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Returns And Allowances",
        "label": "Accrued Sales Returns And Allowances",
        "terseLabel": "Sales returns and allowances"
       }
      }
     },
     "localname": "AccruedSalesReturnsAndAllowances",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AeviGenomicMedicineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aevi Genomic Medicine Inc [Member]",
        "label": "Aevi Genomic Medicine Inc [Member]",
        "terseLabel": "Aevi"
       }
      }
     },
     "localname": "AeviGenomicMedicineIncMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_AnnualBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Base Salary",
        "label": "Annual Base Salary",
        "terseLabel": "Annual base salary"
       }
      }
     },
     "localname": "AnnualBaseSalary",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_ArmisticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Armistice [Member]",
        "label": "Armistice [Member]",
        "terseLabel": "Armistice"
       }
      }
     },
     "localname": "ArmisticeMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_ArmisticePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Armistice Purchase Agreement [Member]",
        "label": "Armistice Purchase Agreement [Member]",
        "terseLabel": "Armistice Purchase Agreement"
       }
      }
     },
     "localname": "ArmisticePurchaseAgreementMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assembled Workforce [Member]",
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled Workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cerc_AssetAcquisitionCashandEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Cash and Equivalents",
        "label": "Asset Acquisition, Cash and Equivalents",
        "terseLabel": "Cash acquired"
       }
      }
     },
     "localname": "AssetAcquisitionCashandEquivalents",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Equity Interests Issued And Issuable",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interests Issued And Issuable",
        "verboseLabel": "Consideration transferred, shares issued"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Liabilities Incurred",
        "label": "Asset Acquisition, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Forgiveness of loan"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration, Liability",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetAcquisitionContingentValueRightNumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Value Right, Number Of Milestones",
        "label": "Asset Acquisition, Contingent Value Right, Number Of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "AssetAcquisitionContingentValueRightNumberOfMilestones",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments",
        "label": "Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentValueRightRightToReceiveContingentPayments",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetAcquisitionDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Disclosure [Text Block]",
        "label": "Asset Acquisition Disclosure [Text Block]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDisclosureTextBlock",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cerc_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Equity Interest Issued Or Issuable, Number Of Shares",
        "label": "Asset Acquisition, Equity Interest Issued Or Issuable, Number Of Shares",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cerc_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Net",
        "label": "Asset Acquisition, Recognized Identifiable Assets Acquired, Goodwill, And Liabilities Assumed, Net",
        "terseLabel": "Fair value of asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Transaction Costs",
        "label": "Asset Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities Lessee [Table Text Block]",
        "label": "Assets And Liabilities Lessee [Table Text Block]",
        "terseLabel": "Assets and Liabilities Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cerc_BusinessCombinationsAndAssetAcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations and Asset Acquisitions [Abstract]",
        "label": "Business Combinations and Asset Acquisitions [Abstract]",
        "terseLabel": "Business Combinations and Asset Acquisitions [Abstract] [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAndAssetAcquisitionsAbstract",
     "nsuri": "http://www.cerecor.com/20210331",
     "xbrltype": "stringItemType"
    },
    "cerc_CAPITALSTRUCTUREAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definitions available.",
        "label": "CAPITAL STRUCTURE [Abstract]",
        "terseLabel": "CAPITAL STRUCTURE"
       }
      }
     },
     "localname": "CAPITALSTRUCTUREAbstract",
     "nsuri": "http://www.cerecor.com/20210331",
     "xbrltype": "stringItemType"
    },
    "cerc_CERC002KKCLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CERC-002 KKC License Agreement",
        "label": "CERC-002 KKC License Agreement [Member]",
        "terseLabel": "CERC-002 KKC License Agreement"
       }
      }
     },
     "localname": "CERC002KKCLicenseAgreementMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CERC006AstellasLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CERC-006 Astellas License Agreement",
        "label": "CERC-006 Astellas License Agreement [Member]",
        "terseLabel": "CERC-006 Astellas License Agreement"
       }
      }
     },
     "localname": "CERC006AstellasLicenseAgreementMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CERC007AstraZenecaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CERC-007 AstraZeneca License Agreement",
        "label": "CERC-007 AstraZeneca License Agreement [Member]",
        "terseLabel": "CERC-007 AstraZeneca License Agreement"
       }
      }
     },
     "localname": "CERC007AstraZenecaLicenseAgreementMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CERC611Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CERC-611 [Member]",
        "label": "CERC-611 [Member]",
        "terseLabel": "CERC-611"
       }
      }
     },
     "localname": "CERC611Member",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CERC801CERC802AndCERC803Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CERC-801, CERC-802, And CERC-803 [Member]",
        "label": "CERC-801, CERC-802, And CERC-803 [Member]",
        "terseLabel": "CERC-801, CERC-802, and CERC-803"
       }
      }
     },
     "localname": "CERC801CERC802AndCERC803Member",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CERC913Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CERC-913 [Member]",
        "label": "CERC-913 [Member]",
        "terseLabel": "CERC-913"
       }
      }
     },
     "localname": "CERC913Member",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CapitalStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of capital stock, including common stock and preferred stock, solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Capital Stock Shares Authorized",
        "terseLabel": "Number of shares of capital stock authorized to issue (in shares)"
       }
      }
     },
     "localname": "CapitalStockSharesAuthorized",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cerc_ClassOfStockNumberOfClassesOfStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Stock, Number Of Classes Of Stock Outstanding",
        "label": "Class Of Stock, Number Of Classes Of Stock Outstanding",
        "terseLabel": "Number of classes of stock outstanding"
       }
      }
     },
     "localname": "ClassOfStockNumberOfClassesOfStockOutstanding",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_ClassOfWarrantOrRightPercentOwnershipThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Percent Ownership Threshold",
        "label": "Class Of Warrant Or Right, Percent Ownership Threshold",
        "terseLabel": "Percent ownership threshold"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentOwnershipThreshold",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_ClinicalStageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Stage [Member]",
        "label": "Clinical Stage [Member]",
        "terseLabel": "Clinical Stage"
       }
      }
     },
     "localname": "ClinicalStageMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CommonStockWarrantsExpirationDateOfJune2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Expiration Date Of June 2024",
        "label": "Common Stock Warrants Expiration Date Of June 2024 [Member]",
        "terseLabel": "Common Stock Warrants Expiration Date Of June 2024"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationDateOfJune2024Member",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CommonStockWarrantsExpirationDateOfMay2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Expiration Date Of May 2022",
        "label": "Common Stock Warrants Expiration Date Of May 2022 [Member]",
        "terseLabel": "Common Stock Warrants Expiration May 2022"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationDateOfMay2022Member",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_CommonStockWarrantsNoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants No Expiration",
        "label": "Common Stock Warrants No Expiration [Member]",
        "terseLabel": "Common Stock Warrants No Expiration"
       }
      }
     },
     "localname": "CommonStockWarrantsNoExpirationMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_DebtInstrumentContingentConsiderationPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Contingent Consideration Paid",
        "label": "Debt Instrument, Contingent Consideration Paid",
        "terseLabel": "Contingent consideration paid"
       }
      }
     },
     "localname": "DebtInstrumentContingentConsiderationPaid",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_DebtInstrumentFutureAggregateDeferredPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Future Aggregate Deferred Payments",
        "label": "Debt Instrument, Future Aggregate Deferred Payments",
        "terseLabel": "Future aggregate deferred payments"
       }
      }
     },
     "localname": "DebtInstrumentFutureAggregateDeferredPayments",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_DebtInstrumentRemainingContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Remaining Contingent Consideration, Liability",
        "label": "Debt Instrument, Remaining Contingent Consideration, Liability",
        "terseLabel": "Remaining contingent consideration"
       }
      }
     },
     "localname": "DebtInstrumentRemainingContingentConsiderationLiability",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_DeerfieldObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deerfield Obligation [Member]",
        "label": "Deerfield Obligation [Member]",
        "terseLabel": "Deerfield Obligation"
       }
      }
     },
     "localname": "DeerfieldObligationMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator [Abstract]",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cerc_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails": {
       "order": 1.0,
       "parentTag": "cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee",
        "label": "Disposal Group, Including Discontinued Operation, Change In Fair Value Of Guarantee",
        "negatedTerseLabel": "Change in value of Guarantee",
        "verboseLabel": "Change in value of Guarantee"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Sales Return Reserve, Current",
        "label": "Disposal Group, Including Discontinued Operation, Sales Return Reserve, Current",
        "terseLabel": "Sales return reserve"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSalesReturnReserveCurrent",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_DisposalGroupIncludingDiscontinuedOperationSalesReturns": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Sales Returns",
        "label": "Disposal Group, Including Discontinued Operation, Sales Returns",
        "terseLabel": "Sales returns disposed of"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSalesReturns",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee Consultants And Directors Stock Options [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_EmployeeStockPurchasePlanESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan (ESPP) [Member]",
        "label": "Employee Stock Purchase Plan (ESPP) [Member]",
        "terseLabel": "Employee Stock Purchase Plan (ESPP)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanESPPMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_FairValueAdjustmentOfWarrantsAndInvestorRightsObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability and investor rights obligation.",
        "label": "Fair Value Adjustment Of Warrants And Investor Rights Obligation",
        "terseLabel": "Change in fair value of warrant liability and unit purchase option liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrantsAndInvestorRightsObligation",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_FairValueMeasurementsChangesInValuationTechniquesNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of changes in valuation techniques during the period.",
        "label": "Fair Value Measurements Changes In Valuation Techniques Number",
        "terseLabel": "Number of changes in valuation techniques"
       }
      }
     },
     "localname": "FairValueMeasurementsChangesInValuationTechniquesNumber",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_IchorionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ichorion [Member]",
        "label": "Ichorion [Member]",
        "terseLabel": "Ichorion"
       }
      }
     },
     "localname": "IchorionMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Liability",
        "label": "Increase (Decrease) In Lease Liability",
        "terseLabel": "Lease liability, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_InventoryPeriodBeforeExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, Period Before Expiration",
        "label": "Inventory, Period Before Expiration",
        "terseLabel": "Period before expiration to be considered as inventory"
       }
      }
     },
     "localname": "InventoryPeriodBeforeExpiration",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cerc_IssuanceOfSharesSharePursuantToRegisteredDirectOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Shares, Share, Pursuant To Registered Direct Offering",
        "label": "Issuance Of Shares, Share, Pursuant To Registered Direct Offering",
        "terseLabel": "Issuance of shares pursuant to registered direct offering, net of offering costs (in shares)"
       }
      }
     },
     "localname": "IssuanceOfSharesSharePursuantToRegisteredDirectOffering",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cerc_IssuanceOfSharesValuePursuantToRegisteredDirectOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Shares, Value, Pursuant To Registered Direct Offering",
        "label": "Issuance Of Shares, Value, Pursuant To Registered Direct Offering",
        "terseLabel": "Issuance of shares pursuant to registered direct offering, net of offering costs"
       }
      }
     },
     "localname": "IssuanceOfSharesValuePursuantToRegisteredDirectOffering",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_KarbinalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Karbinal Agreement [Member]",
        "label": "Karbinal Agreement [Member]",
        "terseLabel": "Karbinal Agreement"
       }
      }
     },
     "localname": "KarbinalAgreementMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_LesseeOperatingLeaseLiabilityAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Annual Base Rent",
        "label": "Lessee, Operating Lease, Liability, Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityAnnualBaseRent",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LesseeOperatingLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Number Of Contracts",
        "label": "Lessee Operating Lease Number Of Contracts",
        "terseLabel": "Number of contracts"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Number Of Renewal Options",
        "label": "Lessee Operating Lease Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_LesseeOperatingLeaseRemainingLeaseTeam": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Remaining Lease Team",
        "label": "Lessee Operating Lease Remaining Lease Team",
        "terseLabel": "Remaining lease team"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTeam",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cerc_LesseeOperatingLeaseRentAbatementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Abatement Period",
        "label": "Lessee, Operating Lease, Rent Abatement Period",
        "terseLabel": "Rent abatement period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentAbatementPeriod",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cerc_LicenseAgreementInstallmentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Installment Payment",
        "label": "License Agreement, Installment Payment",
        "terseLabel": "Installment payment"
       }
      }
     },
     "localname": "LicenseAgreementInstallmentPayment",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementMakeWholePaymentPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Make Whole Payment Per Unit",
        "label": "License Agreement, Make Whole Payment Per Unit",
        "terseLabel": "Make whole payment per unit (in dollars per share)"
       }
      }
     },
     "localname": "LicenseAgreementMakeWholePaymentPerUnit",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cerc_LicenseAgreementMilestonePaymentRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment Recognized",
        "label": "License Agreement, Milestone Payment Recognized",
        "terseLabel": "Milestone payment recognized"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentRecognized",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementPercentOfNetProfitForInstallmentPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percent Of Net Profit For Installment Payment",
        "label": "License Agreement, Percent Of Net Profit For Installment Payment",
        "terseLabel": "Percent of net profit for installment payments"
       }
      }
     },
     "localname": "LicenseAgreementPercentOfNetProfitForInstallmentPayment",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_LicenseAgreementPercentOfPaymentsReceivedFromSublicensing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percent Of Payments Received From Sublicensing",
        "label": "License Agreement, Percent Of Payments Received From Sublicensing",
        "terseLabel": "Percent of payments received from sublicensing"
       }
      }
     },
     "localname": "LicenseAgreementPercentOfPaymentsReceivedFromSublicensing",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_LicenseAgreementPotentialMilestonePaymentNumberOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Potential Milestone Payment Number One",
        "label": "License Agreement, Potential Milestone Payment Number One",
        "terseLabel": "Potential milestone payment"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestonePaymentNumberOne",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementPotentialMilestonePaymentNumberTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Potential Milestone Payment Number Two",
        "label": "License Agreement, Potential Milestone Payment Number Two",
        "terseLabel": "Potential milestone payment two"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestonePaymentNumberTwo",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Potential Milestone Revenue Threshold Number One",
        "label": "License Agreement, Potential Milestone Revenue Threshold Number One",
        "terseLabel": "Potential milestone revenue threshold"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestoneRevenueThresholdNumberOne",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Potential Milestone Revenue Threshold Number Two",
        "label": "License Agreement, Potential Milestone Revenue Threshold Number Two",
        "terseLabel": "Potential milestone revenue threshold two"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestoneRevenueThresholdNumberTwo",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementSemiAnnualLicensePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Semi-Annual License Payment",
        "label": "License Agreement, Semi-Annual License Payment",
        "terseLabel": "Semi-annual license payment"
       }
      }
     },
     "localname": "LicenseAgreementSemiAnnualLicensePayment",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Upfront Fee",
        "label": "License Agreement, Upfront Fee",
        "terseLabel": "License agreement fees"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontFee",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_LicenseObligationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Obligation, Noncurrent",
        "label": "License Obligation, Noncurrent",
        "terseLabel": "License obligations"
       }
      }
     },
     "localname": "LicenseObligationNoncurrent",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_MajorCustomerNumberOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer Number One [Member]",
        "label": "Major Customer Number One [Member]",
        "terseLabel": "Major Customer Number One"
       }
      }
     },
     "localname": "MajorCustomerNumberOneMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MajorCustomerNumberThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer Number Three [Member]",
        "label": "Major Customer Number Three [Member]",
        "terseLabel": "Major Customer Number Three"
       }
      }
     },
     "localname": "MajorCustomerNumberThreeMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MajorCustomerNumberTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer Number Two [Member]",
        "label": "Major Customer Number Two [Member]",
        "terseLabel": "Major Customer Number Two"
       }
      }
     },
     "localname": "MajorCustomerNumberTwoMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cerc_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three [Member]",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two [Member]",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MillipredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Millipred [Member]",
        "label": "Millipred [Member]",
        "terseLabel": "Millipred"
       }
      }
     },
     "localname": "MillipredMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_MonthlyOperationPaymentsAdditionalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly Operation Payments, Additional Term",
        "label": "Monthly Operation Payments, Additional Term",
        "terseLabel": "Additional duration of monthly commercial operation payments"
       }
      }
     },
     "localname": "MonthlyOperationPaymentsAdditionalTerm",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cerc_MonthlyOperationPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly Operation Payments, Term",
        "label": "Monthly Operation Payments, Term",
        "terseLabel": "Duration of monthly commercial operation payments"
       }
      }
     },
     "localname": "MonthlyOperationPaymentsTerm",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cerc_NantahalaCapitalManagementLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nantahala Capital Management LLC",
        "label": "Nantahala Capital Management LLC [Member]",
        "terseLabel": "Nantahala Capital Management LLC"
       }
      }
     },
     "localname": "NantahalaCapitalManagementLLCMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_NantahalaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nantahala",
        "label": "Nantahala [Member]",
        "terseLabel": "Nantahala"
       }
      }
     },
     "localname": "NantahalaMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_NeurologicalClinicalAndPreclinicalStageCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurological Clinical And Preclinical Stage Compounds [Member]",
        "label": "Neurological Clinical And Preclinical Stage Compounds [Member]",
        "terseLabel": "Neurological Clinical And Preclinical Stage Compounds"
       }
      }
     },
     "localname": "NeurologicalClinicalAndPreclinicalStageCompoundsMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_NumberOfClassOfStockAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of classes of stock permitted to be issued by an entity's charter and bylaws.",
        "label": "Number Of Class Of Stock Authorized",
        "terseLabel": "Number of classes of stock authorized to issue"
       }
      }
     },
     "localname": "NumberOfClassOfStockAuthorized",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_NumberOfPreclinicalTherapies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Preclinical Therapies",
        "label": "Number Of Preclinical Therapies",
        "terseLabel": "Number of preclinical therapies"
       }
      }
     },
     "localname": "NumberOfPreclinicalTherapies",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_NumberOfProductsDeveloped": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products Developed",
        "label": "Number of Products Developed",
        "terseLabel": "Number of products in development"
       }
      }
     },
     "localname": "NumberOfProductsDeveloped",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cerc_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator [Abstract]",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cerc_OfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers",
        "label": "Officers [Member]",
        "terseLabel": "Officers"
       }
      }
     },
     "localname": "OfficersMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_OperatingLeasesRentExpenseAnnualIncreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Rent Expense, Annual Increase, Percent",
        "label": "Operating Leases, Rent Expense, Annual Increase, Percent",
        "terseLabel": "Annual rent increase"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseAnnualIncreasePercent",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Asset Acquisition Contingent Consideration Liability Operating Activities",
        "label": "Payment For Asset Acquisition Contingent Consideration Liability Operating Activities",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Asset Acquisitions",
        "label": "Payments For Asset Acquisitions",
        "negatedTerseLabel": "Net cash paid in merger with Aevi"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_PediatricPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Portfolio [Member]",
        "label": "Pediatric Portfolio [Member]",
        "terseLabel": "Pediatric Portfolio"
       }
      }
     },
     "localname": "PediatricPortfolioMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_PotentialFutureRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Regulatory Milestone",
        "label": "Potential Future Regulatory Milestone",
        "terseLabel": "Potential future regulatory milestone"
       }
      }
     },
     "localname": "PotentialFutureRegulatoryMilestone",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock And Warrants",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in underwritten public offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_ProceedsFromOptionOrWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Option Or Warrant Exercises",
        "label": "Proceeds From Option Or Warrant Exercises",
        "terseLabel": "Proceeds from exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromOptionOrWarrantExercises",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_ProceedsFromRegisteredDirectOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Registered Direct Offering",
        "label": "Proceeds From Registered Direct Offering",
        "terseLabel": "Proceeds from registered direct offering, net"
       }
      }
     },
     "localname": "ProceedsFromRegisteredDirectOffering",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment And Operating Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization",
        "label": "Property, Plant And Equipment And Operating Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering [Member]",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments",
        "label": "Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments",
        "terseLabel": "Percentage of net present value of royalty payments"
       }
      }
     },
     "localname": "RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_RoyaltyAgreementPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Payment Received",
        "label": "Royalty Agreement, Payment Received",
        "terseLabel": "Payment received"
       }
      }
     },
     "localname": "RoyaltyAgreementPaymentReceived",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement, Period After Public Launch To Terminate Agreement",
        "label": "Royalty Agreement, Period After Public Launch To Terminate Agreement",
        "terseLabel": "Period after public launch to terminate agreement"
       }
      }
     },
     "localname": "RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cerc_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cerc_ServiceBasedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based Options [Member]",
        "label": "Service Based Options [Member]",
        "terseLabel": "Service Based Options"
       }
      }
     },
     "localname": "ServiceBasedOptionsMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase To Shares Authorized As Percentage Of Outstanding Stock At End Of Preceding Year",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase To Shares Authorized As Percentage Of Outstanding Stock At End Of Preceding Year",
        "terseLabel": "Automatic increase to shares authorized as percentage of outstanding stock at end of preceding year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseToSharesAuthorizedAsPercentageOfOutstandingStockAtEndOfPrecedingYear",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase in the number of shares reserved for issuance under the incentive plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase",
        "terseLabel": "Increase in number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncrease",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent, applied to total number of outstanding shares of common stock on the last trading day in December of the prior year, by which the share reserve automatically increases on the first day of January of each calendar year beginning in 2016.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent",
        "terseLabel": "Annual share reserve increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Price Premium, Threshold Percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Price Premium, Threshold Percentage",
        "terseLabel": "Premium on stock price, threshold percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPricePremiumThresholdPercentage",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cerc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Vested, Granted in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vested, Granted in Period, Gross",
        "terseLabel": "Share-based compensation on service-based vesting conditions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedGrantedInPeriodGross",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Amount of Outstanding Stock Maximum",
        "terseLabel": "Maximum annual amount of fair market value of the company's common stock that a participant may accrue the rights to purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardFairValueAmountofOutstandingStockMaximum",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cerc_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Exercised, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Exercised, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedOptionsExercisedWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cerc_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, New Issues, Private Placement",
        "label": "Stock Issued During Period, Shares, New Issues, Private Placement",
        "terseLabel": "Issuance of shares pursuant to common stock private placement, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cerc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Stock Options And Warrants Exercised",
        "label": "Stock Issued During Period Shares Stock Options And Warrants Exercised",
        "terseLabel": "Exercise of stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "cerc_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, New Issues, Private Placement",
        "label": "Stock Issued During Period, Value, New Issues, Private Placement",
        "terseLabel": "Issuance of shares pursuant to common stock private placement, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesPrivatePlacement",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Stock Options And Warrants Exercised",
        "label": "Stock Issued During Period Value Stock Options And Warrants Exercised",
        "terseLabel": "Exercise of stock options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cerc_StockOptionsWithMarketBasedVestingConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options With Market Based Vesting Conditions [Member]",
        "label": "Stock Options With Market Based Vesting Conditions [Member]",
        "terseLabel": "Market Based Options"
       }
      }
     },
     "localname": "StockOptionsWithMarketBasedVestingConditionsMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. Also include temporary equity.",
        "label": "Stockholders Equity And Temporary Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Structure"
       }
      }
     },
     "localname": "StockholdersEquityAndTemporaryEquityNoteDisclosureTextBlock",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cerc_StockholdersEquityNotePreferredStockConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity Note Preferred Stock Conversion Ratio",
        "label": "Stockholders Equity Note Preferred Stock Conversion Ratio",
        "terseLabel": "Preferred stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNotePreferredStockConversionRatio",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cerc_TRISPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRIS Pharma [Member]",
        "label": "TRIS Pharma [Member]",
        "terseLabel": "TRIS Pharma"
       }
      }
     },
     "localname": "TRISPharmaMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_TevaPharmaceuticalIndustriesLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva Pharmaceutical Industries Ltd. [Member]",
        "label": "Teva Pharmaceutical Industries Ltd. [Member]",
        "terseLabel": "Teva"
       }
      }
     },
     "localname": "TevaPharmaceuticalIndustriesLtd.Member",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_The2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2016 Plan [Member]",
        "label": "The 2016 Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "The2016PlanMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_ThirdAmended2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Amended 2016 Plan",
        "label": "Third Amended 2016 Plan [Member]",
        "terseLabel": "2016 Third Amended Plan"
       }
      }
     },
     "localname": "ThirdAmended2016PlanMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_UnderwritersUnitPurchaseOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the underwriter's unit purchase option that was offered as part of the IPO.",
        "label": "Underwriters Unit Purchase Option [Member]",
        "terseLabel": "Underwriters\u2019 unit purchase option"
       }
      }
     },
     "localname": "UnderwritersUnitPurchaseOptionMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cerc_WarrantCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrant common stock.",
        "label": "Warrant Common Stock [Member]",
        "terseLabel": "Warrants on common stock"
       }
      }
     },
     "localname": "WarrantCommonStockMember",
     "nsuri": "http://www.cerecor.com/20210331",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Chairman of the Board"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r59",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r153",
      "r209",
      "r213",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r233",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r233",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r153",
      "r209",
      "r213",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r150",
      "r209",
      "r211",
      "r347",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r150",
      "r209",
      "r211",
      "r347",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r219",
      "r230",
      "r233",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r219",
      "r230",
      "r233",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails",
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r209",
      "r212",
      "r391",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r209",
      "r212",
      "r391",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r184",
      "r231",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r154",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND",
        "terseLabel": "Maryland"
       }
      }
     },
     "localname": "MD",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r38",
      "r377"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r368",
      "r381"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalty obligation"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r39",
      "r268"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r186",
      "r190",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrant, component of additional paid-in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r237",
      "r262",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r164",
      "r171"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti- dilutive securities excluded from the computation of diluted weighted shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r139",
      "r142",
      "r148",
      "r158",
      "r297",
      "r299",
      "r311",
      "r364",
      "r378"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r26",
      "r27",
      "r58",
      "r91",
      "r158",
      "r297",
      "r299",
      "r311"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r238",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r46",
      "r84"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Investments in money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r312"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r110",
      "r111",
      "r112",
      "r115",
      "r119",
      "r127",
      "r128",
      "r129",
      "r158",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r198",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares available under warrant (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails",
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r198",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common\u00a0stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r37",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock\u2014$0.001 par value; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020; 89,104,816 and 75,004,127 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r153",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r153",
      "r309",
      "r310",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r153",
      "r309",
      "r310",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r132",
      "r133",
      "r153",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r153",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss": {
     "auth_ref": [
      "r160",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.",
        "label": "Contract with Customer, Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for returns"
       }
      }
     },
     "localname": "ContractWithCustomerReceivableAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r347"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r131",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r365",
      "r366",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r52",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r92",
      "r280",
      "r285",
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r137"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r19"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax",
        "totalLabel": "(Loss) income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share, discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share, discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r173",
      "r177"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r15",
      "r22"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r15",
      "r22"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "verboseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Aytu Divestiture"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestiture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r229",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net (loss) income per share of common stock, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r110",
      "r115",
      "r118",
      "r119",
      "r123",
      "r124",
      "r373",
      "r385"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income (loss) per share of common stock, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Basic (loss) income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r110",
      "r115",
      "r118",
      "r119",
      "r123",
      "r124",
      "r373",
      "r385"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income (loss) per share of common stock, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r126",
      "r159",
      "r190",
      "r197",
      "r265",
      "r266",
      "r267",
      "r281",
      "r282",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Change in fair value of Investment in Aytu",
        "terseLabel": "Change in fair value of Investment in Aytu"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Amount of transfers of assets from level 1 to level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Amount of transfers of assets from level 2 to level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r302",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r301",
      "r302",
      "r304",
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r226",
      "r228",
      "r302",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r226",
      "r228",
      "r302",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r302",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r172",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r165",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "verboseLabel": "Intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r161",
      "r162",
      "r363"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r69",
      "r83",
      "r100",
      "r101",
      "r102",
      "r103",
      "r113",
      "r119",
      "r295"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r139",
      "r141",
      "r144",
      "r147",
      "r149",
      "r362",
      "r370",
      "r374",
      "r386"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r62",
      "r65",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r115",
      "r118",
      "r369",
      "r371",
      "r373",
      "r382"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations, basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share, continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r62",
      "r65",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r115",
      "r118",
      "r119",
      "r373",
      "r382",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share, continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r19",
      "r296"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "(Loss) income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r229",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r17",
      "r20",
      "r21",
      "r22",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofCashFlowsDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofIncomeStatementDetails",
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r283",
      "r288",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r106",
      "r107",
      "r138",
      "r276",
      "r284",
      "r289",
      "r387"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "verboseLabel": "Fair value assigned to intangible asset at purchase"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r163",
      "r168"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r25",
      "r57"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "April 1, 2021 through December 31, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less implied interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49",
      "r91",
      "r143",
      "r158",
      "r298",
      "r299",
      "r300",
      "r311"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r43",
      "r91",
      "r158",
      "r311",
      "r367",
      "r380"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r91",
      "r158",
      "r298",
      "r299",
      "r300",
      "r311"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r173",
      "r177"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations",
        "totalLabel": "Total current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureSummaryofLiabilitiesoftheDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.",
        "label": "Long-term Purchase Commitment, Minimum Quantity Required",
        "terseLabel": "Minimum quantity required"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentMinimumQuantityRequired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r130",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r60",
      "r61",
      "r64",
      "r83",
      "r91",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r113",
      "r139",
      "r141",
      "r144",
      "r147",
      "r149",
      "r158",
      "r311",
      "r372",
      "r383"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net from continuing operations"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Nonvested Restricted Stock Shares Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r141",
      "r144",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Total operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r326",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails",
      "http://www.cerecor.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "verboseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r368",
      "r381"
     ],
     "calculation": {
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r238",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u2014$0.001 par value; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; 1,257,143 shares issued and outstanding at March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r26",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from sale of shares pursuant to common stock private placement, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net",
        "verboseLabel": "Product Revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r30",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r227",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r227",
      "r331",
      "r334",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Debt repayment"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r271",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AccruedExpensesandOtherCurrentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "Acquired in-process research and development, including transaction costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r29",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "periodEndLabel": "Restricted cash, current",
        "terseLabel": "Restricted cash, current portion"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r28",
      "r31",
      "r84",
      "r89",
      "r404"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "periodEndLabel": "Restricted cash, non-current",
        "terseLabel": "Restricted cash, net of current portion"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r40",
      "r197",
      "r268",
      "r379",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "(Accumulated deficit) retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r159",
      "r265",
      "r266",
      "r267",
      "r281",
      "r282",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r140",
      "r145",
      "r146",
      "r150",
      "r151",
      "r153",
      "r208",
      "r209",
      "r347"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Total revenues, net",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r68",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Percentage of ownership"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r132",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities Excluded From Computation of Diluted Weighted Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r17",
      "r20",
      "r21",
      "r22",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summary of Liabilities of Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the Computation of Basic and Diluted Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r115",
      "r119",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r237",
      "r261",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r243",
      "r251",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions for Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r54",
      "r90",
      "r127",
      "r128",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r198",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Common Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested RSUs at March 31, 2021 (in shares)",
        "periodStartLabel": "Unvested RSUs at December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested RSUs at March 31, 2021 (in dollars per share)",
        "periodStartLabel": "Unvested RSUs at December 31, 2020 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum portion of earning an employee may contribute to the ESPP Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock remaining for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r245",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance, ending of period (in shares)",
        "periodStartLabel": "Balance, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending of period (in dollars per share)",
        "periodStartLabel": "Beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)",
        "terseLabel": "Increase in shares available (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r236",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeitures (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r235",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "End of period (in dollars per share)",
        "periodStartLabel": "Beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Option Activity, Fair value of options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithCompanysMarketbasedOptionActivityDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested in period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options vested, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r90",
      "r91",
      "r110",
      "r111",
      "r112",
      "r115",
      "r119",
      "r127",
      "r128",
      "r129",
      "r158",
      "r190",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureWarrantsDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails",
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r56",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r126",
      "r159",
      "r190",
      "r197",
      "r265",
      "r266",
      "r267",
      "r281",
      "r282",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r126",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock in Aevi Merger"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r36",
      "r37",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of shares related to Aevi Merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r36",
      "r37",
      "r190",
      "r191",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Conversion to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r36",
      "r37",
      "r190",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of shares of common stock in underwritten public offering, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]",
        "terseLabel": "Restricted Stock Award, Number of Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r37",
      "r190",
      "r197",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercises in period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationStockOptionsWithServicebasedVestingConditionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r56",
      "r190",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of shares related to Aevi Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r56",
      "r190",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r36",
      "r37",
      "r190",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r37",
      "r41",
      "r42",
      "r91",
      "r155",
      "r158",
      "r311"
     ],
     "calculation": {
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/AytuDivestitureNarrativeDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/CommitmentsandContingenciesDetails",
      "http://www.cerecor.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r114",
      "r116",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) from continuing operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.",
        "label": "Undistributed Continuing Operation Earnings (Loss), Allocation to Participating Securities, Basic",
        "terseLabel": "Allocation of undistributed net (loss) income, continuing operations"
       }
      }
     },
     "localname": "UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r114",
      "r116",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) from discontinued operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.",
        "label": "Undistributed Discontinued Operation Earnings (Loss), Allocation to Participating Securities, Basic",
        "terseLabel": "Allocation of undistributed net (loss) income, discontinued operations"
       }
      }
     },
     "localname": "UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/BusinessDetails",
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants outstanding term",
        "verboseLabel": "Expected term of option (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/CapitalStructureNarrativeDetails",
      "http://www.cerecor.com/role/StockBasedCompensationStockbasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cerecor.com/role/NetLossPerShareScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130534-203044"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r416": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r417": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r418": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r419": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001628280-21-010083-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-010083-xbrl.zip
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M)\%/X,G#8*WKZ\-6Z%_YZ3$"XX,/P/G!TFO,J%164!B[-;C=(@0L22$PMUJ
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M37M)8+(B8LN8E\%*1HQ75C"/.0F<<H5%?#$P[82AR;O!;YI^-^\>#I8$G^B
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MD"0FHDDA?#PIA(\73BL645I_K%6/'UZK'D_#RB'&L':(&RX8D]B9Z!%S :.
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M'Z^!-U%Z2LHX1> /!J]3<7-FL/4\6$<5HP3YZ'X@&?!?"==S<X^KISYE97'
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M^3;_/LF39P,.C0WC$^#&8^?F(DF]UQ\GJ8_]G"ONT>:$@8#ODPZG_/2*AZ/
MP-*IQ_W@0L'',!G=KUB%-:C\ 3=-"\(&)\!:!JU>2HB<K <;MLSP9E.^F^OO
MFUYV=/&X-?]Z53%=7_F#7&FR#0$0.K%'T*!T47$^7)G>9WRSM/1C4)DL33LV
M@V%%H]$=O#D;O'[V4--H9F']I-^'-QDM/4GF<FB&)X.E-)=/2B"F7[B.SC&,
M,LH4SUB,,@,.$#/'C<21"QVB77G;#(.;)F^,U%CK9[;ZN5#+\;K8RB.?/E73
M4.N->F"\QN9Z=SS Y"VIC4MZ#BK>R8=#L RA#:K>[W73R-0^JP08I<XJVVG
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MSN&N)<N5H8[%YQ@_=9;&2&^.@%[K^L)[&B4QEU[3XPU=_6J""V/42:]4,G3
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MC#TX#89* =)+'"Q"TJIX_Q%*+9?';WF[+HMCSL4AD=0DDI 6!PO (N)@TZJ
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MQD]4"$[D77OJ%20Z3X!YHT%%0I)AA[@,^?\"/<QSN=3E44[K%[$XB- N>*N
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MJ0X^[;@:*8DHTE/@[+@A=!YZ76_ZAP5TG])A>7G4\C7=Z\_/$GE!A$8@G'/
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M7G"#!1"9<FI5HR"X,<![=RGK-Y6H]T>2+D W$]#MCG,78WD@)M=QD_G<6<0
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MY8[8A$F3:)ZGB7GU)EZ_K BRBVP')U\1""BF;M$KNN,NBG3<[%JWG )<&+I
M.-H=%#U4,AN@1#I199JO@ZH":_U\V4X/X")HAY!> AJCZ"']]6;4#]RP?,Z"
M=!B>= I4G9T./!;HJ:/.X?M@U,.#_Q[#<B=/WQRL1U_[G>BM&F!CAF&Y@D-5
M -'UPO#Y4FM-X*/NJX'%#TKG1.V&"1X.X,,?Z!!9ODNM=R^YQ;.&CU]6>GQ6
MP&LDEML(ES3U(C;62JT,EUQK*HUP8)UY)L!@4]=E5MQ$N-PP\O#^K(HL;@R'
M#OYG9TLC7KC X>V#?9=REG"9D\3SG'">,I*S+"-4)TGJ0$/H1-]$X""KW8I$
M8D&U-2).3,JYEE)Q:;377N:2*9%?%V=N2.2W ,73UL9^+G-K:!(3G_F$<!4+
M+,U/289].ZR&0\K5JS=L_;):F)I$;E\QL!:!+#H!20S0K7,..B'4.X6;^&(P
M'-5J#L76Y>YD+&WHA8@!+.(0[ZV= 0*)AH?]P8C8$')X/557M9JK0PFS=T"C
M#W3;O4=3%^T>.QZLLGNVZH64M5YO'7P/NT\4I;?CI='JYC%ZHTY;1ZV+]N8W
MOOT9C!K#J.1@Q=@D)=S$DFA!$V*\D5*#D$D2_^K-L#BKZ&\Q7(J4Y";[^4=D
M03T"M@%5._9 U"7]!=BR$$@)6,2&J),? [I1"-Q5SP2/U6T$(]S#>:M :>:4
M)YG4:>(3DP,=I<[1C.UO_;3*7"4$OTPB1!OURL&$?@?HKAAA#6(C$$$@PKT9
M"$1/36)S*XG7B0#+V6JB*$M(G,:9\T;!H64H$/,;",2! Z+J!1\/RI[:QSDK
MFJ;2YP#D8'G=(<"XJ%,<@\EZV.\'S%K>:8DJX51=Z02JT?;T?IU^0.HE[@^P
M>QZTKLR7N3/\O6$J33*;2O,P^3+BE^?+O%>#'HB2(<CQKX=@X3R:!)E)%MLQ
M;7UO'[8OWK/=[N[Y[LZ7HK6YP;=W6G3O:)?N7GRF[:._CUN;6VR1N[9WOIWM
MLO=):V>OV#OZ^[#]<>NTM7D@6A?_=MM'_QZ!J&:M[F<0VWN^=;$1MS_O)PZL
M7LD!75@7$RY30W0N48H+J]+4>*_$8H),;CRGBHE4@[0T@LLX9IXE,O<@^@V(
M^84$F398H2C)(MCS*&SZM;DRMTR(N7Y%\V^0"IR E>' .\59+E2J\D0PQWV<
MQ#1+GD "C8'_CC$UPE4$C9Y!D%ZPNQ/7]OM/7VO/=C0>U@!N=-HGIJ/@/+IN
M=-BWI>!:_"L*MO(9^#VX$WH"X)4GCT,]:\HS0/TW[BBXNQJ!L$/?-JQ]&+Z%
MHA;N TH?=@O8K'0-P N@![TPQ4E9?0K0"U3\"+WSF&PPL&&U_0B. 11SSPY1
MY794R"Z!&\Q\&6X<LA01+()ZGV1TP)7U6J^H-'WRKH3%2-2E@"<<[G[?[X=C
MN!?LL]7^<./ P3M\_+;_B@]OAQ#&M@]_<_5?M\<C3+G!DY]@GOB%2>598 T8
MB;9/P0CTWOK8$I4Z1;A/<Z*RS)&,9XDWW*8II:_> /LNQPI,N;\!U@3>ZT^W
M>&V9*T\&SKL!LECX6RD7%OXX>POTZF%&WKP)>5CY^H9HZ%6<.;V[ W@[=0<N
MV(NS*UJK&L."3.F!V8B/PZ+U'_U16#S>L4PZ"]$$K X/OM @ (>5\)J^'OI)
M(DJ 5HF(@HFQ'D7?P (>K!2):W7L;G+SQ6U83'@;.A!) !K+/9_N.(H_%(,G
MX\%)?UBGAF'# 30@(ZV&@''P;[;H!)E52=J301\%7UTYC[?1L"$W.+2M65BY
M%FV + ;Y!.;0.W528)R_I89HN7\ 65E%0M&!['W1*? %8.E+WUF+_OGG77@<
MUMK7;H&H4C.3RQ?#J*@QYMH.W +D5D).<)""R]&DJB:\+#R;^595Y1]/OZ+T
ML(\[>^E7EJHV'TB01Y3>1-O,K7&5DIK]>3B9672B#AS1 Z>.B?)P@S]5YQ1,
MZ5?_F>^[4/3J124IK'IQSR[=&>]_V<Z4Y0@6K?Q )7^.D6W+@.'_58]F+='A
M #7I_[K>S@(+=2>TL\!0"BKAWFCX?_^C;@."K_SP"IQ\+>Y=P,E2I$PPIJWU
ME,M<*9_'.7JIG519[.0CQ<E!$A[V.[9T4"Y&T$X/01)'YK!PONJ^TBTCZB"E
M,+3[=81NZ^AM_QP4096PT3FO0UF5O^ M1JS6:AU1&?H#UU4%0L[+85BIH!;@
M5TPY;# <C?":P_ZJ3*C< )W%F5**RFO"-HLX[%HG%"QYB(UT2^ 53++AN_I-
MZ,M%7[,N^",3MS?V;9;JC'-.F,(>@$8(DL/?B$J4@/.2@AJ.M5K \6N G)<Q
MV"P@N0).(':Y'<UX([P4WACJ& =VE$;YU&9<4)Z!S*'W2C.!3K:&0Q ,5>NS
MX :?I9R2H#!M?]@04$E M/UY/_4L%8DPQ!D#!,25)=HG&4DSJUS*$FEE_NI-
MNL:D6,M6)&W.$-!BW'T6"ZY'7Y"BT&1N]P'%Y0$R=A%C%KWRF.%NZ\_7#K[4
MUU!_L!+!!Q\*@.SSTM%0NTB&XVZ9C+#L2PCW7.UF"(\ITX7FC0!]'NY:KA_-
M!6 7P&-1F<I7>IW+0YXQKBZ[61W,.PD<&/"^PG33R]P[:Y>M%CU%E1.GS#V\
MSK9 :P6[@?56O\V*=[#3L&&YW-HR@.6-\?"O,[/0F-0.E/&,GNTO$/[.U5M;
M7[R\NI7F:Q$*HJNE+=W6>8])7Q6H@-42/PYQU%,UP++H(9 5"DGT1<&2>ZZ4
MY"%C%;_QMP(\-BA3>Z( 'D\'Q0@@(!B(N@.F(( 0-P@6+E[NSMS %,, %<N-
M&[C_CD-J:J\/8!VLN=H*G7CBZH@#F$EE,FP@Z-5F\>O!#83&'\]8:FQ65C<F
M2KWNS#8KGWI3YRCBI(]XO8"-#P8[;/(,3<SM+1[4#TP;' 5_1P'\.X8#G'%T
MAHZ#4\)&?J_.VZ[FG"H$53T0!%B]AG7$MZL?7:W^S^AU\<<<]5>.D9.RKQ^R
M.U (2(E0+5=^B !D4N(WLQ6V)-VPF,H', +3<C@&@BN_68J>RA]0KKQ>ZU_A
M6:\+6,[<?H5\N)I]QB>5E)GE@-G5U_QVWZM;C]XZH\9#%[Y>@-$P87?X6]FA
M$3:^+%\-I8% #61""]6QE4<6^ TI"PEKK?3ZX)=[Z-;VE3,,7GITBA)NV16$
M7PMT."O"2EU6W3_(E?H)6/\'RF#EL\O/ET5^H*]5CGA,V8"W*RKQ4?\1Y7&O
M/RH_#!8/,E.9N%[?)?1;JK7,6@1:ITP%5)-D^#&.?0)Q=U *K=IM5Y=^+KH%
MJY>[MX+J7QA=_&H.G1UWW+9?C#.^Q>/=Z-E*X@0/P$N./;8.]E-.?9IK1L#V
MQ>)\KDB>,$< $GM.7:QR&B_&$A^E%D$$,DT8KWJ5NE$ A)7B+Z%F2>_ F<O,
M?I4&6E0MJ[#9[7.\YMNQKH&H-0X[A(1'AD=,%J"Z6/X[_.//A;9,/XL'?GMC
MUVP]R[*[-';E8IW?L:OIU9\)^@MZI=)UP5FSV&:Q@M^LO^\-VZ?>H&/F]:T1
MZ7-I1=LTH+WY4<^WV;^ZE_[CIH-Y;7H7&K@/+LJO;U'[M+9UUH#]F0:_U_=F
M?79;]VD>"MYKE]^;]$C^E?=X/@V8WTV;)$SZ*PY_I@GQO?6X?OY[/]O<\IYV
MO]G@AK@?Q][?A+B?U[#1U?L0?'K8H.[/Z$Z4=\U\N]O<X]=1;[/(9['(ES!\
M86-:(-#W"T'H.C+Q*S3P;?;PF?9/?Z8MTAVCF>+6.)Q7KE2<6Z]BEFNNM%8I
MT[<9O7OCU*=OLX0[Q3D315L'>K#":4KR._U/LV&UKY.H;X@#/9;>Z7>-_%0C
M(CN=W>^?S]H[AH6QCA>?D^T=>]CJMD3[.]9T?HY;.X?=W:,66^R=OOW]W\.]
MS?>T?;%7P-J/VK#6-GM_OGMQ3'=W#F+X[MGV1_CL8L^WO\Y,E4A=HA-I!:$F
MEX0GJ2=:VX30W#/C\S27VK]ZP^2:X,M5\;=NGOZ$1D8T4NTQO=M#2;4K1-?*
M 0^-\/KUPFLZ^$%0*IQ.8B(Y!>&EDAR$EV?$T4PP+9WDWKYZDR]7KS>"ZS$Q
M=R.X*L&5:*8S)GRJ')?"2QS5;$!H<9:DB;NVV50#QYZH1&,3B:92(_)<YB2-
MO2(\\Y8 .),D9=QE2<Y=K!* 8VLQ2QNAU@BU%R;4&C3V^&07G\@N+BE0LA2$
ML524_4]RI02Q*4MMDOO<87>UY8$(#R*W7H(#?].510WHPG]H#WYSCR=TCY?@
M3?^^NMSJH:<8/Z=!Q2O+;'_2.Q/?PK2ICWBC/.&Z2TY99#O3'6=>[S_1&MO?
MJ_=G!Q/3+.8V312)K:.$)W!R.C.2Y%:H)!;&V5@\/2JIZDJ6B*6AD[O2"9@
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M$BML$J^%TDHDVN%XH&RY3JSQKS1PK8%K#^!?^7FYV]C+CT@83^/G2DLX0.8
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MGHAU(C!)<C5[C%8J434!GRU-9LOT +?]H^U.R/],%*K/*3D;U2>SYYF!5U%
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M;M+PMPOY\%,9OD8*_!K"&LT88"CM !:)LX,[FB"UQ_0$IR7#E?M<+EP-3LN
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M2NTO1S)QR<W*SH!K3DK^Q+>+3\!'0K?8ON.)ZX:B[T 7_)W#<A:&1L_PV*N
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M0!L-#1)Y)WSB.DEI"L)Q(\@FG4.C,Z&%-P;#5FO7WE.D:KMV]2+U;?NR=7[
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M=EG 64!Z99I.3$A.L<D^DNO^*,@(<M?M[$U--_7-^_*,?;IL=QE)-%&&!A[
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M,GTU&>Y..%1ITR(<6ID6XL8<73R.:3&5]U-HXG_=D>;\%L]_>P[SM8*@:Y@
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M&^NE$MK@Z[H;/T5,ZB6;1/,>\<691/= E=HD>C*3" #CG3A@6B<&2X.P208
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M$<$^,M1V1$*3F!,OYK:X5];0WIMUA_KM:*_=>].Q;1)1UPPM9IO$)[X9V18
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M&]70DUO@P\M3U^,T<%S'#$*;F[#?$,E8!%O[!9PDW/-L6. $[4RI;N:5D,K
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M#\=%.CF7QPME_YVFU8F0&+O?*1<9]C6Q@S]*8RQX2B=H.HV+G$_9!$[#2>L
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M)&&V"2+FF@$/[=!A8%BY8BE%S__\7FFR6A\M>,@*M0*::*QLK0'^MDF@;Y.
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MZW,G\ 3Q/4Z)Y\') &J3A1%Q'$TC&%0T@L%-+0*]&QM/0FT(R 3N)VP&?+0
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M*9V@(P,T(J"UO2(_;[R;8*?BB=DX19"#LTW_^SL2K=2)90M?CBO/<-TEW)4
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M*E'WS!@)[&6.L*W0M'S2)@5;58T:"\L&V&\O0\B'V:[YM-#5(:K]:IHDK3O
MK.A<OQRN%9=8_";+30I5ZZ-,8(DN5[_L#L[GJHG0P#/EJE2_L:FGJH7/_&TE
MYJL[J.BZZUAD2,56#G2]=?4Y$BJQR<+'0SI;^ C%8OY#1!GSGV$']84;8KW.
MB"\^OB[&F?M"+L#\A^7YLD\OEGU8(9^%6PCQ;>%A-!TN? 8B\779S,#Z\G3I
MY[D"X LWAX&P=+SL)<<5:6'U.0B-"@N6*6QO6NBU?-[D(,"W:9V$K0HNSR1X
M^GV OP;)X+56E6I21WA@DB<8FJZ;%<VA0+BR<EB"O'%9D5?JK8&?8F&<8.<C
M;':#38_/L?!)RN? &%<I)JIR6!:?9>(L+3/-(8U[5;_7W/Y&*PM;;(": 6R*
M45 TQ&$O3<_.Y<:[0D& -LEDWS5XE;,\YT9"L<SMZY2?5:^$=QC6!X_T(L',
MS>VM?)1)%L.Z3 P[:BD%@W_"*E/-F@'7J= ^3/.T5&%:\=^I_&9PU5#Q-67*
M@+I)JZ'<:F6&.7EL@G0&E?*1TSB=8(5=*8O$5ZBBI==KL6CX=Z_41OJ]Y1IU
M=&$A57>1QEB$IRR44NB!H&8OJ\BT5HBJ^9TL \Q*<:&*-D?*RW?EN3*0)9PI
MF\(VR"2C+_+A& <'<O/8L%DDLK!W!S6U!$QE-?)ZI[7.!&Q$!O*PJX@A%Q_Y
M-S9U@OFIBR4_"%CWM.XW]:JJC-_#*F.YP^2>^_!J;X#WD=:_.NK#R@,@"Q[5
M<]4&4'VCRM9#7NWM*!)D)2J2=$X?F2@VM/8V=;D$LKI<]]H3NOTL1;@I]:C<
M>-*C(4\IQ=BIB_NEC&K9E@_&AAFRY:9\C0OLG57[8&$WZ)9JJ 0R>C% GEJ>
MRP=(3#RAWW3U)WRAJ>F9%%@4RPSTKWQFMR9V.I9OK!N+K80)>:T(<J;V*</]
MTU)NV'!QU*AA$,7OJLL""'-:L.D0;B=%=Y&W07-*ZZ==0_N<RJ+U%U$TGO1
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M=2H5=I;=>'YK*SH=PCH73%6 UA6DIV?VSM?QV3,,&:[Z:LY5$=GCRS]@ALX
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MT!] -P%-D;NIBZ<_?W[Y(KGVILAV^TZ?AZ-JD#+"5+QSF+4$IY%B;=$G4V]
M;QX4B<+>?-[N)7)#Y\$;SP]&Q1PC*5H/5S:>-_\>C\%^A=92(P\?J&RUYE@[
M1^NNHOHZF]7%)AWY%'-CJY?NP_ZW-D';O<<=;^!8_D\E!MS")#V,))A^NSSY
M[4(&@7]#\^?^=XL\4_\CZQE6E95HJB'?[1LT;U+XL[2RI:J8XL9OCK5#-J\B
M7B"O*)%%1-59Z>9>7;J*NA9L*(HSY#B0--SB>VJ\$:,<R;L/D:Y9MC*579<K
M#G:XI&8(;K=BEK\]E#=K=5UN7=#YKJ[R9)GBFA\9KT5<R#9..-:!K-JCQJ2
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M2-9VI )'K)'',1'[)IR-G!0N PEJC[C!/A3R)(0WSEZX3R?/.&.M2:__!ON
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MC-ZTO;0DA-)3[K7-= 9%N %-@A_F,)>3E Q I2CTS%XGM:J5'/2#Y/)[#&I
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MR^M(&7\I@Z.I.NS*]X@+'0&S122'2;=+J.+MS49%,?SR>.H.UR=W-7PG?/Z
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MQTY2KDIBEYV<]'UB+4S6OJ%(-;EE6_WK[P(IRA)%21P :LM5B2QQV%C#AS4
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MK3WS/Z8\G:6K%#C-?_K2SP#!VTU@=O$&,;?(@/";"$<<YN.;28]!P+PO\7.
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M/GR<P?LRJ7Z"E]/Y_(^)OT[C11E7)16><N]&NNTMABVE4YJC=3P+(:Q44CJ
M)+1%_8/(--G=2C\%19''1B)7TW@'U%4Q!:<W:]>5#W"U_'1T/2?OO/\XNKDC
MBA!>X,OY2%#MHN.42"XCFMC&D."I(='*Z!WXB/_N7/F6JU[V\[!<^M9WP"60
MTY_@:C'??%*(00EE:VORO^^'LE+VZ8-[ Y]@<@WS)V&^F/FX&.$*K"W+B= <
M I%29^(M^.),H,.@0@"G6PQM&\C=@7WA\9/99HAK&^1$(Z5X5E7UO)A6E.Q*
M?3B 'W^8SA+,_OXCK:3I7W#<^#PM(?T3'<UGU_/%] /,?OXK7ET7'_7)? [X
M7_K=_S4*GKL0C2:.&82L/2,>74/B#1-)FV0Y$PW)< S6X?G23\&[V=),._<)
MQ?H2:CW[3M[]_-?',DU_$0130MG@*$$SUA!)#2<.5SEBC:>)(ECM0@O:[$7T
MU4\F=63=@ 3/IO/%J_R/Z33-GTS26YA]&D>8OYU>I9$..#!@EK#(  =M,@G+
MD?ODD_!*HD_3@@7[(0U/@TIZFS81>@,ZO($YX 7?(ZSG.*-=33^69V ]^"^3
M6/SW]7@&Z<7D]6R*R.=E0".KK$*#$!\(+?$A,4!)0+.0..^S8I9I#;;-8G,R
MYDLAU%!JN\\XWH9Q-Q!'8,%%JBEAG.%CD+DJN^&)6"$=5TQQYP=DU0VNRV;.
M:>*_SP[1EQW_@ F.^@K1/4D?4,1EQ OT#]<R&*GDI8DI$L]5+@MS)HZZ0%12
M,0,5U+#<@AT/X+H4=M04_WUVR+[L> M75V5>FZ1?_>Q?<&OXHZ0#&M!HHE%I
MT;;&I9/X[#4Q@7F(F5$G8A,/?R^D2^%$):'?IX/J2X<G'Z:SQ?C_+'>47N47
MDX6?O!N'*R@^UV(^DDXX2U4DZ,8)(L$5TPK!)N ^XI 5#:H%)0[#NA1:5!3^
M?6KH&FY.L;4W0QY9BYZWL918R7'F4B81!(9&D/1,H3M'T1MOY=S<!G(IZN\E
MX/L*-]4V-UY,XO3#<C]Y)!SS23%&#'7H6S$T:,KV-1(1@$IE==:TZ;;&%RR7
MLZ%QHGP;>!*_32?3NZC69+PAN$I!<<$\*@H*P1,@.XTE$IUNR05U"9KL:SV(
M[*NG0UW9-W D?D;7=_'Y+<3K&4H6YK]\^FW\#Q34DK@\".63523A%$BD12<G
M<!>)!IVC#,XZVV2GZQ"HX2E168?31@IHL1.^> ^SO<,?:14$I10MVDAQ*:,!
MUT6I-%&""R-RMHDUL14.P[HT@E140H/%!0U:F,%\<0?4;;2_P6*D;2@V+LZ@
M@14C5SGBDF7H"2G'K6<RY":[$5W 71I=JBNDP:*SG\W<<P,I!&*,1TI[ZXC-
M"HAPCD5<A[6U378U']%L,I0%<I2L&VQ2?3&0-X?#X\DU@OP2_/(4\G0&J^_]
M[O^"^<]_X?.!]Q]/_.SS4C0XNEB.E:?+O9<-]T<F41[ :YP4 7]H9+KE*1.(
M/+D4?(G%:C/A-!O35T_$QZ+O!AML-Y#7C]93F*!^%B.AI4) @6@I<7)UWJSF
M<9:"UI[G%&R3G;4]>"Z$0OWDW& 3[6%FCZB$DG?""7=9X5R+KX)2E("%),%Y
M0:$A$PY!NQ!25)-^@SVWNPB?C^=Q!1+2%XQHE;W*R.PGB\5L'*X7/ES![],W
M\+'L'D_>_8Q_L/@\8I1EGE0@BDN<YYA@Q*&!3Z(S:!AR&K1HXG%5&\&%L6TH
M7=XGI>UM@\/BUA8ELRID[@()D27T.'@F5B5/I%74)". Q28!D7=0?/7D.%VF
M]Q7L>N_L^=D$V39_#;.W[_WLBW<I:&)6:$708N)$9I.)4VCWYQ D>I[9X7";
M[.KM ?35J[V*I'=LW_4.C7YX:43(3_U\')>X1RP9RJ731"11IB05B1,T$"JY
MD%XIHVR3<X C<0Y/F#H:/MIP.5T[#3:#.\%]/KZZ+LDL2\ J:VJ"=667"7\(
MFXEWB-\GY:FSWM,V(6I'(_V6"'6RAAIL'N\TGSI86!L#Z^[S(:.3^(\CQL22
MIL ]<48E_,&D--(I2YO,7E5'<2%4/)]F&VQ75QC,G:?.2^ \)4>H!C0X<K3$
MX3\EEIU"TO@HMDD@J#R.[U3MK=T&V^K;,EH^1B,#-% / KU+B4^099Q8+2P1
MD!U^;DUHD[FT$\V%$*>_I!ML16^#6E-SQ&+4QD9%= *$%6@IGL,%22 4(I-*
M^R8G(GOP7"@%3I%V@PWI&__V][+U- *@U =M44<E=\I31;S'848: ^>ZN+BI
MA>[OPJBH\ELUA)H[]SUDN<L)^V%5$>8_XM5T#NGO/RYFU_#E0UQDX*_%SU?+
M&_[]QSF\*R^JT>'9E9_/7^6WBVG\UY._QO,1@QB<04DH$ST*!DW_H!(EZ%9*
MKJR($EQ39FPCJDB2 T6=#I#F!"WO(TPO:;=(:;V%Y_ERTNR$:+157ZIJU/<]
M2#47AGT5L@ZHOY_.MF._ZPA\&"ID$"P#Q:=%1%'V QCQ25/B:'#)^VP:><]#
M4>!.T;$S,N 8.3?):__P83I9 OIU:3&-1$B*6Q](TJH<C@9-/#!!F%":BNQ<
MEKNKG?7.^-A",KQ-V%<]]W(]^LBV06F4UZ@NF,U*<:$OF)C1U)@0B&-HY<I2
MWC%HXP@4?]4R*:3G+?2]"\Q7K_+>$J[XB,]G"\0S3==Q\6JV+IZPG,%PWE+)
M!?1K8HDB+R%2CG*T@;-3D2<I4NBB<;S^+6WCNVU-[P/P%1MU561:<>?\%I[;
M)3+63.X"Z@AS[AB%WT<SK"571U'WM5Y)RFT>\QW@LBW5CX7'%4>G$@D).)FQ
M7#)&N$PA20M=5O/'J/H]%MR FC]&N ULMS6PS2JC=/"4,Z*7,:_"2V*UC"19
M[S03"#4VB06[@V*X!;RB9NZMX:>*=:_)]I\_;<GC);YM5;KSV7L_>0?S\<KR
M?#^]0B3S55I9V[J=G6X\0-'.XP6P7;$S)2Z9$TX6IF14M<D:W[I $YKO>VKH
M'@VA>KE.[:B67EC"M$/6<R2LM4")T2P*')3RT.0@L7ZYSA>3. ,_A^>P^O^+
M'8)\,[VZ^F4Z^]//TB@Q  ;X@,<4.9K8)>);&4]$5,9HR0RC39S6(W$^BM"V
M8UBR(Z2DF5X:.+S+0YCYJ^M%Z:)02GNA$2"3!Y$(Q>4>C?Z,@'(2!"RE3$@M
MJ6H2@W0/R?!4:*J[[4WO7H)O8"O='^J(*N]IUI(8Y2B1+D;B<'TGEHH@$X\Q
MIR8;'_>A7#@7^HF^09S9$M&+^?P:TO/K&;+S-<S&TU6\QOPW^'/YJ_DH!:#H
M$SC"?&!$*AR^5\J2Y(3!_\ PUV11Z0;O&R!-714UB 3;@_)_^:MK^ (R<^--
MI!+U+%.)^T&?$W29"4$RECQ%#W1 'MU%]TW2J(>"6I3G.\1U]##6/;9>Y3]0
M-6B_J1@XKI:$F5 .$:0E9:L2Y0&QM%81,3;)US@.YC?)JQHJ:Q $=N@IN _6
M"J.8P-58*VZ)-&7O1&1/E'3,^V@AQC8F\C$HOTEZ55!8D^BR \_"LI;R?+S*
MNTV,RAQ $F]H";XJ!V'19D)YL-1*FY1J4VRT*\)ODE4]%=4@0?H0_>_@S"Z%
M%#P0F4IG".H="0%%(FR4&CU.Z5*3--6N +])/O534\74YK*%/2KX2O>L5WG%
M\^7/U]>S\NFB9&&_&\]+U9#T?#R#N'B5,Y2AC*3,B>6HD?B*ET*LE%A(0!+.
MM%E#YHYM&>WW=\S[ +A,Z@RFDHH)U#LQ+TG> 7.D0=D0);&T9-09[4FI+T&X
MDAJ,-1ZVX^P[TJ@C@&^(1BU44C,+>PFZV[[&Z]GXDU_ ZRL?EYOW(Z *HI-
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MDK,A"-7< A,I @N]N'/W?M]9=!2+>BBKP;G$&_BXQO4J/X>P&#E0W-,DB?#
MB43/&Q=>X8ED!JRE5-'09'';!O*=5?LS*GJHK&*.UI+E!<"+R7PQNRZ(GBW'
M_&[UZDO"::G@,PH)73A(EF11ZG<!M22P4B%7&@0O2AA9MP8\G6_YG4([)Z8V
M*JN8OK4#Y1LH\D><>^"^'/LPOBHEBIV-UIG 2)8EMC F1QS#5\Y1]#ETM%&Q
M$VC6&<!WTG4@71MU-L@-NPM[57U^'-=+^4B"=#9%1U L#B=>*M$,C*5=L1(F
M:P9AFVMUULJ#J+X3<-_"64^9%5MM[G@Z?KDN.YM/WKV;P3N4Z?-U3<2- 3G2
M4EJ9@D*D02!27.H#XYF@7)A0G$IAN_F&1]WV.Z\Z3&PU55>[ ><=R1P63-F4
MF[\!',MD/@KHU,H<.$%/Q93"JT"LY9Z ,<Y2I:@RW=J5G0C@._%V$V\ ==9N
MWGD:YC<PA]DG>':-CQ).U)I1=)FY(2Y965+/)$$/2!.45]#&4IM!-^3C733?
MR5F1G#T47;,_Z'"27K=04,9:#Y[P4!H06J/+.(&P&+BD:(,HT20<>*#Q#56^
MX+$_&(^95N<NLG!CHM\>YC+F;QG'LZ1+"?&T(OGLO,5URY:T8YV(B\!P+6/@
MM-3:RB8)>@_@.E?\_*.DTK;755&E#:)K#\!;AY=V =@R//]!A.<)TJ^JU^Z<
MZ:&4L[ G)8]VM8>2R59JYU@@WGE.('$NF(_!2GU!K'D@>/^\I#E&%VW(LF.&
M7<'&3_+395;DIMU)IL(:ZTG2-I7>P:75'D*7RN><F= \-FDH= S(X9V?RCJ^
MSZ V"FH2H=1ZZ5\^D,!L*3&/2[V7RTZ=OK17-02R\HE[9G5JTLURF.%]M]OV
MVVV/D& -RC\<!;BD,&^RECO 'LPH[([[/*;B8Z32(>.A,0]:VZ%'P _62A-R
M)-9$7\H[6N),BH1KQ8UQ(@C=9.OI4='W 9OU@ME[C/IKA[^^AC3VB]DXOI[.
M%GEZ-9YNJD-!D)(C'D=U0$= H6%EN2!)@5(&:%1N*P)MS_[^OCN<V6QMI9]I
M;>%6M%I+<;&W\3VDZQ+MO^H3]BLLWD_3E_#L^Y\"%%DLGP['-05A(@F9H;7M
M32(^IDP89Q9Q"V]HE\+_G4HO]@'ZW:*\;U$.JOR*,;(%]SY<ZP>T"[+:16$/
M0QJ^,NQPJITVU4OE,K(/(*1.:YT3SKS+(I8QEYTN)HCVTB>1;5:\B^7U:!ES
MH*#L8R3,,>JH;0D]^?]^_^/I>/HVC@'G;)R&-VNUM"EE4"1SFG'U!T&\HIZ
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MAW=SU^^&Q6[#XC2U5$R@O@&QV8WK *.ZO?#E_L-;!"=J8%N'/<17>Z&_!0<
M&/69$L]+5K[7G(3L .5OLU#2<B&K-<)KKL4#BW5=)1XCM<K*^]7_-?YP_6&S
M7G@5M<R92!P2D4%RXIGTQ,:LP0'7DMM:ZKMSYX%7Y%-E/ZTAN,H+[:\HJB]
M%*?!N:R(%R7_;'FX@<8B<3$J)GSBPG;)@^JFP=MW_@HU>++@&K6>N]WP!/]L
M.;TD!RDJITD0J70ZR9I8\(%DRJ,47#':R3<Z_DQH-Y[O9M6!$Z$**JQ8/^0
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M!YNB5D+M"(GZ:EG3L\M78](<H8MS=_FR LVZ4N:62Q2"M#&2 ,P1H3A0&B%
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MG%7H=I97"= CGBPK$>%$'E;38O5Z$GU$./)*426B)$)37&@$"M%;+HGVGOO
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M\BS$DRCR;;&AIV0;["*LQUKRVG%>6^;/_W.\>/_L>KZ8?H#9SW^M-UF>S.>
M_Z62SF[*&B_ $VTS7^?72ZJ(T5I(SQ./JDFQS!.P7@B9AM)6Q>(#2_Z_F"!>
M_/WG54&$IY"GLU*N8;Q:/$>>2^U,2"B!5"HU\$Q<*=/%(%FJ; HAZ$[3R@,W
MNA :5)?I?7W+"M;I/5Z^@0CC3V5#]LG5U?3/LM6+J^"S&:3QHE35&(E2MQF]
M!Z*!HM7DBTL:LB"!"Q>#T)FI)HF.IX"]$"X-IJ_['%,5]J-V"62UY2\8.IPJ
MX5IJ=3E:\HC-!T6REB!XU)JR5D4=]X(:*OZM*5.J2?VQ1)K=<^2>?GX*D_C^
M@Y_]:[FI2SU-7"A%:+ XLI0U\3&6\M!.))8=?MHD"^0A8.<ZM:O'@(=<ZCZ:
M:+ !?A_?!MUZ\[8+OI9';0\!/,])6UVU/LB9"CHY!W<R=8Y:)@DZ@J5+CD/7
M7^%B*ED262H*3C0)#3@/9QXX9SLO98Y110.JE$.:^7I2_0T6Z_.:J'2F*28<
M(E B@['$9^4)3]((8ZP&WV05VHEF>.NWKM*FM27>()9HQS/P._[IDOX<EU&/
MCCO1&ARNLF"(TR&0S+PQ(3*14I/BD@<P?0O6R$GR;[!==P]: ;9^#KI &]0&
M^8+MT9@?I^GQ(7[T5,(01L<MB,&II).EZWA<A<NHC4(0G$9!.Q8TS^XB^'&\
MJ=&<'L?(O@4MUAL\]R"N%S[*A+(Y,\(%]V6ON,2@:$:RD+YT]K#<-MG9?P#7
M(S Z3M7A-C<J*J"BY3&?+4:_^O^:SC;X5I'[60EEHF2%^Q9M[6B)M?A6ZAA]
MM@Z'W<4SP:O?H@*^VZ;![MM?C%U10;H5#V8*FA*)_RK?P;0QICN .L*(Z*3Z
MO6B&-1MJJ&G:2L85%X/#X$!H3R,KU<4TH#>E2T7^\E;HP&WRGK(NW;H>H^+W
MV .#Z?T8T=:.\;B#Y[?KLMB\FMQ$A&9J4\Z4>% !_5U)20@4"$TZ9Z$BVD!;
M1R9[CF$/W66X1;RB%J8M1%@[[FL'L-__W.1%,<@YH>U 6#9HK3@!),14N!PA
MF8PZ3-V.V _=Y1)U>YH(!WAN?T<UW=!N>6C'(G&2%7M12F)U0'M1H@084!5I
MMVJLA^]SD?H]48P5=W7*8%_/INDZ+E[-WL+LTSBNW$_K LLB1F)T*)5E:296
M(3*OG0:30$+HDGO3:1'>!>"B3._>$JX8)7,+S_S))*T1S=?T[@*JMO&]%\WP
MQG=_1=W7>B4I5S:_]X/S7(><<R AZY*<4P(TN. DVQBXB*G8$U^IZ@^8WP-I
M_ACA5E_(QU=7XX\S2)M\=><U-;8$Y\42\ V<N PE;R"+D%W0JF,=NZT+#[M4
M5Y+UM)*@&AS&K4>X!N.95CD[7'3\,O#-H^T1)+J'6L@$EH=NWO'1&Z1W4'S-
M*NXOU@;;XF_@RB\@O?:SQ>??9WXR]W&90/GT\^W?+">E1$$K)AS17M%R,%"2
M)T4@SB2I@247VT2J=H=X,;9;8^TTB$N]C6=3$+D#HI:'LO<AG><LMI42#W"E
MAP8:SS$W&=_2BE(W$C'AK">5)C8'2[B.UFM&@VT3V#,4)QXX?ST?)8X1?&T[
M\'?XY%^_][,//L+U8AS]U8M)NIXO9F.8OURDOVWJFRO'04$F5$-)"\/%T )%
M;?+LG&.<6=4MX:[;_88_8>VKEFE;F3:P)-]>ASG\^QHFBY]+!L]-K(&402][
M21F>T(SB0I*0?"E9% /3R7-'F]B4>_!<G/U00^[WZ: ;T&'37:4#L)8VPUYD
MYS$=JNCO84[T$'Z+4."] (5#GTAF7 L-NEX2/:[B=>$L&8+SSN@@7;P 5CQ@
M/ Q+BF-DWIX,-U'*BL:H A'<B=(6#(AU.1)KO4I1BNA3D]Y&.]$,;T!4TM9A
M#IP@ZD%*)OT&RT3,US![BW;/2:63MB_1OU3005#;+6*B]LE9*[D)4ECO2SFE
MQ*.T-!>C;W0 7A])+<V)DRHK[;Y0=:GM K@ENR!]2LRYG*27R3!/A7)9IZ05
M%]'%;=G=A]I'@K_Y60E;_-2G2M5#EZPNU<.@M^1KI7$V^Y0%\Y+B1!)#4(Y)
M[WRPS.AM^=Z[>/_9?IS&?K8LVO8JOUU,X[]>WJ3P)FO0$P)-3*(2[6$OB<-'
M!NUAS:30*D!L$KY]&%8OGWA9#V]]Q75@35Y^!IM/7UTOY@L_*;4M1LYI9JUV
M!"!Y(B$%XEE) U-><RDH=:I;N:*C;GN>!:X2#^YXR^VD73NP:0GF_?0*+S7_
M^=_7X\7GWZ8+>(TZA=D,TO+7SZ:33_CK$D9=',=1,MKJK#D)7MD2RJ&(];AH
M!Q4ABLRY,MW.U4ZX^>5PI+7DVZ2\K.&LQ;"<F^>KCQ>0V,@D'W-*BD LE7"4
MTR1$X0F3AJ'5@>MGFQ9M#R*["-ZTT4.#'+HEJ!?S^36DY]<SG.-6A71NPURA
M_P.U,!_EF(*(%(A1-A(9.$Z T1J2E#0JN,"I:^-F'07SHBC44$,5$RGN"^+5
M;#57_@J+]]-4"C7-%P"WQ//T\_TO;[ZVZ?7--9J=MO0MP+$ <'0RK2/" 17<
M>^Y28^NN_R"&JG;3DH'GTNECJ8USTYKAMK6XW&'S@6H62ZP'+4\;#RA6:R3A
MC.=L%2T)<6WFPSV(SG5@<3Z.W)LN:^BJA4EV"\\F9J@#HJ9)ZO<@G>E0HX[.
MMFVO.@(?A@K6!*JRXR2C$TFD=)$X[0S1R7E$K21E;4I5#T2!ATXPAF+ ,7)N
M<7@!Y1C^Z5W?<1/WAU:; 4F)C3&5SDV"^(0^06#!9^IC#(VLG?V8SI!KWE-E
MVZM!)7FWB(#84'ZU CZ;?O@XG>#;5<)EE-1;+@3A',DNF5/$"8X_J("<'?.Y
MT<'F(53?C8MJ.FO@RF]AVK18Z@"JI8VQ$]69S8S^VINV$GV#-6<W.)-R#M:7
M%G#*E-)Q0((6OF02J,0AX%RKOW(^=+4Y!J+#,1)O0(.=:Z# >SMN%3'"9;2N
M$L4U$!21 0=)8S(,FD3=/@YCHX*>[F5R]!1RDPIZ'SY,)[<!60!PVG/B&$-N
M4^Y(,%P3<%Y92W4VLE'1JRTDEZ#R?N+=^Z W#)!Y&]]#NKZ":=[Z1;T@A@=O
M43VHX;A!;04Y>&IP+(E%P85D:!PFBCK43%.AC!3W@AP>O%G/%=O/)N/)NYNK
M/O7S<?RREZM$"LGC?")\\#B+*$M\-,6,I8SADP?6-$F[.@RKU^'V;]<?2J.^
MZ>Q)F"\K\(^H=\)X08F01I<Z,YE89PQ1,KNL6,P&W$.DW'WI,TPZ]?1YYV"Z
MG]0:+#5_3-*X9!J$ZP6D9ZLFC#CPFRZ,&T&41Z9T4UCU?/Q]6A(?QG'\$=].
MWKV%>#U#C:#?7N0T F>!::&0D=FN@B[0_!+$*: RHHF65),]]A:#&8Y[-0@R
M?63:;6 5WQG3SLZAIXW*:E,V+@EZ"XE(;ST)-DF4NF<)%QK%H(EWU68XE\/:
M\VBXXF;/4D#/83+],)[<$9$L#4<=!**R4F4WTY# I2':,:F2*!5\NA4_VG'Q
MRUDQ^TJNP0ST3QB_>X_4?/()Z?@.-D&(J_B.6\&'*]I1FRDX*DF4QN&3D%+)
M^RP[XNAR&$J]-DWRXXY".?!\T5NITZ$T,AQ]GH^ORGQW#_/(12FC+LF#WN-4
M*H(C/D0@0(6-T48*O(DU=23.RZ10%:TT.#IX,4&W&LKZM^FFN&7:E8EX2?<E
M])%5SK D(I&T')WEDE14UF.#<O$ZV"!-D].I(W%^Y21JJ94&H7\[;:N[8]CY
ME=]@\2K_[O^Z.YAH<Y;<( MBZ=P8*$ZKUJM26)RSY#33KLE"5W447SD!SZ?1
MBE4&CWJ:;D_0(Y'P<;+>$C Q$"DM$ \9;6: H"CZJZ";.'%'(_W*:=96,PU*
M&U5X+NX,)YIDI=:6Y*A+C!/5Q$O&21!&<\F]\FU:*U8>QU=.PW-JM45)C?49
MQ:N\TYE^^GEU<+4,N%I%QB!692(/);(*/1F&4[7C:$GP8D5 ##GI)C&(1R,=
M*J:^P2[$,-IY_('S&E(R0J'8,@I02@>KPHE9*"XL/JQ,?R.!\VV)T#DZ_AB%
M#!,2W071MQT=?Y3.'HZ-/D7@0U$AEET0=!AT+I37B02KEM5L%,\R1>V;.(./
M/CJ^.@.ZR[E)UO+]4!K-0FD!!N5@4 JT]GT2B:"ZA%96ABC;*/[\D4I]U=,A
M3*F[;)O4DMX1*A>\R4::0)S4%#$E'*$3BBB:('EF).@F^<6/(QZQLLI[2_@<
MP6E/T+U*Q8T:?X(O9Z[U(M,.7[]Z6-H1P]DN;*143(QZ!KJD;AL7@O?:._",
MAZCN%84Z?*=^S^KN:__\5[RZ1L"K79L/'Z\7ZVJ5VY;L%Y?)2^.BX*Q4.RBU
M:Z4FP:,I:\ &_%Q;R*G%\UUK 'TGO9XXGGR87D\6(Q:DSI#0O\@4EWZ>!?$6
MGV8#V@;!.$C:9+^H"OKAI]6SL'=[,AY>\RU"R5<+U#]+C:_)XM7L33GEO#D?
MOQG5,W]U!>GIY_7WYNLOSD=,>0^F[-8ZP=%F98[XC#:K9BQ9JX/3OLGRWA/W
M-TK9(;7=(M?V9F>EIS17VRXRV)(=J(D3I2V'IJ$TPY2$1JJSMY1+UZ4948_=
MT1K#&&KK]%$0^(P,>"P[L#T'_O3S[@LL-Q^$MT*A?4JDY**4&F*H&HF^"3[J
ME I.0VQR7M!P3.??!1Z>J74-E6J,:; B[$96.FQNBB5WP-=RR_DA@.?9@'XT
MC.C$U)[J/ ?MI,J<2V9)%%FAH40M"2((XJ@S(L@D?)OB+^>AVP.;W5\MVX[1
M8NU&.C]_^'@U_0SP;#J9(YF+&?YDDIZ/9Q#QK^:K0K8?E[$TF^HG7@E<'#P)
MB=)5?KLW0A!FA ?F37+;O37WY L<?>O'XDV=JKKI8'*O74)X[:'=/PJ 4NI
MEXZ2S./#P4(@P?A(J.11@Z'..MN)#/ON<$DZKR+%)DW52II37*SW^Y?E0-^\
M_>.F"($$PR4E/NA,9*2>.*X885;;E''F\\&V6&,.HKH06M370.V,L3\F>)$_
M<; PFQ=8KZ]G\;V?PVINV@"4B$(J04PJ)/8Z$@O2$"^$I\J!M:I;"EF7NUV(
MZMM(MV)T?NE:^ZSL'</L8VDO5\:[M(6R91 ENH>41UR(,CABHU<D,I89SQXG
MK2X16)V::^\"\ V[VE5T4G&**'C>P,<U:Y^\F\$JVF0+XOHQZ0+R"">Y$X$Z
MHQO60ZZCR.E06JAH=!P)UB3!<M!$\5684EGZ+#XD)B1NA3;9=C$^O@:J[/%N
MS\F4(X1?VR_]#0UE_]Y?^?4BR$V.(?!,E):<2*#H_:106ILF@6Z1"D&H3B;&
MUH6'[0+?2/;32H(;I.G:D_D<%D_BOZ_'\^6E3@G-N7>-_N$WAV%M]UW3WF41
M/-,T2U#1.2%IR-E2T,$P-SH$L)>T>L0S[;M4?=EUJYS%1:39"L,2RLX%54(0
MJ*/4&@LYWQ-AG8"DI]?S\03F\UL7_G)D*%D2AD9) M4E2 (?&%]:'T1A=:3"
M!O!-ZF,= M5K%MV68=EM&J=U^M&R6_@JSF]3[A8G(O1$YZNF(4\FJ;Q8&:L^
MZY"E)V6SB4BG!;%<!J(S<\XRY]%'Z33]UD(TO!=8C3EWINNS:*CV]N#V(.Z"
M76%]-=M O5L68T13ELZ4XA<AH^@L=65?DY8P4\/!TQ@4/8E:QZ"X5#HUTT1M
M>Z_K<_!R[,/X:NEOOYB@YXT?C;A,R<I2+--S7O+#,_$A1^*LB)E)"'0["[;G
MY+0#Q*42J)4>:N]3[L!=BF^A@?V__-4U+ /+EC]^G[Z!".-/\.4;K_WG8HG/
M1SZ9%$S,!&E1$AO XAR:T+FB&DK"N&#BY%7N:#07S*BVFJFX![IS ,NGP,?5
M6' M'AD7$9Y,!"W_)>\]"@GEPZ36/BB6F#4GT6;[3I=*B5X2K5CQ8R<X).7T
MW63\?R"]2,C%<1Z7I7/YK958<.K[QW2:_AQ?7:%!=FMBQ.]<?X#T&RQ&/F>A
MG4O$HW^(HF*4^))+8RG-1B4TSN)I2U0-=)=*J\$UUZ!BR(O)6A]PA3-C0DO.
M3]Z-[PUCE)RE0"TO)< TD4E*XH%E8C/8I'SFSC6)!.J([P(HUE(C%:MX[%YS
M_?R]GRR=R$_^:K6B,@@0?28ZE21.EPUQV5.2O4C,)<K<=D)55UOGWKTN0/DM
MI'I?Z:;O;/'+P[QD(\4U14X:''5I'$Q5Z3= ==DS2)Q39F6;UAU=P%T 59KI
MXCY?;!V^O-R!\8\YY.NKE^,,(T ,FE)+#%5 I-&4.(H.GHLL\E*DE)LFU<RZ
M@+LXOE34Q7V^N'J943O$,'_Z^;9-O]J5U);)+"RAP0GDMRS%KE4B@4&I@ZT-
M;U2MYTB@0V4W-6-/4\V<.R=IY^J[*F.2:("@/.$IH<B<]\3*; GCWC,A8P!Y
MVH[-XP@T:J'+0Q;-T3)MO0V\*6;1 =+NR*&.ZCY'#% E#1S29P_Q#:59)D'+
MTC'+\-)>WEGB9$ OR5@9C.0T;F>P/ *-[@G5&5"A1TBMNB+AT_@?RPJ:\5=(
MXUB6KTE<1YLX:T I$TDYW4?[Q):BAB$1)9.5*'XJ?,?Y^,!=!BX76D,'TQ8"
MK'B,NS?*3 <O+."P."MG@@Q=%<LM^K=>Q9BA="RI%H#W.(-]&Z[!5:1^MG#>
M+B"_]7#>HQ1Y4I#F*5HX6S@O]:F< E.BES'O,J/GZEDYU=,LE(TRZ;ML)7P-
M5#DVG+<]4XX1_J!&@_<Q\U*JCMH@RZ9&)#9132A*A*L,UIN.AV./PFAHJ)7.
M9L0Q(FU0[FG_7A8NG;_Z_YK.EB6"EL1G#E=&Y0*!K'#A!*%PS92(/&010E#4
MJ"9!ET=@O&@CI+7.&C2,.0#U"]!;SU@7N"VK<QR)]SS%.IKIOSO/JBFO09+T
ML;!-J3"5LB2:.DUD3I(XRQWQS K'!5,^-"E8^2BX]D"ECL=*M6-TUF)_[ /"
M2_^<SOZ5I[,(ZZ5<!1:4LXD(:B.1R>L2"^6)44&;P+.C\<'4CX-W&/X,K:E>
MMK?/>@MUD*RH7_QXMHR'_!7\_'H&JQ#0.PBZ9?GLOE#_')\. +>3I!2:M%%I
M8Z*3E'J'>G+&,>N2M6BEC!Z$VE^"2[.HGAS7EVLDS5U@M[.F! ],,$$5I9*;
M&*Q1Q@?'H@]:,[E;IO=A]Y?LQC:=YM6#Z^\$T"W>^X6?;?X@^<7--:83_Z:D
MS,_6?5#[5.@>!E@C;;<5X!9O* 4;>;)2E*Y6%+S")Q)R=!X Z61W\Z8ZQ)XF
MV.;ZZRB:.V@V,%Y-;FZ-7_AM.IG=0?+RYK3=69N4P-D_,*[*F4S&]40Z(GEP
MQJ"AT6TOZG@#K>8H>M=E]O/W>(/ROUMA;#<02]NRJVE!-,K!)I8,)]%0M8X\
ML=&BX"S-F7&K0Q,WO3/",Y@Q9^/CO8++3=388F.H@LC6S:Q*'CS@0)@K!<T=
M]\1G;0FWUC)EM*?1/=;'=]"0H\?#TO,H_]S!2_=&CR[NES7VEQG\^QHF\?.J
MIH<!ZDR@).12TT. )I8:0;+(QFJ58S9-PN4Z8#O7'NB92+./NI64UV*#:H<%
M=P/PIJK(PQ";;H0^C/%,FY^U];N//Y65<R8>I9RHL=F1 *;$OHC25XJ7Q'$+
M+FOM(C1IQW$V_CRTH?D(Z'.,3@:BS?QF5MX4(Q(NFBPUB2XE(@/3Q!=C-#,(
M'#*/MHT3T07<&?V'6EKMP)I>*FGI$#S]?//R_QG##&_R_O-+^ 17RX?'!&#2
M*Q2#YHQ(6<H@TVA(UL:46DR&RK;.^D%XWVVCRBJL&--V\&&XCW=SXM ![-"&
MTEZT9S>9JJF]RP1656=#+81[08N8N7?1$I'9,HI8EGJPD4BT%7($:R2-%TJP
M[C;5X^#7,:IJR:L7DX_7B_E2 FR]B&=/\1^G"&2AB=02Q1$$+X5X?$IX+2.:
MM!@[@.EQF%.5M+F/-SU5T=*>N@6-;Z!I36F.G$!:ELY!7\1G)8E!C\1%@?^C
M;:WO^YB^-9:<HHJ!YA*Q:49ALS3"X5SJ8VD<'05ZK!)(=CP)'W- R$.Q1'R;
M+#E%%7M-YN91*K^5MB:E%'[MD_Q[%VYT$G]X %LGZ<;R$E.=!959RLR"\BIE
MEH,L!5WTGJB60T,YKAYPC+-K2#__]1'-*"@G\J\6[V'VK%3@FRQNN7^G:*'[
MQ2O4##YM(%O:X,(D=%9C,IE+6?K&2FFT!N8LEY2)T4E#:J.1TV.1CKW%@-KI
M$+,DHG(L:L.B\](!E'*0(DHJDXW99=9=1SWCF#K?YU;<2]<_Z5.7>P!8 S*B
MEO"V(YA"$HGC@F?*,ZYYP,<=5(C1 GYBCWC2ZXBQ#?-JK*6GWVQ EARUYN)R
M:YAG''U]5+WSGAF<[8%SKJSF1G?7?;5U^)G_.%[XJ[>+V75<E.BC$Q1U[QK]
MY7\8UK8IPSES&:+!AT@"XU91P!4TXT\AK36C0P![2>OTI7#/E>I+KL/"!F"C
MAA281>L/;1#G+==4J&2$LIS)>_+KN7YM7Z[&9/'@->M+]JA'GSKIP067>#;2
M<QJ$9$9D[YA#JX*E>S*^=_6> 9(E%>%57K;E>WD3!16M5RS%XIAY=,P$ Q(\
M"R0PC;,4>*E"D^"SG6CZ]=E9EX"_?>4GUXOWTUFIFSI2$+GR5!$NC2<RQ5(2
MWAFB'?H^0OG@5+?4W,/W&=[![Z_7NUUWZHFQ=G.&FP<$(:T*_=\")G$=#58Y
M$J&$\_G$2"CAH,$ZI\N.E'/=VBH=NLM7K]UJ(FRPE7>KF^P]:-1!B$9S L*&
M4KNX5)<,E%A.DTME%Z-3\9;CIZG]F+YF+M06>8-3[M>HQ65_AMWHHDY!BFB(
M42[AT'' /@1!\ 4UB1J7?!-"'(9U"9RH*/@&"?.W&/O:SU[-WB[\ M)REW+3
ME'2DM&56*E^Z#"-SM<&!<VI(4A+=+!^]I*TGBWW8+H$@M550L>W!;@[O12EC
M\M0O^T]#*5.*QDQP,A(GM '!N$);I_TD<LE<::"(!JT)WOI2F60)\6XCJ56;
MJ1>WVWJ,1'(N&YZ)]25;Q'A+/$! @SC;;)CABC4)X#L&Y"50IYE2*K8HV('U
M3INI=1N@].H.6*Z,<]X#84JH8EDQXCA'\C,;E;*2,MHDQN4HE!=&H<IJ:=#Q
MX!98G!<C3!;^'7[PZL\)S.;OQQ^?0I[.X#9@XX6. ?DN<)HL!;<BL25J3"0>
MO<A!!M>F)/FQ2"^,2PW4TZ CPEH$_RR[B)/%J]FR,]G-3%HBIY?G",_\U16D
MIY_7WYNOOS@?>5'\/PK$,BZ(##&AC1^!)),%]2QEVLB*[H?[$K@VI.I:]%:X
M]:C,QO&+F:>=Y]Z (PIE@#-L,L1:J8D*D"3W4N.<VWK"N@WH$KA21=@[=O-Z
MQV_N)/'/?^'<.9[#$NK-+V^8RT8JQ<BB0BFH@-3-V1)+T1U@(7/)=$H^-5G3
M3D)["?QIKZ8=Y.I78&PGY/6B?+,>_X[LF+^?7J61EC'28"P:<JQTFD$1.2<#
M\=XHK]&L"V%K(=MW,G#4?;]F<K06\PY*]-XP?I+^ZWJ^6%6)FCY):2EL?_7:
MC]%77)][K,>R\B!'/I4B(2*1H$NC*@NE!5$.Q,;@2X<:BK)J,=<<C?1KIM(P
MZME!J+JM<H]J/YZ52\N,Z*@\6OX:8JF ;8D3,066#"1W6D?"Q]T(OO+\,Y@*
M=I"G7^/=I03*I(ASY KU;],%W-T+?3:=?,)?E]V(LB<Q$CQJ;[@A5)3^><:B
MA'!))6C!E4B1Z(*DG3ASPLV_>JJT%O@.AO3>=/Z"9RV'%7-7'R]*2T7KN( D
M<!VE(%<M.+UGCG!IN9.29Z^:K$\/(ON:^=)&_#L(TG]3N:!:37//KTN6.]I>
MXVFZC7,%_P^4_GP4M*,\1$]*5!F1,@#Q4?IR?!\= \:U;G*8=1S,2Z!.0\7L
MX%'OC>77LVD$2/-?4#1K"VOCW\U'UCIM?/"$.V&)!([F5@R)Y.R=<M2!C$VV
M9 Z!N@2.5!/Z#D;TWAK>^/-/)FGET+^Z7LP7?I*0R[_#[,,H6Y\-:"""E^;/
M.3OBM1*$&@?"1"'C=K!D'58\!.P2F%%5^#O84;$U[G+43S\O9;"JKN(=%8$B
M-L6T0N8Z50[J@22G!4.GC.EHFBPR^S$-57VRP3I22="/I2[DV^LP'Z>QGWV^
MM2F]+&V1@K.,<TW09BI-?"(G(91L8.VB\U9KZ=O09A^B\_?!Z:GR;2I5$7V#
MH-[;41S^ [Z\=4*Z*0S6 6'+"D4/0SQ/6:)*.CT05E-1(>>A#N@LP E.($1=
MSB(H\2HEPDW4W*/5K7SK2)I!*?- H:&S,>88/=1N-_/'!"_RYVR\6,#D]76X
M&L=7.<.MNH 2EV*72TL4EJ"4!U?$>9D)1&6-T=1)VRWSYZ$[#6^=UE;-M)5<
M:Z<"/9E]&,\7Y;A[NSGA&ISQ3B<(N(X*1"B%0Y.,*DMLI!&]K\ @=MR"?^!.
MEZ7TJG*M_:2_@7<(#F:0GH]G$!=;?+36)Y^=))ZF2*2TC-CL/7' C==>"*5B
M)Y4?OL]E*;RB3)LD 8T_^06\OO+Q-@FY<4R*C%B"3D1R#L1%*HCCT;'24TTE
MVF+9WPWG8@A14>HM,G]VA2.L"B?JD 5-MD0Z&2*#C01YJXFPSGB6G<AM^J[N
M171IWF4=T3>8'W8"VQ11[0"MI5MY -MY_,E*6NS"C1XJ:)%8? "B]Q L99DH
M9P3:,^@=69LU84YZI1V5JDW]_\'9\8#K.#PYCI%\ U*L,:W7MD!I&0\EVN-*
M*74(Q/((Q A-I;$.@#8Y!KN#XFRG&_WUL_N,XP3A5G042_?Z[5;U2T:#Y<ZG
M5(*!7*ESP#DNA0YM(QX58UHS(;KL1N/U;RD:WVTK>1^ 2S$/J@BXHJ58\+R!
MC]N>ZS;$C87< >01]D$G-G1&-ZR%4$>1TZ&T4'$U. ZL"X$F!XI$81B1T:,'
M)'@IBPWH_VC(*79)3O@:J++'7#@C4XX1?O66YIMML?6*)FA _]<"88 #E6GI
M%.-22;65W*H$&KIM-6U=>#@+H*'L=^XGGB"XVGO&OZ%%XM_[*[_&0E6FTFI.
MC&9(68WKGK/&$*8IY\PDB))W4N+6A2].B7T$5_M)?)4SLFDVWYQ!4$HC,T"\
M*$9JE)18I4TYB- FF<0<"YUT>/>Z%Z?"'F*KN&V38#QZ">_\U<^3Q7CQ>=WU
M),@H@B-*<(UNAD<45##"2_AM4%1JL2/(>;X1^1SBW]Y-/_V$EUZMJ?AB>SG=
M<=M+,<'[2K1B[9T"987BIHO1PSCV&]A':_CVO8<UGWLK85I1@A4GW'MX<(JP
M669#LBDI?EE8$G2*N(3;Q)E-,N[::'^$FMQCW393Y#&"J[UBWJS>ZR2[7_W$
MOULN,B]?/ENO!XH:(S@7!+C%07*!ZT'PG+C@L@$I<0;J5CRSP\V&6UO[J6&G
M!51)A@W:)2W+:A5$J_RG9],/'Z>3DFVY9+'+ ,KD1"+CI9BCRB1(ZTN7,6$@
M9Q54N/_DUD@..8#J4A;A^BIH4.-L"]/&H.P JN4AV4Y49PJWK*>]:2O1-S@'
MV0TN1)F 1DL23HKH(-!,7-*!H.,'22E*99O*B /RX:%8RH'I<(S$VQ9?WK3L
M"M%F32EA'-U#Z7%.# ZG0\.B]A*8HJE);.T]),,?BU70T/Z:J2>(MX&Y<#<W
M>F/"0 A:VV(::4DD,II8Y3)96D861,RQ2<+Q+C"7H/7>0FX15;^9U^X4^%]M
MX=.<F$=/!T)"=,82YT4@:! !RR $^$8)Q'L07:Q]V$OT#<J7WL9S<R[W,*(!
MHJ=N03JS5=A/9[OC8OH*O%VLU&UDUG"JE =BO.,X QI!O!2>..:II^"<;5,F
M:2@*=#4$6S/@&#FW6!A@-H;YTYUK%OALO=:&I) $D88B-.Y+10.3&(^!W3LJ
MJ[0T[,=TWE3P4U2VO1I4DG?UU)JMLDM+JBNK-74FH'GJS"J$*P1 N]5*;JCU
M"7VA;@?>.ZY^*>M\'?%5+"V]$]!F+[0#I-T+?$?-GF/5KJ2!0_KL(;[J42F[
MH<6</+6X&,E8O QE#;$(B62&_J7)+J?MLN"/0*-[%N'A%'J,U*HK$CZ-_P&3
MZ8=Q_!72.);J$I.XR;B+$D!10UA.FDA:"E(I5FH[9ZZM3BEHUDV=!^XRW&I:
M30?3%@)L<3!S'>;P[^NRD_@)?_R.?[;:0A1&>H4KE<H21QS0B@@*@&1.M;).
MY- H=WTWGDM9A&N*O4%5_AVP-N<!'8 U+8.Q#]GYJE_TUM_#G.@A_!8^V%Z
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M\UB83]Q7AA0$X4(P7G9RWV-O>;Z>;&:[]@-Q/+L6:0-KUFMP,FG*Z6-@VE$
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M9+6"X\45Z7<]UD:^6!F3%LPG5\E3#; 0R(R4HO&HHE?0B87HY%/Q%EV^H7H
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M%,0.98 \K?$S&CI]8/<TXZHQ\)[/PG/GP&27XMY833ZA;!IC/3>IK*^:4D]
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M Q9&=B[SP>_=I@.6)[@K[H+>(*[!6YOU9.F \$X:S05.6 /-SR%.T0%-;G0
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MODB ;Z 6Z("$T-!MPW(2;-?)R<E MV5\.%XKP/DSJ,D_69L#;_&;*2[PKW3
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MD1;XI^D?6HDI>G2 775-7=(#%T)C5UD=,\\SDRZM"L<&^.-"Y0XD(", A-H
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M)X_%^EB$BWFO9Q2R!EF+FFB!.I8&DRI2OV\5Y>4B%"W!9B1NHNRPK@F&QXW
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MQJ[6&O8];C@TLM0_<?]@(^K=0O\3M#A!]BLX,7 =+4:R\\8!N;[NJV=0-.F
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MX*4!AC(6O?.OW!LC-$6EXQ5HEGN$ EH+0R:]G<"^? $_ <2E_4R=4NY4-CX
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MMS2T<@/6$!W8XJWH362DA'(9-J'13D1IV-47#V^35CCQZ>I4T['&XFN76J4
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M>%5C!*0H[<4_M0::%@7).+QV:4Y2F&]W*Y[V<EEFS&*2Y.Y4M-ETG,%&Z+,
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M?6F:9'F/SP$5L8I#:OC/I84*N;V'AZ^]CLZMAS[F1IC-WU7=0C8H1K  #UB
M9TBZ-I8%"+E0YP?$^R7,@QW>&?S<]V5?/](EV(^>S-$^^G!VQN_\3)5B,/C
M\O$2TOY0(C8<Q;D1=,&\;X^A4YXQ!<WG>GCZJ/N)T3=B;_;+< YQB@C7GH[U
M'M [3U?RM%J%L@!QY^IEO4XJ6%7UN<61*-$D8UN<]B'V<[Y[E7U]EWL\TK^5
ME\7K"1E*O:F5^7@PD;&P>0^F98G"C03@PI;HXC0@LUM3,"TW2=0CAMGJGJL/
M$K6QRGYF?!K #27>6*@C2DBEV?)9;'A&,FZ2^8/"Y>UV" ,W##8.TJ3^D&J8
MK<S_D,ZI$,W<OLH<H\>98X/-IG?BX3<9N=7 <>QN&$=MVFX2NV^8)YQ3M%.P
MC\K)1J$J/7D$W7.?P[3.71A^QW&AB<=JOB06GS"!;C@<..X4LYEJ=5BH,4VB
M&E;2H8TSKEC+6V;#B5<A]]K$^5QSSNTVFX..+\@ABYSG%?SS?^Y4C3%M _DV
MLT82C.SLK+WGJ?-(LR4L.V@K!CZ%*]/LZ,;DT@QTT+MZT8'$434A@GTY4B/M
MCLC^QJC**:F@:7&-?+\)Q09TV)@DXW5);&B:,ODA\U _]S=5846AFRG;CI=,
MO@F>^]Y62&^PEUQO02=^S69V9;1\>-=S^73FD%MFZ5; QIK<G:PV1$]&-8JY
M-W>0=F=G9I423TH.1W#3]Y3VHM_=)G,\5_4,S')!.24I%83!GRY]Y)0;=;-_
M!E6G1%13^<A2-F1(PT7EYIW&SIH<:_E2C'#D]?A3,>L//B@9+7YK7IM.]%\,
MTSJX_2 ">2O$5;,@P=3=.!-?!'4KMD,X>N9/[C-.5'EMR=P3"+:%),?M*$Z
M(^WXJ54T*%P>2TK+8N1 [2?>YN9+T[2^+;VU?Y_8$/&95!\7UV4U\X":20JD
M^)(YFGAX8<A&3=0++2?TQ8'W=L#ROH>Q2V8BD!\\:GO=TSPT.(Z; X37(<)P
M,#6<R!.*D2TA T,W>99J'(=M'U2LV2<[.\@1Y"/:O#B/1;0,JD)KD!:8_M7I
M]56T4^"[E[ZA!*D"QT< 0*OT^"%+^;7RMAM:70G)B5M^"0G6;F@#Y4_GFQ(2
M(KRJK997&G4N;O4R8C&8HVSH=1@.(N$F&I-0D\/:$FQUJXTD'MZ-JP>[)%N^
MWL?=--GN<.E';F/PV%46@'-W!>$@LP_"_6NC<#LQ\X5'247"=Z9<;V_3R-V(
M3L>A.F'S!,$N91%+H-]7\1CH1!OHKH/W2;GX!,1.?&!0IE\O,]F]"6F=U7I
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MH*7I%[)<?7)?55UOELFQ,J_OZ[KJ1VZ\H@6<<S=N8.[J\08>H69WUC>,2;,
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MV9S'; 6O>:&X68 E!>":ZD>:*[*U!\8",+%2+$ /[R!R*8$%."U+6F76];
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MELQLS@/_UV\TA"5SD@V0U\ <'5C"(AO],G_MBOWJ_V\O#K55KV,!MF411UF
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M)R UD_M !JL[LA)1$"9!0D:T^!/7O#\F9%C!ODZPQ>_#:3$Z_<^E]'5X '_
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M*L^&O)N;$]92EMT>GO,V2: FX7LI]:K7HE=K_#ZO^%EI/1TTI@493F);I*,
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M$<ZDT_(SM\&-L7]7.B0ASGJ3B.9+88S9<.0T!7"3U!E[!V&X^P_SF%J@;RB
M76/2.2A]%F)PQIWV<_IO)FQU)4DX6-H5V!/UF30\\N-.(?(VR/X_2]G\2\36
MD!NS9^AU4?U:F7^E7U@8^'S,[V0VTG!T_7ML 9:2#^?FX5QK3$N3>ARGTB,H
M & 2!6 ]O,>2:_ JRX0XVGZ^/G*"__A'9)+_&T*C@H-2_R(>Z<093 @T1;*O
MWHQL<#";8\D 2N7=ZVW*)SJBZ2F X<-*"@!>2 '@_-;WS1WN.MZ.#Q(>+/8R
M_?9L8R"O^*;3.WB7'-&)#*^'GIZ=KW.N(C)'8Q?HW$S"T;^1Q/G@=I;&PT0)
M<I@T</,GD'2J]0_;,\.=L13 *H[QG^W_V?[_^_;EP0:;IY@$4:/PS?[0D&4Y
MS*6)Z-'JK29J#MX9Q)^%)2OLS:**\6YBG1KS)@\!S(#+E\28S?."_R']Z[\K
MUAFO*8 E=P+T+""* G@@.S4M@ $=<RF#*0 ;# 4P<@T0%OSO4@V*_UUIZQAR
MFO#7Q0PDH-SY@D:0A8[?,!O9%BS_0QZ5+_H<B2^5$'7)G8?Y)_=%,_^61V/W
M+QD!$_\[(Z#@G9%&V*.P[_^()\7GXN6*;LY<TH#DL.>4#1MLZ%  5_222$=M
M%,#7"'/??U6BUI.W<^JU;.[+\C# R=>S@<<[013 J\M)Q(?N\-7V53(UY^\[
M%<=\OV;S;(;^;H.B%)6(_Y\]KUI3O3"^+<YAA24",H\]+0)82JVL&$EAH#,?
MT$\SO]OO;-^,IWI;O0-AK-;R]PX^40"+X'/X1CO])P607ZE% 5Q$M:!$7^[<
MER":M3B1SEQ!1-8)>&?].&AUX[S=UX:JAEC $O(_^_8=JA0*X(W;1_CP5-'Y
MD#RT2*(VTN2P>B")SG7#^0.#+IFE*I," %DED2_5 _&5OL/')Q-PO%AY9>'+
M?W;[SV[_V>T_N_UGM__L]O^E;DWQ#+F\:5A&9O"C,66O =H(459H2U\J<1KZ
M-]!)YL+QVNE#>+_A!'P>LF$+M4W^MR5(X[^F:.)A_R=%\Z^SC:+>_2-$P_(W
M;.(JQ__@:R9 ,;JCV8;DNRKF*V&11AHLQTRGM_Y!0.4"5(\"L$5O4P!&5GZ9
M'RD !/0(_JE2L3,D5X9\O3!65/KO'KOPWR+I_Q=$ 1@-Y%6^BF\TCM G2$3S
M54\()@V!M3U6FM]KG1UJ)\<B:%:>TM",M: 9 ^/^)#C&.54X3X^L6SDL/;<0
MKYSUUN[X<.:M$GV[C:\W"Q1/9B Y$-BZ<VFZA/IL>:>WQ HF-MV7Z3[].J:K
M4Z:=TW[M;>AM\%':M"WH5-=9$=*)O.)J>PDY#E-QPR;H5:0:3HB%:Y0 ++<=
M4JX_D!(>_A%X=S%%;26E[>9&Z8]M]/BO]"U1W\:U@).UYOT$ECVV+G1"1E9&
MCQ*<^MS+O^E._F-F(\MAH@%5Q^I/L%X+,+K#Y]U=**])G=SLD_;M^[H5>817
M(.KP&7*B2IS5(,8_*XYHC67OW3(9WDU^'>)_-F4IV<C-*VF0MD\!1$UG[(VO
MO-*11Y#D,DCUQ])K*-$5(!#VHGV4S*>^**:%-8UZB1O=CW-+,+!MJ@_7S7VX
MK7&:S!_[7./K0I\3 2!I>8BL,X_V8WP)8O'C8KQNN7ZR^MKINF5@MD%#O$8H
ME[OS\FZT/6.DP]/+4@K,S;[>8-&S_MF]X_ T5)(YM >RJUI5V $C""4I^^%]
M, RM!+J>O-NU4SOB'K?<Q"[=-:;34\6:TY:O"N\)&+5YW@U":?>ZQ8]1 ,[@
M?,; QF\N;#V#?-C'&\'O%&U+"F<MOE%99=903VVQ7ZL' F+H['D+RTP\K=NA
MT'SHAEZ P,1C[ATWR#+Z9%I]?5[7J'%,9J/\M%DY6]<B+ZCXFY*1FJ,"=PX@
MV#R="#^L(IIB/1YW]@[T/$Y%?]$U:__24A?KJ'*Q7^;QZYQX^KVL+;( O/\^
MP?PLO JYKSO]O2&XMXR0= C&9W0!&8DWNTW6S<W,[N7Z&(];S?Y99S'#4<6*
M(<(N*?E[>X>],;$>+!WM([2C?_3H[994(N"=Z)70=@W8*$$)%^$"9.'ZJD=@
MZ,-,91>MO;6VV6"3(QCX!2E'+,=*WK,WI:629A&Z2\/C)JI[5E8? HGH4$+&
M&8[#P%6_.2L4-3,KP;U\#1,)W]2H*V)?L$.5TO15]2?>!:7A$!L(B17N*1==
M@W%=LM:(K3(QX2-)B0)X#3]]S%6&;#APEG&#UQ0VS)3,U^?[T-]">6L:Z%\S
M*($]&*E'<+B%L=2VN?@-<BHX=#3>TRX42 O05$]#S?"^QG:X$YLQ\&@RUP3Y
M9CX+<6J\Y\2O+[YN*DT_@R>GH9$OC%I3E?<VW6K@'"U".=FV%H/D)B8](0X2
M[+HV@J"R>3'/2G5+P#:W^YB-!^@KEN?-@XQ_-/<K4,7>L*YL=T<O%I'AJMB5
MH\J&9)+]Z$:]AM^@[$'IZ+1AO8?E+3:QIX(0E6=B==IV0XO-.'_)/-%EW:1$
MU/0;93\,LT%\!R_QY<G'>FC)NBW7N+L8+I$ZL^'X[>/X(5C#+=BF3UZH"&F!
MGO#F:"NA2LN.P+#S9UK;?1[4SRS3XC<>>IB>CQQ74(K'4:LJ@T^>!? .40#A
MR(.]C0^/S8RW*XFM<(AX5KZI^?U"TL.1-G7L_+D+SI8@5UMP1;_@0K@&4]!G
M*^7[AI5O&><%VYX/@XGYA)LX\V[(-6>R9$07+R]^:[ @<='EK8W^GV]%@VBY
M+WQYN_ESQO.),)5LV![.K!(#8H7YY9OD;YV (C8K/.M.)81ONNFXVF1XO^SS
MP>W<3/Q5L6^T A\8W!TG'9)S=\1-V[>(LR?DY!U?\UB8U CY[OI;(K1'<;J;
M2S3;YJ'"]DZ;7 N_#I396'!'G&/B./L=TY[D4VV$6_D[:YN\)<W'CS?L?H!<
M)(Z9*N";?$!R;'J')Z(8_C<5[?WP>;9RD/(P" TL_.OTFO&O_ZG^G<8WQOHQ
MTFPPN2KZ=ECW=_%YITCX/9L#DIM6:NZ4O;-3:.JWD2H2?OC8R-_Y].;7#L5Q
M4E!1Y7)VD(\@*W8RT99U7_7#H0JYF:H8$=<FALU5_W;2;968*Y$A]>+[7''<
MO$4 #050=1]1#J/#58+ZLA07+!LSI)YYBEDL8Z#JZXQVZ(VWJE12 PZO,Y1E
M(TB,HU(_AQ2^GRIFZ84)Z6@PFT>&8/ZG(0Y+L["[H[+7@O?4ZZ=\3W-=!ZDS
M%-WEM8_N"?=RX&B\(YJ\M;RLZG?97OEQR,!G#7!I))%*,434F*\Y=9E#XOQ+
MA:WDAVZ9I35Z9U]W!OS:QT[GDQ!NXAL]5F*)[2Z%UANLK">36 ZQNC5/(T\A
MHYP:3?T5*IJW2IS'%_L.ZXG]H7@S4*PH1N(J(M+=\3I:=%"AJ>5GIQ3^EC>?
MH>63G;O>5P&)HA4$^3B9<P,2-IE_5?PI?B%39;L<4R9+IV),J%(=]V@1SKU.
M_4[3/"] LV_%G:G'91.5EN^?3[ZX3/PU@!(W%SASS<#XK </X"F V#H(*WC0
MJV#]D'.P3>J]0(9!L\[4_<M2\89OV>U?!*UT*)R],^A&$"'Y+# T4>-/X*PP
M!7!5#EVWC3[=#(V;O3^</<LR0OY)EFP9(U\(' ;C R)(H(_K]XB1SF$_H,L-
MM5^9J)3'K'7_N& :(U)Q@>X-(.NQH@T%( (/15X+($4-!GE3 ,'H")+OKY/U
M9CB ]"=^NH>.Y^%>%V?&86[]&]POZZ9P[0;]EZQ_*I8IT-_GX#Y 7"8:G!H$
MYEL09TJ)5#TWB4!;/>,QW3@/DZ_3N];J=(6U[,L+@WO/&('B4HSWB\]>(I<T
M"#MG"=/Y)^*<)325IQ *0%#WX+F/E< ".@)>L),G0"Q81%]""V1$*X,+?ILG
MAILV3M3?\5BRYW_YS>85WZV]33>#+O*=T3;P4XDZ%:L^RQHAY^;Q;>/ O;7F
MJQR(-%5^(E2'X$1BINI4]&PLF7%3],WC2LX;-FS4P3QG70PW^D9#?5'A4SV:
M;@U] >Z.!F@LEON-^N:S6PU<+BU&D=*KGLCQ&+YH4M(&/&51Z,4]SGG2?/LH
M;6L7NE=MDIJD!-:</BZF $PV%467H'&0>J%N>*3T>E;:N?Y9_/*E93<ITG$*
MY>&OW398T%GTFCJ<BUU ;8F;<UE5=:-#@2"_Q8(WL<"?!(9);-&9!&!^'=Q4
M9>ZGE2G<<7+/SQC8FGIW>P6;/CB+;UH68!%?@Q!T#U27"MNXL'W=%$",ZE5R
M7UUC/J8W@N^7EMA*);;=9FM+J&5)YUJ=VNOWU!<Y3N]M7W,G#U  W)X=*C"5
MYBD_.CJW:_J=9#W%-7=["2A?81$T/D5_C#M 13&+&:Q7E;_Z[#[_6"C\Q^I?
M]^M<>O.O0;Y_OT,X#?Y_!C*'R/>@7QWR7L4CNLKG+]6KZ#XAR'Y* 9O/BML+
MW[P48T3E;<]'X[5FZT\!7".!>2KGQXD0*[";U("/M,L>]4O$ H,_1GLG+^T
MG@3"[1VZ_#5;*0"UAJK\+EO%:0327>)FH&>H?I ,EX<\D\ML-6V^.-M\X\>M
M(;2\-;<3"V%D4)*Y3-Y!,$U'J2,YMY*8[Z2,N&96[#D'W2PJW%!8V-E6O=6.
MAT3[SG.*V>ZH36SY9H:_W_E8FWPK%!UP@P7E,YN5WO>5]\XD7TW*0%=P^US
MYV'7$8L?6#^32,FWR'O4\3B%P5"=Q7Q.MS!E(I2P+08WRGX2.<2!0HF&TZJ]
MSKY @W^U7 #P2LXKGG**4_:H(O(=:A&]O#ZL!W#J#?:,QNIL@=W?4/UY&N '
MJ*EZL!'/*R5:[V@ZEZ:J\7.9?7MK1RN[T: ;$^1 ?=R,%HE?KFG'R/*>*I&2
M<CS"N(DU)R>[0[.=)X,]RWFJXU#6?&F=RYJ:!W1IWP\^6T'?^%4Z2.0;C.[L
MI'S3G:^OK_TN-N$DJ/=A$RB\A"O81S2&B<(>$!A23Q_"Q$<KZG6V9 :6(L&M
M%MI/FIS\-1= T1Y4@/WU>T&?\X#5)@3YPYCJVM=!XVN$]XO1WMM38S=?S:5#
M?T[?]?G<,8#Z06>Q)P;1N=.ZMNK3>LH0T2W"](E\I^=WQX1U6OV:FS2V''YM
M_<A*K+?Z<EJ(7+(G]G[]E:WY2JQ=O*CVY9$PA\4\W%3=5@<GL6/7&=N(KVI4
MKGG0*,P=[/MS\*:3^\M+R_H,7 4](<@(F>QYB4-!0EN&?\VLP,+'U*_V-AWV
M(5L9+P[G*D"TVZJB@7L0?$7^17??!#.<?EU'[,B\EN?LH\4@6A;"@#A/ATF?
MBJ*Y_9Y(WN18"3-:.O&LL(3LO(=+-TY@GRX7\M3W8#LZAH/SN:J20P7+SK(:
MS*]].NXP^-7]I^.>=$*V9.X,CGW0V6WA,D'HS=/$4+>NDX])] G5_,B:]$N.
MO2_H/O7WA$YZ%*,LR2.0FWYZJF/"RCH,KZ"RL4]973C8):DFWL7H'!TA1(BZ
M6 A3(&X1TC-,U!??/M"36YC)0N&>"/P,N,!_]Q.XP(SI>M%VRKW+;GGW?ZZK
MHWII1PVA-J'DA?R8F;NQS.LB4I]VA&2YQ-A$D.U5&;L'RGLX\RXX U$+(]1U
M#:HS3AXH<Y-S!!^W'0.'H.*"0U//V=)!O@SU*]ZP^P1[1;5)>WQO399%TM"I
MC\MNM)R=4N/6;'S D.A&C,P6R+3Z+,NC_E&BKER2ET[8AN)L[VC$1@9=7]B[
M0*?>/.6VLVI9/89U['&;<H>W3FD'SH/G4_3[8KHC-<>9/3^!Z&'7WD0'JQP!
MEAV%4QUYH3$IUX'AW9'?W0Z^(HI^P):L4BX-L:4.H8;\.*>^/" ^L17;+Z!W
M4V-"-N,UU>VUPQI]0][7KVEX&"&/)U,Q$HFW,Y_#+P>^$K!WH?8H&6+_O"AM
MYZ369'_X_0"!:)/&?*, :&N[&X)Y2\H"-<>@K//U'TLPY5<1CBG\[Q(^*K!Y
MEWXWY,;1MB<R2B)@P5G#A\7XV9KU*45F__[B0=9*^O05B&RBT_4.N8L+ED,C
MVDEYOU#WZX,/!#B9QVN@X'V=2O_)5K#?Q'*>0537F$GW$]<M,3'2H(K\J"C:
M*90Q=1].O\%[*W%;3T*G8Z*HSD!NN6(KSXC69^^^H7\BH]#(E$=H"4&Z\Y "
MJ!WNS(\QF97QF@^L-3T52QRBG6W9GNG3*R@%IL' ME54/ ?+(F]ML?5M^WIG
M@[]V?;AI#D,2[BL-+I S7$(/D7/_A?@"^J^=&*?<?T^MB,H@R1.W2HFHX9ZC
MK&+6!8YJ_/:G$_<,\XR!956&D>5,0T']RU=5M&1G9XC37:CT:L%D%X1+AE6%
M6_/FL[:$5:-U0[G%^_N(6 I@Y24)3@%4OX>O/?&;(69_#:9YU69YJF+S6]&F
M(R,@P(?3>@Y<-2-.Q:\1GS#9OS"7@^_VK7 9'$A3;8M;O5,*;ULH9@ZJ/*,
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M.Q7E7\+=Q1BZNEK\.A+L?#!!G&XA,DQ%;\?HWRKF)TL%IT@%(=A'2528-0K
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M?D/PHZD2?CJ08SB' '$]V"!.E<\5!>I%7 F4&N(2K)ZJFSUM=LSE_I[R\.8
MK?J%NO3[WX5&8O>26 )/<8@W,*_%'?I!4%?_-DQ/[*>A'L\;\O<_[QU70*17
MD[_V&$5A2 L7S\H[>+3DXY0UL(BZWR=%-(1K$SYU"A:]UXM=7OH,^8R8/R/$
MD?5O+IJ?A;FB3QXYQ]JN@M%X;PK@CT'D@N]?</@FZ4 %].TJ]OV^+.^];*U\
MRSTNL8*>N_ZGH*@8RVP5GR$1,3#6Z;4,2Y.'04^P8$[#$= ^L^J _3F37IW\
MN]GWSP[?^N>]4*M*[W DZN$'.A>DB*V$SG,P-+)YD/UFZLT[N&?TG]7=4[^M
M;S<\3,?=O:_ 33 *:5;]00'XZ!Z(8G0'9_'0?945"@#+]J:N?%!QZ*B[125W
MH?CSE*$UI#O%YO+I1P&Q#)J&N97/)!/"!(B>S$.,Z-[[_%UF5BM+8;8XQ8ZI
ME'3U1U)OASH^JG.'3GY3%)O@Z<$ZM6%U*EYP>]U<,L;3<';X]H,;F@.W-!(>
MT#[8Z!-LW4FPY9\DF13#>/&V&45S@;7&2%W(]?5@7W/)!T>L4]^3HH(L[C"*
M2I@,=2U4&>KM"DU*I'8@^;,%=/H6W-S."#6-@W7)Z\!:9(^'#]8IRB]:V?*9
M2_$Y>IK@[#.JJ3&WR!#A%3+<[*.OG#NX7-/!0G)OW"5YD^\3;#-*M1RP9^HZ
MXV#C/#K)I4<F]H_UYY<\E7,:E;,PR@+8X1N!3H?ED:?=>?3->,U\W*#2IJII
MSUD[:CC459YO^TVTL9W2O5_]:_I$JD7&"\32;B"GY\&6A,[D@0;!MN32]PD6
M0;<0XQEVL^'TB@!2%\?L]/)BR-ZLOOE1F09HH]!^/26!/'::8T\!+ ;5A6K1
MC\X]3.G>N&M\Q][W5OE%J2M\GTJGWY![&MENPBZ,F2ZEN-V!2OPQOO0VQ6K2
MDULK/#C^A<I+A&^)PFZKQ :9T1N[74][I_!#T8\V<SM"WG W9RK1W 0?5E0X
M?WUJ=&-D3ETEZ<<%PV?4?S9?ZO HS7%BZ9/8;(47P63Q6XEQV#OFO2>\->3;
M468MC2#'O.V'O18+LO<MWLLM,#P 3(],9F"AS"Z\]*.>?J$!Q@UCO@->F9Y5
M2TR%AU1"S<H7)E)?&62G!8,A>N;8# 0X2D+Z3,67U+$=!5P\5\V#54%DV29\
M;E4&MX#9<->:S]U4;:](%\'9:BW0'9.<@ZJ+&X<>DXYGA=,]&Y]F&*E4EH*7
M6C17]Q(_O941O673ZK_+G3OS?6VA58*6/ ZG)[E463F?0&+Y%!-62<%=02Y>
M+H=):EQZG**IOX3O;]D6F>]HE%FAIX]G3HHU4_3ED0=DJV"Y0'2"*CMQ_#&Q
MQ N'CLHXN=4Q46'W9=(7<3TF?<&+0_"^L?8KAQ<,<RRW8I5=\#M8FNZD5V0Q
M_'2T'Y Q_X;;U9I?+H1!EK3/#E<>;G*@MZO%ZD(W[2ZVI\0FU0Z<!4AL^?B1
MD[_!'A/-V;K1KX_"KK6VRAGK>=S0"KJQO>L87\[_TNLMSX4^#HXUB[ ;-<39
ML[*/8&*&(?Y)L$9K66OK^.V6E&V"^1<M5#+KMIJ[TRO;VB=0V4%Y@XF[[N('
M=&"WC=T-%S>9'RES+#9#?,;>2Q)"'%]7RC/WY-&0_ ,*@#KQ26$&]'LE=DO0
M ]X9/)7A^3UU84;/@TM;VW"8ZXX0(,?^Q$S^&P5 LP #$<$8Z+5UJ6^RAQFE
M72XRZ16#-Q7O4)<]O0HT%/V"4#S7JU?QIYBI^K.D*F*B@JRI@>1FI<?'UG2!
M7K7D9UIW[JD=5T^5*-F*5B+I*(!LL0W'$PBA\9B/JC>?'N92 C-N(NQT#9Q=
MA[B:2?YR;3&/?C0 58A/Y2[C?U#31.-)^U8#U .A)4$(=AB&9LPPYX:B7E5K
MB)2UI4$!^+O8II6<5K2CYKS04";_F]-NP#W141(0)W:S;P%8/ZVL\JGK\YKY
M_=VJIT(NW[Y1\ZI17U<#Q*)**\Q%UXAN\)]6.GL2Q%"Q8V?85A5,F/B-<-,0
M;],7YX>X.CL;& "NG<@:U@+'VQS;[Z05)TLAPA_V?A"W2)FC_7T@\0J55X]%
MQAWYK+^8<2'+CE7*;%AZ9&:%^"=>Y?/W$[DLA0-(?A_RLAVT1G0AHU%.W8,2
M1L@Q3$LX%\_C5=UDSU'3^"\=?:+UV<M"!0JJ'XS#=KT:X;W]9&T=[WH)C2-Y
M@9,\7C25ZIWU!2 Q%#.[D7_9I87MM9^>ZI%CNKCRP&2C5[I2T46YV=2ZRW-]
MZ1=;H5PP.4(/LC<.RDL4W'E@YU4LGO#)<F/A!1WGX,K5VY)4Z4L)%0]P".40
M 1;8-FFX%2Y700%<\.;/,9O27<J=Q@8-=^U$*6:\)@O!= @\<X<UY_[SRI";
M-L9?2O./B 'H/1; C>"G>2JBM)!74AMY(L1O<K5>GBA@HMC=K6=@?SOEVZ)V
M-VLO%JC-J8M?71L2K2/""4JZQ&10S/-QL9UGY&^3CJ/;]BT)IO99RI[./ZKG
MVA+U&>O]#G+KS&=Z)-+2D-1Q5G)31R0HV2D>=A^/[(704P!/G14[$!@.DFSQ
MZW"]AU.BZ1,2MQ+\"VOD^!*BJ7PN0UT/@^]\?I=3'Y+*_NEW@W+180H%D,S9
M1^Z4I !^E[FMK)]H_8>JT\W_G2[5]M](EZJ$TP66&N+#JEF+2G67?^9(R0O?
M/C+C.5\A&XENMV,S-:7CXM/&1:3>\9>P.295*__]O6_%Q\>SB\!POY"$9\H/
M:@=*UZJ756T;;<LB)GTF3A+O+X7>A&2M, MC-IJ,TZ:7E\(*,IZ+8%^LEUC,
MD,.>_4L2S[/_R=ZX+4T1Z0+A<CX!C84GV+>/ZZ=A$X"GJD,L*0:J]^4TF]^Z
MH]CN!$OS:K'LO#-NV&EQ6SKB.0DJ/7)->N^+GH'WR,&KYW<Z R9D?+#"2^*-
MNC)(>^":F[S8\LYI$= 'L0J>@M?N1'N0)4FB!#O;M2A]/"**3;L]6E<HE[^3
M36^44>*2=U>ZB!>J/:/75FZD ^@LO6'+-RFV'RI^@VINKH%-J/#5Y/M#P VW
M=T2WTT<P)2+RTYQ%H&[WX4GE_M45E7+UNS<\?EN:/3'^:F]?Y94,%GYL[ ,^
MQZ9X-F#_^R8-#;4ML@=HD"\"#_H&XB7)$PG8'2;GD]*H;1@;MGRR?>*/=LL.
M--.%H5_A"?E!PW?[$K\>8#S^)0:I=ZJT0;[8,BWS238$P237".67N)M>(\A\
MUS@EMDN!?Y'[NN)T"TSKK$B5&R8P<:.KQU:D?APZHQZ:S)>.=: IL(^Q?,<[
M0R7;CC_"GB\C41>)LD #Z_JI2CZ/%/:KYC&M-)H7WN8?OAQ\!!W8WDPQWW=!
MM'PO V?;S"(7LN#![L<;F/S-1AR(@>2)1R0>.,-HBJQ<TL=GK5W"F&K3)U6=
M<YEZE\YPY]-9TOL>H-=M#.D(C%"<_@:Y1LPVF-JN$%^9.)A-T&<=7PHPC9F\
M&+D0%WG,\.#[VF P35('/]$.XQ]UAL!6.LYJC \<NPE\XV]]FOOI,YWD5R':
MJ]@:57:2+UZHUZ ^B888>^VYKB']R+&QNHCPHGS&[7*/88Y>D>-ET=G"QH6=
MX]1^]GKX^H^^=)(548C 9W16( ./Z:!JQ7]*-1A#UO8T1A<W ZKWU'F^E/*Y
MY\"ZDL?J5'E( (+>=(\O,9, ZE8,J\7J@AWKQGVW6-ETN:B?JCE([$G^+_;>
M.ZRI+NL;/HJ"4@6E2 L*"%(5:0HD-IJ(%*67B(J4 %%I 0)1%) NH" @1$%$
MNM(B14(1D";2E19(Z#6A!M*^.,\[]]PS[S?/S#/S7=_U/L][_W&NZVS(VGNO
M=?9>^[?.V?NWFC3,J)<3$:U&A2$#V(/E/(*&DP4,0/A'0T&K<H)4B'W1D0<N
M^VUOAJM)$!\TL17+N^"M6KL!Y#'8#1(\LL@GKSBI,QQ(-)%_=P]TYTH71H+Z
MHY6M]XUZ5HU[RK=MS'A'HOGSDFG4BT3L:/P+7YX?)JU&DUA>A'OO;+V&I=40
M/ ".5[S8<G?P9;(E;WF-T.5<T>>C 3H/8(,ATB'=XF<&()-FBYE\ ZJ:2+,)
MV.5*5]]XS9_?D.][GKH.A:A$Q'"&+QPH<26BFD$'R>N-GGA/#L>RNN])_NE!
MV X#OY@/S\"<=SCYA+@/J*5,*,?5[2._*5D(5 Y#ZK)BWKOES=@7E9L'N+]=
M'BWE/T" C-VV?(7OMUSH7K'$CAJ9O9C:\G>TK:&[DDPB<64R<=H.I(NMK99=
M$PXA]&!Q,8AI7ZV%LUKSB]IVUAW/[":75R]X8N[,GB74TI[3V18A>VI%2ERK
M!U8R@A57RM2H*FYODB$GLV-O')&KX?D:8O9,!3CQN33JBJ<,_Q!U=2>V03U]
MGFY)_1,]U6_;AOZ:7K>XLDKY( /X^A./VUWEH3]T95GOVWK" !+?O&< U=C!
MVO'/DG]=QL*9@</HKP1((?H3.Q@*#46"=/[*KL(CN[1:=YK<9 [GK/CVP1G.
MM4QOA]Q]$HQV-3TGT[TMN#J; ^XFZ,>4,P Q1T0[SF:-:N@/>J&S^O.-UI![
ML?J1'YJZ<Y\+(K.JZHHN#DXY6':X%%#&2ZKZ-M-VP?XYU75IRC6YM_-ZZF3(
MZ4V[J*<>'FIG]I<\Y4^Z'O\ULI9XB:7CI/SVR JA2#>?JD<2P$S0E!NWJ^,S
MWKAYW2DO7[L-58Q;\=_/&;+N*U/D[6,1Q&XU,V75LX2YTD9-COZ*AML.S@9;
MKMY=&>I:H)25#?Y2Y0M8MH>J^QX&<AU4#=,MK:*HRD_OO]6QEK_?@R^$J+JH
M'$,_TX>$!^ I#@\,M"\A:KR4>H4>OKC'*JQ3<Z"Q1"3(I>C^C1LTVU#[VJC!
MR@Z7ZHW@*$3:&O*;U[:)?W4/Y$;E4B!;9 @$06D1!N?D+(H?3Z:8]%\1>2I^
MX&)E(WM8(]=C.6Y!8'L!INQ(+L"C#QM/[J@IFH[6/<Q/<UL[#I4X:8[UU5O]
MA W2D4_*>GZJ_.1(8IKE4@HLQ#9P_U7+XT6T'+W5=T6?E5'=4(=K@P2"?JQ7
MK4>=LF?@'1)?RS'*G=.MXJ:<^^]8'.A8TN.60XDB_4BX+YX*;G7'2)Q#@R*/
MTWVB9'F_3GGQYJ\T3+EHJC7TZ _<FV^YDE;KU^,V_Z.D^):G]+*T&[Q@:*BJ
M'P8]7&N"%Y,YWP>O<),J_WY#*>UC2X):Y=Z'E[+"I3P=#66B%I2Q;KC(W;BX
MW3OCBE44^=;ITW$';C\O/DVO, 4';]^MK8LR;YR<27RA60,K'5OA;;EU<U6X
MU-;.O_1GH.0\) )U6/L8 V!7;VI$$3/<45R^(T&SU=5UI>69M_T3?^R\D7A4
M_KI%_^3WJ'I:=IW\'.BPK_)!MT!=6O-R92S;SUG2_@V%1/LR#]:+K[WJAZV)
M!Z4F LD._&V<E<]/@VR,QY<W>BI<>AG B:6XMKN^.>&[18F69G684O]5S]WA
MI6WL< GA1 +IQ&I3FE6$[UE?!Y!1Q0FCJN.(F+[*(XG%^0_X]37I9QP/ZO(/
MA#7V-?3<<%O".ER[ZBCW3KVLZ+J_9V6/7:?\WU*ZVW?][7DZ=UQC2O;I-U3K
MP)).&B<3UJQ);EWBH!^",&&4RX( A!@W#[G5[[R^ZEG7))CB?>("[OAR4^7Y
MLQZOHBI\)X.%=XW5C3).M$QN#'+=ZAV1%#$'@"\&.]P Y=.<_+4H-C\7.P3,
MH*Q?>75YHT!6N0+8/]WI-U=J__#4OAA6*$N<]PT&,,E"[-X"OC-OQ'I1'_DQ
ML1I+IX-?JGNCE;U&IY+Z/GOU&'U5ZA2! .3;QC;)?4UIQOE='AXYUAZW+DBQ
M%1J'39^%G"1DOE 89R=NMB2YY!B]GD]T2_8JM;/1>7572,R[(D%]V5SEWGG"
MB4K7=ZS(3/'>=X-9@U)]"E,#^*<-8A2[-QF29Z7WO1P53&JYWY:?0!9INN]Z
MQM5MDJ:H:I..3'/_>5DQHU1$47SL[11+XKE'=C[FI1QE*H3&7;6I78_U>8$S
M7>]0K3&)=I)JN4#(7,+:/6#G_G<+$5P$^'!_!4<T!<LQ-V0U)-O3[:N.YNB0
M2P@M;'Y0'W= [7O/>8>7U;F/J&>+W0;30G(F:<JF'\H .]LQ&WT%TX>G]LJ?
MY'@($'H+1\A,&PZ@;V!Z"U_WC_-C8#^6>^ZZAI\*JQ^]<?.FBRA[3];+VI@#
M(2"R(\[N7*>C2*_D( ?\7*CU924-<?K=L9_;7:X:$>7O!H=L/%4Z%Q8%GU4_
M>@3^+OG-[^#I&J\@%_X0YI,R[=.&Y,R5C7?ENE7Z'79L=ZE.'-P7F_MLTU^.
M=69J[8$[[>\3(5PG7WR_:'L"C==1FC4>\'C=KTH)^ZE6T>E$\-V0&%B05T_J
M25O.URYH0I4.-78?A&WM#J9,BB#4Y /V?>^0_K*NX,5]24[KQ3YQ/3:Q?!Z^
MD#;FO*MU*($NGBL)TQW,"98WN7^J7RE[?&HJHT#6C+S'L4I7[.'ZSSH P1[,
MTE0M/Z=5WLUC+U*D JKHIL<?\VS&!*2GS\QR&A2AA)"*1&R\6BR/Q9#JQX#W
M<TD!N\'MW0K&'"N6W5\[/CG?F"S5+"Z.\A^DP5%HE)D/YNLD^!B5DRC3[#;Y
MB602H5BA]3Y\H(J;V(4I395TOJ43V:J6.\$3[BA(MLLQS$78Z4<8E+^@M@FH
MN[B)"'5H\76UYA5G11F-_8 [="H+(T0ND"/?&&4CXHT>6_;=.19S9N^IIFSY
MO>R9M:$\)S[6B5(%B5:-T H0N^NA>7,'X$1Z9Z*;/??%U834CYD_F_WZ3<MK
MSF_V9#H4AG1"."H8P&%#/',&L_WLSC=4SI#<22Q\ 'Y@DV7%^U$FZ<5L'<P(
M+U./VDNUS&R$'YF3SS-TX@T?\>PG'OC^[,JCP^\E'PW6[)ZTL5%ZZN]?-<,
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M&K-1".>BBI%RGX8HNHVKDTC$HL(TKXS[N87@HW$/MO'.["V3TT"864;^F=#
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MR]I[\,PHH96@"+'KS>GWH1G,DVRZ]WT\Q7>Y0[#]QN-G)CKO8^P,/3:I2@Q
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M9N@&2S4U@MSS^\*@!E5*.)>VC_G,5RFH6-!?5?R @$H#>3/U?YS.0BVC##&
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M00A%&S'=$RVQB0Y2E57AZ\*59^[(O8H\Y-GVK)5-:&=J&G0JN,]>$%<V87U
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M?[=O:\1W='0?Q@"<##HRTQGJ3T0WF[^52_6VB9"< %^3:_'G7&5C "YU$AB
M@_T:!J!OPWZ_R.7:RJ@,/?69G=N&S&S%F]8;#XISC=F.O0<:D#@!]+8#DR:;
M&%D*][1$LWJ0NDF5S=M^4$7?TYP+>TEP,YXCEC1"JR?TLIN$^F(NK &[==7
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M89^9 H:5GP*U)2NO^"&=9M3C_?*;%#\<?A99.,=S%RS($ZZO*AP(SNXSS,5
M8A@ 33VF.@=5V6S^)*TI[SKUK2$,"76!IB2G*(1./CG8XWKF*"8K(<?!X<*M
M**Z"P]?$O]4F0=*%@ ^S(O,N;3_.S_WZW[Q;1$PI^L@?,0X,P,-S3*MQKWS+
M)RAWVH1]*?CJM]A>BW**79DG6Y)&VYUKAUF3SF\[[..4?V]/:P!M'V'.):;N
M)%<?1&,5LU]^7/V4L=&/GT=D.K[%M8)]7,J2DO>8ZG5.0'IY@VQ*_[VM0Y9N
M9,( M/3]8PW;V,IG^$[9*F3J/+*0C)Z/FV2JAWW=R(,:^EED"'+Q! .0:,X
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M>T_:P0.;*X"CUII]VDJ5&6(V%5\=]^.3PH\?"[5W^4!O!1W34"A:.L"D3S$
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M[?=HQ5[.5?.YDNCBC/U!PTL1WN=Q/_]H723886J$<7'')6JNT 56($R^),H
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M<IOK&IUQX0JIT<HWH;*3;U:K(T<[?(_8#1T?E,=/:%YUXCNG*23T-;Y+[4$
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MT7HY#OP^>P#ARR-7?G'\O" 4F8\C+EH&DX7["TP)EF8ZC[8[+]?5)%"[K,2
MU:>$15A!\Q>X#PJ2W-A*ARF -F')92?-5H(LCD\+I_$>"K3!*#&HC$-?9)I\
MO%R2$B&93?6:5[\LJ)7C$/$$KCKJ6NUL;N"B/.&B.\[[P'_JAD$:"]1-WT/V
M]INK[_U:$>G*%P)',QAQJ/92)E2/LK3]9%Y#$],OB'U#@K1L0DZ@5Y#I;S,
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MQ:#,A/@"\E :J!-U;HZ@KY6_;CF%F>G4,WMO=)P9^^=%?(VNLM7/=1,@/1D
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M$53(JY8]>8UTX-2RN*=89&7<Z[H7RTX[%KH9^0,WV4KFYU4FA!<J1RR^'CT
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MJG;1&Y'GD)>W*.Z-S#_8VQG3%7Z^[.]V&O@M./)VP=^1Y3^]F2;X']-Y913
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M,S-^',@5,'?)[IC\X/14E[8=>1Y*NY \P?YXB*^<_*>:S7>KEEG2K%OV='=
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M!K/VM+S1/Z'=%('_Q>7I0P'8C))]_%?_D3\S[A\?A/"PP!S QZK_A]"#_FV
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MIN7I1]$*U%@J"]R*1[).,K2Z]NKSJG5;FXM^+H_[?6IG^Z,X9'#5[;T4360
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M$%>(8@04+N34VG@/:?9!!T&59C5=6K5!=%<^EZQGW>'B^AE,\W5^3EK'Z2)
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M<9M+-K^IBEN&AH([.7$_C"!<##5O(,#$H]U?OD9RHBV'-X-VHW*P>B*T#N+
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M;<BS! G\[>,V-(//0:@,>Q$R_,+A>V [](?5]6X>N\=FWDDO:F:]EI+;!\D
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MJV2,-?I^V56VZYYOO!&/">96V5Z>ZH1^;S#57O9HW4AO*0>G6OL\P]=.NW?
M!3-K,F K7?)LW>C%1_F*1<5,XUICHNA[1J:HMIVO-K$]UGJ4W[.+KTCP8 ]S
MON=D#@T-#1\^U,.EUV:MBA_YD2+SC3&3UV]5UE;&2EKSS%S0.R,I\T9JI)]@
M)'=_P@.#BP!+.U(R4IW !6_=O'B+!$H,H):-]#M3"-7ZV6"?390;JCB69W"@
MML5JZMRQP+,)E[YX=9CUD!O:.Q1A>Z5?8TM0QATAM.%G/]M<\+2.\=>85D 5
MEV25O2;],O -A?-2M4:8M\'E.%T#5KW8,'O/:'%DBGUMSM,#5FW!7;U/+R4K
M)L:I!$17X>;1$:)^U'IX^IF*P8KC8NTM>PA7W\5XG%3:5\IV\ K\VMY:/Y,]
MDJUNT)U*7K<QGDY)+#7 0-'?7J;LS+TOPG=RZ79 ND3Y$'4<YBU)8/6&8($-
MWBMXD7(!-]XAE%FM:IXI0N1C33VF:G/A_X3G;"^6:/- 40TIA[>'NUH5J]+Y
M<Z%OT*AG6%49-Q FEGA$ H2[V);JHDP44^V_5^IX;]=[JX]C</[*#3NTIL5J
MSW(V"POWH0W=R 1D J9@"?F00"W4B@IE,8S\VOW5@N"TNCC-."H@BC9?U"[M
MN(CK \A0=4;7^1@)X6F;/9+EV\ 8:H(%.^C9.U.QZN"CWKD&%RO#FQVZP()'
MAQ3L]7 WPE210_'Q,R_0T]A]W,H5O]Q^^A2-4Z/FFAG5:M($O$'DH@_:/:_E
M)]&>,%!@_S-[FJ=B< -5_NY9?\WXN2".]=+HGM%J4G^6B?:# 97LT>F]+(;U
M2K2CU-[KF;PT2[O!G \EARF9.>!Q"=?W^CYV)QN..56J'5)+07OPJUILIGUQ
M?MD]-^^'^KW&E9\9?MMD4\Y?C-<);[#%^IWMA2KY%CA(F1F)L/J&+]B>M;RX
M1_.M^Z;50A_%EQ(-I&EF6,JSQH:#B:,]4[A?2+RZ?B/8%5Q5B"<J_C4?IL](
M%8<F:0@%P=;Y3[76K(2OT7BKU=!_HA/_5%<U^?CW(H'_.\N/V'J%Z\09XT@%
M+Z_<ZW4'W[\T2$/W\-8S;>E7HY'T(F&QSGX:$:FFX(Q%,N :DEXN!,>H2?##
M,M^L?35X+=%G_W6'^-4@XPQKBJPW:O2=7A+-\JP-M!DK2)IRM RCZY>5KH2$
MHZF1QB%0N#63^<^K*J\N _J(;T2H?'OI"U-<7?T\2<C7/3%\^8(I,! /M!]_
MN:<=+5^Y5X&\.BPZH66!:=;D5BALVP)[<DZ8,:7%+6FKO>B)O?Q6X?PH*1HG
MU,Z8S-E.9=1VE![O.@=G64'D7?A&(Q 4H7FN\ZK##XF8A,D?1G+32/1)2"X9
MX A[#;,=)P/ WIS6Q[!8)"RNWC-QT<JC=W*C[V&O13X9D A-U_+;0*&/:F';
M._"!DVX!?P<RP/.5U\7BT]]*D,=]=4^[-J>(0D.9<V VO7EK GQEGROX(N_K
M<3&H7GC$*WG>K9V#\P0.52[IQK\@'.L/EL!FI:HJWZ?1\^@Z6(;&G7G%MO']
M99FF(T_0B@49H/P\>Z'7OYIHCL$^L<P"NU7/EL[!KQ&E\8E*B8H#>R=&+;1>
MKD\-@L%K?"6FI",>\WQFMDMS5D'W%9Q2#3F#_9F(Q@1U>C(@A'@EGZ!(!K3H
M66AY6I$!E&>G!$;>QO=4 "TO6!O8\+PJD)3</SBZ6RN^>;2U= (#?EM0-W$C
MRA>FFV-U@GW(@ \RWK@\$%RWM!9R):5ZA/?>S\J>'O""4]@#)FIX*@,3>R^P
M@G"JNY!^2I"D[#>TXYQG?^T&O9?VQEK7B#!P.TW5R'K:RA8.Y.?XZ6_ .@Z(
MG=^+(<H'TH@VG"]\#+G6QL%**,]</8ILK+ 0'.TKS)LRV8S9T"BRN>W^ O7
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M/P]3/&;F79.=0F90U[W2F7D'=@4T#</$Q[>L;'F^YY50/GL##H?3]U4FBHQ
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M#._FYQ"]0S'L+-_5\Q?F_F58 S+@S_-0_1.+EH]&.!>I\[&PF 3Y?[AFA61
MRZ]!^:7Q Q)!AR08_9=9_F8.IV[;J72Z_V>N_F54(S(@J#0;UE^Y=8*#$\TY
M_S+'M>>PSW)9H225_YF54AT]%3$/_%1IB1&E?]HW=G\:5 ST9X["_C2_8EW2
MBZ.H.X?,5G]_'SJ@_LS+O\S--(O8_*_]\G_J?G&7C6[;X#A:?71Y$G@8<E8]
M7I&ZX*JS8MN TV2+UWU%HS>6IQSX!S-SKS!2;W,!_</%,'>D.]/]#_GC7O&,
M@O<?$3TZ\)@M\1_L/S10&?"_@ K[WED4K?!<>]L;^45VSKS1NKK_(P3/_Z^I
M& $!)B;'"8'M-\RG3JK<$ZX/>;^48"_NH] 6/C2"_"725/0,#O2'LAF8/U;4
M (4MPK<J4:>G_^&1+Q<9$&/!2KQ!# CC0SPX4/QCJ?&_U?[3H*2J+*+Q45;B
M7[RN_&THA^A@GX-H&>$,!W^F(*>]_FNK=_.5;-JH955$LGBN!M#-(2^MA>V/
MW\NZ0WE7U1TQ^12;QTCY>E<&I$&H+2$^K3YEEKL<JU=>ZPYFO/?"9D81\ H8
MJ#CP8#+*.W&QJ>FR=[\#WE$8ZI@-/== D,)<W5N14>+NMDO^Y-&T4A0M3@:(
M3MK:W:3=:))DY]]@X3?0N[>BJ@IIV2?^8&?6Z.TQ\'4</JQN15T30USQ_PFB
MTM.\4M@HK8IS64&S9'ML.K[OXM'+??J"MN.,9#/](HBF0D!5 0?I'*N4Y0 #
M'?7;&"*M>7<=+Z5Z]WDV:9_/=F^) T'0 GC^V9)P/+!EV\YT]:DCBW(23U5<
M3\)=QLVZZOSNU4M+.?*O)S_EG/BNOHXNS._XZ0\G4)RNR,/%_D"IXIRE]@_
M#A]X!&>'3W#\[:0LB5"W\T-<VX#[S6?5CB<0/YQ3T[/#=C:H9SEJ,[V<CILM
MN'_Z\UM,G62,2LM33W74475-U;*G#<2(/.;Y./G62X;Z*Y3Q6&J9XP;> /%A
MLQ)^PPMA4JX2U;?4YA-:)_XE@#KA;#[S^;U^"_X1?GLCW?BYXE'4[?%J#"(I
MXL&@<\61K-Q\&FD!HK2$N>3%KS\ <_!H('4CHY]4XZ#BPJ >6E$YRPJEGIV
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MY$S\(6W(E4+:O[CNUNL%B6@X)]\&8O<?2'9_=[=H0C T?R46,:V9+_ T)OZ
MU^/4ZH]\:AI1FX/+GMAM@.R4>^Q0O4HUC-9!D3AAW%-RTE#M.@)P!E)M;_@3
M1 @FK;)+J)?73"WTNO*_<+JL,/Z5.>K2K$]8] R\G?F_L/?>84T^W;IP% 05
M 4%I4J*"HB*@5)&0"$H3(0(*4J,B4B)%:H! % 2D"P@H"$@3D!*IH4>ZB/0F
M-23T$DBH@83DB_N<??;O?;_][GW*=;[S[7/M/^:?YWIF9LV:9V;=ZYDU]ZKS
M(9EJD-%A0&C_EUI,'!P3%:G4YY0P<+96-.OX38PO>3V4KA:S\XF\$T&X-,,
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M9KK$]-I,;L[+,\!@N@ E:V:]S88,WF@;YO";APO)*EXL=QV?Q<V]6IF_=BC
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M37$H)()@"Y?6AL8MZ]I\#&+E/=E"&_4$MR( O%+)D#)<BSYDQY64'9/;Y4V
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M>41[PK8U>AU,2M^)3UT[8W;L^]&4URKB$J^7M<-HBA0XG@I[!3SUPF-=R#Y
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MB\:2BZ#N?*)X9XV'*B=]8Q_*4M](T<F6R6FH?2:R+^WOI'G3,\? ,&F# 4C
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M<Y-+ADL1.465?2<U/CRYN!:PH)^%-M^Z>275H1Z':C6C'W[D"[<=)WG#I+9
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M@)J&UN>8>]!863-=9@!D(1H:BC2U(T"YS0^^S#1[)]_7UW\WS:;C_>[WU>Q
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MG^*K[^9ZH71_-Z%AN!::!P4>QHP 4;P.I)MXY+OM1HH2QZ2516V)^4Y?QF9
M?&ZBD9.5#D=:% >'_?*L==N)0!U.9Z$DY7G\B<R77&C^IG](@X;%LX7LZI !
M"\R7NK5X^9N'\U/",@UGA<K76AT?U6N%\\<9[5QO_<9W:@7>E9[XTV+PHC8^
MP3)<58&DY,\143TKJ+#!DK\^DX+$#!<.PQZ>Y2H:+2@$:ADG8P1*2'3#V]J-
M4TUCV8R-.>23*V*H,8_W^Z\?WHY1<_H-04G\,03=V$+=\3-*9N-LD]G+<>M
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M/:<K9+Y1G!=X.7N#:6HYPF)*F3 =1&.@U,(9;5%.@2O_ /3BU&8;-+7]]#[
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M^4>39GC__6V_SI]G9IULXK'X*@-<]^]7M4-$BQ)+/_\2>G.E#2'#-QW=O+0
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MH.NT%N]HX3EFZ0'/5MHWH-*?I3P7XU6N^E;-Q<NB:RO&+N-,[<HCU*LSQJU
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M:8O%6_4X6 *<9QE"]XI06M50^E8VICKTLY^'=X-90X_.EV/\+/5G\P56:4[
M]UJYI8Q(G8SYN4U89AK2#;@^]B)=]-1K9NEA#PE2G?YB41PAX0,$XF5[0\7R
MI9?0<&-K%69Y!BM+E=R/@DVZOXUJ^K$Z+_J/F++S"-C>H1X0/>@%ODX^(RAR
M9D\UK">R/N&IYBTW=C?*+,Z TX&Y"7A"7PY?/<%JI=+L!<$72W -T"H#2XJ5
MX[!G]"+I)[2V<46?U"PP:N92OKDRSP'J'K?W07>G]*#G)J&<R; "I_F^E-H3
MYX/$*_QF>W=NZ%Z[S>W"6^&;#NW%$55W]AHA^N<!U4C,'BR=J!8QKL9#N%A&
M,A R^KK0@3,5Z)Z=)G@(>N7QE.C)7,HGN<U[K^A3>O>?_/V4-0TB.(,B1*&J
M@^#]86?P!XCK+F;2=9%:Z%J.S5R4Z8/$@*[0^T8ZOV]QHFXM\]QIC%-3</)#
M115&=+7T5$5]?%NX>;7/./3\<6W^_#-^>%W#0MTC6S[:QR(]354Z'9*\0;U(
MID]:]ZL"'EO%%_].23FE&RQSUE"TLE]:$!;OPD]^+UTL^ )MU=\S@\5'3*@)
M$&+R? S7.,"S5;M0_H01*P-A8-.4(/TZMYT6E.-7D0;'G^NC;,.^)ST):$'@
MI;FU5N\-8DC];X=@C$=]]GLQUS</)W\\X]MOEU2XW2Z<JMP[?Y<*I>Z+_T$&
M=-;Z2'<!*PC^'5X,/I9++\B SQ$]QO"QA?ZK]QO"KHW1;$G\>_X9$\[0YIN6
M>WUZ_9\WUC]!M$B.))ISMII?[R/7PUWT2T\PN1ON4D;-I/B(4I4&Q%_\[A (
MXY=EN?#U77B2\H5A"X7%HB_42.OC2GW=U-8ZW384<D$""-Q?]M2C;@K=*15U
M%9.MG@=\O0&$Z9W.BXN_@#_M M4^$2OI(43Q$A<Y[Y;"KH&BZTJ?9Y0@T_/,
MBB/7N\>ZQSL_2#V-+: UI)1=!S'"]0I\:K'%[8'ZFM,B1W%*!N\(_ MAG4 &
M>I?VX"U=/FX:!Z(((0PS&H:@PS=&P-W]H44^J9YMS[8@4GB\9SG??JT6/]QQ
MK>FNT$TYBN2F'8NV!PL-B)PLY/J%B_61Y1[THI6(7/[GSQ-%DB0H=YPHR2)*
M*_L8T5/B:E_3\'H?H*^>9&FNED/MVKS*5G,_H&F<"/+8&V$KV_ZS'E;- F"V
MX<J%MN&*AD;F_6#:V?O?3)\JW(L;E*)C.E#O0E*[!-'C^_ZA\K>]=J"EZ(V6
MCN1%C0.-%HG!B+&RGR\.9;>0MTD@M/S*HWBF_/&OG\9R:Q5&48"@5V[1,8T$
MY"VK?=YO:%)N-/!(-2WZ847<D_\3TO;_K_\+U;07PT.S3"A='C@4JEZ?6#WX
MT=H _Z3YU?7!1[[G_3Z>M_,??4S*T>C@BF/T?$XGG8"Q::XFH+H6[^,3HMX?
MV6'6TB!*?3H3.9WB2D\EZVI9FKYEA?$]- FV7Y?=_&)LN#O#5%ER::#"_]](
MX?O_:OFJ=^>BE;MR;Q-?%6U8)OJXBHFE"2WN. 2+W*!,&0D]<=P!2=T\UM9;
MW&K3I<Q#(21]8)UH:T1>N=7VL=<O"QJ-O]Q<4P)6/I%\I\.<MVND@KV%$\TX
M/[T^Z<Z=[>O*95!Y5;3=DN1;=:_%PE&_(>W#V$UN=0&Z1;I?Q!&^)59*/V%/
M0!PH!NWB1 ;4D@&Q_W@SL%AE*,WBDUKKWY//,9 L5U_6M'<*JU$#LE+)88)B
MY41D=5]_25]&6?3LW![RB.#9;'IR'(XK1(8<@1@[;B"]"S:/>= &0F-045.?
MH->L!4WQ"O/9[<$\2://#E7%C1),)R'B>:;F56_UDEX#.BPT "L(FH"CE=%3
MB6;8/\,&,F!<<K*JXH@N/)T,N.&IS$,/3I\$FXTY6Q:PG'U.1B_HB)9+/)C/
M?<2LK?7(]NDNK9O[Y"/GEU^491 G_&>\&0QNQ6R(4F2S(,EQO,YL,*T%%:TF
M;("G,(HPP"_LK!95^A8XH;@Y4*)UY\)77)_U6C*WQ0R[];E_L_N@0:5F''TF
MC-GI17HN0VZ F"PKTZ,L1\1W6.F34EVO!A,>/EO.RKG%.:-G\\@F-QI)5-]Z
MOU"PLH58AQ*@8QM.U5E!2CZ973-G9G&['GLLA$$8BS/S+^#M#&H7J5GGE <L
M\;?2QM4&;YB)B,G+H93C%YI"36?J1[D"# G";]4CZR&/NFQP/<.D<FC!0EO9
M@D0T9<<CMZR4@_NTWQ,KFH?I$^1BSL:1%_5+1XR%0UYD0*4M\G@5.G;&8SWS
M#R[[PX4=42@_6W=.[2M6]>[/\"\9D]]_C/3:KRU?!7.8XX^JLC$0:5#-I"?H
MSJR+^/M[!MQCP^+IDAP.]OS/OM]FBUK5<<&)^BUBH3=)8Z3;;=/U<9IZN-7B
M.9E9,4^KM*98@S<37VV@TK_3)-J)OZ2OTM[DC5:QAJIW+<T6MWMGW*BLG+4&
M+6QP!U16+/SV:HY4<5[377QM?Y=*@(73-ENFD*^U"?9W@0RH)E"Y?33;SR7I
M0[?/4%O/NF",__ %-ERD_FFKWS7@O1V'RR7P^+4"D&\HAU]QGH7'@R%C/YN=
M.B&6AUGMP>P6>K'&H<#G'3A0&CAY"#%9,43O71WBVY>AC>.]V_[0[>5U=3$]
M_L:,HNH"TH07-P]I?JKJ<". 4F:'\X3R_63AX+WL\2?%F;'$#IT7L;2/Y/0N
MUTJZ<#(16:D?:+(Q<7K ?T;BCF@Q!G'Y>)/NZJG;,Q(R/ZXDT!M@+]2&CZCU
MHV05TQ9,;D6:VX=ZIRN\B7!_5O$/Q!%,15GA,]=MPXAGZC;:0O#BW<#R[*^]
MA0H(A@9:<P9W[STPLU:5=XBZ%OC]IW*0T8U_"[KG:JX-2WA8_GE4;'/%F3J!
M9PU!.N,NQ4)9G;GIK&7K_9&_Q H#F;/!Y\4P*>R3)X*#M-*A ^U<P^]1?4IM
M/:,]XI]@%"J:6%%-X^;I*KB^G:-J3]M%3_%71$ IO,"PC+^3;A' 9?A!V\"/
MLML :%1+*,?D1EA"D-%'!E?GM#+-F^O&9:N%C5J@"D]#K(9B2@HE\VP__-KE
M*U$TC@YH<%7US3C_D7MT(>5[=K@*W(/ 0-.(\"K'[MP[,F0 -:&\L^7ZE+R)
MC4^\[W)=,M,+=AFC;^;]^E>OO+KWACM0"16\O2A(B,,=8!)B1'?OS\@(6PW[
M#79UH<-;O:]?7!16SD<F[R4K%HG8O@N,XY5^F\*W$J?.ZD-)NE.=D'O=H*BM
MTH4]H-$O1#:G!B9ZRD#-\GM(Y/>$T-N.QW,*UQYE_8U]@2HF7MLA%&Z??"Z8
M GED$B>(F8=J23^:U!/84Q<3<&9]+#,L+RQLYC9.3+K<H??C=;.TNZ5^*E[C
MQL*57S>BB/(89 BZ/CV.:'!1CVV=$U5^!6^:LG1:C5Y;<F=L#.C@*+J!,N_H
M'V+F2Y%\/;(8LRY<>.KR.O<1<)KX(P66$S&%0H'>_FIJWG=HVK=S5OG*XI$0
M;#C--;!!6?D!1W28#%I85N9HX["<V(._$3SGK[PHZQ(MC>85KNQD&>3*#Y9W
MWYR![T\:(7# GFIN'Z4^\^E=#T]<\,Q.BLF48UL:>EFZNU>QR"M)XXKA0O?5
M6ZQ5/!TM]<=MGN="+NS9.[WYL(\W\OE09FYUOP9[!W[]_JTG.)]1HJ5ODP';
M(0,J]+*R7EB;0'>-P0=J+3\06N/UU1P!ICAH9(!!D3-"J1FO<H**^;&XR;Y:
M6)3Z[DUV\LVX<IOO24$::VQYMG.9)7/6$=WE2\RSVPA.E(I=$2'_\L/\>X@R
M;L1!B#^'BER>;SED>#:D.F0P/E_.\S2J\,H*-894HX[,R(!/Z&.45?Q970L(
MYQS4> @TH/N Q,<G%/GD/\/M#"^E5FPE&<AF-WY9']8-^4:[+!?KRJ4[XC,,
M,?L=)(#;#5M)B"<#;N[M'+6!7_V<KA,^O1QTQG7'QM,\;_;!J3AKY$_%M^S?
M[4XB.#UGC$;Q\BMFL435$K!23VX$D1=L!X$4._M5]J2,RN#9+'W?A<V8W7_R
MW300Z9.H-VPF%J5Z1.0 K1X$*HFYMLD036#5\_Z>3'@R(!K^$3NG'G&6$('!
MFY:D9U!VZXO3H;?'!]6F1?-99TT=>V>SGV9:^26>:R_/*A[^"9K$]:T<1^3-
M@I5F\G^ ;7C@S2UUTT>*>PVC[S=,G7Z/]$IUFIJ4O*)E65TV^=4H;P"[64H"
M[G$MH!O*R8#D52(90#&_49T EZ\(T"0DX>I5'/,VU13@^-X\89"Y"_/9:H'2
M(TBZR]Q%7/6KV_<9[*"?^_7>"2K(H@. T_6Y-#YGZ];X3D+#:'M"L56,J&9G
MXT2%DFB[&3@"'DZY<._ZRPB/-)&WNG\G_SH7BI(!RS!]U#2E+(D+AB$#BC<"
M.;3,?C9%[_:B?<2NS]_MK>;J3'P:_?C^+X6_[GV<J"$8&SPP?T.-$X$7_*SR
M=H7F13?:M1R@% M#,VSLKV%XDQ>.[TT>?W:# [P?#H@GF\2MY2T1)RXT!MS<
MR0#KT?*'U;E\D_4\'*0IDLC87H!^U9R/2]>3FA9V[>S24:<$Z;IHG@##JJ]L
M_4\HN%IKZZAZ4BQ1:@(^ZUB1NYL(I:F*0ZOC<8]QC*@;C1R'ZL]\F2KV8\H,
MDUU#>[/'5S\1GZ36 0>0R5[G>V0 K=P_],&EY20F%(.C9A!"5IL(E9A.9G:!
M<BR-W;^H0 ^9O=H*+R.9'$MXI<SXT?W(E_-_3#Y.2A-Y,WO<B?)C"?&BB"%L
M?>@0TF!<;MWT$>?7KT463VK0']-4:%/_^@%##_^0 6 @VZ)J;TVF]:4_ILJ8
MQH;>SW%[69).P\/Y=#;6/8Q-UM2XU%F5B0RXMK0AZF!05S^)=PXJ'O<P^YW#
M5C.C=C]H]&2)P57E;;4YH6$+O6U6FS'Z,D-8F)ZZ.?J*4\4]G\YN)F+_GX9U
MOG76:)X[X%QF-=$ L9!UF^E#55Y+'/"XM[C(V2P97;'/$M<0KDW#-M^U_H3'
M2;CUMMM#>3'#<I@H!QDP9YZ5_'J!Y[20#&@4#I)3^_X#X8Z7C_6D"PU2("04
M-Y26+%E8^]AP@30:$?",U;RF2-G:'@Y=BRA'"<F_R:]3D@W>; ;=PZLL7L?U
M=8&1=UW<"#4JMA[Z%S;*WYAWK71OP7UO?VJ\.K,F*RBXMWST0W+-90%"!A2Z
M(9MW[Z;S[ZV3 04'XFT\KXQ!,D0?_+M/CM\)BV2 #AX6ZZH"RN_A&QO]T9 G
M&IXM8^=G-=@P</SXAMI;!?%PY3G6KGKE'2B6LH\N0NE57Y0L1%QG"LZ)SBFT
M*[31=VDT\4U*I-#NR%>./!T+1U.MWW;65CG6O]1!X_$FJTMGT^(H$NN927,N
MA0\9 "1\XFXZ\Y WBN,U;1I?/S<IV\VX2_$+8O=%<3F+YZW-6VCQ?,!CPC0V
M]]8".&,W^Q(,MYSE)&?1FRV5PW63!A\J>K'.X]TI4I&=P?^Z^&.N&H*%CSWQ
MUX*NX!+B6:R:INN;^^*.]+WA->/K\ S'Z]*\/6"&]R.W1L::%;C"Z/4:-Y9(
MSY,OL<VT[B PG9X!) .N0(E(AC^RR$BT:^@*&4#C\P1+73Q53ZAZ5Y\F\X+J
M)J/T'O^G:R&2P8%XZU<^=+&RD;*C:. R(@_"-?7!H'C[>:F_LVA%UYV2TQ^I
MKZ;PQ&>J8)Z.!J7J'O$0I=SNF&J6;30L"GI]+;^X+;Y<AMG/I8LW\O[YHY\A
M3Z_>1P[KB#?_\K.USJ=U]F@C W!"X@-!UZO] FJVP0$3CA/3PT1M_%HNKJ]#
M"1GMJ>OJ*G,A):[D]&_:TM2Z(\CH]_>LI*EHO#HU8<6,L(0=!6RTI!4&_MAL
MY*:-Z3Z+0R1Y\L<V-MYMZ2Y=Z^U\&6=XTBFU.]_<SUJEOL)=6.H41$$X6M:K
MUU]PU)[P&.+2,<PTSJYRA:1A!GRXO?G_7DD1@J=1?4P&E&=Q0@,OVS)P'R:N
M>JN87R[70'T?;'4 \CUJ:]M_O5FSV)LLX_94X&7?B 8;!7=]]O(> ZSS+::<
MR^Y<^,6XVE3%TIL94=*H-RUK%5^"H+-"_WH>$Q9)$:!1%J #QPM>KBB;<_WF
ML7S(@[F. >6G#3=YK[U^799E(/+=57N5*6A3D,\7%:$"Q,+H \0OLG] F;?3
MTBUW*STA)4L=?KW8M7N"I]:9RDU&5]ZG+L?>N=FLN?C1>@5Z[G=\<7M%N4/O
M.)VD#R;)JPW\0'@VH3P3PM54"'EY3NCZHYVPW,\LW>P!?L?YHGNS8NG#3ZZA
M:(=7&[IM*\XU*%D'JJ3;46E!4GAHQQIN/3Y #^L_%\G7AG>H4..')S^$C9^$
M-\7Q4T.C^E_%N A?-7-FHD]0GH028"0M$H]P5K/\$NDJ[-RM<73]:$?+_2-7
M-KSV]]R#*.K6-UD/V0037/KP\TH[?2%'_41Q&3D2K[^0&3!C^6J46M?/1 T>
M?RX-[N_1N*6(1B6;RN_;0?0SKBJ>>81.449$83XAU*+5NUER9\$;XL;_QNY
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MJ5EWN-FN<E+4ZS'%':;\JSXE Y):S+Z8>4.'#IJ/:-P0K(2X(D)MSZ((;K6
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M*Y5DP.>]^L!G?5UHVC!PX+&JH%%.IU7YM]G>4X%/$T\B2X/S@H?L0S]9DF1
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MR,0(]B\MY-I AM2=\+"@S]NK9W^;)%P!Z*N./%UMVL?;3*1'<\O<L^'EWN6
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M=V.T[P(Q>Q6PW2ZS6J1*,P XDX:N-QLB7,/Y=E1+4ETP] SNFLS3,KR8TZX
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MHHND0&Z9:,YYR&]=L03A:;+R#WT7Q;I33U=4OI#<8NQ8:%J>]2XED/]17/J
M[.OZ6ZLD.N[_T$\T=RUEE_HDUC6\NMZMTSFQ?/?;;)$5&TX,DY'5]?R[KG?Q
MENW(7G.$(HI+0TY[7;V'H_?)A%Z\7&G:XF?4^F.-HXO%[AX?N!?R<N@M#/^\
M"(G?T,&9S3OF:AM.<.E&*OL=9#,-]GSQ' @K6V50Q5G#^.KW8[TB;H/XZ&U/
MS3EERKV5AB<_.E\\:D@_VV%I:__NM>QBPEN:/85%].28W 8A$;% O:DC61;W
M1LQN@X/UHU]&U"2_S-,XA#]^@@U\6HVD>["BP?9!Z;^C5-/1>ZW__=M*K7*$
M=SM7=M?0_R1@X"QLB@28R)UBZSFPM72$@N3NS^U1C4,1E<((T>J%-[Z+PG@3
MUYJ@M+%NVPAH99!S-^L)PLE3V\"-VMYN0U#<.4]<Z"U[)OGK9</.77,PG!(Y
M[\')6NF.R6=TAPM,O%G[R3G_O%-C9$I>+M#F W: RZ7#"<H&UOW]CNR:(OEN
M:Z')</KOC\ [2XW7;V9<KIR_$4P$SC5V3X!1#?L73;WZCM!Y,ROH;.!U*SB<
M;>_*D T<"%_0DE:S/K"\S&Y3$HL\!M,,E&_[VGID3X!F510<A+-H?:JY+D\2
M"<4%I)&4J\O)=Y&@/,#D=69P!;GVJ-QV$/V!/FHQLEYQ8;S7I*M_;8'>,O]G
M@7Y"EQ)3W?,9:L(X2O!V#CA1*,B)M_C>I/$W[S[J5L&U&AG!@<$\@(9N0#9O
MH7>E^UL'!_? $*D#5_^DPT>3^I'ZPTYI.AL<9];8\*!".[%)(KGL:A7K8\OM
M2ZV9*X!"#G:CBPM(B6^UF3FJ=GX.A<[(V)X<Z@[3OCJEB4^Z,ZQGX=S Q/J@
MZ#"^'B>$'LW!:6LW3D!M]JIW=_>KC\E *A:^PO+D#XPD:8N2@T;5XK<JDILK
MM;^[M<24OZTY.;$\L.^O UA7B+\$"-,L!RJISY=KK<$&4>$]/H?*6<!92%L7
MKJ\K5Z5O-H^S>4JL)?J(UDS:<<I.M2RXD.8&?.T^\,LJ#5](]TP$%3(HW0P6
M;M<-YY\Z,@K7]3<@:/E[4R.#!WLF9=>"=^(W@I**)2A,D[[?V5;GPN28< <9
MZ>%8/OCJNE3,]822!E*QZAHRR,< /M'1WQ,.G1FQ;%AH*<5OXO]];"GG.@)A
M9PE+B\')Q1?J^.<VDV&^+F%@F1\X?\S2PE=AXYGZ"@GAS%6Q_J$&.;% S<+X
MNMHPKO1N6_MLS[[D-AN>I)$TZZ4NGIZZ"Q\R"9NA!T_>;+WMO<D;<KS>SAF?
ME[E9NEQ]QC)S"1E9.A3?Y#0NB2J:<\\.H_9T=J6RZZ3:8.R-9S%W_4/B:%(>
M,<PI6HAN-^K2PJ;CLV=_9V7)7UM-)Y2]715#_\%9J?/9+;/6 <\4(1D3[5Z-
MM*;*E+@Q^IX?RWZ3ZK.>E-",M@L]>9W? JPC[8>Y* 3=T5F^TGDKD9.8=06(
ME!3A\K.\ HB<H8@DKV?1\*\@G,Q*'Z7&W'3)1+J^F\UL/T-5WHL7RGM+>1=U
MR=/1_ECZ+I5%3ISE1Y_32;N@6,MTNTQG^:H9V)MG59_DR_Z:IMKXMC:IO1=L
MN2X#CVPX%%W)M1"J?2W-8*NOUO/N$)!1+7\,/[T2P+(?@-M.GH;JU07L$@,)
MQV2NM<=0A#2]RF0$^>8,476\S:5L^WP/@=&0%HWA:M=S>_2ER#A&@=E4V..6
MX:!$G=BZ]#MR3PR0;I,H@R46%W@T8K:-IZ079]:9#):XRBTYN*.BIGPDO^(1
M. 4BBTG,FV/(SM*N28-'0'9@^L:96MB93N@AM!YVO_?^,<O\LUE%?Y3%.6(,
M1W&1-AE^!= ]BR!/>WAQSQU<$63R;%K= A,>LO%[LD\FX_*'/\# @KFFUP"M
M^[8CL?6FP%_-M_+T=FA(C"WPPS&0S8/5=]%0Y>.^)BJHOH4EB5#'*_0[D89D
M-E!CNZ8@9KXVHI6P"X'W,YE"6R*R8.MC<K#+?#]JOEOXYP_KIOS#-5=^C[Z:
M\*\,+F1K7$UO8W*^V](D8F,K7Q30?ZMF:XG,;Y\);^G YSBKM."UNEA3?*O.
MUR]UT=:^(#K90+W( '.'G*J,.:TGBO7-.8MW/INF$.1W)=8<SD\<(TX=[%57
MP\<VSNX?EAC O) +*AOL&^PKU9JOU]:7,,@+Z$\;NP'9+N#$ZKGLNSW%*P!,
MN133'MJ=YF"7\PR9CNK]].,"Y0R+N3/$JQEHZ91X@X0?T0&A:ZB-1= ?+9';
M*/7LI3J_\31?DF]+TS,4OF_Q+ +WC\QKFTTE(,1XMR<Z_R3IZ%EKI^MZ7-O9
MC;2Z?769E??I':,>LG2+2UNV=+F!%9N(O^??3G #OJ5GVUIS11+4^NNR] VK
M7MS<KS,W:[(C$-B(RT#:ZV<I@;[5.$4M]B1X@@U]$23O"7%L_;.<QN'7DVGG
M+?/YSP!<B#2!PKEAA=<]/?KFK*JJ;&>HL5KO"&;H/_):Y)_E,LYZK.!AUG&[
M/U"_(YG=69>_E,S<U7NA-3%$Q"<;UAVNHH__^#U(V4TFQWRFVDMF=SV)^7<Y
MW0)ZX$5';A?[<_SSUG18*-&6R/7SU^/+ZK--_.ZZ[_]S.F?+D\CG?MUJ&6O5
MW>H=>,RVC5,>!]ED]3,*)_'S>RZT2OD$.O.4A]W&W33!K>;Q&VMRE3U-J# N
ML@\OM@@T9C<;_N*<<19#V;G=49,=*R8-=(@X1HQ0BGA93)HT$Q,/^A&N[8)\
M !"1PB'0_KKTGELDNQ5.JJ \)R<,;?7L @]45J0>,"DLO[#,@V%=C:>@#FS6
MD\?A=EUY_!-O8G)8JXL'Z'.D:[2F!M/ZA,UD(KR>"\0\9/G';-9*A$/6B;@Y
M"%#V0%] K&LNIVM\<QNSQ-A7)CV+TFK,W%+PF7@12<4^S*7\+=C1LO,T,N:L
MG$B"!SLM\^T&H]OATU"'E]N[(3'EY:J*I_)D5,V,!8(5950LC ]NEOB *C<'
M:N]CK?J6* DZ.&(QVH3>Q+M\S/DU&&@6<_>$P]QH3;Y'!A*D_?9Q9!OW7?YX
M[U9/V4U(9L(>^:N:$^#LUM"B!/XY&,/'CL17=#G.J-^M[7J)!"ULBBZT7?CR
M?]+;]*8I/_@IS/"=T)?=F7+BB1V.((=0)6G;>&I .S$W%6%&(IU-3!\#OG+0
MK<[?'[4^/'3-_A<A%68[H4F/#Y"VLX#"I]0WG\C-N:<693%]2A+*L/0GE1"J
MVW@G63GA;^?@:U0_5?7:+D&RWPQ#^6E553[&DN^9+F.;Q<HXL6TI[X>DBKL_
MP0^V]B.VDJ U":WE=>.5S@,53_G9A>:$!A6Z,+2,,M]_:YZFUYG(N'2_ALWL
M\DN86CG>UPH[,*O^T!/-\\BP]#J>(<AU9FACYB/K!M?!P[?<68RM#:') 6\!
M1];'GNYM[LK9YW1C]-7QH]D;*(;])MDH\M2D+NI#\*B:Y9J)R3;B;!O_X_@"
M(7LPB978# D+>9KC[DSY.A[)',W1+V5A#GBJMFPE64J0A8ZWA5?@2Y_,*&FH
M;XUP9V>FTW^:"?01?JV4&M7]RA(%T[2/I^OI5]^HAK<:4:LE?+W)CDXJ>M%N
M<%.,EV#U!9^ULI:<A24A2KAG&_<<1]GT!-/E!TJ@!@</) ##!0^*O,:X6IY[
M#C1KZ1]> =0B (4%D6=AB/^<T4)^APG]7P(7'._.LU[D)]G09"C#:4V<(IUH
MJ(XY.,$.>Q\<]3E" [N!Y$>[(/L)?Q2/G05V(\X/9;*#/_:4,&B;\VR^'"Y7
M]-'9;EWG>!+#06KE2YKG=W<@$?SL[U%_%81F"SE3KORSI3?J,B83-@9^=05X
M8Y32B'I7["57>!KZT:FNF2M\<V'AE)BU?0HL[G\J'P]R/=\^!\Y<HZ:C"%ZA
M%-_7L=&E.M-<O67:?J3ZH>7#+&/.5Y%DW50]T@A;45.]_G$KC@[2-/]KCWAO
M B[LWAB 3%BP=;"VK]Z-*722S?!U??L].DVYDZ-3B(;#0#W*P<*;*(?/+<4_
MMYT\NO,&3'B(,<(OAH:S&1H@?:D8>%W=>83BY0RXBOQI@ASZXJU"1!:O %IX
MRK JB\Q]*-SVOQ7)(4T^K/FY/@KX#*<)PQCN%1RHCQ@OZWZ\CQ:,O%,X:G@6
MS_I/X1W9BRXL7Y<DMO I'G(7WCRAN%PRL;E!&4A:MK;R]=6#[ZIU_?S.B0QZ
M#Q%H</P,+S].D<B)F#C6H@E*NQ<QE>WX,Q6<M[3&ZV=V;4158SR+)#/-_H-W
MJ ID>_ *D(X8&V9!U&KA6<^XE=]C2Y:,<>:\PM/'N\X]+2/%K;9_YT&WYJ73
M[E]N9/"TW>5W_1WC4_SS^RN:*%_T1I>&)+HV5J;!6-4HIU4R9RAG3G.^?\<V
M4&;[H"*I69@D.=>PIC'>$2C;>P7(^Y[12&SA!:$1[T\6&6)XU/1PKA\;K@ T
M75JY;+$_FJ-VQFE1;44Y Q>/^UIS"[Q6PR=T0Z2G6Q901C>_LH@\2APW&&\B
M=8XQH\I_^Y"G,@^WT4VKA=[-2_<MZ_*7][ M;DRG@%J\_#5ZP9CC2W-'PV#@
MZ%:+!\\:3P *"RQ^;RLS-'N=MI'!Q 1L"+*KQQ88IP1D L'%$1,OTF@504QV
M._5,@)I!@1CY/7.R)0'?Q,,T8Y_SC9TZ]&YHERTL1@3']M&S3:S,?BA(D<NN
MR;D1EJU_2*VW:/+%_+Z,4*#;*??NLC-2,O;_PR_,TRA#\*\SQ.'VTK-QT0O0
MJ>R! G3_O>U3Z(JD+ MJVW8Q"4/-(Z\A,7/Z-$_DH$#_M7!A;_\:C$$G?JA#
M0!O0-4I4#I.&8?<[_CLJ(MEEJ;J.P)BP.4K] BHU9)DYV#?@.$2;OS+H4D7?
MY&IK('E;& 74&]=7:#F^!./;'TIZ("HE99O0ZH;8Y"$''$_L1REH^/,N31$H
M](+:(UNMJR4TPB1#V%=?V.M'\O)C+]*WNFIV^/_.3G8B_G+VEE=YF%7WPU.L
M,W>DC]@>!PKCY.\8S)GHZE!.>7;R'WPB3H:8(V\58[3P.FU/U<5+%HU<@VOB
MJGG9P\K#FD7N2G=^ZRU-T]'9)5V)/T9Q_5625 MM=6<%@>)FK(L<DZOD*4[X
MXY6@5X":[4D$YK%I2NO!1</99FE)K #;[[]@16.($8X^3JF6S0YDB7!NXFSX
M5%&D9LV2?$\P7E$L6.3WGI:,'=5W4!#?;]\@V8>QC],=IP@/N4G,.(Z=P.M]
MG!45)4[Q<AV>H]:LPM_2'<B8:XX/+ZD:%X&S_[SARGAGT(ITJ,[LR^EC67I0
MR[UL-4_]QP<T,>+FE(+^V>*,GW>?#ZZRD#*.F,W Z9&+0147W=E:<?ZUE-NJ
MB93@LGFW7:_?Q\]>*J>*Q9C3%?++D[UAHA1BW_]7O';IH:5 WLE+.0'GQ?LL
MZ8ZC@W9?ODXMRM86KA_<L35\Y3O4>E<X??[\A:56/)P%&13;8[DH^G/&'TB-
MC^%R?G4>D_PGLPDVX,1<-\9<UT1C^#]G7'F:SZ"XS1>7#8X2COFWE1V3KUS(
M/)BP2H'QUZ,)]%K(8B<QV.ZOR:NT<K\".%B=_7"KY;L6%(4/L<O$+WDBV!B$
M=\76>4PY.B>T3'JCK=F&=@S)3,G[\KE(4S^%A=7W9]])Z*!8K:X\P6;<5,O'
MMF83=I0=<HOAZZ,"J3NF--;/+)K'1)IOPEC^*9JW^Q&A@81.]]KC'^LMX(X+
M$(0UR+<[I#1!71\C;=2%,:\C3F3/.9NG"7%)"LOI5;WU;4HZNRFESP+2Q4L6
MN$7<P.E_^-XRQ6>,8YZ=7# 2CGNMUS+V14@  /!2\Z%36V^_T39*G[2$7!3%
M\2;\")+LSA/(>M!J)XG*$9O$?'AL"J3>6.CMB^'>+=E7*YV[G+4B>!Z29J@I
MC=<B["+8U/=[',FCNK18&VY7;BY*:-)/MMW)UHVI1 =.<6)LTBR& X%S^$].
MS/*$'Y2NHP8D >HWL7N'&/W(L.>%0;]YO,-D97[-:G*$.VZY3.\Z.52E<W"?
M]0_)G*2,B/Q>ENLE"\WX-N;K3CIA-^ N'%<S<\@BRR$D8ETNF?IG5]B[4\/#
MH\85I*75:S][#!^KDY#4:T-0'* F4#4;TN@4TH5_JE&.0'RK(TX*;I7.Y)$"
MYC85YZ]C1&DSM7++CO"_E'N4,3]G\A%!>Y2?H,G0A)UIFKWYI"F3PX5UE#%G
M*/45=1H]:1DYG+*3!U114'):OV-[&J!^J(V7+'7/$Y\XWM6VGU4W\B_L$N9\
M$C+2[2.:5Z-<9YQ::+ F!W\U(K0<OI-FHA9Z(?LO"\[1C$40A(FB4;_3')16
M;;E56+?)VF+ :E1$_>Q!/F'AY.VQ)^_T?\U^"[/%7Z)EHR0]>6$:/3/%WG6%
M$T=_NV<U[0R$#K\:D@C1>#?WDV+E@TIRU@W!DS.G%_O5_=[Q"?"EV<WB!-Y[
M>&V^%"ZSR.NH"-:/^^L8[!_9&<5%C+S]#ACZ*AC\TNH9RP<S?O7\MF$C?T@4
MITM?7+7_);W%M#I?5=>K;-""6S7E;938>=-J?%!Q4J,OM'&/HW?'VVY1 [?W
M%;O]B#.O1$;TT#5Y8F9T5$L>LX?1CD-_])'?"7GU[K[P.\HJ!%6893V.+T&&
M(!M>N)7'CN-I+X-S>M7\S,R;;UQ25HFT<7:A"4AM?:NA>V=IYPI@&_%Q=UQS
MN-RN]KAV:W:DYI]KG";#9IXX-KPFNL+#%KIZ @.5H;;E[:/":9%U+KE<7CW\
MZ1\HA "[%&SQE=\)MR?]('&LBRHM,\?5OMWC-D:E[>N%BKHNT7/6XLGWQF][
MC9)Z1*V_[/R:8 6N!EEJ<DW(*AF;[4GRJ(Z*YF'67R-3"Q(SQ38=_?UQ!\B^
M_^QY_'XG7 **C>-UGUV%PNY*P]_*<,X_]?H0=-8<^_9YVO?G"8&3Y_#\^,FU
M55H_R'0N,2#D'*%0CYM]?P2)6^1H_>,_%- TN:=<=[#JMIHT'2546$YF8WV#
M8D^27!NO"W;&>&H!9\)TJ_&M9I.";@T;,]GS(GDXZ (3Q4NS'81X(,W?9<;T
M/&3OR9)9?>3>A-N>IY>0S<ML49HT(9I*<9Z'I-Q31QF8OPUI^I3?"=SC86IH
M+=:@$.36Y4Z;86!H<*#P+X%4WG\O'W)0 &[BK\L[W4$E.DS-<_D:"-Q567*&
MI$N^NK-\D[U_2\_@CT0F/^ I8!1P;EG-W-:N10M'H^S.B6J7&R28_<AL\B1-
M 3=>.7CVN8:^/A73(B6#W?R.K["CSV>1QOM232Z=8O>+<>2_J3V!O5::=R;;
MKL?D:ME6;T0].^&XY#EET/W=25'>TV6^0S'4CKSV\7Y928.A3!8A\**SLG')
M+H(KO"]S+F(4SCE)$$*#Z;2#*\.CNK(W3BYS!MZF2(Z*I!FG*0C,?\V(?<U/
MT^AC8HH!QJJ"X]M<T%I,"V/^/*<Q14V9$_<<=)Z^3AB$R+$(OVN7T]=LEZPH
M2&@G0J(1 C[5$?MCA+FU62# K^L2YED2E-+-R_?GN#6V9<K/6#Z(%1DLK 47
MR&/-%A##410]'.BE' $%I2_O)55WH2$[VSE+U MX5_&B1;<2D32D:,J06^00
M=^HO^6A2^?P65:M 7;: 7\1JV,*? "O$<<T5 /)\.$P6>VUY/R]*M=3-JC_R
MU[I-P7EAED;@>J_X^-%P(K/GRZ>/7_3U_GFO^7@.F_(;!:0)RG^&$UFLKPC*
MZE;)''B%3*YZ0<_2<M>)QIW45*^R*5-+QE ]>]>M8/]_&T-*W@\B:K?/0Z*9
M30V<=)F?D8\NDF'Y/E1= =SWXZUJT2.\8I-51Y7;P<1.!I"[@YB[BS9,8D?/
M)E8X&12-VRM&YR2)=>;)8U7>0QU$\KMG;J#ZS*C],HEB^8/IPZD;*FE%%<-:
M8?ERG>HOX66_L*^32O'IUK/+OR@K/7#:9$>[0C^_"M((.7S(8*=; (P&CWB/
M$T?YZ N-#!!U7HXS@YO@-SO%TV#>F5&7K!%Z4FGQY-NMQ."*1":$WR>_4A&.
MGO9T8%0K06OYZZCZ8, %D)"$4/MF]2&,[P?A!;X:9T'P+$8%)6YR?E"US'6I
M>"":W/L759@9;>W$J?>R9Y8FH%:=JKB*((T-W]]U*K19#'(VG'H!(1]3+R".
MJF5FN^TY)8FD%M%,&-Q>6^QN5)NM#LI?WH\.<Z@:J03:.'26V]LEV"54RSYO
MF5Q<%Q@753XHS2:_1__MQH/RX['H" X<Z;G4X5]C=^]"G1<_\XW:\WX;" H\
MC%.D^]#[2+;?T)&<^9%]#?TOV/+T)7@_9&G*-T5%?K\6D]LN5;T)UEV+8,36
M1.,@F+$>A15CF<EN,1UXK-%DPX*9@+JR<N\"]P S^%.2I)=(QP 2<(]EU;:X
M;5$<^]]R&=WBEM6IK49I#V6#$?6X#R982LC=E-DHMYM,FM?WFXP"T#(H!TT?
M3;"I,JQTM'6T\_#5/G'?5\Q]NOTT$W,]#E"PD/S[OYK>Z8FOID[YJ CBWJ5X
MKZX+5O8W;??]>?8RP%YC- 'U_ +6$@Q<7"FTGWS3:.\8ZF=>WO<[<H=M7;=@
MK%AMH# RH^70YKPD[6@:LBSY=-$%Y[M<50>+]@H365ZXV<W+^2=[RRZ%Y(G0
MKX;V3 NJ^N]_G>1+1U*4O&/>,#P%_8'3X+,>XER[DL1,L2.Y,[F%?,KL;\ *
MZW;L:WY!<?,=9"XN)-9E +(.@&5L@B:/6X1B4^2&6?R)6I.SF^6V\53-&]&[
M=62%[M*K>J^$;T(_<G#T@DRZ(K@F"'S?Y]Q:I#_;!F2YL,=3N^FQ,$/DGQJ*
MI1D*I[F+AS9"9JX LP12,;Y@I4L(<*)U<J,68"B\1 %QX_"R\CP$M>!S4@P
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M(YA6V*GT59$:.Q29M>/S)MJ)JTH<.P;1NU5OO/CQW:\S>N+D_LS,LU341[H
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M3)@H>ELZZ%A%9@N-%;.D\11Q^V*9WETFE5@UIT/E-O<[6.9!K IW,8N \G*
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M:\B'_N*KT/F5K:Q&,-N315-G-N*>78Z55LK>V.X5T3 EJA;V["U9G3!YQFL
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M<3NRR$,'\%=V.FP/KNIEO0&1K',S476OU@CYE<2^*E#&^.4^\ <'EYH@O5(
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ML45/F_5W8'R^SUDP_EX.3FW'M'&L##7H4F8E<74R*/CK>*#M5E<S/0  R*4
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MJ[^=JRVM'_/IM9@=)2WQP-=7HUGG_8?]Q7'(0C-!'O]'XTE66+Q*KJ.K[.Q
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M]:H?JE7[O)O I'A#P^\>L%5IL@12-%"];/[F6L*\<2+*0AA-/*V"<?7K3)P
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ML1IG&NG_((^HHQ?TR=JV(^L.6L&$;>*G5L&) *=)H_-Q:DN,4Y\YG1Y?4^N
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M;0ZX1K2I]!A\?#B[HO=_!EGYGT&^[A+?G/GDO,W9(QGVB)I5T^M$O,Z53V+
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M=7HK:!(N/.HP8V/I,@28%;Z(Z(.+G;*2X!"6GII%2$\_5*G.&H/?#]'W6KT
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MZI0%'-"X\Y3CM63/VA?I+P .VSY7[5M+!-G5*N-M>G3RX@5 M(94*VW:O+P
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MXWJ+F>8D[CSDX-&Q&-?SV#^&>4ZN9)%-YWHZ]MR]C"\]X3X0N.93T*81ILY
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M^Y4-T_^OEB3__PWZB^G_!5!+ P04    " !R.:U221.I7^#_   4Z@H %0
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M)C CF\&!'9B':OEU[>>VNE^EPE;>[86.,*1"N6MSY:55\%<1+D!KXK!2SCE
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M8?2@\=8=-GKMK#^L;NRW#GDW+QH/3/#UE+ [9QR\Y+-0$MR2;R]=*!D@&8E
MP%C$ B*.0YB&J:)YHCMI> CAR*J_NV/YIC85;,L^V"K&M8U%$H:8$ DYU<7S
M?(0A193 2%*6(A*$?B#LUCBO:.777P'QP^_ )$UOMD)Z17,.[&OL?*]KN2_
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MG+#R]WEYWY:-?O^M.7;5Y*#^C]^2;[.8T80% 86!1,I]"1(&,>$IE)BE'.%
M)F$P4R^]V4?<0P*C%SRM7_!6CN'>\=NL) N0UVH4/3[W/C;P,?52Z<<0H3B"
M2/$GQ!(E,.(B#) O$HZ$#94.9841&7?'#L-;P(R7!\9U8/INI-\4E]+R@Z]*
M =!JH'-FVCB;5@F=$.V.Z\^ T.64T$>,46>.,W!Z.<&<\ZA^\]!ZD[WI.:*7
M$!]R\8^56++G9AU#U)P3)4C ($I2->^("*94>)#'4<I#AD0:4QO.,QAS:ARW
M)2E8BVJY5+2!W(SD' ,Y,*GUQ-":MRQ0<<E3)L..RDL6.+SD(9M;G296Z\/
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M:VW 9U&"3UE1Z(9Y-6OIZ]1M#UF3P6\Y(?6TI^%$,[R5AIY M@S4ZK#!_N*
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M6]2SF/JUF#]5SJ&^H<ZIO@#%BOZ7ND%?H4FN"IE6QL_4-6KZ4K_)YZRIS$[
M<IV:VZ3M- \3=2P?*=4UQ:-@<SG7)4#5K6H$4M1KL#HR6U].VI8KKF;#WJ]
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M"@VG]:./#C9NO>A3.N_5ASYY0S^N^$T4^HBH;69-HR"6H81>JA>(1'HP3;B
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M.25[>)A7#3Z*RZ4B?MT [TXLV5P4NB'>(BM6N;BD19D35L[2,(UB@3B4<1A
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MJ*E,=Q?)GW+%2VW@-_7&?"PI8[T1=HO-!.<Y\#+DH0;90U=T[&_M:]+I'[4
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M'&=!M".-FZ$)S!2U?(8@FCIQ8>BA%P2O53+.#C1N-8P^74^J7O1>/"!):>M
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M,94]*&[L=%;O7DXZO&,\)CHKZ6'+^[-7!(H%FE$A6))K.U51DIBRM0HPEN>
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M;B6-MJ+>;2,XOOB'SH&//4(X$@W? J4;\UIBTTNXUYXQ'L]::G- K[;W# N
M^WTARJIIDRB%Z?:V7*S+Q4:*UO^S7+QONPM^7%;5_;R>+OW3Q^5GNEJ7O'RN
MG41?)=^L:N9_0ZN2SXH8%YE()4 ""X YPH *F0%!LQ3%$)$46_%Q6#&GQN0[
MN4WH_69?YV@AU]$O<ZW<7]K^BW=U9\P.AVC9 5&YA>L%>@'Z5X[I3&O@->=
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M2_A59N?$4GX=*08< +R3<J5*.1</;%Y^J\5LO999(FD."PF@X@A@HBB@(E-
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MW)GT^KMMID^GR>AGQ,.@#7TN["C5JY\%#T/1YOQWX),'>*K:RM;UJ.T@K<<
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M5>\V<L9P(CF,!6 \TQ86RQB@G.1Z>HI8QH@D*9>S>BMD1W>V SLQW7;X@+O
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MJ'J#\BT?-5YXOIMN!X'ZCK<.K1C_=K-:Z<=^D<_+E:E-8VQ-;7"(N% %1P)
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M79EBGN9(MB%>7]=TM1X#V./APL';>3'I.EH_R8C);^5B42Z^W0RKP@5&4+.
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MB#K%;%T=<6H4\';Y_5DNJN;@Q5C-3"ZD*EWK(%Y'VLYH\(I?:&YH906K1MC
M(3;6T/BT(*X/.JH988W!L2UA?^,PIOF5EJNZ8.*;E^U?_Y]2KO2#GEX^RA\:
ME9]E-5-I@9*"04"*S+@\4 *(@GIO$C.$8 8SO=]WH1N[8:?&.4;4IBQHM!6V
MYIY/]W^+_C 2.QZ36Z)O1T'^,0W,0[? Z<Q";NCXI"++D4?E(S<TCDG)\>X!
MIUC';2\_+]?ZSY+.?ROGLEHO%_(S?3&_V+I^9X5(8IXDW+2G--TJ<P**G.9
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MM#4NB[)\=N08%\@=]B/" 3DRMQRLB:VH]D/M!K27-AQP?MFA @$XT9[#O5G
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M>[+@XU[U#J./^R\>X-UR_U!LY*UI5BH)XR2[,P/<!@<A%-NS#\ 2:1;M+-6
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MNHX(G+CBNMXWP!GED[&35J7ZLJO7^'E=EVNTCK:<2,6% GF>F/6-/2?D BE
M5(RQ(I*2&#E[G'1T-#<::40]+&+IX=#0A6@WB83$:6SR:"#:BWD3[04-A):'
MCT<@U"9RY!B(GI^?A@,DG<X87?=/YW'AH,616X7+]4.WQ8VTJVT=Y?"U*/_Y
M3JW$PR/;_+-9@R"=XRSC# BEC?7%= Z8+6VMD:T$J&.M&?';W^WN<&ZT>21O
M9 6.=A(/7/KU8NZZ+1P.R=%WB:\!<<"NL1LR83>1>_J<>$_9#8'3+6;'^P88
M9>^>RV)EC+[WZT=>K&H+Q!9F?N4R5NY\ZE5&8 :),FAC"7":9;94%@$YBQ..
M!$TRZN3'-:CWN?%0*W]TJ$"U'W7B0'D8U.CBG1]@J!Q,P#$'8&3Z&HC]F(![
M6)%C C^1:1EZ /QLSJ$ =AJBWHU.9YT.U??(9!W<R)!<Y5\__G;WP#:/K#E7
M1WFN<RX$2!*: )PS#:AYLH!*<0YQ"K6$3NEWS[8^MYG!RA?5 OIDUWZ-F0.%
M7X/$R!1] ,*@7..OT?#),'X%*E/E%?=!QS.I^ 7MNU.)O[YIP@3B%^0]3AM^
MZ:(K:DO7F:=^?MX4JV^U?UOE$5=^5G]4?RH7*D$RS?/4K*UM+%Q,&.!<"T"@
MY *J/-7(ZZ##K=NYT5F5F,N,XT'50QO*6_L952YK4;&JRQ_^L2FV6[6*GI[Y
MLA#F,JVLFC?12E6U9-LOS-TV$]S@(HF.X^>V; \_*B-3:^W;U:31JT5N"KK<
MU"6QJEP$?]17!"QJZ =4\,K6_3U/7^7:&8VS%:_=[QY@@WDD4['ITLNO:ON\
M67U5I=J\J#9AA]0(:Y)2P#,-Z[())$ERD%.L:,8S@823,VDPB>9&CI6@T::2
MU/RH1/4P<X(,DH.A.#7T(S.@?X:I>IQJM:)&K_YD+6.]5>ZV[-0#-Y'].]4
M^IG.(<'N-+>#=#2=B1X2ER.S/FC# ^;(N\U:*"7+7XR^=;W&+YLF'?R'[^:"
MHC169)KQ.*,: RC,1(A53 "C3 *I$)692F*NG;PNG7N<VQS7RAS9QR)2C9C5
M<J"R1-=/^^V_IOZYCR>#TR XS'&AH1UY#MNA:N5MZM5&7S:[.N8[F4-#Z3'[
MA(9THMGE>FC]Y@T?F#KG!:>&IN-]'[V.>-WKQH%;./5\\*+,+/%9;7?!;S;7
M;2:!((H## 4&C! )<IP+RH@BU#,'V[E>YL;/K6E42>FYD7(61<=]DVNQ&9E@
M&]$.'1N"A\-U8A!T!^1L1]-N>'3I>K*_T7GQM#FR&T-Q=U2;(YA1FFN 9)8
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MIS),PSWTGA;J4/"ZC5;O5B>T8X=J?&S:#F[EBLP.M3-G\X:H/$$"IC;A(M0
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M7O/8@!8F#F1IG&)OI2SL![;\N2C%<FT-R++U+E]PD2$E4C-P$B& J<P!2:$
M21*;53U7G$*G.I&32#LWD^\DR&2C;*TH^RJ+)I."K05F1'FLCG9^*+;Q/=D9
M=_@=S<2Y#.K8UN7U 2&[D(^]SM&!TO.*Z_ 9GEE$:3@)_.>(N?#!/E@$A5>G
M5TQ7O%\V?D&V@Q/"5U$<7UMR?;_GUGM#K7"14RU2(@G(L(8 <XD!@Q !EN0*
M)B1.,?6?Q*;586Y3VSNVM)E^!LQ5$X^]QPPVWQ']$\UK!TB<"6;<H1$=P!%9
M/ )/=V\SEL$GP8G5F'YJ?)MQ.CMAOI$H5Z>=[YOLRTNS?9T]/<LPA+$60&!"
M (8H R26$@@D8TX$RR1V<H@)+MG<IKRCU.P.C%EV4N;5:?"O'';'>?$M!G/L
MV6[:<;PF+7\8S$=*XG^E<&^5\C\,IAT% @)U$'0WL-W/H3D6/$44D,0L@C!/
M.."2)D!!G2I&$QL &V [;Z;[<;WU?CZ;I\ENQ+>IVQQV8X:,PE6[:O/>%@L%
M:ZA-KNEWJ>:TS31LG^BZC9[*;?$]>RJV;'D^JI&D&*/$6)Q0*0TPRV/ <EOA
M)*-98OA)IK%3<9/>GN;&/W4U:6MWM+$=.A*U_'70QV%,Z78=%67YK/R#/OI'
MH)N @N(Z,O<T8C:)>]WC23T!\W#;#@7<1([;]P\J>FSREJQVS^?14WD3%2NQ
M?);UN=7CHS&/FZ=U):.GD[ E(_SR1\2VT=8TO:X6R%4);_-;]4!O_A(]F15P
ML=W63SEOOJ^.O=DJ4E6%A7\O(V'0,Z]EU0W_L61_E'\-Y$CN,D:=KN2=#4SG
M3.ZBQY$[N=,-(YU#7[1[]VD=5_+./)R?S>/Z\]KNFRQD@B')!0.2P!S@5')
M"8F!HD) *'$LB9=?^1A"SFV6.<Q 6DL8QGJ];B0#G22//#XCSU8^0Q/^F/<*
M["8]W1TBYQRL[2!(>Y_E7M/7,*;_N!(;97K[6=4_/ZZJ1'N-NV9I9*BJ@:SD
M:>WH1:QIHIBD0*:* 8PP <0P.J"<R(RS-*&I5UKL*V29'6]?KCX_N.K\-4/E
MQM@3#<#(Q-QJ$?W4ZO$7Z^%:YVIM=8D:9:J!.5/3/AR5!P U)&-?(\ZDQ!P
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MB$NVW-93CEO/9,A5\DU=B!O6QZH+MMZ5TX!%>WCM<,\-I!"(,1X7D+>.V*R
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M)L@Z7, -F+O+D1>7O?ZNPGY!$[-"*X(N)2<RFTR<PJ JAS(*.&2'XJF2]'V
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MAX=MTS<E-*BL XE42B*-PS5EUZV,=> F&0FLSEG&+FH: <[QVMY9M7Z,Z!O
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M<],B^/[YZ_:BW)L?<7TK[B/N%&_0B4$EL&2I3383 P9]9&X=^L@VD9",#-X
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M[N_VOHK+5%AC/4EEBI:T-*,?CJR60;(Y,Z%Y/&&LO)O(9K%W"#[NHZ^.LAH
M8OT=9KWX@5G+0)?NO9(32;TGSD=#("N?N&=6IRK-YD_#WK#7#YZ#D] @S!I8
M?'LQ6*[W;XU9L%::D".QI@P(,+BI.I,BX5IQ8YP(0E>)%0^D]V?WH?>'WC&G
M*0?B8.B+B!\@C7WIC_UA-E_FV60\N^R-!$%*CO0[J@,ZAPHW3,L%20J4,D"C
M<G=NL3XTK_N!)S3DFM32[:QO00_<$O$ZVUVN@2PO_@K++V4&;<F(ED5\_U6
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M5'7R<A][RL]^N?0XP/6KI%;1=BWG-4N9)^K H^FB@#9>&UYFH@E"-;? 1(K
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MCB5:6NUZ+;A7TE<)2/]9;G4DMH<JM]H', VX+"<J1I!",6<E[J;E1K-4PI)
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M0D:OD5)D-8)%0\(5@622<OAB2#MFX)T4U7=I'L:V/SM4'Z7JW@J@3N"1++_
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M^:Q]Q6P91(D!$.41-]L,CMCH%8F,9<:S1^/:I:8"/_^&$<+O[AJ@APAHY8+
M8"%E+YH9&%D?X=MV;5Q->;W+TG8Q9I,$RT$3Q3?W XNEM2@A$Q*W0IMLN^Q[
MG>#6F:IA7.]^%#^KK86A][OWZ SZ+W[BMP:7FQQ#X)DH+3F10#$Z2,B*S4E@
MV*!"$*K3UG;G@X<#026]S7H28@.^])'&^=U5H:^7QD7!6>DJ1,O('DV"YX$8
ML %?UQ9RE5.:OA@8N"'4\+OEH(AX_BOAQ==B6$8L2)TAP?_/WILMN9'D:H.O
M,C;W..W[8C8W6:JJ'LU1E30J5;>=N:'Y I?X=XJL)IGJTO_T R>9&W,+DA$,
M9W976Z=RC<#R 0ZXPP'(A5(=)8J$X PCIHV+D@M4;)#RA5ZH;W&C;&C@]8O^
M U#01!7/]E+X=H?H_>)C+4Z^*8F_D<.;<'F)^8?OV]];;G]Q.>$Z!+2U6,E+
M6O4*]Q"*1S"<9^=,]"8,<KW^2+I;W.D[,>!/J?E&.[A=+)>XNDC_O)HNI_51
MA]3K/'A&'S4YSQ-V9-W-.GK]X6I)*%HN"6BQEHS5LX*+6=Y]\?*V;U9A7-L2
MP=AZ%R'5MLVF=@G,!#5$);+OEB/L^^:C,IW=I]9ZM<OY\NKND,<@LW2.)PA8
M6Q&JP,!'S! EIB"L5$FE3IQU>-F(UZ@&U?B]S*AOH9^)]SBBZ.^I1PWA2X8H
MY3L,8,8:(Z-T$+V@8(FA7Y>"@@DV>EH_T(ANK:=/Y5(>)FW7;[[[EA^^W_EJ
MFY89QU4A3EGT9$I,U5O,FM#.L5YP-E8,U#UO3T+/R3WM@YZG*_0&4.#8NWN[
M(MLTD<LL8M0!1*YM['T(X%1QP$4(G+QM)']^T"+74@W;$,I\;F';6[*M0>.Z
M#1A7:%0= &-%[?OL'7@5"SCK5+1*L+1;3M8U AKQ+* GC3T;V.POOM$1@-^F
M?UW?$TF_8)ZFFDK.TG8+VSN+6ML$3-3KGM;5=@TQ@Z:03V4L3(:.3N*9MS2$
MAD/T-Q]"F"V>8IL8I$,2@^ EU-H@"TZX0NNK3JE@[;[2V[%BRZ?8 RXJO<C^
M;,ZI6<@8F61@UF<3J@CP@1=@TO#H2R"1=;F'^JK/J?=2_$'GU/MHH>G%*H14
M1.U=REPDKVUKE5!F!AA)4.B"+MAN([':6ZP&U&CGY6L?\39PB/?S=#9=X;OI
M-\QO24.SSU-RRNOUGISU+^%_S1?K_>ZUD7%/OEC["%@TN6J4FKRT(DYCD3%&
MS:P>I*WK'C2V<B@]X.(WM.;:!N4M8W<LV=83FUP4&.8-J)(5>"<\!.ZD%Y+K
M$ <II=B3SG'3_<'PTAV71RMO](65V/A*[.2_SQ?_*/-%PJW7UY%'[5T&R>JV
M? X&8K5FJZ.Q413/THN;V<^^H5GL'*_3W9V"HP7<@ =[Q/^_NSE]5CQ+RY(B
M#DPM=E "0IT>EJ0SB4D7,0RRCCY'U,CSU4ZY</:FFQ:\T=UMF7JM;9JWS40^
M+<)LN:'I>IHPO1:7J^5FV-S%+-=/-M(,Q<12K4G6ZTS>2,J>5 13N/>.^T"Q
M\4'[F(=2-*ZWZP\@SVV"GD1;H]9*/<KV??8VW+U?7#-WOZGHA-$:XFUM'1IK
M6N^8K]<O69V2804&EB@4.0B8^U Q[H;::< XF%;.Q4>^FX8XO5Q7;E$N?U6_
M-1$J9Z<H;(E!B-KCKD"()5$H(U/AJFX>=-PI.9R(<1/:<3WAL3II$'NU53O)
M_6_A\@K7]8#K#Y_F'S$A1=>WO_$A?*];5\M)R#9'F^JVE*S3I-"1M\^,8AZ#
MM>6=Y/+@M7EO:L:-$D^&QF&UU!HLUQ87TH9WBC@FUB=BA])]R_W:QD+-M01P
M94R(FF?N#CO6WGW3.(TK3PNGHZ3;&E3( .:?9]/_C?EM)@E/RS3<; 2L?XWH
M^^M\GO\UO;RDD/6. Z??N?J*^5=<34(ITGB?(9AH2;2<0:BCSQQCQ>I,X6LZ
M;%GM@[IQVE">%I(GUV(#&S)O9QG+>A?K\K%=K&NV)]D[ALR)VC#>@,I*04!>
MP!5T68<BO!^D0U1'^CK!TYX-/(?43GNI[YNP_!)FZP3_6[C<Q T<(Z90P.0Z
M*]07"_7D$4J0F?O,N-^]!-HUNGOPKD[0<6<#G2$DW("?^OEE*^ 3+0PC"[ D
MI4*VP+0 SYFI>T%9",:=PD'N3'8AKA/,_-G ;#"]-'&+\>ESG=^76*XNWTT+
M3I"H-HPYL$QCK6A@X!DEWS[Q).H8'V$'Z8/?A;AN&\7L3.'6HV*:[0O^<Y@N
MUHGV+QCJ5:?-/L,]JKO=!7K\07W<!.I 8D\MO6_>='OUZ_;B!L<0+0L<.#<.
M5. )*%TLP&7Q05'B&$L<Q Z?(>IH!_3(LV\ONZ&.WGE66X.D=3/I $[09_7(
MEU&N+#7SI^)XY*N(O2/D@<?I31.-7CM\U(K7I\G]N9OMXP9S.H^1>PK74U"K
M(+BM>U:*PAE:Q8(W"G1BCML0G!-GYWIN:PYNWK*-Y^YM>6S%G]_7;9.KQ6([
MX'"CBEL#<9:Y* TE%ZQ>]0TL0DA81W8XJ86PJ ,?0D*]<M&P:]L'@4_?6CRU
MIL_)%5Y+:5XVP@GWA+/Z$E:DQ6L9A=7-,^:S<%]>1]SG/@UA@[GG845X$D=O
M ^=!&W#:UWY_ZPU=G2!8YZUPK-"WS\W1[VOT] N_SF>+ASY@8FIK.[0"N*]=
MBNK]Z5 HTA+..:ZM"2P-&X\>RT'+#GX/Y#T9NYY4PRWL%EXS_L/W.W[HYP7^
M\PIGZ?NFA:=%YBE*AUAJ"T])*Z=C5D*1Q3JC2RIVD!X*'6AK!(ZG1<U3V.U)
MA2VA\C&&MA7BN61F7?$0T=:[PU(!";&6E#GTQ1B?<)#^9QUH:P25?>'A*;SU
MI)Q&\;:\,=OK-K/2)UN4@>1S!A4Y)1"93+9PC *+2"X.<WFM W&-(*XO1'1
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M7\(2+SXO<-WY8\N,#=YDC.2QI:KWAWR$R+0#EUARWD2.J>.TWA?>-.[&\)"
MZ57&8P/F(WXF9B@OR3].*3E9[6#?N9!#\0H"RPF4<AQ<"0$H5;7!!"FU3IW@
M\OQ[QBWF'A(L/<JW@7CGPV+Z+:SPPV5(=P$OK.=*%J(]UFXM0M3R*B;!B^1Y
MY"KK/,B5V\?)&;=8>R P]:B!!G"TSB/>E^VFU'9/:M-^W,0B67:@#;>@HDM
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M]AM>7M:A9+/\2UC\ VLWK_O\F"2#UQQ!E'I%S'$!,8< UEC'K5-&EV&N^+Y
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M8IV>&"QX$0U(3#8C\U(,TR?Q599#[86$9\NA]E%+ Y@:IE2"2TE!7P%N,LG
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M88. P^77C.:WZ'?:\>R5!U8[&RD;$@F#11#"%.%0Y9+9?KH??;T_0CF/ZO@
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MMVBX U' L<X2=/#Z%+=RKF9!XC-3 TI2ZXQY)&BTPO6__7;H:B<PT04ZW"?
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MS:8^-SA,H8H4[QE$7IC[]"L(!)I--H/IQJ08T-+B:#0M=9<C8,]AVV@,^#X
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M9U21OV(9:+@H<T4^CHJ+Q!ZEVRBGAXW14$3DY(V.@6,-%7[3$+<F"BB>IFI
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M$V,$)9QJ$<]8+#=53(4.BHGCZ,/4[F#Y)IN(!SH,=4(/3TF7@-E,5\>\37N
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MBDVQQJ;CR$%( @MEYX%JM)!IB+VTZ8C;0D=U0UH6V"-S#91C50XE,HU!N5-
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M/:@\UHHFM0U8CBF98=?$O;^_>J]RW5=/B]Q\N/@@8[L,7/KBS,4U7 .\-+&
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M&,<&(<3\<)WD6(>*YB&E(2DJX92-R:[- Y2$64+BH# 6@C/CAE$E0?4IB+(
M8>6-C8!/$OR;'(:/G':P=0B:FV2@/WC#J@GI0#?@@<FLUFI2-G(1N/(U0A@U
M07G@+@/?0:L&JV=QYX8^^L5J,MU_2TI_732-&8M51C"".UR0A<< RI%_P<6H
M4Z&V/I?QH!K)9?2L\.2S-ZA&%K;A2I, )(\%'A]4.&US0<2"0C38BX9Z=#$7
M63JEQ+4F@5"$\Z130/3,\1^&LC]NO+JAL4?H724VW"\Z6X!-:B<W]HKQ%=75
M0]FO'*A':WP24#32/XEB$.!ZL4<ILWLJ2.^[%?Z48R48[LLOL,4$/0D7N]*I
M8X)C'ETH&)2 V+WW\H."D69D;HLY,=R0X.,^4C1MW?'9^'F(=8A8)T0ESFW^
M;)Q6<5948 4$D;$I9%YYAA1BT'R@G;:NR4G9RY9Y4/T(1_PL2]0"H:>B[@X[
M7\ *4<!IQ)1DU A7ZJD^E?(!^12\'Z4)_XFX.+!>N(:?18/K.1E)63N%0.BF
M@SJRB:C04SH^UJ9I\I!JR[D>(8Y4)Z)GC^A#L<H0]0A;I\P[1PA3=%X(S,^M
M'FR)JVBX[;$VWFZ6M?$9_U/]=XI4(81@MC;P 89Q-O822A["914C8%&>!MR4
M<'94Y"OT[/ OK50J83]]MX%(QPIF,2;^8HK&$3"J*#$DI_&O7E"# N%(*:"U
M0S9[Y7S7W)E\PWI(IP)<&Q,PXO7_8^A']-OHF^D#.;*% Y,/C+*JZ,@4\9D$
MOU[,ZV?%Y-FG(OZ2B!.##@XBO=0Q(Y2M*DD<^=)U*"4XV5@1UD$D2)C&EH&[
MZ^$$(Q&;R,_?99],]NG=IF:?5C1AA:.U]!37P':5?D4WYHVX,;J?R,@B[A\N
MHZT\(0?KWU@!6D1?M"4>]L(V0< /-^OT.D9</LY;&J$)N^J0F1=A\D@3$+4F
M91*H']/* -I 5I&% 0:Q2=[<ZGTYPJO#03N64] 5A6#HSSWSB=H)]ZILJK\
M7_<GZ[?>K7*Z&^RGZ,**;Y*8$NGNF<?>#N 8N"D<L$/F#]ZG'K14$ 0..)0#
M*%YE'B\_EUI[81-;7[$UW(R]SL61H7- :?YP?1I<$IG70^I\4R:D6S1MFH]*
MP,AAC?(<&7#(CN]$VK$W:Z;(U-]AS"XQU2YL?X-]9?X4!BFAF4W^&^2WFD]!
M,C^5&  =PG1\Y9!F=6N3Q7[%P_LY/&M.:?%HA'E[K$>#.8TKM]!_6E3<!149
M<?%_N6XN3X*] XX6:0( MPK'\/'@R="FB?!T,94_H0W1F&]4_9F8>5%7!4LV
MGG'A1VV2)@X=,<X:>PVV=FF>(\J9KD;? ([ >4D;=EJ,.<R[00?;JBMEOW%?
M>KY*#V%[.OZ/G]*WKPX/7XXFK^*7HS>O7C^/H[>3YP>'HS>C=X=Q?/@V^>^#
M5R]^>O#US_>7#N"OUHM'E]?#X[/3X' ?OWQX?GUZ=G9Z?/WYZ"SX='GQZ?3R
M^O?^B7WB+*ZWFNR>G\-^NH>+^QQTY6TZ"Z2@]A+OHT-U").189H%T3*?R@)C
MWCOZC3__&; :FT:_04:51=^LVLVJNJI]) *6.K6R0M1/P6M,\14H[&X_<N>;
MX+D4AH^_Y,5]EHQO-)2%V4I\BGO;)SC+X=-EK]@0H4$B:0#"L$8P DKPW1Z-
M4P>@;(L$?<-*RE$$UE[.<9"/%G/_BS2]]J"8XVV/D7(*+JN0NS4,54O(&\42
M6R3D&U8C^H\BA>$,<VPXC/&/-2"'4=@3R?,?.#YL%'*?D__1'"^[-.3LT?4D
MF5&.;D;*2453LRG;HOF$9BPHTP*>FQ($UO=8+%!U>P1VPPKM>.$*LE-7+*P?
M^/0VQ!:*0T3__/Z6B7<([B2BYH"F^3<O1]_U)\J.$<:O(;5A0#@0C5BFSJ0X
M3 _P1.FPA'F,DBGW"1?O!R)FK-RSZ/Z[:N*5>CF]QL:'%"Z_"=&+J9)XSM1'
MH$,^(L0RR;4M@7?@;68@8.V4S8M-\W5:EL_*C\>U#YL=KI;IU>8EB$3&M3=]
M$Q9SQ!(MI?1 1&U7J.FCD'S599'1S1/1&#-'8X!2GCH*0VC(R!H)N0S&.1@V
M(-JYXF4+'[]*A'5[[#*A8N]<)XODKV\QK31.JKA,1X)\R1"+7Q$E_0Z&HFOT
M\OD.AO*D"2-.[WBPOBEEW?P'^Z]7S-R*O-C)UP>W)+5<V$WGPTEZ:M<X24JA
MK!2UB1BF%S_<UNKE#^HVU5&O?XQR4!OC-;*U:*H.OF=J?$W)4&Q<46MGN$2&
M7,_ZMBSF-]P>KDHR;9D2WQ8$1@^E<DT.X3UFMR<*P6($$Q'5AC$5+Q@HUL8<
MSWOV&$:,!X5J0&H3.*JK$&&K536G.Z0/KU8@/',J#*I!ZY3OC5M*".@:-D8*
M[O)BWZU/$CA^1%'4#HY>CP16OR+YAC=1C,HS8P3TQ4URILP(,"NX#@4S[@A
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M9D5%!."LG2,.(S,,A816F@#BOS/X4!0+9/6<ETFCYH/GA<F"[8R1*J#H%*D
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MD<EJDAIF%'93%;L;HFM_/4K;N$116I+K1R=-@6X#XMQ\(^] J[PJXK(03)P
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MN=BB0C[;868[4?^^$2Q/\TF)DBEYD-:WG@4$6DSESS!(M2*9O#V]T#.+H9"
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MXB3A@F7S71R4?S9)2[AM[]U!55-P7DAXN*^WM/[4QG6=;\9&!E*Q?Y<6\XI
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MCBJ.A% I0^.D,OA%37R"/XU..*<:2-].R+BY2Y-[&W72EP@-\\BP+*/!5,W
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M*@U2HXJF7C=+1#^-8%(#;-HV=0I;,E@-$!'G>]SOJ&^Y@4(Y@3>;'G\^1^+
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M8*1A<($%6( %6( %6*P+"QAI,-(PN, "+, "+, "+!K( D8:C#0,+K  "[
M"[  BP:R@)'V@)%62E>YXO\AIP>C#BS  BS  BS X@?DR2YC>,"L@^\-HPXL
MP (LP (LP**!+&"DP4C#X (+L  +L  +L&@@"QAI,-(PN, "+, "+, "+!K(
M D8:C#0,+K  "[  "[  BP:R@)$&(PV#"RS  BS  BS HH$L8*3!2,/@ @NP
M  NP  NP:" +&&DPTC"XP (LP (LP (L&L@"1AJ,- PNL  +L  +L "+!K*
MD08C#8,++, "+, "+,"B@2Q@I,%(P^ ""[  "[  "[!H( L8:3#2,+C  BS
M BS  BP:R )&&HPT#"ZP  NP  NP (L&LH"1!B,-@PLLP (LP (LP**!+&"D
MP4C#X (+L  +L  +L&@@"QAI,-(PN, "+, "+, "+!K( D8:C#0,+K  "[
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M259QBH6=1'?T!ZRQ'^2,UZ\:D)S<IS]\7_]<OJFPXJ6-F'B2NYY7-,\^F,!
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MP''\__W<CV4'G1#8'LR5 /CAOAIWZ+[@@)>LPB_V55-.[[%D._9GB[;EK?9
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M,2YH=&U02P$"% ,4    " !R.:U2UFX%\0L6  #@[0  $0
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M+FAT;5!+ 0(4 Q0    ( '(YK5+V+E5YE0@  ),L   4              "
M 1AA" !Q,3(P,C%C97)C97@M,S$R+FAT;5!+ 0(4 Q0    ( '(YK5+<'.=C
ME@8  * F   4              "  =]I" !Q,3(P,C%C97)C97@M,S(Q+FAT
7;5!+!08     "P + -X"  "G< @    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
